Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Cassini A, Högberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis 2018; published online Nov 5. http://dx.doi.org/10.1016/ S1473-3099(18)30605-4. 1 Burden of antimicrobial resistance Appendix to “Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the European Union and the European Economic Area in 2015: a population- level health estimate” 2 Contents Literature review report ........................................................................................... 3 Literature selection grids ...................................................................................... 142 Final disease outcome trees ................................................................................. 168 Methodology protocol to estimate incidence ................................................... 191 GATHER checklist and further analysis on MRSA and attribution as healthcare-associated infections ........................................................................ 213 Country specific results ......................................................................................... 223 3 Burden of antimicrobial resistance Literature review report Literature search undergone by Ana Hoxha and Victoria Simpkin Report written by Ana Hoxha and Alessandro Cassini with contributions from Carl Suetens, Liselotte Diaz Högberg, Diamantis Plachouras and Dominique Monnet 4 Contents List of abbreviations ......................................................................................................... 5 Introduction ..................................................................................................................... 6 Methodology .................................................................................................................... 6 PICO Questions................................................................................................................. 7 PRISMA Checklist ............................................................................................................. 9 Results ........................................................................................................................... 14 1. Carbapenem resistant Acinetobacter baumannii .............................................................................. 14 2. Colistin resistant Acinetobacter baumannii ........................................................................................ 21 3. Multidrug resistant Acinetobacter baumannii ................................................................................... 24 4. Carbapenem resistant Escherichia coli ............................................................................................... 31 5. Colistin resistant Escherichia coli ......................................................................................................... 35 6. Third-generation Cephalosporin resistant Escherichia coli ................................................................. 38 7. Carbapenem resistant Klebsiella pneumoniae ................................................................................... 47 8. Colistin resistant Klebsiella pneumoniae ............................................................................................ 55 9. Third-generation Cephalosporin resistant Klebsiella pneumoniae .................................................... 58 10. Methicillin resistant Staphylococcus aureus ....................................................................................... 66 11. Carbapenem resistant Pseudomonas aeruginosa .............................................................................. 86 12. Colistin resistant Pseudomonas aeruginosa ....................................................................................... 92 13. Multidrug resistant Pseudomonas aeruginosa .................................................................................. 94 14. Penicillin resistant Streptococcus pneumoniae ................................................................................ 101 15. Penicillin and macrolide resistant Streptococcus pneumoniae ........................................................ 106 16. Vancomycin resistant Enterococcus faecalis and faecium ............................................................... 107 Conclusions .................................................................................................................. 116 References ................................................................................................................... 118 5 List of abbreviations 3GCREC third-generation cephalosporin-resistant E. coli 3GCRKP third-generation cephalosporin-resistant K. pneumoniae AMR antimicrobial resistance BSI bloodstream infection CAI Community-associated infections CI confidence interval ColRACI colistin-resistant Acinetobacter spp. ColREC colistin-resistant E. coli ColRKP colistin-resistant K. pneumoniae ColRPA colistin-resistant P. aeruginosa CRACI carbapenem-resistant Acinetobacter spp. CREC carbapenem-resistant E. coli CRKP carbapenem-resistant K. pneumoniae CRPA carbapenem-resistant P. aeruginosa CSF cerebral spine fluid DALY disability-adjusted life years EARS-Net European Antimicrobial Resistance Surveillance Network EEA European Economic Area EU European Union HAI healthcare-associated infection LOS length of stay MDR multidrug-resistant MDRACI multidrug-resistant Acinetobacter spp MDRPA multidrug-resistant P. aeruginosa MRSA meticillin-resistant Staphylococcus aureus MS Member State NI OECD Non infected Organisation for Economic Co-operation and Development OTH other infection site including digestive tract infections, skin and soft tissue infections (SSTI), eye, ear, nose or mouth infections, bone and joint infections, cardiovascular infections, reproductive tract infections and other less frequent infections PMRSP penicillin- and macrolide-resistant S. pneumoniae PPS point prevalence survey of healthcare-associated infections and antimicrobial use in acute care hospitals PRSP penicillin-resistant S. pneumoniae; R RESP Resistant respiratory infections (including pneumonia, and low respiratory tract infection) S S-BSI Susceptible secondary BSI SP specified pathogens SPDAR specified pathogens with defined antimicrobial resistance SSI surgical site infection UTI urinary tract infection VRE vancomycin-resistant enterococci 6 Introduction This document is part of the burden of antibiotic resistance in Europe project. The objective of this research was to retrieve available evidence from peer-reviewed publications on the attributable case fatality and attributable length of stay (LOS) of resistant bacteria under surveillance by the European Antimicrobial Resistance Surveillance Network (EARS-Net) and as defined in the Supplementary appendix 4. The aim of the review is to provide information for relevant disease progression models. Methodology The bacteria included in the review were the followings; Acinetobacter baumanni, Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, Streptococcus pneumoniae, Enterococcus faecalis and Enterococcus faecium. For each of these bacteria we performed separate reviews to study the resistance to specific antibiotics or specific antibiotic class. The following literature reviews were performed: 1. Colistin Resistant Acinetobacter baumannii 2. Carbapenem Resistant Acinetobacter baumannii 3. Multidrug resistant Acinetobacter baumannii 4. Colistin Resistant Escherichia coli 5. Carbapenem Resistant Escherichia coli 6. Third-generation Cephalosporin Resistant Escherichia coli 7. Colistin Resistant Klebsiella pneumoniae 8. Carbapenem Resistant Klebsiella pneumoniae 9. Third-generation Cephalosporin Resistant Klebsiella pneumoniae 10. Meticillin-resistant Staphylococcus aureus 11. Colistin Resistant Pseudomonas aeruginosa 12. Carbapenem Resistant Pseudomonas aeruginosa 13. Multidrug resistant Pseudomonas aeruginosa 14. Penicillin resistant Streptococcus pneumoniae 15. Penicillin and macrolide resistant Streptococcus pneumoniae 16. Vancomycin resistant Enterococcus faecalis and faecium The databases used for the literature review were PubMed, EMBASE and Cochrane Database of Systematic Reviews. Each review was performed using specific key words; research filters were applied where specified below. No time filter was applied, except for meticillin-resistant Staphylococcus aureus (MRSA), see below. Searches were undergone between April 2016 and December 2016, articles published after these dates might not be included. Most studies identified were based on hospitalized populations. Therefore, we define as “attributable” the quantitative information below on mortality and/or case fatality (CF) and/or length of stay (LOS) as being attributable to the infection, factoring out the risk resulting from the underlying co-morbidity. This attributable risk (risk difference) is the comparison of the absolute risks between patients with the respective resistant (R) infection 7 and patients (with similar characteristics) without the infection (non-infected, NI) or infected with a susceptible (S) infection. Primary studies reporting original results were considered eligible. Existing systematic reviews and meta-analysis were also included To be eligible, a study had to fulfil the following inclusion criteria defined a priori: 1. Original study reporting mortality rates, attributable mortality data, case fatality rates, attributable case fatality data. 2. Original study reporting length of stay in hospital or/and attributable length of stay as compared to controls. 3. Include a control group defined as affected by a susceptible infection or/and a control group of not infected patients. Relevant data were extracted, collected in excel spread sheets and presented in the relevant tables below. Matched case-control or cohort studies were considered having a higher value of evidence, though we did not apply any evaluation criteria to the included studies. Studies focusing on specific sites of infection (e.g. blood stream infections) were prioritized, although studies not specifying the infection site were also included and the data extracted. Case report studies and articles with less than 5 case patients were excluded. Most eligible studies reported an infected case group and a control group. The latter could be represented by non-infected (NI) patients or patients reporting an infection susceptible (S) to the considered antibiotic/class of antibiotics. PICO Questions Research question: What is the attributable mortality and the attributable length of stay of patients with infections with antibiotic-resistant bacteria when compared with non-infected or susceptible infection? Population Patients with defined infections with antibiotic-resistant bacteria, stratified for age group and infection type/site. Intervention (exposure) Infection due to: − Colistin Resistant Acinetobacter baumannii − Carbapenem Resistant Acinetobacter baumannii − Multidrug resistant Acinetobacter baumannii − Colistin Resistant Escherichia coli − Carbapenem Resistant Escherichia coli − Third-generation Cephalosporin Resistant Escherichia coli − Colistin Resistant Klebsiella pneumoniae − Carbapenem Resistant Klebsiella pneumoniae 8 − Third-generation Cephalosporin Resistant Klebsiella pneumoniae − Methicillin-resistant Staphylococcus aureus − Colistin Resistant Pseudomonas aeruginosa − Carbapenem Resistant Pseudomonas aeruginosa − Multidrug resistant Pseudomonas aeruginosa − Penicillin resistant Streptococcus pneumoniae − Penicillin and macrolide resistant Streptococcus pneumoniae − Vancomycin resistant Enterococcus faecalis and Enterococcus faecium Comparison Non-infected patients or patients infected with susceptible strain of the same species. Outcome Attributable case fatality and attributable length of stay. 9 PRISMA Checklist Section/topic # Checklist item TITLE Title 1 Burden of infections with antibiotic resistant bacteria: a systematic literature review of case fatality and length of stay ABSTRACT Structured summary 2 Background and Objectives: in order to estimate the burden infections with antibiotic-resistant we built disease progression models. We performed several systematic reviews of the literature to extract the best available evidence on the attributable case fatality proportion and attributable length of stay (LOS) in order to inform the disease progression models. Separate systematic literature reviews were performed for each bacteria under surveillance by the European Antimicrobial Resistance Surveillance Network (EARS-Net), each type of resistance and each infection type/site. Data source: The articles were searched on PubMed, Embase and the Cochrane Database of Systematic Reviews. Study Eligibility criteria: The review included primary studies reporting case fatality rate and LOS of patients with the resistant (R) infection and patients (with similar characteristics) without the infection (non-infected, NI) or infected with a susceptible (S) strain, for each resistant bacteria and each infection type/site. Participants: The cases were infected patients with a resistant infection while the controls had a susceptible or infection or were non-infected. Both groups were followed up for a period of 14-30 days measuring their mortality and LOS rates. Results: The number of studies varied between the different types of resistance considered, ranging from the 0 for colistin resistant E. coli to 44 for meticillin resistant S. aureus. The information was extracted for all studies included in the review and outcomes are available in Table form. Limitations: The major limitation of the review includes the heterogeneity of the studies, in terms of settings as well as type of patients and outcomes. Conclusions: We found a wide difference between the studies identified in our search. Many are limited to specific healthcare services (e.g. ICUs) and/or performed on particular groups of patients (e.g. only children, only elderly) and/or with specific underlying conditions (e.g. immunodeficiency, organ transplant). Therefore, extracting valid case attributable fatality proportions and attributable LOS will be particularly challenging. Based on the heterogeneity of the studies detected, we advise to avoid pooling and averaging the results based on our categorizing criteria. We suggest an alternative method for selecting and extracting the data for the disease progression models. 10 INTRODUCTION Rationale 3 In order to estimate the burden infections with antibiotic-resistant we built disease progression models. We performed several systematic reviews of the literature to extract the best available evidence on the attributable case fatality proportion and attributable length of stay (LOS) in order to inform the disease progression models. Separate systematic literature reviews were performed for each bacteria under surveillance by the European Antimicrobial Resistance Surveillance Network (EARS-Net), each type of resistance and each infection type/site. Objectives 4 To identify evidence from published scientific literature on the attributable case fatality and attributable length of stay (LOS) of infections due to antibiotic-resistant bacteria under surveillance by the European Antimicrobial Resistance Surveillance Network (EARS-Net). METHODS Protocol and registration 5 NA Eligibility criteria 6 To be eligible, a study had to fulfil the following inclusion criteria defined a priori: − Original study reporting mortality rates, attributable mortality data, case fatality rates, attributable case fatality data. − Original study reporting length of stay in hospital or/and attributable length of stay as compared to controls. − Include a control group defined as affected by a susceptible infection or/and a control group of not infected patients. The bacteria included in the review were the following; Acinetobacter baumanni, Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, Streptococcus pneumoniae, Enterococcus faecalis and Enterococcus faecium. For each of these bacteria we performed separate reviews to study the resistance to specific antibiotics or specific antibiotic class. The following literature reviews were performed: 1. Colistin Resistant Acinetobacter baumannii 2. Carbapenem Resistant Acinetobacter baumannii 3. Multidrug resistant Acinetobacter baumannii 4. Colistin Resistant Escherichia coli 5. Carbapenem Resistant Escherichia coli 6. Third-generation Cephalosporin Resistant Escherichia coli 7. Colistin Resistant Klebsiella pneumoniae 8. Carbapenem Resistant Klebsiella pneumoniae 9. Third-generation Cephalosporin Resistant Klebsiella pneumoniae 10. Methicillin-resistant Staphylococcus aureus 11 11. Colistin Resistant Pseudomonas aeruginosa 12. Carbapenem Resistant Pseudomonas aeruginosa 13. Multidrug resistant Pseudomonas aeruginosa 14. Penicillin resistant Streptococcus pneumoniae 15. Penicillin and macrolide resistant Streptococcus pneumoniae 16. Vancomycin resistant Enterococcus faecalis and Enterococcus faecium Information sources 7 PubMed, Embase, Cochrane Database of Systematic Reviews Search 8 In the different information sources, we used the following string types: Pubmed: we used once the mesh term “bacteria name” AND all fields “antibiotic name resistant”, and the second time the mesh term “bacteria name” AND all fields “antibiotic name resistance”. Both times a filter for human studies was applied. Embase: we searched for ‘bacteria name’ AND ‘antibiotic name resistant’, and ‘bacteria name AND ‘antibiotic name resistance’. We applied a filter to include only human studies. Cochrane Library: we performed an advanced search using terms “bacteria name” AND “antibiotic name”. Study selection 9 All results from the three different data sources were exported in a reference manager and duplicates were removed. The first screening was performed by the articles titles, then by the abstract and finally by the evaluation of the full text. Data collection process 10 The data of the included studies were extracted in an excel file containing a list of indicators of interest and are displayed in Tables in the report of the systematic review and in excel files for scoring (Appendix 2). Data items 11 The indicators reported in the Literature review report tables (Appendix 1) include: • Author • Study period • Outcome • Location • Period of Outcome • Population • Matching criteria • LOS (days) • Notes/comments The indicators collected during the study evaluation (Appendix 2) were: 12 • First author, year • Study type • Sample size: Number cases and controls, Calculation a priori of the sample size • Representativeness: Geographical, Demographical, Clinical • Matching or controlling for confounders: Underlying disease, Infection site, Hospital and unit/ward, Follow-up • Risk difference: Case fatality, LOS, Statistically significant outcome results Risk of bias in individual studies 12 Every indicator was scored using the following scoring scale: ++ : Matches completely/is completely fulfilled + : Matches incompletely but sufficiently/is only partly but sufficiently fulfilled - : Does not match or matches insufficiently/is insufficiently c.b.e : Cannot be evaluated Summary measures 13 Attributable case fatality and attributable LOS Synthesis of results 14 The results were evaluated from ECDC experts. Risk of bias across studies 15 Publication bias was not assessed, although some bias was expected due to the lower propensity to publish negative studies. Studies were conducted in different countries and different settings, making their direct comparison challenging. We scored each individual study for the criteria/indicators listed above (Appendix 2) Additional analyses 16 NA RESULTS Study selection 17 The study selection process for each antibiotic resistance-bacterium combination is shown in specific Figures in Appendix 1. Study characteristics 18 These are presented in Appendix 1 (Tables) and Appendix 2 (excel form). Risk of bias within studies 19 These were scored according to a set criteria/indicators and the results are presented in Appendix: 2 Results of individual studies 20 Tables in Appendix 1 and excel in Appendix 2. Synthesis of results 21 The articles included in the review were further analysed and evaluated by ECDC experts and those considered of higher quality were used as a source for the estimate of the attributable case fatality and attributable LOS, see 13 Appendix 3. Appendix 3 provides an overview of the final decisions for the disease progression models. Risk of bias across studies 22 Very often the studies were conducted in different countries and different settings, making their direct comparison challenging. To mitigate this heterogeneity, we used the scoring system of the indicators in order to better summarise the information. Majority of studies identified were observational and carry inherent biases related to their design. Additional analysis 23 NA DISCUSSION Summary of evidence 24 The synthetized results showed an increased mortality and LOS in infected patients. For some antibiotic resistance- bacterium combinations, the resistant infection showed increased mortality and LOS compared to the susceptible infections. There was a large variation across different types of infection, bacterial species and resistant phenotypes. Limitations 25 The major limitation of the review includes the heterogeneity of the studies, in terms of study design, settings as well as type of patients and outcomes. Conclusions 26 We found a wide difference between the studies identified in our search. Many are limited to specific healthcare services (e.g. ICUs) and/or performed on particular groups of patients (e.g. only children, only elderly) and/or with specific underlying conditions (e.g. immunodeficiency, organ transplant). Therefore, extracting valid case attributable fatality proportions and attributable LOS will be particularly challenging. Based on the heterogeneity of the studies detected, we advise to avoid pooling and averaging the results based on our categorizing criteria. Therefore, we chose to score the evidence identified by a self-designed evaluation grid, see Appendix 2. FUNDING Funding 27 Funding provided by ECDC 14 Results The results of the reviews are presented separately for every bacteria and are antibiotic or antibiotic class specific. Each chapter includes: • a short description of the key words researched in every database; • a scheme of the number of articles included and excluded during each step of the reviewing process; • the articles selected as eligible for the review listed in separate tables based on the infection site and the comparison control group; • some final considerations regarding the specific review. 1. Carbapenem resistant Acinetobacter baumannii To research the attributable case fatality and the attributable LOS to carbapenem resistant Acinetobacter baumannii (CRAB) we performed 2 advanced searches on Pubmed using once the mesh term “Acinetobacter baumannii” AND all fields “carbapenem resistant”, and the second time the mesh term “Acinetobacter baumannii” AND all fields “carbapenem resistance”. Both times a filter for human studies was applied. Embase was searched for ‘Acinetobacter baumannii’ AND ‘carbapenem resistant’, and ‘Acinetobacter baumannii AND ‘carbapenem resistance’. We applied a filter to include only human studies. An advanced search on the Cochrane Library was performed using terms “Acinetobacter baumannii” AND “carbapenem”. No language restrictions were made, and no further filters were applied. The flow diagram, presented in Figure 1 describes the steps in the literature review of carbapenem resistant Acinetobacter baumannii infections. The results obtained using the two different strings for PubMed and Embase were aggregated. Once identified the studies reporting relevant data, these were grouped based on the site of infection. All eligible studies reported a CRAB infected group and a control group. The latter could be represented by non-infected (NI) or carbapenem susceptible Acinetobacter baumannii (CSAB) infected patients. Figure 1: Search for studies on carbapenem resistant Acinetobacter baumannii. Inclusion and exclusion diagram. 15 * One of these studies was a systematic review and meta-analysis. The following tables include studies reporting results for BSI, respiratory tract and for mixed site of infection due to CRAB, based on the comparison group they used. All information is reported as was presented in the original papers. Studies that include both a susceptible and a non-infected control group, were categorized in the latter group since we prioritized the non-infected comparator. 16 Table 1: Short extraction table of original articles on BSI mortality of CRAB infected patients vs non infected patients Table 2: Short extraction table of original articles on BSI mortality of CRAB infected patients vs CSAB infected patients Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Deris 20113 no info Cross sectional case-control study Mort. rate cases=64.3% Mort. rate controls=40.5% OR=0.38; 95%CI(0.11-1.36) *Mort. rate cases=42.9% *Mort. rate controls=24.3% OR=2.33; 95%CI(0.64-8.65) Malaysia hospitaliz 15 cases 41 controls none median (IQR) cases=32.3(16.4) controls=32.8(25. 0) *attributable mortality; within 72h from isolation 2 Esterly 20114 01/05- 12/08 Retrospective cohort study Mort. rate cases=56.8% Mort. rate controls=23.8% Model1 OR=0.58; 95%CI (0.037–9.22) Model2 OR=0.73; 95%CI(0.14–3.84) Chicago USA hospitaliz 37 cases 42 controls none Prior isolation median (IQR) cases=16(1-30) controls=0(0-9) Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Kim 20141 01/05- 12/11 Retrospective case-control study Mort. rate cases=94.7% Mort. rate controls=8.3% Korea hospitaliz 19 cases 38 controls undelying condition median (range) cases=35(30–47) controls=29(26.75– 34) all patients were hematopoietic stem cell transplantation recipients 2 Thatrimo ntrichai 20132 01/91- 12/10 Case-case- control study Mort. rate resist=42.9% Mort. rate sensit=13.2% Mort. rate controls=6.8% OR RvsS=5; 95%CI(1.2- 20-4) OR RvsNI=10.2; 95%CI(2.1-50) Thailand hospitaliz 14 resistant 38 sensitive 44 controls age, ICU median(range) resist=34(2-206) sensitive=53.5(3-188) controls=24.5(1-102) patients were neonates in ICU 17 3 Huang 20125 06/02- 12/07 Retrospective cohort study Mort. rate cases=35.5% Mort. rate controls=20.7% OR= 1.03 ; 95%CI(0.48-2.20) Taiwan 14 days 62 cases 164 controls none Prior isolation mean±SD cases=35.9±33.6 controls=28.2±44 4 Jamulitrat 20096 Cohort study Mort. rate cases=52.2% Mort. rate controls=19.9% aHR=1.7; 95%CI(0.9-2.9) Thailand hospitaliz 67 cases 131 controls none median ±IQR cases=37±32 controls=27±37 5 Kim 2012 7 06/07- 06/10 Retrospective study Mort. rate cases=49.1% Mort. rate controls=9.5% OR=7.29; 95%CI(1.57-33.8) Korea 14 days 53 cases 42 controls none Prior isolation mean±SD cases=30.0±33.3 controls=30.4±68. 3 the study differentiates those who received appropriate therapy from those who did not 6 Kumar 20148 01/10- 12/12 Retrospective chart review Mort. rate cases=27.3% Mort. rate controls=9.4% India hospitaliz 33 cases 32 controls age, ICU no data patients were neonates in ICU 7 Routsi 20109 09/04- 01/06 Prospective observational study Mort. rate cases=43.3% Mort. rate controls=46.9% Greece hospitaliz 30 cases 66 controls none median (IQR) cases=33(18.8- 55.8) controls=28.5(14. 5-51.0) 8 Tal-Jasper 201610 01/07- 12/12 Retrospective cohort study a) Mort. rate cases=70.5% Mort. rate controls=45.1% b) Mort. rate cases=66.2% Mort. rate controls=44.4% c)Mort. rate cases=73.6% Mort. rate controls=53.3% OR 90days=0.6, 95%CI (0.1– 2.3) Israel a) hospitaliz b)30 days c) 90 days 149 cases 91 controls none median (IQR) cases=21(10.8- 39.5) controls=10(7- 20.5) 18 Table 3: Short extraction table of original articles on respiratory tract infection mortality of CRAB infected patients vs sensitive and vs non infected patients Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Thatrimontrichai 201611 01/09- 12/14 Case-case- control study Mort. rate resist=15.9% Mort. sensit=7.7% Mort. control=0% Thailand hospitaliz 63 resistant 13 sensitive 25 controls age, ICU median(range) resist=29(8-93) senstiv=20(8-31) controls=22(8-68) patients were neonates in ICU Table 4: Short extraction table of original articles on respiratory tract infection mortality of CRAB infected patients vs sensitive infected patients Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Chang 201112 01/05- 12/07 Retrospective observational study Mort. rate cases=61.3% Mort. rate controls=46.0% Taiwan hospitaliz 93 cases 87 controls none after VAP onset median±SD cases=23.1±24.3 controls=26.7±24. 3 all patients were critically ill 2 Garnacho- Montero 200313 01/97- 06/01 Prospective cohort study Mort. rate cases=61.9% Mort. rate controls=64.2% *VAP related mortality Mort. rate cases=38% Mort. rate controls=35.7% Spain hospitaliz 21 cases 14 controls underlying condition mean±SD cases=45.2±30.7 controls=53.9±50 cases treated with colistin, controls with imipenem-cilastatin *occurring during treatment, when signs of pneumonia remained and due to septic shock 3 Zheng 201314 01/06- 12/11 Retrospective study Mort. rate cases=45.6% Mort. rate controls=29.9% China 28 days 97 cases 145 controls underlying condition before pneu mean±SD cases=17.7±6.6 controls=18±6.2 19 Table 5 and Table 6 present the results of studies that include patients with different sites of infection. Almost all the articles specify the number of cases for the different infection sites but they do not report different mortalities based on the infection site. When it was possible the results are presented differentiating the mortality for each site of infection. Table 5: Short extraction table of original articles on mortality of CRAB infected patients vs non infected patients for different infection sites Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Henig 201515 01/07- 12/12 Matched case-control study Mort. rate cases=73% Mort. rate controls=55% aHR=2.33; 95%CI(2.08– 2.6) Israel hospitaliz 1190 cases 1190 controls age, ward, season, Charlson score, LOS matching criteria median (range) cases=18 (0–97) controls=17 (0– 96) the study considers also 241 cases and controls with BSI but gives not info on their mortality 2 Nazer 201516 01/10- 12/13 Matched case-control study Mort. rate cases=73% Mort. rate controls=61.2% Jordan in ICU stay 142 cases 232 controls age, gender, APACHE II, type of malignancy, mechanical ventilation median (IQR) cases=12(6-13) controls=3(1.7) all patients were critically ill with cancer and in ICU Table 6: Short extraction table of original articles on mortality of CRAB infected patients vs CSAB infected patients for different infection sites Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Aydemir 201217 01/05- 12/06 Retrospective case-control study Mort. rate cases=61.8% Mort. rate controls=52.7% Turkey hospitaliz 110 cases 55 controls none after isolation mean±SD cases=18.1±14.0 controls=15.7±12.3 2 de Gouvea 201218 01/02- 01/09 Retrospective study Mort. rate cases=44.4% Mort. rate controls=29.0% Inf. related. OR=0.73; 95%CI(0.12 – 4.47) Brasil 30 days 18 cases 31 controls undelying condition no data all patients had solid organ transplant 20 Overall mort. OR=1,93; 95%CI(0.48 – 7.85) 3 del Mar 200519 10/01- 08/02 Case-control study Mort. rate cases=43.3% Mort. rate controls=19% *Related mortality=30% Spain 30 days 30 cases 31 controls same period of isolation attributable LOS=14 days cases were multi resistant * when infection was established, by clinical criteria, as the primary cause of death 4 Lautenbach 200920 01/89- 12/04 Prospective cohort study Mort. rate cases=18% Mort. rate controls=21.2% RR=0.85; 95% CI(0.52– 1.39) New Jersey, USA 30 days 89 cases 297 controls none median(range) cases=21(14-29) controls=16(12-18) 5 Lemos 2014 a21 04/06- 04/10 Prospective, multicentre cohort study Mort. rate cases=40% Mort. rate controls=12.2% aHR=1.45; 95%CI(0.74- 2.87) New York, USA 30 days 104 cases 61 controls ICU adjusted mean cases=19.3 controls=16.2 patients were in ICU 6 Lemos 2014 b22 up to 05/13 Systematic review and meta-analysis crude OR=2.22; 95% CI=1.66-2.98 World 7 Sheng 201023 05/04- 11/06 Multicentre retrospective study a) Mort. rate cases=13.3% Mort. rate controls=20% b) Mort. rate cases=33% Mort. rate controls=17.5% Taiwan hospitaliz 30 cases 30 controls none Median (range) a)cases=41 (5–282) controls=29 (2–227) b) cases=37 (1–218) controls=23 (1–151) a) colonized patients b) infected patients 8 The Brooklyn Antibiotic Resistance Task Force, 200224 3 months 1999 Matched case- control study a) Mort. rate cases=34% Mort. rate controls=27% b) Mort. rate cases=20% Mort. rate controls=30% USA hospitaliz a) 44 cases 33 controls b) 10 cases 10 controls age, site of infect, underlying diseases, operative procedure, type of infection after infection median cases=31.5 controls=13 a) all cases and controls b) 10 matched pairs 21 Some of the detected studies reported pooled results for gram negative bacteria, or for Acinetobacter baumannii and Pseudomonas aeruginosa. These were not included. We detected different studies that reported treatment options for the resistant infections, comparing two or more therapeutic strategies. All these studies included mortality data of CRAB infected patients, but since they used just cases infected with CRAB and no control group, as defined by our eligibility criteria, these studies were not included in the results of this review. All studies were performed in healthcare settings and considered HAI, though some of them report cases of infection that originated in the community or that had the onset in the community, but none of them reported only CAI cases. 2. Colistin resistant Acinetobacter baumannii To research the attributable case fatality and the attributable LOS to colistin resistant Acinetobacter baumannii (CoRAB) we performed 2 advanced searches on Pubmed using once the mesh term “Acinetobacter baumannii” AND all fields “colistin resistant”, and the second time the mesh term “Acinetobacter baumannii” AND all fields “colistin resistance”. Embase was searched for ‘Acinetobacter baumannii’ AND ‘colistin resistance’, and for ‘Acinetobacter baumannii’ AND ‘colistin resistant’. An advanced search on the Cochrane Library was performed using terms “Acinetobacter baumannii” AND “colistin”. No language restrictions were made, and no filters were applied. The flow diagram, presented in Figure 2 describes the steps in the literature review of colistin resistant Acinetobacter baumannii infections. The results obtained using the two different key words in PubMed and Embase were aggregated. 22 Figure 2: Search for studies on colistin resistant Acinetobacter baumannii. Inclusion and exclusion diagram. The following table 7 includes studies reporting mortality data for CoRAB. All information is reported as was presented in the original papers. 23 Table 7: Short extraction table of original articles on BSI mortality of CoRAN* infected patients vs CoSAB infected patients Nr Author Study Period Study type Outcome Location Period of outcome Population LOS (days) Matching Notes 1 Wang 201525 1998- 2008 Retrospective study a) Mort. rate cases=10.3% Mort. rate controls=10.3% b) Mort. rate cases=15.5% Mort. rate controls=15% Taiwan a) 14 days b) 28 days 58 cases 213 controls prior infection median (IQR) cases=56 (32-101) controls=37 (22-65) none *The study in table 7 deals with A. nosocomialis instead of A. baumanni but we decided to include it in the review as eligible for the purposes of the project. Table 8: Short extraction table of original articles on UTI mortality of CoRAB infected patients vs CoSAB infected patients Nr Author Study Period Study type Outcome Location Period of outcome Population LOS (days) Matching Notes 1 Taneja 201126 02/07- 06/08 Prospective cohort study Mort. rate both=0% India hospitaliz 8 cases 42 controls No data all bacteria were MDR patients with complicated urinary tract infection 24 We identified 4 additional studies27-30 investigating the mortality due to CoRAB, but they did not use a comparison group. In these studies the mortality for the cases ranged from 0%- 70%. We did not apply any specific filter to the literature research because we wanted to be as broad as possible in including all the papers that had as subjects Acinetobacter baumannii and colistin resistance. The research produced numerous results, but not all of them were eligible for the purposes of this review. Many detected papers reported studies on the efficacy of colistin on multi-drug resistant Acinetobacte baumannii strains, where multidrug resistance was defined as resistance to all antibiotics except for colistin. The colistin resistant Acinetobacter baumannii infections are a relative new research topic, and it seems that no structured studies were conducted yet to investigate the burden of these infections in terms of attributable mortality or attributable length of stay in hospital. 3. Multidrug resistant Acinetobacter baumannii For the purposes of this project a multidrug resistant isolate is defined as resistant to at least three classes of antimicrobial agents, all penicillins and cephalosporins (including inhibitor combinations), fluroquinolones, and aminoglycosides. Here are excluded those resistant to carbapenem and/or to colistin. If an isolate is multidrug resistant and also resistant to carbapenem and/or colistin, it will be classified as resistant to the latter antibiotic. To research the attributable case fatality and the attributable LOS to multidrug resistant Acinetobacter baumannii (MDRAB) we performed 3 advanced searches on Pubmed using once the mesh term “Acinetobacter baumannii” AND all fields “multidrug resistant” AND all fields “mortality”, the second time the mesh term “Acinetobacter baumannii” AND all fields “multidrug resistance” AND all fields “mortality”, and the third time the mesh term “Acinetobacter baumannii” AND all fields “MDR” AND all fields “mortality”. All times a filter for human studies was applied. Embase was searched for ‘Acinetobacter baumannii’ AND ‘multidrug resistant’ AND ‘mortality’, and ‘Acinetobacter baumannii AND ‘multidrug resistance’ AND ‘mortality’. We applied a filter to include only human studies. Two advanced searches were also performed on the Cochrane Library, using once the terms “Acinetobacter baumannii” AND “multidrug resistant”, and the second time the terms “Acinetobacter baumannii” AND “multidrug resistance”. No language restrictions were made, and no further filters were applied. The flow diagram, presented in Figure 3 describes the steps in the literature review of Multidrug resistant Acinetobacter baumannii infections. The results obtained using the different strings for PubMed, Embase and the Cochrane Library were aggregated. Once identified the studies reporting relevant data, these were grouped based on the site of infection. All eligible studies reported a MDRAB infected group and a control group. The latter could represent patients non infected (NI) or infected with susceptible (S) A. baumannii infections. 25 Figure 3: Search for studies on multidrug resistant Acinetobacter baumannii. Inclusion and exclusion diagram. The following tables include studies reporting results for BSI, respiratory tract and for mixed site of infection due to MDRAB, based on the comparison group they used. All information is reported as was presented in the original articles. 26 Table 9: Short extraction table of original articles on BSI mortality of MDRAB infected patients vs non infected patients Table 10: Short extraction table of original articles on BSI mortality of MDRAB infected patients vs MDSAB infected patients Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Anunnatsiri 201133 01/05- 12/07 Retrospective study Mort. cases=91.7% Mort. controls=48% OR=11.92; 95%CI(2.30-61.83) Thailand hospitaliz 24 cases 25 controls none before BSI median (range) cases=21.5(4-161) controls=14(2-86) 2 Fitzpatrick 201534 06/05- 10/12 Retrospective cohort study a) Mort. cases=36% Mort. controls=8% b) Mort. cases=44% Mort. controls=8% Chicago, USA a) 14 days b) 30 days 92 cases 24 controls none Post culture median(range) cases=11.5(2-69) controls=6(2-38) 3 Guo 201635 06/12- 06/15 Retrospective study Mort. cases=44.8% Mort. controls=4.3% OR=26.3; 95%CI(3.0- 231.4) China 30 days 64 cases 23 controls none in ICU mean cases=51 controls=5 4 Lee 200736 04/96- 08/01 Retrospective matched cohort study a) Mort. cases=47.8% Mort. controls=39.1% b) Mort. cases=34.8% Taiwan hospitaliz 46 cases 46 controls sex, age, severity of underlying mean±SD cases=54.2±42.8 controls=34.1±30.5 a) crude mortality b) sepsis related mortality Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Al Jarousha 200931 02/04- 01/05 Prospective case-control study Mort. cases=37.5% Mort. controls=12% Palestine hospitaliz 40 cases 100 controls age, birth weight no specific data patients were in neonatal ICU 2 Gulen 201532 01/07- 12/10 Retrospective cohort study a) Mort. cases=30% b) Mort. cases=52.4% c)Mort. Cases=53.7% Attribut. mort.=24.4% Turkey a) 14 days b) 28 days c) hospitaliz 41 cases 45 controls* BSI before BSI mean±SD cases=25.49±21.47 controls=22.80±19.28 *patients had other gram-negative infections 27 Mort. controls=13.0% and acute illness 5 Lee 201037 01/00- 12/05 Retrospective study Mort. cases=32% Mort. controls=8,3% OR=7.46; 95%CI(3.78-14.70) Taiwan 30 days 147 cases 144 controls none no specific data the study investigated the difference between gen. sp.2 vs gen. sp. 3 data were extrapolated 6 Smolyako 200338 01/05- 12/05 Prospective study Mort. cases=29.4% Mort. controls=11.6% OR=4 Israel hospitaliz 51 cases 43 controls none mean±SD cases=37.7±30 controls=24.3±18.3 Table 11: Short extraction table of original articles on respiratory tract infection mortality of MDRAB infected patients vs MDSAB infected patients Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Cai 201239 01/09- 08/11 Prospective study Mort. cases=18.26% Mort. controls=4.44% China hospitaliz 115 cases 45 controls ward in ICU mean±SD cases=17.39±7.05 controls=14.43±3.92 patients were children with pneumonia 2 Inchai 201540 01/05- 12/11 Retrospective cohort study a)Mort. cases=31.9% Mort. controls=21.2% b)Mort. cases=44.4% Mort. controls=27.3% HR=1.03; 95%CI(0.44–2.45) Thailand a) 30 days b) hospitaliz 72 cases 33 controls ICU no data patients were in ICU 3 Park 200641 01/02- 11/04 Retrospective study Mort. cases=58.8% Mort. controls=40% Korea hospitaliz 17 cases 30 controls no data mean±SD cases=42.8±24.0 controls=66.2±56.1 28 Table 12 and Table 13 present results of studies that include patients with different sites of infection. Almost all the articles specify the number of cases for the different infection sites but they do not report different mortalities based on the infection site. When it was possible the results are presented differentiating the mortality for each site of infection. Table 12: Short extraction table of original articles on mortality of MDRAB infected patients vs non infected patients for different infection sites Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Abbo 200742 01/01- 06/01 Retrospective matched cohort study Mort. cases=36% Mort. controls=21% OR=2.21, 95%CI(1.17– 4.16) Israel hospitaliz 118 cases 118 controls ward, month of hosp, LOS before culture median cases=17 controls=11 2 Fukuta 201343 01/08- 12/11 Case-control study Mort. cases=41.9% Mort. controls=29% Pittsburgh, USA 90 days 31 cases 62 controls underlying condition median(IQR) cases=28 (9-59) controls=10(5-18) patients had cancer 3 Lee 201644 01/12- 12/14 Retrospective propensity- matched cohort study Mort. cases=32% Mort. controls=36.8% OR=3.64; 95%CI(1.80- 7.37) Korea hospitaliz 122 cases 122 controls propensity score mean±SD cases=40.3±40.6 controls=24.6±28 presence of MDRAB isolate without signs or symptoms Table 13: Short extraction table of original articles on mortality of MDRAB infected patients vs MDSAB infected patients for different infection sites Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Brahmi 200745 01/04- 12/05 Prospective study Mort. cases=67.5% Mort. controls=46.7% Tunisia hospitaliz 29 cases 34 controls ward in ICU mean±SD cases=27±17.8 controls=32.3±23.9 patients were in ICU 2 Daniels 200846 06/03- 06/06 Retrospective propensity- matched cohort study a)Mort. cases=15.8% Mort. controls=9.5% b) Mort. cases=14.3% Mort. controls=9.5% Tennessee, USA 28 days a)146 cases 42 controls) b) 42 cases 42 controls propensity score median (IQR) cases=32.5(22-51) controls=26.5(16-43) patients were in ICU a) all patients b) matched pairs 29 3 Lemos 201147 04/06- 04/10 Prospective, observational multicentre study a) Mort. cases=31% Mort. controls=9% b) Mort. cases=41% Mort. controls=9% b) RR=1,219; 95%CI(0,923–1,611) Colombia 14 days 103 cases 62 controls ICU median(IQR) pre ICU cases=4(1.2-18) controls=5(1.5-22.3) in ICU cases=15(13-60) controls=13(8-44) patients were in ICU 4 Pierri 201548 01/09- 12/11 Retrospective matched cohort study Mort. cases=57% Mort. controls=46% Italy hospitaliz 14 cases 26 controls propensity score mean±SD cases=36±20 controls=25±18 patients underwent cardiac surgery 5 Zilberberg 201649 01/09- 12/13 Retrospective cohort study Mort. cases=23.7% Mort. controls=12.7% USA hospitaliz 1171 cases 252 controls underlying condition no data patients had pneumonia or sepsis The vast majority of papers containing information on mortality did not report a comparison group. Many studies reported treatment options for the resistant infections, but since they used just cases infected with MRDAB and no control group, as defined by our eligibility criteria, these studies were not included. All studies were performed in healthcare settings though some of them report cases of infection that originated in the community, but none of them treated only patients with infection onset in the community. The studies that included patients with MDRAB which were also resistant to carbapenems were also not included. We did not perform a literature review for third-generation cephalosporin resistant Acinetobacter baumannii (3GCRAB), but we decided to report here the results of a multicentre European study50 that investigated the mortality of patients infected with 3GCRAB. The authors compared patients with resistant and susceptible A. baumannii to cefetizime (3GCRAB vs 3GCSAB), for BSI and respiratory tract infections. Table 14 reports the characteristics and results of this study. 30 Table 14: Short extraction table of the original article on mortality of 3GCRAB infected patients vs 3GCSAB infected patients for BSI and respiratory tract infections Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Lambert 201150 01/05- 12/08 Prospective cohort study a) Mort. cases=43% Mort. controls=55% aHR=0.8; 95%CI(0.3- 2.1) b) Mort. cases=38% Mort. controls=40% aHR=1.0; 95%CI(0.6- 1.8) Europe ICU hospitaliza tion a)31 cases 11 controls b)130 cases 43 controls ICU From infection to discharge median (IQR) a)cases= 20 (7–38) controls=9 (2-13) b)cases= 14 (11–26) controls= 25(14-40) patients were in ICU a)patients with BSI b)patients with pneumonia 31 4. Carbapenem resistant Escherichia coli To research the attributable case fatality and the attributable LOS to carbapenem resistant Escherichia coli (CREC) we performed an advanced search on Pubmed using “Escherichia coli” [MeSH Terms] AND “carbapenem resistance” all fields, together with the string “Escherichia coli” [MeSH Terms] AND “carbapenem resistant” all fields. No filters were applied. Embase was searched for ‘Escherichia coli’ AND ‘carbapenem resistance’, and for ‘Escherichia coli’ AND ‘carbapenem resistant’. No filters were applied. An advanced search on the Cochrane Library was performed using terms “Escherichia coli” AND “carbapenem”. Studies on animals, cells and tissues, as well as case report studies were excluded from the results. No language restrictions were made to any database. The following flow diagram describes the steps in the literature review of carbapenem resistant Escherichia coli infections. 32 Figure 4: Search for studies on carbapenem resistant Escherichia coli. Inclusion and exclusion diagram. The following tables include studies reporting results for BSI and mixed site infection, based on the comparison group they used, carbapenem susceptible Escherichia coli (CSEC) infected patients or non-infected (NI). All information is reported as was presented in the original papers 33 Table 15: Short extraction table of original articles on BSI mortality of CREC infected patients vs CSEC infected patients Table 16 and Table 17 present the results of studies that include patients with different sites of infection. Almost all the articles specify the number of cases for the different infection sites but they do not report different mortalities based on the infection site. Table 16: Short extraction table of original articles on mortality of CREC infected patients vs non infected patients for different infection sites Nr Author Study Period Study type Outcome Location Period of outcome Population LOS (days) Matching Notes 1 Epstein 201452 01/13- 12/13 Case-control study Mort. rate cases=25%* Mort. rate controls=0% Illinois, USA hospitaliz 8 cases 27 controls median cases=8.5 controls=25.0 mean(SD)[range] cases=13.3 (12.0) [1- 37] patients from the same ward patients fro the same ward * death not related to Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Chang 201151 01/06- 12/08 Matched case-control study a)Mort. rate cases=47.06% Mort. rate controls=38.24% b)Mort. rate cases=70.59% Mort. rate controls=47.06% c)Mort. rate cases=94.12% Mort. rate controls=50% Taiwan a) ≤14 days b) ≤ 28 days c) hospitaliz 17 cases 34 controls gender, age, year of hosp, length stay before isolation mean±SD (min- max) cases=68.4± 56.4 (7-161) controls=35.8±3 4.5 (4-141) Cases are non- susceptible, MIC non reported 34 controls=30.2 (13.2) [14-65] CREC * deaths not related to CREC (author’s statement) Table 17: Short extraction table of original articles on mortality of CREC infected patients vs CSEC infected patients for different infection sites Nr Author Study Period Study type Outcome Location Period of outcome Population Matching LOS (days) Notes 1 Ahn 201453 10/06 - 12/10 Matched case- controls study Mort. rate cases=14.8% Mort. rate controls=10.2% Korea 28 days 57 cases 114 controls Site of infection mean±SD cases=26.6±37.9 controls=13.1±41.3 Table 18: Short extraction table of original articles on mortality of CREC infected patients without a control group Nr Study Study Period Study type Outcome Location Period of outcome Population Matchin g LOS (days) Notes 1 Balkan 201454 02/11- 03/13 Retrospective nested case– control study Mort. rate cases=50% Turkey hospitaliz 8 cases none No data comp. with klebsiella and enteorbacter 2 Poirel 201455 03/12- 09/12 Observational study Mort. rate cases=33.3% Bulgaria hospitaliz 12 cases none No data study on Enterobacteriaceae 3 Porwal 201456 05/11- 05/12 Retrospective study Mort. rate cases=38.5% Chenmai, India 30 days 13 cases none No data study on Gram- 4 Shukla 201357 Retrospective study Mort. rate cases= 6% Mumbai, India hospitaliz 17 cases none No data study on Gram- 35 The studies included in table 18 are not eligible studies since they do not have a control group. They are part of this report as further possible source of information on the mortality of carbapenem resistant Escherichia coli infections, since the number of eligible studies detected with this literature review was limited. These studies included investigated the mortality of Gram negative or Enterobacteriacea, only comparing the different bacteria on each group. 5. Colistin resistant Escherichia coli Escherichia coli resistance to colistin was attributed to chromosomal mutations until November 2015, when Liu et al.58 published a research, from China, showing that the resistance, in animals and humans, was due to the mcr-1 gene, which can be horizontally transmitted through plasmids. After the publication the gene was detected in other countries, both in animals and humans. To research the attributable case fatality and the attributable LOS to colistin resistant Escherichia coli (CoREC) we performed 2 advanced searches on Pubmed using once the mesh term “Escherichia coli” AND all fields “colistin resistant”, and the second time the mesh term “Escherichia coli” AND all fields “colistin resistance”. Embase was searched for ‘Escherichia coli’ AND ‘colistin resistance’, and for ‘Escherichia coli’ AND ‘colistin resistant’. An advanced search on the Cochrane Library was performed using terms “Escherichia coli” AND “colistin”. No language restrictions were made, and no filters were applied. The flow diagram, presented in Figure 5 describes the steps in the literature review of colistin resistant Escherichia coli infections. The results obtained using the two different key words in PubMed and Embase were aggregated. 36 Figure 5: Search for studies on colistin resistant Escherichia coli. Inclusion and exclusion diagram. The following table includes 3 studies reporting mortality data for CoREC infected patients without a comparison group. Though these studies do not fulfil our eligibility criteria, they were reported since no other evidence on the mortality due CoREC was available. All information is reported as was presented in the original papers. 37 Table 19: Short extraction table of original articles on CoREC infected patients Nr Author Study Period Infection site Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Kontopidou 201128 11/03- 12/06 not defined Retrospectiv e cohort study Mort. rate=0% Athens, Greece hospitaliz 2 cases none no data the study analysed Gram- bacteria 2 Nordmann 201659 2015 BSI Prospective cohort study Mort. rate=0% Switzerland hospitaliz 2 cases none no data the first 2 cases in a row in the hosp 3 Oostdijk 201160 01/08- 10/10 different Retrospectiv e cohort study no data Utrecht, Netherlands hospitaliz 11 cases none *median(range, IQR) cases=29 (8−96, 29.8) *info based on 18 patients (not just the EC cases) with Gram- inf. 38 We did not apply any filter to the literature research because we wanted to be as broad as possible in including all the papers that had Escherichia coli and colistin resistance as subjects. The first search yielded numerous studies; however, after analysing them the vast majority was excluded because not relevant for our study question and none of them fulfilled our eligibility criteria. Many papers reported CoREC strains in animal samples or referred to molecular characterization of resistant bacteria. Resistance in humans was analysed in studies which included different Gram negative bacteria or all Enterobacteriaceae. When it was possible, the results of mortality due to CoREC infections were extrapolated from these studies, otherwise they were excluded as unspecific for our research purpose. The colistin resistant Escherichia coli infections are a relative new research topic, and it seems that no structured study was yet conducted to investigate the burden of these infections in terms of attributable mortality or attributable length of stay in hospital 6. Third-generation Cephalosporin resistant Escherichia coli The resistance to the 3rd generation of cephalosporin is due to the production of extended- spectrum beta-lactamase enzymes (ESBL). These enzymes can deactivate extended spectrum (3rd generation) cephalosporins (e.g., ceftazidime, cefotaxime, and ceftriaxone) and monobactams (e.g., aztreonam). The guidelines internationally accepted for the detection of ESBL-producing bacteria, including Escherichia coli, have been defined in 1999 by the US-based National Committee for Clinical Laboratory Standards (now the Clinical and Laboratory Standards Institute). For the purpose of these review, 3rd generation cephalosporin resistant Escherichia coli (3GCREC) and ESBL producing Escherichia coli (ESBL-EC) will be considered equivalent. To research the attributable case fatality and the attributable LOS to third-generation cephalosporin resistant Escherichia coli (3GCREC) we performed 2 advanced searches on Pubmed using once the mesh term “Escherichia coli” AND all fields “third generation cephalosporin”, and the second time the mesh term “Escherichia” AND all fields “ESBL OR extended-spectrum beta lactamase”. Both times a filter for human studies was applied. Embase was searched for ‘Escherichia AND third generation cephalosporin’, and ‘Escherichia coli AND (ESBL OR extended-spectrum beta-lactamase’. We applied a filter to include only human studies and to exclude abstracts that did not have a correspondent article. An advanced search on the Cochrane Library was performed using terms “Escherichia coli” AND “third generation cephalosporin”, plus a second search using “Escherichia coli” AND “ESBL OR extended-spectrum beta-lactamase”. No language restrictions were made, and filter for research in humans was applied. The flow diagram, presented in Figure 6 describes the steps in the literature review of 3rd generation cephalosporin resistant Escherichia coli infections. The results obtained using ESBL and 3rd generation cephalosporin as key words were aggregated. 39 Once identified the studies reporting relevant data, these were grouped based on the site of infection. The majority of them reported BSI infections, even though not all of them had a control group. Figure 6: Search for studies on 3rd generation cephalosporin resistant Escherichia coli. Inclusion and exclusion diagram. *These studies reported results for ESBL-Enterobacteriaceae or together for E.coli and Klebsiella pneumoniae. The following tables include studies reporting results for BSI, UTI, rectal swab and for mixed site of infection due to 3GCREC, based on the comparison group they used. All information is reported as was presented in the original papers. 40 Table 20: Short extraction table of original articles on BSI mortality of 3GCREC infected patients vs 3GCSEC infected patients and vs non infected patients Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 de Kraker 201161 07/07- 06/08 Prospective parallel matched double cohort a)C1: Mort. resist=32% Mort. control=6% OR=4.6, 95%CI(1.7–12.3) C2: Mort. sensit=17% Mort. control=7% OR=1.9; 95%CI(1.4–2.5) OR R vs S= 2.5; 95%CI(0.9–6.8) b)C1: Mort. resist=36% Mort. control=5% HR=5.7; 95%CI(2.5–13.0) C2:Mort. sensit=17% Mort. control=7% HR=2.0; 95%CI(1.5–2.5) HR R vs S=2.9; 95%CI(1.2–6.9) 13 EU countries a)30 days b) hospitaliz C1) 111 resistant 204 NI controls for resistant C2) 1110 sensitive 2084 controls for sensitive LOS before enrolment median (IQR) resist=12(6-25) sensit=10(6-17) control=6(3-16) 41 Table 21: Short extraction table of original articles on BSI mortality of 3GCREC infected patients vs 3GCSEC infected patients Nr Author Study Period Study type Outcome Location Period of outcome Matching Population LOS (days) Notes 1 Anunnatsiri 201262 2005- 2006 Retrospective case-control study Mort. cases=29% Mort. controls= 11.5% Thailand hospitaliz none 32 cases 113 controls prior BSI median (range) cases=4 (0-66) controls=0 (0-82) 2 Apisarnthan arak 200863 07/03- 12/07 Retrospective case-control study Mort. cases=8% Mort. controls= 15%* Thailand hospitaliz microorganism, site of infection, unit, date of admission 24 cases 108 controls * median (range) cases=8 (1–43) controls=6 (3–15) *controls have EC or KP 3 Cornejo- Juarez 201264 2004- 2009 Retrospective case-control study a)Mort. cases=38.6% Mort. controls= 21.6% b)Mort. cases=19.3% Mort. controls= 36.4% Mexico 60 days unit 88 cases 88 controls difficult to interpret patients with haematological malignancies a) death related to infection b) death not related to infection 4 Courpon- Claudinon 201165 2005 Prospective multi-centre study Mort. cases=30.8% Mort. controls= 12.3% France hospitaliz none 39 cases 1012 controls no data surveillance study 5 Ortega 200966 01/91- 12/07 Prospective study Mort. cases=15.6% Mort. controls= 7.6% Spain a) 7days b) 30days none 211 cases 3247 controls no data 6 Trecarichi 200967 01/00- 12/07 Retrospective cohort Mort. cases=42.3% Mort. controls= 5.6% OR=8.84; 95%CI(1.48- 52.91) Italy 30 days none 26 cases 36 controls no data patients with haematological malignancies 42 7 Hsieh 201068 01/05- 12/06 Retrospective cohort Mort. cases=21.1% Mort. controls= 12.2% Taiwan, China 30 days emergency room patients 19 cases 385 controls mean (±SD) cases=15.5(±8.5) controls=6.1(±6.9 ) patients with community onset infection 8 Tumbarello 201069 01/06- 12/06 Retrospective cohort Mort. cases=29.7% Mort. controls= 6.1% OR=4.43; 95%CI(2.46- 7.95) Italy 21 days none 37 cases 97 controls mean (±SD) cases=20(±17) controls=13(±9) 9 Gudiol 201070 01/06- 10/08 Prospective cohort a)Mort. cases=12% Mort. controls= 8% b)Mort. cases=35% Mort. controls= 19% Spain a) 7days b) 30days underlying condition 17 cases 118 controls no data patients with cancer/stem cell transplant 10 Ho 200271 01/97- 12/98 Retrospective case-control study Mort. cases=18% Mort. controls= 7% China 30 days specialty, sex, age(±10), date of isolation 50 cases 100 controls no data 11 Rodriguez- Bano 201072 10/04- 01/06 Prospective cohort Mort. cases=17% Mort. controls= 8% Spain 14 days hosp, time period 95 cases 188 controls no data patients with community onset infection 12 Kang 201073 09/08- 04/09 Retrospective cohort Mort. cases=15% Mort. controls= 7.6% OR=2.99; 95%CI(1.01– 8.84) Republic of Korea 30 days none 82 case 783 controls no data 13 Garcia- Hernandez74 01/06- 07/07 Retrospective and prospective cohort study a)Mort. cases=35.5%
 Mort. controls= 16.8% b)Mort. cases=26.5%
 Mort. controls= 9.2% Spain a)within 7 days b)within 30 days none 34 cases 119 controls mean (±SD) cases=24.3(±22) controls=20.9(±2 6.7) 14 Denis 201575 01/05- 12/09 Retrospective study Mort. cases=30% Mort. controls= 27% OR=1.23; 95%CI(0.36– 4.23) France 30 days date of isolation 41 cases 41 controls median (range) cases=15 (10-21) controls=11 (7- 17) 43 15 Ha 201376 01/10- 05/12 Retrospective cohort study Mort. cases=22.1% Mort. controls= 12.2% OR = 3.01; 95%CI(1.45– 6.28) Republic of Korea 30 days underlying condition 95 cases 255 controls no data all patients had cancer 16 Kaya 201377 01/07- 10/11 Retrospective case-control study Mort. cases=36.4% Mort. controls= 27.5% Turkey hospitaliz none 44 cases 69 controls no data 17 Kim 201378 01/07- 12/08 Retrospective study Mort. cases=6.7% Mort. controls= 5.5% South Korea 30 days underlying condition 15 cases 72 controls no data neutropenic patients 18 Lambert 201150 01/05- 12/08 Retrospective cohort study a)Mort. cases=50% Mort. controls= 40% aHR=1.3; 95%CI(0.8– 2.2) b)Mort. cases=47% Mort. controls= 29% aHR=1.4; 95%CI (0.9– 2.3) Eu countries hospitaliz ICU 42 cases 217 controls *median (IQR) cases=18(11-29) controls=17(9-29) a)BSI b)pneumonia patients admitted to ICU *from infection to discharge 19 Leistner 2014 a79 01/08- 12/10 Retrospective cohort study Mort. cases=26% Mort. controls=18% Germany hospitaliz none 115 cases 983 controls median (range) cases=27 (12-53) controls=15 (8- 32) 20 Leistner 2014 b80 01/08- 12/11 Retrospective cohort study Mort. cases=25.3% Mort. controls=17.6% Germany hospitaliz none 178 cases 1322 controls Multiplicative effect cases=1.07 controls=0.83 21 Martelius 201681 01/99- 12/13 Retrospective study a)Mort. cases=7.7% Mort. controls= 5.9% b)Mort. cases=14.3% Mort. controls= 11.9% Finland a) 7 days b) 28 days Unit, specimen 182 cases 2035 controls no data 22 Park 201182 01/05- 12/10 Retrospective cohort study a) Mort. cases=8% Mort. controls= 6% b)Mort. cases=18% Mort. controls= 8% Republic of Korea a) 7days b) 30days community- onset infection, time period 50 cases 100 controls no data patients with community -onset infection 44 OR=6.4; 95%CI(0.3– 145.5) 23 Yip 200683 10/94- 08/03 Retrospective study Mort. cases=27.3% Mort. controls= 3.9% Hong Kong hospitaliz underlying condition 11 cases 77 controls no data patients were in continuous ambulatory peritoneal dialysis 24 Van Aken 201484 01/11- 09/12 Retrospective case-control study Mort. cases=9% Mort. controls= 7% 14 days time period, study location 70 cases 140 controls median±SD cases=11±12 controls=9±10 25 Melzer 200785 06/03- 11/05 Retrospective cohort Mort. cases=60.9% Mort. controls= 23.7% OR=3.57; 95%CI(1.48- 8.60) United Kingdom 30 days none 46 cases 308 controls median cases=9 controls=12 Table 22: Short extraction table of original articles on UTI mortality of 3GCREC infected patients vs 3GCSEC infected patients Nr Author Study Period Study type Outcome Location Period of outcome Matching Population LOS (days) Notes 1 Al-Otaibi 201386 06/09- 06/11` Retrospective case-control study Mort. cases=8.9% Mort. controls= 0.9% Saudi Arabia hospitaliz none 113 cases 226 controls no data hospitalised and outpatients 2 Ena 200687 01/99- 12/04 Retrospective cohort Mort. cases=8% Mort. controls= 8%* Spain hospitaliz temporal occurrence 61 cases 61 controls no data *author reports that death was not attributable 3 Suankratay 200888 01/04- 12/06 Prospective cohort Mort. cases=2.9% Mort. controls= 0%* Thailand b) 14days underlying condition 35 cases 71 controls* no data female patient with acute pyelonephritis *controls were EC, KP, PM 4 Esteve-Palau 201589 08/10- 07/13 Matched cohort study Mort. cases=10% Mort. controls= 7% OR=8.011; 95%CI(2.48- 25.92)* Barcelon a, Spain 30 days sex, age, date of admission 60 cases 60 controls mean (±SD) cases=11.6(±1 .5) controls=7.5(± 0.8) *Risk of failure within 7 days (R vs S) 45 5 Park 201590 01/07- 12/13 Retrospective case-control study Mort. cases=1.3% Mort. controls= 1.8% Republic of Korea 7 days time of treatment 75 cases 225 controls no data patients with community-acquired infection, and acute pyelonephritis Table 23: Short extraction table of original articles on rectal swab infections mortality of 3GCREC infected patients vs non infected patients Nr Author Study Period Study type Outcome Location Period of outcome Matching Population LOS (days) Notes 1 Arnan 201191 05/06- 12/07 Prospective multicentre cohort study a)Mort. cases=1.6% Mort. controls= 0% b)Mort. cases=10% Mort. controls= 11% Barcelona, Spain a) 7days b)hospitaliz undelying condition 63 cases 154controls mean (±SD) cases=30.15 (±13.70) controls=29. 05 (±12.11) patients with acute leukaemia undergoing haematopoietic stem cell transplantation, and who received chemotherapy and developed grade IV neutropenia Table 24 and Table 25 present the results of studies that include patients with different sites of infection. Almost all the articles specify the number of cases for the different infection sites but they do not report different mortalities based on the infection site. When it was possible, the results are presented differentiating the mortality for each site of infection. Table 24: Short extraction table of original articles on mortality of CRKP infected patients vs non infected patients for different infection sites Nr Author Study Period Study type Outcome Location Period of outcome Matching Population LOS (days) Notes 1 Nicolas- Chanoine 201292 11/08- 06/09 Prospective case-control- control study Mort. resist=12% Mort. sensit=7% Mort. control=5% France hospitaliz none 152 resist 152 sensit 152 controls no data 46 2 Hayakawa 201393 02/10- 07/11 Retrospective case-case- control study a)Mort. resist=5.7% Mort. sensit=3.5% Mort. NI=3.8% OR R vs S= 1.66; 95%CI(0.37–7.34) OR R vs NI=2.33; 95%CI(0.9–6.07) b)Mort. resist=13.7% Mort. sensit=10.2% Mort. NI=7.6% OR R vs S=1.4; 95%CI(0.52–3.75) OR R vs NI=2.36; 95%CI(1.17–4.78) USA a) hospitaliz b) 3 months none 319 resist 58 sensit 319 controls median (IQR) resist=7(4-12) sensit=7(3-20) NIl=4(2-6) Table 25: Short extraction table of original articles on mortality of 3GCREC infected patients vs 3GCREC infected patients for different infection sites Nr Author Study Period Study type Outcome Location Period of outcome Matching Population LOS (days) Notes 1 Pena 200894 01/96- 12/03 Retrospective matched cohort study a)Mort. cases=16% Mort. controls= 6% b)Mort. cases=25% Mort. controls= 11% Spain a)7 days b)30 days site of infection, date of admission 100 cases 100 controls no data 2 Kang 201195 09/10- 05/11 Retrospective case-control study Mort. cases=7.4% Mort. controls= 2% Republic of Korea 30 days none 108 cases 100 controls no data patients with community onset infection 3 Maslikowska 201696 06/10- 04/13 Retrospective case-control study a)Mort. cases=15% Mort. controls= 2% b)Mort. cases=5% Mort. controls= 2% Canada 14 days sex, age, type of inf, bed allocation 61 cases 49 controls not specific for EC a) all cause mortality b) attributable mortality: defined as chart-documented indication of infection contributing to the cause of death 47 This literature research produced a large amount of results, but not all of them fulfilled our selection criteria. Information on mortality is often published, but this was not specific for Escherichia coli: they were pooled for Enterobacteriaceae, or for Escherichia coli and Klebsiella pneumoniae together. Many studies were excluded because they did not report a comparison group. Several studies referred to genetic analyses and were not eligible for the purposes of this review. All studies were performed in healthcare settings, though some of them report cases of infection that originated in the community or that had onset in the community. 7. Carbapenem resistant Klebsiella pneumoniae To research the attributable case fatality and the attributable LOS to carbapenem resistant Klebsiella pneumoniae (CRKP) we performed an advanced search on Pubmed using mesh term “Klebsiella pneumoniae” and all fields “carbapenem resistant”. Embase was searched for “carbapenem resistant klebsiella pneumoniae”. An advanced search on the Cochrane Library was performed using terms “klebsiella pneumonia” and “carbapenem”. No language restrictions were made, and a filter for research in humans was applied. Once identified the studies reporting relevant data, these were grouped based on the site of infection. The majority of them reported mixed samples, as for example blood and urine, blood and bronco-specimens, etc. 48 Figure 7: Search for studies on carbapenem-resistant Klebsiella pneumoniae. Inclusion and exclusion diagram. From the 13 studies focusing on BSI, 10 were eligible for our purposes. 3 studies were discarded because the comparison was different from those in our inclusion criteria. The same was applied to the studies with mixed site of infection. In the results were also included 3 systematic review of the literature studies97-99 of which; • 1 reported a meta-analysis of data97 • 2 reported results for bacteraemia97,98, • 1 does not specify the infection site99 All 3 reviews considered CSKP infected patients as a comparison group. Those considering bacteraemia were included in the results for BSI in the R vs S group. References included in the systematic reviews were examined in order to include primary studies if they were missed by our initial search. The published results of 2 systematic reviews are also reported in the tables below. 49 The following tables include studies reporting results for BSI and UTI from CRKP, based on the comparison group they used. All information is reported as was presented in the original papers. Table 26: Short extraction table of original articles on BSI mortality of CRKP infected patients vs non infected patients ∗ Hospitalization period, LOS, Charlson comorbidity index, McCabe score, underlying disease, age and sex ∗∗ same month/year of occurrence and same medical unit Table 27: Short extraction table of original articles on BSI mortality of CRKP infected patients vs CSKP infected patients Nr Author Study Period Study type Outcome Location Period of outcome Population LOS (days) Notes 1 Falagas 201497 until 04/12 Review Meta-analysis Attribut. mort.= 26-44% in 7 studies Attribut. mort. = (-3)-(-4)% in 2 studies RR=2.05; 95%CI(1.56– 2.69)* World different based on the study 985 patients no data * referred to all 9 studies ** only 6 BSI studies *** remaining 3 (not BSI/mixed site of infection) studies Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Borer 2009100 10/05- 10/08 Matched retrospective study Mort. cases=71.9% Mort. controls=21.9% RR=3.3; 95%CI(2.9-28.5) Beer- Sheva Israel hospitaliz 32 cases 32 controls ∗ median: cases=21 contr=18 2 Gallagher 2014101 06/05- 10/10 Case-case- control study Mort. cases= 45% Mort. contr= 18% OR=3.8; 95%CI(1.4-9.9) Philadelp hia USA hospitaliz 43 cases 154 controls ∗∗ controls are hospitalized for >= 72h mean: cases=54 contr=19.5 -controls are patients hospitalized for >= 72h 3 Mouloudi 2014102 01/08- 12/11 Observational matched cohort study Mort. cases=82.7% Mort. contr=32% Thessalo niki Greece hospitaliz 17 cases 34 controls Liver transplant median (range): cases=28(10-64) in ICU -patients are liver transplant recipients -controls had also live transplant but no KP infection 50 RR 2.19; 95%CI(1.82– 2.63)** 2RR=1.46; 95%CI(0.47– 43.49)*** 2 Mouloudi 2010103 01/07- 12/08 Nested case- control study a) Mort.cases= 56.8%
 Mort. contr= 41% b) Mort. cases= 67.6%
 Mort. contr= 41% Mort. cases= 27%
 Mort. contr= 14% Thessaloniki Greece a) mortality in ICU b) mortality in hospital c) attributable mortality* 37 cases 22 controls median(range): total=26 (8-90) in ICU *within 24h from infection or with infection symptoms despite appropriate therapy 3 Simkins 2014104 06-10 Case-control study Mort. cases= 46% Mort. contr= 0% New York, USA 6.5 months 13 cases 39 controls no data -patients are kidney transplant recipients 4 Viale et 201398 1977- 2012 Review Crude mortality rates =20- 70% Attribut. mort. patients: -hematologic=75% -ICU=11% -transplant=7% -LTC=5% -medicine=2% -surgery=2% Italy median time in developing CRKP infections in hospital (range): cases=14(0- 152) -it is a review not a meta- analysis -good source of references. 5 Hussein 2013105 01/06- 12/08 Retrospective case-control study Mort.cases= 43.7% Mort.contr= 29% Haifa, Israel 30 days 103 cases 214 controls median (range): cases=17(1-125) controls=12(1-202) 6 Ben- David 2012106 01/06- 12/06 Retrospective cohort study a)Mort. cases=69% Mort. controls=24% b)Mort. cases=48% Mort. controls=17% Sheba, Israel a)hospitaliz b)infection- related mortality 42 cases 85 controls mean LOS before infection detection ±SD: survivors=25±81 deceased=27±37 7 Daikos. 2009107 02/04- 03/06 Prospective observational study Mort.cases= 42.8% Mort.contr= 16.9% OR=3.95; 95%CI(0.94–16.6) Athens, Greece 14 days 14 cases 148 controls mean LOS before bacteraemia ±SD: both groups=25.85 ± 37.87 -all patients were infected with VIM-1-producing KP 51 Table 28: Short extraction table of original articles on UTI mortality of CRKP infected patients vs CSKP infected patients Nr Author Study Period Study type Outcome Location Period of outcome Population Matching LOS (days) Notes 1 Brizendine 2015108 2006- 2012 Retrospective cohort study Mort. cases=18% Mort. contr.=2% Cleveland, USA hospitaliz 22 cases 64 controls Patients had solid organ transpalantation median: cases=7 contr=1 4/22 cases died 1/64 controls died -controls are susceptible 2 Pouch 2015109 01/07- 12/10 Case-control study Mort. cases=30% Mort. contr.=10% HR=3.0; 95%CI(1.0–9.0) New York, USA not defined 20 cases 252 controls patients had kidney transplantation median(IQR): cases=17(9-43) controls=7(5-10) -patients are kidney transplant recipients 3 Shilo 2013110 01/06- 04/09 Case-control study Mort. cases=29% Mort. contr.=25% Jerusalem, Isreael hospitaliz 135 cases 127 controls mean±SD cases=28±33 controls=22±28 -controls are CSKP producing ESBL In the study of Brizendine et al.108, 7 case patients (32%) and 8 control patients (13%) had also bacteraemia of CRKP. Pouch et al.109 reported in their study that 15% of cases and 3% of controls developed bacteraemia within 14 day of bacteriuria onset, while the study of Shilo et al.110, 3 patients (4%) in both groups had also bacteraemia. These cases were not excluded from the results displayed in table 28. In Pouch et al. 2 deaths in the cases group followed CRKP sepsis, while none of the deaths in the control group was related to CSKP sepsis. Table 29 and Table 30 present the results of studies that include patients with different sites of infection. Almost all the articles specify the number of cases for the different infection sites but they do not report different mortalities based on the infection site. When it was possible the results are presented differentiating the mortality for each site of infection. Table 29: Short extraction table of original articles on mortality of CRKP infected patients vs non infected patients for different infection sites Nr Study Study Period Study type Outcome Location Period of outcome Population Matching LOS (days) Notes 52 1 Giannella 2014111 06/11- 06/13 Matched case-control study a)Mort cases=0% Mort. contr.=5% b)Mort. cases=0% Mort. contr.=15% Bologna, Italy a)30 days b)60 days 10 cases 20 controls liver transplant median (range): cases=16(14-27) controls=20(15- 62) -all patients had liver transplant 2 Luebbert 2014112 09/10- 09/11 Case-control study Mort. cases=78% Mort. contr.=11% Leipzig, Germany 3 months after last case 9 cases 18 controls liver transplant cases=60 controls=32 -patients are liver transplant recipients -controls had also live transplant but not KP infection 3 Nouvenne 2014113 08/11- 05/12 Cross- sectional study Mort. cases =21.8% (Mort. Infected=47.5% Mort. Colonized=10.7%) Mort.contr. =15% Parma, Italy hospitaliz 133 cases (93 colonized, 40infected) 400 controls mean±SD cases=35±24 controls=18±12 4 Bleumin 2012114 01/06- 06/09 Nested case- control study Mort. cases= 88% Mort. contr.= 52% aHR=5.9; 95%CI(3.2-11.0) Jerusalem, Isreael study period 43 cases 150 controls -patients had hemodialysis for at least 14 days no data -patients had hemodialysis for at least 14 days 5 Debby 2012115 05/07- 04/ 08 Prospective cohort study Mort. cases=45.8% Mort. contr.=38.6% Tel Hashomer, Israel hospitaliz 48 cases 132 controls mean±SD cases=6.06±1.2 3 controls=8.39 ±1.49 -the cases acquired the infection in the hospital 6 Schwaber 2008116 2003- 2006 Case-case- control study Mort. rate cases=44% Mort. rate controls=2% OR=6.7; 95%CI(2.4–18.8) Tel-Aviv, Israel hospitaliz 48 CRKP 59 controls median (IQR): cases=19 (9-38) controls=2 (1-4) 7 Pereira 2015117 01/10- 01/13 Retrospectiv e cohort study Mort. rate cases=45% Mort. rate contr.=7% R vs NI: HR=6.92; 95%CI(3.24–14.79) New York, USA 1 year from transplant 20 CRKP 248 controls -patients had liver transplant Median (range): cases=40(23-82) controls=12 (9- 21) -patients are liver transplant recipients 8 Kofteridis 2014118 01/09- 12/11 Case-case- control study Mort. rate cases=27% Mort. rate contr=4% Heraklion, Greece not defined 83 cases 161 controls no data none 53 Table 30: Short extraction table of original articles on mortality of CRKP infected patients vs CSKP infected patients for different infection sites Nr Study Study Period Study type Outcome Location Period of outcome Population LOS (days) Matching Notes 1 Candevir Ulu 2015119 01/12- 12/12 Retrospective cohort study Mortality cases=44,7% Mortality contr.=51% Adana, Turkey hospitaliz 47 cases 51 controls mean: cases=37.3 contr.=29.94 median: cases=19 contr.=11 none 2 Dizbay 2014120 2004- 2010 Retrospective study Mortality cases=57.1% Mortality contr.=27.4% Turkey not defined 42 cases 798 controls mean cases=38.27 contr.=28.17 none -cases had nosocomial infections - K spp 3 Hoxha 2016121 12/12- 07/13 Matched cohort study a)Attribut. mort.= 16% b)Attribut. mort.= 41% mIRR=3.0; 95%CI(1.3- 7.1) Italy a)6 days b)30 days 49 cases 49 controls no data Age, infection site hospital 4 Jiao 2015122 01/10- 12/11 Retrospective case-control study Mort. cases=33.6% Mort. contr.=16.6% Shangai, China hospitaliz 30 cases 30 controls mean: cases=33.8 controls=18 none 5 Kofteridis 2014118 01/09- 12/11 Case-case- control study Mort. rate cases=27% Mort. Rate contr.=15% Heraklion, Greece not defined 83 cases 79 controls no data none 6 Patel 2008123 07/04- 06/06 Matched case- case study Mort. cases=48% Mort. contr.=26% OR=4.69; 95%CI(1.9– 11.58 New York, USA hospitaliz 99 cases 99 controls mean±SD cases=25.19±24.9 controls=6.44±10. 1 median: cases=21 controls=1 Inf. site 7 Correa 2013124 01/06- 08/08 Matched case- control study Mort. cases=50% Mort. contr.=27.5% Sao Paulo, Brazil hospitaliz 20 cases 40 controls mean: cases=45.5 controls=27 Inf. date, inf. site, unit where acquired 54 8 CDC Atalanta 2011125 04/09- 02/11 Matched case- case study Mortality cases=5% Mortality controls=8% West Virginia, USA hospitaliz 19 cases 38 controls mean: cases=11.4 controls=7.4 Age, data of sample collection -cases likely arrived at the hospital with the infection 9 Schwaber 2008116 2003- 2006 Case-case- control study Mort. rate cases=44% Mort. rate contr.=12.5% OR=5.4; 95%CI(1.7– 17.1) Tel-Aviv, Israel hospitaliz 48 CRKP 56 controls median (IQR): cases=19(9-38) controls= 1 (1-8) none 10 Falagas 2007126 10/00- 04/06 * 10/03- 04/06 ** Matched case- control study Mortality cases=30.1% Mortality controls=33.9% Athens and Crete, Greece hospitaliz 53 cases 53 controls mean±SD cases=21.4±23.9 contr.=15.3±19.9 Age, LOS, inf. site, year of admission *Athens **Crete 11 Pereira 2015117 01/10- 01/13 Retrospective cohort study Mort. rate cases=45% Mort. rate contr.=28% New York, USA 1 year from transplant 20 CRKP 36 controls Median (range) CRKP=40(23-82) CSKP=12 (9-21) none -patients are liver transplant recipients 12 Hauck 2016127 12/11- 09/14 Prospective multicenter observational study Mort.rate BSI=38% aHR=2.59; 95%CI(1.52– 4.50) Mort.rate Pneu=34% aHR=3.44; 95%CI(1.80– 6.48) Mort.rate UTI=7% aHR=0.68; 95%CI(0.30– 1.45) Mort.rate contr.=9% San Diego, USA hospitaliza tion 260 cases: (90 BSI, 49 pneumonia, 121 UTI) 223 controls* median (IQR) BSI=14 (9-24) Pneu=19 (10-30) UTI=10 (6-17) contr=9 (5-16) none *R vs CRKP urinary colonization * controls had CRKP urinary colonization 55 All studies were performed in healthcare settings, though some of them report cases of infection that might have been originated in other settings. Comparing our review with the systemic review of the literature published by the World Health Organisation (WHO) in 2014128, we detected more recent publications (2014-2016). The WHO report includes studies comparing with CSKP, while we also included NI as a comparator. We excluded two studies reported in the WHO review as they did not agree with our eligibility criteria. Daikos et al. 2007129 defined cases as VIM-1-producing K. pneumoniae but did not test the samples for carbapenem resistance, while Lee et al. 2012130 defined cases as non-susceptible (intermediately susceptible or resistant) to carbapenem. 8. Colistin resistant Klebsiella pneumoniae To research the attributable case fatality and the attributable LOS to colistin resistant Klebsiella pneumoniae (CoRKP) we performed 2 advanced searches on Pubmed using once the mesh term “Klebsiella pneumoniae” AND all fields “colistin resistant”, and the second time the mesh term “Klebsiella pneumoniae” AND all fields “colistin resistance”. Embase was searched for ‘Klebsiella pneumoniae’ AND ‘colistin resistance’, and for ‘Klebsiella pneumoniae’ AND ‘colistin resistant’. An advanced search on the Cochrane Library was performed using terms “Klebsiella pneumoniae” AND “colistin”. No language restrictions were made, and no filters were applied. The flow diagram, presented in Figure 8 describes the steps in the literature review of colistin resistant Klebsiella pneumoniae infections. The results obtained using the two different key words in PubMed and Embase were aggregated. 56 Figure 8: Search for studies on colistin resistant Klebsiella pneumoniae. Inclusion and exclusion diagram. The following table includes studies reporting mortality data for CoRKP. All information is reported as was presented in the original papers. 57 Table 31: Short extraction table of original articles on mortality of CoRKP infected patients vs CoSKP infected patients for mixed site of infection Nr Author Study Period Study type Outcome Location Period of outcome Population LOS (days) Matching Notes 1 Marchaim 2010131 09/08- 08/09 Case-cohort Study Mort. rate cases=40% Mort. rate controls=26% Detroit, USA hospitaliz 5 cases 60 controls Mean±SD Cases=33±23 Controls=30±23 none Outbreak patients, controls were CRKP 2 Zarkotou 2010132 04/08- 06/09 Matched Case- Control Study Mort. rate cases=69.2% Mort. Rate controls=35.9% Mort. Attributed to KPC- KP* =37.5% in both groups Piraeus, Greece hospitaliz 13 cases 39 controls Mean±SD Cases= 20.5±20.8 Controls= 16.4±12.3 Infection site *not explained how was defined 3 Capone 2013133 12/10- 05/11 Multicentre Prospective Study Mort. rate cases=40.6% Mort. rate controls=20.3% Rome, Italy hospitaliz 35 cases 62 controls Not specific none all patients were CRKP The following table reports an article identified after the review was concluded, but we report it since it fulfils our eligibility criteria. The article from Rojas et al.134, studied patients with CoRKP and CoSKP infection in different site of infection. Table 32: Short extraction table of original articles on mortality of CoRKP infected patients vs CoSKP infected patients for mixed site of infection Nr Author Study Period Study type Outcome Location Period of outcome Population LOS (days) Matching Notes 1 Rojas134 12/11- 10/14 Prospective nested cohort study Mort. rate cases=51% Mort. rate controls=39% aHR(95%CI)=3.48 (1.77- 6.57) p<0.001 USA 30 days 31 cases 215 controls Median(IQR) Cases=8(5-12) Controls=13(7-26) none All samples were resistant to carbapenems too 58 Between the non-eligible articles, many reported mortality data for CoRKP infections in a group of selected patients without a comparison group. In these studies28,135-139 the overall case fatality for the CoRKP infected patients ranged between 20 and 100%. Similar results were reported also in the review of Ah et al. in 2014140, while the infection related deaths for CoRKP infected patients in range between 25-71%. Many papers reported outbreak studies or characterization of the CoRKP baceria, and few of them included data on mortality. We excluded the majority of studies reporting mortality data because they did not report a comparison group. The colistin resistant Klebsiella pneumoniae infections are a relative new research topic, and there is a lot of interest on studying them. Many studies on the risk factor and the mortality rate of the infections are published, but few of them try to estimate the attributable mortality or the attributable length of stay of this resistance. 9. Third-generation Cephalosporin resistant Klebsiella pneumoniae The resistance to the 3rd generation of cephalosporin is due to the production from the bacteria of extended-spectrum beta-lactamase enzymes (ESBL). These enzymes can deactivate extended spectrum (3rd generation) cephalosporins (e.g., ceftazidime, cefotaxime, and ceftriaxone) and monobactams (e.g., aztreonam). The guidelines internationally accepted for the detection of ESBL-producing bacteria, including K. pneumoniae, have been defined in 1999 by the US-based National Committee for Clinical Laboratory Standards (now the Clinical and Laboratory Standards Institute). For the purpose of this review, 3rd generation cephalosporin resistant Klebsiella pneumoniae (3GCRKP) and ESBL producing Klebsiella pneumoniae (ESBL-KP) will be used to define the same phenomenon. To research the attributable case fatality and the attributable LOS to third-generation cephalosporin resistant Klebsiella pneumoniae (3GCRKP) we performed 2 advanced searches on Pubmed using once the mesh term “Klebsiella pneumoniae” AND all fields “third generation cephalosporin”, and the second time the mesh term “Klebsiella pneumoniae” AND all fields “ESBL OR extende-spectrum beta lactamase”. Embase was searched for ‘klebsiella pneumoniae AND third generation cephalosporin’, and ‘Klebsiella pneumoniae AND (ESBL OR extended-spectrum beta-lactamase’). An advanced search on the Cochrane Library was performed using terms “klebsiella pneumonia” AND “third generation cephalosporin”, plus a second search using “klebsiella pneumoniae” AND “ESBL OR extended-spectrum beta-lactamase”. No language restrictions were made, and a filter for research in humans was applied. The flow diagram, presented in Figure 9 describes the steps in the literature review of 3rd generation cephalorporin resistant Klebsiella pneumoniae infections. The results obtained using ESBL and 3rd generation cephalosporin as key words were aggregated. Though we did not apply any language filter, 2 studies were excluded from the final results since they were in Chinese language. 59 Once identified the studies reporting relevant data, these were grouped based on the site of infection. The majority of them reported BSI infections, even though not all of them had a control group. Figure 9: Search for studies on 3rd generation cephalosporin resistant Klebsiella pneumoniae. Inclusion and exclusion diagram. *These studies reported results for ESBL-Enterobacteriaceae or together for K. pneumoniae and Escherichia coli From the 18 studies focusing on BSI, 13 were eligible for our purposes. 5 studies were discarded because the comparison was different from those in our inclusion criteria. The same was applied to the studies for respiratory tract and with mixed site of infection. 60 We also identified a systematic review of the literature on the crude mortality of ESBL-KP infections (Viale et al98), which did not consider a comparison group. The crude mortality rate for a BSI infections of ESBL-KP in this review ranged between 14.1% and 43.3%. The following tables include studies reporting results for BSI, UTI and respiratory tract from 3GCRKP, based on the comparison group they used. All information is reported as was presented in the original papers 61 Table 33: Short extraction table of original articles on BSI mortality of 3GCRKP infected patients vs non infected patients Table 34: Short extraction table of original articles on BSI mortality of 3GCRKP infected patients vs 3GCSKP infected patients Nr Author Study Period Study type Outcome Location Period of outcome Population LOS (days) Notes 1 Lee 201453 01/03- 12/09 Retrospective case-control study a)Mort. rate cases=33.3% Mort. rate controls=24.2% b)Mort. rate cases=33.3% Mort. rate controls=16.3% Daegu, Korea a)30 day mortality b)BSI- related mortality 9 cases 153 controls not reported community acquired infection, study included also EC results 2 Panhotra 2004142 07/01- 07/03 Retrospective case-control study Mort. rate cases=60% Mort. controls=6.2% Saudi Arabia hospitaliz 10 cases 16 controls cases=44.2 controls-24.1 hospital acquired infection 3 Tumbarello 2006143 01/99- 12/03 Case-case- control study a) Mort. rate cases= 25% Mort. rate controls=11% b) Mort. rate cases=52% Mort. rate controls=29% Italy a) 7 days b) 21 days 48 cases 99 controls mean ± SD cases=34±20 controls=31±17 4 Marra 2006144 01/96- 05/01 Retrospective cohort study Mort. rate cases=32% Mort. rate controls=15% Brazil 15 days 56 cases 52 controls 5 Kang 2004145 01/98- 12/02 Retrospective cohort study Mort. rate cases=60% Mort. rate controls=30% South- Korea 30 days 10 cases 20 controls patients had spontaneous bacterial peritonitis with advanced liver cirrhosis Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Gallagher 2014141 06/05- 10/10 Case-case- control study Mort. rate cases=32% Mort. rate contr.=13% OR=3.6; 95%CI(1.2 to 10.5) Pennsylva nia, USA hospitaliz 111 cases 111 controls Month and medical unit, min 72h hospitaliz mean cases=63 controls= 20 62 6 Kim BN 2002146 07/96- 06/00 Retrospective cohort study Mort. rate cases=23% Mort. rate controls=20% South- Korea hospitaliz 44 cases 118 controls Mean cases=39.6 controls=23.9 7 Ariffin 2000147 01/96- 12/97 Retrospective cohort study Mort. rate cases=50% Mort. rate controls=13% OR=6.5; 95%CI(1.1-38.6) Malaysia Hospitaliz 16 cases 15 controls -patients are children with febrile neutropia 8 Mosqueda- Gomez 2008148 01/93- 12/02 Retrospective case-control study Mort. rate cases=35% Mort. rate controls=26.9% Mexico Hospitaliz 17 cases 104 controls mean cases=20.9 controls=15.9 9 Szilagyi 2009149 01/05- 12/08 Retrospective cohort study a)Mort. rate cases=36% Mort. rate controls=23% OR=2.5; 95%CI(1.0–5.4) b)Mort. rate cases=18% Mort. rate controls=18% OR=5; 95%CI(1.5–16.2) Hungary Hospitaliz 100 cases 100 controls median cases=10.5 controls=10 a) all cause mort. b)inf. related mort. 10 Pena 2001150 05/93- 06/95 Prospective cohort study a)Mort. rate cases=32% Mort. rate controls=24% b)Mort. rate cases=16% Mort. rate controls=14% Barcelona, Spain Hospitaliz 49 cases 43 controls -hospital acquires infection a)overall mortality b)attributable mortality 11 Paterson 2004151 01/96- 12/97 International prospective study Mort. rate cases=27% Mort. rate controls=23% South Africa, Taiwan, Australia, Argentina, the United States, Belgium, and Turkey 14 days 78 cases 175 controls 12 Tuon 2010152 01/06- 01/09 Cohort study Mort. rate cases=49.2% Mort. rate controls=41.9% Brazil 30 days 63 cases 41 controls Mean ± SD cases= 52.2 ± 39.6 controls=36.0 ±29.4 patients are older than 12 13 Lee 2011153 01/02- 09/09 Case-control study Mort. rate cases=12.1% Mort. rate controls=16% South Korea 30 days 33 cases 219 controls Mean ± SD cases=26.5 ± 39.0 controls=19.9 ± 42.4 the infection had community onset 63 Table 35: Short extraction table of original articles on UTI mortality of 3GCRKP infected patients vs 3GCSKP infected patients Nr Author Study Period Study type Outcome Location Period of outcome Population Matching LOS (days) Notes 1 Brizendine 2015154 2006- 2012 Retrospective cohort study Mort. cases=18% Mort. contr.=2% Cleveland, USA hospitaliz 22 cases 64 controls Patients had solid organ transplantation Prior to UTI Median (IQR) cases=8(1-14) controls=1(1-4) patients had solid organ transplant Brizendine et al.108 (Table 35) reports that 4 cases (18%) and 8 controls (13%) had also bacteraemia of ESBL-KP, but these cases were not excluded from the results displayed in table 35. Table 36: Short extraction table of original articles on respiratory tract infections mortality of 3GCRKP infected patients vs 3GCSKP infected patients Nr Study Study Period Study type Outcome Location Period of outcome Population Matching LOS (days) Notes 1 Loh 2006155 01/04- 12/04 Retrospective cohort study Mort. rate cases=21.3% Mort. rate controls=12.4% Malaysia hospitaliz 47 cases 394 controls None Median (IQR) cases=14(8-32) controls=5(3-10) -community and hospital acquired infections Table 37 presents the results of studies that include patients with different sites of infection. Almost all the articles specify the number of cases for the different infection sites but they do not report different mortalities based on the infection site. When possible, results are presented differentiating the mortality for each site of infection. Table 37: Short extraction table of original articles on mortality of 3GCRKP infected patients vs 3GCSKP infected patients for different infection sites 64 Nr Study Study Period Study type Outcome Location Period of outcome Population LOS (days) Matching Notes 1 Gomes 2006156 01/98- 12/98 Retrospective cohort study Mort. rate cases=20.6% Mort. rate controls=21.3% Brazil 21 days 68 cases 75 controls no data none 2 Lin 2003157 05/01- 09/01 Case-control study Mort. rate cases=27.9% Mort. rate controls=20.9% Taiwan hospitaliz 43 cases 86 controls mean(range) cases=45 (0-143) controls=18 0-82) type of speciment, date of isolation 3 Kuo 2007158 01/00- 10/05 Case-control study Mort. rate cases=15% Mort. rate controls=13% Taiwan 30 days 54 cases 54 controls Mean ± SD cases=34.4 ± 5.2 controls=14.3± 2.3 type of speciment, date of isolation 4 Chiu 2005159 01/01- 12/01 Case-control study Mort. rate cases=20% Mort. rate controls=12.5% Taiwan hospitaliz 15 cases 16 controls Not reported none patients are in NICU 5 Huang 2007160 01/00- 12/02 Prospective cohort study Mort. rate cases=10.5% Mort. rate controls=0% China 30 days 19 cases 12 controls Not reported none 6 BARTF* 200224 1999 Survey Mort. rate cases=44% Mort. rate controls=33% Brooklyn, USA hospitaliz 9 cases 9 controls median: cases=20 controls=33.5 Site of infection * Brooklyn Antibiotic Resistance Task Force The following table reports a study which considers the mortality of BSI infections caused by third-generation cephalosporine resistant (3GCRE) and susceptible (3GCSE) Enterobacteriaceae . The bacteria included were Escherichia coli, Klebsiella spp. and Proteus spp. But the results are not separated for each strain. Even though the study is not fully eligible for our purposes we decided to include it in this report because of its methodological value. Table 38: Short extraction table of original articles on BSI mortality of 3GCRE infected patients vs 3GCSE infected patients vs non-infected (NI) 65 Nr Study Study Period Study type Outcome Location Period of outcome Population LOS (days) Matching Notes 1 Stewardson 2016161 01/10- 12/11 Multicentre retrospective cohort study Mort. rate cases=16.1% Mort. rate controls=10.1% Mort. rate NI=1.7% HR=1.39/1.43/1.63* Europe hospitaliz 360 cases 2100 controls 604797 NI no specific data, see full-text for modelling values* none * the study models the excess in LOS and mortality between groups proposing 3 models for each 66 The terms ESBL and extended-spectrum beta-lactamase are widely used in the literature. Our very broad searching strategy produced 580 unique studies but not all the studies were eligible for our study question. Many of the detected studies were abstracts proposed in congresses and never finalised with a peer reviewed paper. These were not included in the results. All studies were performed in healthcare settings, though some of them report cases of infection that originated in the community. 10. Methicillin resistant Staphylococcus aureus Information on the attributable case fatality and the attributable LOS to meticillin resistant Staphylococcus aureus (MRSA), was initially retrieved from the WHO Antimicrobial Resistance Global report on surveillance162. We identified the 140 articles included in their literature review, accessed the full text of these papers and extracted the useful data for our study. The WHO report identifies 46 studies that report the bacterium attributable mortality. The criteria used to classify the deaths due to the infection may vary from study to study, but all the 46 studies considered them as attributable. Some of the studies reported also the all- cause mortality rates for the cases and controls. The 46 studies are actually 45 unique articles, since one article, Kuint et al. 2007163, is reported twice, considering once MRSA cases (which was considered in our review) and the second time multi-drug resistant MRSA. We classified the 45 studies based on the site, Figure 10.1 shows their distributions. All the studies included a case group of MRSA infected patients and a comparison group of methicillin susceptible Staphylococcus aureus (MSSA). Figure 10.1. Classification of 46 studies that analyse the attributable mortality to MRSA, reported in the WHO Antimicrobial resistance report 2014162, based on the site of infection 67 The WHO report considers that the data of these studies were sufficiently similar and of sufficient quality to include them in meta-analyses. The conclusion of this meta-analysis was the following; "There was a significant increase in bacterium-attributable mortality for patients with MRSA infections (RR 1.64, 95% CI: 1.43 to 1.87, P < 0.00001).”162 The absolute effect of MRSA compared to MSSA is 108 more deaths per 1,000 cases (from 73 to 147). The following tables report the results of the 46 papers based on the site of infection. 68 Table 39: Short extraction table of original articles on BSI mortality of MRSA infected patients vs MSSA infected patients Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Guilarde 2006164 01/00- 12/01 Retrospectiv e cohort study Mort. rate cases=23.5% Mort. rate controls=21.6% Brazil 30 days 61 cases 50 controls none 2 Castillo 2012165 01/05- 12/08 Multicentre cohort study Mort. rate cases=57% Mort. rate controls=46.2% Attribut. mort. cases=71.7% Attribut. mort. controls=57% Colombia 30 days 186 cases 186 controls hospital, year median(IQR) (before BSI) cases=12(2-15) controls=5(1-9) 3 Lawes 2012166 01/06- 12/10 Retrospectiv e cohort study a)Mort. rate cases=20% Mort. rate controls=17% b)Mort. rate cases=25% Mort. rate controls=21% Scotland a)30 days b)hospitaliz 659 cases 208 controls none 4 Blot 2002167 01/92- 12/98 Retrospectiv e cohort study a)Mort. rate cases=43% Mort. rate controls=16% b)Mort. rate cases=53% Mort. rate controls=18% c)Mort. rate cases=64% Mort. rate controls=24% Belgium a)15days b)30 days c)hospitaliz 47 cases 38 controls APACHE II score, diagnostic category (in ICU) mean±SD cases=37±28.7 controls=18±16.2 median (IQR) cases=28(12-54) controls=14(3-24) 5 Talon 2002168 97-98 Prospective cohort study Mort. rate cases=43.3% Mort. rate controls=20.3% France hospitaliz 30 cases 69 controls none no data 6 Soriano 2000169 01/91- 12/98 Cohort study Mort. rate cases=22% Mort. rate controls=9% Spain hospitaliz 225 cases 683 controls pre-existing comorbidities , underlying disease, LOS, and age mean cases=18 controls=8 Patients with nosocomial SA bacteraemia 7 Selvey 2000170 92-97 Retrospectiv e cohort study Attribut. mort. rate cases=13.8 Attribut. mort. rate controls=8.2% Australia hospitaliz 188 cases 316 controls none (prior BSI) median cases=16 controls=6 Inpatients with nosocomial SA bacteraemia 8 Rubio- Terres 2009171 01/05- 12/05 Retrospectiv e multi a)Mort. rate cases=61.7% Mort.rate controls=56.2% b)Mort. rate cases=29.8% Spain hospitaliz 121 cases 245 controls none mean (95%CI) cases=24.88 (19.9–29.9) SA bacteraemia patients a) related to 69 centre cohort study Mort. rate controls=34.4% c)Mort. rate cases=8.5% Mort. rate controls=9.4% controls=22.66 (18.8–26.5) infection; b)underlying conditions; c)other causes 9 Romero- Vivas 1995172 01/90- 09/93 Prospective cohort study Mort. rate cases=58.3% Mort. rate controls=32% Spain hospitaliz 84 cases 100 controls none mean cases=32 controls=14 N SA bacteraemia patients 10 Reshad 1994173 01/83- 12/91 Cohort study Mort. rate cases=73.9% Mort. rate controls=47.9% Japan no data* 46 cases 48 controls no data* no data* Patients with SA septicaemia * not possible to extract the data because the full- text is in Japanese 11 Quilty 2009174 07/04- 06/07 Retrospectiv e audit Mort. rate cases=60% Mort. rate controls=40% Australia no data 5 cases 5 controls Underlying disease no data Chemotherapy- induced febrile neutropenia patients with SA sepsis 12 Hakim 2007175 01/00- 12/04 Retrospectiv e cohort study Mort. rate cases=12% Mort. rate controls=0% New York, USA hospitaliz 14 cases 22 controls none no data Bacteraemia in children 13 Nickerson 2006176 06/03- 12/04 Retrospectiv e cohort study Mort. rate cases=69% Mort. rate controls=44% *Attribut. mort.=48% Thailand hospitaliz 36 cases none no data *it is not defined how it calculated 14 Kim 2003177 01/98- 11/01 Retrospectiv e cohort study Mort.rate cases=40% Mort.rate controls=33.3% Seul, Korea hospitaliz 127 cases 111 controls none (before inf.) mean±SD cases=33.9±34.6 controls=17.7±34. 3 15 Melzer 2003178 01/95- 12/00 Cohort study a)Mort. rate cases=11.8% Mort. rate controls=5.1% b)Mort. rate cases=17.8% Mort. rate controls=8.5% England, UK hospitaliz 433 cases 382 controls none no data nosocomial BSI, a)mort. due to inf. b)mort. due to other causes 70 16 Kuint 2007163 01/93- 12/03 Retrospectiv e cohort study a)Mort.rate cases=9% Mort.rate controls=8% b)Mort. rate cases=27% Mort. rate controls=25% Tel Aviv, Israel hospitaliz 11 cases 12 controls none no data patients in neonatal ICU a)sepsis related mort. b)all cause mort. 17 Khatib 2006179 01/02- 12/02 Prospective observationa l study Attribut. mort=12.2%* Detroit, USA hospitaliz 174 cases 168 controls none no data *Attributable mortality was defined as death with positive blood culture or persistent sepsis 18 Lodise 2005180 01/99- 01/01 Retrospectiv e cohort study Mort. rate cases=30.6% Mort. rate controls=15.3% Michigan, USA 30 days 170 cases 183 controls none mean cases=20.1 controls=13.7 19 Nickerson 2009181 11/06- 11/07 Prospective observationa l study Mort. rate cases=68% Mort. rate controls=46% Thailand 12 weeks 27 cases 71 controls none no data 20 Harbarth 1998182 01/89- 12/95 Case-control study a)Mort. rate cases=18% Mort. rate controls=24% b)For both groups=34% Geneva, Switzerlan d hospitaliz 38 cases 38 controls age, LOS, nr. comorbidities , McCabe score, Jackson score (after BSI) median (range) cases=30(1-141) controls=23(1- 178) a) mort. caused by infection b)all cause mort. 21 Cunney 1994183 12/91- 05/93 Retrospectiv e cohort study Mort. rate cases=22% Mort. rate controls=3% Dublin, Ireland hospitaliz 18 cases 60 controls none no data hospital acquired inf. 22 Das 2006184 11/01- 12/02 Prospective cohort study a)Mort. rate cases=33% Mort. rate controls=16% b)Mort. rate cases=56% Mort. rate controls=39% Birmingha m, UK 3 months 84 cases 56 controls none (before BSI) median cases=14 controls=8 a)attribut. mort b)all cause mort. 23 Austin 2003185 01/94- 01/99 Matched case-control study a)Mort. rate cases=36% Mort. rate controls=20% b)Mort. rate cases=50% Mort. rate controls=69% Ontario, Canada hospitaliz 50 cases 50 controls sex, age, primary diagnoses mean cases=44.1 controls=33.9 Inpatient bacteraemia a)attribut. mort b)all cause mort. 24 Conterno 1999186 01/91- 09/92 Nested case- control study *Mort. rate cases=10-90% Mort. rate controls=4-76% Brazil 14 days 90 cases 46 controls none no data *the mortality is estimated with predictive models 71 25 Hill 2008187 06/00- 12/06 Cohort study Mort. rate cases=56% Mort. rate controls=30% a)Mort. rate cases=25% Mort. rate controls=67% b)Mort. rate cases=86% Mort. rate controls=100% Belgium 6 months 16 cases 56 controls Underlying disease no data Infective endocarditis a)CA inf. b)antimicrobial therapy due to a contraindication to surgery 26 Ganga 2009188 11/05- 12/06 Prospective observationa l study a)Mort. rate cases=23.9% Mort. rate controls=8.9% b)Mort. rate cases=7.4% Mort. rate controls=2.2% Michigan, USA hospitaliz 163 cases 90 controls none inpatients with SA bacteraemia a) all cause mort. b) attributable mort. 27 Burke 2009189 2001- 2006 Retrospctive study Mort. rate cases=10% Mort. rate controls=4% California, USA hospitaliz 29 cases 121 controls age mean cases=36 controls=16.3 median(IQR) cases=38(16-73) controls=16(7-42) all patients were children 28 de Oliveira 2002190 90- 91/95- 96 Nested case- control study Mort. rate cases=45.9% Mort. rate controls=20.7% Brazil 14 days 159 cases 92 controls none no data patients with <14 years 29 Lesens 2003191 05/01- 05/02 Prospective cohort study Mort. rate cases=34% Mort. rate controls=20.4% France hospitaliz 53 cases 113 controls none no data 30 O'kane 1998192 01/93- 12/93 Retrospectiv e study Mort. rate cases=9% * Mort. rate controls=6%* Australia hospitaliz 32 cases 73 controls none post infection mean cases=24 controls=19 *directly attributable mortality 31 De Kraker 2011193 07/07- 06/08 Prospective parallel matched- cohort study R vs NI (Cohort I) a) Mort. rate resist= 31% Mort. rate NI=8% aOR=4.4 b) Mort. rate resist= 36% Mort. rate NI=9% aHR=3.1 S vs NI (Cohort II) a) Mort. rate sensit=22% Europe a)30 days b)hospitaliz I) 248 resistant 453 NI II) 618 sensitive 1170 NI LOS median (IQR) Cohort I resistant=16 (6- 32)* NI=7(3-18)* Cohort II sensitive=15(7- 26)* NI=8(4-14)* 72 Mort. rate NI=8% aOR=2.4 b) Mort. rate sensit=23% Mort. rate NI=7% aHR=3.1 R vs S a) OR=1.8 b) HR= 1.1 excess LOS R vs NI= 9.2* S vs NI= 8.6* R vs S= 0.6 Table 40: Short extraction table of original articles on joint infections mortality of MRSA infected patients vs MSSA infected patients Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Salgado 2007194 01/95- 12/04 Retrospective cohort study Mort. rate both=0% South Carolina, USA hospitaliz 31 cases 12 controls none Median cases=15 controls=10 Patients with prosthetic joint infection from SA 2 Al-Nammari 2007195 06/00- 06/05 Retrospective study a)Mort. rate cases=13% Mort. rate controls=5% b)Mort. rate cases=26% Mort. rate controls=7% England, UK a) sepsis related b)6 months 15 cases 43 controls septic arthritis no data Table 41: Short extraction table of original articles on mortality of MRSA infected patients vs MSSA infected patients for different infection sites Nr Author Study Period Study type Outcome Location Period of outcome Population Matchin g criteria LOS (days) Notes 1 Rello 2013196 Retrospective cohort study a)Mort. rate cases=60% Mort. rate controls=50% b)Mort. rate cases=33.3% Mort. rate controls=10% a)Latin America b)Europe hospitaliz a)5 cases 6 controls b)15 cases 30 controls VAP no data patients in ICU 73 2 Spindel 1995197 01/87- 12/91 Observational analitical study Mort. rate cases=10.7% Mort. rate controls=10% Oregon, USA hospitaliz 20 cases 48 controls mean cases=15 controls=12 Veterans’ nursing home, elderly men with severe underlying diseases 3 Davis 2007198 10/03- 12/05 Prospective cohort study No death related to infections USA 102 cases 102 controls none Patients with community associated SA infections 4 Graffunder 2002199 97-99 Case-control study a)Attibut. mort. rate cases=8.3% Attribut. mort. rate controls=5.7% b)Mort. rate cases=28.8% Mort. rate controls=19.5% USA hospitaliz 121 cases 123 controls none (before culture) mean(range) cases=18.8(2-98) controls=8.4(2- 45) nosocomial infection a) to the infection b) all cause 5 Priest 2005200 94-00 Retrospective case-control study a)Mort. rate cases=55% Mort. rate controls=4% b)Mort. rate cases=27% Mort. rate controls=0% North Carolina, USA hospitaliz 11 cases 24 controls vertebral osteomy elitis no data Inpatients with SA haematogenous vertebral osteomyelitis a)all cause mort. b)inf. related mort. 6 Hershow 1992201 01/89- 12/89 Retrospective cohort study Mort. rate cases=1% Mort. rate controls=0% Illinois, USA hospitaliz 22 cases 22 controls none median cases=14 controls=10 Adults with nosocomial SA infection 7 Hulten 2010202 08/01- 07/07 Retrospective cohort study Mort. rate cases=17.2% Mort. rate controls=7.0%* Texas, USA hospitaliz 29 cases 71 controls none mean cases=57.6 controls=68.2 median(range) cases=29 (3–339) controls=56 (0– 158) patients were children *mortality was calculated just for bacteraemia and catheter associated inf., not all cases and controls of the study 8 Joo 2012203 2007- 2009 Matched case- control study a)Mort. rate cases=9.5% Mort. rate controls=4.8% b)Mort. rate cases=9.5% Mort. rate controls=3.6% Seul, Korea hospitaliz 84 cases 84 controls admissio n date median(range) cases=20 (2–202) controls=22 (2– 158) Community-onset SA infection, a) all cause mort. b)inf. Related mort. 74 9 Capitano 2003204 01/96- 08/00 Retrospective cohort study Mort. rate cases=10% * Mort. rate controls=10%* Connecticut, USA hospitaliz 41 cases 49 controls long- term care facility no data all patients were in long term care facility * infection related mortality 10 Clancy 2005205 01/02- 06/04 Retrospective cohort study Mort. rate cases=0% Mort. rate controls=1.5% Colorado, USA 30 days 57 cases 136 controls CA-SA no data infections were community-acquired Table 42: Short extraction table of original articles on mortality of MRSA infected patients vs MSSA infected patients with respiratory tract infection Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Rello 1994206 01/91- 06/93 Retrospective cohort study a)Mort. rate cases=61.7% Mort. rate controls=56.2% b)Mort. rate cases=18.1% Mort. rate controls=26.3% Spain hospitaliz 11 cases 38 controls none no data patients with VAP a)mort. related to infection; b)mort. non related to infection 2 Gonzalez 1999207 01/90- 12/95 Retrospective cohort study a)Mort. rate cases=25% Mort. rate controls=14.8% b)Mort. rate cases=56.3% Mort. rate controls=40.7% Spain a) first 48h b) due to infection 32 cases 54 controls bacteremic pneumoniae mean±SD cases=44.4±27.7 controls=30.3±21. 7 3 Pujol 1998208 01/90- 12/94 Prospective cohort study Mort. rate cases=56.1% Mort. rate controls=37.8% Spain hospitaliz 41 cases 98 controls Underlying disease prior inf. mean±SD cases=26.2±17.7 controls=5±6.4*; 15.8±13.3** Mechanically ventilated ICU patients who developed SA pneumonia, *early onset; **late onset 75 We also performed a separate literature review using time filters from April 2013 up to the 12th of December 2016 to detect new articles. We performed an advanced search on Pubmed using the mesh term “MRSA” AND all fields “mortality”. On Embase was searched for ‘MRSA’ AND ‘mortality’ and an advanced search was performed on the Cochrane Library was performed using terms “MRSA” AND “mortality”. We applied a filter to include only human studies, and included only published articles. No language restrictions were made, and no further filters were applied. The flow diagram presented in Figure 10.2 describes the steps in the literature review of MRSA infections. Once identified the studies reporting relevant data, these were grouped based on the site of infection. The majority reported BSI infections, even though not all of them had a control group. Figure 10.2. Search for studies on MRSA infections. Inclusion and exclusion diagram. As shown in Figures 10.2., even though we applied a time filter and looked for papers containing the term “mortality”, which makes the research very specific, more than 700 unique papers were detected. After the different exclusion steps the vast majority of them were not eligible for the purposes of our study, but we still could include 44 articles. This is the highest number of eligible articles among all the reviews performed. 76 The following tables include studies reporting results for the different site of infection based on the comparison group they used. All information is reported as was presented in the original papers. 77 Table 43: Short extraction table of original articles on mortality of patients with MRSA BSI infections vs non-infected patients Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Atmaca 2014128 01/04- 12/11 Nested case- control study Mort. rate cases= 47.5% Mort. rate controls=29.3% Turkey hospitaliz 99 cases 99 controls BSI, ward, period of time median cases=59 controls=8 data extracted from original paper in Turkish with help of google translate 2 McMaster 2015209 04/07- 11/13 Prospective study a) Mort. rate cases= 19% Mort. rate controls=21.2% b) Mort. rate cases= 32.8% Mort. rate controls=34.5% Glasgow, UK a) hospitaliz b) 180 days 58 cases 174 controls age, APACHE II, LOS in ICU, surgical/non- surgical status in ICU median (range) cases=16.6 (1.5- 124.1) controls=16.9 (1.9-92.1) all patients were in ICU Table 44: Short extraction table of original articles on BSI mortality of MRSA infected patients vs MSSA infected patients and vs non infected patients Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Stewards on 2016161 01/20- 12/12 Multicentre retrospective cohort study Mort. rate resistant=22.1% Mort.rate sensitive=16.8% Mort.rate NI=1.7% R vs NI: HR*=3.81/2.61/2.42 R vs S: HR*=1.19/1.20/1.26 Europe hospitaliz 163 resistant 885 sensitive 604797 NI none no specific data, see full-text for modelling values* * the study models the excess in LOS between groups proposing 3 models for each 2 Yasmin 2016210 01/12- 10/14 Case-case- control study a)Mort. rate resist= 22% Mort. rate sensit=19.5% Mort. rate NI=1.7% b)Mort. rate resist=19.5% Mort. rate sensit=10.3% New York, USA hospitaliz 118 resistant 145 sensitive 118 NI date of hosp. no specific data a) mortality during hospitalisation b) attributable mortality 78 Table 45: Short extraction table of original articles on BSI mortality of MRSA infected patients vs MSSA infected patients Nr Author Study Period Study type Outcome Location Period of outcome Population Matchin g criteria LOS (days) Notes 1 De la Calle 2016211 01/00- 12/14 Retrospectiv e study a) Mort. rate cases= 40.5% Mort. rate controls=37.5% b) Mort. rate cases= 50% Mort. rate controls=44.6% Spain a) 30 days b) infection related 42 cases 56 controls pneumo nia no data all patients had bacteremic pneumonia 2 De Rosa 2016212 2010- 2011 Retrospectiv e study Mort. rate cases= 17.9% Mort. rate controls=14.3% Italy 21 days 106 cases 83 controls BSI no data 3 Deodhar 2015213 05/11- 06/12 Prospective study Mort. rate cases= 21% Mort. rate controls=21.3% India hospitaliz 40 cases 61 controls none no data 4 Dolapo 2014214 2000- 2009 Retrospectiv e study a) Mort. rate cases= 0% Mort. rate controls=9.8% b) Mort. rate cases= 15.7% Mort. rate controls=5.2% Tennessee, USA 14 days a) 10 cases 31 controls b) 64 cases 51 controls NICU mean±SD a) cases=80.6±42.4 controls=87.4±40.6 b) cases=53.6±36.6 controls=55.7±30.2 patients were in NICU a) period A (2000- 2003) b) period B (2004- 2009 5 Fortuin- de Smidt 2015215 09/12- 09/13 Cross- sectional study Mort. rate cases= 29.1% Mort. rate controls=14.3% South Africa hospitaliz 86 cases 154 controls none median (IQR) cases=38 (14–64) controls=19 (7–33) 6 Kim D.H 2014216 06/06- 02/11 Retrospectiv e study Mort. rate cases= 62% Mort. rate controls=0% OR=0.158; 95%CI(0.047– 0.534) Tennessee, USA hospitaliz 29 cases 8 controls cardiac implant no specific data all patients had Cardiac Implanted Electronic Device- Related Infective Endocarditis 7 Kobayash i 2014217 04/04- 03/11 Retrospectiv e cohort study Mort. rate cases= 39.7% Mort. rate controls=30.7% Japan 90 days 151 cases 189 controls none no data 8 Lee J.Y 2014218 01/04- 12/12 1-a)Mort. rate cases= 3.2% Mort. rate controls=3.6% 1-b) Mort. rate cases= 6.5% Mort. rate controls=13.8% 1-c) Mort. rate cases= 16.1% South Korea a) 1 week b) 30 days c) 12 weeks 31 cases 138 controls median (IQR) cases=47 (19–87) controls=24 (14– 44.5) patients had CA- infections 1-a/b/c) all-cause mortality 2-a/b/c) infection related mortality 79 Mort. rate controls=19.6% 2-a) Mort. rate cases= 0% Mort. rate controls=3.6% 2-b) Mort. rate cases= 3.2% Mort. rate controls=9.4% 2-c) Mort. rate cases= 6.5% Mort. rate controls=13% 9 Manandh ar 2016219 01/10- 06/13 Retrospectiv e study a) Mort. rate cases= 26.7% Mort. rate controls=38.1% OR=0.62; 95%CI(0.15–2.61) b) Mort. rate cases= 26.7% Mort. rate controls=42.9% OR=0.51; 95%CI(0.12–2.14) Pittsburgh, USA a) 30 days b) 90 days 15 cases 21 controls bacteruri a no specific data all patients had S. aureus bacteruria also 10 McMulla n 2016220 01/07- 12/12 Prospective cohort study a) Mort. rate cases= 3.5% Mort. rate controls=2.5% b) Mort. rate cases= 8.5% Mort. rate controls=4.1% Australia & New Zeeland a) 7 days b) 30 days 142 cases 931 controls age median (IQR) cases=17 (8-38) controls=14 (7-33) patients were children 11 Nagao 2016221 2006- 2014 Retrospectiv e cohort study Mort. rate cases= 9% Mort. rate controls=5.8% Japan 30 days 199 cases 278 controls BSI no data 12 Naidoo 2013222 01/07- 12/11 Retrospectiv e study MRSA OR (95%CI) univariate=3.71 (1.77- 7.76)* multivariate=3.76 (1.12- 12.67)* *(p<0.05) South Africa 30 days 95 cases 270 controls BSI no specific data the mortality was not available in % 13 Ong 2013223 01/98- 12/07 Retrospectiv e cohort study Mort. rate cases= 63% Mort. rate controls=39% HR=1.37; 95%CI(0.95–1.97) Australia 1 year 76 cases 363 controls none no data the study aimed the log-term survival rate 14 Park 2013224 1998- 2009 Review and Meta- analysis OR fixed= 2.33; 95%CI(1.42- 3.82) World hospitaliz 191 cases 476 controls age no data all patients were neonates and children 15 Simsek 2014225 01/04- 06/12 Retrospectiv e study Mort. rate cases= 49% Mort. rate controls=15% OR=12.117; 95%CI(3.159 46.475) Turkey hospitaliz 13 cases 47 controls Poststern otomy Mediasti nitis no specific data all patients had Poststernotomy Mediastinitis 80 16 Thaden 2015226 1997- 2012 Retrospectiv e study 1-a)Mort. rate cases= 3% Mort. rate controls=4% 1-b) Mort. rate cases= 8% Mort. rate controls=8% 1-c) Mort. rate cases= 11% Mort. rate controls=10% 2-a) Mort. rate cases= 4% Mort. rate controls=2% 2-b) Mort. rate cases= 9% Mort. rate controls=3% 2-c) Mort. rate cases= 12% Mort. rate controls=4% North Carolina ,USA a) 7 days b) 30 days c) hospitaliz 1) 567 cases 2047 controls 2) 280 cases 445 controls age, ICU no data all patients were infants in ICU 1) with adequate therapy 2) with inadequate therapy 17 Theodoro u 2013227 01/89- 12/09 Retrospectiv e cohort study Mort. rate cases= 33.3% Mort. rate controls=24.4% OR=1.55, 95%CI(0.56–4.28) Germany hospitaliz 33 cases 41 controls thermal injuries median cases=28.5 controls21 all patients had thermal injuries 18 Wang 2015228 01/11- 12/13 Retrospectiv e cohort study a) Mort. rate cases= 47.5% OR=2.249; 95%CI(1.188- 4.259)
 b) Mort. rate cases= 30.5% OR=0.998; 95%CI(0.453- 2.200)
 c) Mort. rate cases=35.3% OR=1.223; 95%CI(0.466- 3.210) Mort. rate controls=25.3% Total MRSA OR=1.707 Taiwan hospitaliz a) 101 cases b) 59 cases 159 controls none no data a) HA-MRSA b) CA-MRSA c) unclassified-MRSA 19 Yaw 2014229 07/97- 06/07 Observationa l cohort study a) Mort. rate cases= 15% Mort. rate controls=12% b) Mort. rate cases= 28% Mort. rate controls=19% c) Mort. rate cases= 75% Mort. rate controls=62% Australia a) 8 days b) 30 days c) follow- up* 185 cases 397 controls none no data * 01/03/2013 20 Yilmaz 2016230 2010- 2012 Prospective multicentre study Mort. rate cases= 22% Mort. rate controls=11.7% Turkey 28 days 100 cases 145 controls none no specific data 81 Table 46: Short extraction table of original articles on the mortality of MRSA bone infected patients vs MSSA skin wound infected patients Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Shoji 2016231 01/07- 12/11 Retrospective study Mort. rate cases= 25% Mort. rate controls=5.5% Japan hospitaliz 16 cases 55 controls vertebral osteomyelitis no data all patients had vertebral osteomyelitis infected by S. aureus Table 47: Short extraction table of original articles on the mortality of MRSA skin wound infected patients vs MSSA skin wound infected patients Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Alizadeh 2014232 2008- 2010 Cross- sectional study No deaths reported in any group Iran hospitaliz 82 cases 32 controls none no data Table 48: Short extraction table of original articles on mortality of patients with MRSA infections with mixed infection site vs non-infected patients Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Balm 2013233 06/07- 06/11 Retrospective cohort study a) Mort. rate cases= 16.5% Mort. rate controls=4.6% OR=5.49; 95%CI(2.75- 10.95) b) Mort. rate cases= 28.9% Mort. rate controls=12.5% Singapore a) 30 days b) 6 months 121 cases 716 controls none no data * controls had positive nasal swab for MRSA 82 OR=2.94; 95%CI(1.78 – 4.85) 2 Nelson 2015234 10/07- 09/10 Retrospective cohort study a) MRSA aHR (95%CI)=1.420(1.322- 1.525)* b) MRSA aHR (95%CI)=1.370(1.231- 1.524)* *(p<0.05) Utah, USA 1 year a) 3599 cases 366144 controls b) 3592 cases 3592 controls propensity score (b) mean a) cases=22.4 controls=9.3 b) cases=20.1 controls=23.2 a) full cohort b) propensity score matched 3 Tran 2016235 01/10- 12/12 Retrospective cohort study a)Mort. rate cases= 8.2%
 Mort. rate controls=5.7% b)Mort. rate cases= 8%
 Mort. rate controls=7% Canada hospitaliz 745 cases 17649 cosntrols none mean a)cases=12.8 controls=7.6 b) cases=11.9 controls=9.1 a) pre-match cohort b) post-match cohort Table 49: Short extraction table of original articles on mortality of patients with MRSA infections with mixed infection site vs patients with MSSA infections N r Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Ericson 2015236 1997- 2012 Multicentre retrospective study a)Mort. rate cases= 11.9% Mort. rate controls=9.6% RR=1.19; 95%CI(0.96-1.49) b)Mort. rate cases= 3.8% Mort. rate controls=3.8% RR=0.90; 95%CI(0.65-1.24) c)Mort. rate cases= 8.7% Mort. rate controls=7.2% RR=1.15; 95%CI(0.90-1.46) USA a) before discharg e b) 7days c) 30 days 1063 cases 2825 controls NICU Both groups=64 Patients were in NICU 2 Gimenes 2016237 2006- 2011 Retrospective study Mort. rate cases= 33.8% Mort. rate controls=52.17% Brazil hospitaliz 71 cases 23 controls ICU median (IQR) cases=20 (20) controls=19 (17) all patients were in ICU 83 3 Kim E.S 2014238 01/12- 12/12 Prospective study Mort. rate cases= 16.8% Mort. rate controls=14% South Korea 30 days 303 cases 357 controls none no data the infection had community onset Table 50: Short extraction table of original articles on mortality of patients colonised with MRSA in the nasal mucosa vs no-colonised patients N r Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Altinbas 2013239 04/06- 04/07 Prospective study Mort. rate cases= 18.1% Mort. rate controls=37.3% Turkey 1 year 11 cases 257 controls ICU mean cases=18 controls=8 the difference in mortality is not statistically significant 2 Chan 2015240 11/08- 12/09 Prospective cohort study a) Mort. rate cases= 64% Mort. rate controls=44.6% b) Mort. rate cases= 30.7% Mort. rate controls=18.8% HR=1.96, 95%CI(1.01-3.78) Hong Kong hospitaliz 75 cases 117 controls none all patients were in a nursering home a) all-cause mortality b) infection related mortality* * according to International Classification of Diseases, 9th Revision, Clinical Modification 3 Chen 2013241 07/09- 06/10 Retrospective cohort study Mort. rate cases= 12.2% Mort. rate controls=15.6% Texas, USA hospitaliz 90 cases 90 controls none mean±SD cases=5.2±7.4 controls=5.9± 8.8 4 Moore 2014242 01/07- 12/12 Retrospective study a) Mort. rate cases= 17% Mort. rate controls=7% b) Mort. rate cases= 3.6% Mort. rate controls=0% Ireland 5 years 28 cases 56 controls age & gender recipient & donor, CMI, cause of renal failure pre-operatively, date of transpl. no data all patients were renal transplant recipients a) all-cause mortality b) infection related mortality Table 51: Short extraction table of original articles on respiratory tract infections mortality of MRSA infected patients vs non-infected patients 84 N r Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Minejima 2014243 01/05- 10-11 Retrospective study Mort. rate cases= 22% Mort. rate controls=3% California, USA 28 days 134 cases 134 controls pneumonia mean cases=10 controls=5 * patients had non- MRSA pneumonia Table 52: Short extraction table of original articles on respiratory tract infections mortality of MRSA infected patients vs MSSA infected patients N r Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Hill 2013244 01/04- 12/09 Retrospective study Mort. rate cases= 17.5% Mort. rate controls=25.4% Tennesse e, USA hospitaliz no exact data* ∼80 cases ∼60 controls VAP in ICU mean cases=34 controls=35 patients had Ventilator- associated pneumonia (VAP) *population estimated from graph 2 Tosh245 2013 09/08- 08/10 Retrospective study Mort. rate cases= 12% Mort. rate controls=2% USA hospitaliz 42 cases 52 controls LRI mean cases=9 controls=6 all patients had lower respiratory tract infection (LRI) 3 Jung 2013246 01/08- 12/11 Retrospective study Mort. rate cases= 33.3% Mort. rate controls=21.5% South Korea hospitaliz 78 cases 865 controls* pneumoni a median (IQR) cases=16.5 (10–30) controls=11 (6–20) * controls were patients with non-nosocomial pneumonia due to other bacteria (non- MRSA) 4 Rello 2013196 not clear Retrospective comparison of 2 cohorts a) Mort. rate cases= 33.3% Mort. rate controls=10% b) Mort. rate cases= 60% Mort. rate controls=50% Europe & Latin America * in ICU a) 15 cases 30 controls b) 5 cases 6 controls none no data all patients had pneumonia and were in ICU *the study aimed to compare 2 cohorts from different continents a) Europe b) Latin America 5 Self 2016247 2,5 years Prospective study Mort. rate cases= 13.3% Mort. rate controls=9.1% Australia hospitaliz 15 cases 22 controls CA- pneumoni a median (IQR) cases=9 (8- all patients had CA-pneumonia 85 13) controls=6 (4–10) Table 53: Short extraction table of original articles on joint infections mortality of MRSA infected patients vs MSSA infected patients N r Author Study Period Study type Outcome Location Period of outcome Population Matchin g criteria LOS (days) Notes 1 Lin 2015248 01/08- 12/11 Clinical case- series Mort. rate cases= 5.3% Mort. rate controls=5.5% Taiwan hospitaliz 38 cases 55 controls joint infection no data all patients had septic arthritis caused by S. aureus 2 Minguez 2015249 1984- 2011 Retrospective study Mort. rate cases= 57.1% Mort. rate controls=17.6% Mexico hospitaliz 7 cases 17 controls joint infection mean cases=33 controls=20 all patients had septic arthritis due to S. aureus During the review we have identified an article of 2011(Lambert et al.50) which was not included in WHO review and which reports mortality data for MRSA and MSSA patients with BSI and pneumonia. We decided to report the results of this article given its high quality. Table 54: Short extraction table of the original article reporting BSI and pneumonia infections due to MRSA vs MSSA organisms. Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Lambert 201150 01/05- 12/08 Prospective cohort study a) Mort. cases=38% Mort. controls=26% aHR=1.6; 95%CI(1.1- 2.3) b) Mort. cases=33% Mort. controls=23% aHR=1.3; 95%CI(1.0- 1.6) Europe ICU hospitaliza tion a)171 cases 284 controls b)524 cases 1014 controls ICU From infection to discharge median (IQR) a)cases=14(6-24) controls=11 (5-24) b)cases= 15(8-27) controls=14 (8–25) patients were in ICU a)patients with BSI b)patients with pneumonia 86 Additionally to the primary studies included in the WHO AMR report and in our literature review, we would like to report the analytical study from de Kraker et al of 2011250. In this study the authors estimate the excess number of deaths, bed-days and hospital costs associated with BSI caused by MRSA and G3CREC in 31 European countries that participated in the EARSS for 2007. Official data from ECDC, WHO and OECD together with previously published mortality data 61,193 and model equations251 are used to model the indicators for each country individually and for all of them pooled. The results resumed are: "In 2007, 27,711 episodes of MRSA BSIs were associated with 5,503 excess deaths and 255,683 excess hospital days in the participating countries, whereas 15,183 episodes of G3CREC BSIs were associated with 2,712 excess deaths and 120,065 extra hospital days. The total costs attributable to excess hospital stay were 44.0 and 18.1 million euros (63.1 and 29.7 million international dollars), respectively.” For further details on the methodology and country specific results we invite the reader to access the full text article. 11. Carbapenem resistant Pseudomonas aeruginosa To research the attributable case fatality and the attributable LOS to carbapenem resistant Pseudomonas aeruginosa (CRPA) we performed 2 advanced searches on Pubmed using once the mesh term “Pseudomonas aeruginosa” AND all fields “carbapenem resistant” AND “mortality”, and the second time the mesh term “Pseudomonas aeruginosa” AND all fields “carbapenem resistance” AND “mortality”. Embase was searched for ‘Pseudomonas aeruginosa’ AND ‘carbapenem resistant’ AND ‘mortality’, and ‘Pseudomonas aeruginosa AND ‘carbapenem resistance’ AND ‘mortality’. We applied a filter to include only human studies. An advanced search on the Cochrane Library was performed using terms “Pseudomonas aeruginosa” AND “carbapenem”. No language restrictions were made, and no further filters were applied. The flow diagram, presented in Figure 11 describes the steps in the literature review of carbapenem resistant Pseudomonas aeruginosa infections. The results obtained using the two different strings for PubMed and Embase were aggregated. Once identified the studies reporting relevant data, these were grouped based on the site of infection. 87 Figure 11: Search for studies on carbapenem resistant Pseudomonas aeruginosa. Inclusion and exclusion diagram. As shown in Figure 11, 6 studies were not detected by our searching strategy (because they used imipenem in their key words instead of the generic term carbapenem) and included in the review because were found in a meta-analysis from Liu et al, 2015252 which was part of our results. The following tables include studies reporting results for BSI, respiratory tract and for mixed site of infection due to CRPA, based on the comparison group they used. All information is reported as was presented in the original papers. Studies that include both a sensitive and a non-infected control group, were categorised in the latter group. 88 Table 55: Short extraction table of original articles on BSI mortality of CRPA infected patients vs CSPA infected patients Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Dantas 2014253 05/09- 08/11 Retrospective study Mort. cases= 47.3% Mort. controls= 36.9% OR=1.53 Brazil 30 days 55 cases 65 controls BSI mean (range) cases=48(4-205) controls=41(3-378) 2 Hatteme r 2013254 08/99- 01/10 Retrospective study Mort. cases= 54% Mort. controls= 32% New York, USA 30 days 13 cases 137 controls BSI no data patients had HAI or CAI 3 Joo 2011255 10/07- 03/09 Retrospective cohort study Mort. cases= 39.1% Mort. controls= 21.2%OR=2.40; 95%CI(1.18– 4.86) aOR=2.74: 95%(1.02–7.37)* Korea 30 days 46 cases 156 controls BSI median (IQR) cases=16(14-42) controls=16(9-29) *adjusted for corticosteroid use, nosocomial acquisition, polymicrobial infection, Charlson’s weighted index of co-morbidity, and admission to ICUs 4 Kang 2005256 01/98- 12/02 Retrospective study Mort. cases= 53.6% Mort. controls= 35.2% OR=2.216; 95%CI(0.946– 4.776) Korea 30 days 28 cases 158 controls none no data 5 Kim 2014257 01/10- 12/12 Retrospective study Mort. cases= 22.0% Mort. controls= 22.4% OR=3.65; 95%CI(0.72-18.67) Korea 14 days 118 cases 116 controls BSI no data the study was focused on survivors and non- surivors 6 Pena 2012258 01/08- 12/09 Prospective multicentre study a) Mort. cases= 13% Mort. controls= 13% b)Mort. cases= 35% Mort. controls= 27% Spain a) 48h b) 30 days 145 cases 487 controls BSI no data 7 Suarez 2010259 01/05- 12/05 Retrospective cohort study Mort. cases= 46% Mort. controls= 36% *Attribut. mort. cases=33% Attribut. mort. controls=30% Spain 30 days 33 cases 88 controls BSI mean (range) cases=19(2-98) controls=9(2-56) *within 7 days from BSI and excluding other causes 89 Table 56: Short extraction table of original articles on respiratory tract infection mortality of CRPA infected patients vs CSPA infected patients Nr Author Study Period Study type Outcome Locatio n Period of outcome Population Matching criteria LOS (days) Notes 1 Luyt 2014261 18 months Prospective observation al study Mort. cases= 37% Mort. controls= 31% France In ICU stay 68* cases 101 controls none median (IQR) cases=37(23-57) controls=29(19-46) * cases included resistant and intermediate susceptible PA, was not possible to separate them Table 57 and Table 58 present the results of studies that include patients with different sites of infection. Almost all the articles specify the number of cases for the different infection sites but they do not report different mortalities based on the infection site. When it was possible the results are presented differentiating the mortality for each site of infection. The study in Table 57 includes a not infected and a susceptible infected control group. Table 57: Short extraction table of original articles on mortality of CRKP infected vs non infected vs CSPA infected patients, for different infection sites Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Eagye 2009262 02/06- 10/06 Case-control-control study Mort. resit= 31% Mort. sensit= 15% Mort. control=9% Connecticut, USA hospitaliz 58 resistant 125 sensitive 57 non infected none median(IQR) resist=30(15-70) sensit=16(6-33) control=10(6-17) OR=1.8; 95%CI(0.5–6.8) 8 Tuon 2012260 01/06- 01/09 Case-control study Mort. cases= 54.2% Mort. controls= 44.8% OR=0.68; 95%CI(0.27–1.73) Brazil 30 days 29 cases 48 controls BSI mean±SD cases=43±31.7 controls=43.1±31.2 90 Table 58: Short extraction table of original articles on mortality of CRPA infected patients vs CSPA infected patients for different infection sites Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Judd 2016263 01/11- 12/13 Retrospectiv e observationa l cohort study Mort. cases= 28.1% Mort. controls= 8.9% OR=2.89; 95%CI(1.15- 7.28) Kentucky, USA hospitaliz 32 cases 350 controls none median (IQR) cases=14(8-29) controls=9(5- 15) 2 Lautenbach 2006264 01/91- 12/00 Case-control study Mort. cases= 31.1% Mort. controls= 16.7% RR=1.86; 95%CI(1.38- 2.51) Pennsylvani a USA hospitaliz 142 cases 737 controls none median (IQR) cases=11(1-41) controls=4(1- 15) study considers all the cases recovered with PA 3 Lautenbach 2010265 01/01- 12/06 Case-control study Mort. cases= 17.4% Mort. controls= 13.4% RR=1.39; 95%CI(1.09– 1.76) Pennsylvani a USA hospitaliz 253 cases 2289 controls none prior isolation median (IQR) cases=8(4-12) controls=4(4-5) study considers all the cases recovered with PA 4 Lin 2014266 01/00- 12/10 Retrospectiv e study Mort. cases= 22.0% Mort. controls= 19.5% Taiwan hospitaliz 82 cases 82 controls none no data matched randomly by computer 5 Liu 2015252 1994- 2014 Meta- analyses Crude OR=1.64 (95%CI=1.40, 1.93) Adjusted OR=2.38 (95%CI=1.53, 3.69) World 16 studies 6 Meradji 2015267 01/12- 12/13 Prospective observationa l study Mort. cases= 13.34% Mort. controls= 1.53% Morocco hospitaliz 15 cases 65 controls none no data 7 Brooklyn Antibiotic Resistance Task Force 2002268 1999 Matched case-control study Mort. cases= 20% Mort. controls= 10% USA hospitaliz 10 cases 10 controls age, site of infection, major diagnosis, operative procedure s, type of infection median preinfection cases=12 controls=15 postinfection cases=33.5 controls=20 91 Many studies were excluded because they did not report a comparison group. Other studies identified were genetic analyses and were not eligible for the purposes of this review. We also identified a meta-analysis that calculated the mortality due to carbapenem resistant Pseudomonas aeruginosa compared to a susceptible group. The published studies included in this meta-analysis were also identified in our literature search, except for six publications which we subsequently included since they fulfilled the eligibility criteria. We decided to report in this chapter the study of Lambert et al50 since it included information on 3rd generation cephalosporin resistant Pseudomonas aeruginosa, which might be useful in the evaluation of the resistances of this bacterium. This article studied the mortality rates of patients with BSI or pneumonia due to 3rd generation cephalosporin resistant P. aeruginosa (3GCRPA) and 3rd generation cephalosporin susceptible P. aeruginosa (3GCSPA) Table 59: Short extraction table of the original article reporting BSI and pneumonia infections due to 3GCRPA vs 3GCSPA organisms Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Lambert 201150 01/05- 12/08 Prospective cohort study a) Mort. cases=41% Mort. controls=39% aHR=1.2; 95%CI(0.8- 1.9) b) Mort. cases=43% Mort. controls=37% aHR=1.2; 95%CI(1.0- 1.5) Europe ICU hospitaliza tion a)82 cases 282 controls b)366 cases 1266 controls ICU From infection to discharge median (IQR) a)cases=16(7-33) controls=14 (6-26) b)cases= 18(11-33) controls=16 (9–29) patients were in ICU a)patients with BSI b)patients with pneumonia 92 12. Colistin resistant Pseudomonas aeruginosa To research the attributable case fatality and the attributable LOS to colistin resistant Psudomonas aeruginosa (CoRPA) we performed 2 advanced searches on Pubmed using once the mesh term “Pseudomonas aeruginosa” AND all fields “colistin resistant”, and the second time the mesh term “Pseudomonas aeruginosa” AND all fields “colistin resistance”. Embase was searched for ‘Pseudomonas aeruginosa’ AND ‘colistin resistance’, and for ‘Pseudomonas aeruginosa’ AND ‘colistin resistant’. In Embase studies was filtered, including just those conducted in humans. An advanced search on the Cochrane Library was performed using terms “Pseudomonas aeruginosa” AND “colistin”. No language restrictions were made, and no other filters were applied. The flow diagram, presented in Figure 12 describes the steps in the literature review of colistin resistant Pseudomonas aeruginosa infections. The results obtained using the two different key words in PubMed and Embase were aggregated. 93 Figure 12: Search for studies on colistin resistant Pseudomonas aeruginosa. Inclusion and exclusion diagram. The review did not identify any published study eligible with the selection criteria. However, two articles reported studies on colistin resistance in patients infected with Pseudomonas aeruginosa. Matthaiou et al. in 2008269 studied the risk factors associated with the isolation of colistin- resistant Gram-negative bacteria in a matched case-control study. Amongst 40 patients, two reported a CoRPA infection but the sample could not be considered representative. Yilmaz et al 2016270, also studied the risk factors of colistin-resistant Gram-negative bacteria in a multicentre study and included in their sample of 56 resistant patients, 18 infected with CoRPA. The sample is more representative but the results of the study are presented pooled together for all patients infected with Gram-negative bacteria. They reported a mortality rate of cases (resistant to colistin) of 53.6%, compared to the mortality rate of controls (sensitive to colistin) of 45%. The colistin resistant Pseudomonas aeruginosa infections are a relatively new research topic, and it seems that no structured studies were conducted yet to investigate the burden of these infections in terms of attributable mortality or attributable length of stay in hospital. 94 13. Multidrug resistant Pseudomonas aeruginosa For the purposes of these project a multidrug resistant isolate is defined as resistant to at least three classes of antimicrobial agents, all penicillins and cephalosporins (including inhibitor combinations), fluroquinolones, and aminoglycosides. Here are excluded those resistant to carbapenem and/or to colistin. If an isolate is multidrug resistant and also resistant to carbapenem and/or colistin, it will be classified as resistant to the latter antibiotic. To research the attributable case fatality and the attributable LOS to multidrug resistant Pseudomonas aeruginosa (MDRPA) we performed 3 advanced searches on Pubmed using once the mesh term “Pseudomonas aeruginosa” AND all fields “multidrug resistant” AND all fields “mortality”, the second time the mesh term “Pseudomonas aeruginosa” AND all fields “multidrug resistance” AND all fields “mortality”, and the third time the mesh term “Pseudomonas aeruginosa” AND all fields “MDR” AND all fields “mortality”. A filter for human studies was applied. Embase was also searched for 3 different strings; once ‘Pseudomonas aeruginosa’ AND ‘multidrug resistant’ AND ‘mortality’, the second time ‘Pseudomonas aeruginosa AND ‘multidrug resistance’ AND ‘mortality’, and the third time ‘Pseudomonas aeruginosa’ AND ‘MDR AND ‘mortality’. We applied a filter to include only human studies. Two advanced searches were also performed on the Cochrane Library using once the terms “Pseudomonas aeruginosa” AND “multidrug resistant”, and the second time the terms “Pseudomonas aeruginosa” AND “multidrug resistance”. No language restrictions were made, and no further filters were applied. The flow diagram, presented in Figure 13 describes the steps in the literature review of multidrug resistant Pseudomonas aeruginosa infections. The results obtained using the different strings for PubMed, Embase and the Cochrane Library were summed up together. 95 Figure 13: Search for studies on multidrug resistant Pseudomonas aeruginosa. Inclusion and exclusion diagram. The following tables include studies reporting results for BSI, respiratory tract and for mixed site of infection due to MDRPA, based on the comparison group they used. All information is reported as was presented in the original papers. 96 Table 60: Short extraction table of original articles on BSI mortality of MDRPA infected patients vs MDSPA infected patients Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Caselli 2010271 01/00- 12/08 Retrospective study Mort. rate cases=35%.8 Mort. rate controls=12.5% aOR=4.3; 95%CI(1.67- 11.07) Italy 30 days 39 cases 88 controls underlying condition no data patients were children under chemotherapy and HSC transplant 2 Johnson 2009272 01/96- 12/05 Retrospective cohort study Mort. rate cases=36.6% Mort. rate controls=46% OR=0.68; 95%CI(0.27-1.71) Boston, USA 28 days 41 cases 50 controls transplant no specific data patients were trasplant recipients 3 Morata 2012273 01/00- 12/08 Prospective study Mort. rate cases=17.2% Mort. rate controls=32.3% Spain 30 days 127 cases 582 controls BSI mean±SD cases=31.83±30 controls=16.38±18 4 Tam 2010274 01/05- 12/08 Retrospective cohort study I) Mort. rate cases=40% Mort. rate controls=11.9% OR=6.829; 95%CI(1.945– 23.984) II) Mort. rate cases=52% Mort. rate controls=9.5% III) Mort. rate cases=56% Mort. rate controls=16.7% IV) c) Mort. rate cases=61.9% Mort. rate controls=9.5% Houston, USA I) 30 days II) infection related III) overall mortality IV) matched pairs 25 cases 84 controls BSI prior isolation mean±SD cases=32.6±37.3 controls=14.4±43.6 5 Theodorou 2013275 01/89- 12(09 Retrospective cohort study Mort. rate cases=42.2% Mort. rate controls=45.2% OR=1.076; 95%CI(0.356– 3.254) Germany hospitaliz 45 cases 42 controls underlying condition prior isolation mean±SD cases=28.2±23.8 controls=26.6±22.3 patients were in a burn ICU 6 Trecarichi 2011276 01/09- ? Prospective study Mort. rate cases=40.7% Mort. rate controls=9.1% Italy 21 days 27 cases 11 controls underlying condition patients had haematological malignancies 97 7 Tumbarell o 2011277 01/06- 12/07 Case-case- control study Mort. rate cases=50% Mort. rate controls=24.2% Italy 21 days 40 cases 66 controls BSI mean±SD cases=27±14 controls=17±13 8 Dantas 2014253 05/09- 08/11 Retrospective study Mort. rate cases=42.1% Mort. rate controls=41.2% Brazil 30 days 57 cases 63 controls BSI mean (range) cases=59 (4–205) controls=62 (3– 378) 9 Joo 2011255 10/07- 03/09 Retrospective cohort study Mort. rate cases=38.1% Mort. rate controls=21.9% OR=2.20; 95%CI(1.06– 4.55) aOR=2.24; 95%CI (0.80– 6.29)* Korea 30 days 42 cases 160 controls BSI median (IQR) cases=25 (13–38) controls=16 (10– 31) *adjusted for corticosteroid use, nosocomial acquisition, polymicrobial infection, Charlson’s weighted index of co-morbidity, and admission to ICUs Table 61: Short extraction table of original articles on respiratory tract infection mortality of MDRPA infected patients vs MDSPA infected patients Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Cilloniz 2016278 01/99- 12/14 Prospective observationa l study Mort. Rate cases=22.7% Mort. rate controls=17.4% Spain 30 days 22 cases 46 controls pneumonia median (IQR) cases=14(12-21) controls=11(7-16) patients had all CAI 2 Montero 2009279 01/00- 12/05 Case-control study Mort. rate cases=60% Mort. rate controls=28% OR=6.2; 95%CI(1.7–22.1) Spain 2 years 50 cases 50 controls age, sex, date of adm, degree of air obstruction no data Patients had COPD the isolation sample was sputum 3 Micek 2015280 no data Multicentre retrospective study Mort. rate cases=44.7% Mort. rate controls=31.7% World* hospitaliz 226 cases 514 controls pneumonia median (IQR) cases=27(14-56.3) controls=25(13-46) *USA, Europe (4 countries) 98 HR=1.39; 95%CI(1.05- 1.83) 4 Pena 2013281 01/06- 12/11 Retrospectiv e study a) Mort. rate cases=15% Mort. rate controls=29% b) Mort. rate cases=50% Mort. rate controls=55% Spain a) 7 days b) hospitaliz 60 cases 31 controls pneumonia no data 5 Tumbarell o 2013282 01/08- 12/10 Retrospectiv e study Mort. rate cases=59.5% Mort. rate controls=35.2% OR=2.69; 95%CI(1.14– 6.43) Italy in ICU 42 cases 68 controls ICU no data patients were in ICU 6 Yang 2009283 10/02- 04/06 Prospective observationa l study Mort. rate cases=35% Mort. rate controls=29% San Francisco , USA 28 days 20 cases 55 controls VAP median (IQR) cases=37(28.5-72) controls=34(21-47) 7 Yayan 2015284 01/04- 08/14 Retrospectiv e study a) Mort. rate cases=28.6% Mort. rate controls=23.8% b) Mort. rate cases=7.4% Mort. rate controls=18.5% Germany hospitaliz a) HAI 14 cases 63 controls b) CAI 27 cases 64 controls VAP no specific data data were extracted since presented from different prospective Table 62 and Table 63 present the results of studies that include patients with different sites of infection. Almost all the articles specify the number of cases for the different infection sites but do not report different mortalities based on the infection site. When it was possible the results are presented differentiating the mortality for each site of infection. Table 62: Short extraction table of original articles on mortality of MDRPA infected patients vs non infected patients for different infection sites Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Aloush 2016285 no data Matched cohort study Mort. rate cases=21% Mort. rate controls=12% OR=4.4 Israel hospitaliz 82 cases 82 controls ward, LOS, calendar time matching criteria 2 Paramythiotou 2004286 01/99- 12/00 Matched case- control study a) Mort. rate cases=44% Mort. rate controls=47% Greece a) in ICU b) hospitaliz 34 cases 34 controls severity of illness, LOS in ICU in ICU mean±SD patients were in ICU 99 b) Mort. rate cases=47% Mort. rate controls=50% cases=11.1±18.6 controls=5.8±10.4 Table 63: Short extraction table of original articles on mortality of MDRPA infected patients vs MDSPA infected patients for different infection sites Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Cao 2004287 01/99- 12/02 Retrospective cohort study Mort. rate cases=54.5% Mort. rate controls=16.2% China hospitaliz 44 cases 68 controls none in ICU mean(SD) cases=21(47.7) 11(16.2) 2 da Matos 2016288 01/10- 02/12 Retrospective cohort study Mort. rate cases=70% Mort. rate controls=58.9% OR=1.6333; 95%CI(0.5043–5.2901) Adults: cases=81.3% controls=71.4% paediatric: cases=25.0% controls=55.0% Brazil hospitaliz 20 cases 34 controls ICU no specific data adults, children and neonates patients in ICU 3 Morales 2012289 01/05- 12/06 Retrospective study Mort. rate cases=24.6% Mort. rate controls=12.8% OR=1.77; 95%CI(1.41-2.22) Spain hospitaliz 134 cases 149 controls none mean(SD), median cases=25.1(16.1), 20 controls=39.0(30.3), 30 4 Nathwan i 2014290 01/00- 02/13 Review and meta-analysis Mort. rate cases=25-60% Mort. rate controls=7-50% RR=2.34, 95%CI(1.53 – 3.57) World hospitaliz 559 cases 7881 controls 5 Ortega 2004291 01/01- 12/01 Prospective study Mort. rate cases=22% Mort. rate controls=23% Netherlands in ICU 18 cases* 35 controls** underlying condition In ICU median (range) cases=18(0-40) controls=10(0-44) all patients were critically ill *resistant of at least 2 antibiotics **susceptible or 100 resistant to only 1 antibiotic 6 Peng 2014292 07/08- 12/12 Case-control study Mort. rate cases=26.1% Mort. rate controls=12.5% China hospitaliz 188 cases 168 controls none median (range) cases=35(5-697) controls=24(1-262) it was a surveillance study 7 Su 2016293 01/03- 06/15 Retrospective double centre study a) Mort. rate cases=36% Mort. rate controls=31.0% b) Mort. rate cases=47.6% Mort. rate controls=37.9% China 30 days 25 cases 29 controls none no specific data a) related mortality b) overall mortality 101 This literature research was specific in the searching strings and we did not detect many unspecific articles. The introduction of the term mortality excluded many ineligible studies. The vast majority of papers contained related information to mortality but very often they did not report a comparison group. Many studies reported treatment options for the resistant infections, but since they used just cases infected with MRDPA and no control group, as defined by our eligibility criteria, these were excluded. All studies were performed in healthcare settings, although some report cases of infection that originated in the community; only one study treated only patients with infection onset in the community. The studies that included patients with MDRPA which were all also resistant to carbapenems were also not included in this review since the mortality reported in these cases is not only attributable to the multidrug resistance but also to the carbapenem resistance. The only exception is the meta-analysis reported in Table 63 from Nathwani et al 2014290 which included patients resistant to carbapenems. 14. Penicillin resistant Streptococcus pneumoniae To research the attributable case fatality and the attributable LOS to penicillin resistant Streptococcus pneumoniae (PRSP) we searched the following databases: PubMed, EMBASE and Cochrane Database of Systematic Reviews. We performed an advanced search on Pubmed using MeSH term “Streptococcus pneumoniae” and all fields “penicillin resistant”. Embase was searched for “penicillin resistant’’ AND streptococcus pneumoniae”. An advanced search on the Cochrane Library was performed using terms “streptococcus pneumoniae” and “penicillin”. No language restrictions were made, and filter for research in humans was applied. Relevant data were extracted and retrospective extraction tables are shown in the results section. The flow diagram shown in Figure 14 describes the steps in the literature review of penicillin resistant Streptococcus pneumoniae. Once identified, the studies reporting relevant data were grouped based on the site of infection. All studies compared penicillin-resistant Streptococcus pneumoniae (PRSP) with penicillin- susceptible Streptococcus pneumoniae (PSSP). No studies were found with non-infected patients as comparator. 102 Figure 14: Search for studies on Penicillin resistant Streptococcus pneumoniae. Inclusion and exclusion diagram. One systematic review and meta-analysis was found294. The following tables include studies reporting results for BSI, respiratory tract and mixed site of infection, based on the comparison group they used. All information is reported as was presented in the original papers. 103 Table 64. Short extraction table of original articles on meningitis mortality of PRSP infected patients vs PSSP patients. Table 65. Short extraction table of original articles on BSI mortality of PRSP infected patients vs PSSP patients. Table 66. Short extraction table of original articles on pneumonia mortality of PRSP infected patients vs PSSP patients. Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Cost (US dollars) 1 Gouveia 2011297 1996 - 2006 Observational study Mortality: adjusted hazard ratio*: 1.62 (1.08-2.43) Salvador, Brazil hospitaliz 93 cases 548 Total population N/A N/A 2 Reechaipichitkul 2006298 01/95- 12/04 Cross- sectional study a)Mort. rate case=9.1% Mort. rate controls=11.9% b)Mort. rate case=9.1% Mort. rate controls=9.5% Khon Kaen, Thailand Hospitalization a) all-cause mortality b) pneumonia related mortality 22 cases 42 controls N/A Mean(SD) R: 12 (9) S: 15.5 (17.7) p=0.43 3 Sun 2006299 1999 – 2003 Retrospective cohort study Mort. rate case=9% Mort. rate controls=14% Connecticut, USA Hospitalization 44 cases 168 controls N/A N/A Median R: $10,809 (6,118- 22,209) Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) 1 Yu 2003295 12/98- 01/01 Prospective, international, observational study Mort. rate case=23.7% Mort. rate controls=15.1% Global >14 days after onset of BSI 76 cases 598 controls N/A N/A Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Notes 1 Watanabe 2000296 12/92- 05/97 Retrospective comparative study a)Mort. rate case=0% Mort. rate controls=8% b) Mort. rate case=12.5% Mort. rate controls=20% Japan 7 days after start of treatment 24 cases 25 controls N/A N/A a) infection related mortality b) mortality due to complications 104 (cases are non- susceptible) S: ($8,503) (5,452- 15,862) 4 Song 2004300 01/00- 06/01 Retrospective study Mort. rate case=16% Mort. rate controls=12.4% OR=1.3; 95%CI(0.5– 3.4) Asia 30 days after diagnosis 69 cases 105 controls N/A N/A N/A 5 Einarsson 1998301 1988 – 1994 Retrospective case-control study Mort. rate case=11% Mort. rate controls=5.5% Iceland not defined but most probably mortality in hospital 36 cases 36 controls Age, gender, hospitalised at the same time Mean Case: 26.8 Control 11.5 (p=0.001) Average pharmacy costs $736 vs. $213 (p<0.01) 6 Sangthawan 2003302 1998- 2001 Prospective study Mort. rate case=36.8% Mort. rate controls=18.5% Thailand not defined but most probably mortality in hospital 19 cases 27 controls N/A N/A N/A 7 Falco 2004303 1997- 2001 Retrospective and prospective a)Mort. rate case=26.7% Mort. rate controls=12.7% b)Mort. rate case=13.3% Mort. rate controls=9.9% Barcelona, Spain Hospitalization a) all-cause mortality b) pneumonia related mortality 15 cases 181 controls N/A N/A N/A 8 Pallares 1995 304 1984 – 1993 Prospective study Mort. rate case=27.6% Mort. rate controls=21.8% aOR=1.0; 95%CI(0.5- 1.9) Barcelona, Spain Within one month of discharge 47 cases 440 controls N/A N/A N/A 9 Ewig 1999 305 1996 – 1998 Prospective study Mort. rate case=18% Mort. rate controls=5.8% Barcelona, Spain Hospitalization 33 cases 52 controls N/A N/A 10 Aspa 2014306 01/99- 04/00 Prospective multi-centre study Mort. rate case=18.3% Mort. rate controls=12.2% Spain 30 days 64 cases 409 controls N/A No data N/A 11 Feikin 2000307 1995 – 1997 Population- based a) OR= 1.3; 95%CI(0.5- 3.7) USA 30 days a) resistant a) 37 cases b) 20 cases 383 controls N/A No data N/A 105 surveillance study b) OR=2.3 ; 95%CI(0.7- 7.4) b) highly resistant, MIC>4 12 Tleyjeh 2006294 Up to 01/05 Review and meta- analyses a) Mort. rate non susceptible=19.4% Mort. rate controls=15.7% b)OR non- suscptible=1.3; 95%CI(1.08–1.59) OR intermediate=1.34; 95% CI(1.13–1.60) OR resistant=1.29; 95% CI(1.01–1.66) c) aRR non susceptible=1.29; 95%CI(1.04–1.59) World different based on the included studies a) pooled mortality rate b) all-cause mortality c) combined adjusted (6 studies) 10 studies (some included also non susceptible) N/A No data N/A 13 Yigla 1995308 11/89- 04/90 Prospective study Mort. rate case=43% Mort. rate controls=33% Israel Hospitalization 7 cases 15 controls N/A No data N/A 14 Pallares 2002309 01/94- 10/00 Prospective study Mort. rate case=43% Mort. rate controls=20.3% Barcelona, Spain 30 days 77 cases 300 controls N/A No data N/A 15 Jehl 2002310 09/98- 04/00 Prospective survey a)Mort. rate case=8.3% Mort. rate controls=3.5% b)Mort. rate case=4.2% Mort. rate controls=10.4% c)Mort. rate case=12.5% Mort. rate controls=13.9% France a) 3 days b) 30 days c) total 49 cases 246 controls N/A No data N/A *After adjusting for age group, PR pneumococcal meningitis cases had higher case fatality than cases caused by penicillin-susceptible organisms 106 There was a limited number of case-control studies reporting outcomes of interest. Many studies reviewed penicillin non-susceptible Streptococcus pneumoniae (including intermediately resistant and resistant) rather than solely penicillin-resistant Streptococcus pneumoniae. The majority of infections in the non-susceptible group fall into the intermediate categories. Most evidence indicates that standard treatment with a beta-lactam antimicrobial is effective against pneumococcal pneumonia caused by strains with penicillin MIC <2, thus including these studies may skew the results and they were excluded. In January 2008 the Clinical and Laboratory Standards Institute revised the penicillin susceptibility breakpoints for non-meningeal pneumococcal infections from <0.06 micrograms/ml to <2 micrograms/ml311. Most studies found, however, predate this change but were not excluded and may represent a limitation when applied to incidence data from EARS-Net. 15. Penicillin and macrolide resistant Streptococcus pneumoniae To research the attributable case fatality and the attributable LOS to penicillin and macrolide resistant Streptococcus pneumoniae (PMRSP) the following databases were searched: PubMed, EMBASE and Cochrane Database of Systematic Reviews. We performed an advanced search on Pubmed using MeSH term “Streptococcus pneumoniae” and all fields “penicillin and macrolide resistant”. Embase was searched for “penicillin and macrolide resistant’’ AND streptococcus pneumoniae”. An advanced search on the Cochrane Library was performed using terms “streptococcus pneumoniae” and “penicillin and macrolide”. No language restrictions were made and filter for research in humans was applied. The following flow diagram in Figure 15 describes the steps in the literature review of penicillin resistant Streptococcus pneumoniae. 107 Figure 15: Search for studies on Penicillin- and macrolide-resistant Streptococcus pneumoniae. Inclusion and exclusion diagram. Unfortunately, no studies were found which focused solely on penicillin and macrolide resistant Streptococcus pneumoniae. Studies were available for penicillin resistant streptococcus pneumoniae and macrolide resistant streptococcus pneumoniae individually. 16. Vancomycin resistant Enterococcus faecalis and faecium To research the attributable case fatality and the attributable LOS to vancomycin resistant Enterococcus faecalis and faecium (VRE), we searched the following databases: PubMed, EMBASE and Cochrane Database of Systematic Reviews. We performed an advanced search on Pubmed using MeSH term “Enterococcus faec*” and all fields “vancomycin-resistant”. Embase was searched for “vancomycin resistant’’ AND “enterococcus faec*”. An advanced search on the Cochrane Library was performed using terms “enterococcus faec*” and “vancomycin’’. No language restrictions were made, and filter for research in humans was applied. Relevant data were extracted from relevant studies identified during the literature search using a standardised data extraction form. The following flow diagram describes the steps in the literature review of vancomycin-resistant Enterococcus. Once identified the studies reporting relevant data were grouped based on the site of infection. All eligible studies reported a VRE infected group and a control group. The latter could represent NI or S infections. 108 Figure 16: Search for studies on Vancomycin resistant Enterococcus faecalis or faecium. Inclusion and exclusion diagram. The sum of the studies categorised for infection site is higher than the total of 29 eligible studies because one study, Carmeli et al. 2002312, reported specific data for different infection sites, therefore was categorised three times. In addition, two meta-analyses reviewing bacteraemia were found and the references included in the systematic reviews were hand-searched for further primary studies missed in the literature search313,314. The following tables include studies reporting results for BSIs, UTIs, SSTIs and other infections from VRE, based on the comparison group they used. All information is reported as was presented in the original papers. All the included studies reported at least one health or economic outcome of interest. 109 Table 67. Short extraction table of original articles on BSI mortality of VRE infected patients vs. VSE patients. Nr Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Cost per admissio n 1 Da Silva 2014315 1998 - 2008 Retrospective cohort study OR 2.73; 95% CI: 1.09-7.78 Brazil In-hospital 30 cases 284 controls same unit and time interval N/A N/A 2 Yoo 2005316 2000 – 2001 Retrospective cohort study Mort. rate cases=78.9% Mort. rate controls=62.5% Seoul Post-discharge 19 cases 8 controls same time period Mean Case 56.2 (28.2) Control 22.9 (13.3) N/A 3 Lodise 2002317 1996 – 2000 Retrospective matched case- control a)Mort. rate cases=52.8% Mort. rate controls=26.4% aOR=4.0; 95%CI(1.2–13.3) a)Mort. rate cases=37.7% Mort. rate controls=20.8% aOR=52; 95%CI(1.4-2.0) Michigan, USA 7 days a) all-cause mortality b) infection related mortality 53 cases 53 controls age, APACHE score at onset, admitting service, LOS prior to onset Mean Case 22.7 (1.88) Control 15.9 (1.7) (after diagnosis) N/A 4 Peset 2000318 1994 – 1996 Prospective case-control Mort. rate cases=23.5% Mort. rate controls=12.4% OR=2.7; 95%CI(0.47–7.89) Valencia, Spain In-hospital 17 cases 169 controls Controls selected consecutivel y Mean Case: 74.75 (46.27) Control 47.26 (37.59) N/A 5 Garbutt 2000319 1995 – 1997 Retrospective cohort a)Mort. rate cases=48% Mort. rate controls=30% OR=1.74; 95%CI(0.50–6.12) b)Mort. rate cases=43% Mort. rate controls=36% OR=1.28; 95%CI(0.47–3.51) Missouri, USA In-hospital 46 cases 23 controls Mean Case: 39.7 Control: 20.9 N/A 6 Bhavnani 2000320 1995 – 1997 Multicentre, case-control a)Mort. rate cases=52% Mort. rate controls=27% aOR=3.34; 95%CI(1.61-6.91) b)Mort. rate cases=32% USA Within 30-days of BSI 150 cases 150 controls Time of occurrence and N/A N/A 110 Mort. rate controls=17% enterococcal species 7 Lucas 1998321 1991 – 1996 Case-control Mort. rate cases=45% Mort. rate controls=27% aOR=2.07; 95%CI(0.96-4.42) Baltimore, USA In-hospital 93 cases 101 controls Timing Mean Case: 49.1 (48.3) Control: 38.6 (31.2) N/A 8 Stosor 1998322 1992 – 1995 Retrospective comparison a) Mort. rate cases=76% Mort. rate controls=41% b)Mort. rate cases=38% Mort. rate controls=9% c)Mort. rate cases=24% Mort. rate controls=19% d)Mort. rate cases=14% Mort. rate controls=13% Chicago, USA In-hospital a) overall mortality b) infection directly related mortality c) infection indirectly related mortality d) unrelated mortality 21 cases 32 controls Mean Case: 34.8 (23.3) Control 16.7 (16.1) Case $83,897 Control $56,707 Excess cost: $27,190 9 Linden 1996323 1991 – 1994 Retrospective cohort a)Mort. rate cases=57% Mort. rate controls=35% aRR=3.47(1.47-8.19) b)Mort. rate cases=46% Mort. rate controls=25% Pittsburgh, USA In-hospital a) all-cause mortality b) infection related mortality 54 cases 48 controls Liver transplant patients with VREF or VSEF Median: Case 46 Control 19 After diagnosis N/A 10 Krcmery 2001324 Retrospective review Mort. rate cases=22% Mort. rate controls=41.3% Slovak Republic 9 cases 92 controls N/A N/A 11 Vergis, 2000 325 1995- 1997 Prospective multicentre observational Mort. rate cases=33% Mort. rate controls=11% aOR=2.1(1.14-3.88) USA 14 days from 1st positive BC 147 cases 251 controls N/A N/A 12 Shay 1995 326 1991 – 1993 Retrospective case- control Mort. rate cases=33% Mort. rate controls=6.5% aOR=3.3(0.7-15) NY, USA 46 cases 46 controls Randomly selected control pts during study period N/A N/A 13 Wells 1995 327 1994 Retrospective case-control Mort. rate cases=17% Mort. rate controls=27% USA In-hospital 6 cases 37 controls Same time period N/A N/A 14 Cheah 2013 328 2002 – 2010 Retrospective matched cohort Mort. rate cases=36% Mort. rate controls=26% aOR=1.21; 95%CI(0.52-2.79) Australia In-hospital 116 cases 116 controls Date and unit of admission Median excess 4.89 (0.56 – 11.52) Excess cost: Australia n $ 28,872 111 15 DiazGranado s 2005 329 1994 – 2001 Retrospective cohort Mort. rate cases=63.6% Mort. rate controls=41% aHR=4.97; 95%CI(1.21-20.44) Atlanta, USA 60 days from BSI 22 cases 61 controls Patients with neutropenia Median Case: 42 (24-75) Control 31 (2-72) N/A 16 Peel 2012 330 2000- 2009 Case-case- control Mort. rate resistant=37.5% Mort. rate sensitive=23.8% Mort. rate NI=2.5% Australia 80 resistant 80 sensitive 80 NI Time N/A N/A 17 Mainous 1997 331 1992 – 1994 Retrospective cohort Mort. rate cases=40% Mort. rate controls=39% Baltimore, USA In-hospital 10 cases 31 controls Stay in SICU mean (SD) cases=28 (18) controls=12 (10) N/A 18 Salgado 2003314 01/86- 04/02 Review and Meta-analyses a)Mort. rate cases=41.5(0- 66.7)% Mort. rate controls=47.8(17- 100)% b)Mort. rate cases=45.2% Mort. rate controls=19.0% RR=2.38; 95%CI(2.13-2.66) c)Mort. rate cases=48.9% Mort. rate controls=19% RR=2.57; 95%CI(2.27-2.91) d)Mort. rate cases=28.7% Mort. rate controls=10.9% RR=2.62; 95%CI(1.84-3.73) e)Mort. rate cases=39.1% Mort. rate controls=21.8% RR=1.79; 95%CI(1.28-1-5) f) Attributable mortality =17- 46% World a)crude mortality rates of pooled cases (14 studies) and controls (26 studies) b) pooled cases and controls from 13 studies c) pooled cases and controls from 9 studies with higher sample size d) pooled cases and controls from 5 studies with infection related mortality e) studies of point d) excluded one that was producing heterogeneity f) range of values from 4 studies which matched for severity of illness 856 cases 1180 controls Excess of total stay of VRE vs VSE=10-46 days N/A 19 DiazGranado s 2005(b)313 Up to 03/03 Review and Meta-analyses OR=2.52; 95%CI(1.9–3.4) World N/A 683 cases 891 controls (pooled cases and controls Severity of illness N/A N/A 112 Table 68. Short extraction table of original articles on BSI mortality of VRE infected patients versus NI from 9 studies) 20 CDC 1993332 01/89- 03/93 Surveillance study Mort. rate cases=36.6% Mort. rate controls=16.4% USA not specified, but most probably mortality in hospital 71 cases 1810 controls N/A N/A 21 Lautenbach 1999333 01/93- 12/95 Historical cohort study Mort. rate cases=45.8% Mort. rate controls=33.5% USA not specified, but most probably mortality in hospital 72 cases 188 controls Unit median (range) cases= 23 (19.18-27.82) controls= 12 (9.0-15.0) N/A 22 Stroud 1996334 01/89- 06/93 Retrospective cohort study Mort. rate cases=69% Mort. rate controls=76% USA not specified, but most probably mortality in hospital 26 cases 119 controls overall cases+controls mean(range)=8 1(9-583) median=60 N/A Nr Author Study Period Study type Outcome Location Period of outcome Population Matchin g criteria LOS (days) Cost per admission 1 Song 2003 335 1993 - 2000 Population- based matched cohort study Mort. rate cases=50.3% Mort. rate controls=27.7% aOR=3.04; 95%CI(1.66-5.53) Baltimore, USA In-hospital 159 cases 159 controls * Median Case 53 Control 28 Excess cost $81,208 2 Carmeli 2002 312 1993 - 1997 Matched cohort study RR= 12.3 Attributable mortality=25% USA In-hospital 233 cases 647 controls ** Multiplicative effect: 2.06 Attributable days 15 Attributable $13,537 113 *matched based on age, year of admission, exposure time, same principle diagnosis at admission, same primary procedure, same APR-DRGs, subgroup of matched case-patients and control patients who had the same APR-DRG complexity level. ** hospital ward, calendar date (within 7 days), duration of hospital stay at time of matching, up to three controls for each case. ***control hospitalised during same period and at least as long as case patient; matched for underlying disease, matched for age within 10 years, matched for gender, matched for surgical procedure. ****hospitalised on oncology unit during study period. Underlying haematological disorder, hospitalised for at least as long as matched case patient had been up until 1st BC yielded VREF. Five studies reported mortality for patients with VRE BSI compared with no infection. Two of these studies undertook a multivariate analysis adjusting for severity of illness. One study was found for UTI mortality for patients with VRE versus VSE. This study only reported mortality and no other outcome of interest. Table 69: Short extraction table of original articles on UTI mortality of VRE infected patients versus VSE patients. 3 Edmond 1996 336 1993 – 1995 Matched retrospective cohort study Mort. rate cases=67% Mort. rate controls=30% OR=2.3; 95%CI(1.2-4.1) USA In-hospital 27 cases 27 controls *** N/A N/A 4 Edmond 1995 337 1993 Pairwise matched case- control Mort. rate cases=73% Mort. rate controls=30% USA In-hospital 11 cases 22 controls **** Mean Case: 74.75± 46.27 Control: 47.26± 37.59 N/A 5 Butler 2010 338 2002- 2003 Retrospective cohort Mort. rate resistant= 32% Mort. rate sensitive=17% Mort. rate controls=4% Missouri, USA In-hospital 94 resistant 182 sensitive 20150 NI Non- surgical patients Attributable LOS VRE: 2.2 (1.7-2.7) Attributable LOS VSE: 1.1 (0.9-1.4) Attributable costs VRE: $4,036 (3,170-5,140) VSE: $2,023 (1,588-2,575) Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Khair 2013 339 2011 Prospective cohort study Mort. rate cases=14% Mort. rate controls=7% Missouri, USA In-hospital 74 cases 180 controls N/A after bacteruria mean (range) cases= 6.8(0.1-150.8) controls= 5(0.2-78.2) 114 One study was found for reporting mortality, LOS and cost for patients with VRE UTIs, SSTIs and VRE intraabdominal infection versus non-infected patients (NI). Table 70. Short extraction table of original articles on UTI mortality of VRE infected patients versus NI patients. *Adjusted mortality reported as RR and attributable percentage **Study reported LOS as ME (multiplicative effect) and attributable days ***hospital ward, calendar date (within 7 days), duration of hospital stay at time of matching, up to three controls for each case. Table 71. Short extraction table of original articles on SST mortality of VRE infected patients versus NI patients. *Adjusted mortality reported as RR and attributable percentage **Study reported LOS as ME (multiplicative effect) and attributable days *** hospital ward, calendar date (within 7 days), duration of hospital stay at time of matching, up to three controls for each case. Author Study Period Study type Outcome* Location Period of outcome Population Matching criteria LOS (days)** Cost per admission Carmeli 2002 312 1993 – 1997 Matched cohort study RR: 4.28 Attributable to VRE: 9% USA In-hospital 233 cases 647 controls *** ME:1.75 Attributable 5.4 days Attributable: $6,665 Author Study Period Study type Outcome* Location Period of outcome Population Matchin g criteria LOS (days)** Cost per admission Carmeli 2002 312 1993 – 1997 Matched cohort study RR: 2.00 Attributable to VRE: 6% USA In-hospital 233 cases 647 controls *** ME: 1.78 Attributable 6.2 days Attributable: $13,884 115 Table 72. Short extraction table of original articles on intraabdominal infection of VRE infected patients versus NI patients. *Adjusted mortality reported as RR and attributable percentage ***Study reported LOS as ME (multiplicative effect) and attributable days Table 73. Short extraction table of original articles of VRE infected patients versus NI patients for mixed site of infection Author Study Period Study type Outcome* Location Period of outcome Population Matching criteria LOS (days)** Cost per admission Carmeli 2002 312 1993 – 1997 Matched cohort study RR: 3.75 Attributable to VRE: 3% USA In-hospital 233 cases 647 controls ME: 1.42 Attributable 2.6 days Attributable: $22,896 Author Study Period Study type Outcome Location Period of outcome Population Matching criteria LOS (days) Cost per admission Tornieporth, 1996 340 1990-1992 Case control study a)Mort. rate cases=37% Mort. rate controls=19% b)Mort. rate cases=58% Mort. rate controls=43% NY, USA In-hospital a) overall mortality b) ICU admitted patients mortality 24 cases 23 controls VSEF isolates within 1 month of VREF isolates mean (range) cases=64.5 (2-290) controls=40.8 (2-248) median cases= 48 controls=26 N/A 116 The most recent published eligible study found was in 2014 with studies found dating back to 1995. A limited number of studies focused solely on Enterococcus faecium and faecalis but rather more generally on enterococcal species. These two species do however constitute the majority of VRE infections. Conclusions The literature reviews conducted to determine the attributable case fatality and the attributable length of stay due to the selected resistant bacterial infections have detected 281 original articles eligible for the purposes of the project. These peer reviewed publications vary based, amongst other, for the underlying study design, type of patients, time of outcome, control for adjusting and confounding variables, unit or set of study. As described in the objectives of our literature review, for each pathogen/resistance combination we categorized the detected studies based on the site of infection and on the control group they used to compare the cases with the resistant infection. We noticed a wide difference between the studies identified in our search. Many are limited to specific healthcare services (e.g. ICUs) and/or performed on particular groups of patients (e.g. only children, only elderly) and/or with specific underlying conditions (e.g. immunodeficiency, organ transplant). Therefore, extracting valid case fatality proportions from published risk differences for the burden of AMR project will be particularly challenging. Based on the heterogeneity of the studies detected, we advise to avoid pooling and averaging the results based on our categorizing criteria. We suggest below a list of methods for the selection of the studies identified. This list is not mutually exclusive and we recommend using a combination of the methods below to identify the published data to include in the disease models for the burden of AMR project. Different Approaches a) Grading of Recommendations, Assessment, Development and Evaluations (GRADE); it is a widely accepted systematic and explicit approach to grading the quality of evidence and strength of recommendations. This approach was used in the WHO 2014 Antimicrobial Resistance Global Report on Surveillance. The quality of evidence was collected into four categories: very low, low, moderate and high. Most studies identified in the WHO report were observational and were graded as low and very low. Our systematic review also found a predominance of observational studies and we can easily deduce that the evidence offered by our detected studies might be similar. b) Sample size criteria; in every statistical and inferential approach the sample size effect is fundamental to determine if an observed value or characteristic is just a case or an evidence of a reliable and repeatable phenomenon that describes the studied population. Very often studies on antibiotic resistant infections are not based on a large population and they do not include sample size calculations. A small sample size 117 weakens the evidence produced by their results; the approach, therefore, would consist of including only studies that have a “large” sample size. The definition of large can be described as consistent with a sample size calculation that we can perform based on the data available in literature. c) Control for confounders and biases; the control for confounders and biases is another fundamental criterion in the evaluation of the evidence. The best quality studies we identified were matched case control studies with matching for the main variables of the two groups that might interfere in the disease outcome (e.g. age, underlying health conditions, therapy etc.). The final selection would include studies that control the cases and control groups by matching them for specific and defined variables or those performing statistical analysis that controls for those variables (e.g. multivariate logistic regression model). If a study seems of good quality but lacks one or two essential quality criteria (e.g. control for confounders and biases), one could contact the author/s of the study and ask for raw data. However, this approach might be very time- consuming and the outcome is uncertain. d) Meta-analysis; Meta-analyses of the results of all detected studies as they are reported in the articles could be possible. Another approach would entail extracting information on each single patient and their characteristics and insert them in a self-build database. However, this would require contacting authors in order to fill in the information gaps of the published studies. e) Self-designed evaluation grid; the previously described approaches (b-d) give us useful information on the quality and reliability of the evidence produced by a study. this information could be pooled together in a grid showing the selected criteria to be assigned to every study (we suggest those listed in b, c and d). The criteria would be qualitative ordinal variables with pre-assigned values. The grid would lead to an approach similar to the GRADE but could be tailored for studies on antibiotic resistance. The aspects to consider and their ranking should be agreed with antibiotic resistance experts. The purpose of this summary is to list some aspects that should be considered in the evaluation of the detected studies. Further expert’s opinions and a specific literature research can help considering the best approach and include additional aspects. 118 References 1. Kim SB, Min YH, Cheong JW, et al. Incidence and risk factors for carbapenem- and multidrug-resistant Acinetobacter baumannii bacteremia in hematopoietic stem cell transplantation recipients. Scandinavian journal of infectious diseases. Feb 2014;46(2):81- 88. 2. Thatrimontrichai A, Apisarnthanarak A, Chanvitan P, Janjindamai W, Dissaneevate S, Maneenil G. Risk factors and outcomes of carbapenem-resistant Acinetobacter baumannii bacteremia in neonatal intensive care unit: a case-case-control study. The Pediatric infectious disease journal. Feb 2013;32(2):140-145. 3. Deris ZZ, Shafei MN, Harun A. Risk factors and outcomes of imipenem-resistant Acinetobacter bloodstream infection in North-Eastern Malaysia. Asian Pacific journal of tropical biomedicine. Aug 2011;1(4):313-315. 4. Esterly JS, Griffith M, Qi C, Malczynski M, Postelnick MJ, Scheetz MH. Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections. Antimicrobial agents and chemotherapy. Oct 2011;55(10):4844-4849. 5. Huang ST, Chiang MC, Kuo SC, et al. Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. Oct 2012;45(5):356-362. 6. Jamulitrat S, Arunpan P, Phainuphong P. Attributable mortality of imipenem-resistant nosocomial Acinetobacter baumannii bloodstream infection. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. Mar 2009;92(3):413-419. 7. Kim YJ, Kim SI, Hong KW, Kim YR, Park YJ, Kang MW. Risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia: impact of appropriate antimicrobial therapy. Journal of Korean medical science. May 2012;27(5):471-475. 8. Kumar A, Randhawa VS, Nirupam N, Rai Y, Saili A. Risk factors for carbapenem-resistant Acinetobacter baumanii blood stream infections in a neonatal intensive care unit, Delhi, India. Journal of infection in developing countries. Aug 13 2014;8(8):1049-1054. 9. Routsi C, Pratikaki M, Platsouka E, et al. Carbapenem-resistant versus carbapenem- susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes. Infection. Jun 2010;38(3):173-180. 10. Tal-Jasper R, Katz DE, Amrami N, et al. Clinical and epidemiological significance of carbapenem resistance in Acinetobacter baumannii infections. Antimicrobial agents and chemotherapy. 2016;60(5):3127-3131. 11. Thatrimontrichai A, Techato C, Dissaneevate S, et al. Risk factors and outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia in the neonate: A case-case-control study. Journal of Infection and Chemotherapy. 2016;22(7):444-449. 12. Chang HC, Chen YC, Lin MC, et al. Mortality risk factors in patients with Acinetobacter baumannii ventilator: associated pneumonia. Journal of the Formosan Medical Association = Taiwan yi zhi. Sep 2011;110(9):564-571. 13. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al. Treatment of multidrug- resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. May 1 2003;36(9):1111-1118. 119 14. Zheng YL, Wan YF, Zhou LY, et al. Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia. American journal of infection control. Jul 2013;41(7):e59-63. 15. Henig O, Weber G, Hoshen MB, et al. Risk factors for and impact of carbapenem-resistant Acinetobacter baumannii colonization and infection: matched case-control study. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. Oct 2015;34(10):2063-2068. 16. Nazer LH, Kharabsheh A, Rimawi D, Mubarak S, Hawari F. Characteristics and Outcomes of Acinetobacter baumannii Infections in Critically Ill Patients with Cancer: A Matched Case- Control Study. Microbial drug resistance (Larchmont, N.Y.). Oct 2015;21(5):556-561. 17. Aydemir H, Celebi G, Piskin N, et al. Mortality attributable to carbapenem-resistant nosocomial Acinetobacter baumannii infections in a Turkish university hospital. Japanese journal of infectious diseases. 2012;65(1):66-71. 18. de Gouvea EF, Martins IS, Halpern M, et al. The influence of carbapenem resistance on mortality in solid organ transplant recipients with Acinetobacter baumannii infection. BMC infectious diseases. Dec 13 2012;12:351. 19. del Mar Tomas M, Cartelle M, Pertega S, et al. Hospital outbreak caused by a carbapenem- resistant strain of Acinetobacter baumannii: patient prognosis and risk-factors for colonisation and infection. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. Jul 2005;11(7):540- 546. 20. Lautenbach E, Synnestvedt M, Weiner MG, et al. Epidemiology and impact of imipenem resistance in Acinetobacter baumannii. Infection control and hospital epidemiology. Dec 2009;30(12):1186-1192. 21. Lemos EV, de la Hoz FP, Alvis N, et al. Impact of carbapenem resistance on clinical and economic outcomes among patients with Acinetobacter baumannii infection in Colombia. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. Feb 2014;20(2):174-180. 22. Lemos EV, de la Hoz FP, Einarson TR, et al. Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. May 2014;20(5):416-423. 23. Sheng WH, Liao CH, Lauderdale TL, et al. A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. Sep 2010;14(9):e764-769. 24. Brooklyn Antibiotic Resistance Task Force. The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudmonas aeruginosa on length of hospital stay. Infection control and hospital epidemiology. Feb 2002;23(2):106-108. 25. Wang YC, Lee YT, Yang YS, et al. Risk factors and outcome for colistin-resistant Acinetobacter nosocomialis bacteraemia in patients without previous colistin exposure. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. Aug 2015;21(8):758-764. 26. Taneja N, Singh G, Singh M, Sharma M. Emergence of tigecycline & colistin resistant Acinetobacter baumanii in patients with complicated urinary tract infections in north India. Indian J Med Res. Jun 2011;133:681-684. 27. Baran I, Mumcuoglu I, Aksu N, et al. Evaluation of colistin-resistant Acinetobacter strains. Clinical Microbiology and Infection. 2012;18:321. 120 28. Kontopidou F, Plachouras D, Papadomichelakis E, et al. Colonization and infection by colistin-resistant Gram-negative bacteria in a cohort of critically ill patients. Clinical Microbiology and Infection. 2011;17(11):E9-E11. 29. Lee SY, Shin JH, Park KH, et al. Identification, genotypic relation, and clinical features of colistin-resistant isolates of Acinetobacter genomic species 13BJ/14TU from bloodstreams of patients in a university hospital. Journal of Clinical Microbiology. 2014;52(3):931-939. 30. Qureshi ZA, Hittle LE, O'Hara JA, et al. Colistin-resistant acinetobacter baumannii: Beyond carbapenem resistance. Clinical Infectious Diseases. 2015;60(9):1295-1303. 31. Al Jarousha AM, El Jadba AH, Al Afifi AS, El Qouqa IA. Nosocomial multidrug-resistant Acinetobacter baumannii in the neonatal intensive care unit in Gaza City, Palestine. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. Sep 2009;13(5):623-628. 32. Gulen TA, Guner R, Celikbilek N, Keske S, Tasyaran M. Clinical importance and cost of bacteremia caused by nosocomial multi drug resistant acinetobacter baumannii. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. Sep 2015;38:32-35. 33. Anunnatsiri S, Tonsawan P. Risk factors and clinical outcomes of multidrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Thailand. The Southeast Asian journal of tropical medicine and public health. May 2011;42(3):693-703. 34. Fitzpatrick MA, Ozer E, Bolon MK, Hauser AR. Influence of ACB complex genospecies on clinical outcomes in a U.S. hospital with high rates of multidrug resistance. The Journal of infection. Feb 2015;70(2):144-152. 35. Guo N, Xue W, Tang D, Ding J, Zhao B. Risk factors and outcomes of hospitalized patients with blood infections caused by multidrug-resistant Acinetobacter baumannii complex in a hospital of Northern China. American journal of infection control. 2016;44(4):e37-e39. 36. Lee NY, Lee HC, Ko NY, et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infection control and hospital epidemiology. Jun 2007;28(6):713-719. 37. Lee NY, Chang TC, Wu CJ, et al. Clinical manifestations, antimicrobial therapy, and prognostic factors of monomicrobial Acinetobacter baumannii complex bacteremia. The Journal of infection. Sep 2010;61(3):219-227. 38. Smolyakov R, Borer A, Riesenberg K, et al. Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment. The Journal of hospital infection. May 2003;54(1):32-38. 39. Cai XF, Sun JM, Bao LS, Li WB. Risk factors and antibiotic resistance of pneumonia caused by multidrug resistant Acinetobacter baumannii in pediatric intensive care unit. World Journal of Emergency Medicine. 2012;3(3):202-207. 40. Inchai J, Pothirat C, Bumroongkit C, Limsukon A, Khositsakulchai W, Liwsrisakun C. Prognostic factors associated with mortality of drug-resistant Acinetobacter baumannii ventilator-associated pneumonia. Journal of Intensive Care. 2015;3(1). 41. Park II, Kim IK, Koo HC, et al. Clinical characteristics and prognosis of Acinetobacter nosocomial pneumonia between MDR and non-MDR. Tuberculosis and Respiratory Diseases. 2006;61(1):13-19. 42. Abbo A, Carmeli Y, Navon-Venezia S, Siegman-Igra Y, Schwaber MJ. Impact of multi-drug- resistant Acinetobacter baumannii on clinical outcomes. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. Nov 2007;26(11):793-800. 121 43. Fukuta Y, Doi Y, Muder RR, et al. Risk factors for acquisition of multi-drug resistant Acinetobacter baumannii among cancer patients. International Journal of Antimicrobial Agents. 2013;42:S140-S141. 44. Lee H, Lee H. Clinical and economic evaluation of multidrug-resistant Acinetobacter baumannii colonization in the intensive care unit. Infection and Chemotherapy. 2016;48(3):174-180. 45. Brahmi N, Beji O, Abidi N, et al. Epidemiology and risk factors for colonization and infection by Acinetobacter baumannii in an ICU in Tunisia, where this pathogen is endemic. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. Dec 2007;13(6):400-404. 46. Daniels TL, Deppen S, Arbogast PG, Griffin MR, Schaffner W, Talbot TR. Mortality rates associated with multidrug-resistant Acinetobacter baumannii infection in surgical intensive care units. Infection control and hospital epidemiology. Nov 2008;29(11):1080-1083. 47. Lemos EV, De la Hoz Restrepo F, Alvis N, Quevedo E, Canon O, Leon Y. [Acinetobacter baumannii - related mortality in intensive care units in Colombia]. Revista panamericana de salud publica = Pan American journal of public health. Oct 2011;30(4):287-294. 48. Pierri MD, Crescenzi G, Capestro F, et al. Risk Factors and Impact on Clinical Outcome of Multidrug-Resistant Acinetobacter Baumannii Acquisition in Cardiac Surgery Patients. Journal of Cardiothoracic and Vascular Anesthesia. 2016;30(3):680-686. 49. Zilberberg MD, Nathanson BH, Sulham K, Fan W, Shorr AF. Multidrug resistance, inappropriate empiric therapy, and hospital mortality in Acinetobacter baumannii pneumonia and sepsis. Critical Care. 2016;20(1). 50. Lambert ML, Suetens C, Savey A, et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: A cohort study. The Lancet Infectious Diseases. 2011;11(1):30-38. 51. Chang HJ, Hsu PC, Yang CC, et al. Risk factors and outcomes of carbapenem- nonsusceptible Escherichia coli bacteremia: A matched case-control study. Journal of Microbiology, Immunology and Infection. 2011;44(2):125-130. 52. Epstein L, Hunter JC, Arwady MA, et al. New Delhi metallo-β-lactamase-producing carbapenem-resistant escherichia coli associated with exposure to duodenoscopes. JAMA - Journal of the American Medical Association. 2014;312(14):1447-1455. 53. Ahn JY, Song JE, Kim MH, et al. Risk factors for the acquisition of carbapenem-resistant Escherichia coli at a tertiary care center in South Korea: A matched case-control study. American journal of infection control. 2014;42(6):621-625. 54. Balkan, II, Aygun G, Aydin S, et al. Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae: treatment and survival. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. Sep 2014;26:51-56. 55. Poirel L, Savov E, Nazli A, et al. Outbreak caused by NDM-1- and RmtB-producing Escherichia coli in Bulgaria. Antimicrobial agents and chemotherapy. 2014;58(4):2472- 2474. 56. Porwal R, Gopalakrishnan R, Rajesh NJ, Ramasubramanian V. Carbapenem resistant Gram- negative bacteremia in an Indian intensive care unit: A review of the clinical profile and treatment outcome of 50 patients. Indian Journal of Critical Care Medicine. 2014;18(11):750-753. 57. Shukla N, Tulasigeri C, Kate A, et al. High carbapenem resistance in gram negative bacterial isolates: An outcome study. American Journal of Respiratory and Critical Care Medicine. 2013;187. 122 58. Liu YY, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. The Lancet. Infectious diseases. Feb 2016;16(2):161-168. 59. Nordmann P, Lienhard R, Kieffer N, Clerc O, Poirel L. Plasmid-mediated colistin-resistant Escherichia coli in bacteremia in Switzerland. Clinical Infectious Diseases. 2016;62(10):1322-1323. 60. Oostdijk EA, Leverstein-van Hall M, Muilwijk J, Kesecioglu J, Bonten MJ. Colistin resistance in Gram-negative bacteria during prophylactic colistin use in intensive care units. Clinical Microbiology and Infection. 2011;17:S294. 61. de Kraker MEA, Wolkewitz M, Davey PG, et al. Burden of antimicrobial resistance in European hospitals: Excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. Journal of Antimicrobial Chemotherapy. 2011;66(2):398-407. 62. Anunnatsiri S, Towiwat P, Chaimanee P. Risk factors and clinical outcomes of extended spectrum beta-lactamase (ESBL)-producing Escherichia coli septicemia at Srinagarind University Hospital, Thailand. The Southeast Asian journal of tropical medicine and public health. Sep 2012;43(5):1169-1177. 63. Apisarnthanarak A, Kiratisin P, Mundy LM. Predictors of mortality from community-onset bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infection control and hospital epidemiology. Jul 2008;29(7):671-674. 64. Cornejo-Juarez P, Perez-Jimenez C, Silva-Sanchez J, et al. Molecular analysis and risk factors for Escherichia coli producing extended-spectrum beta-lactamase bloodstream infection in hematological malignancies. PloS one. 2012;7(4):e35780. 65. Courpon-Claudinon A, Lefort A, Panhard X, et al. Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: Prevalence, molecular epidemiology and clinical features. Clinical Microbiology and Infection. 2011;17(4):557-565. 66. Ortega M, Marco F, Soriano A, et al. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. The Journal of antimicrobial chemotherapy. Mar 2009;63(3):568-574. 67. Trecarichi EM, Tumbarello M, Spanu T, et al. Incidence and clinical impact of extended- spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. The Journal of infection. Apr 2009;58(4):299-307. 68. Hsieh CJ, Shen YH, Hwang KP. Clinical implications, risk factors and mortality following community-onset bacteremia caused by extended-spectrum beta-lactamase (ESBL) and non-ESBL producing Escherichia coli. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. Jun 2010;43(3):240-248. 69. Tumbarello M, Spanu T, Di Bidino R, et al. Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. Antimicrobial agents and chemotherapy. Oct 2010;54(10):4085-4091. 70. Gudiol C, Calatayud L, Garcia-Vidal C, et al. Bacteraemia due to extended-spectrum beta- lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. The Journal of antimicrobial chemotherapy. Feb 2010;65(2):333-341. 71. Ho PL, Chan WM, Tsang KW, Wong SS, Young K. Bacteremia caused by Escherichia coli producing extended-spectrum beta-lactamase: a case-control study of risk factors and outcomes. Scandinavian journal of infectious diseases. 2002;34(8):567-573. 123 72. Rodriguez-Bano J, Picon E, Gijon P, et al. Community-onset bacteremia due to extended- spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Jan 1 2010;50(1):40-48. 73. Kang CI, Song JH, Chung DR, et al. Risk factors and treatment outcomes of community- onset bacteraemia caused by extended-spectrum beta-lactamase-producing Escherichia coli. Int J Antimicrob Agents. Sep 2010;36(3):284-287. 74. Garcia Hernandez A, Garcia-Vazquez E, Gomez Gomez J, Canteras M, Hernandez-Torres A, Ruiz Gomez J. [Predictive factors of ESBL versus non-ESBL Escherichia coli bacteraemia and influence of resistance on the mortality of the patients]. Medicina clinica. Jan 29 2011;136(2):56-60. 75. Denis B, Lafaurie M, Donay JL, et al. Prevalence, risk factors, and impact on clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteraemia: a five-year study. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. Oct 2015;39:1-6. 76. Ha YE, Kang CI, Cha MK, et al. Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in patients with cancer. Int J Antimicrob Agents. Nov 2013;42(5):403-409. 77. Kaya O, Akcam FZ, Gonen I, Unal O, Ceylan T. Risk factors for bacteremia due to extended- spectrum beta-lactamase-producing Escherichia coli in a Turkish hospital. Journal of infection in developing countries. Jul 15 2013;7(7):507-512. 78. Kim SH, Kwon JC, Choi SM, et al. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum beta- lactamase production and its impact on outcome. Annals of hematology. Apr 2013;92(4):533-541. 79. Leistner R, Gurntke S, Sakellariou C, et al. Bloodstream infection due to extended- spectrum beta-lactamase (ESBL)-positive K. pneumoniae and E. coli: an analysis of the disease burden in a large cohort. Infection. Dec 2014;42(6):991-997. 80. Leistner R, Sakellariou C, Gürntke S, et al. Mortality and molecular epidemiology associated with extended-spectrum β-lactamase production in Escherichia coli from bloodstream infection. Infection and Drug Resistance. 2014;7:57-62. 81. Martelius T, Jalava J, Karki T, Mottonen T, Ollgren J, Lyytikainen O. Nosocomial bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae resistant to third-generation cephalosporins, Finland, 1999-2013: Trends, patient characteristics and mortality. Infectious diseases (London, England). 2016;48(3):229-234. 82. Park SH, Choi SM, Lee DG, et al. Emergence of extended-spectrum beta-lactamase- producing escherichia coli as a cause of community-onset bacteremia in South Korea: risk factors and clinical outcomes. Microbial drug resistance (Larchmont, N.Y.). Dec 2011;17(4):537-544. 83. Yip T, Tse KC, Lam MF, et al. Risk factors and outcomes of extended-spectrum beta- lactamase-producing E. coli peritonitis in CAPD patients. Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis. Mar-Apr 2006;26(2):191-197. 84. Van Aken S, Lund N, Ahl J, Odenholt I, Tham J. Risk factors, outcome and impact of empirical antimicrobial treatment in extended-spectrum beta-lactamase-producing Escherichia coli bacteraemia. Scandinavian journal of infectious diseases. Nov 2014;46(11):753-762. 85. Melzer M, Petersen I. Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. The Journal of infection. Sep 2007;55(3):254-259. 124 86. Al-Otaibi FE, Bukhari EE. Clinical and laboratory profiles of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in a tertiary care center in central Saudi Arabia. Saudi medical journal. Feb 2013;34(2):171-176. 87. Ena J, Arjona F, Martinez-Peinado C, Lopez-Perezagua Mdel M, Amador C. Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Urology. Dec 2006;68(6):1169-1174. 88. Suankratay C, Jutivorakool K, Jirajariyavej S. A prospective study of ceftriaxone treatment in acute pyelonephritis caused by extended-spectrum beta-lactamase-producing bacteria. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. Aug 2008;91(8):1172-1181. 89. Esteve-Palau E, Solande G, Sanchez F, et al. Clinical and economic impact of urinary tract infections caused by ESBL-producing Escherichia coli requiring hospitalization: A matched cohort study. The Journal of infection. Dec 2015;71(6):667-674. 90. Park SH, Choi SM, Lee DG, et al. Impact of extended-spectrum beta-lactamase production on treatment outcomes of acute pyelonephritis caused by escherichia coli in patients without health care-associated risk factors. Antimicrobial agents and chemotherapy. Apr 2015;59(4):1962-1968. 91. Arnan M, Gudiol C, Calatayud L, et al. Risk factors for, and clinical relevance of, faecal extended-spectrum beta-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. Mar 2011;30(3):355-360. 92. Nicolas-Chanoine MH, Jarlier V, Robert J, et al. Patient's origin and lifestyle associated with CTX-M-producing Escherichia coli: a case-control-control study. PloS one. 2012;7(1):e30498. 93. Hayakawa K, Gattu S, Marchaim D, et al. Epidemiology and risk factors for isolation of Escherichia coli producing CTX-M-type extended-spectrum beta-lactamase in a large U.S. Medical Center. Antimicrobial agents and chemotherapy. Aug 2013;57(8):4010-4018. 94. Pena C, Gudiol C, Calatayud L, et al. Infections due to Escherichia coli producing extended- spectrum beta-lactamase among hospitalised patients: factors influencing mortality. The Journal of hospital infection. Feb 2008;68(2):116-122. 95. Kang CI, Wi YM, Lee MY, et al. Epidemiology and risk factors of community onset infections caused by extended-spectrum beta-lactamase-producing Escherichia coli strains. J Clin Microbiol. Feb 2012;50(2):312-317. 96. Maslikowska JA, Walker SAN, Elligsen M, et al. Impact of infection with extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella species on outcome and hospitalization costs. Journal of Hospital Infection. 2016;92(1):33-41. 97. Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerging infectious diseases. Jul 2014;20(7):1170-1175. 98. Viale P, Giannella M, Lewis R, Trecarichi EM, Petrosillo N, Tumbarello M. Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections. Expert Review of Anti-Infective Therapy. 2013;11(10):1053-1063. 99. Boyle DP, Zembower TR. Epidemiology and Management of Emerging Drug-Resistant Gram-Negative Bacteria: Extended-Spectrum beta-Lactamases and Beyond. The Urologic clinics of North America. Nov 2015;42(4):493-505. 100. Borer A, Saidel-Odes L, Riesenberg K, et al. Attributable mortality rate for carbapenem- resistant Klebsiella pneumoniae bacteremia. Infection control and hospital epidemiology. 2009;30(10):972-976. 125 101. Gallagher JC, Kuriakose S, Haynes K, Axelrod P. Case-case-control study of patients with carbapenem-resistant and third-generation-cephalosporin-resistant Klebsiella pneumoniae bloodstream infections. Antimicrobial agents and chemotherapy. Oct 2014;58(10):5732-5735. 102. Mouloudi E, Massa E, Papadopoulos S, et al. Bloodstream infections caused by carbapenemase-producing klebsiella pneumoniae among intensive care unit patients after orthotopic liver transplantation: Risk factors for infection and impact of resistance on outcomes. Transplantation Proceedings. 2014;46(9):3216-3218. 103. Mouloudi E, Protonotariou E, Zagorianou A, et al. Bloodstream infections caused by metallo-beta-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes. Infection control and hospital epidemiology. Dec 2010;31(12):1250-1256. 104. Simkins J, Muggia V, Cohen HW, Minamoto GY. Carbapenem-resistant Klebsiella pneumoniae infections in kidney transplant recipients: A case-control study. Transplant Infectious Disease. 2014;16(5):775-782. 105. Hussein K, Raz-Pasteur A, Finkelstein R, et al. Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by Klebsiella pneumoniae. Journal of Hospital Infection. 2013;83(4):307-313. 106. Ben-David D, Kordevani R, Keller N, et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clinical Microbiology and Infection. 2012;18(1):54- 60. 107. Daikos GL, Petrikkos P, Psichogiou M, et al. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrobial agents and chemotherapy. May 2009;53(5):1868- 1873. 108. Brizendine KD, Richter SS, Cober ED, Van Duin D. Carbapenem-resistant Klebsiella pneumoniae urinary tract infection following solid organ transplantation. Antimicrobial agents and chemotherapy. 2015;59(1):553-557. 109. Pouch SM, Kubin CJ, Satlin MJ, et al. Epidemiology and outcomes of carbapenem-resistant Klebsiella pneumoniae bacteriuria in kidney transplant recipients. Transplant Infectious Disease. 2015;17(6):800-809. 110. Shilo S, Assous MV, Lachish T, et al. Risk factors for bacteriuria with carbapenem-resistant Klebsiella pneumoniae and its impact on mortality: A case-control study. Infection. 2013;41(2):503-509. 111. Giannella M, Morelli MC, Cristini F, et al. Carbapenem-resistant Klebsiella pneumoniae colonization at liver transplantation: a management challenge. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. May 2014;20(5):631-633. 112. Lubbert C, Becker-Rux D, Rodloff AC, et al. Colonization of liver transplant recipients with KPC-producing Klebsiella pneumoniae is associated with high infection rates and excess mortality: a case-control analysis. Infection. Apr 2014;42(2):309-316. 113. Nouvenne A, Ticinesi A, Lauretani F, et al. Comorbidities and disease severity as risk factors for carbapenem-resistant Klebsiella pneumoniae colonization: report of an experience in an internal medicine unit. PloS one. 2014;9(10):e110001. 114. Bleumin D, Cohen MJ, Moranne O, et al. Carbapenem-resistant Klebsiella pneumoniae is associated with poor outcome in hemodialysis patients. The Journal of infection. Oct 2012;65(4):318-325. 126 115. Debby BD, Ganor O, Yasmin M, et al. Epidemiology of carbapenem resistant Klebsiella pneumoniae colonization in an intensive care unit. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. Aug 2012;31(8):1811-1817. 116. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrobial agents and chemotherapy. Mar 2008;52(3):1028-1033. 117. Pereira MR, Scully BF, Pouch SM, et al. Risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. Dec 2015;21(12):1511-1519. 118. Kofteridis DP, Valachis A, Dimopoulou D, et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection/colonization: a case-case-control study. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. May 2014;20(5):293-297. 119. Candevir Ulu A, Kurtaran B, Inal AS, et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infection: a serious threat in ICUs. Medical science monitor : international medical journal of experimental and clinical research. 2015;21:219-224. 120. Dizbay M, Guzel Tunccan O, Karasahin O, Aktas F. Emergence of carbapenem-resistant Klebsiella spp. infections in a Turkish university hospital: epidemiology and risk factors. Journal of infection in developing countries. Jan 2014;8(1):44-49. 121. Hoxha A, Karki T, Giambi C, et al. Attributable mortality of carbapenem-resistant Klebsiella pneumoniae infections in a prospective matched cohort study in Italy, 2012-2013. The Journal of hospital infection. Jan 2016;92(1):61-66. 122. Jiao Y, Qin Y, Liu J, et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection/colonization and predictors of mortality: a retrospective study. Pathogens and global health. Mar 2015;109(2):68-74. 123. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infection control and hospital epidemiology. Dec 2008;29(12):1099-1106. 124. Correa L, Martino MD, Siqueira I, et al. A hospital-based matched case-control study to identify clinical outcome and risk factors associated with carbapenem-resistant Klebsiella pneumoniae infection. BMC infectious diseases. 2013;13:80. 125. Centers for Disease Control and Prevention C. Carbapenem-Resistant Klebsiella pneumoniae Associated with a Long-Term--Care Facility--West Virginia, 2009-2011 October 21 2011. 126. Falagas ME, Rafailidis PI, Kofteridis D, et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. The Journal of antimicrobial chemotherapy. Nov 2007;60(5):1124-1130. 127. Hauck C, Cober E, Richter SS, et al. Spectrum of excess mortality due to carbapenem- resistant Klebsiella pneumoniae infections. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. Jun 2016;22(6):513-519. 128. Atmaca O, Zarakolu P, Karahan C, Cakir B, Unal S. [Risk factors and antibiotic use in methicillin-resistant Staphylococcus aureus bacteremia in hospitalized patients at Hacettepe University Adult and Oncology Hospitals (2004-2011) and antimicrobial susceptibilities of the isolates: a nested case-control study]. Mikrobiyoloji bulteni. Oct 2014;48(4):523-537. 127 129. Daikos GL, Karabinis A, Paramythiotou E, et al. VIM-1-producing Klebsiella pneumoniae bloodstream infections: analysis of 28 cases. Int J Antimicrob Agents. Apr 2007;29(4):471- 473. 130. Lee NY, Wu JJ, Lin SH, Ko WC, Tsai LH, Yan JJ. Characterization of carbapenem- nonsusceptible Klebsiella pneumoniae bloodstream isolates at a Taiwanese hospital: clinical impacts of lowered breakpoints for carbapenems. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. Aug 2012;31(8):1941-1950. 131. Marchaim D, Chopra T, Pogue JM, et al. Outbreak of colistin-resistant, carbapenem- resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan. Antimicrobial agents and chemotherapy. Feb 2011;55(2):593-599. 132. Zarkotou O, Pournaras S, Voulgari E, et al. Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae: a matched case- control study. J Clin Microbiol. Jun 2010;48(6):2271-2274. 133. Capone A, Giannella M, Fortini D, et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. Jan 2013;19(1):E23-30. 134. Rojas LJ, Salim M, Cober E, et al. Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae: Laboratory Detection and Impact on Mortality. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Dec 10 2016. 135. Falagas ME, Rafailidis PI, Matthaiou DK, Virtzili S, Nikita D, Michalopoulos A. Pandrug- resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents. Nov 2008;32(5):450-454. 136. Falagas ME, Bliziotis IA, Kasiakou SK, Samonis G, Athanassopoulou P, Michalopoulos A. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC infectious diseases. Apr 08 2005;5:24. 137. Antoniadou A, Kontopidou F, Poulakou G, et al. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. The Journal of antimicrobial chemotherapy. Apr 2007;59(4):786-790. 138. Toth A, Damjanova I, Puskas E, et al. Emergence of a colistin-resistant KPC-2-producing Klebsiella pneumoniae ST258 clone in Hungary. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. Jul 2010;29(7):765-769. 139. Kontopoulou K, Protonotariou E, Vasilakos K, et al. Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 beta-lactamase resistant to colistin. The Journal of hospital infection. Sep 2010;76(1):70-73. 140. Ah YM, Kim AJ, Lee JY. Colistin resistance in Klebsiella pneumoniae. Int J Antimicrob Agents. Jul 2014;44(1):8-15. 141. Gallagher JC, Kuriakose S, Haynes K, Axelrod P. Case-case-control study of patients with carbapenem-resistant and third-generation-cephalosporin-resistant Klebsiella pneumoniae bloodstream infections. Antimicrob. Agents Chemother. 2014;58(10):5732- 5735. 142. Panhotra BR, Saxena AK, Al-Ghamdi AM. Extended-spectrum beta-lactamase-producing Klebsiella pneumoniae hospital acquired bacteremia. Risk factors and clinical outcome. Saudi medical journal. Dec 2004;25(12):1871-1876. 143. Tumbarello M, Spanu T, Sanguinetti M, et al. Bloodstream infections caused by extended- spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular 128 epidemiology, and clinical outcome. Antimicrobial agents and chemotherapy. Feb 2006;50(2):498-504. 144. Marra AR, Wey SB, Castelo A, et al. Nosocomial bloodstream infections caused by Klebsiella pneumoniae: impact of extended-spectrum beta-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence. BMC infectious diseases. 2006;6:24. 145. Kang CI, Kim SH, Park WB, et al. Clinical outcome of bacteremic spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. The Korean journal of internal medicine. Sep 2004;19(3):160-164. 146. Kim BN, Woo JH, Kim MN, Ryu J, Kim YS. Clinical implications of extended-spectrum beta- lactamase-producing Klebsiella pneumoniae bacteraemia. The Journal of hospital infection. Oct 2002;52(2):99-106. 147. Ariffin H, Navaratnam P, Mohamed M, et al. Ceftazidime-resistant Klebsiella pneumoniae bloodstream infection in children with febrile neutropenia. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2000;4(1):21-25. 148. Mosqueda-Gomez JL, Montano-Loza A, Rolon AL, et al. Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae A case-control study. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. Nov 2008;12(6):653-659. 149. Szilagyi E, Fuzi M, Borocz K, Kurcz A, Toth A, Nagy K. Risk factors and outcomes for bloodstream infections with extended-spectrum beta -lactamase-producing Klebsiella pneumoniae ; Findings of the nosocomial surveillance system in Hungary. Acta microbiologica et immunologica Hungarica. Sep 2009;56(3):251-262. 150. Pena C, Pujol M, Ardanuy C, et al. An outbreak of hospital-acquired Klebsiella pneumoniae bacteraemia, including strains producing extended-spectrum beta-lactamase. The Journal of hospital infection. Jan 2001;47(1):53-59. 151. Paterson DL, Ko WC, Von Gottberg A, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Annals of internal medicine. Jan 6 2004;140(1):26-32. 152. Tuon FF, Kruger M, Terreri M, Penteado-Filho SR, Gortz L. Klebsiella ESBL bacteremia- mortality and risk factors. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. Nov-Dec 2011;15(6):594-598. 153. Lee JA, Kang CI, Joo EJ, et al. Epidemiology and clinical features of community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Microbial drug resistance (Larchmont, N.Y.). Jun 2011;17(2):267-273. 154. Brizendine KD, Richter SS, Cober ED, van Duin D. Carbapenem-resistant Klebsiella pneumoniae urinary tract infection following solid organ transplantation. Antimicrobial agents and chemotherapy. Jan 2015;59(1):553-557. 155. Loh LC, Nor Izran Hanim Bt Abdul S, Rosdara Masayuni Bt Mohd S, Raman S, Thayaparan T, Kumar S. Hospital Outcomes of Adult Respiratory Tract Infections with Extended-Spectrum B-Lactamase (ESBL) Producing Klebsiella Pneumoniae. The Malaysian journal of medical sciences : MJMS. Jul 2007;14(2):36-40. 156. Gomes CC, Vormittag E, Santos CR, Levin AS. Nosocomial infection with cephalosporin- resistant Klebsiella pneumoniae is not associated with increased mortality. Infection control and hospital epidemiology. Sep 2006;27(9):907-912. 129 157. Lin MF, Huang ML, Lai SH. Risk factors in the acquisition of extended-spectrum beta- lactamase Klebsiella pneumoniae: a case-control study in a district teaching hospital in Taiwan. The Journal of hospital infection. Jan 2003;53(1):39-45. 158. Kuo KC, Shen YH, Hwang KP. Clinical implications and risk factors of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae infection in children: a case-control retrospective study in a medical center in southern Taiwan. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. Jun 2007;40(3):248-254. 159. Chiu S, Huang YC, Lien RI, Chou YH, Lin TY. Clinical features of nosocomial infections by extended-spectrum beta-lactamase-producing Enterobacteriaceae in neonatal intensive care units. Acta paediatrica. Nov 2005;94(11):1644-1649. 160. Huang Y, Zhuang S, Du M. Risk factors of nosocomial infection with extended-spectrum beta-lactamase-producing bacteria in a neonatal intensive care unit in China. Infection. Oct 2007;35(5):339-345. 161. Stewardson AJ, Allignol A, Beyersmann J, et al. The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: A multicentre retrospective cohort study. Eurosurveillance. 2016;21(33). 162. WHO. Antimicrobial resistance: global report on surveillance. France: WHO;2014. 163. Kuint J, Barzilai A, Regev-Yochay G, Rubinstein E, Keller N, Maayan-Metzger A. Comparison of community-acquired methicillin-resistant Staphylococcus aureus bacteremia to other staphylococcal species in a neonatal intensive care unit. Eur J Pediatr. Apr 2007;166(4):319-325. 164. Guilarde AO, Turchi MD, Martelli CM, Primo MG. Staphylococcus aureus bacteraemia: incidence, risk factors and predictors for death in a Brazilian teaching hospital. The Journal of hospital infection. Jul 2006;63(3):330-336. 165. Castillo JS, Leal AL, Cortes JA, et al. Mortality among critically ill patients with methicillin- resistant Staphylococcus aureus bacteremia: a multicenter cohort study in Colombia. Revista panamericana de salud publica = Pan American journal of public health. Nov 2012;32(5):343-350. 166. Lawes T, Edwards B, Lopez-Lozano JM, Gould I. Trends in Staphylococcus aureus bacteraemia and impacts of infection control practices including universal MRSA admission screening in a hospital in Scotland, 2006-2010: retrospective cohort study and time-series intervention analysis. BMJ Open. 2012;2(3). 167. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Outcome and attributable mortality in critically Ill patients with bacteremia involving methicillin-susceptible and methicillin- resistant Staphylococcus aureus. Arch Intern Med. Oct 28 2002;162(19):2229-2235. 168. Talon D, Woronoff-Lemsi MC, Limat S, et al. The impact of resistance to methicillin in Staphylococcus aureus bacteremia on mortality. Eur J Intern Med. Feb 2002;13(1):31-36. 169. Soriano A, Martinez JA, Mensa J, et al. Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Feb 2000;30(2):368-373. 170. Selvey LA, Whitby M, Johnson B. Nosocomial methicillin-resistant Staphylococcus aureus bacteremia: is it any worse than nosocomial methicillin-sensitive Staphylococcus aureus bacteremia? Infection control and hospital epidemiology. Oct 2000;21(10):645-648. 171. Rubio-Terres C, Garau J, Grau S, Martinez-Martinez L, Cast of Resistance Study g. Cost of bacteraemia caused by methicillin-resistant vs. methicillin-susceptible Staphylococcus aureus in Spain: a retrospective cohort study. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. Jun 2010;16(6):722-728. 130 172. Romero-Vivas J, Rubio M, Fernandez C, Picazo JJ. Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Dec 1995;21(6):1417- 1423. 173. Reshad K, Tanaka F, Sekine T, et al. [A prospective study of septic episodes due to Staphylococcus aureus and the background of the patients]. Kansenshogaku Zasshi. Feb 1994;68(2):171-176. 174. Quilty S, Kwok G, Hajkowicz K, Currie B. High incidence of methicillin-resistant Staphylococcus aureus sepsis and death in patients with febrile neutropenia at Royal Darwin Hospital. Intern Med J. Aug 2009;39(8):557-559. 175. Hakim H, Mylotte JM, Faden H. Morbidity and mortality of Staphylococcal bacteremia in children. American journal of infection control. Mar 2007;35(2):102-105. 176. Nickerson EK, Wuthiekanun V, Day NP, Chaowagul W, Peacock SJ. Meticillin-resistant Staphylococcus aureus in rural Asia. The Lancet. Infectious diseases. Feb 2006;6(2):70-71. 177. Kim SH, Park WB, Lee KD, et al. Outcome of Staphylococcus aureus bacteremia in patients with eradicable foci versus noneradicable foci. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Sep 15 2003;37(6):794-799. 178. Melzer M, Eykyn SJ, Gransden WR, Chinn S. Is methicillin-resistant Staphylococcus aureus more virulent than methicillin-susceptible S. aureus? A comparative cohort study of British patients with nosocomial infection and bacteremia. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Dec 01 2003;37(11):1453-1460. 179. Khatib R, Johnson LB, Fakih MG, et al. Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome. Scandinavian journal of infectious diseases. 2006;38(1):7-14. 180. Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis. Jun 2005;52(2):113- 122. 181. Nickerson EK, Hongsuwan M, Limmathurotsakul D, et al. Staphylococcus aureus bacteraemia in a tropical setting: patient outcome and impact of antibiotic resistance. PloS one. 2009;4(1):e4308. 182. Harbarth S, Rutschmann O, Sudre P, Pittet D. Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus. Arch Intern Med. Jan 26 1998;158(2):182-189. 183. Cunney RJ, McNamara EB, alAnsari N, Smyth EG. Community and hospital acquired Staphylococcus aureus septicaemia: 115 cases from a Dublin teaching hospital. The Journal of infection. Jul 1996;33(1):11-13. 184. Das I, O'Connell N, Lambert P. Epidemiology, clinical and laboratory characteristics of Staphylococcus aureus bacteraemia in a university hospital in UK. The Journal of hospital infection. Feb 2007;65(2):117-123. 185. Austin TW, Austin MA, Coleman B. Methicillin-resistant/methicillin-sensitive Staphylococcus aureus bacteremia. Saudi medical journal. Mar 2003;24(3):256-260. 186. Conterno LO, Wey SB, Castelo A. Risk factors for mortality in Staphylococcus aureus bacteremia. Infection control and hospital epidemiology. Jan 1998;19(1):32-37. 187. Hill EE, Peetermans WE, Vanderschueren S, Claus P, Herregods MC, Herijgers P. Methicillin-resistant versus methicillin-sensitive Staphylococcus aureus infective endocarditis. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. Jun 2008;27(6):445-450. 188. Ganga R, Riederer K, Sharma M, et al. Role of SCCmec type in outcome of Staphylococcus aureus bacteremia in a single medical center. J Clin Microbiol. Mar 2009;47(3):590-595. 131 189. Burke RE, Halpern MS, Baron EJ, Gutierrez K. Pediatric and neonatal Staphylococcus aureus bacteremia: epidemiology, risk factors, and outcome. Infection control and hospital epidemiology. Jul 2009;30(7):636-644. 190. de Oliveira Conterno L, Wey SB, Castelo A. Staphylococcus aureus bacteremia: comparison of two periods and a predictive model of mortality. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. Dec 2002;6(6):288-297. 191. Lesens O, Methlin C, Hansmann Y, et al. Role of comorbidity in mortality related to Staphylococcus aureus bacteremia: a prospective study using the Charlson weighted index of comorbidity. Infection control and hospital epidemiology. Dec 2003;24(12):890-896. 192. O'Kane GM, Gottlieb T, Bradbury R. Staphylococcal bacteraemia: the hospital or the home? A review of Staphylococcus aureus bacteraemia at Concord Hospital in 1993. Aust N Z J Med. Feb 1998;28(1):23-27. 193. de Kraker ME, Wolkewitz M, Davey PG, et al. Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin- resistant Staphylococcus aureus bloodstream infections. Antimicrobial agents and chemotherapy. Apr 2011;55(4):1598-1605. 194. Salgado CD, Dash S, Cantey JR, Marculescu CE. Higher risk of failure of methicillin-resistant Staphylococcus aureus prosthetic joint infections. Clin Orthop Relat Res. Aug 2007;461:48- 53. 195. Al-Nammari SS, Bobak P, Venkatesh R. Methicillin resistant Staphylococcus aureus versus methicillin sensitive Staphylococcus aureus adult haematogenous septic arthritis. Arch Orthop Trauma Surg. Sep 2007;127(7):537-542. 196. Rello J, Molano D, Villabon M, et al. Differences in hospital- and ventilator-associated pneumonia due to Staphylococcus aureus (methicillin-susceptible and methicillin- resistant) between Europe and Latin America: a comparison of the EUVAP and LATINVAP study cohorts. Med Intensiva. May 2013;37(4):241-247. 197. Spindel SJ, Strausbaugh LJ, Jacobson C. Infections caused by Staphylococcus aureus in a Veterans' Affairs nursing home care unit: a 5-year experience. Infection control and hospital epidemiology. Apr 1995;16(4):217-223. 198. Davis SL, Perri MB, Donabedian SM, et al. Epidemiology and outcomes of community- associated methicillin-resistant Staphylococcus aureus infection. J Clin Microbiol. Jun 2007;45(6):1705-1711. 199. Graffunder EM, Venezia RA. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. The Journal of antimicrobial chemotherapy. Jun 2002;49(6):999-1005. 200. Priest DH, Peacock JE, Jr. Hematogenous vertebral osteomyelitis due to Staphylococcus aureus in the adult: clinical features and therapeutic outcomes. South Med J. Sep 2005;98(9):854-862. 201. Hershow RC, Khayr WF, Smith NL. A comparison of clinical virulence of nosocomially acquired methicillin-resistant and methicillin-sensitive Staphylococcus aureus infections in a university hospital. Infection control and hospital epidemiology. Oct 1992;13(10):587- 593. 202. Hulten KG, Kaplan SL, Lamberth LB, et al. Hospital-acquired Staphylococcus aureus infections at Texas Children's Hospital, 2001-2007. Infection control and hospital epidemiology. Feb 2010;31(2):183-190. 203. Joo EJ, Chung DR, Ha YE, et al. Clinical predictors of community-genotype ST72-methicillin- resistant Staphylococcus aureus-SCCmec type IV in patients with community-onset S. aureus infection. The Journal of antimicrobial chemotherapy. Jul 2012;67(7):1755-1759. 132 204. Capitano B, Leshem OA, Nightingale CH, Nicolau DP. Cost effect of managing methicillin- resistant Staphylococcus aureus in a long-term care facility. J Am Geriatr Soc. Jan 2003;51(1):10-16. 205. Clancy MJ, Graepler A, Breese PE, Price CS, Burman WJ. Widespread emergence of methicillin resistance in community-acquired Staphylococcus aureus infections in Denver. South Med J. Nov 2005;98(11):1069-1075. 206. Rello J, Torres A, Ricart M, et al. Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med. Dec 1994;150(6 Pt 1):1545-1549. 207. Gonzalez C, Rubio M, Romero-Vivas J, Gonzalez M, Picazo JJ. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Nov 1999;29(5):1171-1177. 208. Pujol M, Pena C, Pallares R, et al. Nosocomial Staphylococcus aureus bacteremia among nasal carriers of methicillin-resistant and methicillin-susceptible strains. Am J Med. May 1996;100(5):509-516. 209. McMaster J, Booth MG, Smith A, Hamilton K. Meticillin-resistant Staphylococcus aureus in the intensive care unit: its effect on outcome and risk factors for acquisition. The Journal of hospital infection. Aug 2015;90(4):327-332. 210. Yasmin M, El Hage H, Obeid R, El Haddad H, Zaarour M, Khalil A. Epidemiology of bloodstream infections caused by methicillin-resistant Staphylococcus aureus at a tertiary care hospital in New York. American journal of infection control. 2016;44(1):41-46. 211. De la Calle C, Morata L, Cobos-Trigueros N, et al. Staphylococcus aureus bacteremic pneumonia. European Journal of Clinical Microbiology and Infectious Diseases. 2016;35(3):497-502. 212. De Rosa FG, Corcione S, Motta I, et al. Risk factors for mortality in patients with Staphylococcus aureus bloodstream infection. Journal of Chemotherapy. 2016;28(3):187- 190. 213. Deodhar D, Varghese G, Balaji V, et al. Prevalence of toxin genes among the clinical isolates of Staphylococcus aureus and its clinical impact. Journal of Global Infectious Diseases. 2015;7(3):97-102. 214. Dolapo O, Dhanireddy R, Talati AJ. Trends of Staphylococcus aureus bloodstream infections in a neonatal intensive care unit from 2000-2009. BMC pediatrics. May 09 2014;14:121. 215. Fortuin-de Smidt MC, Singh-Moodley A, Badat R, et al. Staphylococcus aureus bacteraemia in Gauteng academic hospitals, South Africa. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. Jan 2015;30:41-48. 216. Kim DH, Tate J, Dresen WF, et al. Cardiac implanted electronic device-related infective endocarditis: clinical features, management, and outcomes of 80 consecutive patients. Pacing and clinical electrophysiology : PACE. Aug 2014;37(8):978-985. 217. Kobayashi D, Yokota K, Takahashi O, Arioka H, Fukui T. A predictive rule for mortality of inpatients with Staphylococcus aureus bacteraemia: A classification and regression tree analysis. European journal of internal medicine. Dec 2014;25(10):914-918. 218. Lee JY, Chong YP, Kim T, et al. Bone and joint infection as a predictor of community- acquired methicillin-resistant Staphylococcus aureus bacteraemia: a comparative cohort study. The Journal of antimicrobial chemotherapy. Jul 2014;69(7):1966-1971. 219. Manandhar S, Pai G, Gidwani H, et al. Does staphylococcus aureus bacteriuria predict clinical outcomes in patients with bacteremia?: Analysis of 274 patients with 133 staphylococcus aureus blood stream infection. Infectious Diseases in Clinical Practice. 2016;24(3):151-154. 220. McMullan BJ, Bowen A, Blyth CC, et al. Epidemiology and mortality of staphylococcus aureus Bacteremia in Australian and New Zealand children. JAMA pediatrics. 2016;170(10):979-986. 221. Nagao M, Yamamoto M, Matsumura Y, et al. Complete adherence to evidence-based quality-of-care indicators for Staphylococcus aureus bacteremia resulted in better prognosis. Infection. 2016:1-9. 222. Naidoo R, Nuttall J, Whitelaw A, Eley B. Epidemiology of Staphylococcus aureus bacteraemia at a tertiary children's hospital in Cape Town, South Africa. PloS one. 2013;8(10):e78396. 223. Ong CW, Roberts JL, Collignon PJ. Long-term survival outcome following staphylococcus aureus bacteraemia. Healthcare Infection. 2013;18(3):102-109. 224. Park DA, Lee SM, Peck KR, Joo EJ, Oh EG. Impact of methicillin-resistance on mortality in children and neonates with staphylococcus aureus bacteremia: A meta-analysis. Infection and Chemotherapy. 2013;45(2):202-210. 225. Simsek Yavuz S, Sensoy A, Ceken S, Deniz D, Yekeler I. Methicillin-resistant Staphylococcus aureus infection: an independent risk factor for mortality in patients with poststernotomy mediastinitis. Medical principles and practice : international journal of the Kuwait University, Health Science Centre. 2014;23(6):517-523. 226. Thaden JT, Ericson JE, Cross H, et al. Survival benefit of empirical therapy for staphylococcus aureus bloodstream infections in infants. Pediatric Infectious Disease Journal. 2015;34(11):1175-1179. 227. Theodorou P, Lefering R, Perbix W, et al. Staphylococcus aureus bacteremia after thermal injury: the clinical impact of methicillin resistance. Burns : journal of the International Society for Burn Injuries. May 2013;39(3):404-412. 228. Wang JT, Hsu LY, Lauderdale TL, Fan WC, Wang FD. Comparison of Outcomes among Adult Patients with Nosocomial Bacteremia Caused by Methicillin-Susceptible and Methicillin- Resistant Staphylococcus aureus: A Retrospective Cohort Study. PloS one. 2015;10(12). 229. Yaw LK, Robinson JO, Ho KM. A comparison of long-term outcomes after meticillin- resistant and meticillin-sensitive Staphylococcus aureus bacteraemia: an observational cohort study. The Lancet Infectious Diseases. 2014. 230. Yilmaz M, Elaldi N, Balkan, et al. Mortality predictors of Staphylococcus aureus bacteremia: A prospective multicenter study. Annals of Clinical Microbiology and Antimicrobials. 2016;15(1). 231. Shoji H, Urakawa T, Watanabe K, et al. Clinical features, outcomes, and survival factor in patients with vertebral osteomyelitis infected by methicillin-resistant staphylococci. Journal of Orthopaedic Science. 2016;21(3):282-286. 232. Alizadeh N, Oskuee ABE, Golchai J, et al. Methicillin-resistant Staphylococcus aureus (MRSA) an important microorganism: Determination of its prevalence and evaluation of its associated factors in hospitalized dermatologic patients. Iranian Journal of Dermatology. 2014;17(68):54-58. 233. Balm MN, Lover AA, Salmon S, Tambyah PA, Fisher DA. Progression from new methicillin- resistant Staphylococcus aureus colonisation to infection: an observational study in a hospital cohort. BMC infectious diseases. Oct 22 2013;13:491. 234. Nelson RE, Stevens VW, Jones M, Samore MH, Rubin MA. Health care-associated methicillin-resistant Staphylococcus aureus infections increases the risk of postdischarge mortality. American journal of infection control. Jan 2015;43(1):38-43. 134 235. Tran K, Bell C, Stall N, et al. The Effect of Hospital Isolation Precautions on Patient Outcomes and Cost of Care: A Multi-Site, Retrospective, Propensity Score-Matched Cohort Study. Journal of General Internal Medicine. 2016:1-7. 236. Ericson JE, Popoola VO, Smith PB, et al. Burden of Invasive Staphylococcus aureus Infections in Hospitalized Infants. JAMA pediatrics. Dec 2015;169(12):1105-1111. 237. Gimenes M, Salci TP, Tognim MCB, Siqueira VLD, Caparroz-Assef SM. Treating Staphylococcus aureus infections in an intensive care unit at a University Hospital in Brazil. International Journal of Clinical Pharmacy. 2016;38(2):228-232. 238. Kim ES, Kim HB, Kim G, et al. Clinical and epidemiological factors associated with methicillin resistance in community-onset invasive Staphylococcus aureus infections: prospective multicenter cross-sectional study in Korea. PloS one. 2014;9(12):e114127. 239. Altinbas A, Shorbagi A, Ascioglu S, Zarakolu P, Cetinkaya-Sardan Y. Risk factors for intensive care unit acquired nasal colonization of MRSA and its impact on MRSA infection. Journal of clinical laboratory analysis. Sep 2013;27(5):412-417. 240. Chan TC, Cheng VC, Hung IF, Chan FH, Ng WC, Yuen KY. The association between methicillin resistant staphylococcus aureus colonization and mortality in Chinese nursing home older adults: a 2-year prospective cohort. Journal of the American Medical Directors Association. Sep 01 2015;16(9):796-797. 241. Chen CC, Pass SE. Risk factors for and impact of methicillin-resistant Staphylococcus aureus nasal colonization in patients in a medical intensive care unit. American journal of infection control. Nov 2013;41(11):1100-1101. 242. Moore C, Davis NF, Burke JP, et al. Colonisation with methicillin-resistant Staphylococcus aureus prior to renal transplantation is associated with long-term renal allograft failure. Transplant international : official journal of the European Society for Organ Transplantation. Sep 2014;27(9):926-930. 243. Minejima E, Lou M, Nieberg P, Wong-Beringer A. Patients presenting to the hospital with MRSA pneumonia: differentiating characteristics and outcomes with empiric treatment. BMC infectious diseases. May 10 2014;14:252. 244. Hill DM, Schroeppel TJ, Magnotti LJ, et al. Methicillin-resistant Staphylococcus aureus in early ventilator-associated pneumonia: cause for concern? Surgical infections. Dec 2013;14(6):520-524. 245. Tosh PK, Bulens SN, Nadle J, et al. Characterization of hospitalized community-onset staphylococcus aureus lower respiratory tract infections among generally healthy persons 50 years of age or younger. Infectious Diseases in Clinical Practice. 2013;21(6):359-365. 246. Jung WJ, Kang YA, Park MS, et al. Prediction of methicillin-resistant Staphylococcus aureus in patients with non-nosocomial pneumonia. BMC infectious diseases. Aug 09 2013;13:370. 247. Self WH, Wunderink RG, Williams DJ, et al. Staphylococcus aureus Community-acquired Pneumonia: Prevalence, Clinical Characteristics, and Outcomes. Clinical Infectious Diseases. 2016;63(3):300-309. 248. Lin WT, Wu CD, Cheng SC, et al. High Prevalence of Methicillin-Resistant Staphylococcus aureus among Patients with Septic Arthritis Caused by Staphylococcus aureus. PloS one. 2015;10(5):e0127150. 249. Mínguez S, Molinos S, Mateo L, et al. Septic arthritis due to methylcyllin-resistant Staphylococcus aureus in adults. Reumatologia Clinica. 2015;11(6):381-386. 250. de Kraker ME, Davey PG, Grundmann H, group Bs. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe. PLoS Med. Oct 2011;8(10):e1001104. 135 251. Bender R, Blettner M. Calculating the "number needed to be exposed" with adjustment for confounding variables in epidemiological studies. J Clin Epidemiol. May 2002;55(5):525- 530. 252. Liu Q, Li X, Li W, et al. Influence of carbapenem resistance on mortality of patients with Pseudomonas aeruginosa infection: a meta-analysis. Scientific reports. Jun 25 2015;5:11715. 253. Dantas RC, Ferreira ML, Gontijo-Filho PP, Ribas RM. Pseudomonas aeruginosa bacteraemia: independent risk factors for mortality and impact of resistance on outcome. Journal of medical microbiology. Dec 2014;63(Pt 12):1679-1687. 254. Hattemer A, Hauser A, Diaz M, et al. Bacterial and clinical characteristics of health care- and community-acquired bloodstream infections due to Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy. Aug 2013;57(8):3969-3975. 255. Joo EJ, Kang CI, Ha YE, et al. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome. Microbial drug resistance (Larchmont, N.Y.). Jun 2011;17(2):305-312. 256. Kang CI, Kim SH, Park WB, et al. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Microbial drug resistance (Larchmont, N.Y.). Spring 2005;11(1):68-74. 257. Kim YJ, Jun YH, Kim YR, et al. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy. BMC infectious diseases. Mar 24 2014;14:161. 258. Pena C, Suarez C, Gozalo M, et al. Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections. Antimicrobial agents and chemotherapy. Mar 2012;56(3):1265-1272. 259. Suarez C, Pena C, Gavalda L, et al. Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. Sep 2010;14 Suppl 3:e73-78. 260. Tuon FF, Gortz LW, Rocha JL. Risk factors for pan-resistant Pseudomonas aeruginosa bacteremia and the adequacy of antibiotic therapy. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. Jul-Aug 2012;16(4):351-356. 261. Luyt CE, Aubry A, Lu Q, et al. Imipenem, meropenem or doripenem to treat patients with pseudomonas aeruginosa ventilator-associated pneumonia. American Journal of Respiratory and Critical Care Medicine. 2014;189. 262. Eagye KJ, Kuti JL, Nicolau DP. Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosa. Infection control and hospital epidemiology. Aug 2009;30(8):746-752. 263. Judd WR, Ratliff PD, Hickson RP, Stephens DM, Kennedy CA. Clinical and economic impact of meropenem resistance in Pseudomonas aeruginosa–infected patients. American journal of infection control. 2016;44(11):1275-1279. 264. Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO. Imipenem resistance among pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infection control and hospital epidemiology. Sep 2006;27(9):893-900. 265. Lautenbach E, Synnestvedt M, Weiner MG, et al. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infection control and hospital epidemiology. Jan 2010;31(1):47-53. 136 266. Lin KY, Lauderdale TL, Wang JT, Chang SC. Carbapenem-resistant Pseudomonas aeruginosa in Taiwan: Prevalence, risk factors, and impact on outcome of infections. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. Feb 2016;49(1):52- 59. 267. Meradji S, Barguigua A, Zerouali K, et al. Epidemiology of carbapenem non-susceptible Pseudomonas aeruginosa isolates in Eastern Algeria. Antimicrobial Resistance and Infection Control. 2015;4(1). 268. The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudmonas aeruginosa on length of hospital stay. Infection control and hospital epidemiology. Feb 2002;23(2):106-108. 269. Matthaiou DK, Michalopoulos A, Rafailidis PI, et al. Risk factors associated with the isolation of colistin-resistant Gram-negative bacteria: A matched case-control study. Critical Care Medicine. 2008;36(3):807-811. 270. Yilmaz GR, Dizbay M, Guven T, et al. Risk factors for infection with colistin-resistant gram- negative microorganisms: A multicenter study. Annals of Saudi Medicine. 2016;36(3):216- 222. 271. Caselli D, Cesaro S, Ziino O, et al. Multidrug resistant Pseudomonas aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantation. Haematologica. Sep 2010;95(9):1612-1615. 272. Johnson LE, D'Agata EM, Paterson DL, et al. Pseudomonas aeruginosa bacteremia over a 10-year period: multidrug resistance and outcomes in transplant recipients. Transplant infectious disease : an official journal of the Transplantation Society. Jun 2009;11(3):227- 234. 273. Morata L, Cobos-Trigueros N, Martinez JA, et al. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrobial agents and chemotherapy. Sep 2012;56(9):4833-4837. 274. Tam VH, Rogers CA, Chang KT, Weston JS, Caeiro JP, Garey KW. Impact of multidrug- resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrobial agents and chemotherapy. Sep 2010;54(9):3717-3722. 275. Theodorou P, Thamm OC, Perbix W, Phan VT. Pseudomonas aeruginosa bacteremia after burn injury: the impact of multiple-drug resistance. Journal of burn care & research : official publication of the American Burn Association. Nov-Dec 2013;34(6):649-658. 276. Trecarichi EM, Tumbarello M, Caira M, et al. Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies. Haematologica. Jan 2011;96(1):e1-3; author reply e4. 277. Tumbarello M, Repetto E, Trecarichi EM, et al. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality. Epidemiology and infection. Nov 2011;139(11):1740-1749. 278. Cillóniz C, Gabarrús A, Ferrer M, et al. Community-Acquired Pneumonia Due to Multidrug- and Non–Multidrug-Resistant Pseudomonas aeruginosa. Chest. 2016;150(2):415-425. 279. Montero M, Dominguez M, Orozco-Levi M, Salvado M, Knobel H. Mortality of COPD patients infected with multi-resistant Pseudomonas aeruginosa: a case and control study. Infection. Feb 2009;37(1):16-19. 280. Micek ST, Wunderink RG, Kollef MH, et al. An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance. Critical care (London, England). May 06 2015;19:219. 281. Pena C, Gomez-Zorrilla S, Oriol I, et al. Impact of multidrug resistance on Pseudomonas aeruginosa ventilator-associated pneumonia outcome: predictors of early and crude 137 mortality. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. Mar 2013;32(3):413-420. 282. Tumbarello M, De Pascale G, Trecarichi EM, et al. Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients. Intensive care medicine. Apr 2013;39(4):682-692. 283. Yang K, Zhuo H, Guglielmo BJ, Wiener-Kronish J. Multidrug-resistant Pseudomonas aeruginosa ventilator-associated pneumonia: the role of endotracheal aspirate surveillance cultures. The Annals of pharmacotherapy. Jan 2009;43(1):28-35. 284. Yayan J, Ghebremedhin B, Rasche K. Antibiotic resistance of pseudomonas aeruginosa in pneumonia at a single university hospital center in Germany over a 10-Year Period. PloS one. 2015;10(10). 285. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrobial agents and chemotherapy. Jan 2006;50(1):43-48. 286. Paramythiotou E, Lucet JC, Timsit JF, et al. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Mar 1 2004;38(5):670-677. 287. Cao B, Wang H, Sun H, Zhu Y, Chen M. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. The Journal of hospital infection. Jun 2004;57(2):112-118. 288. de Matos ECO, De Matos HJ, Conceição ML, Rodrigues YC, Carneiro ICRS, Lima KVB. Clinical and microbiological features of infections caused by pseudomonas aeruginosa in patients hospitalized in intensive care units. Revista da Sociedade Brasileira de Medicina Tropical. 2016;49(3):305-311. 289. Morales E, Cots F, Sala M, et al. Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition. BMC health services research. May 23 2012;12:122. 290. Nathwani D, Raman G, Sulham K, Gavaghan M, Menon V. Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: A systematic review and meta-analysis. Antimicrobial Resistance and Infection Control. 2014;3(1). 291. Ortega B, Groeneveld AB, Schultsz C. Endemic multidrug-resistant Pseudomonas aeruginosa in critically ill patients. Infection control and hospital epidemiology. Oct 2004;25(10):825-831. 292. Peng Y, Bi J, Shi J, et al. Multidrug-resistant Pseudomonas aeruginosa infections pose growing threat to health careeassociated infection control in the hospitals of Southern China: A case-control surveillance study. American journal of infection control. 2014;42(12):1308-1311. 293. Su H, Ye Q, Wan Q, Zhou J. Predictors of Mortality in Abdominal Organ Transplant Recipients with Pseudomonas aeruginosa Infections. Annals of transplantation. Feb 09 2016;21:86-93. 294. Tleyjeh IM, Tlaygeh HM, Hejal R, Montori VM, Baddour LM. The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Mar 15 2006;42(6):788-797. 295. Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Jul 15 2003;37(2):230-237. 138 296. Watanabe H, Sato S, Kawakami K, et al. A comparative clinical study of pneumonia by penicillin-resistant and -sensitive Streptococcus pneumoniae in a community hospital. Respirology. Mar 2000;5(1):59-64. 297. Gouveia EL, Reis JN, Flannery B, et al. Clinical outcome of pneumococcal meningitis during the emergence of pencillin-resistant Streptococcus pneumoniae: an observational study. BMC infectious diseases. 2011;11:323. 298. Reechaipichitkul W, Assawasanti K, Chaimanee P. Risk factors and clinical outcomes of penicillin resistant S. pneumoniae community-acquired pneumonia in Khon Kaen, Thailand. The Southeast Asian journal of tropical medicine and public health. Mar 2006;37(2):320-326. 299. Sun HK, Nicolau DP, Kuti JL. Resource utilization of adults admitted to a large urban hospital with community-acquired pneumonia caused by Streptococcus pneumoniae. Chest. Sep 2006;130(3):807-814. 300. Song JH, Jung SI, Ki HK, et al. Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in asian countries: a study by the Asian Network for Surveillance of Resistant Pathogens. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Jun 1 2004;38(11):1570-1578. 301. Einarsson S, Kristjansson M, Kristinsson KG, Kjartansson G, Jonsson S. Pneumonia caused by penicillin-non-susceptible and penicillin-susceptible pneumococci in adults: a case- control study. Scandinavian journal of infectious diseases. 1998;30(3):253-256. 302. Sangthawan P, Chantaratchada S, Chanthadisai N, Wattanathum A. Prevalence and clinical significance of community-acquired penicillin-resistant pneumococcal pneumonia in Thailand. Respirology. Jun 2003;8(2):208-212. 303. Falco V, Almirante B, Jordano Q, et al. Influence of penicillin resistance on outcome in adult patients with invasive pneumococcal pneumonia: is penicillin useful against intermediately resistant strains? The Journal of antimicrobial chemotherapy. Aug 2004;54(2):481-488. 304. Pallares R, Linares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med. Aug 24 1995;333(8):474-480. 305. Ewig S, Ruiz M, Torres A, et al. Pneumonia acquired in the community through drug- resistant Streptococcus pneumoniae. Am J Respir Crit Care Med. Jun 1999;159(6):1835- 1842. 306. Aspa J, Rajas O, Rodriguez de Castro F, et al. Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Mar 15 2004;38(6):787-798. 307. Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health. Feb 2000;90(2):223-229. 308. Yigla M, Finkelstein R, Hashman N, Green P, Cohn L, Merzbach D. Epidemiology and clinical spectrum of pneumococcal infections: an Israeli viewpoint. The Journal of hospital infection. Jan 1995;29(1):57-64. 309. Pallares R, Capdevila O, Linares J, et al. The effect of cephalosporin resistance on mortality in adult patients with nonmeningeal systemic pneumococcal infections. Am J Med. Aug 01 2002;113(2):120-126. 310. Jehl FB, JP.; Poirer, R.; Leophonte, P.; Sirot, J.; Chardon H. Enquête nationale sur les pneumonies communautaires à pneumocoque chez des malades adultes hospitalisés. Médecine et maladies infectieuses. 2002;+ 139 32(6):267-283. 311. Weinstein MP, Klugman KP, Jones RN. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Jun 1 2009;48(11):1596-1600. 312. Carmeli Y, Eliopoulos G, Mozaffari E, Samore M. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med. Oct 28 2002;162(19):2223-2228. 313. DiazGranados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Aug 1 2005;41(3):327-333. 314. Salgado CD, Farr BM. Outcomes associated with vancomycin-resistant enterococci: a meta-analysis. Infection control and hospital epidemiology. Sep 2003;24(9):690-698. 315. da Silva NS, Muniz VD, Estofolete CF, Furtado GH, Rubio FG. Identification of temporal clusters and risk factors of bacteremia by nosocomial vancomycin-resistant enterococci. American journal of infection control. Apr 2014;42(4):389-392. 316. Yoo J-H, Lee, D-G., Choi, SM., Choi, J-H., Shin, W-S., Kim, M., Yong, D., Lee, K., Min, W-S., Kim, C-C. Vancomycin-resistant Enterococcal Bacteremia in a Hematology Unit: Molecular Epidemioogy and Analysis of Clinical Course. Journal of Korean medical science. 2005;20:169-176. 317. Lodise TP, McKinnon PS, Tam VH, Rybak MJ. Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Apr 1 2002;34(7):922-929. 318. Peset V, Tallon P, Sola C, et al. Epidemiological, microbiological, clinical, and prognostic factors of bacteremia caused by high-level vancomycin-resistant Enterococcus species. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. Oct 2000;19(10):742-749. 319. Garbutt JM, Ventrapragada M, Littenberg B, Mundy LM. Association between resistance to vancomycin and death in cases of Enterococcus faecium bacteremia. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Mar 2000;30(3):466-472. 320. Bhavnani S, Drake, JA., Forrest, A., Deinhart, JA., Jones, RN. Biedenbach, DJ., Ballow, CH. Nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis. 2000;36:145-158. 321. Lucas GM, Lechtzin N, Puryear DW, Yau LL, Flexner CW, Moore RD. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. May 1998;26(5):1127-1133. 322. Stosor V, Peterson LR, Postelnick M, Noskin GA. Enterococcus faecium bacteremia: does vancomycin resistance make a difference? Arch Intern Med. Mar 9 1998;158(5):522-527. 323. Linden PK, Pasculle AW, Manez R, et al. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Apr 1996;22(4):663-670. 324. Krcmery V, Bilikova E, Svetlansky I, Kovacicova G. Is vancomycin resistance in enterococci predictive of inferior outcome of enterococcal bacteremia? Clinical infectious diseases : an 140 official publication of the Infectious Diseases Society of America. Apr 1 2001;32(7):1110- 1112. 325. Vergis EN, Hayden MK, Chow JW, et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. a prospective multicenter study. Annals of internal medicine. Oct 2 2001;135(7):484-492. 326. Shay DK, Maloney SA, Montecalvo M, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis. Oct 1995;172(4):993-1000. 327. Wells CL, Juni BA, Cameron SB, et al. Stool carriage, clinical isolation, and mortality during an outbreak of vancomycin-resistant enterococci in hospitalized medical and/or surgical patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Jul 1995;21(1):45-50. 328. Cheah AL, Spelman T, Liew D, et al. Enterococcal bacteraemia: factors influencing mortality, length of stay and costs of hospitalization. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. Apr 2013;19(4):E181-189. 329. DiazGranados CA, Jernigan JA. Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. J Infect Dis. Feb 15 2005;191(4):588-595. 330. Peel T, Cheng AC, Spelman T, Huysmans M, Spelman D. Differing risk factors for vancomycin-resistant and vancomycin-sensitive enterococcal bacteraemia. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. Apr 2012;18(4):388-394. 331. Mainous MR, Lipsett PA, O'Brien M. Enterococcal bacteremia in the surgical intensive care unit. Does vancomycin resistance affect mortality? The Johns Hopkins SICU Study Group. Arch Surg. Jan 1997;132(1):76-81. 332. Centers for Disease C, Prevention. Nosocomial enterococci resistant to vancomycin-- United States, 1989-1993. MMWR Morb Mortal Wkly Rep. Aug 06 1993;42(30):597-599. 333. Lautenbach E, Bilker WB, Brennan PJ. Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infection control and hospital epidemiology. May 1999;20(5):318-323. 334. Stroud L, Edwards J, Danzing L, Culver D, Gaynes R. Risk factors for mortality associated with enterococcal bloodstream infections. Infection control and hospital epidemiology. Sep 1996;17(9):576-580. 335. Song X, Srinivasan A, Plaut D, Perl TM. Effect of nosocomial vancomycin-resistant enterococcal bacteremia on mortality, length of stay, and costs. Infection control and hospital epidemiology. Apr 2003;24(4):251-256. 336. Edmond MB, Ober JF, Dawson JD, Weinbaum DL, Wenzel RP. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Dec 1996;23(6):1234-1239. 337. Edmond MB, Ober JF, Weinbaum DL, et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. May 1995;20(5):1126-1133. 338. Butler AM, Olsen MA, Merz LR, et al. Attributable costs of enterococcal bloodstream infections in a nonsurgical hospital cohort. Infection control and hospital epidemiology. Jan 2010;31(1):28-35. 141 339. Khair HN, VanTassell P, Henderson JP, Warren DK, Marschall J, Program CDCPE. Vancomycin resistance has no influence on outcomes of enterococcal bacteriuria. The Journal of hospital infection. Nov 2013;85(3):183-188. 340. Tornieporth NG, Roberts RB, John J, Hafner A, Riley LW. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Oct 1996;23(4):767-772. 142 Burden of antimicrobial resistance Literature selection grids Alessandro Cassini and Diamantis Plachouras with contributions from Ana Hoxha, Liselotte Diaz Högberg and Carl Suetens 143 Sample size N refers to total number of cases and controls (no score) Calculation a priori: ++ if performed (e.g. based on expected prevalence or on litterature data) or the study refers to large national surveys; - if not performed Study type Study type: ++ matched cohort or case-control studies; + prospective cohort or case-control studies; - restrospective database studies Infection type HCA: health-care associated; CA: community associated; Mix: health-care and community associated together Geographical: ++ if the study was conducted in an EU/EEA setting; + if the study was conducted in high-income country(ref. World bank); - if the study was not conducted in an EU/EEA or high-in Representativeness Demographical: ++ if the study population represents all age groups; + if the study population represents selected age-specific groups (e.g. elderly, infants); - if the study population represents a Clinical: ++ if the study population represents the overall hospital population; + if the study population partially represents the hospital population; - if the study population represents a disease-sp Exlusion/inclusion criteria: ++ if the same exclusion/inclusion criteria were adopted for both cases and controls; + if some (but not all) exclusion/inclusion criteria were adopted for both cases an Demographics: ++ if performed for age and sex; + if performed only for age or only for sex; - if not performed at all Matching or controlling for confounders Underlying disease: ++ if performed for two or more criteria (e.g. comorbidity score, McCabe score, severity index, n. comorbidities, allergy, immunosuppression status, prior hospitalisation etc..) Infection site: ++ if performed ; - if not performed Hospital and unit/ward: ++ if same hospital and same unit/ward; + if same hospital but different unit/ward; - if not same hospital and/or not same unit/ward Follow-up: ++ if ≥ 28 days; - if < 28 days Risk difference Statistically significant outcome results: ++ if results and 95%CI are statistically significant; - if results and 95%CI are not statistically significant Case fatality and LOS refer to risk difference estimates in cases and controls (no score) Scoring table ++ Matches completely/is completely fulfilled + Matches incompletely but sufficiently/is only partly but sufficiently fulfilled - Does not match or matches insufficiently/is insufficiently fulfilled c.b.e. Cannot be evaluated 144 etting tegory and age-specific groups (e.g. liver transplanted patients, cancer patients, etc..) xclusion/inclusion criteria were different in cases and controls for only one criteria; - if not performed at all 145 3GCREC third-generation cephalosporin-resistant E. coli 3GCRKP third-generation cephalosporin-resistant K. pneumoniae AMR antimicrobial resistance BSI bloodstream infection CAI Community-associated infections CI confidence interval ColRACI colistin-resistant Acinetobacter spp. ColREC colistin-resistant E. coli ColRKP colistin-resistant K. pneumoniae ColRPA colistin-resistant P. aeruginosa CRACI carbapenem-resistant Acinetobacter spp. CREC carbapenem-resistant E. coli CRKP carbapenem-resistant K. pneumoniae CRPA carbapenem-resistant P. aeruginosa CSF cerebral spine fluid DALY disability-adjusted life years EARS-Net European Antimicrobial Resistance Surveillance Network EEA European Economic Area EU European Union HAI healthcare-associated infection LOS length of stay MDR multidrug-resistant MDRACI multidrug-resistant Acinetobacter spp MDRPA multidrug-resistant P. aeruginosa MRSA meticillin-resistant Staphylococcus aureus MS Member State OECD Organisation for Economic Co-operation and Development OTH other infection site including digestive tract infections, skin and soft tissue infections (SSTI), eye, ear, nose or mouth infections, bone and joint infections, cardiovascular infections, reproductive tract infections and other less frequent infections PMRSP penicillin- and macrolide-resistant S. pneumoniae PPS point prevalence survey of healthcare-associated infections and antimicrobial use in acute care hospitals PRSP penicillin-resistant S. pneumoniae ; RESP respiratory infections (including pneumonia, and low respiratory tract infection) S-BSI secondary BSI SP specified pathogens SPDAR specified pathogens with defined antimicrobial resistance SSI surgical site infection UTI urinary tract infection VRE vancomycin-resistant enterococci 146 Checklist for the evaluation of the most relevant studies for building antimicrobial resistance (AMR) outcome trees, healthcare-associated infection (HAI) attributable case fatality and attributable length-of-stay (LOS) Study Study type Infection type Sample size Representativeness Matching or controlling for confounders Risk difference N (cases;controls) calculation a priori Geographical Demographical Clinical Exclusion/inclusion criteria Demographics Underlying disease Infection site Hospital and unit/ward Follow-up Statistically significat outcome results Case fatality LOS Nr. First author, year HCA; CA; Mix; c.b.e □ ++; □ -; □ c.b.e □ ++; +; -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; -; □ c.b.e □ ++; □ -; □ c.b.e %; RR; OR; aHR; etc (days) 1 Gallagher, 2014 Score ++ c.b.e 111 cases 111 controls - + ++ ++ ++ - - - ++ c.b.e ++ Mort. rate cases=32% Mort.rate contr=13% OR=3.6; 95%CI(1.2 to 10.5) mean cases=63 controls=20 Comments Matched Case-control study (matched only by month/year and unit) no information in the article no univariate analyses no univariate analyses R vs NI mortality in hospital 2 Stewardson, 2016 Score - Mix 360 cases 2100 controls 604797 NI ++ ++ ++ + ++ - - - - c.b.e ++ Mort. rate resistant=16.1% Mort.rate sensitive=10.1% Mort.rate NI=1.7% R vs NI: HR*=2.88/2.25/1.80 R vs S: HR*=1.39/1.43/1.63 no specific data, see full-text for modelling values* Comments Multicentre retrospective cohort study HC onset: 59.4% cases, 37.1% controls community onset: 40.6% cases, 62.9% controls the study analysed Enterobacteriaceae (E. coli, K. spp. and Proteus spp), but included because of its methodological value patients with acute- care episodes lasting more than one day no univariate analyses matched in model 2 no univariate analyses all BSI or NI mortality in hospital all HR * the study models the excess in LOS and mortality between groups proposing 3 models for each * the study models the excess in LOS and mortality between groups proposing 3 models for each 1 Lee, 2014 Score - CA 9 cases 153 controls - + ++ ++ ++ - - - + ++ - a)Mort.rate cases=33.3% Mort.rate controls=24.2% b)Mort.rate cases=33.3% Mort.rate controls=16.3% no data Comments Retrospective case-control study no univariate analyses no univariate analyses all BSI a)30 day mortality b)bacteremia- related mortality a)30 day mortality b)bacteremia-related mortality 2 Panhotra, 2014 Score - HCA 10 cases 16 controls - + ++ ++ ++ - - - + c.b.e ++ Mort.rate cases=60% Mort.controls=6.2% cases=44.2 controls-24.1 Comments Retrospective case-control study all BSI mortality in hospital 3 Tumbarello, 2006 Score - Mix 48 cases 99 controls - ++ ++ ++ ++ + ++ - + - ++ a) Mort.rate cases= 25% Mort.rate controls=11% b) Mort. rate cases=52% Mort.rate controls=29% OR=2.62; 95%CI(1.28 -5.35) mean ± SD cases=34±20 controls=31±17 Comments Retrospective case-case- control study HCA: 96% cases, 82% controls not matched but controlled in univariate analyses for gender, age was higher in not matched but controlled in univariate analyses for Charlson index, APACHE II score and main all BSI a)7 days b)21 days a)7 days b)21 days 4 Marra, 2006 Score - HCA 56 cases 52 controls - - ++ ++ ++ ++ ++ - + - ++ Mort. rate cases=32% Mort.rate controls=15% no specific data Comments Retrospective cohort study included adults and infants not matched but controlled in univariate analyses not matched but controlled in univariate analyses for McCabe score and nr. Of comorbidities all BSI 15 days 5 Kang, 2004 Score - Mix 10 cases 20 controls - + ++ - ++ ++ ++ - + ++ c.b.e Mort. rate cases=60% Mort.rate controls=30% Comments Retrospective cohort study HCA: 93.3% cases, 93.3% controls all patients had liver chirrosis and spontaneous bacterial peritonitis matched for Child- Pugh score (severity o chirrosis) and APACHE II score all BSI 30 days no test for KP since the study researched KP and EC together, mortality data were available only for KP 6 Kim BN, 2002 Score - Mix 44 cases 118 controls - + ++ ++ ++ ++ ++ - + c.b.e - Mort. rate cases=23% Mort.rate controls=20% Mean cases=39.6 controls=23.9 Comments Retrospective cohort study HCA: 86.4% cases, 42.4% controls not matched but controlled in univariate analyses not matched but controlled in univariate analyses for McCabe score all BSI mortality in hospital 7 Ariffin, 2000 Score - c.b.e 16 cases 15 controls - - + - ++ c.b.e + - ++ c.b.e ++ Mort. rate cases=50% Mort.rate controls=13% OR=6.5; 95%CI(1.1-38.6) Comments Retrospective cohort study no information in the article all patients are pediatric patients <12 years all patients were in pediatric oncology unit and had febrile neutropenia no information not matched but controlled in univariate analyses for hematological malignacies all BSI mortality in hospital the article defines the outcome as sepsis related mortality 8 Mosqueda-Gomez, 2008 Score - Mix 17 cases 104 controls - - ++ ++ ++ + - - + c.b.e - Mort. rate cases=35% Mort.rate controls=26.9% mean cases=20.9 controls=15.9 Comments Retrospecti ve case- control study HCA: 100% cases, 45.2% controls not matched but controlled for gender in univariate analyses, age was higher in controls all BSI mortality in hospital 9 Szilagyi, 2009 Score - HCA 100 cases 100 controls - ++ ++ ++ ++ ++ - - - c.b.e ++ a) Mort. rate cases=36% Mort.rate controls=23% OR=2.5; 95%CI(1.0–5.4) b) Mort. rate cases=18% Mort.rate controls=18% OR=5; 95%CI(1.5–16.2) median cases=10.5 controls=10 Comments Retrospective cohort study not matched but controlled in univariate analyses all BSI mortality in hospital a)all cause mort.
 b)inf. related mort. 10 Pena, 2001 Score + HCA 49 cases 43 controls - ++ ++ + ++ ++ - - + c.b.e - a)Mort. rate cases=32% Mort.rate controls=24% b)Mort. rate cases=16% Mort.rate controls=14% Comments Prospective cohort study patients were part of an outbreak of ESBL- KP not matched but controlled in univariate analyses all BSI mortality in hospital a)overall mortality b)attributable mortality 11 Paterson, 2004 Score + HCA 78 cases 175 controls - c.b.e ++ ++ ++ ++ - - - - - Mort. rate cases=27% Mort.rate controls=23% before isolation mean±SD cases=36.3±5.4 controls=19.9±1.9 Comments International prospective study different countries; South Africa, Taiwan, Australia, Argentina, the United States, Belgium, and Turkey >16 years not matched but controlled in univariate analyses all BSI 14 days 12 Tuon, 2010 Score - c.b.e 63 cases 41 controls - - ++ ++ ++ + + - + ++ - Mort. rate cases=49.2% Mort.rate controls=41.9% Mean ± SD cases= 52.2 ± 39.6 controls=36.0 ±29.4 Comments Retrospective cohort study no information in the article >12 years not matched but controlled in univariate analyses for age, gender was not equally distributed not matched but controlled in univariate analyses for main diseases, only diabetes was higher in controls all BSI 30 days 13 Lee, 2011 Score - CA 33 cases 219 controls - + ++ + ++ ++ ++ - + c.b.e - Mort. rate cases=12.1% Mort.rate controls=16% Mean ± SD cases=26.5 ± 39.0 controls=19.9 ± 42.4 Comments Retrospecti ve case- control study community onset infection HCA: 75.8% cases, 56.2% controls community-onset bacteremia patients from Emergency department, with community onset infection not matched but controlled in univariate analyses not matched but controlled in univariate analyses for McCabe score and main diseases all BSI mortality in hospital 22 cases Mort. cases=18% Prior to UTI 64 controls Mort. Contr.=2% Median (IQR) Score - HCA - + ++ - ++ + + - + c.b.e - cases=8(1-14) controls=1(1-4) 1 Brizendine, 2015 not matched but Comments Retrospecti ve cohort study not expicitly said in the article, but very specific patients all patients had solid organ transplant controlled in univariate analyses for age, gender was not equally distributed all patients had solid organ transplant all UTIs mortality in hospital 1 Loh, 2006 Score - Mix 47 cases 394 controls - - ++ ++ ++ ++ ++ - + c.b.e - Mort. rate cases=21.3% Mort.rate controls=12.4% Median (IQR) cases=14(8-32) controls=5(3-10) Comments Retrospective cohort study no data on proportion HCA/CA >12 years not matched but controlled in univariate analyses not matched but controlled in univariate analyses for comorbidity scoring all Resp tract mortality in hospital 1 Gomes, 2006 Score - HCA 68 cases 75 controls ++ - ++ ++ ++ - - - + - c.b.e Mort. rate cases=20.6% Mort.rate controls=21.3% no data Comments Retrospecti ve cohort study univariate not available because compared died vs survived patients 21 days univariate not available because compared died vs survived patients 2 Lin, 2003 Score + Mix 43 cases 86 controls - + ++ ++ ++ + ++ ++ + c.b.e - Mort. rate cases=27.9% Mort.rate controls=20.9% mean(range) cases=45 (0-143) controls=18 0-82) Comments Prospective case-control study HCA: 44.2% cases, 14% controls not matched but controlled in univariate analyses for gender, age was higher in cases not matched but controlled in univariate analyses for main diseases mortality in hospital 3 Kuo, 2007 Score - Mix 54 cases 54 controls - + + + ++ ++ - ++ ++ ++ - Mort. rate cases=15% Mort.rate controls=13% mean(range) cases=45 (0-143) controls=18 0-82) Comments Retrospecti ve case- control study HCA: 79.6% cases, 48.1% controls all patients were children patients were in ICU not matched but controlled in univariate analyses 30 days 4 Chiu, 2005 Score - HCA 15 cases 16 controls - + + + ++ + c.b.e c.be ++ c.b.e c.b.e Mort. rate cases=20% Mort.rate controls=12.5% no data Comments Retrospecti ve case- control study nosocomial infections all patients were neonatals patients were in NICU not matched but controlled in univariate analyses for age the study was on Enterobacteriaceae and despite mortality data no else could be extrapolated the study was on Enterobacteriace ae and despite mortality data no else could be extrapolated mortality in hospital the study was on Enterobacteriaceae and despite mortality data no else could be extrapolated 5 Huang, 2007 Score + HCA 19 cases 12 controls - - + + ++ c.b.e - - ++ ++ c.b.e Mort. rate cases=10.5% Mort.rate controls=0% no data Comments Prospective cohort study nosocomial infections all patients were neonatals patients were in NICU study was on KP and EC and data could not be separated 30 days study was on KP and EC and data could not be separated 6 BARF, 2002 Score - Mix 9 cases 9 controls - + ++ ++ ++ + ++ ++ - c.b.e - Mort. rate cases=44% Mort.rate controls=33% median: cases=20 controls=33.5 Comments Survey HCA: 95% cases, 39% controls matched for age matched for major diseases mortality in hospital Sample size N refers to total number of cases and controls (no score) Calculation a priori: ++ if performed (e.g. based on expected prevalence or on litterature data) or the study refers to large national surveys; - if not performed Study type Study type: ++ matched cohort or case-control studies; + prospective cohort or case-control studies; - restrospective database studies Infection type HCA: health-care associated; CA: community associated; Mix: health-care and community associated together Geographical: ++ if the study was conducted in an EU/EEA setting; + if the study was conducted in high-income country(ref. World bank); - if the study was not conducted in an EU/EEA or high-income country setting Representativeness Demographical: ++ if the study population represents all age groups; + if the study population represents selected age-specific groups (e.g. elderly, infants); - if the study population represents a selected sex category and age-specific groups Clinical: ++ if the study population represents the overall hospital population; + if the study population partially represents the hospital population; - if the study population represents a disease-specific population (e.g. liver transplanted patients, cancer patients, etc..) Exlusion/inclusion criteria: ++ if the same exclusion/inclusion criteria were adopted for both cases and controls; + if some (but not all) exclusion/inclusion criteria were adopted for both cases and controls; - if exclusion/inclusion criteria were different in cases and controls Demographics: ++ if performed for age and sex; + if performed only for age or only for sex; - if not performed at all Matching or controlling for Underlying disease: ++ if performed for two or more criteria (e.g. comorbidity score, McCabe score, severity index, n. comorbidities, allergy, immunosuppression status, prior hospitalisation etc..); + if performed for only one criteria; - if not performed at all confounders Risk difference Infection site: ++ if performed ; - if not performed Hospital and unit/ward: ++ if same hospital and same unit/ward; + if same hospital but different unit/ward; - if not same hospital and/or not same unit/ward Follow-up: ++ if ≥ 28 days; - if < 28 days Statistically significant outcome results: ++ if results and 95%CI are statistically significant; - if results and 95%CI are not statistically significant Case fatality and LOS refer to risk difference estimates in cases and controls (no score) Scoring table Mixed inf. site R vs S Resp tract R vs S UTI R vs S BSI R vs S BSI R vs NI 3GCRKP 147 ++ Matches completely/is completely fulfilled + Matches incompletely but sufficiently/is only partly but sufficiently fulfilled - Does not match or matches insufficiently/i s insufficiently fulfilled c.b.e. Cannot be evaluated 148 Checklist for the evaluation of the most relevant studies for building antimicrobial resistance (AMR) outcome trees, healthcare-associated infection (HAI) attributable case fatality and attributable length-of-stay (LOS) Study Study type Infection type Sample size Representativeness Matching or controlling for confounders Risk difference N (cases;controls) calculation a priori Geographical Demographical Clinical Exclusion/inclusion criteria Demographics Underlying disease Infection site Hospital and unit/ward Follow-up Statistically significat outcome results Case fatality LOS Nr. First author, year HCA; CA; Mix; c.b.e □ ++; □ -; □ c.b.e □ ++; +; -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; -; □ c.b.e □ ++; □ -; □ c.b.e %; RR; OR; aHR; etc (days) BSI R vs NI 1 Borer, 2009 Score ++ c.b.e 32 cases 32 controls - + ++ ++ ++ ++ ++ - + c.b.e ++ Mort. rate cases=71.9% Mort. rate controls=21.9% RR=3.3; 95%CI(2.9-28.5) median: cases=21 controls=18 Comments Matched retrospective study no information in the article controls had an infectious disease but not BSI BSI vs NI (without BSI) mortality in hospital 2 Gallagher, 2014 Score ++ c.b.e 43 cases 154 controls - + ++ ++ ++ - - - ++ c.b.e ++ Mort.cases= 45%
 Mort.contr= 18% OR=3.8; 95%CI(1.4-9.9) mean: cases=54 controls=19 Comments Matched Case-control study (matched only by month/year and unit) no information in the article no univariate analyses no univariate analyses BSI vs NI mortality in hospital 3 Mouloudi, 2014 Score ++ HCA 17 cases 34 controls - ++ ++ - ++ ++ ++ - ++ c.b.e c.b.e Mort.cases=82.7% Mort. contr=32% □ in ICU median (range): cases=28(10-64) controls=no info Comments Observational matched cohort study patients with liver transplant in ICU patients with liver transplant in ICU not matched but controlled in univariate analyses not matched but controlled in univariate analyses for main indicators BSI vs NI ICU mortality in hospital no infrmation 985 patients Attribut. mort.= 26-44% no data in 7 studies (-3) and (-4)% in 2 remaining BSI R vs S Score - c.b.e - c.b.e ++ ++ ++ c.b.e c.b.e - c.b.e ++ studies RR=2.05; 95%CI(1.56–2.69)* RR 2.19; 95%CI(1.82–2.63)** 1 Falagas, 2014 RR=1.46; 95%CI(0.47–4.49)*** Review the same refered to cases and controls of each study different in the different different in the different Metanalysis studies studies 6 studies were on * referred to all 9 studies Comments (on Enterobacteri no information in the article Articles from different countries BSI, the other 3 were on mixed different in different studies only RR* and RR** ** only 6 BSI studies *** remaining 3 (not BSI/mixed site of aceae, but site of infection infection) studies 8/9 studies 37 cases a) Mort.cases= 56.8%
 median(range): 22 controls Mort.contr= 41% total=26 (8-90) in ICU Score + HCA - ++ ++ + ++ ++ ++ - ++ c.b.e c.b.e b) Mort.cases= 67.6%
Mort.contr= 41% c)Mort.cases= 27%
 2 Mouloudi, 2010 Mort.contr= 14% cases were all CRKP, 18 not matched but not matched but a) mortality in ICU Comments Prospective nested case- control study metallo-β-lactamase KP and 17 carbapenemase- producing KP. The mortality for data were ICU patientd controlled in univariate analyses controlled in univariate analyses for main diseases all BSI mortality in hospital no information b) mortality in hospital c) attributable mortality (within 24h from infection or with infection symptoms despite appropriate summed up together therapy) 13 cases + Mort.cases= 46% no data 3 Simkins, 2014 Score c.b.e 39 controls ++ Mort.contr= 0% Comments Case-control no information in 6.5 months study the article Crude mortality rates =20-70% median time in Attribut. mort. patients: developing CRKP -hematologic=75% infections in hospital Score - Mix c.b.e - c.b.e ++ ++ NA c.b.e c.b.e - NA c.b.e c.b.e -ICU=11% -transplant=7% (range): cases=14(0- 152) 4 Viale, 2013 -LTC=5% -medicine=2% -surgery=2% the review does not pool articled with different articled with different Comments Review the patients together, but considers every study Articles from different countries results results all BSI different in different studies separately 103 cases + + ++ Mort.cases= 43.7% median (range): Score - HCA 214 controls - ++ ++ - - + ++ ++ Mort.contr= 29% cases=17(1-125) controls=12(1-202) 5 Hussein, 2013 Retrospecti not matched but Comments ve case- control all patients had health-care associated infection controlled in univariate analyses all BSI 30 days study 42 cases a)Mort. cases=69% mean LOS before 85 controls Mort. controls=24% infection detection Score - Mix - + ++ ++ ++ ++ ++ - + c.b.e ++ b)Mort. cases=48% ±SD: survivors=25±81 Mort. controls=17% deceased=27±37 6 Ben-David, 2012 Comments Retrospecti ve cohort study HCA: 100% cases, 79% controls not matched but controlled in univariate analyses not matched but controlled in univariate analyses for Charlson's score, not all BSI mortality in hospital a)in hospital mortality b)infection related mortality other diseases 14 cases Mort.cases= 42.8% mean LOS before Score + c.b.e 148 controls - ++ ++ ++ ++ + - - - - - Mort.contr= 16.9% OR=3.95; 95%CI(0.94–16.6) bacteraemia ±SD: both groups=25.85 ± 7 Daikos, 2009 37.87 Comments Prospective observation al study no information in the article not matched but controlled in univariate analyses for gender, age higher in controls all BSI 2 hospitals 14 days 22 cases Mort. cases=18% median: UTI R vs S Score - c.b.e 64 controls - + ++ - ++ ++ + - + c.b.e c.b.e Mort. contr.=2% cases=7 controls=1 1 Brizendine, 2015 Comments Retrospecti ve cohort study no information in the article all patients had solid organ transplant not matched but controlled in univariate analyses all patients had solid organ transplant, no other comorbidieties considered all UTI mortality in hospital no information 20 cases Mort. cases=30% median(IQR): Score - HCA 80 controls - + ++ - ++ ++ - - + c.b.e ++ Mort. contr.=10% HR=3.0; 95%CI(1.0–9.0) cases=17(9-43) controls=7(5-10) 2 Pouch, 2015 Comments Retrospecti ve case- control study not expicitly said in the article, but very specific patients all patients had solid kideny transplant not matched but controlled in univariate analyses all UTI not defined 135 cases Mort. cases=29% mean±SD Score - c.b.e 127 controls ++ + ++ ++ ++ ++ ++ - + c.b.e - Mort. contr.=25% cases=28±33 controls=22±28 3 Shilo, 2013 Comments Retrospecti ve case- control study no information in the article cases defined as bacteruria, since UTI relates with symptomps while bacteruria not always not matched but controlled in univariate analyses not matched but controlled in univariate analyses for main diseases all bacteruria mortality in hospital 10 cases a)Mort cases=0% median (range): Mixed inf. 20 controls Mort. Contr.=5% cases=16(14-27) site R vs NI Score ++ HCA - ++ ++ - ++ ++ ++ - + ++ - b)Mort. cases=0% Mort. contr.=15% controls=20(15-62) 1 Giannella, 2014 Comments Matched case-control study not expicitly said in the article, but very specific patients the cases were selected as colonized, though all of them after developed BSI all patients had liver transplant not matched but controlled in univariate analyses not matched but controlled in univariate analyses all cases had positive rectal swabs initially and BSIs after a)30 days b)60 days a)30 days b)60 days 9 cases ++ ++ - Mort. cases=78% cases=60 Score - HCA 18 controls - ++ ++ - - + ++ ++ Mort. contr.=11% controls=32 2 Luebbert, 2014 Comments Retrospecti ve case- control study not expicitly said in the article, but very specific patients all patients had liver transplant R vs NI 3 months from last case 133 cases Mort. cases =21.8% mean±SD (93 colonized, (Mort. Infected=47.5% cases=35±24 Score - c.b.e 40infected) - ++ ++ ++ + ++ - - ++ c.b.e - Mort. Colonized=10.7%) controls=18±12 400 controls Mort.contr. =15% 3 Nouvenne, 2014 Comments Retrospecti ve cross- sectional study no information in the article cases were part of an outbreak, while controls were randomly selcted not matched but controlled in univariate analyses R vs NI mortality in hospital referes only yo the comparison of all cases (infected+colonized) with controls 43 cases Mort.cases= 88% no data Score + HCA 150 controls - + ++ - ++ + ++ - ++ c.b.e ++ Mort.contr.= 52% aHR=5.9; 95%CI(3.2-11.0) 4 Bleumin, 2012 Comments Prospective nested case- control study all patients were cronic hemodialyses patients not matched but controlled in univariate analyses for age, cases had more female patients not matched but controlled in univariate analyses for main diseases, differences in central catheter R vs NI study period presence 48 cases Mort.cases=45.8% mean±SD Score + HCA 132 controls - + ++ + ++ ++ ++ - ++ c.b.e - Mort.contr.=38.6% cases=6.06±1.23 controls=8.39 ±1.49 5 Debby, 2012 Comments Prospective cohort study all cases were detected with rectal swab analyses, but developed BSI, ICU patients not matched but controlled in univariate analyses not matched but controlled in univariate analyses for main R vs NI mortality in hospital pneumonia, etc diseases 48 CRKP Mort. rate resistant=44% median (IQR): 56 CSKP Mort. rate sensitive=12.5% cases=19 (9-38) 59 controls Mort. rate NI=2% controls=2 (1-4) Score - HCA - + ++ ++ ++ ++ - - + c.b.e ++ R vs S: OR=5.4; 95%CI(1.7–17.1) R vs NI: OR=6.7; 6 Schwaber, 2008 95%CI(2.4–18.8) Comments Retrospecti ve case- case-control not matched but controlled in univariate analyses mortality in hospital study 20 CRKP Mort. rate resistant=45% Median (range): 36 CSKP Mort. rate sensitive=28% cases=40(23-82) Score - HCA 248 controls - + ++ - ++ ++ - - + ++ ++ Mort.rate NI=7% controls=12 (9-21) 7 Pereira, 2015 R vs NI: HR=6.92; 95%CI(3.24–14.79) Comments Retrospecti ve cohort study not expicitly said in the article, but very specific patients the results are presented for R vs (S+NI) all patients had liver transplant not matched but controlled in univariate analyses 1 year from transplant HR, no data on mortality rates Mortality rates extraxcted from survival analyses 83 resistant Mort. rate resistant=27% no data Score c.b.e 78 sensitive 161 NI - ++ ++ ++ ++ + - - + c.b.e ++ Mort. rate sensitive=15% Mort.rate NI=4% 8 Kofteridis, 2014 Comments Case-case- control study no information in the article not matched but controlled in univariate analyses for age not defined significative R vs NI, not significant R vs S Mixed inf. site R vs S 1 Candevir Ulu, 2015 Score - HCA 47 cases 51 controls - - ++ ++ ++ + - - + c.b.e - Mortality cases=44,7% Mortality contr.=51% mean: cases=37.3 controls=29.94 median: cases=19 controls=11 Comments Retrospecti ve cohort study not matched but controlled in univariate analyses for age mortality in hospital 2 Dizbay, 2014 Score - HCA 42 cases 798 controls - - ++ ++ ++ ++ - - + c.b.e ++ Mortality cases=57.1% Mortality contr.=27.4% mean cases=38.27 controls=28.17 Comments Retrospecti ve study not matched but controlled in univariate analyses not defined CRKP 149 3 Hoxha 2016 Score ++ c.b.e 49 cases 49 controls ++ ++ ++ ++ ++ ++ ++ ++ - ++ ++ a) Attribut. mort.= 16% b) Attribut. mort.= 41% mIRR=3.0; 95%CI(1.3-7.1) no data Comments Matched cohort study no information in the article Matched for age and controlled in univariate analyese for gender not matched but controlled in univariate analyses for Charlson index and SAPS 2 score a)6 days b)30 days a)6 days b)30 days 4 Jiao, 2015 Score - HCA 30 cases 30 controls - - ++ ++ ++ ++ - - + c.b.e c.b.e Mort. cases=33.6% Mort. contr.=16.6% mean: cases=33.8 controls=18 Comments Retrospecti ve case- control study Matched for age and controlled in univariate analyese for gender mortality in hospital no information 5 Patel, 2008 Score ++ c.b.e 99 cases 99 controls - + ++ ++ ++ ++ ++ ++ + c.b.e ++ Mort. cases=48% Mort. contr.=26% OR=4.69; 95%CI(1.9–11.58) mean±SD cases=25.19±24.9 controls=6.44±10.1 median: cases=21 controls=1 Comments Matched case-case study no information in the article not matched but controlled in univariate analyses not matched but controlled in univariate analyses for main diseases mortality in hospital 6 Correa, 2013 Score ++ HCA 20 cases 40 controls - - ++ ++ ++ ++ + ++ ++ c.b.e - Mort. cases=50% Mort. contr.=27.5% mean: cases=45.5 controls=27 Comments Matched case-control study all HCA infections not matched but controlled in univariate analyses not matched but controlled in univariate analyses for MC Cabe score, APACHE II score at admission was different mortality in hospital 7 CDC Atlanta, 2011 Score ++ c.b.e 19 cases 38 controls - + ++ ++ ++ + ++ - - c.b.e c.b.e Mortality cases=5% Mortality controls=8% mean: cases=11.4 controls=7.4 Comments Matched case-case study no information in the article outbreak patients matched for age not matched but controlled in univariate analyses for Charlson index mortality in hospital no information 8 Falagas, 2007 Score ++ HCA 53 cases 53 controls - ++ ++ ++ ++ ++ - ++ - c.b.e - Mortality cases=30.1% Mortality controls=33.9% mean±SD cases=21.4±23.9 contr.=15.3±19.9 Comments Matched case-control study matched for age, and controlled for gender in univariate analyses mortality in hospital 9 Hauck, 2016 Score - c.b.e 260 cases: (90 BSI, 49 pneumonia, 121 UTI) 223 controls* - + ++ ++ ++ ++ ++ NA - c.b.e ++ Mort.rate BSI=38% aHR=2.59; 95%CI(1.52–4.50) Mort.rate Pneu=34% aHR=3.44; 95%CI(1.80–6.48) Mort.rate UTI=7% aHR=0.68; 95%CI(0.30–1.45) Mort.rate contr.=9% median (IQR) BSI=14 (9-24) Pneu=19 (10-30) UTI=10 (6-17) controls=9 (5-16) Comments Prospective multicenter observation al study no information in the article *R vs CRKP urinary colonization not matched but controlled in univariate analyses for age and gender (Pneu & UTI). For BSI were both different not matched but controlled in univariate analyses for Charlson index and main diseases mortality in hospital aHR BSI and aHR Pneu Sample size N refers to total number of cases and controls (no score) Calculation a priori: ++ if performed (e.g. based on expected prevalence or on litterature data) or the study refers to large national surveys; - if not performed Study type Study type: ++ matched cohort or case-control studies; + prospective cohort or case-control studies; - restrospective database studies Infection type HCA: health-care associated; CA: community associated; Mix: health-care and community associated together Geographical: ++ if the study was conducted in an EU/EEA setting; + if the study was conducted in high-income country(ref. World bank); - if the study was not conducted in an EU/EEA or high-income country setting Representativeness Demographical: ++ if the study population represents all age groups; + if the study population represents selected age-specific groups (e.g. elderly, infants); - if the study population represents a selected sex category and age-specific groups Clinical: ++ if the study population represents the overall hospital population; + if the study population partially represents the hospital population; - if the study population represents a disease-specific population (e.g. liver transplanted patients, cancer patients, etc..) Exlusion/inclusion criteria: ++ if the same exclusion/inclusion criteria were adopted for both cases and controls; + if some (but not all) exclusion/inclusion criteria were adopted for both cases and controls; - if exclusion/inclusion criteria were different in cases and controls Demographics: ++ if performed for age and sex; + if performed only for age or only for sex; - if not performed at all Matching or controlling for Underlying disease: ++ if performed for two or more criteria (e.g. comorbidity score, McCabe score, severity index, n. comorbidities, allergy, immunosuppression status, prior hospitalisation etc..); + if performed for only one criteria; - if not performed at all confounders Risk difference Infection site: ++ if performed ; - if not performed Hospital and unit/ward: ++ if same hospital and same unit/ward; + if same hospital but different unit/ward; - if not same hospital and/or not same unit/ward Follow-up: ++ if ≥ 28 days; - if < 28 days Statistically significant outcome results: ++ if results and 95%CI are statistically significant; - if results and 95%CI are not statistically significant Case fatality and LOS refer to risk difference estimates in cases and controls (no score) Scoring table ++ Matches completely/is completely fulfilled + Matches incompletely but sufficiently/is only partly but sufficiently fulfilled - Does not match or matches insufficiently/i s insufficiently fulfilled c.b.e. Cannot be evaluated 150 Checklist for the evaluation of the most relevant studies for building antimicrobial resistance (AMR) outcome trees, healthcare-associated infection (HAI) attributable case fatality and attributable length-of-stay (LOS) Study Study type Infection type Sample size Representativeness Matching or controlling for confounders Risk difference N (cases;controls) calculation a priori Geographical Demographical Clinical Exclusion/inclusion criteria Demographics Underlying disease Infection site Hospital and unit/ward Follow-up Statistically significat outcome results Case fatality LOS Nr. First author, year HCA; CA; Mix; c.b.e □ ++; □ -; □ c.b.e □ ++; +; -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; -; □ c.b.e □ ++; □ -; □ c.b.e %; RR; OR; aHR; etc (days) 1 Marchaim, 2010 Score + HCA 5 cases 60 controls - + ++ ++ ++ - - - - c.b.e. - Mort. rate cases=40% Mort. rate controls=26% Mean±SD Cases=33±23 Controls=30±23 Comments Prospective case-cohort Study all patients were also CRKP mortality in hospital 2 Zarkotou, 2010 Score ++ HCA 13 cases 39 controls - ++ ++ ++ ++ + ++ ++ ++ c.b.e. ++ Mort. rate cases=69.2% Mort. Rate controls=35.9% Attribut. mort.*=37.5% in both groups Mean±SD Cases= 20.5±20.8 Controls= 16.4±12.3 Comments Matched Case- Control Study not matched but controlled for age in univariate analyese. Gender is different not matched but controlled for main comorbidities and there was no difference mortality in hospital difference in all cause mortality *not defined in the paper 3 Capone, 2013 Score + HCA 35 cases 62 controls - ++ ++ ++ ++ c.b.e c.b.e c.b.e c.b.e c.b.e. ++ Mort. rate cases=40.6% Mort. rate controls=20.3% not specific data Comments Multicentre Prospective Study study not specific for colistin resistance, only mortality data availble for the two groups study not specific for colistin resistance, only mortality data availble for the two groups study not specific for colistin resistance, only mortality data availble for the two groups study not specific for colistin resistance, only mortality data availble for the two groups mortality in hospital 4 Rojas, 2016 Score Mix 31 cases 215 controls - + ++ ++ ++ ++ ++ - - ++ ++ Mort. rate cases=51% Mort. rate controls=39% aHR=3.48; 95%CI(1.77-6.57) Median(IQR) Cases=8(5-12) Controls=13(7-26) Comments Prospective nested cohort study HCA: 32% cases, 49% controls all patients were also CRKP not matched but controlled in univariate analyese not matched but controlled for main comorbidities and Charlson's index 30 days Sample size N refers to total number of cases and controls (no score) Calculation a priori: ++ if performed (e.g. based on expected prevalence or on litterature data) or the study refers to large national surveys; - if not performed Study type Study type: ++ matched cohort or case-control studies; + prospective cohort or case-control studies; - restrospective database studies Infection type HCA: health-care associated; CA: community associated; Mix: health-care and community associated together Geographical: ++ if the study was conducted in an EU/EEA setting; + if the study was conducted in high-income country(ref. World bank); - if the study was not conducted in an EU/EEA or high-income country setting Representativeness Demographical: ++ if the study population represents all age groups; + if the study population represents selected age-specific groups (e.g. elderly, infants); - if the study population represents a selected sex category and age-specific groups Clinical: ++ if the study population represents the overall hospital population; + if the study population partially represents the hospital population; - if the study population represents a disease-specific population (e.g. liver transplanted patients, cancer patients, etc..) Exlusion/inclusion criteria: ++ if the same exclusion/inclusion criteria were adopted for both cases and controls; + if some (but not all) exclusion/inclusion criteria were adopted for both cases and controls; - if exclusion/inclusion criteria were different in cases and controls Demographics: ++ if performed for age and sex; + if performed only for age or only for sex; - if not performed at all Matching or controlling for Underlying disease: ++ if performed for two or more criteria (e.g. comorbidity score, McCabe score, severity index, n. comorbidities, allergy, immunosuppression status, prior hospitalisation etc..); + if performed for only one criteria; - if not performed at all confounders Risk difference Infection site: ++ if performed ; - if not performed Hospital and unit/ward: ++ if same hospital and same unit/ward; + if same hospital but different unit/ward; - if not same hospital and/or not same unit/ward Follow-up: ++ if ≥ 28 days; - if < 28 days Statistically significant outcome results: ++ if results and 95%CI are statistically significant; - if results and 95%CI are not statistically significant Case fatality and LOS refer to risk difference estimates in cases and controls (no score) Scoring table ++ Matches completely/is completely fulfilled + Matches incompletely but sufficiently/is only partly but sufficiently fulfilled - Does not match or matches insufficiently/i s insufficiently fulfilled c.b.e. Cannot be evaluated Mixed inf. site R vs S ColRKP 151 Checklist for the evaluation of the most relevant studies for building antimicrobial resistance (AMR) outcome trees, healthcare-associated infection (HAI) attributable case fatality and attributable length-of-stay (LOS) Study Study type Infection type Sample size Representativeness Matching or controlling for confounders Risk difference N (cases;controls) calculation a priori Geographical Demographical Clinical Exclusion/inclusion criteria Demographics Underlying disease Infection site Hospital and unit/ward Follow-up Statistically significat outcome results Case fatality LOS Nr. First author, year HCA; CA; Mix; c.b.e □ ++; □ -; □ c.b.e □ ++; +; -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; -; □ c.b.e □ ++; □ -; □ c.b.e %; RR; OR; aHR; etc (days) 1 de Kraker, 2011 Score ++ Mix C1) 111 resistant 204 NI controls for resistant C2) 1110 sensitive 2084 NI controls for sensitive - ++ ++ ++ ++ ++ - - - ++ ++ a) C1: Mort. resist=32% Mort. control=6% OR=4.6, 95%CI(1.7–12.3) C2: Mort. sensit=17% Mort. control=7% OR=1.9; 95%CI(1.4–2.5) OR R vs S= 2.5; 95%CI(0.9–6.8) b) C1: Mort. resist=36% Mort. control=5% HR=5.7; 95%CI(2.5–13.0) C2:Mort. sensit=17% Mort. control=7% HR=2.0; 95%CI(1.5–2.5) HR R vs S=2.9; 95%CI(1.2–6.9) median (IQR) C1: resist=12(6-25) control=6(3-16) C2: sensit=10(6-17) control=7 (4–14) Comments Prospective parallel matched double cohort hospital onset of BSI: 57% resistant 28% sensitive the study considered the patients as two cohorts, C1=R vs NI and C2=S vs NI not matched but controlled in the univariate analyses. In the sensitive-control groups the age was higher in the cases all BSI a)30 days b)hospitaliz a)30 days b)hospitaliz 1 Anunatsiri, 2012 Score - Mix 32 cases 113 controls - - ++ ++ ++ ++ ++ - + c.b.e ++ Mort. cases=29% Mort. controls= 11.5% prior bacteremia median (range) cases=4 (0-66) controls=0 (0-82) Comments Retrospective case-control study HCA: 75% cases, 26.5% controls CA: 25% cases, 73.5% controls >15 years not matched but controlled in univariate analyses not matched but controlled in univariate analyses for main diseases and APACHE II score all BSI mortality in hospital 2 Apisarnthanarak, 2008 Score - CA 24 cases 108 controls* - - ++ ++ ++ c.b.e c.b.e ++ ++ c.b.e c.b.e Mort. cases=8% Mort. controls= 15%* median (range)
 cases=8 (1– 43)
controls=6 (3–15) Comments Retrospective case-control study all cases had community onset BSI *controls had EC or KP the study included EC and KP but it was possible to have the mortality only for EC cases the study results included EC and KP the study results included EC and KP mortality in hospital the study results included EC and KP *controls had EC or KP for cases and controls with EC or KP 3 Cornejo-Juarez, 2012 Score - HCA 88 cases 88 controls - - - - ++ ++ - - ++ ++ c.b.e a)Mort. cases=38.6% Mort. controls= 21.6% b)Mort. cases=19.3% Mort. controls= 25% difficult to interpret Comments Retrospective case-control study the study started with 100 patients for each group, but 12 from each group were lost at follow-up all patients had hematological malignacies not matched but controlled in univariate analyses all BSI 60 days the results were presented separately for appropriate and unappropriate therapy. Here we pooled them. a) death related to infection b) death not related to infection 4 Courpon-Claudinon, 2011 Score + Mix 39 cases 1012 controls - ++ ++ ++ ++ + - - - c.b.e ++ Mort. cases=30.8%
 Mort. controls= 12.3% no data Comments Prospective multi-centre study HCA: 23.1% cases, 19.1% controls CA: 76.9% cases, 80.9% controls not matched but controlled and age is not signficantly different, gender does all BSI mortality in hospital 5 Ortega, 2009 Score + Mix 211 cases 3247 controls - ++ ++ ++ ++ c.b.e c.b.e - + ++ c.b.e Mort. cases=15.6% Mort. controls= 7.6% no data Comments Prospective study cases: 61% HCA, 39% CA controls: no specific info data on the ESBL-EC available only on supplementary tables which are inaccessable data on the ESBL-EC available only on supplementary tables which are inaccessable all BSI a) 7days b) 30days data on the ESBL-EC available only on supplementary tables which are inaccessable 6 Trecarichi, 2009 Score - Mix 26 cases 36 controls - ++ ++ - ++ + - ++ ++ Mort. cases=42.3% Mort. controls= 5.6% OR=8.84; 95%CI(1.48-52.91) no data Comments Retrospecti ve cohort HCA: 96.1% cases, 75% controls CA: 3.8% cases, 25% controls all patients had hematological malignacies not matched but controlled and gende is not signficantly different, age is higher in cases different type of hematological melignacies all BSI 30 days OR 7 Hsieh, 2010 Score - CA 19 cases 385 controls - + ++ ++ ++ ++ ++ - + ++ - Mort. cases=21.1%
 Mort. controls= 12.2% mean (±SD)
 cases=15.5(±8.5)
 controls=6.1(±6.9) Comments Retrospecti ve cohort community onset BSI not matched but controlled in univariate analyses not matched but controlled in univariate analyses for main diseases all BSI 30 days 8 Tumbarello, 2010 Score - Mix 37 cases 97 controls - ++ ++ ++ ++ ++ - - + - ++ Mort. cases=29.7% Mort. controls= 6.1% OR=4.43; 95%CI(2.46-7.95) mean (±SD) cases=20(±17) controls=13(±9) Comments Retrospecti ve cohort HCA: 91.8% cases, 69% controls CA: 8.2% cases, 30.9% controls not matched but controlled in univariate analyses not matched but controlled in univariate analyses for APACHE score. There are differences in solid tumors, more in controls all BSI 21 days OR 9 Gudiol, 2010 Score + Mix 17 cases 118 controls - ++ ++ - ++ + ++ - + ++* - a)Mort. cases=12% Mort. controls= 8% b)Mort. cases=35% Mort. controls= 19% no data Comments Prospective cohort HCA: 94% cases, 88% controls hospitalized patients with cancer or hematological malignacies not matched but controlled and age is not signficantly different, gender does not matched but controlled for additional comorbidities all BSI a) within 7days b) within 30days a) within 7days b) within 30days 10 Ho, 2002 Score - Mix 50 cases 100 controls - + ++ ++ ++ ++ - - + ++ ++ Mort. cases=18% Mort. controls= 7% no data Comments Retrospecti ve case- control study HCA: 80% cases, 22.2% controls all BSI within 30 days 11 Rodriguez-Bano, 2010 Score + CA 95 cases 188 controls - ++ ++ ++ ++ ++ - - - - ++ Mort. cases=17% Mort. controls= 8% no data Comments Prospective cohort community onset BSI HCA: 76% cases. 53% controls patients with community onset BSI patients with community onset BSI not matched but controlled in univariate analyses all BSI patients in different hospitals but matched for hospital 14 days 12 Kang, 2010 Score - CA 82 case 783 controls - + ++ ++ ++ + - - - ++ ++ Mort. cases=15% Mort. controls= 7.6% OR=2.99; 95%CI(1.01–8.84) no data Comments Retrospecti ve cohort community onset BSI HCA: 36.6% cases. 15.7% controls patients with community onset BSI patients with community onset BSI not matched but controlled and age is not signficantly different, gender does all BSI 30 days OR 13 Garcia-Hernandez, 2010 Score c.b.e Mix 34 cases 119 controls - ++ ++ ++ ++ ++ - - + - ++ a)Mort. cases=35.5%
 Mort. controls= 16.8% b)Mort. cases=26.5%
Mort. controls= 9.2% mean (±SD) cases=24.3(±22) controls=20.9(±26.7) Comments Retrospecti ve and prospective cohort study HCA: 47.1% cases, 44.5% controls CA: 52.9% cases, 55.5% controls not matched but controlled in univariate analyses all BSI 7 days a) within 72h b)within 7days 14 Denis, 2015 Score - Mix 41 cases 41 controls - ++ ++ ++ ++ ++ - - + ++ - Mort. cases=30% Mort. controls= 27% OR=1.23; 95%CI(0.36–4.23) median (range) cases=15 (10-21) controls=11 (7-17) Comments Retrospecti ve study HCA: 83% cases, 71% controls not matched but controlled in univariate analyses not matched but controlled in univariate analyses for APACHE II score. There are differences in hematological malignacies, more in cases all BSI 30 days 15 Ha, 2013 Score - Mix 95 cases 255 controls - + ++ - ++ + - - + ++ ++ Mort. cases=22.1%
 Mort. controls= 12.2% OR = 3.01; 95%CI(1.45–6.28) no data Comments Retrospecti ve cohort study HCA: 85.3% cases, 66.3% controls CA: 85.3% cases, 33.7% controls patients with cancer not matched but controlled and gende is not signficantly different, age is higher in cases all BSI 30 days 16 Kaya, 2013 Score - Mix 44 cases 69 controls - - ++ - ++ ++ - - + c.b.e - Mort. cases=36.4%
 Mort. controls= 27.5% no data Comments Retrospecti ve case- control study Cases: 51.4% hospital onset, 38.6% community onset patients with systemic inflammatory response syndrome not matched but controlled in univariate analyses all BSI mortality in hospital 17 Kim, 2013 Score - HCA 15 cases 72 controls - + ++ - ++ c.b.e c.b.e - ++ ++ c.b.e Mort. cases=6.7% Mort. controls= 5.5% no data Comments Retrospecti ve study patients who had hematological diseases and neutropenic fever data for EC not available because pooled with KP cases data for EC not available because pooled with KP cases all BSI 30 days data for EC not available because pooled with KP cases mortality data extracted for EC 18 Lambert, 2011 Score - Mix a)42 cases 218 controls b)58 cases 464 controls - ++ ++ + ++ c.b.e - ++ ++ c.b.e - a) Mort. cases=50% Mort. controls= 40% aHR=1.3; 95%CI(0.8–2.2) b) Mort. cases=47% Mort. controls= 29% aHR=1.4; 95%CI (0.9–2.3) from infection to discharge* median (IQR)
 a)cases=16(4- 24)
controls=9(5- 20) b)cases=18(11- 29)
 controls=17(9-29) Comments Retrospecti ve cohort study no specific information available a)BSI b)pneumonia ICU patients all ICU patients mortality in hospital a)BSI b)pneumonia *for those disacherged alive a)BSI b)pneumonia 19 Leistner, 2014 a Score - Mix 115 cases 983 controls - ++ ++ ++ ++ - - - + c.b.e - Mort. cases=26% Mort. controls=18% median (range) cases=27 (12-53) controls=15 (8-32) Comments Retrospecti ve cohort study HCA: 58% cases, 38% controls all BSI mortality in hospital 20 Leistner, 2014 b Score - Mix 178 cases 1322 controls - ++ ++ ++ ++ c.b.e c.b.e - + c.b.e c.b.e Mort. cases=25.3% Mort. controls=17.6% no specific data Comments Retrospecti ve cohort study no specific information available no information becasue data are pooled with KP infections no information becasue data are pooled with KP infections all BSI mortality in hospital no information becasue data are pooled with KP infections 21 Martellius, 2016 Score - HCA 182 cases 2035 controls - ++ ++ ++ ++ ++ - - - ++ - a)Mort. cases=7.7% Mort. controls= 5.9% b)Mort. cases=14.3% Mort. controls= 11.9% no data Comments Retrospecti ve study not matched but controlled in univariate analyses all BSI a) 7days b) 28days a) 7 days b) 28 days 22 Park, 2011 Score - Mix 50 cases 100 controls - + ++ ++ ++ ++ - - + ++ - a)Mort. cases=8% Mort. controls= 6% b)Mort. cases=18% Mort. controls= 8% OR=6.4; 95%CI(0.3–145.5) no data Comments Retrospecti ve cohort study HCA community onset BSI not matched but controlled in univariate analyses all BSI a) 7days b) 30days a) 7days b) 30days Score - HCA 11 cases 77 controls - + ++ - ++ ++ - - + c.b.e ++ Mort. cases=27.3% Mort. controls= 3.9% no data BSI R vs S BSI R vs NI 3GCREC 152 23 Yip, 2006 Comments Retrospecti ve study not expicitly said in the article, but very specific patients patients undergoing continuous ambulatory peritoneal dialysis not matched but controlled in univariate analyses continuous ambulatory peritoneal dialysis all BSI mortality in hospital 24 Van Aken, 2014 Score - Mix 70 cases 140 controls - ++ ++ ++ ++ + ++ - - - - Mort. cases=9% Mort. controls= 7% median±SD cases=11±12 controls=9±10 Comments Retrospecti ve case- control study HCA: 31.4% cases, 31.4% controls CA: 68.8% cases, 68.6% controls not matched but controlled and gende is not signficantly different, age is higher in controls not matched but controlled for Charlson's comorbidity index all BSI 14 days 25 Melzer, 2007 Score - Mix 46 cases 308 controls - ++ ++ ++ ++ - - - + ++ ++ Mort. cases=60.9%
 Mort. controls= 23.7% OR=3.57; 95%CI(1.48-8.60) median cases=9 controls=12 Comments Retrospecti ve cohort HCA: 65.2% cases, 26.6% controls CA: 34.8% cases, 73.4% controls all BSI 30 days 1 Al-Otaibi, 2013 Score - Mix 113 cases 226 controls - + ++ + ++ - - - ++ c.b.e ++ Mort. cases=8.9% Mort. controls= 0.9% no data Comments Retrospecti ve case- control study Cases: 43% HCA, 57% CA children and aduls together patients from bacteriology unit all UTI mortality in hospital 2 Ena, 2006 Score - Mix 61 cases 61 controls - ++ ++ ++ ++ + ++ - + c.b.e - Mort. cases=8% Mort. controls= 8%* no data Comments Retrospecti ve cohort HCA: 54% cases, 42% controls CA: 46% cases, 59% controls not matched but controlled in unvariate analyses for gender. Age was different, cases were older not matched but controlled in univariate analyses for main disease and Charlson's morbidity score. all UTI mortality in hospital *deaths in both groups were not attributable, not occurred during the phase of active infection or while the patient was receiving antibiotic therapy 3 Suankratay, 2008 Score + Mix 35 cases 71 controls* - - + - ++ c.b.e - - + - - Mort. cases=2.9% Mort. controls= 0%* no data Comments Prospective cohort no info on proportion HCA/CA *controls were EC, KP, PM and was not possible to separate them patients were only women >15 years patients with acute pyelonephritis cases and controls pooled with patients with other infections, KP, PM all UTI 14 days *controls were EC, KP, PM and was not possible to separate them 4 Esteve-Palau, 2015 Score ++ Mix 60 cases 60 controls ++ ++ ++ - ++ ++ - - + ++ ++ Mort. cases=10% Mort. controls= 7% OR=8.011; 95%CI(2.48-25.92)* mean (±SD) 
 cases=11.6(±1.5)
 controls=7.5(±0.8) Comments Matched cohort study HCA: 60% cases, 33% controls CA: 40% cases, 67% controls patients with symtomatic UTI all UTI within 30 days OR *Risk of failure within 7 days (R vs S) 5 Park, 2015 Score - CA 75 cases 225 controls - + ++ - ++ + - - + - c.b.e Mort. cases=1.3% Mort. controls= 1.8% no data Comments Retrospecti ve case- control study >15 years patients with acute pyelonephritis not matched but controlled in unvariate analyses for gender. Age was different, cases were older all UTI 7 days no information on mortality because the outcome as aclinical failure included relapses. 63 cases a)Mort. cases=1.6% mean (±SD) Rectal 154controls Mort. controls= 0% cases=30.15 (±13.70) swab R vs NI Score + Mix - ++ ++ - ++ ++ - - - c.b.e - b)Mort. cases=10% Mort. controls= 11% controls=29.05 (±12.11) 1 Arnan, 2011 Comments Prospective multicentre cohort study HCA: 75% cases, 81% controls patients with hematological malignacies not matched but controlled in univariate analyses not matched but all patients had hematological malignacies all rectal swabs a) 7days b) hospitaliz a) 7days b) hospitaliz 1 Nicolas-Chanoine, 2012 Score + Mix 152 resistant 152 sensitive 152 NI ++ ++ ++ ++ ++ ++ - - - c.b.e ++ Mort. resist=12% Mort. sensit=7% Mort. NI=5% no data Comments Prospective case-control- control study no info on proportion HCA/CA not matched but controlled in univariate analyses mortality in hospital only mortality of resistant vs NI 2 Hayakawa, 2013 Score - Mix 319 resistant 58 sensitive 319 NI - + ++ ++ ++ - - - ++ ++ ++* a) Mort. resist=5.7% Mort. sensit=3.5% Mort. NI=3.8% OR R vs S= 1.66; 95%CI(0.37–7.34) OR R vs NI=2.33; 95%CI(0.9–6.07) b) Mort. resist=13.7% Mort. sensit=10.2% Mort NI=7 6% median (IQR) resist=7(4-12) sensit=7(3-20) NI=4(2-6) Comments Retrospecti ve case- case-control study no info on proportion HCA/CA different hospitals but cases were matched for hospital unit a) hospitaliz b) 3 months *only 3 months OR R vs NI a) hospitaliz b) 3 months 100 cases a)Mort. cases=16% no data Mixed inf. 100 controls Mort. controls= 6% site R vs S Score ++ c.b.e - ++ ++ ++ ++ c.b.e. c.b.e. ++ + ++ ++ b)Mort. cases=25% Mort. controls= 11% 1 Pena, 2008 information not specific information not specific information not specific for Retrospecti for 2 groups, but for for 2 groups, but for a) 7 days a) 7 days 2 groups, but for died and Comments ve matched no information died and survived died and survived b) 30 days both mortalites are significant b) 30 days survived cohort study 108 cases + ++ ++ Mort. cases=7.4% no data Score - CA 100 controls - ++ ++ - ++ ++ ++ - Mort. controls= 2% 2 Kang, 2011 Comments Retrospecti ve case- control study community onset infection HCA: 51.9% cases, 19.4% controls community onset infection >15 years not matched but controlled and age is not signficantly different, gender does 30 days 61 cases a)Mort. cases=15% not specific for EC 49 controls Mort. controls= 2% Score - Mix - + ++ ++ ++ ++* ++* ++* ++* - ++ b)Mort. cases=5% Mort. controls= 2% 3 Maslikowska, 2016 Comments Retrospecti ve case- control study no info on proportion HCA/CA *original study reporting EC or KP infections not matched but controlled for Charlson comorbidity index and APACHE II score *original study reporting EC or KP *original study reporting EC or KP infections *original study reporting EC or KP infections 14 days only all cause mortality data extracted only for EC a) all cause mortality b) attributable mortality: infection cause of death infections Sample size N refers to total number of cases and controls (no score) Calculation a priori: ++ if performed (e.g. based on expected prevalence or on litterature data) or the study refers to large national surveys; - if not performed Study type Study type: ++ matched cohort or case-control studies; + prospective cohort or case-control studies; - restrospective database studies Infection type HCA: health-care associated; CA: community associated; Mix: health-care and community associated together Geographical: ++ if the study was conducted in an EU/EEA setting; + if the study was conducted in high-income country(ref. World bank); - if the study was not conducted in an EU/EEA or high-income country setting Representativeness Demographical: ++ if the study population represents all age groups; + if the study population represents selected age-specific groups (e.g. elderly, infants); - if the study population represents a selected sex category and age-specific groups Clinical: ++ if the study population represents the overall hospital population; + if the study population partially represents the hospital population; - if the study population represents a disease-specific population (e.g. liver transplanted patients, cancer patients, etc..) Exlusion/inclusion criteria: ++ if the same exclusion/inclusion criteria were adopted for both cases and controls; + if some (but not all) exclusion/inclusion criteria were adopted for both cases and controls; - if exclusion/inclusion criteria were different in cases and controls Demographics: ++ if performed for age and sex; + if performed only for age or only for sex; - if not performed at all Matching or controlling for Underlying disease: ++ if performed for two or more criteria (e.g. comorbidity score, McCabe score, severity index, n. comorbidities, allergy, immunosuppression status, prior hospitalisation etc..); + if performed for only one criteria; - if not performed at all confounders Risk difference Infection site: ++ if performed ; - if not performed Hospital and unit/ward: ++ if same hospital and same unit/ward; + if same hospital but different unit/ward; - if not same hospital and/or not same unit/ward Follow-up: ++ if ≥ 28 days; - if < 28 days Statistically significant outcome results: ++ if results and 95%CI are statistically significant; - if results and 95%CI are not statistically significant Case fatality and LOS refer to risk difference estimates in cases and controls (no score) Scoring table ++ Matches completely/is completely fulfilled + Matches incompletely but sufficiently/is only partly but sufficiently fulfilled - Does not match or matches insufficiently/i s insufficiently fulfilled c.b.e. Cannot be evaluated Mixed inf. site R vs NI UTI R vs S 153 Checklist for the evaluation of the most relevant studies for building antimicrobial resistance (AMR) outcome trees, healthcare-associated infection (HAI) attributable case fatality and attributable length-of-stay (LOS) Study Study type Infection type Sample size Representativeness Matching or controlling for confounders Risk difference N (cases;controls) calculation a priori Geographical Demographical Clinical Exclusion/inclusion criteria Demographics Underlying disease Infection site Hospital and unit/ward Follow-up Statistically significat outcome results Case fatality LOS Nr. First author, year HCA; CA; Mix; c.b.e □ ++; □ -; □ c.b.e □ ++; +; -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; -; □ c.b.e □ ++; □ -; □ c.b.e %; RR; OR; aHR; etc (days) 1 Chang, 2011 Score ++ Mix 17 cases 34 controls - + ++ ++ ++ ++ - - + ++ ++* a)Mort.cases=47.06% Mort.controls=38.24% b)Mort.cases=70.59% Mort.controls=47.06% c)Mort.cases=94.12% Mort.controls=50% mean±SD (min-max) cases=68.4± 56.4 (7- 161) controls=35.8±34.5 (4-141) Comments Matched case- control study "mostly HCA" but not specified Cases are non-susceptible (i.e. resistant and intermediate MIC values) but was not possible to differentiate them all BSI a) ≤14 days b) ≤ 28 days c) hospitaliz *only mortality during hospitalization © was significantly higher in cases compared to controls a) ≤14 days b) ≤ 28 days c) hospitaliz 8 cases Mort.cases=25%* median 27 controls Mort.controls=0% cases=8.5 controls=25.0 Score + HCA - + ++ + ++ ++ - - ++ c.b.e. c.b.e mean(SD)[range] cases=13.3 (12.0) [1-37] controls=30.2 (13.2) [14- 1 Epstein, 2014 65] Comments Prospective case-control study cases exposed to duodenoscopes, considered the source of infection cases are exposed to duodenoscopes and controls are from rehabilitation ward not matched but controlled in the univariate analyses hospitalization no information * death not related to CREC 1 Ahn, 2014 Score ++ Mix 57 cases 114 controls - + ++ ++ ++ ++ - ++ + ++ - Mort.cases=14.8% Mort.controls=10.2% mean±SD cases=26.6±37.9 controls=13.1±41.3 Comments Matched case- controls study HCA: 84.2% cases, 71.9% controls CA: 15.8% cases, 28.1% controls not matched but controlled in the univariate analyses 28 days Sample size N refers to total number of cases and controls (no score) Calculation a priori: ++ if performed (e.g. based on expected prevalence or on litterature data) or the study refers to large national surveys; - if not performed Study type Study type: ++ matched cohort or case-control studies; + prospective cohort or case-control studies; - restrospective database studies Infection type HCA: health-care associated; CA: community associated; Mix: health-care and community associated together Geographical: ++ if the study was conducted in an EU/EEA setting; + if the study was conducted in high-income country(ref. World bank); - if the study was not conducted in an EU/EEA or high-income country setting Representativeness Matching or controlling for confounders Risk difference Demographical: ++ if the study population represents all age groups; + if the study population represents selected age-specific groups (e.g. elderly, infants); - if the study population represents a selected sex category and age-specific groups Clinical: ++ if the study population represents the overall hospital population; + if the study population partially represents the hospital population; - if the study population represents a disease-specific population (e.g. liver transplanted patients, cancer patients, etc..) Exlusion/inclusion criteria: ++ if the same exclusion/inclusion criteria were adopted for both cases and controls; + if some (but not all) exclusion/inclusion criteria were adopted for both cases and controls; - if exclusion/inclusion criteria were different in cases and controls Demographics: ++ if performed for age and sex; + if performed only for age or only for sex; - if not performed at all Underlying disease: ++ if performed for two or more criteria (e.g. comorbidity score, McCabe score, severity index, n. comorbidities, allergy, immunosuppression status, prior hospitalisation etc..); + if performed for only one criteria; - if not performed at all Infection site: ++ if performed ; - if not performed Hospital and unit/ward: ++ if same hospital and same unit/ward; + if same hospital but different unit/ward; - if not same hospital and/or not same unit/ward Follow-up: ++ if ≥ 28 days; - if < 28 days Statistically significant outcome results: ++ if results and 95%CI are statistically significant; - if results and 95%CI are not statistically significant Case fatality and LOS refer to risk difference estimates in cases and controls (no score) Scoring table ++ Matches completely/is completely fulfilled + Matches incompletely but sufficiently/is only partly but sufficiently fulfilled - Does not match or matches insufficiently/is insufficiently fulfilled c.b.e. Cannot be evaluated Mixed inf. site R vs S Mixed inf. site R vs NI BSI R vs S 154 Checklist for the evaluation of the most relevant studies for building antimicrobial resistance (AMR) outcome trees, healthcare-associated infection (HAI) attributable case fatality and attributable length-of-stay (LOS) Study Study type Infection type Sample size Representativeness Matching or controlling for confounders Risk difference N (cases;controls) calculation a priori Geographical Demographical Clinical Exclusion/inclusion criteria Demographics Underlying disease Infection site Hospital and unit/ward Follow-up Statistically significat outcome results Case fatality LOS Nr. First author, year HCA; CA; Mix; c.b.e □ ++; □ -; □ c.b.e □ ++; +; -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; -; □ c.b.e □ ++; □ -; □ c.b.e %; RR; OR; aHR; etc (days) 1 Al Jarousha, 2009 Score + HCA 40 cases 100 controls - - + - ++ ++ - - - c.b.e ++ Mort. cases=37.5% Mort. controls=12% no specific data Comments Prospective case-control study neonates in ICU NICU patients matched for age and controlled in the univariate analyses for gender all BSI 2 hospitals mortality in hospital test on the mortality rates 2 Gulen, 2015 Score - HCA 41 cases 45 controls* - - ++ + ++ ++ - - ++ ++ c.b.e a) Mort. cases=30% b) Mort. cases=52.4% c)Mort. Cases=53.7% Attribut. mort.=24.4% before BSI mean±SD cases=25.49±21.47 controls=22.80±19.28 Comments Retrospective cohort study *patients had other gram- negative infections ICU patients not matched but controlled in the univariate analyses all BSI ICU 3 mortalities measured a) 14 days b) 28 days c)hospitaliz 1 Anunnatsiri, 2011 Score - Mix 24 cases 25 controls - - ++ ++ ++ ++ - - + c.b.e ++ Mort. cases=91.7% Mort. controls=48% OR=11.92; 95%CI(2.30-61.83) before BSI median (range) cases=21.5(4-161) cotnrols=14(2-86) Comments Retrospective study cases were 100% HCA, controls were 76% HCA and 24% CA not matched but controlled in the univariate analyses all BSI mortality in hospital both, the mortality rates and the OR 2 Fitzpatrick, 2015 Score - Mix 92 cases 24 controls - + ++ ++ ++ ++ - - + ++ ++ a) Mort. cases=36% Mort. controls=8% b) Mort. cases=44% Mort. controls=8% postculture median(range) cases=11.5(2-69) controls=6(2-38) Comments Retrospective cohort study 63 % cases and 39% controls were HCA, no information about the rest not matched but controlled in the univariate analyses all BSI a) 14 days b) 30 days mortality signficantly higher for resistant both at 14 and 30 days a) 14 days b) 30 days 3 Guo, 2016 Score - c.b.e 64 cases 23 controls - - ++ ++ ++ - - - + ++ ++ Mort. cases=44.8% Mort. controls=4.3% OR=26.3; 95%CI(3.0-231.4) in ICU mean cases=51 controls=5 Comments Retrospective study no information available in the article no info on eventual univariate analyses all BSI 30 days significant OR, no test on mortality rates 4 Lee, 2007 Score ++ HCA 46 cases 46 controls - + ++ ++ ++ ++ ++ - + c.b.e ++ a) Mort. cases=47.8% Mort. controls=39.1% b) Mort. cases=34.8% Mort. controls=13.0% mean±SD cases=54.2±42.8 controls=34.1±30.5 Comments Retrospective matched cohort study all BSI hospitalization only the difference in sepsis related mortality was significant a) crude mortality b) sepsis related mortality 5 Lee, 2010 Score - MIx 147 cases 144 controls - + ++ ++ ++ c.b.e c.b.e - + ++ ++ Mort. cases=32% Mort. controls=8,3% OR=7.46; 95%CI(3.78-14.70) no specific data Comments Retrospecti ve study not possible to extract data all BSI 30 days OR, no test on mortality 6 Smolyako, 2003 Score + HCA 51 cases 43 controls - + ++ ++ ++ + - + c.b.e ++ Mort. cases=29.4% Mort. controls=11.6% OR=4 mean±SD cases=37.7±30 controls=24.3±18.3 Comments Prospective study controlled for gen, while age is significantly higher in the control group all BSI hospitalization f 1 Cai, 2012 Score + HCA 115 cases 45 controls - - + + ++ + + - + c.b.e ++ Mort. cases=18.26%
 Mort. controls=4.44% in ICU mean±SD cases=17.39±7.05 controls=14.43±3.92 Comments Prospective study all patients were children children with pneumonia controlled in the univariate analyses only for age univariate analyses for main basic diseases in not significant for any condition all repsiratory tract infections hospitalization 2 Inchai, 2015 Score - HCA 72 cases 33 controls - - ++ + ++ ++ - - + ++ - a)Mort. cases=31.9% Mort. controls=21.2% b)Mort. cases=44.4% Mort. controls=27.3% HR=1.03; 95%CI(0.44–2.45) no data Comments Retrospecti ve cohort study patienst in ICU not matched but controlled in the univariate analyses all repsiratory tract infections a) 30 days b) hospitalization a) 30 days b) hospitalization 3 Park, 2006 Score - HCA 17 cases 30 controls c.b.e + c.b.e - c.b.e - ++ - + c.b.e - Mort. cases=58.8% Mort. controls=40% mean±SD cases=42.8±24.0 controls=66.2±56.1 Comments Retrospecti ve study full text in korean language, data extracted from abstract and tables in english full text in korean language, data extracted from abstract and tables in english patients with pneumonia full text in korean language, data extracted from abstract and tables in english not matched, but APACHE II score is not significantly different all repsiratory tract infections full text in korean language, data extracted from abstract and tables in english 1 Abbo, 2007 Score ++ c.b.e 118 cases 118 controls - + ++ ++ ++ ++ - - + c.b.e ++ Mort. cases=36% Mort. controls=21% OR=2.21, 95%CI(1.17–4.16) median cases=17 controls=11 Comments Retrospecti ve matched cohort study no information available in the article not matched but controlled in the univariate analyses matching criteria were ward, calendar month of hospit., and duration of hospit. before culture hospitalization 2 Fukuta, 2013 Score c.b.e 31 cases 62 controls - + ++ + ++ ++ + - + ++ - Mort. cases=41.9% Mort. controls=29% median(IQR) cases=28 (9-59) controls=10(5-18) Comments Case- control study no information available in the article all patients had cancer not matched but controlled in the univariate analyses the type of cancer was not the same in all patients 90 days 3 Lee, 2016 Score ++ HCA 122 cases 122 controls - + ++ + ++ ++ ++ - ++ c.b.e ++ Mort. cases=49.2% Mort. controls=32% OR=3.64; 95%CI(1.80-7.37) mean±SD cases=40.3±40.6 controls=24.6±28 Comments Retrospecti ve propensity- matched cohort study not expicitly said in the article, but very specific patients all patients were only colonized with AB, not infected patients in ICU not matched but controlled in the univariate analyses not matched but controlled in the univariate analyses hospitalization 1 Brahmi, 2007 Score + HCA 29 cases 34 controls - - ++ + ++ + ++ - ++ c.b.e ++ Mort. cases=67.5% Mort. controls=46.7% in ICU mean±SD cases=27±17.8 controls=32.3±23.9 Comments Prospective study patients in ICU not matched but controlled in the univariate analyses for age only not matched but controlled in the univariate analyses hospitalization 2 Daniels, 2008 Score - HCA a)146 cases 42 controls b)42 cases 42 controls - + ++ ++ ++ ++ ++ ++ ++ ++ - a) Mort. cases=15.8% Mort. controls=9.5% b) Mort. cases=14.3% Mort. controls=9.5% median (IQR) cases=32.5(22-51) controls=26.5(16-43) Comments Retrospecti ve propensity- matched cohort study a) all patients b) matched pairs patients in ICU not matched but controlled in the univariate analyses, both groups 42 pairs matched for propensity score, the whole grops had also no difference in the univariate analyses not matched but controlled in the univariate analyses, both groups 28 days none of the mortality rates a) all patients b) matched pairs 3 Lemos, 2011 Score + HCA 103 cases 62 controls - - ++ + ++ ++ - - - ++ ++ a) Mort. cases=31% Mort. controls=9% b) Mort. cases=41% Mort. controls=9% b) RR=1,219; 95%CI(0,923–1,611) median(IQR) pre ICU cases=4(1.2-18) controls=5(1.5-22.3) in ICU cases=15(13-60) controls=13(8-44) Comments Prospective, observation al multicentre study patients in ICU not matched but controlled in the univariate analyses ICU of different hospitals a)14 days b) 30 days 30 days 4 Pierri, 2015 Score ++ HCA 14 cases 26 controls - ++ ++ + ++ ++ ++ - ++ c.b.e - Mort. cases=57% Mort. controls=46% mean±SD cases=36±20 controls=25±18 Comments Retrospecti ve matched cohort study not expicitly said in the article, but very specific patients patients in cardiac surgery ICU not matched but controlled in the univariate analyses matched for propensity score hospitalization 5 Zilberberg, 2016 Score - Mix 1171 cases 252 controls - + ++ ++ ++ + - ++ - c.b.e ++ Mort. cases=23.7% Mort. controls=12.7% no data Comments Retrospecti ve cohort study HCA: 45.9% cases; 42.5% controls CA: 54.1% cases; 57.5% controls controlled in the univariate analyses only for gender, age older in cases not matched but controlled in the univariate analyses, were only BSI and resp tract infections hospitalization Sample size N refers to total number of cases and controls (no score) Calculation a priori: ++ if performed (e.g. based on expected prevalence or on litterature data) or the study refers to large national surveys; - if not performed Study type Study type: ++ matched cohort or case-control studies; + prospective cohort or case-control studies; - restrospective database studies Infection type HCA: health-care associated; CA: community associated; Mix: health-care and community associated together Geographical: ++ if the study was conducted in an EU/EEA setting; + if the study was conducted in high-income country(ref. World bank); - if the study was not conducted in an EU/EEA or high-income country setting Representativeness Demographical: ++ if the study population represents all age groups; + if the study population represents selected age-specific groups (e.g. elderly, infants); - if the study population represents a selected sex category and age-specific groups Clinical: ++ if the study population represents the overall hospital population; + if the study population partially represents the hospital population; - if the study population represents a disease-specific population (e.g. liver transplanted patients, cancer patients, etc..) Exlusion/inclusion criteria: ++ if the same exclusion/inclusion criteria were adopted for both cases and controls; + if some (but not all) exclusion/inclusion criteria were adopted for both cases and controls; - if exclusion/inclusion criteria were different in cases and controls Demographics: ++ if performed for age and sex; + if performed only for age or only for sex; - if not performed at all Matching or controlling for Underlying disease: ++ if performed for two or more criteria (e.g. comorbidity score, McCabe score, severity index, n. comorbidities, allergy, immunosuppression status, prior hospitalisation etc..); + if performed for only one criteria; - if not performed at all confounders Risk difference Infection site: ++ if performed ; - if not performed Hospital and unit/ward: ++ if same hospital and same unit/ward; + if same hospital but different unit/ward; - if not same hospital and/or not same unit/ward Follow-up: ++ if ≥ 28 days; - if < 28 days Statistically significant outcome results: ++ if results and 95%CI are statistically significant; - if results and 95%CI are not statistically significant Case fatality and LOS refer to risk difference estimates in cases and controls (no score) Scoring table ++ Matches completely/is completely fulfilled + Matches incompletely but sufficiently/is only partly but sufficiently fulfilled - Does not match or matches insufficiently/i s insufficiently fulfilled c.b.e. Cannot be evaluated Mixed inf. site R vs S Mixed inf. site R vs NI Resp. Tract R vs S BSI R vs S BSI R vs NI MDRACI 155 Checklist for the evaluation of the most relevant studies for building antimicrobial resistance (AMR) outcome trees, healthcare-associated infection (HAI) attributable case fatality and attributable length-of-stay (LOS) Study Study type Infection type Sample size Representativeness Matching or controlling for confounders Risk difference N (cases;controls) calculation a priori Geographical Demographical Clinical Exclusion/inclusion criteria Demographics Underlying disease Infection site Hospital and unit/ward Follow-up Statistically significat outcome results Case fatality LOS Nr. First author, year HCA; CA; Mix; c.b.e □ ++; □ -; □ c.b.e □ ++; +; -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; -; □ c.b.e □ ++; □ -; □ c.b.e %; RR; OR; aHR; etc (days) 1 Kim, 2014 Score - HCA 19 cases 38 controls - + ++ - ++ ++ + - ++ c.b.e ++ Mort. rate cases=94.7% Mort.rate controls=8.3% median (range) cases=35(30–47) controls=29(26.75–34 ) Comments Retrospective case-control study not expicitly said in the article, but very specific patients hemopoietic stem-cell transplantation recipients hemopoietic stem-cell transplantation recipients not matched but differences were not dignificant hemopoietic stem-cell transplantation recipients all BSI mortality in hospital Fisher’s exact test on the fatality rates total admission duration including the trasplantation 2 Thatrimontrichai, 2013 Score - HCA 14 resistant 38 sensitive 44 controls - - + + ++ - + - ++ - ++ Mort. rate resist=42.9% Mort. rate sensit=13.2% Mort. rate controls=6.8% OR RvsS=5; 95%CI(1.2-20-4) OR RvsNI=10.2; 95%CI(2.1-50) median(range) resist=34(2-206) sensit=53.5(3-188) controls=24.5(1-102) Comments Case-case- control study not expicitly said in the article, but very specific patients neonates neonates in ICU not matched but all were neonates presence in ICU all BSI all in NICU 7 days mortlaity OR for mortality 1 Deris, 2011 Score - HCA 15 cases 41 controls - - ++ ++ ++ ++ - - + c.b.e _ Mort. rate cases=64.3% Mort.rate controls=40.5% OR (95%CI)=0.38 (0.11-1.36) *Attrib.mort. rate cases=42.9% Attib. mort.rate controls=24.3% OR (95%CI)= 2.33(0.64-8.65) median (IQR) cases=32.3(16.4) controls=32.8(25.0) Comments Cross sectional case-control study not matched but differences were not dignificant all BSI mortality in hospital neither the all-cause nor the attributable mortality * within 72h from isolation 2 Esterly, 2011 Score - c.b.e 37 cases 42 controls - + ++ ++ ++ ++ + - + c.b.e a) ++ b) - Mort. rate cases=56.8%
 Mort.rate controls=23.8% Model1 OR=0.58; 95%CI (0.037–9.22) Prior isolation median (IQR) cases=16(1-30) controls=0(0-9) Comments Retrospective cohort study no information available in the article not matched but controlled in the multivariate models multivariate analysis controlled for underlying conditions all BSI mortality in hospital a) comparison of mortality rates b) OR multivariate analyses (none is significant) 3 Huang, 2012 Score - c.b.e 62 cases 164 controls - + ++ ++ ++ ++ ++ - + - ++ Mort. rate cases=35.5%
 Mort.rate controls=20.7% OR= 1.03 ; 95%CI(0.48-2.20) Prior isolation mean±SD cases=35.9±33.6 controls=28.2±44 Comments Retrospective cohort study no information available in the article not matched but differences were not dignificant not matched, but controlled for Apache II score all BSI 14 days Resistance was significant for mortality in a univariate analyses, but not in the multivariate 4 Jumalitrat, 2009 Score - HCA 67 cases 131 controls - - ++ ++ ++ ++ ++ - + - ++ Mort. rate cases=52.2%
 Mort.rate controls=19.9% aHR=1.7; 95%CI(0.9-2.9) median ±IQR cases=37±32 controls=27±37 Comments Retrospective cohort study >15 years not matched but controlled in the HR model controlled for ASA score in aHR all BSI mortality in hospital significant only the difference between the mortality rates 5 Kim 2012 Score - c.b.e 53 cases 42 controls - + ++ ++ ++ ++ - - + - ++ Mort. rate cases=49.1% Mort.rate controls=9.5% OR=7.29; 95%CI(1.57-33.8) Prior isolation mean±SD cases=30.0±33.3 controls=30.4±68.3 Comments Retrospecti ve study no information available in the article >16 years not matched but controlled in the univariate analyses all BSI 14 days significant OR 6 Kumar 2014 Score - HCA 33 cases 32 controls - - + + ++ - - - ++ c.b.e - Mort. rate cases=27.3% Mort.rate controls=9.4% no data Comments Retrospecti ve chart review neonates neonates in ICU neonates in ICU all BSI all in NICU mortality in hospital 7 Routsi, 2010 Score + HCA 30 cases 66 controls - ++ ++ + ++ ++ - - ++ c.b.e - Mort. rate cases=43.3% Mort.rate controls=46.9% median (IQR) cases=33(18.8-55.8) controls=28.5(14.5- 51.0) Comments Prospective observation al study not expicitly said in the article, but very specific patients only ICU patients not matched but controlled in the univariate analyses all BSI all in ICU mortality in hospital 8 Tal-Jasper 2016 Score - c.b.e 149 cases 91 controls - + ++ ++ ++ + - - + ++ ++ a) Mort. rate cases=70.5% Mort.rate controls=45.1%
 b) Mort. rate cases=66.2%
Mort.rate controls=44.4%
c)Mort. rate cases=73.6%
Mort.rate controls=53.3% OR 90days=0.6, 95%CI (0.1–2.3) median (IQR) cases=21(10.8-39.5) controls=10(7-20.5) Comments Retrospecti ve cohort study no information available in the article not matched but controlled in the univariate analyses for age all BSI a) in hospital b) 30 days c)90 days differences between mortality rates were always significant, OR was significant only for 90 days a) in hospital b) 30 days c)90 days 1 Thatrimontrichai, 2016 Score - HCA 63 resistant 13 sensitive 25 non-infected - - + + ++ ++ + - ++ c.b.e ++ Mort. rate resit=15.9% Mort. sensit=7.7% Mort. NI=0% median(range) resist=29(8-93) senstiv=20(8-31) NI=22(8-68) Comments Retrospecti ve Case- case-control study not expicitly said in the article, but very specific patients resistants include also intermediate MIC values (numbers not specified) all neonates all neonates in ICU with VAP not matched but controlled in the univariate analyses VAP all resp. Tract infections all in NICU mortality in hospital significant difference between the mortality rates of R vs NI 1 Chang, 2011 Score - HCA 93 cases 87 controls - + ++ ++ ++ ++ - - + c.b.e ++ Mort. rate cases=61.3%
 Mort.rate controls=46.0% after VAP onset median±SD cases=23.1±24.3 controls=26.7±24.3 Comments Retrospecti ve observation al study not matched but controlled in the univariate analyses all resp. Tract infections mortality in hospital comparison of mortality rates 2 Garnacho-Montero, 2003 Score + HCA 21 cases 14 controls - ++ ++ + ++ - ++ - ++ c.b.e - Mort. rate cases=61.9% Mort.rate controls=64.2% *VAP related mortality Mort. rate cases=38% Mort.rate controls=35.7% mean±SD cases=45.2±30.7 controls=53.9±50 Comments Prospective cohort study not expicitly said in the article, but very specific patients ICU patients not matched but controlled for ApacheII and SOFA all resp. Tract infections all in ICU mortality in hospital no difference in any mortality *occurred during the treatment period, when the signs of pneumonia remained, an 3 Zheng, 2013 Score - HCA 97 cases 145 controls - - ++ ++ ++ ++ - - + ++ ++ Mort. rate cases=45.6%
 Mort.rate controls=29.9% before pneum mean±SD cases=17.7±6.6 controls=18±6.2 Comments Retrospecti ve study not matched but controlled in the univariate analyses all resp. Tract infections comparison of mortality rates 1 Henig, 2015 Score ++ Mix 1190 cases 1190 controls - + ++ ++ ++ + ++ - ++ c.b.e ++ Mort. rate cases=73% Mort.rate controls=55% aHR=2.33; 95%CI(2.08–2.6) median (range) cases=18 (0–97) controls=17 (0–96) Comments Matched case-control study no information on the proportion HCA/CA matched for age Charlson index is a matching criteria not defined, most probably hospitalization significant aHR, no info on the comparison of mortality rates 2 Nazer, 2015 Score ++ HCA 142 cases 232 controls - - ++ - ++ ++ ++ - ++ c.b.e ++ Mort. rate cases=73% Mort.rate controls=61.2% median (IQR) cases=12(6-13) controls=3(1.7) Comments Matched case-control study not expicitly said in the article, but very specific patients critically ill patients with cancer in ICU all in ICU mortality in ICU comparison of mortality rates 1 Aydemir, 2012 Score - HCA 110 cases 55 controls - - ++ ++ ++ ++ - - + c.b.e - Mort. rate cases=61.8%
 Mort.rate controls=52.7% after isolation mean±SD cases=18.1±14.0 controls=15.7±12.3 Comments Retrospecti ve case- control study >16 years not matched but controlled in the univariate analyses mortality in ICU 2 de Gouvea, 2012 Score - HCA 18 cases 31 controls - - ++ - + ++ - - + ++ - Mort. rate cases=44.4%
 Mort.rate controls=29.0% Inf. related. OR=0.73; 95%CI(0.12 – 4.47) Overall mort. OR=1,93; 95%CI(0.48 – 7.85) no data Comments Retrospecti ve study liver and kidney transpant patient not matched but controlled in the univariate analyses 30 days none of the data on mortality is significant 3 del Mar, 2005 Score c.b.e HCA 30 cases 31 controls - ++ ++ + ++ ++ - - ++ ++ c.b.e Mort. rate cases=43.3% Mort.rate controls=19% *Related mortality=30% attributable LOS=14 days Comments Case- control study (Not specified if prospective or retrospectiv e) it was an hospital outbreak RU and ICU patients not matched but controlled in the univariate analyses RU and ICU 30 days * when infection was established, by clinical criteria, as the primary cause of death 4 Lautenbach, 2009 Score + c.b.e 89 cases 297 controls - + ++ ++ ++ - - - - ++ - Mort. rate cases=18% Mort.rate controls=21.2% RR=0.85; 95% CI(0.52–1.39) median(range) cases=21(14-29) controls=16(12-18) Comments Prospective cohort study no information available in the article significant difference in age 2 hospitals 30 days 5 Lemos, 2014 a Score + c.b.e 104 cases 61 controls - - ++ + ++ + - - ++ ++ - Mort. rate cases=40% Mort.rate controls=12.2% aHR=1.45; 95%CI(0.74-2.87) adjusted mean(range) cases=19.3(16-22.5) controls=16.2(11.5- 19.9) Comments Prospetive, multicentre cohort study no information available in the article ICU patients not matched but controlled, age is significantly different 30 days 6 Lemos, 2014 b Score - NA 1013 cases 1553 controls - c.b.e ++ ++ c.b.e - - - - c.b.e ++ crude OR=2.22 95% CI=1.66-2.98 Comments Systematic review and meta- analysis sum of cases and controls of all studies studies from all the world the criteria refer to the included studies study specific 7 Sheng, 2010 Score - HCA a)30 cases 30 controls b) 91 cases 97 controls - + ++ ++ ++ ++ ++ ++ - ++ ++ a)Mort. rate cases=13.3% Mort.rate controls=20% b)Mort. rate cases=33% Mort.rate controls=17.5% after isolation median(range) a)cases=41 (5–282) controls=29 (2–227) b) cases=37 (1–218) controls=23 (1–151) Comments Multicentre retrospectiv e study a) colonized patients b) infected patients not matched but no significant difference in test distribution not matched but no significant difference in test distribution not matched but controlled in the univariate analyses 30 days significant only for infection (b) a) colonized patients b) infected patients a) colonized patients b) infected patients 8 The Brooklyn Antibiotic Resistance Task Force Score ++ Mix a)44 cases 33 controls b) 10 cases 10 controls - + ++ ++ ++ + ++ ++ - c.b.e - a)Mort. rate cases=34% Mort.rate controls=27% b)Mort. rate cases=20% Mort.rate controls=30% after isolation median b) cases=31.5 controls=13 Mixed inf. site R vs S Mixed inf. site R vs NI Resp. Tract R vs S Resp. Tract R vs NI BSI R vs S BSI R vs NI CRACI 156 Comments Matched case-control study 100% of cases and 85% of controls were HCA a) all cases and control b) matched pairs matched for age the 10 pairs only the 10 matched pairs only the 10 matched pairs mortality in hospital none of the data on mortality is significant data not available for group a) Sample size N refers to total number of cases and controls (no score) Calculation a priori: ++ if performed (e.g. based on expected prevalence or on litterature data) or the study refers to large national surveys; - if not performed Study type Study type: ++ matched cohort or case-control studies; + prospective cohort or case-control studies; - restrospective database studies Infection type HCA: health-care associated; CA: community associated; Mix: health-care and community associated together Geographical: ++ if the study was conducted in an EU/EEA setting; + if the study was conducted in high-income country(ref. World bank); - if the study was not conducted in an EU/EEA or high-income country setting Representativeness Demographical: ++ if the study population represents all age groups; + if the study population represents selected age-specific groups (e.g. elderly, infants); - if the study population represents a selected sex category and age-specific groups Clinical: ++ if the study population represents the overall hospital population; + if the study population partially represents the hospital population; - if the study population represents a disease-specific population (e.g. liver transplanted patients, cancer patients, etc..) Exlusion/inclusion criteria: ++ if the same exclusion/inclusion criteria were adopted for both cases and controls; + if some (but not all) exclusion/inclusion criteria were adopted for both cases and controls; - if exclusion/inclusion criteria were different in cases and controls Demographics: ++ if performed for age and sex; + if performed only for age or only for sex; - if not performed at all Matching or controlling for Underlying disease: ++ if performed for two or more criteria (e.g. comorbidity score, McCabe score, severity index, n. comorbidities, allergy, immunosuppression status, prior hospitalisation etc..); + if performed for only one criteria; - if not performed at all confounders Risk difference Infection site: ++ if performed ; - if not performed Hospital and unit/ward: ++ if same hospital and same unit/ward; + if same hospital but different unit/ward; - if not same hospital and/or not same unit/ward Follow-up: ++ if ≥ 28 days; - if < 28 days Statistically significant outcome results: ++ if results and 95%CI are statistically significant; - if results and 95%CI are not statistically significant Case fatality and LOS refer to risk difference estimates in cases and controls (no score) Scoring table Cannot be evaluated c.b.e. Does not match or matches insufficiently/i s insufficiently fulfilled Matches incompletely but sufficiently/is only partly but sufficiently fulfilled Matches completely fulfilled ++ 157 Checklist for the evaluation of the most relevant studies for building antimicrobial resistance (AMR) outcome trees, healthcare-associated infection (HAI) attributable case fatality and attributable length-of-stay (LOS) Study Study type Infection type Sample size Representativeness Matching or controlling for confounders Risk difference N (cases;controls) calculation a priori Geographical Demographical Clinical Exclusion/inclusion criteria Demographics Underlying disease Infection site Hospital and unit/ward Follow-up Statistically significat outcome results Case fatality LOS Nr. First author, year HCA; CA; Mix; c.b.e □ ++; □ -; □ c.b.e □ ++; +; -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; -; □ c.b.e □ ++; □ -; □ c.b.e %; RR; OR; aHR; etc (days) 1 Wang, 2015 Score - c.b.e 58 cases 213 controls - + ++ ++ ++ ++ - - + - - a) Mort. rate cases=10.3% Mort.rate controls=10.3% b) Mort. rate cases=15.5% Mort.rate controls=15% prior infection median (IQR) cases=56 (32-101) controls=37 (22-65) Comments Retrospective study no information available in the article all patient had A.nosomialis BSI but all they had also experienced at least one A. calcoaceticus-baumannii complex BSI not matched but controlled in the univariate analyses all BSI infections a) 14 days b) 18 days none of the follow up mortalities a) 14 days b) 18 days 1 Taneja, 2011 Score - c.b.e 8 cases 42 controls - - ++ - ++ - - - - c.b.e - Mort. Rate both groups=0% no data Comments Prospective cohort study no information available in the article all patients had complicated UTI infections all UTI infections Sample size N refers to total number of cases and controls (no score) Calculation a priori: ++ if performed (e.g. based on expected prevalence or on litterature data) or the study refers to large national surveys; - if not performed Study type Study type: ++ matched cohort or case-control studies; + prospective cohort or case-control studies; - restrospective database studies Infection type HCA: health-care associated; CA: community associated; Mix: health-care and community associated together Geographical: ++ if the study was conducted in an EU/EEA setting; + if the study was conducted in high-income country(ref. World bank); - if the study was not conducted in an EU/EEA or high-income country setting Representativeness Demographical: ++ if the study population represents all age groups; + if the study population represents selected age-specific groups (e.g. elderly, infants); - if the study population represents a selected sex category and age-specific groups Clinical: ++ if the study population represents the overall hospital population; + if the study population partially represents the hospital population; - if the study population represents a disease-specific population (e.g. liver transplanted patients, cancer patients, etc..) Exlusion/inclusion criteria: ++ if the same exclusion/inclusion criteria were adopted for both cases and controls; + if some (but not all) exclusion/inclusion criteria were adopted for both cases and controls; - if exclusion/inclusion criteria were different in cases and controls Demographics: ++ if performed for age and sex; + if performed only for age or only for sex; - if not performed at all Matching or controlling for Underlying disease: ++ if performed for two or more criteria (e.g. comorbidity score, McCabe score, severity index, n. comorbidities, allergy, immunosuppression status, prior hospitalisation etc..); + if performed for only one criteria; - if not performed at all confounders Risk difference Infection site: ++ if performed ; - if not performed Hospital and unit/ward: ++ if same hospital and same unit/ward; + if same hospital but different unit/ward; - if not same hospital and/or not same unit/ward Follow-up: ++ if ≥ 28 days; - if < 28 days Statistically significant outcome results: ++ if results and 95%CI are statistically significant; - if results and 95%CI are not statistically significant Case fatality and LOS refer to risk difference estimates in cases and controls (no score) Scoring table ++ Matches completely/is completely fulfilled + Matches incompletely but sufficiently/is only partly but sufficiently fulfilled - Does not match or matches insufficiently/i s insufficiently fulfilled c.b.e. Cannot be evaluated UTI R vs S BSI R vs S ColRACI 158 Checklist for the evaluation of the most relevant studies for building antimicrobial resistance (AMR) outcome trees, healthcare-associated infection (HAI) attributable case fatality and attributable length-of-stay (LOS) Study Study type Sample size Representativeness Matching or controlling for confounders Risk difference N (cases;controls) calculation a priori Geographical Demographical Clinical Exclusion/inclusion criteria Demographics Underlying disease Infection site Hospital and unit/ward Follow-up Statistically significat outcome results Case fatality LOS Nr. First author, year □ ++; □ -; □ c.b.e □ ++; +; -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; -; □ c.b.e □ ++; □ -; □ c.b.e %; RR; OR; aHR; etc (days) BSI R vs S 1 Caselli, 2010 Score - 39 cases 88 controls - ++ + - ++ - - - - ++ ++ Mort. rate cases=35%.8 Mort. rate controls=12.5% aOR=4.3; 95%CI(1.67-11.07) no data Comments Retrospective study children patients children under chemotherapy and HSC transplant all BSI 30 days OR adjusted for gender, type of cancer and neutopenia 2 Johnson, 2009 Score - 41 cases 50 controls - + ++ - ++ c.b.e c.b.e - - ++ - Mort. rate cases=36.6% Mort. rate controls=46% OR=0.68; 95%CI(0.27-1.71) no specific data Comments Retrospective cohort study transplanted patients no information no information all BSI 28 days 3 Morata, 2012 Score + 127 cases 582 - ++ ++ ++ ++ ++ ++ - + ++ ++ Mort. rate cases=17.2% Mort. rate controls=32.3% mean±SD cases=31.83±30 controls=16.38±18 Comments Prospective study not matched but controlled in univariate not matched but controlled in univariate all BSI 30 days 4 Tam, 2010 Score - a) 25 cases 84 controls b) 21 cases 21 controls - + ++ ++ ++ a) ++ b) ++ a) - b) ++ - + ++ ++ I) Mort. rate cases=40% Mort. rate controls=11.9% OR=6.829; 95%CI(1.945–23.984) II) Mort. rate cases=52% Mort. rate controls=9.5% III) Mort. rate cases=56% Mort. rate controls=16.7% IV) c) Mort. rate cases=61.9% Mort. rate controls=9.5% mean±SD cases=26.4±28.3 controls=16.5 ±23.6 Comments Retrospective cohort study a) whole sample b) matched pairs a) whole sample b) matched pairs group a) was controlled in univariate analyses a) whole sample b) matched pairs all BSI I) 30 days II) infection related III) overall mortality IV) matched pairs all results are significant I) 30 days II) infection related III) overall mortality IV) matched pairs 5 Theodorou, 2013 Score - 45 cases 42 controls - ++ ++ - ++ - - - ++ - - Mort. rate cases=42.2% Mort. rate controls=45.2% OR=1.076; 95%CI(0.356–3.254) In ICU mean±SD cases=49.3±34.6 controls=46.8±32.3 Comments Retrospectiv e cohort study burned patients in ICU all BSI mortality in hospital 6 Trecarichi, 2011 Score + 27 cases 11 controls - ++ ++ - ++ ++ ++ - - - - Mort. rate cases=40.7%
Mort. rate controls=9.1% no data Comments Prospective study patients with hematological malignancies not matched but controlled in univariate analyses not matched but controlled in univariate analyses all BSI 21 days 7 Tumbarello, 2011 Score - 40 cases 66 controls - ++ ++ - ++ - - - - - ++ Mort. rate cases=50% Mort. rate controls=24.2% OR=3.31; 95%CI(1.27–8.59) mean±SD cases=27±14 controls=17±13 Comments Retrospectiv e case- control study patients with BSI and systemic inflammatory response syndrome all BSI 21 days 8 Dantas, 2014 Score - 57 cases 63 controls - - ++ ++ ++ c.b.e c.b.e - + ++ - Mort. rate cases=42.1% Mort. rate controls=41.2% mean (range) cases=59 (4–205) controls=62 (3–378) Comments Retrospective study the study considered more resistances and no information was available for the matching the study considered more resistance and no information was available for the CRAB matching all BSI 30 days 9 Joo 2011 Score - 42 cases 160 controls - + ++ ++ ++ c.b.e c.b.e - + ++ ++ Mort. rate cases=38.1% Mort. rate controls=21.9% OR=2.20; 95%CI(1.06–4.55) aOR=2.24; 95%CI (0.80–6.29)* median (IQR) cases=25 (13–38) controls=16 (10–31) Comments Retrospective study the article did not compare cases with controls, instead suvivors with non survivors the article did not compare cases with controls, instead suvivors with non survivors all BSI 30 days *adjusted for corticosteroid use, nosocomial acquisition, polymicrobial infection, Charlson’s weighted index of co-morbidity, and admission to ICUs Resp tract R vs S 1 Cilloniz, 2016 Score + 22 cases 46 controls - ++ ++ ++ ++ ++ ++ - + ++ - Mort. Rate cases=22.7% Mort. rate controls=17.4% median (IQR) cases=14(12-21) controls=11(7-16) Comments Prospective observationa l study there are some exclusione criteria for immunosoppressed patients (look full text) not matched but controlled in univariate analyses not matched but controlled in univariate analyses all pneumonia 30 days 2 Montero, 2009 Score c.b.e 50 cases 50 controls - ++ ++ - ++ ++ + - + ++ ++ Mort. rate cases=60% Mort. rate controls=28% OR=6.2; 95%CI(1.7–22.1) no data Comments Case-control study patients with COPD, isolation sample was sputum patients with COPD acute exacerbation matched for age, controlle for gender mathced for degree of airway obstruction all resp tract 2 years 3 Micek, 2015 Score - 226 cases 31 controls - ++ ++ ++ ++ - ++ - - - ++ Mort. rate cases=44.7% Mort. rate controls=31.7% HR=1.39; 95%CI(1.05-1.83) median (IQR) cases=27(14-56.3) controls=25(13-46) Comments Multicentre restrospectiv e study EU coutnries + USA not matched but controlled in univariate analyses for Charlson score all resp tract mortality in hospital 4 Pena, 2013 Score - 60 cases 31 controls - ++ ++ ++ ++ + + - + - - a) Mort. rate cases=15%
 Mort. rate controls=29%
 b) Mort. rate cases=50%
Mort. rate controls=55% no data Comments Retrospectiv e study not matched but controlled in univariate analyses for gender, age is higher in cases not matched but controlled in univariate analyses for Charlson score all resp tract a) 7 days b) mortality in hospital a) 7 days b) mortality in hospital 5 Tumbarello, 2013 Score - 42 cases 68 controls - ++ ++ + ++ c.b.e c.b.e - + - ++ Mort. rate cases=59.5% Mort. rate controls=35.2% OR=2.69; 95%CI(1.14–6.43) no data Comments Retrospectiv e study ICU patients no matching and no comparison between cases and controls no matching and no comparison between cases and controls all resp tract mortality in ICU 6 Yang, 2009 Score + 20 cases 55 controls - + ++ ++ ++ ++ ++ - + ++ - Mort. rate cases=35% Mort. rate controls=29% median (IQR) cases=37(28.5-72) controls=34(21-47) Comments Prospective observationa l study excluded patients with known risk factors (loot at full text) not matched but controlled in univariate analyses not matched but controlled in univariate analyses all resp tract 28 days 7 Yayan, 2015 Score - a) 14 cases 63 controls b) 27 cases 64 controls - ++ ++ ++ ++ c.b.e c.b.e - + - - a) Mort. rate cases=28.6% Mort. rate controls=23.8% b) Mort. rate cases=7.4% Mort. rate controls=18.5% Mean ± SD a) cases= 25.8 ± 23.6 b) cases=17.5 ± 20.8 Comments Retrospectiv e study a) HAI b) CAI cases and controls are not compared, the comparison is between HAI and CAI cases and controls are not compared, the comparison is between HAI and CAI all resp tract mortality in hospital a) HAI b) CAI a) HAI b) CAI Mixed inf. 82 cases ++ ++ ++ Mort. rate cases=21% median site Score ++ 82 controls - ++ ++ + NA ++ - ++ Mort. rate controls=12% cases=20 R vs NI 1 Aloush, 2006 OR=4.4 controls=10 Comments Matched cohort study not matched but controlled in univariate analyses not matched but controlled in univariate analyses for McCabe mortality in hospital only OR score 34 cases a) Mort. rate cases=44%
 mean SD 34 control Mort. rate controls=47%
 cases=57.0±37.3 Score ++ - ++ ++ + ++ ++ ++ NA ++ - - b) Mort. rate cases=47%
 controls=46.9±22.5 Mort. rate controls=50% 2 Paramythiotou, 2004 Comments Matched case-control study patients in ICU not matched but controlled in univariate analyses a) mortality in ICU b) mortality in hospital a) mortality in ICU b) mortality in hospital 6 Peng 2014 MDRPA 44 cases Mort. rate cases=54.5% in ICU Mixed inf. 68 controls Mort. rate controls=16.2% mean(SD) site R vs S Score - - - ++ ++ ++ ++ - - + - ++ cases=21(47.7) control=11(16.2) 1 Cao, 2004 Comments Retrospectiv e cohort study cases are resistant and intermediate not matched but controlled in univariate analyses for gender, age is higher in cases mortality in hospital 20 cases Mort. rate cases=70% no specific data 34 controls Mort. rate controls=58.9% OR=1.6333; Score - - - ++ + ++ - - - ++ - - 95%CI(0.5043–5.2901) Adults: 2 de Matos, 2016 cases=81.3% controls=71.4% paediatric: cases=25.0% Comments Retrospectiv e cohort study adluts, children and neonates patients in ICU mortality in hospital 134 cases Mort. rate cases=24.6% mean(SD), median 149 controls Mort. rate controls=12.8% cases=25.1(16.1), 20 Score - - ++ ++ ++ ++ + + ++ + - ++ OR=1.77; 95%CI(1.41-2.22) controls=39.0(30.3), 30 3 Morales, 2012 not matched but not matched but Comments Retrospectiv e study controlled in univariate analyses for age, gender is different controlled in univariate analyses for main diseases, only renal not matched but controlled in univariate mortality in hospital disease is higher in analyses cases 559 cases Mort. rate cases=25-60% Score - 7881 controls - NA ++ ++ ++ NA NA NA - - ++ Mort. rate controls=7-50% RR=2.34, 95%CI(1.53 – 3.57) 4 Nathawani, 2014 Comments Review and Meta- analyses different countries mortality in hospital significant RR 18 cases Mort. rate cases=22% in ICU Score + 35 controls - ++ ++ + ++ ++ ++ ++ ++ - - Mort. rate controls=23% median (range)
cases=18(0-40)
 5 Ortega, 2004 controls=10(0-44) Comments Prospective study patients in ICU not mathced but controlled in univariate analyses not mathced but controlled in univariate analyses not mathced but controlled in univariate mortality in ICU analyses 188 cases Mort. rate cases=26.1% median (range) Score - 168 controls - - ++ ++ ++ c.b.e c.b.e - - - ++ Mort. rate controls=12.5% cases=39(5-697) controls=24(1-262) 159 Comments Retrospectiv e case- control study no information available no information available mortality in hospital 7 Su, 2016 Score - 25 cases 29 controls - - ++ - ++ c.b.e c.b.e - - ++ - a) Mort. rate cases=36% Mort. rate controls=31.0% b) Mort. rate cases=47.6% Mort. rate controls=37.9% no specific data Comments Retrospectiv e double centre study patients with abdominal organ transplantation no comparison between cases and controls, but between dead patients and not no comparison between cases and controls, but between dead patients and not 30 days a) related mortality b) overall mortality no comparison between cases and controls, but between dead patients and not Sample size N refers to total number of cases and controls (no score) Calculation a priori: ++ if performed (e.g. based on expected prevalence or on litterature data) or the study refers to large national surveys; - if not performed Study type Study type: ++ matched cohort or case-control studies; + prospective cohort or case-control studies; - restrospective database studies Geographical: ++ if the study was conducted in an EU/EEA setting; + if the study was conducted in high-income country(ref. World bank); - if the study was not conducted in an EU/EEA or high-income country setting Representativeness Matching or controlling for confounders Risk difference Demographical: ++ if the study population represents all age groups; + if the study population represents selected age-specific groups (e.g. elderly, infants); - if the study population represents a selected sex category and age-specific groups Clinical: ++ if the study population represents the overall hospital population; + if the study population partially represents the hospital population; - if the study population represents a disease-specific population (e.g. liver transplanted patients, cancer patients, etc..) Exlusion/inclusion criteria: ++ if the same exclusion/inclusion criteria were adopted for both cases and controls; + if some (but not all) exclusion/inclusion criteria were adopted for both cases and controls; - if exclusion/inclusion criteria were different in cases and controls Demographics: ++ if performed for age and sex; + if performed only for age or only for sex; - if not performed at all Underlying disease: ++ if performed for two or more criteria (e.g. comorbidity score, McCabe score, severity index, n. comorbidities, allergy, immunosuppression status, prior hospitalisation etc..); + if performed for only one criteria; - if not performed at all Infection site: ++ if performed ; - if not performed Hospital and unit/ward: ++ if same hospital and same unit/ward; + if same hospital but different unit/ward; - if not same hospital and/or not same unit/ward Follow-up: ++ if ≥ 28 days; - if < 28 days Statistically significant outcome results: ++ if results and 95%CI are statistically significant; - if results and 95%CI are not statistically significant Case fatality and LOS refer to risk difference estimates in cases and controls (no score) Scoring table insufficiently/is sufficiently/is 160 Checklist for the evaluation of the most relevant studies for building antimicrobial resistance (AMR) outcome trees, healthcare-associated infection (HAI) attributable case fatality and attributable length-of-stay (LOS) Study Study type Sample size Representativeness Matching or controlling for confounders Risk difference N (cases;controls) calculation a priori Geographical Demographical Clinical Exclusion/inclusion criteria Demographics Underlying disease Infection site Hospital and unit/ward Follow-up Statistically significat outcome results Case fatality LOS Nr. First author, year □ ++; □ -; □ c.b.e □ ++; +; -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; -; □ c.b.e □ ++; □ -; □ c.b.e %; RR; OR; aHR; etc (days) BSI R vs S 1 Dantas, 2014 Score - 55 cases 65 controls - - ++ ++ ++ c.b.e c.b.e - + ++ - Mort. cases= 47.3% Mort. controls= 36.9% OR=1.53 mean (range)
cases=48(4- 205) controls=41(3- 378) Comments Retrospective study the study considered more resistance and no information was available for the CRAB matching the study considered more resistance and no information was available for the CRAB matching all BSI 30 days 2 Hattemer, 2013 Score - 13 cases 137 controls - + ++ ++ ++ ++ ++ - - ++ - Mort. cases= 54% Mort. controls= 32% no specific data Retrospective study not matched but contolled in univariate analyses not matched but contolled in univariate analyses all BSI 2 hospitals 30 days 3 Joo, 2011 Score - 44 cases 156 controls - + ++ ++ ++ c.b.e c.b.e - + ++ ++ Mort. cases= 39.1% Mort. controls= 21.2% OR=2.40; 95%CI(1.18–4.86) aOR=2.74: 95%(1.02–7.37)* median (IQR) cases=16(14-42) controls=16(9-29) Comments Retrospective cohort study the article did not compare cases with controls, instead suvivors with non the article did not compare cases with controls, instead suvivors with non all BSI 30 days *adjusted for corticosteroid use, nosocomial acquisition, polymicrobial infection, Charlson’s weighted index of co-morbidity, and admission to 4 Kang, 2005 Score - 28 cases 158 controls - + ++ ++ ++ c.b.e c.b.e - + ++ - Mort. cases= 53.6% Mort. controls= 35.2% OR=2.216; 95%CI(0.946–4.776) no data Comments Retrospective study the information was not specific the information was not specific all BSI 30 days 5 Kim, 2014 Score - 118 cases 116 controls - + ++ ++ ++ c.b.e c.b.e - + - - Mort. cases= 22.0% Mort. controls= 22.4% OR=3.65; 95%CI(0.72-18.67) no data Comments Retrospectiv e study the article did not compare cases with controls, instead suvivors with non survivors the article did not compare cases with controls, instead suvivors with non survivors all BSI 14 days the article did not compare cases with controls, instead suvivors with non survivors 6 Pena, 2012 Score + 145 cases 487 controls ++ ++ ++ ++ ++ + ++ - - ++ - a) Mort. cases= 13% Mort. controls= 13% b)Mort. cases= 35% Mort. controls= 27% no data Comments Prospective multicentre study not matched but contolled in univariate analyses for age, gender is different not matched but contolled in univariate analyses for SAPS score, Charlson index and main diseases. Only immunosuppresive therapy is higher in cases all BSI 10 hospitals a) 48h b) 30 days a) 48h b) 30 days 7 Suarez, 2010 Score - 33 cases 88 controls - ++ ++ ++ ++ c.b.e ++ - + ++ - a)Mort. cases= 46% Mort. controls= 36% b)Attribut. mort. cases=33% Attribut. mort. controls=30% OR=1.8; 95%CI(0.5–6.8) mean (range) cases=19(2-98) controls=9(2-56) Comments Retrospectiv e cohort study the article did not compare cases with controls, instead suvivors with non survivors not matched but controlled in univariate analyses all BSI a) 30 days b) 7 days a) 30 days b) 7 days (defined as attributable mortality) 8 Tuon, 2012 Score c.b.e 29 cases 48 controls - - ++ ++ ++ ++ ++ - + ++ - Mort. cases= 54.2% Mort. controls= 44.8% OR=0.68; 95%CI(0.27–1.73) mean±SD cases=43±31.7 controls=43.1±31.2 Comments Case-control study not matched but controlled in univariate analyses not matched but contolled in univariate analyses for main comorbidities all BSI 30 days Recsp tract R vs S 1 Luyt, 2014 Score + 68 cases* 101 controls - ++ ++ + ++ ++ ++ - ++ - - Mort. cases= 37% Mort. controls= 31% median (IQR)
cases=37(23-57)
 controls=29(19-46) Comments Prospective observationa l study * cases included resistant and intermediate susceptible PA, was not possible to separate them ICU patients not matched but controlled in univariate analyses not matched but controlled in univariate analyses all Resp tract ICU mortality during ICU stay Mixed inf. site R vs NI Score - 58 resistant 125 sensitive 57 non infected - + ++ ++ ++ a) ++ b) + a) ++ b) ++ - ++ - - Mort. resit= 31% Mort. sensit= 15% Mort. control=9% median(IQR) resist=30(15-70) sensit=16(6-33) control=10(6-17) 1 Eagye, 2009 Comments Retrospectiv e case- control- control study not matched but controlled in univariate analyses a) R vs S b) R vs NI (only gender) not matched but controlled in univariate analyses a) R vs S, except congestive heart failure b) R vs NI, except COPD mortality in hospital Mixed inf. site R vs S Score - 32 cases 350 controls - + ++ ++ ++ ++ - - + - ++ Mort. cases= 28.1%
Mort. controls= 8.9% OR=2.89; 95%CI(1.15-7.28) median (IQR) cases=14(8-29) controls=9(5-15) 1 Judd, 2016 Retrospectiv not matched but Comments e observationa controlled in univariate analyses mortality in hospital l cohort 135 cases + ++ ++ Mort. cases= 31.1% median (IQR) Score - 719 controls - ++ - - - + - ++ Mort. controls= 16.7% cases=11(1-41) 2 Lautenbach, 2006 RR=1.86; 95%CI(1.38-2.51) controls=4(1-15) Comments Retrospectiv e cohort study mortality in hospital 253 cases Mort. cases= 17.4% prior isolation 2289 controls Mort. controls= 13.4% median (IQR) Score - - + ++ ++ ++ - - - - - ++ RR=1.39; 95%CI(1.09–1.76) cases=8(4-12) 3 Lautenbach, 2010 controls=4(4-5) Comments Retrospectiv e cohort study mortality in hospital 82 cases + ++ ++ Mort. cases= 22.0% no data Score - 82 controls - ++ ++ ++ - - - - Mort. controls= 19.5% 4 Lin, 2014 Comments Retrospectiv e study not matched but controlled in univariate analyses not matched but controlled in univariate analyses mortality in hospital 16 studies NA ++ ++ Crude OR=1.64; 95%CI(1.40, no data Score - - ++ NA NA - - c.b.e ++ 1.93) 5 Liu, 2015 Adjusted OR=2.38; 95%CI(1.53, Comments Meta- analyses articles from different countries different in the different articles 15 cases - ++ ++ Mort. cases= 13.34% no data Score + 65 controls - ++ ++ ++ - - - - Mort. controls= 1.53% 6 Meradji, 2015 Comments Prospective observationa l study not matched but controlled in univariate analyses not matched but controlled in univariate analyses mortality in hospital 10 cases Mort. cases= 20% median 10 controls Mort. controls= 10% preinfection cases=12 Score ++ - + ++ ++ ++ + ++ ++ - - - controls=15 postinfection 7 Brooklyn Antibiotic Resistance Task Force cases=33.5 controls=20 Comments Matched case-control study matched for age mortality in hospital Sample size N refers to total number of cases and controls (no score) Calculation a priori: ++ if performed (e.g. based on expected prevalence or on litterature data) or the study refers to large national surveys; - if not performed Study type Study type: ++ matched cohort or case-control studies; + prospective cohort or case-control studies; - restrospective database studies Geographical: ++ if the study was conducted in an EU/EEA setting; + if the study was conducted in high-income country(ref. World bank); - if the study was not conducted in an EU/EEA or high-income country setting Representativeness Matching or controlling for confounders Risk difference Demographical: ++ if the study population represents all age groups; + if the study population represents selected age-specific groups (e.g. elderly, infants); - if the study population represents a selected sex category and age-specific groups Clinical: ++ if the study population represents the overall hospital population; + if the study population partially represents the hospital population; - if the study population represents a disease-specific population (e.g. liver transplanted patients, cancer patients, etc..) Exlusion/inclusion criteria: ++ if the same exclusion/inclusion criteria were adopted for both cases and controls; + if some (but not all) exclusion/inclusion criteria were adopted for both cases and controls; - if exclusion/inclusion criteria were different in cases and controls Demographics: ++ if performed for age and sex; + if performed only for age or only for sex; - if not performed at all Underlying disease: ++ if performed for two or more criteria (e.g. comorbidity score, McCabe score, severity index, n. comorbidities, allergy, immunosuppression status, prior hospitalisation etc..); + if performed for only one criteria; - if not performed at all Infection site: ++ if performed ; - if not performed Hospital and unit/ward: ++ if same hospital and same unit/ward; + if same hospital but different unit/ward; - if not same hospital and/or not same unit/ward Follow-up: ++ if ≥ 28 days; - if < 28 days Statistically significant outcome results: ++ if results and 95%CI are statistically significant; - if results and 95%CI are not statistically significant Case fatality and LOS refer to risk difference estimates in cases and controls (no score) Scoring table ++ Matches completely/is completely fulfilled + Matches incompletely but sufficiently/is only partly but sufficiently fulfilled - Does not match or matches insufficiently/is insufficiently fulfilled c.b.e. Cannot be evaluated CRPA 161 Checklist for the evaluation of the most relevant studies for building antimicrobial resistance (AMR) outcome trees, healthcare-associated infection (HAI) attributable case fatality and attributable length-of-stay (LOS) Study Study type Infection type Sample size Representativeness Matching or controlling for confounders Risk difference N (cases;controls) calculation a priori Geographical Demographical Clinical Exclusion/inclusion criteria Demographics Underlying disease Infection site Hospital and unit/ward Follow-up Statistically significant outcome results Case fatality LOS Nr. First author, year HCA; CA; Mix; c.b.e □ ++; □ -; □ c.b.e □ ++; +; -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; -; □ c.b.e □ ++; □ -; □ c.b.e %; RR; OR; aHR; etc (days) 1 Atmaca, 2014 Score c.b.e c.b.e 99 cases 99 controls + - ++ + ++ ++ ++ - ++ c.b.e ++ Mort. rate cases= 47.5% Mort. rate controls=29.3% median cases=59 controls=8 Comments Nested case control study full-text in turkish, data extracted from abstracted in english patients in infectious disease unit not matched but controlled in univariate analyses not matched but controlled in univariate analyses all BSI mortality in hospital data extracted from original paper in Turkish with help of google translate data extracted from original paper in Turkish with help of google translate 2 McMaster, 2015 Score + HCA* 58 cases* 174 controls (231 cases**) - ++ ++ + ++ ++ ++ - ++ ++ - a) Mort. rate cases= 19%
 Mort. rate controls=21.2%
 b) Mort. rate cases*= 32.8%
Mort. rate controls=34.5% (Mort. rate cases**= 42.9%) in ICU median (range) cases*=16.6 (1.5- 124.1) controls=16.9 (1.9- 92.1) (cases**=2.9 (0.4- 497.2)) Comments Prospective study not esplicit in the paper but most probably all HCA * infection aquired in ICU ** infection acquired before ICU admission all ICU patients cases acquires in ICU (*) were matched with controls cases acquires in ICU (*) were matched with controls (APACHE II) all BSI a) hospitaliz b) 180 days a) hospitaliz b) 180 days * infection aquired in ICU ** infection acquired before ICU admission * infection aquired in ICU ** infection acquired before ICU admission 1 Stewardson, 2016 Score - Mix 163 resistant 885 sensitive 604797 NI ++ ++ ++ + - - - - c.b.e ++ Mort. rate resistant=22.1% Mort.rate sensitive=16.8% Mort.rate NI=1.7% R vs NI: HR*=3.81/2.61/2.42 R vs S: HR*=1.19/1.20/1.26 no specific data, see full-text for modelling values* Comments Multicentre retrospectiv e cohort study HC onset: 38% cases, 51% controls community onset: 62% cases, 49% controls patients with acute- care episodes lasting more than one day no univariate analyses, matched in model 2 no univariate analyses all BSI or NI mortality in hospital only R vs NI * the study models the excess in LOS and mortality between groups proposing 3 models for each * the study models the excess in LOS and mortality between groups proposing 3 models for each 2 Yasmin, 2016 Score - Mix 118 resistant 145 sensitive 118 NI - + ++ ++ ++ ++ - - + c.b.e - a)Mort. rate resist= 22% Mort. rate sensit=19.5% Mort. rate NI=1.7% b)Mort. rate resist=19.5% Mort. rate sensit=10.3% no specific data Comments Retrospecti ve case- case-cohort study HC onset: 14% cases, 10% controls community onset: 75.4% cases, 63.4% controls not matched but controlled in univariate analyses all BSI mortality in hospital a) mortality during hospitalisation b) attributable mortality I) 248 resistant R vs NI (Cohort I) median (IQR) 453 NI a) Mort. rate resist= 31%* Cohort I II) 618 sensitive Mort. rate NI=8%* resistant=16 (6-32)* 1170 NI aOR=4.4* NI=7(3-18)* b) Mort. rate resist= 36%* Cohort II Mort. rate NI=9%* sensitive=15(7-26)* aHR=3.1* NI=8(4-14)* Score ++ c.b.e - ++ ++ ++ ++ + - - - ++ ++ S vs NI (Cohort II) a) Mort. rate sensit=22%* excess LOS R vs NI= 9.2* Mort. rate NI=8%* S vs NI= 8.6* 3 De Kraker 2011 aOR=2.4* R vs S= 0.6 b) Mort. rate sensit=23%* Mort. rate NI=7%* aHR=3.1* R vs S a) OR=1.8* Comments Prospective parallel matched- cohort study no information available I) cohort I II) cohort II 13 EU countries not matched but controlled in univariate analyses for age, gender is different all BSI a) 30 days b) mortality in hospital all the outcomes with * a) 30 days mortality b) mortality in hospital 1 De la Calle, 2016 Score - Mix 42 cases 56 controls - ++ ++ ++ ++ + + - + ++ - a) Mort. rate cases= 40.5%
 Mort. rate controls=37.5%
 no data Comments Retrospecti ve study similar HCA/CA between cases and control, but no specific info all patients had bacteremic pneumonia with a positive BSI not matched but controlled in univariate analyses fot gender, while age was higher in the cases not matched but controlled in univariate analyses for different diseases, except for cardiovascular diseases that were higher in cases all BSI a) 30 days b) related mortality a) 30 days b) related mortality (patient died without a definitive infection control) 2 De Rosa, 2016 Score - c.b.e 106 cases 83 controls - ++ ++ ++ ++ - - - + - c.b.e Mort. rate cases= 17.9% Mort. rate controls=14.3% no data Comments Retrospecti ve study no information available all BSI 21 days no information available 3 Deodhars, 2015 Score + c.b.e 40 cases 61 controls - - ++ ++ ++ c.b.e c.b.e - + c.b.e - Mort. rate cases= 21%
 Mort. rate controls=21.3% no data Comments Prospective study most probably all HCA patients >12 years no matching and the control is for died vs survived no matching and the control is for died vs survived all BSI mortality in hospital 4 Dolapo, 2014 Score - HCA a) 10 cases
 31 controls
 b) 64 cases
51 controls - + + + ++ c.b.e c.b.e - ++ - c.b.e a) Mort. rate cases= 0% Mort. rate controls=9.8% b) Mort. rate cases= 15.7% Mort. rate controls=5.2% mean±SD a) cases=80.6±42.4 controls=87.4±40.6 b) cases=53.6±36.6 controls=55.7±30.2 Comments Retrospecti ve study not specified in the article but patients are neonates in ICU a) period A (2000-2003) b) period B (2004-2009) neonates patients patients in NICU no matching and no control for cases vs controls no matching and no control for cases vs controls all BSI 14 days no information available a) period A (2000-2003) b) period B (2004-2009) a) period A (2000-2003) b) period B (2004-2009) 5 Fortuin de Smidt, 2015 Score + Mix 86 cases 154 controls - - ++ ++ ++ ++ + - - c.b.e ++ Mort. rate cases= 29.1% Mort. rate controls=14.3% median (IQR) cases=38 (14–64) controls=19 (7–33) Comments Prospective cross- sectional study HCA: 76% cases, 50% controls CA: 24% cases, 49% controls not matched but controlled in univariate analyses not matched but controlled for Pitt bacteremia score all BSI mortality in hospital 6 Kim D.H, 2014 Score - c.b.e 29 cases 8 controls - + ++ - ++ c.b.e c.b.e - + c.b.e ++ Mort. rate cases= 62% Mort. rate controls=0% OR=0.158; 95%CI(0.047–0.534) no specific data Comments Retrospecti ve study no information available patients had Cardiac Implanted Electronic Device-Related Infective Endocarditis (CIED-related IE) no matching and no control for cases vs controls no matching and no control for cases vs controls all BSI mortality in hospital 7 Kobayashi, 2014 Score - c.b.e 151 cases 189 controls - + ++ ++ ++ c.b.e c.b.e - + ++ c.b.e Mort. rate cases= 39.7% Mort. rate controls=30.7% no data Comments Retrospecti ve cohort study no information available no matching and no control for cases vs controls no matching and no control for cases vs controls all BSI 90 days no information available 8 Lee J.Y, 2014 Score c.b.e CA 31 cases 138 controls - + ++ ++ ++ ++ ++ - + ++ - 1-a)Mort. rate cases= 3.2% Mort. rate controls=3.6% 1-b) Mort. rate cases= 6.5% Mort. rate controls=13.8% 1-c) Mort. rate cases= 16.1% Mort. rate controls=19.6% 2-a) Mort. rate cases= 0% Mort. rate controls=3.6% 2-b) Mort. rate cases= 3.2% Mort. rate controls=9.4% 2-c) Mort. rate cases= 6.5% Mort. rate controls=13% median (IQR) cases=47 (19–87) controls=24 (14–44.5) Comments Cohort study (with prospective and retrospectiv e studies) not matched but controlled in univariate analyses not matched but controlled in univariate analyses all BSI a) 1 week b) 30 days c) 12 weeks none of the results is significant 1- a/b/c) all-cause mortality 2- a/b/c) infection related mortality 9 Manandhar, 2016 Score - c.b.e 15 cases 21 controls - + ++ ++ ++ + ++ - + ++ - a) Mort. rate cases= 26.7% Mort. rate controls=38.1% OR=0.62; 95%CI(0.15–2.61) b) Mort. rate cases= 26.7% Mort. rate controls=42.9% OR=0.51; 95%CI(0.12–2.14) no specific data Comments Retrospecti ve study no information available all patients had BSI and UTI not matched but controlled in univariate analyses for gender not matched but controlled in univariate analyses all BSI a) 30 days b) 90 days a) 30 days b) 90 days 10 McMullan, 2016 Score + Mix 142 cases 931 controls - + + ++ ++ + - - - ++ - a) Mort. rate cases= 3.5%
 Mort. rate controls=2.5%
 b) Mort. rate cases= 8.5%
Mort. rate controls=4.1% median (IQR) cases=17 (8-38) controls=14 (7-33) Comments Prospective study HCA: 48.6% cases, 51.7% controls CA: 51.4% cases, 48.3% controls pediatric patients <18 years not matched but controlled in univariate analyses for gender all BSI a) 7 days b) 30 days a) 7 days b) 30 days 11 Nagao, 2016 Score - Mix 199 cases 278 controls - + ++ ++ ++ c.b.e c.b.e - + ++ - Mort. rate cases= 9% Mort. rate controls=5.8% no data Comments Retrospecti ve cohort study HCA: total=70.2% CA: total=29.8% no matching and no control for cases vs controls no matching and no control for cases vs controls all BSI 30 days 12 Naidoo, 2013 Score - Mix 95 cases 270 controls - - + ++ ++ + - - + c.b.e ++ MRSA OR (95%CI) univariate=3.71 (1.77-7.76) multivariate=3.76 (1.12-12.67) no specific data Comments Retrospecti ve study HCA: total=49% CA: total=51% pediatric patients <13 years not matched but controlled in univariate analyses for gender, age (in months) was different all BSI mortality in hospital the mortality was not available in % 13 Ong, 2013 Score - Mix 76 cases 363 controls - + ++ ++ ++ - - - + ++ - Mort. rate cases= 63% Mort. rate controls=39% HR=1.37; 95%CI(0.95–1.97) no data Comments Retrospecti ve cohort study HCA: total=57% CA: total=42% all BSI 1 year the study aimed the log-term survival rate 14 Park, 2013 Score - c.b.e 191 cases 476 controls - c.b.e + - ++ NA NA - - c.b.e ++ OR fixed= 2.33; 95%CI(1.42- 3.82) no data Comments Review and meta- analyses no information available papers from different countries patients are children and neonates endocarditis was in serching criteria all BSI mortality in hospital 15 Simsek, 2014 Score - HCA 13 cases 47 controls - - ++ - ++ c.b.e c.b.e - + c.b.e ++ Mort. rate cases= 49% Mort. rate controls=15% OR=12.117; 95%CI(3.159 46.475) no specific data Comments Retrospecti ve study not specified in the article but very specific patients patients with with poststernotomy mediastinitis no matching and no control for cases vs controls no matching and no control for cases vs controls all BSI mortality in hospital BSI R vs S BSI R vs NI vs R BSI R vs NI MRSA 162 16 Thaden, 2015 Score - HCA 1) 567 cases 2047 controls 2) 280 cases 445 controls - + + + ++ c.b.e c.b.e - - ++ c.b.e 1-a)Mort. rate cases= 3%
 Mort. rate controls=4%
 1-b) Mort. rate cases= 8%
Mort. rate controls=8%
 1-c) Mort. rate cases= 11%
Mort. rate controls=10%
 2-a) Mort. rate cases= 4%
Mort. rate controls=2%
 2-b) Mort. rate cases= 9%
Mort. rate controls=3%
 2-c) Mort. rate cases= 12%
Mort. rate controls=4% no data Comments Retrospecti ve study not specified in the article but very specific patients 1) with adequate therapy 2) with inadequate therapy patients are infants in NICU patients in NICU no matching, and comparison between adequate and inadequate therapy no matching, and comparison between adequate and inadequate therapy all BSI a) 7 days b) 30 days c) hospitaliz comparison between adequate and inadequate therapy 1) with adequate therapy 2) with inadequate therapy a) 7 days b) 30 days c) hospitaliz 17 Theodorou, 2013 Score - Mix 33 cases 41 controls - ++ ++ - ++ ++ - - c.b.e - Mort. rate cases= 33.3% Mort. rate controls=24.4% OR=1.55, 95%CI(0.56–4.28) median cases=28.5 controls=21 Comments Retrospecti ve cohort study HCA: 89.2% no other infos burned patients in ICU not matched but controlled in univariate analyses all BSI mortality in hospital 18 Wang, 2015 Score - Mix a) 101 cases b) 59 cases c) 35 cases 159 controls - - ++ ++ ++ c.b.e c.b.e - - c.b.e ++ a) Mort. rate cases= 47.5% OR=2.249; 95%CI(1.188- 4.259)
 b) Mort. rate cases= 30.5% OR=0.998; 95%CI(0.453- 2.200)
 c) Mort. rate cases=35.3% OR=1.223; 95%CI(0.466-3.210) Mort. rate controls=25.3% Total MRSA OR=1.707 no data Comments Retrospecti ve cohort study separated by infection type a) HA-MRSA b) CA-MRSA c) unclassified-MRSA not matched and the comparison resulta are not undestandable not matched and the comparison resulta are not undestandable all BSI mortality in hospital only OR HA-MRSA and Total MRSA OR a) HA-MRSA b) CA-MRSA c) unclassified-MRSA 19 Yaw, 2014 Score - Mix 185 cases 397 controls - + ++ ++ ++ + + - + ++ ++ a) Mort. rate cases= 15% Mort. rate controls=12% b) Mort. rate cases= 28% Mort. rate controls=19% c) Mort. rate cases= 75% Mort. rate controls=62% no data Comments Retrospecti ve observation al cohort study HCA: 90% cases, 75% controls CA: 10% cases, 25% controls not matched but controlled in univariate analyses for gender not matched but controlled in univariate analyses for Charlson index, SAPS score is different all BSI a) 8 days b) 30 days c) follow up at 01/03/2013 significative only b) and c) a) 8 days b) 30 days c) follow up at 01/03/2013 20 Yilmaz, 2016 Score + Mix 100 cases 145 controls - - ++ ++ ++ c.b.e c.b.e - - ++ - Mort. rate cases= 22%
 Mort. rate controls=11.7% HR=0.99; 95%CI(0.33–3.0) no data Comments Prospective multicentre study HCA: 95% cases, 30% controls CA: 5% cases, 70% controls no matching and no control for cases vs controls no matching and no control for cases vs controls all BSI 28 days Bone R vs S 1 Shoji, 2016 Score - Mix 16 cases 55 controls - + ++ - ++ ++ + - - c.b.e ++ Mort. rate cases= 25% Mort. rate controls=5.5% no data Comments Retrospecti ve study Hosp onset: 37.5% cases, 27.3% controls no further info patients with vertebral osteomyelitis not matched but controlled in univariate analyses. Differences in age≥65years not matched but controlled for main diseases. Differences only in diabetes mellitus all vertebrae mortality in hospital Skin Wound R vs S 1 Alizadeh, 2014 Score c.b.e c.b.e 82 cases 32 controls - - ++ - ++ + - - ++ c.b.e NA no deaths reported in any group no data Comments Cross- sectional study no information available patients with cutaneous lesions not matched but controlled in univariate analyses for gender, age distribution was different underlying conditions were different in the two groups all skin wound infections mortality in hospital Mixed inf. site R vs NI 1 Balm, 2013 Score - HCA 121 cases 716 controls - + ++ ++ ++ - - - + ++ ++ a) Mort. rate cases= 16.5% Mort. rate controls=4.6% OR=5.49; 95%CI(2.75- 10.95) b) Mort. rate cases= 28.9% Mort. rate controls=12.5% OR=2.94; 95%CI(1.78 – 4.85) no data Comments Retrospecti ve cohort study All patients were negative to infection when admitted to the hosp cases had clinical MRSA infection controls were only colonized with MRSA (nasal swab) not matched and not controlled not matched and not controlled a) 30 days b) 6 months Both ORs, no information on mortality rates comparison a) 30 days b) 6 months 2 Nelson, 2015 Score ++ HCA a) 3599 cases 366144 controls b) 3592 cases 3592 controls - + ++ ++ ++ ++ ++ - + ++ ++ a) aHR=1.420; 95%CI(1.322- 1.525)
 b) aHR=1.370; 95%CI(1.231- 1.524) mean a) cases=22.4 controls=9.3 b) cases=20.1 controls=23.2 Comments Retrospecti ve matched cohort study a) full cohort b) propensity score matched Paper studies the mortality post hosp discharge propensity score matching 1 year after discharge a) full cohort b) propensity score matched Data for all-cause mortality 1 year after hosp discharge 3 Tran, 2016 Score ++ HCA a)745 cases 17649 controls b)737 cases 737 controls - + ++ ++ ++ ++ ++ - - c.b.e ++ a)Mort. rate cases= 8.2%
 Mort. rate controls=5.7% b)Mort. rate cases= 8%
Mort. rate controls=7% mean a)cases=12.8 controls=7.6 b) cases=11.9 controls=9.1 Comments Retrospecti ve matched cohort study a) pre-match cohort b) post-match cohort propensity score matching mortality in hospital only a) was significant a) pre-match cohort b) post-match cohort a) pre-match cohort b) post-match cohort Mixed inf. site R vs S 1 Ericson, 2015 Score - c.b.e 1063 cases 2825 controls - + + + ++ ++ - - - ++ - a) Mort. rate cases= 11.9% Mort. rate controls=9.6% RR=1.19; 95%CI(0.96-1.49) b) Mort. rate cases= 3.8% Mort. rate controls=3.8% RR=0.90; 95%CI(0.65-1.24) c) Mort. rate cases= 8.7% Mort. rate controls=7.2% RR=1.15; 95%CI(0.90-1.46) both groups=64 Comments Multicentre retrospectiv e study no information available invasive infection; included blood, cerebrospinal fluid, abscess, and sterile sites patients were infants patients in NICU not matched but controlled in univariate analyses a) before discharge b) 7days c) 30 days a) before discharge b) 7days c) 30 days 2 Gimenes, 2016 Score - c.b.e 71 cases 23 controls - - ++ + ++ + - - ++ c.b.e c.b.e Mort. rate cases= 33.8% Mort. rate controls=52.17% median (IQR) cases=20 (20) controls=19 (17) Comments Retrospecti ve study no information available patients in ICU not matched but controlled in univariate analyses for age, gender was different mortality in hospital no comparison between rates Kaplan Meier survival curve was not significantly different 3 Kim E.S, 2014 Score + Mix 303 cases 357 controls - + ++ ++ ++ c.b.e c.b.e - - ++ - Mort. rate cases= 16.8%
 Mort. rate controls=14% OR=1.243; 95%CI(0.813–1.899) no data Comments Prospective study difficult to have the right % of remaing patients because 126 were excluded because without a follow-up infection had comunity onset no matching and difficult to evaluate the control since 126 patients were escluded because without a follow-up no matching and difficult to evaluate the control since 126 patients were escluded because without a follow-up 30 days Nasalal swab R vs NI 1 Altinbas, 2013 Score + HCA 11 cases 257 controls - - ++ + ++ ++ ++ - + ++ - Mort. rate cases= 18.1% Mort. rate controls=37.3% mean cases=18 controls=8 Comments Prospective study patients in ICU not matched but controlled in univariate analyses not matched but controlled in univariate analyses for main diseases, difference only in Gastrostomy and Femoral catheter all nasal swabs 1 year 2 Chan, 2015 Score + c.b.e 75 cases 117 controls - + + + ++ - - - ++ ++ ++ a) Mort. rate cases= 64%
 Mort. rate controls=44.6%
 b) Mort. rate cases= 30.7%
Mort. rate controls=18.8% HR=1.96, 95%CI(1.01-3.78) no data Comments Prospective chort study no information available elderly patients patients were nursing home residents all nasal swabs 2 years a) all cause mortality b) infection related mortality all patients were in nursering home 3 Chen, 2013 Score - c.b.e 90 cases 90 controls - + ++ + ++ - - - ++ c.b.e - Mort. rate cases= 12.2% Mort. rate controls=15.6% mean±SD
 cases=5.2±7.4
 controls=5.9±8.8 Comments Retrospecti ve cohort study no information available patients in ICU all nasal swabs mortality in hospital 4 Moore, 2014 Score ++ c.b.e 28 cases 56 controls - ++ ++ - ++ ++ + - ++ ++ - a) Mort. rate cases= 17% Mort. rate controls=7% b) Mort. rate cases= 3.6% Mort. rate controls=0% no data Comments Matched case-control study no information available patients prior renal transplant not matched but controlled in univariate analyses for Charlson index, some other disease were different all nasal swabs 5 years a) all-cause mortality b) infection related mortality Resp. Tract R vs NI 1 Minejima, 2014 Score - CA 134 cases 134 controls - + ++ ++ ++ + - - + ++ ++ Mort. rate cases= 22% Mort. rate controls=3% mean cases=10 controls=5 Comments Retrospecti ve study community onset, not specified if 100% CA patients had non-MRSA pneumonia patients with penuomonia not matched but controlled in univariate analyses for gender, age was different 28 days Resp. Tract R vs S 1 Hill, 2013 Score - c.b.e n∼o exact data* 80 casess 60 controls - + ++ - ++ ++ - - ++ c.b.e - Mort. rate cases= 17.5% Mort. rate controls=25.4% in ICU mean cases=34 controls=35 Comments Retrospecti ve study no information available *population estimated from graph trauma patients with VAP not matched but controlled in univariate analyses all Resp tract mortality in hospital 2 Tosh, 2013 Score - CA 42 cases 52 controls - + + ++ ++ ++ + - - c.b.e - Mort. rate cases= 12% Mort. rate controls=2% mean
 cases=9
 controls=6 Comments Retrospecti ve study community onset, not specified if 100% CA patients ≤50 years patients with penuomonia not matched but controlled in univariate analyses not matched but controlled in univariate analyses for Charlson index mortality in hospital Score - CA 78 cases 865 controls* - + ++ ++ ++ + - - + c.b.e ++ Mort. rate cases= 33.3% Mort. rate controls=21.5% median (IQR) 
 cases=16.5 (10– 30)
controls=11 (6–20) 163 3 Jung, 2013 Comments Retrospecti ve study defined as "non- nosocomial pneumonia" * controls were patients with non-nosocomial pneumonia due to other bacteria (non-MRSA) patients with penuomonia not matched but controlled in univariate analyses for gender, age was differet mortality in hospital 4 Rello, 2013 Score - HCA a) 15 cases 30 controls b) 5 cases 6 controls - ++* ++ + ++ - - - - c.b.e c.b.e. a) Mort. rate cases= 33.3% Mort. rate controls=10% b) Mort. rate cases= 60% Mort. rate controls=50% no data Comments Retrospecti ve comparison of 2 cohorts patient with HCA and ventilator associated penumonia a) Europe b) Latin America *Europe and South America patients in ICU, with pneumonia mortality in ICU no information available 5 Self, 2016 Score + CA 15 cases 22 controls - + ++ ++ ++ - - - - c.b.e c.b.e Mort. rate cases= 13.3% Mort. rate controls=9.1% median (IQR) cases=9 (8-13) controls=6 (4–10) Comments Prospective study patients with pneumonia mortality in hospital no information available 1 Lin, 2015 Score - Mix 38 cases 55 controls - - ++ - ++ + ++ - - c.b.e - Mort. rate cases= 5.3%
 Mort. rate controls=5.5% no data Comments Retrospecti ve clinical case-series HCA: 0% cases, 18.4% controls CA: 100% cases, 81.6% controls all patients had septic arthritis caused by S. aureus patients with septic arthritis not matched but controlled in univariate analyses for gender, age was differet all sinuvial fluid mortality in hospital 2 Minguez, 2015 Score - c.b.e 7 cases 17 controls - - ++ - ++ + - - + c.b.e - Mort. rate cases= 57.1% Mort. rate controls=17.6% mean cases=33 controls=20 Comments Retrospecti ve study no information available all patients had septic arthritis caused by S. aureus patients with septic arthritis not matched but controlled in univariate analyses for gender, age was differet all sinuvial fluid mortality in hospital Sample size N refers to total number of cases and controls (no score) Calculation a priori: ++ if performed (e.g. based on expected prevalence or on litterature data) or the study refers to large national surveys; - if not performed Study type Study type: ++ matched cohort or case-control studies; + prospective cohort or case-control studies; - restrospective database studies Infection type HCA: health-care associated; CA: community associated; Mix: health-care and community associated together Geographical: ++ if the study was conducted in an EU/EEA setting; + if the study was conducted in high-income country(ref. World bank); - if the study was not conducted in an EU/EEA or high-income country setting Representativeness Demographical: ++ if the study population represents all age groups; + if the study population represents selected age-specific groups (e.g. elderly, infants); - if the study population represents a selected sex category and age-specific groups Clinical: ++ if the study population represents the overall hospital population; + if the study population partially represents the hospital population; - if the study population represents a disease-specific population (e.g. liver transplanted patients, cancer patients, etc..) Exlusion/inclusion criteria: ++ if the same exclusion/inclusion criteria were adopted for both cases and controls; + if some (but not all) exclusion/inclusion criteria were adopted for both cases and controls; - if exclusion/inclusion criteria were different in cases and controls Demographics: ++ if performed for age and sex; + if performed only for age or only for sex; - if not performed at all Matching or controlling for Underlying disease: ++ if performed for two or more criteria (e.g. comorbidity score, McCabe score, severity index, n. comorbidities, allergy, immunosuppression status, prior hospitalisation etc..); + if performed for only one criteria; - if not performed at all confounders Risk difference Infection site: ++ if performed ; - if not performed Hospital and unit/ward: ++ if same hospital and same unit/ward; + if same hospital but different unit/ward; - if not same hospital and/or not same unit/ward Follow-up: ++ if ≥ 28 days; - if < 28 days Statistically significant outcome results: ++ if results and 95%CI are statistically significant; - if results and 95%CI are not statistically significant Case fatality and LOS refer to risk difference estimates in cases and controls (no score) Scoring table ++ Matches completely/is completely fulfilled + Matches incompletely but sufficiently/is only partly but sufficiently fulfilled - Does not match or matches insufficiently/i s insufficiently fulfilled c.b.e. Cannot be evaluated Sinuvial fluid R vs S 164 Checklist for the evaluation of the most relevant studies for building antimicrobial resistance (AMR) outcome trees, healthcare-associated infection (HAI) attributable case fatality and attributable length-of-stay (LOS) Study Study type Sample size Representativeness Matching or controlling for confounders Risk difference N (cases;controls) calculation a priori Geographical Demographical Clinical Exclusion/inclusion criteria Demographics Underlying disease Infection site Hospital and unit/ward Follow-up Statistically significat outcome results Case fatality LOS Nr. First author, year □ ++; □ -; □ c.b.e □ ++; +; -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; -; □ c.b.e □ ++; □ -; □ c.b.e %; RR; OR; aHR; etc (days) 1 De Silva, 2014 Score - 30 cases 284 controls - - ++ ++ ++ - - - ++ c.b.e ++ OR 2.73; 95% CI: 1.09-7.78 no data Comments Retrospectiv e cohort study all BSI same hospital and controlled in univariate analyses fot ward mortality in hospital 2 Yoo, 2005 Score - 19 cases 8 controls - + ++ - ++ ++ + - ++ c.b.e - Mort. rate cases=78.9% Mort. rate controls=62.5% Mean (SD) Case=56.2 (28.2) Controls=33.4(15.6) Comments Retrospectiv e cohort study patients who received hematopoietic stem cell transplantation or cytotoxic chemotherapy not matched but controlled in univariate analyses not matched but controlled in univariate analyses for SAPS II score all BSI post-discharge mortality 3 Lodise, 2002 Score ++ 53 cases 53 controls - + ++ ++ ++ ++ + - ++ - ++ a)Mort. rate cases=52.8% Mort. rate controls=26.4% aOR=4.0; 95%CI(1.2–13.3) a)Mort. rate cases=37.7% Mort. rate controls=20.8% aOR=52; 95%CI(1.4-2.0) After diagnosis Mean (SD) Cases=22.7 (1.88) Controls=15.9 (1.7) Comments Retrospectiv e matched matched for age and controlled in univariate matched for APACHE II score all BSI 7 days a) all-cause mortality b) infection related mortality 4 Peset, 2000 Score + 17 cases 169 controls - ++ ++ ++ ++ ++ - - + c.b.e - Mort. rate cases=23.5% Mort. rate controls=12.4% OR=2.7; 95%CI(0.47–7.89) Mean (SD) Cases=74.75 (46.27) Controls=47.26 (37.59) Comments Prospective case-control not matched but controlled in univariate analyses all BSI mortality in hospital 5 Garbutt, 2000 Score - a)46 cases 23 controls b) 76 cases 50 controls - + ++ ++ ++ - - - + c.b.e - a) Mort. rate cases=48% Mort. rate controls=30% OR=1.74; 95%CI(0.50–6.12) b) Mort. rate cases=43% Mort. rate controls=36% OR=1.28; 95%CI(0.47–3.51) Mean (SD) Cases=39.7(25.5) Controls=21(16.3) Comments Retrospectiv e cohort study a) main cohort (2 positive samples) b) full cohort (1 positive sample) all patients of cohort a) are present also in cohort b) all BSI mortality in hospital a) main cohort (2 positive samples) b) full cohort (1 positive sample) all patients of cohort a) are present also in cohort b) 6 Bhavnani, 2000 Score c.b.e 150 cases 150 controls - + ++ ++ ++ ++ ++ - - ++ ++ a) Mort. rate cases=52% Mort. rate controls=27% aOR=3.34; 95%CI(1.61-6.91) b) Mort. rate cases=32% Mort. rate controls=17% no data Comments Multicentre case-control (both prospective and retrospectiv e data) not matched but controlled in univariate analyses not matched but controlled in univariate analyses for main diseases, differences only in chronic renal failure all BSI 30 days a) all-cause mortality b) infection related mortality 7 Lucas, 1998 Score c.b.e 93 cases 101 controls - + ++ ++ ++ ++ - - + c.b.e ++ Mort. rate cases=45% Mort. rate controls=27% aOR=2.07; 95%CI(0.96-4.42) Mean Cases=49.1 (48.3) Controls=38.6 (31.2) Comments Case-control study not matched but controlled in univariate analyses all BSI mortality in hospital only mortality rates comparison 8 Stosor, 1998 Score - 21 cases 32 controls - + ++ ++ ++ - ++ - + c.b.e ++ a) Mort. rate cases=76% Mort. rate controls=41% b)Mort. rate cases=38% Mort. rate controls=9% c)Mort. rate cases=24% Mort. rate controls=19% d)Mort. rate cases=14% Mort. rate controls=13% Mean Cases=34.8 (23.3) Controls=16.7 (16.1) Comments Retrospectiv e comparison not matched but controlled in univariate analyses for severity of illness score all BSI mortality in hospital only a) and b) a) overall mortality b) infection directly related mortality c) infection indirectly related mortality d) unrelated mortality 9 Linden, 1996 Score - 54 cases 48 controls - + ++ - ++ - - - ++ c.b.e ++ a) Mort. rate cases=57% Mort. rate controls=35% aRR=3.47(1.47-8.19) b) Mort. rate cases=46% Mort. rate controls=25% After diagnosis Median: Cases=46 Controls=19 Comments Retrospectiv e cohort study the patients are either awaiting liver transplantation or have received a liver transplan all BSI mortality in hospital a) all-cause mortality b) infection related mortality 10 Krcmery, 2001 Score - 9 cases 92 controls - ++ ++ ++ ++ - - - - c.b.e - Mort. rate cases=22% Mort. rate controls=41.3% no data Comments Retrospectiv e review all ages included all BSI not specified, but most probably mortality in hospital 11 Vergis, 2000 Score + 147 cases 251 controls - + ++ ++ ++ + - - - - ++ Mort. rate cases=33% Mort. rate controls=11% aOR=2.1(1.14-3.88) median cases=17 controls=3 Comments Prospective multicentre observationa l study not matched but controlled in univariate analyses for gender, age is different all BSI 14 days 12 Shay, 1995 Score - 46 cases 46 controls - + ++ ++ ++ - - - + c.b.e - Mort. rate cases=33% Mort. rate controls=6.5% aOR=3.3(0.7-15) no data Comments Retrospectiv e case- control all BSI not specified, but most probably mortality in hospital 13 Wells, 1995 Score - 6 cases 37 controls - + ++ ++ ++ - - - + c.b.e - Mort. rate cases=17% Mort. rate controls=27% no data Comments Retrospectiv e case- control all BSI mortality in hospital 14 Cheah, 2013 Score ++ 116 cases 116 controls - + ++ ++ ++ ++ - - - c.b.e ++ Mort. rate cases=36% Mort. rate controls=26% aOR=1.21; 95%CI(0.52-2.79) Median (IQR) cases=35(22.5–50.5) controls=25(16–45.5) Comments Retrospectiv e matched cohort study not matched but controlled in univariate analyses all BSI mortality in hospital only the comparison between the mortality rates 15 DiazGranados, 2005(a) Score - 22 cases 61 controls ++ + ++ - ++ ++ + - + ++ ++ Mort. rate cases=63.6% Mort. rate controls=41% aHR=4.97; 95%CI(1.21-20.44) Median Cases=42 (24-75) Controls=31 (2-72) Comments Retrospectiv e cohort study patients with neutropenia not matched but controlled in univariate analyses not matched but controlled in univariate analyses for APACHE II score all BSI 60 days only HR 16 Peel 2012 Score - 80 resistant 80 sensitive 80 NI - + ++ ++ ++ - - - ++ c.b.e ++ Mort. rate resistant=37.5% Mort. rate sensitive=23.8% Mort. rate NI=2.5% no data Comments Case-case- control study all BSI not specified, but most probably mortality in hospital in R and S higher than in NI 17 Mainous, 1997 Score - 10 cases 31 controls - + ++ + ++ - - NA ++ c.b.e - Mort. rate cases=40% Mort. rate controls=39% mean (SD) cases=28 (18) controls=12 (10) Comments Retrospectiv e cohort study patients in ICU mortality in hospital 18 Salgado, 2003 Score ++ a)856 cases 1180 controls ++ NA ++ ++ ++ NA NA - - NA ++ a)Mort. rate cases=41.5(0-66.7)% Mort. rate controls=47.8(17-100)% b)Mort. rate cases=45.2% Mort. rate controls=19.0% RR=2.38; 95%CI(2.13-2.66) c) Mort. rate cases=48.9% Mort. rate controls=19% RR=2.57; 95%CI(2.27-2.91) d) Mort. rate cases=28.7% Mort. rate controls=10.9% RR=2.62; 95%CI(1.84-3.73) e) Mort. rate cases=39.1% Mort. rate controls=21.8% RR=1.79; 95%CI(1.28-1-5) f) Attributable mortality =17-46% Excess of total stay of VRE vs VSE=10-46 days Comments Review and Meta- analyses a)pooled cases (14 studies) and controls (26 studies) articles from different countries diffent in different studies diffent in different studies all BSI b), c), d) and e) a)crude mortality rates of pooled cases (14 studies) and controls (26 studies) b) pooled cases and controls from 13 studies c) pooled cases and controls from 9 studies with higher sample size d) pooled cases and controls from 5 studies with infection related mortality e) studies of point d) excluded one that was producing heterogeneity f) range of values from 4 studies which matched for severity of illness 19 DiazGranados, 2005(b) Score ++ 683 cases 891 controls - NA ++ ++ ++ NA ++ - - NA ++ OR=2.52; 95%CI(1.9–3.4) Comments Review and Meta- analyses pooled cases and controls from 9 studies articles from different countries 1 study neutropenic patiens, 1 liver transplant patients but controlled with sensitivity analyses diffent in different studies studies matched or controlled for severity of illness all BSI 20 CDC, 1993 Score - 71 cases 1810 controls - + ++ ++ ++ - - - - c.b.e - Mort. rate cases=36.6% Mort. rate controls=16.4% no data Comments Surveillance study all BSI not specified, but most probably mortality in hospital 21 Lautenbach, 1999 Score - 72 cases 188 controls - + ++ ++ ++ - - - + c.b.e c.b.e Mort. rate cases=45.8% Mort. rate controls=33.5% median (range) cases= 23 (19.18- 27.82) controls= 12 (9.0-15.0) Comments Historical cohort study all BSI not specified, but most probably mortality in hospital mortality rates were not compared and resistance was not significantly associated with mortality once severity of illness and age were taken into account BSI R vs S VRE 165 26 cases Mort. rate cases=69% overall cases+controls 119 controls Mort. rate controls=76% mean(range)=81(9- Score - - + ++ ++ ++ - - - - c.b.e c.b.e 583) median=60 22 Stroud, 1996 not specified, Comments Retrospectiv e cohort study patient>16 years all BSI but most probably mortality in no information information extracted from available data in the article hospital 1 Song, 2003 Score ++ 159 cases 159 controls ++ + ++ ++ ++ ++ + NA ++ c.b.e ++ Mort. rate cases=50.3% Mort. rate controls=27.7% aOR=3.04; 95%CI(1.66-5.53) Median Cases=53 Controls=28 Comments Population based matched cohort study matched for APR-DRG complexity levels mortality in hospital 2 Carmeli, 2002 Score ++ 233 cases 647 controls - + ++ ++ ++ ++ - NA + c.b.e ++ RR= 12.3 Attributable mortality=25% Multiplicative effect: 2.06 Comments Matched cohort study total sample not matched but controlled in univariate analyses mortality in hospital infection site specific results 3 Edmond, 1996 Score ++ 27 cases 27 controls - + ++ ++ ++ ++ ++ NA + c.b.e ++ Mort. rate cases=67% Mort. rate controls=30% OR=2.3; 95%CI(1.2-4.1) median cases=31 controls=36 Comments Matched retrospectiv e cohort mortality in hospital 4 Edmond, 1995 Score ++ 11 cases 22 controls - + ++ - ++ ++ - NA ++ c.b.e - Mort. rate cases=73% Mort. rate controls=30% Mean Cases=74.75± 46.27 Controls=47.26± 37.59 Comments Pairwise matched case-control study Patients with tumor not matched but controlled in univariate analyses not matched but all patient with cance mortality in hospital 5 Butler, 2010 Score - a)94 cases 182 cases 20150 controls - + ++ + ++ ++ ++ NA + c.b.e ++ Mort. rate resistant= 32% Mort. rate sensitive=17% Mort. rate controls=4% Attributable LOS VRE=2.2 (1.7-2.7) Attributable LOS VSE=1.1 (0.9-1.4) Comments Retrospectiv e cohort study nor surgical units matched for propensity score mortality in hospital 1 Khair, 2013 Score + 74 cases 180 controls ++ + ++ ++ ++ ++ - - + c.b.e - Mort. rate cases=14% Mort. rate controls=7% after bacteruria mean (range) cases= 6.8(0.1-150.8) controls= 5(0.2-78.2) Comments Prospective cohort study not matched but controlled in univariate analyses all UTI mortality in hospital 1 Carmeli, 2002 Score ++ 233 cases 647 controls - + ++ ++ ++ ++ - NA + c.b.e ++ RR=4.28 Attributable to VRE=9% Multiplicative effect=1.75 Attributable=5.4 days Comments Matched cohort study total sample not matched but controlled in univariate analyses mortality in hospital infection site specific results 1 Carmeli, 2002 Score ++ 233 cases 647 controls - + ++ ++ ++ ++ - NA + c.b.e - RR=2.00 Attributable to VRE=6% Multiplicative effect=1.78 Attributable=6.2 days Comments Matched cohort study total sample not matched but controlled in univariate analyses mortality in hospital infection site specific results 1 Carmeli, 2002 Score ++ 647 controls - + ++ ++ ++ ++ - NA + c.b.e ++ RR=3.75 Attributable to VRE=3% Multiplicative effect=1.42 Attributable=2.6 days Comments Matched cohort study total sample not matched but controlled in univariate analyses mortality in hospital infection site specific results 1 Tornieporth, 1996 Score c.b.e 145 cases 145 controls - + ++ ++ ++ + + ++ + c.b.e - a)Mort. rate cases=37% Mort. rate controls=19% b)Mort. rate cases=58% Mort. rate controls=43% mean (range) cases=64.5 (2-290) controls=40.8 (2-248) median cases= 48 controls=26 Comments Case-control study not matched but controlled in univariate analyses for gender, age is different not matched but controlled in univariate analyses for main diseases, though there were some differences not matched but controlle in univariate analyses by source of speciment mortality in hospital a) overall mortality b) ICU admitted patients mortality Sample size N refers to total number of cases and controls (no score) Calculation a priori: ++ if performed (e.g. based on expected prevalence or on litterature data) or the study refers to large national surveys; - if not performed Study type Study type: ++ matched cohort or case-control studies; + prospective cohort or case-control studies; - restrospective database studies Geographical: ++ if the study was conducted in an EU/EEA setting; + if the study was conducted in high-income country(ref. World bank); - if the study was not conducted in an EU/EEA or high-income country setting Representativeness Matching or controlling for confounders Risk difference Demographical: ++ if the study population represents all age groups; + if the study population represents selected age-specific groups (e.g. elderly, infants); - if the study population represents a selected sex category and age-specific groups Clinical: ++ if the study population represents the overall hospital population; + if the study population partially represents the hospital population; - if the study population represents a disease-specific population (e.g. liver transplanted patients, cancer patients, etc..) Exlusion/inclusion criteria: ++ if the same exclusion/inclusion criteria were adopted for both cases and controls; + if some (but not all) exclusion/inclusion criteria were adopted for both cases and controls; - if exclusion/inclusion criteria were different in cases and controls Demographics: ++ if performed for age and sex; + if performed only for age or only for sex; - if not performed at all Underlying disease: ++ if performed for two or more criteria (e.g. comorbidity score, McCabe score, severity index, n. comorbidities, allergy, immunosuppression status, prior hospitalisation etc..); + if performed for only one criteria; - if not performed at all Infection site: ++ if performed ; - if not performed Hospital and unit/ward: ++ if same hospital and same unit/ward; + if same hospital but different unit/ward; - if not same hospital and/or not same unit/ward Follow-up: ++ if ≥ 28 days; - if < 28 days Statistically significant outcome results: ++ if results and 95%CI are statistically significant; - if results and 95%CI are not statistically significant Case fatality and LOS refer to risk difference estimates in cases and controls (no score) Scoring table ++ Matches completely/is completely fulfilled + Matches incompletely but sufficiently/is only partly but sufficiently fulfilled - Does not match or matches insufficiently/is insufficiently fulfilled c.b.e. Cannot be evaluated Mixed R vs S Other R vs NI SSTs R vs NI UTI R vs NI UTI R vs S BSI R vs NI 166 Checklist for the evaluation of the most relevant studies for building antimicrobial resistance (AMR) outcome trees, healthcare-associated infection (HAI) attributable case fatality and attributable length-of-stay (LOS) Study Study type Sample size Representativeness Matching or controlling for confounders Risk difference N (cases;controls) calculation a priori Geographical Demographical Clinical Exclusion/inclusion criteria Demographics Underlying disease Infection site Hospital and unit/ward Follow-up Statistically significat outcome results Case fatality LOS Nr. First author, year □ ++; □ -; □ c.b.e □ ++; +; -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; □ -; □ c.b.e □ ++; □ +; □ -; □ c.b.e □ ++; -; □ c.b.e □ ++; □ -; □ c.b.e %; RR; OR; aHR; etc (days) 1 Yu, 2003 Score + 76 cases 598 controls - NA ++ ++ ++ - - - - - - Mort. rate case=23.7% Mort. rate controls=15.1% no data Comments Prospective international observational study global all BSI >14 days 1 Watanabe, 2000 Score - 24 cases 25 controls - + ++ + ++ ++ ++ - + - - a) Mort. rate case=0% Mort. rate controls=8% b) Mort. rate case=12.5% Mort. rate controls=20% no data Comments Retrospective comparative study patients with pneumonia not matched but controlled in univariate analyses not matched but controlled in univariate analyses all resp tract inf, 1 control had BSI also 7 days after treatment a) infection related mortality b) mortality due to complications 1 Gouveia, 2011 Score + 93 cases 548 total population - - ++ - ++ - - - + c.b.e - aHR=1.62; 95%CI (1.08-2.43) no data Comments Prospective observational study all ages patients with meningitis mortality in hospital 2 Reechaipichitkul, 2006 Score - 22 cases 42 controls - - ++ + ++ - - - + c.b.e - a)Mort. rate case=9.1% Mort. rate controls=11.9% b)Mort. rate case=9.1% Mort. rate controls=9.5% Mean(SD) cases= 12 (9) controls= (17.7) Comments Cross- sectional patients with CA pneumonia mortality in hospital a) all-cause mortality b) pneumonia related mortality 3 Sun, 2006 Score - 44 cases 168 controls - + ++ + ++ ++ ++ - + c.b.e - Mort. rate case=9% Mort. rate controls=14% median (range) cases=6 (4–9.5) 6 (4–10.5) Comments Retrospective cohort study cases are non susceptible patients with CA pneumonia not matched but controlled in univariate analyses not matched but controlled in univariate analyses for main diseases mortality in hospital 4 Song, 2004 Score - 69 cases 105 controls - NA ++ + ++ - - - - ++ - Mort. rate case=16% Mort. rate controls=12.4% OR=1.3; 95%CI(0.5–3.4) no data Comments Retrospective cohort study Asia patients with pneumonia 30 days 5 Einarsson, 1998 Score - 36 cases 36 controls - ++ ++ + ++ ++ + - + c.b.e - Mort. rate case=11% Mort. rate controls=5.5% Mean Cases= 26.8 Controls= 11.5 Comments Retrospective case-control study patients with pneumonia not matched but controlled in univariate analyses fot APACHE II score, differences in chronic diseases not defined but most probably mortality in hospital 6 Sangthawan, 2003 Score + 19 cases 27 controls - - ++ + ++ - - - + c.b.e - Mort. rate case=36.8% Mort. rate controls=18.5% no data Comments Prospective study cases were resistant and non susceptible patients>15 years patients with pneumonia not defined but most probably mortality in hospital 7 Falco, 2004 Score c.b.e 15 cases 181 controls - ++ ++ + ++ - - - + c.b.e - a)Mort. rate case=26.7% Mort. rate controls=12.7% b)Mort. rate case=13.3% Mort. rate controls=9.9% no data Comments Retrospective and prospective study patients with pneumonia mortality in hospital a) all-cause mortality b) pneumonia related mortality 8 Pallares, 1995 Score + 47 cases 440 controls - ++ ++ + ++ - - - + c.b.e ++ Mort. rate case= Mort. rate controls= aOR=1.0; 95%CI(0.5-1.9) no data Comments Prospective study patients with pneumonia mortality in hospital only the comparison between the mortality rates 9 Ewig, 1999 Score + 33 cases 52 controls - ++ ++ + ++ - - - + c.b.e - Mort. rate case=18% Mort. rate controls=5.8% no specific data Comments Prospective study patients with CA pneumonia mortality in hospital 10 Aspa, 2004 Score + 64 cases 409 controls - ++ ++ + ++ - - - - ++ - Mort. rate case=18.3% Mort. rate controls=12.2% no data Comments Prospective multi-centre study patients>16 years patients with pneumonia 30 days 11 Faikin, 2000 Score - a) 37 cases b) 20 cases 383 controls - + ++ + ++ - - - - ++ - a) OR= 1.3; 95%CI(0.5-3.7) b) OR=2.3 ; 95%CI(0.7-7.4) no data Comments Population- based surveillance study a) resistant b) highly resistant, MIC>4 patients with CA pneumonia 30 days a) resistant b) highly resistant, MIC>4 12 Tjeyjeh, 2006 Score + 10 studies - NA ++ + ++ NA NA - - c.b.e ++ a) Mort. rate non susceptible=19.4% Mort. rate controls=15.7% b)OR non-suscptible=1.3; 95%CI(1.08–1.59) OR intermediate=1.34; 95% CI(1.13–1.60) OR resistant=1.29; 95% CI(1.01–1.66) c) aRR non susceptible=1.29; 95%CI(1.04–1.59) no data Comments Review and meta- analyses some inlcuded also non susceptible patients with CA pneumonia different based on the inlcuded studies a) pooled mortality rate b) all cause mortality c) combined adjusted (6 studies) 13 Yigla, 1995 Score + 7 cases 15 controls - + ++ + ++ ++ ++ - + c.b.e - Mort. rate case=43% Mort. rate controls=33% no data Comments Prospective study patients with pneumonia not matched but controlled in univariate analyses not matched but controlled in univariate analyses for main diseases mortality in hospital 14 Pallares, 2002 Score + 77 cases 300 controls - ++ ++ ++ ++ - - - + ++ c.b.e Mort. rate case=43% Mort. rate controls=20.3% no data Comments Prospective study data extrapolated from the articles table 3 patients with nonmeningeal systemic pneumococcal infections 30 days no information on the article because is focused on cephalosporin resistance, data extrapolated 15 Jehl, 2002 Score - 49 cases 246 controls - ++ ++ + ++ - - - - ++ - a)Mort. rate case=8.3% Mort. rate controls=3.5% b)Mort. rate case=4.2% Mort. rate controls=10.4% c)Mort. rate case=12.5% Mort. rate controls=13.9% no data Comments Prospective survey patients with pneumonia a) 3 days b) 30 days c) total a) 3 days b) 30 days c) total Sample size N refers to total number of cases and controls (no score) Calculation a priori: ++ if performed (e.g. based on expected prevalence or on litterature data) or the study refers to large national surveys; - if not performed Study type Study type: ++ matched cohort or case-control studies; + prospective cohort or case-control studies; - restrospective database studies Geographical: ++ if the study was conducted in an EU/EEA setting; + if the study was conducted in high-income country(ref. World bank); - if the study was not conducted in an EU/EEA or high-income country setting Representativeness Demographical: ++ if the study population represents all age groups; + if the study population represents selected age-specific groups (e.g. elderly, infants); - if the study population represents a selected sex category and age-specific groups Clinical: ++ if the study population represents the overall hospital population; + if the study population partially represents the hospital population; - if the study population represents a disease-specific population (e.g. liver transplanted patients, cancer patients, etc..) Exlusion/inclusion criteria: ++ if the same exclusion/inclusion criteria were adopted for both cases and controls; + if some (but not all) exclusion/inclusion criteria were adopted for both cases and controls; - if exclusion/inclusion criteria were different in cases and controls Demographics: ++ if performed for age and sex; + if performed only for age or only for sex; - if not performed at all Matching or controlling for Underlying disease: ++ if performed for two or more criteria (e.g. comorbidity score, McCabe score, severity index, n. comorbidities, allergy, immunosuppression status, prior hospitalisation etc..); + if performed for only one criteria; - if not performed at all confounders Risk difference Infection site: ++ if performed ; - if not performed Hospital and unit/ward: ++ if same hospital and same unit/ward; + if same hospital but different unit/ward; - if not same hospital and/or not same unit/ward Follow-up: ++ if ≥ 28 days; - if < 28 days Statistically significant outcome results: ++ if results and 95%CI are statistically significant; - if results and 95%CI are not statistically significant Case fatality and LOS refer to risk difference estimates in cases and controls (no score) Resp. Tract R vs S BSI R vs S PRSP 167 Scoring table ++ Matches completely/is completely fulfilled + Matches incompletely but sufficiently/is only partly but sufficiently fulfilled - Does not match or matches insufficiently/i s insufficiently fulfilled c.b.e. Cannot be evaluated Mixed R vs S 168 Burden of antimicrobial resistance Final disease outcome trees Written by Alessandro Cassini and Diamantis Plachouras with contributions from Brecht Devleesschauwer, Daniel Lewandowski (for addressing comorbidities), Ana Hoxha, Carl Suetens, Liselotte Diaz Högberg, and Dominique Monnet 169 Contents List of abbreviations .............................................................................................. 171 1. Disease outcome trees – baseline syndromic models ............................. 172 1.1. Blood-stream infections ........................................................................................................... 172 1.2. Respiratory tract infections .................................................................................................... 173 1.3. Urinary tract infections ............................................................................................................ 174 1.4. Surgical site infections ............................................................................................................. 175 1.5. Other site infections .................................................................................................................. 175 2. Klebsiella pneumoniae resistant to third-generation cephalosporin infections .................................................................................................................. 177 2.1. Blood-stream infections ........................................................................................................... 177 2.2. Respiratory tract infections .................................................................................................... 177 2.3. Urinary tract infections ............................................................................................................ 177 2.4. Surgical site and other site infections ................................................................................. 177 3. Klebsiella pneumoniae resistant to carbapenem infections .................. 177 3.1. Blood-stream infections ........................................................................................................... 177 3.2. Respiratory tract and surgical site infections .................................................................. 178 3.3. Urinary tract infections ............................................................................................................ 178 3.4. Other site infections .................................................................................................................. 178 4. Klebsiella pneumoniae resistant to colistin infections ........................... 178 4.1. All infection sites ......................................................................................................................... 178 5. Escherichia coli resistant to third-generation cephalosporin infections 179 5.1. Blood-stream infections ........................................................................................................... 179 5.2. Urinary tract infections ............................................................................................................ 179 5.3. Surgical site, respiratory tract and other site infections .............................................. 179 6. Escerichia coli resistant to carbapenem infections ................................. 179 6.1. All infection sites ......................................................................................................................... 179 7. Escerichia coli resistant to colistin infections ........................................... 180 7.1. All infection sites ......................................................................................................................... 180 8. Multidrug resistant Acinetobacter infections ............................................ 180 8.1. Blood-stream infections ........................................................................................................... 180 8.2. Respiratory tract infections .................................................................................................... 180 8.3. Urinary tract, surgical site and other site infections...................................................... 180 9. Carbapenem resistant Acinetobacter infections ...................................... 181 9.1. Blood-stream infections ........................................................................................................... 181 9.2. Respiratory tract infections .................................................................................................... 181 9.3. Urinary tract, surgical site and other site infections...................................................... 181 10. Colistin resistant Acinetobacter infections ............................................ 181 10.1. Blood-stream infections ........................................................................................................... 181 10.2. Urinary tract infections ............................................................................................................ 181 10.3. Respiratory tract, surgical site and other site infections ............................................. 181 11. Multidrug resistant Pseudomonas aeruginosa infections................... 182 170 11.1. Blood-stream infections ........................................................................................................... 182 11.2. Respiratory tract infections .................................................................................................... 182 11.3. Urinary tract, surgical site and other site infections...................................................... 182 12. Carbapenem resistant Pseudomonas aeruginosa infections ............. 182 12.1. Blood-stream infections ........................................................................................................... 182 12.2. Respiratory tract infections .................................................................................................... 183 12.3. Urinary tract, surgical site and other site infections...................................................... 183 13. Colistin resistant Pseudomonas aeruginosa infections ....................... 183 13.1. All infection sites ......................................................................................................................... 183 14. Meticillin resistant Staphylococcus aureus infections ......................... 183 14.1. Blood-stream infections ........................................................................................................... 183 14.2. Respiratory tract infections .................................................................................................... 184 14.3. Urinary tract, surgical site and other site infections...................................................... 184 15. Vancomycin resistant Enterococcus faecalis and faecium infections 184 15.1. Blood-stream infections ........................................................................................................... 184 15.2. Respiratory tract, urinary tract, surgical site and other site infections .................. 184 16. Penicillin resistant Streptococcus pneumoniae infections ................. 185 16.1. Blood-stream infections ........................................................................................................... 185 16.2. Respiratory tract, urinary tract, surgical site and other site infections .................. 185 17. Macrolide and penicillin resistant Streptococcus pneumoniae infections .................................................................................................................. 185 17.1. All infection sites ......................................................................................................................... 185 References ................................................................................................................ 186 171 List of abbreviations 3GCREC third-generation cephalosporin-resistant E. coli 3GCRKP third-generation cephalosporin-resistant K. pneumoniae AMR antimicrobial resistance BSI bloodstream infection CAI Community-associated infections CI confidence interval ColRACI colistin-resistant Acinetobacter spp. ColREC colistin-resistant E. coli ColRKP colistin-resistant K. pneumoniae ColRPA colistin-resistant P. aeruginosa CRACI carbapenem-resistant Acinetobacter spp. CREC carbapenem-resistant E. coli CRKP carbapenem-resistant K. pneumoniae CRPA carbapenem-resistant P. aeruginosa CSF cerebral spine fluid DALY disability-adjusted life years EARS-Net European Antimicrobial Resistance Surveillance Network EEA European Economic Area EU European Union HAI healthcare-associated infection LOS length of stay MDR multidrug-resistant MDRACI multidrug-resistant Acinetobacter spp MDRPA multidrug-resistant P. aeruginosa MRSA meticillin-resistant Staphylococcus aureus MS Member State OECD Organisation for Economic Co-operation and Development OTH other infection site including digestive tract infections, skin and soft tissue infections (SSTI), eye, ear, nose or mouth infections, bone and joint infections, cardiovascular infections, reproductive tract infections and other less frequent infections PMRSP penicillin- and macrolide-resistant S. pneumoniae PPS point prevalence survey of healthcare-associated infections and antimicrobial use in acute care hospitals PRSP penicillin-resistant S. pneumoniae; RESP respiratory infections (including pneumonia, and low respiratory tract infection) S-BSI secondary BSI SP specified pathogens SPDAR specified pathogens with defined antimicrobial resistance SSI surgical site infection UTI urinary tract infection VRE vancomycin-resistant enterococci 172 1. Disease outcome trees – baseline syndromic models The systematic review of the literature on healthcare-associated infections was the main reference for the development of the baseline models (RKI, 2016). The baseline models were built starting from the models already published for the burden of HAIs (Cassini & Plachouras, 2016). Disability weights for recurrent health outcomes between the burden of HAIs and the burden of AMR studies remained unvaried, except when corrections accounting for comorbidity were addressed (see below). Disability weights were derived from the European disability weight study (Haagsma, 2015). A summary of disease health outcome parameters (case fatality proportion [CFP] and length of stay [LOS]) are available, see Table 1. The outcome tree for blood-stream infections (BSI) had a number of long-term sequelae that could happen at the same time. The issue of co-morbidities has been addressed in order to account for concurrent health outcomes and with the aim to estimate their related transition probabilities and disability weights. We assumed that the health outcomes were independent. Therefore, considering that x health outcomes will result in 2^x possible combinations, we estimated 2^4=16 possible combinations. However, considering that physical impairment is always present as a consequence of complicated BSI infection (and discarding the ones without any transition), we considered 8 possible health outcomes, see Figure 1. The probability of each of these combinations is the product of the probability of observing each individual health state. Moreover, we also took the uncertainties around the original risk of developing the long-term sequelae through a Monte Carlo simulation approach, which implied simulating four vectors of random values for each probability and then performed calculations for each quadruplet of simulated values. One important assumption was internal comorbidity: the health outcomes are assumed to be due to a single exposure (infection with BSI) and not to multiple exposures (external comorbidity). The resulting estimated transition probabilities, median, 2.5% and 97.5% intervals, for long-term sequelae following complicated BSI infection are described in Figure 1. As far as correcting for comorbidity of disability weights is concerned, we chose to follow the multiplicative approach (Haagsma, 2011). Here again we took uncertainties into account through Monte Carlo simulations, which resulted in a median, 2.5% and 97.5% intervals included in the related health outcomes, see Figure 1. The multiplicative approach is recommended for combining disability weights of simultaneously occurring health states. The approach allows for an increase of disability when health states are combined, while preventing the total disability level to become larger than 1, which would equal to “worse than death”. 1.1. Blood-stream infections The baseline attributable case fatality proportion (CFP) for blood-stream infections (BSI) was set to 7.1% (Oleachea, 2013; corresponding to mortality due to non-resistant bacterial infections as defined in the study) to 20.3% (Renaud, 2001). The baseline attributable length of stay (LOS) was set to 5.87-11.54 days based on an extensive European study on Enterobacteriaceae and Staphylococcus aureus (Stewardson, 2016). The risk of complications remained the same as for the Burden of HAIs as no specific information related to resistance patterns of the bacterial infections were available. Figure 1. Baseline disease outcome tree for BSI 173 1.2. Respiratory tract infections In order to estimate the CFP of respiratory infections for the baseline model, we analysed the data form the HAI-Net ICU from 2008 to 2012. After excluding all pneumonia infections developing secondary BSI and performing a propensity score matching (successful for 96.5% of pneumonia without secondary BSI), the attributable mortality was 3.6% (95% CI 2.7-4.5) and the median attributable LOS was 14 days. The lower value of the attributable LOS remained the same as for the Burden of HAIs (7 days), as it was deemed that the propensity score matching was not ideal to estimate LOS; the higher value was set to 14 days. The burden of HAI study considered that 39% of all patients develop severe sepsis/septic shock. Assuming that all patients with bacteraemia also have severe/septic shock, we calculated the number of patients developing secondary bacteraemia after pneumonia from the 2014 ICU-acquired infection surveillance data (ECDC, 2017). In this study 5,852 pneumonia episodes and 654 bacteraemia secondary to pneumonia were reported representing 11% of the episodes. Therefore, in order not to double-count bacteraemia we chose to subtract 11% from the 39% of risk of developing severe sepsis/septic shock. The risk of developing severe sepsis/septic shock is set to 28% and the risk of developing long-term sequelae remains the same as for the baseline BSI outcome tree described above. Figure 2. Baseline disease outcome tree for respiratory infections 174 1.3. Urinary tract infections It was considered that there is no risk of death due to urinary tract infections (UTIs) without development of secondary BSI (S-BSI). Therefore, the model does not include attributable CFP. Limited evidence was available on the attributable LOS due to UTIs. Therefore, we chose to estimate the additional LOS caused by the infection from information available in the PPS 2011-2012 (ECDC, 2013). We estimated the median LN-INT, where LN is the length of stay of patients with an HAI, and INT is the length of stay before the onset of the HAI. All UTI infections were included except the resistant pathogens included in our study. Uncertainty intervals were derived by the inter-quartile range (IQR). The baseline attributable LOS was set to 7 days (4-11). Considering a high variability between cases, it was chosen to apply the 2.5% lower bound disability weight for “infectious disease, acute episode, moderate” and the 97.5% higher bound disability weight for “infectious disease, acute episode, severe”. Figure 3. Baseline disease outcome tree for UTIs 175 1.4. Surgical site infections Attributable CFP remained the same as for the burden of HAIs study becaue no specific information related to bacterial infections susceptible to antibiotics were available. Moreover, death as an outcome of SSI without developing a secondary BSI was considered possible. Attributable LOS was set to an average of 8.5 days (0-15.2 days) (Astagneau, 2001); this was lower than the attributable LOS chosen for the Burden of HAIs study because we did not exclude superficial SSI from the present burden of AMR study. Considering a high variability between cases, it was chosen to apply the 2.5% lower bound disability weight for “infectious disease, acute episode, moderate” and the 97.5% higher bound disability weight for “infectious disease, acute episode, severe”. Figure 4. Baseline disease outcome tree for SSIs 1.5. Other site infections Other site infections include digestive tract infections, skin and soft tissue infections (SSTI), eye, ear, nose or mouth infections, bone and joint infections, cardiovascular infections, reproductive tract infections and other less frequent infections. Deaths from these infections without concomitant BSI were considered sufficiently rare. In combination with the lack of reliable data, we chose not to consider CFP in this baseline model. Given the lack of published evidence and the variability of OTH site infections, the additional LOS caused by the infection was derived from information available in the PPS 2011-2012 (ECDC, 2013). For the OTH infection sites, we estimated the median LN-INT, where LN is the length of stay of patients with an HAI, and INT is the length of stay before the onset of the HAI. All infections defined above as OTH were included except the resistant pathogens included in our study. Uncertainty intervals were derived by the inter-quartile range (IQR). The baseline attributable LOS was set to 6 days (3-11). Considering a high variability between cases, it was chosen to apply the 2.5% lower bound disability weight for “infectious disease, acute episode, moderate” and the 97.5% higher bound disability weight for “infectious disease, acute episode, severe” Figure 5. Baseline disease outcome tree for OTH site infections 176 Table 1. Summary of disease health outcome parameters: case fatality proportion (CFP) and length of stay (LOS). Staphylococcus aureus Enterococcus faecalis and E. faecium 3GCRKP CRKP ColRKP 3GCREC CREC ColREC MDRACI CRACI ColRACI MDRPA CRPA ColRPA MRSA VRE PRSP PMRSP BSI Case fatality proportion (%) 7.1-20.3 14.4-19 20-51.3 32-88.8 17.1 (9.5-26) 20-51.3 32-88.8 7.1-32.9 7.1-34 7.1-34 7.1-35.2 7.1-38.7 7.1-38.7 17.9 (14.4-21.8) 22.9 (21.8-23.8) 15.7-20.3 15.7-20.3 Duration (days) 5.87-11.5 9.28 (9.20–9.35) 15-35 15-39.1 6-18.5 15-35 15-39.1 5.87-20.1 5.87-20.1 5.87-20.1 14.87-21.5 14.87-21.5 14.87-21.5 8.99-14.62 6.97-18.3 Baseline Baseline RESP Case fatality proportion (%) 3.6 (2.7-4.5) Baseline Baseline Baseline Baseline Baseline Baseline Baseline Baseline Baseline 2.7-9.8 2.7-10.5 2.7-10.5 Baseline Baseline Baseline Baseline Duration (days) 7-14 13.6-18.1 13.6-18.1 13.6-18.1 Baseline 13.6-18.1 13.6-18.1 Baseline Baseline Baseline 10-17 15-22 15-22 Baseline Baseline Baseline Baseline UTI Case fatality proportion (%) 0 Baseline Baseline Baseline Baseline Baseline Baseline Baseline Baseline Baseline Baseline Baseline Baseline Baseline Baseline N/A N/A Duration (days) 7 (4-11) 7 (5-12) 7.5 (4-14) 7.5 (4-14) 7 (5-12) 7.5 (4-14) 7.5 (4-14) 8 (4-11) 8 (4-11) 8 (4-11) 8 (4-11) 8 (4-11) 8 (4-11) Baseline Baseline N/A N/A SSI Case fatality proportion (%) 0.9<65; 3.6>64 Baseline Baseline Baseline Baseline Baseline Baseline Baseline Baseline Baseline Baseline Baseline Baseline Baseline Baseline N/A N/A Duration (days) 8.5 (0-15.2) Baseline Baseline Baseline Baseline Baseline Baseline Baseline Baseline Baseline Baseline Baseline Baseline Baseline Baseline N/A N/A OTHER Case fatality proportion (%) 0 Baseline Baseline Baseline Baseline Baseline Baseline Baseline Baseline Baseline Baseline Baseline Baseline Baseline Baseline 0 0 Duration (days) 6 (3-11) 12 (8-21) 12 (6-27) 12 (6-27) 12 (8-21) 12 (6-27) 12 (6-27) 14.5 (9-19) 14.5 (9-19) 14.5 (9-19) 14.5 (9-19) 14 (9-19) 14.5 (9-19) 12 (8-19) Baseline 5-10 5-10 Streptococcus pneumoniae Baseline model Klebsiella pneumoniae Escherichia coli Acinetobacter spp. Pseudomonas aeruginosa 177 2. Klebsiella pneumoniae resistant to third-generation cephalosporin infections 2.1. Blood-stream infections The review of the literature identified two studies comparing 3GCRKP infections to non-infected. A recent publication estimated an attributable CFP of 18% for MDRKP (Brady, 2017). Attributable LOS to the 3GCRKP was set to 9.28 (9.20–9.35) (Stewardson, 2016) and the attributable CFP was set to 14.4-19% (Stewardson, 2016; Gallagher, 2014). 2.2. Respiratory tract infections The review of the literature identified two studies comparing 3GCRKP infections to 3GCSKP. One study found a CFP risk difference of 8.9% and an added LOS of 9 days (Loh, 2006), whereas the second study found no added CFP and an attributable LOS of 6.6 days (Lee, 2011). Given that the first study was done in a setting not representative of the European healthcare situation, we focused on the second study and have not added any CFP to the baseline model. We chose to add 6.6 days to the baseline model. 2.3. Urinary tract infections The review of the literature identified one study focusing on solid organ transplant recipients. Moreover, this study did not exclude patients developing BSI and was excluded. Therefore, we chose to estimate the attributable LOS by applying the same methodology as the one chosen for the baseline infection model. All third-generation cephalosporin resistant Enterobacteriaceae from the PPS 2011-2012 were included and the attributable UTI LOS was set to 7 days (5-12). 2.4. Surgical site and other site infections The review of the literature identified studies that did not differentiate other infection sites. Therefore, we kept the baseline models for SSIs. The same approach for the baseline attributable LOS for OTH infection sites was used to estimate LOS. However, given the small number of observations for 3GCRKP, we chose to include all third- generation cephalosporin resistant Enterobacteriaceae from the PPS 2011-2012 in our estimation. We set the attributable LOS of OTH infections sites to 12 days (8-21). 3. Klebsiella pneumoniae resistant to carbapenem infections 3.1. Blood-stream infections The review of the literature identified ten studies, three of which had non-infected patients as comparator. We excluded studies performed in specific populations, e.g. liver transplant patients (Mouloudi, 2014). Of the two remaining studies, attributable CFP ranged from 27% to 50% and attributable LOS ranged from 3 to 35 days (Gallagher, 2014; Borer, 2009). Seven studies compared susceptible infected patients to resistant. A met-analysis comparing CRKP to CSKP infections (Falagas, 2014) found an attributable CFP of 26-44% (this publication also reported two studies that showed no attributable mortality but these included mixed site of infection). A good- quality study (Mouloudi, 2010) found an attributable CFP compared to susceptible infections of 13%, similar to another study which found 14.7% (Hussein, 2013). The latter also found an attributable LOS of 5 days. Another retrospective cohort study found a higher attributable CFP, 31% (Ben-David, 2012), similar to a prospective observational study, 25.9% (Daikos, 2009). When considering the baseline disease model for BSI and adding the attributable CFP, the latter ranges from 20% to 51.3%, which is similar to the studies using non-infected as comparator. Therefore, we chose to apply a CFP of 20-51.3% to the CRKP BSI disease model. 178 Attributable LOS was set to 15 days (10 days from the baseline model to which we added 5 days [Hussein, 2013]) to 35 days (Gallagher, 2014). 3.2. Respiratory tract and surgical site infections The literature review identified seven articles comparing CRKP infections to non-infected. We discarded those focusing on specific populations (e.g. transplant patients). Of the remaining studies, none provided specific mortality information based on site of infection. Therefore, the models baseline parameters were unvaried. Following the review for 3GCRKP, we chose the following: • Respiratory site infections: no added CFP. 6.6 days were added to the baseline model; • SSI: no difference from baseline model; 3.3. Urinary tract infections The review of the literature identified one study finding that CRKP UTIs have 6 added days of hospitalization compared to 3GCRKP. We chose to estimate the attributable LOS by applying the same methodology as the one chosen for the baseline infection model. All carbapenem resistant Enterobacteriaceae from the PPS 2011-2012 were included and the attributable UTI LOS was set to 7.5 days (4-14). 3.4. Other site infections The same approach for the baseline attributable LOS for OTH infection sites was used to estimate LOS. However, given the small number of observations for CRKP, we chose to include all carbapenem resistant Enterobacteriaceae in the PPS 2011-2012 in our estimation. We set the attributable LOS of OTH infections sites to 12 days (6-27). 4. Klebsiella pneumoniae resistant to colistin infections 4.1. All infection sites The review of the literature identified four studies, all of which focused on mixed site of infection. The selection grid exercise clearly showed that two studies (matched case-control and prospective nested cohort) had a higher quality (Zarkotou, 2010; Rojas, 2016). Attributable case fatality ranged from 12% (Rojas, 2016) to 37.5% (Zarkotou, 2010), and the attributable LOS ranged from no added days to 4.1 (+/- 8.5); however, it must be noted that controls were generally carbapenem resistant K. pneumoniae infections. Rojas et al. show that increased attributable mortality is associated mostly with isolation in the blood. Therefore, the following decisions were made relatively to the disease models: • Attributable CFP: • BSI: 12%-37.5% increase over CRKP • RESP: no increase from CRKP • SSI: no increase from CRKP • OTH: no increase from CRKP • Attributable LOS • BSI: 0-4.1 days increase over CRKP • RESP: no increase from CRKP • SSI: no increase from CRKP • OTH: no increase from CRKP 179 5. Escherichia coli resistant to third-generation cephalosporin infections 5.1. Blood-stream infections The review of the literature found one study comparing BSI resistant infections versus non-infected in 13 EU countries (de Kraker, 2011a). The univariate and multivariate analysis showed a significant impact of infections (with and without resistance) on the 30-day mortality. Death within 30 days after enrolment for resistant cases was 32% versus 6% in non-infected controls. LOS was 12 days (6-25) compared to 6 (3-16). Another EU publication (de Kraker, 2011b) estimated that 15,183 episodes of G3CREC BSIs were associated with 2,712 excess deaths, resulting in a CFP of 17.8% The review also found 25 studies comparing BSI resistant versus susceptible infections. We excluded eight studies focusing on specific populations (e.g. haematological diseases) or where results for 3GCREC were not specifically addressed. Risk difference for CFP ranged from 2% (Van Aken, 2014) to 37.2%, although the latter was from a single-centre in 2003-2005 where the authors indicate that delayed treatment was the significant factor contributing to death (Melzer, 2007). One study with appropriate representativeness as well as a high number of cases (Martelius, 2016) found a CFP risk difference of 2.4%; another study with robust methodology undergone in the EU (Lambert, 2011) found 10% risk difference and 7 days LOS. Of those providing ORS, three studies estimated a significant difference in mortality and three did not find a significant difference. When cumulating the information from the seventeen published studies considered above, we notice that 1,323 cases account for 276 deaths and that 10,991 controls account for 1,166 deaths. The risk difference was 10.3% (Wilson sample proportion 95% CI 8.71- 11.9), which if added to the baseline values would account for a CFP of 17.4% to 30.6%. However, we chose to combine the information from the more robust studies above and have added 2.4% and 10% to the baseline CFP of 7.1%, as well as considering the 26% from the first study. We had a similar approach for the LOS and considered 6 days (de Kraker, 2011a) compared to non- infected and 7 days (Lambert, 2011) to be added to the baseline LOS. We applied a CFP of 17.1% (9.5-26) and a LOS of 6-18.5 days. 5.2. Urinary tract infections The review of the literature found one study considering the difference in LOS between resistant infections and susceptible ones in patients with symptomatic UTIs. The study found 4.1 days LOS attributable to the resistant infection (Esteve-Palau, 2015) which if added to the baseline model would be 6.7 days. Therefore, we chose to estimate the attributable LOS by applying the same methodology as the one chosen for the baseline infection model. All third-generation cephalosporin resistant Enterobacteriaceae from the PPS 2011-2012 were included and the attributable UTI LOS was set to 7 days (5-12). 5.3. Surgical site, respiratory tract and other site infections The review of the literature did not find any specific information for other infections sites and we chose to apply the baseline models for SSI and RESP infections sites. The same approach for the baseline attributable LOS for OTH infection sites was used to estimate LOS. However, given the small number of observations for 3CGREC, we chose to include all third- generation cephalosporin resistant Enterobacteriaceae in the PPS 2011-2012 in our estimation. We set the attributable LOS of OTH infections sites to 12 days (8-21). 6. Escerichia coli resistant to carbapenem infections 6.1. All infection sites The review of the literature did not retrieve studies of sufficient quality or representativeness. Therefore, we decided to apply the same values as those for CRKP. 180 We chose to estimate the attributable UTI LOS by applying the same methodology as the one chosen for the baseline infection model. All carbapenem resistant Enterobacteriaceae from the PPS 2011- 2012 were included and the attributable UTI LOS was set to 7.5 days (4-14). The same approach for the baseline attributable LOS for OTH infection sites was used to estimate LOS. However, given the small number of observations for CREC, we chose to include all carbapenem resistant Enterobacteriaceae in the PPS 2011-2012 in our estimation. We set the attributable LOS of OTH infections sites to 12 days (6-27). 7. Escerichia coli resistant to colistin infections 7.1. All infection sites The review of the literature did not retrieve studies of sufficient quality or representativeness. Therefore, we decided to apply the same values as those for ColRKP. 8. Multidrug resistant Acinetobacter infections 8.1. Blood-stream infections The review of the literature identified two studies comparing MDRACI infections to non-infected. One study was excluded because it focused on ICU neonatal population (Al Jarousha, 2009). The other study found an attributable CFP of 24.4% (Gulen, 2015). The review also found six studies comparing MDRACI BSI to susceptible BSI. Attributable CFP ranged from 17.8% (Smolyako, 2003) to 43.7% (Anunnatsiri, 2011) and LOS from 5.5 days (Fitzpatrick, 2015) to 20.1 days (Lee, 2007). All four studies providing ORs found a significant impact of the resistant infection compared to the susceptible ones. When aggregating the information from the six studies, we found that 424 cases accounted for 162 deaths and 305 control accounted for 38 deaths. The risk difference was 25.8% (Wilson sample proportion 95% CI 24.5-26.2), which if added to the baseline values would account for a CFP of 32.9% to 46%. Considering a methodologically robust study (Lambert, 2011) that found no CFP difference between susceptible and ceftazidime resistant infections, we chose to apply the baseline CFP (7.1%) and added the risk difference described above (25.8%) to this baseline CFP. Therefore, we set the MDRACI CFP to 7.1% to 32.9%. For the same reason, the lower bound value for attributable LOS of the baseline model was maintained (5.87 days) and the higher value was set to 20.1 days (Lee, 2007). 8.2. Respiratory tract infections The review of the literature identified three studies comparing MDRACI infections to susceptible. We excluded one study because performed in a specific population (children) (Cai, 2012). One study found no significant difference (hazard ratio) between cases and controls (Inchai, 2015) and another had a small sample size (Park, 2006). Therefore, we chose not to change the baseline parameters. 8.3. Urinary tract, surgical site and other site infections The review of the literature identified studies that did not differentiate other infection sites (mixed infection sites). Therefore, we kept the baseline models for SSIs. We chose to estimate the attributable UTI LOS by applying the same methodology as the one chosen for the baseline infection model. All resistant Acinetobacter and Pseudomonas aeruginosa from the PPS 2011-2012 were included and the attributable UTI LOS was set to 8 days (4-11). The same approach for the baseline attributable LOS for OTH infection sites was used to estimate LOS. However, given the small number of observations, we chose to include all resistant 181 Acinetobacter and Pseudomonas aeruginosa from the PPS 2011-2012 in our estimation. We set the attributable LOS of OTH infections sites to 14.5 days (9-19). 9. Carbapenem resistant Acinetobacter infections 9.1. Blood-stream infections The review of the literature identified two studies comparing CRACI infections to non-infected. Both were excluded because focused on specific populations (neonates in ICU and hematopoietic transplant patients). The review also found eight studies comparing CRACI BSI to susceptible BSI. Excluding one study for the above-mentioned reasons (Kumar, 2014), attributable CFP OR was significant only in one study (Kim, 2012). All other studies estimating an OR (five studies) predominately showed no significant difference. When aggregating the information from the seven studies, we found that 413 cases accounted for 222 deaths and 577 controls accounted for 155 deaths. The risk difference was 26.9% (Wilson sample proportion 95% CI 25.5-27.9), which if added to the baseline values would account for a CFP of 34% to 47.2%. Given the high uncertainty of the available evidence, we chose to maintain the baseline lower CFP (7.1%) and added the risk difference described above. Therefore, we set the CRACI CFP to 7.1% to 34%. Two studies found an attributable LOS of 10 days (Jamulitrat, 2009; Tal-Jasper, 2016), hence we chose to maintain the same LOS as the one set for MDRACI. 9.2. Respiratory tract infections The review of the literature identified one study comparing to non-infected (excluded because focusing on neonates in ICU) and three comparing to susceptible infections. The latter did not test for or find a significant attributable CFP or LOS, and the baseline parameters were kept. 9.3. Urinary tract, surgical site and other site infections The review of the literature identified studies that did not differentiate other infection sites (mixed infection sites). Therefore, we kept the baseline models for SSIs. We chose to estimate the attributable UTI LOS by applying the same methodology as the one chosen for the baseline infection model. All resistant Acinetobacter and Pseudomonas aeruginosa from the PPS 2011-2012 were included and the attributable UTI LOS was set to 8 days (4-11). The same approach for the baseline attributable LOS for OTH infection sites was used to estimate LOS. However, given the small number of observations, we chose to include all resistant Acinetobacter and Pseudomonas aeruginosa from the PPS 2011-2012 in our estimation. We set the attributable LOS of OTH infections sites to 14.5 days (9-19). 10. Colistin resistant Acinetobacter infections 10.1. Blood-stream infections The review of the literature identified one study comparing ColRACI infections to susceptible infections (Wang, 2015). No differences were reported and the CRACI model was maintained. 10.2. Urinary tract infections The review of the literature identified one study comparing to susceptible infections (Taneja, 2011). No differences were reported and the CRACI model was maintained. 10.3. Respiratory tract, surgical site and other site infections The review of the literature did not identify any other studies. Therefore, we kept the baseline models for respiratory tract infections and SSIs. 182 The same approach for the baseline attributable LOS for OTH infection sites was used to estimate LOS. However, given the small number of observations, we chose to include all resistant Acinetobacter and Pseudomonas aeruginosa from the PPS 2011-2012 in our estimation. We set the attributable LOS of OTH infections sites to 14.5 days (9-19). 11. Multidrug resistant Pseudomonas aeruginosa infections 11.1. Blood-stream infections The review of the literature identified nine studies comparing MDRPA infections to susceptible infection. We discarded four studies that focused on specific populations (children, transplant patients, burned patients, haematological malignancies) and one without proper information on matching. Out of the remaining studies, the attributable CFP ranged from 0% (Morata, 2012; Joo, 2011) to 28.1% (Tam, 2010) and the attributable LOS ranged from 9 (Joo, 2011) days to 10 days (Tam, 2010; Tumbarello, 2011). Only two studies provided ORs, one indicating a significant difference in mortality and the other a non-significant difference. When aggregating the information from the four studies, we found that 234 cases accounted for 71 deaths and that the 892 controls accounted for 245 deaths. The risk difference was 2.65% (Wilson sample proportion 95% CI 0-5.79). When added to the baseline scenario, the CFP ranged from 9.75% to 23%. We chose to add 28.1% to the baseline CFP of 7.1% and kept 7.1% as the lower bound of the range. The MDRPA disease model was set to 7.1% to 35.2%. The attributable LOS was set 14.87 days to 21.5 days. 11.2. Respiratory tract infections The review of the literature identified seven studies comparing to susceptible infections. We discarded one study that focused on COPD patients (Montero, 2009) and on ICU patients only without matching (Tumbarello, 2013); of the remaining studies, the attributable CFP ranged from 0% (Pena, 2013) to 13% (Micek, 2015) and the attributable LOS ranged from 2 (Micek, 2015) days to 3 days (Yang, 2009). We also discarded those including secondary BSI (Micek, 2015; Yang, 2009) and the remaining studies found 0%, 4.8% (Yayan, 2015) and 5.3% (Cillóniz, 2016). We added the highest value to the highest in the baseline (4.5%); the disease model CFP was set to 2.7% to 9.8%. We set the attributable LOS to 10 to 17 days. 11.3. Urinary tract, surgical site and other site infections The review of the literature did not identify any other studies. Therefore, we kept the baseline models for SSIs. We chose to estimate the attributable UTI LOS by applying the same methodology as the one chosen for the baseline infection model. All resistant Acinetobacter and Pseudomonas aeruginosa from the PPS 2011-2012 were included and the attributable UTI LOS was set to 8 days (4-11). The same approach for the baseline attributable LOS for OTH infection sites was used to estimate LOS. However, given the small number of observations, we chose to include all resistant Acinetobacter and Pseudomonas aeruginosa from the PPS 2011-2012 in our estimation. We set the attributable LOS of OTH infections sites to 14.5 days (9-19). 12. Carbapenem resistant Pseudomonas aeruginosa infections 12.1. Blood-stream infections The review of the literature identified eight studies comparing CRPA infections to susceptible ones; we excluded one study because of a low number of cases (Hattemer, 2013) and another because of limited information on matching (Dantas, 2014). The attributable CFP ranged from 0% (Tuon, 2012; 183 Kim, 2014) to 18.4% (Kang, 2005) the attributable LOS ranged from 0 days (Tuon, 2012; Joo, 2011) to 10 days (Suarez, 2010). One study found a significant difference between the mortality of resistant cases compared to susceptible, and 4 studies did not find a significant difference. When aggregating the information from the seven studies (all except the one without clear matching) and found that 410 cases accounted for 143 deaths and that 1,190 controls accounted for 338 deaths. The risk difference 6.48% (Wilson sample proportion 95% CI 4.51-8.58), which if added to the baseline would average a CFP of 13.6% to 26.8%. Given the uncertainty and variability, we chose to maintain the baseline lower bound (7.1%) and added 18.4% to the baseline higher bound. The CRPA BSI CFP was set to 7.1%-38.7% and the attributable LOS was kept the same as for the MDRPA model. 12.2. Respiratory tract infections The review of the literature identified one study comparing to susceptible that found 6% risk difference (Luyt, 2014) and 8 added days over susceptible infections. Therefore, we set the CFP to 2.7%-10.5% and the LOS to 15-22 days. 12.3. Urinary tract, surgical site and other site infections The review of the literature did not identify any other studies. Therefore, we kept the baseline models for SSIs. We chose to estimate the attributable UTI LOS by applying the same methodology as the one chosen for the baseline infection model. All resistant Acinetobacter and Pseudomonas aeruginosa from the PPS 2011-2012 were included and the attributable UTI LOS was set to 8 days (4-11). The same approach for the baseline attributable LOS for OTH infection sites was used to estimate LOS. However, given the small number of observations, we chose to include all resistant Acinetobacter and Pseudomonas aeruginosa from the PPS 2011-2012 in our estimation. We set the attributable LOS of OTH infections sites to 14.5 days (9-19). 13. Colistin resistant Pseudomonas aeruginosa infections 13.1. All infection sites The review of the literature did not retrieve studies eligible with the chosen selection criteria. Therefore, we decided to apply the same values as those for CRPA. 14. Meticillin resistant Staphylococcus aureus infections 14.1. Blood-stream infections The review of the literature identified a large number of studies comparing attributable mortality and attributable LOS of MRSA to MSSA and/or non-infected patients. The WHO systematic review (WHO, 2014) found a significant impact of the resistant infection compared to susceptible ones. This meta- analysis of the WHO systematic review found an attributable mortality compared to MSSA of 10.8% (7.3-14.7) and an attributable LOS of 3.12 days (1.79-4.44). Added to the 7.1% CFP of the baseline model, the attributable CFP of MRSA would be 17.9% (14.4-21.8). When adding the attributable LOS to the baseline LOS (5.87-11.5 days), we estimated an attributable LOS compared to non-infected of 8.99-14.62 days. A recent publication estimated an attributable CFP of 19.5% (Brady, 2017). The review of the literature identified twenty studies comparing MRSA and MSSA BSI attributable mortality. When aggregating the information from fourteen studies (after excluding those focusing only on specific populations, e.g. neonatal patients, patients with cardiac implants) we found that 1,353 cases accounted for 360 deaths and 2,954 controls accounted for 467 deaths. The resulting risk difference was 10.8% (Wilson sample proportion 95% CI 9.79-11.9), validating the result of the WHO review. Within EU countries, De Kraker et al. (de Kraker, 2011b) found that in 2007, 27,711 episodes 184 of MRSA BSIs were associated with 5,503 excess deaths, resulting in a 19.9% CFP. Moreover, more recent studies not included in the WHO systematic review (Stewardson, 2016; Yasmin, 2016; Atmaca, 2014) found similar attributable mortality compared to non-infected (20.4%, 20.3% and 18.2%). Therefore, we chose to apply the CFP of 17.9% (14.4-21.8). Stewardson et al. also found an attributable LOS of 12.22 to 13.33 depending on the model used. These findings are in line with the chose attributable LOS for the MRSA model (8.99-14.62 days). 14.2. Respiratory tract infections The review of the literature identified one study comparing MRSA to non-infected and five studies comparing to MSSA. However, these studies included S-BSI patients and were discarded. We chose to apply the baseline parameters to the MRSA model. 14.3. Urinary tract, surgical site and other site infections The review of the literature did not identify any other studies. Therefore, we kept the baseline models for urinary tract infections, SSIs. The same approach for the baseline attributable LOS for OTH infection sites was used to estimate LOS. The estimated attributable LOS of MRSA OTH infection sites was set to 12 days (8-19). 15. Vancomycin resistant Enterococcus faecalis and faecium infections 15.1. Blood-stream infections The review of the literature identified five studies comparing VRE infection attributable CFP to non- infected. CFP ranged from 12.6% to 37%. Moreover, the review also identified two meta-analysis comparing VRE to VSE which found an attributable CFP of 17% (Salgado, 2003) and the other study did not provide a risk difference but also found a significant odds ratio (DiazGranados, 2005). A recent publication estimated an attributable CFP of 13.4% for vancomycin resistant E. faecalis and of 19.1% for vancomycin resistant E. faecium (Brady, 2017). The review of the literature identified seventeen studies comparing VRE infection VSE. Attributable CFP ranged from 0% to 29%, after excluding studies focusing only in specific populations (e.g. patients with malignancy). When aggregating the information from thirteen studies, we found that 824 cases accounted for 297 deaths and 1208 controls accounted for 245 deaths. The resulting attributable CFP was 15.8% (Wilson sample proportion 95% CI 14.7-16.7), similar to the results of the meta-analysis mentioned above. Therefore, we decided to add this result to the baseline conservative value of 7.1% and set the attributable CFP of the VRE model to 22.9% (Wilson sample proportion 95% CI 21.8-23.8). Attributable LOS ranged from 1.1 days to 6.8 days which were added to the baseline LOS; the attributable LOS for the VRE BSI model was set to 6.97 to 18.3 days. 15.2. Respiratory tract, urinary tract, surgical site and other site infections The review of the literature identified studies focusing on other infection sites but did not exclude death by S-BSI and were excluded. The review of the literature did not identify any other studies. Therefore, we kept the baseline models for respiratory tract infections, UTIs, SSIs and OTH infection sites. For the attributable LOS of the OTH infection sites, we explored the possibility of adopting the same approach as for the baseline model but there was a limited number of observations. Therefore, we chose to adopt the baseline attributable LOS for VRE. 185 16. Penicillin resistant Streptococcus pneumoniae infections 16.1. Blood-stream infections The review of the literature identified one study comparing PRSP BSI to susceptible BSI infections and found a mortality risk difference of 8.6% (Yu, 2003). No information on attributable LOS was available. The review of the literature identified one study comparing PRSP respiratory to susceptible infections and found no difference in mortality (Watanabe, 2000). No information on attributable LOS was available. A recent publication estimated an attributable CFP of 16.7% (Brady, 2017). Therefore, for BSIs we chose to add 8.6% to the lower baseline value and keep the higher value. The PRSP BSI attributable mortality was set to 15.7%-20.3% and the baseline attributable LOS was kept unvaried. No changes on the baseline respiratory tract infection model was made. 16.2. Respiratory tract, urinary tract, surgical site and other site infections The review of the literature did not retrieve studies eligible with the chosen selection criteria. Therefore, we decided to apply the same baseline values. The only exception was the duration of OTH infection site (mainly otitis and sinusitis) to which we chose to apply 5-10 days (Mandell, 2015). 17. Macrolide and penicillin resistant Streptococcus pneumoniae infections 17.1. All infection sites The review of the literature did not retrieve studies eligible with the chosen selection criteria. Therefore, we decided to apply the same values as those for PRSP. 186 References Al Jarousha AM, El Jadba AH, Al Afifi AS, El Qouqa IA. Nosocomial multidrug-resistant Acinetobacter baumannii in the neonatal intensive care unit in Gaza City, Palestine. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. Sep 2009;13(5):623-628. Anunnatsiri S, Tonsawan P. Risk factors and clinical outcomes of multidrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Thailand. The Southeast Asian journal of tropical medicine and public health. May 2011;42(3):693-703. Astagneau P, Rioux C, Golliot F, Brucker G, Group INS. Morbidity and mortality associated with surgical site infections: results from the 1997-1999 INCISO surveillance. J Hosp Infect. 2001 Aug;48(4):267-74. Atmaca O, Zarakolu P, Karahan C, Cakir B, Unal S. [Risk factors and antibiotic use in methicillin- resistant Staphylococcus aureus bacteremia in hospitalized patients at Hacettepe University Adult and Oncology Hospitals (2004-2011) and antimicrobial susceptibilities of the isolates: a nested case- control study]. Mikrobiyoloji bulteni. Oct 2014;48(4):523-537. Ben-David D, Kordevani R, Keller N, et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clinical Microbiology and Infection. 2012;18(1):54-60. Borer A, Saidel-Odes L, Riesenberg K, et al. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infection control and hospital epidemiology. 2009;30(10):972-976. Brady M, Oza A, Cunney R, Burns K. Attributable mortality of hospital-acquired bloodstream infections in Ireland. J Hosp Infect. 2017 May;96(1):35-41. Cai XF, Sun JM, Bao LS, Li WB. Risk factors and antibiotic resistance of pneumonia caused by multidrug resistant Acinetobacter baumannii in pediatric intensive care unit. World Journal of Emergency Medicine. 2012;3(3):202-207. Cassini A, Plachouras D, Eckmanns T, Abu Sin M, Blank HP, Ducomble T, et al. Burden of Six Healthcare-Associated Infections on European Population Health: Estimating Incidence-Based Disability-Adjusted Life Years through a Population Prevalence-Based Modelling Study. PLoS Med. 2016;13(10):e1002150. DOI: 10.1371/journal.pone.0144988 PMID: 26672751 Cillóniz C, Gabarrús A, Ferrer M, et al. Community-Acquired Pneumonia Due to Multidrug- and Non– Multidrug-Resistant Pseudomonas aeruginosa. Chest. 2016;150(2):415-425. Daikos GL, Petrikkos P, Psichogiou M, et al. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrobial agents and chemotherapy. May 2009;53(5):1868-1873. Dantas RC, Ferreira ML, Gontijo-Filho PP, Ribas RM. Pseudomonas aeruginosa bacteraemia: independent risk factors for mortality and impact of resistance on outcome. Journal of medical microbiology. Dec 2014;63(Pt 12):1679-1687. a) de Kraker MEA, Wolkewitz M, Davey PG, et al. Burden of antimicrobial resistance in European hospitals: Excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. Journal of Antimicrobial Chemotherapy. 2011;66(2):398-407. b) de Kraker ME, Davey PG, Grundmann H, group Bs. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe. PLoS Med. Oct 2011;8(10):e1001104. DiazGranados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta- analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Aug 1 2005;41(3):327-333. 187 Esteve-Palau E, Solande G, Sanchez F, et al. Clinical and economic impact of urinary tract infections caused by ESBL-producing Escherichia coli requiring hospitalization: A matched cohort study. The Journal of infection. Dec 2015;71(6):667-674. European Centre for Disease prevention and Control. Point prevalence survey of healthcare- associated infections and antimicrobial use in European acute care hospitals. Stockholm: ECDC; 2013. http://ecdc.europa.eu/en/publications/Publications/healthcare-associated-infections-antimicrobialuse- PPS.pdf. European Centre for Disease Prevention and Control. Annual Epidemiological Report 2016 – Healthcare-associated infections acquired in intensive care units. [Internet]. Stockholm: ECDC; 2016. [cited 3 July 2017]. Available from: http://ecdc.europa.eu/en/healthtopics/HCAI_ICU/Pages/Annual- epidemiological-report-2016.aspx European Centre for Disease Prevention and Control. Surveillance of healthcare-associated infections in intensive care units in Europe 2008–2012, including attributable mortality analyses. Stockholm: ECDC, 2017. Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ. Deaths attributable to carbapenem- resistant Enterobacteriaceae infections. Emerging infectious diseases. Jul 2014;20(7):1170-1175. Fitzpatrick MA, Ozer E, Bolon MK, Hauser AR. Influence of ACB complex genospecies on clinical outcomes in a U.S. hospital with high rates of multidrug resistance. The Journal of infection. Feb 2015;70(2):144-152. Gallagher JC, Kuriakose S, Haynes K, Axelrod P. Case-case-control study of patients with carbapenem-resistant and third-generation-cephalosporin-resistant Klebsiella pneumoniae bloodstream infections. Antimicrobial agents and chemotherapy. Oct 2014;58(10):5732-5735. Gulen TA, Guner R, Celikbilek N, Keske S, Tasyaran M. Clinical importance and cost of bacteremia caused by nosocomial multi drug resistant Acinetobacter baumannii. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. Sep 2015;38:32-35. Haagsma JA, van Beeck EF, Polinder S, Toet H, Panneman M, Bonsel GJ. The effect of comorbidity on health-related quality of life for injury patients in the first year following injury: comparison of three comorbidity adjustment approaches. Population Health Metrics. 2011;9:10. doi:10.1186/1478-7954-9- 10. Haagsma JA, Maertens de Noordhout C, Polinder S, Vos T, Havelaar AH, Cassini A, et al. Assessing disability weights based on the responses of 30,660 people from four European countries. Popul Health Metr. 2015; 13: 1±15. doi: 10.1186/s12963-015-0042-4 PMID: 26778920. Hattemer A, Hauser A, Diaz M, et al. Bacterial and clinical characteristics of health care- and community-acquired bloodstream infections due to Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy. Aug 2013;57(8):3969-3975. Hussein K, Raz-Pasteur A, Finkelstein R, et al. Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by Klebsiella pneumoniae. Journal of Hospital Infection. 2013;83(4):307-313. Inchai J, Pothirat C, Bumroongkit C, Limsukon A, Khositsakulchai W, Liwsrisakun C. Prognostic factors associated with mortality of drug-resistant Acinetobacter baumannii ventilator-associated pneumonia. Journal of Intensive Care. 2015;3(1). Jamulitrat S, Arunpan P, Phainuphong P. Attributable mortality of imipenem-resistant nosocomial Acinetobacter baumannii bloodstream infection. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. Mar 2009;92(3):413-419. Joo EJ, Kang CI, Ha YE, et al. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome. Microbial drug resistance (Larchmont, N.Y.). Jun 2011;17(2):305-312. 188 Kang CI, Kim SH, Park WB, et al. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Microbial drug resistance (Larchmont, N.Y.). Spring 2005;11(1):68-74. Kim YJ, Kim SI, Hong KW, Kim YR, Park YJ, Kang MW. Risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia: impact of appropriate antimicrobial therapy. Journal of Korean medical science. May 2012;27(5):471-475. Kim YJ, Jun YH, Kim YR, et al. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy. BMC infectious diseases. Mar 24 2014;14:161. Kumar A, Randhawa VS, Nirupam N, Rai Y, Saili A. Risk factors for carbapenem-resistant Acinetobacter baumanii blood stream infections in a neonatal intensive care unit, Delhi, India. Journal of infection in developing countries. Aug 13 2014;8(8):1049-1054. Lambert ML, Suetens C, Savey A, et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: A cohort study. The Lancet Infectious Diseases. 2011;11(1):30-38. Lee NY, Lee HC, Ko NY, et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infection control and hospital epidemiology. Jun 2007;28(6):713-719. Lee JA, Kang CI, Joo EJ, et al. Epidemiology and clinical features of community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Microbial drug resistance (Larchmont, N.Y.). Jun 2011;17(2):267-273. Loh LC, Nor Izran Hanim Bt Abdul S, Rosdara Masayuni Bt Mohd S, Raman S, Thayaparan T, Kumar S. Hospital Outcomes of Adult Respiratory Tract Infections with Extended-Spectrum B-Lactamase (ESBL) Producing Klebsiella Pneumoniae. The Malaysian journal of medical sciences : MJMS. Jul 2007;14(2):36-40. Luyt CE, Aubry A, Lu Q, et al. Imipenem, meropenem or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia. American Journal of Respiratory and Critical Care Medicine. 2014;189. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, Eighth Edition (2015) Eds: John E. Bennett, Raphael Dolin, Martin J. Blaser. ISBN: 13-978-1-4557-4801-3, Elsevier Saunders Martelius T, Jalava J, Karki T, Mottonen T, Ollgren J, Lyytikainen O. Nosocomial bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae resistant to third-generation cephalosporins, Finland, 1999-2013: Trends, patient characteristics and mortality. Infectious diseases (London, England). 2016;48(3):229-234. Melzer M, Petersen I. Mortality following bacteraemic infection caused by extended spectrum beta- lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. The Journal of infection. Sep 2007;55(3):254-259. Micek ST, Wunderink RG, Kollef MH, et al. An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance. Critical care (London, England). May 06 2015;19:219. Montero M, Dominguez M, Orozco-Levi M, Salvado M, Knobel H. Mortality of COPD patients infected with multi-resistant Pseudomonas aeruginosa: a case and control study. Infection. Feb 2009;37(1):16-19. Morata L, Cobos-Trigueros N, Martinez JA, et al. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrobial agents and chemotherapy. Sep 2012;56(9):4833-4837. Mouloudi E, Massa E, Papadopoulos S, et al. Bloodstream infections caused by carbapenemase- producing Klebsiella pneumoniae among intensive care unit patients after orthotopic liver 189 transplantation: Risk factors for infection and impact of resistance on outcomes. Transplantation Proceedings. 2014;46(9):3216-3218. Mouloudi E, Protonotariou E, Zagorianou A, et al. Bloodstream infections caused by metallo-beta- lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes. Infection control and hospital epidemiology. Dec 2010;31(12):1250-1256. Olaechea PM, Palomar M, Alvarez-Lerma F, Otal JJ, Insausti J, Lopez-Pueyo MJ, et al. Morbidity and mortality associated with primary and catheter-related bloodstream infections in critically ill patients. Rev Esp Quimioter. 2013 Mar;26(1):21-9. Renaud B, Brun-Buisson C, Group IC-BS. Outcomes of primary and catheter-related bacteremia. A cohort and case-control study in critically ill patients. Am J Respir Crit Care Med. 2001;163(7):1584-90. Park II, Kim IK, Koo HC, et al. Clinical characteristics and prognosis of Acinetobacter nosocomial pneumonia between MDR and non-MDR. Tuberculosis and Respiratory Diseases. 2006;61(1):13-19. Pena C, Gomez-Zorrilla S, Oriol I, et al. Impact of multidrug resistance on Pseudomonas aeruginosa ventilator-associated pneumonia outcome: predictors of early and crude mortality. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. Mar 2013;32(3):413-420. Robert Koch Institute. Burden of healthcare associated infection (BHAI)—evidence-based and comorbidity-adjusted outcome trees for estimation of burden of disease. Berlin: RKI; 2016. http://www.rki.de/DE/Content/Institut/OrgEinheiten/Abt3/FG37/Research_Report_BHAI.pdf?blob=pu blicationFile. Rojas LJ, Salim M, Cober E, et al. Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae: Laboratory Detection and Impact on Mortality. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Dec 10 2016. Salgado CD, Farr BM. Outcomes associated with vancomycin-resistant enterococci: a meta-analysis. Infection control and hospital epidemiology. Sep 2003;24(9):690-698. Smolyakov R, Borer A, Riesenberg K, et al. Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment. The Journal of hospital infection. May 2003;54(1):32-38. Stewardson AJ, Allignol A, Beyersmann J, et al. The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: A multicentre retrospective cohort study. Eurosurveillance. 2016;21(33). Suarez C, Pena C, Gavalda L, et al. Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. Sep 2010;14 Suppl 3:e73-78. Tal-Jasper R, Katz DE, Amrami N, et al. Clinical and epidemiological significance of carbapenem resistance in Acinetobacter baumannii infections. Antimicrobial agents and chemotherapy. 2016;60(5):3127-3131. Tam VH, Rogers CA, Chang KT, Weston JS, Caeiro JP, Garey KW. Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrobial agents and chemotherapy. Sep 2010;54(9):3717-3722. Taneja N, Singh G, Singh M, Sharma M. Emergence of tigecycline & colistin resistant Acinetobacter baumanii in patients with complicated urinary tract infections in north India. Indian J Med Res. Jun 2011;133:681-684. Tumbarello M, Repetto E, Trecarichi EM, et al. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality. Epidemiology and infection. Nov 2011;139(11):1740-1749. 190 Tumbarello M, De Pascale G, Trecarichi EM, et al. Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients. Intensive care medicine. Apr 2013;39(4):682-692. Tuon FF, Gortz LW, Rocha JL. Risk factors for pan-resistant Pseudomonas aeruginosa bacteremia and the adequacy of antibiotic therapy. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. Jul-Aug 2012;16(4):351-356. Van Aken S, Lund N, Ahl J, Odenholt I, Tham J. Risk factors, outcome and impact of empirical antimicrobial treatment in extended-spectrum beta-lactamase-producing Escherichia coli bacteraemia. Scandinavian journal of infectious diseases. Nov 2014;46(11):753-762. Wang YC, Lee YT, Yang YS, et al. Risk factors and outcome for colistin-resistant Acinetobacter nosocomialis bacteraemia in patients without previous colistin exposure. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. Aug 2015;21(8):758-764. Watanabe H, Sato S, Kawakami K, et al. A comparative clinical study of pneumonia by penicillin- resistant and -sensitive Streptococcus pneumoniae in a community hospital. Respirology. Mar 2000;5(1):59-64. WHO. Antimicrobial resistance: global report on surveillance. France: WHO;2014. Yang K, Zhuo H, Guglielmo BJ, Wiener-Kronish J. Multidrug-resistant Pseudomonas aeruginosa ventilator-associated pneumonia: the role of endotracheal aspirate surveillance cultures. The Annals of pharmacotherapy. Jan 2009;43(1):28-35. Yayan J, Ghebremedhin B, Rasche K. Antibiotic resistance of Pseudomonas aeruginosa in pneumonia at a single university hospital center in Germany over a 10-Year Period. PloS one. 2015;10(10). Yasmin M, El Hage H, Obeid R, El Haddad H, Zaarour M, Khalil A. Epidemiology of bloodstream infections caused by methicillin-resistant Staphylococcus aureus at a tertiary care hospital in New York. American journal of infection control. 2016;44(1):41-46. Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Jul 15 2003;37(2):230- 237. Zarkotou O, Pournaras S, Voulgari E, et al. Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae: a matched case-control study. J Clin Microbiol. Jun 2010;48(6):2271-2274. 191 Burden of antimicrobial resistance Methodology protocol to estimate incidence Written by Annalisa Quattrocchi and Alessandro Cassini with contributions from Carl Suetens, Liselotte Diaz Högberg, Mélanie Colomb-Cotinat, Diamantis Plachouras and Dominique Monnet 192 193 Contents List of abbreviations .............................................................................................. 194 1. Introduction and background information ................................................ 195 1.1. European Antimicrobial Resistance Surveillance Network (EARS-Net) ................ 195 1.2. Point Prevalence Survey of healthcare-associated infections and antimicrobial use in acute care hospitals (PPS 2011-2012) .............................................................................. 196 2. Step-by-step approach to estimate AMR infections ................................ 197 2.1. Selection of Specified Pathogens (SP) ............................................................................... 197 2.2. Data modelling for estimating total SPDAR infections................................................. 198 2.2.1. Step 1: Country-coverage adjustment .................................................................. 198 2.2.2. Step 2: Estimation of number of other infection sites ........................................ 200 2.2.3. Step 3: Adjustment for secondary BSI .................................................................. 200 3. Approach to estimate conversion factors for penicillin-resistant and combined penicillin- and macrolide-resistant S. pneumoniae ..................... 202 4. Limitations ......................................................................................................... 204 References ................................................................................................................ 206 Addendum 1 ............................................................................................................. 171 Addendum 2 ............................................................................................................. 172 Addendum 3 ............................................................................................................. 172 Addendum 4 ............................................................................................................. 173 194 List of abbreviations 3GCREC third-generation cephalosporin-resistant E. coli 3GCRKP third-generation cephalosporin-resistant K. pneumoniae AMR antimicrobial resistance BSI bloodstream infection CAI Community-associated infections CI confidence interval ColRACI colistin-resistant Acinetobacter spp. ColREC colistin-resistant E. coli ColRKP colistin-resistant K. pneumoniae ColRPA colistin-resistant P. aeruginosa CRACI carbapenem-resistant Acinetobacter spp. CREC carbapenem-resistant E. coli CRKP carbapenem-resistant K. pneumoniae CRPA carbapenem-resistant P. aeruginosa CSF cerebral spine fluid DALY disability-adjusted life years EARS-Net European Antimicrobial Resistance Surveillance Network EEA European Economic Area EU European Union HAI healthcare-associated infection LOS length of stay MDR multidrug-resistant MDRACI multidrug-resistant Acinetobacter spp MDRPA multidrug-resistant P. aeruginosa MRSA meticillin-resistant Staphylococcus aureus MS Member State OECD Organisation for Economic Co-operation and Development OTH other infection site including digestive tract infections, skin and soft tissue infections (SSTI), eye, ear, nose or mouth infections, bone and joint infections, cardiovascular infections, reproductive tract infections and other less frequent infections PMRSP penicillin- and macrolide-resistant S. pneumoniae PPS point prevalence survey of healthcare-associated infections and antimicrobial use in acute care hospitals PRSP penicillin-resistant S. pneumoniae; RESP respiratory infections (including pneumonia, and low respiratory tract infection) S-BSI secondary BSI SP specified pathogens SPDAR specified pathogens with defined antimicrobial resistance SSI surgical site infection UTI urinary tract infection VRE vancomycin-resistant enterococci 195 1. Introduction and background information The aim of this study is to estimate the incidence of infections due to selected antimicrobial resistant (AMR) bacteria for the burden of AMR project in EU/EEA countries. Further objectives of the burden of AMR project are the estimation of the attributable case fatality, attributable length of stay (LOS), disability-adjusted life years (DALYs) and economic impact of these selected AMR infections in EU/EEA Member States. The primary data source for the estimation of the incidence of AMR infections was the European Antimicrobial Resistance Surveillance Network (EARS-Net), for the year 2015 [3]. EARS-Net notifies the number of resistant invasive infections for a selection of pathogens. EARS-Net cases were adjusted through data from the point prevalence survey of healthcare-associated infections and antimicrobial use in acute care hospitals (PPS 2011-2012) [1] in order to estimate total country- specific number of infections, i.e. the number of non-BSI infections. This project is conducted in collaboration with the Organisation for Economic Co-operation and Development (OECD) for the estimation of the economic burden of AMR. a. European Antimicrobial Resistance Surveillance Network (EARS-Net) EARS-Net is the main EU surveillance system for antimicrobial resistance, based on a network of representatives from the Member States collecting routine clinical antimicrobial susceptibility data from national AMR surveillance initiatives. The network collects antimicrobial susceptibility data of the first blood and/or cerebrospinal fluid isolate of every patient with an invasive infection associated with one of the pathogens under surveillance. Both antimicrobial-susceptible and antimicrobial-non-susceptible isolates are reported. The objective of EARS-Net is to measure the percentage of non-susceptible or resistant bacteria by species. Assuming that all eligible invasive isolates are reported by the participating laboratories and with country-level knowledge of the denominators (country coverage), we estimated the incidence of cases. The panels of antimicrobial agent combinations under surveillance for each microorganism, as well as algorithms for isolate prioritisation and deduplication, are defined in the EARS-Net reporting protocol [4]. Cerebrospinal fluid isolates represented 0-3% of all isolates reported to EARS-Net (6% for S. pneumoniae); we assumed that the patients with meningitis would most likely also have a BSI and were included in our study as BSIs. EARS-Net performs surveillance of antimicrobial susceptibility of eight bacterial pathogens commonly causing infections in humans, hereafter referred to as “specified pathogens” (SP) and listed in table 1. Table 1. Specified pathogens (SP) Specified pathogen Acinetobacter spp. Enterococcus faecalis and E. faecium Escherichia coli Klebsiella pneumoniae Pseudomonas aeruginosa Staphylococcus aureus Streptococcus pneumoniae A total of 30 countries (all EU Member States, Iceland and Norway) reported AMR data for 2015 to EARS-Net. For this study, an isolate was considered resistant to an antimicrobial group when tested and interpreted as resistant (R) in accordance with the clinical breakpoint criteria used by the local laboratory. Specific rules were applied to determine MRSA and penicillin susceptibility in S. 196 pneumoniae, in accordance with the EARS-Net methodology. The definition of resistance on antimicrobial group level is provided in the EARS-Net protocol [4]. b. Point Prevalence Survey of healthcare-associated infections and antimicrobial use in acute care hospitals (PPS 2011-2012) The ECDC PPS was conducted in 2011–2012 in 29 EU/EEA Member States and Croatia, and included data from a total of 273,753 patients in 1,149 hospitals [1]. It represented the first EU/EEA-wide, ECDC-coordinated PPS of healthcare-associated infections (HAIs) and antimicrobial use in acute care hospitals, representing more than 510 million citizens according to 2011 Eurostat data. PPS collects patient-based risk factors and case-based data on selected antimicrobial resistance markers depending on microorganism, if isolated, for each HAI. Selected antimicrobial susceptibility testing data were available on the day of the survey for 85% of microorganisms reported in HAIs. The percentage of microorganisms with known antimicrobial susceptibility testing results varied between 58% and 92%. Representativeness of the PPS data by country (based on compliance with the recommended sampling methodology of hospitals and sample size) was reported as being optimal or good in 76% of countries. 197 2. Step-by-step approach to estimate AMR infections a. Selection of Specified Pathogens (SP) The number of reported isolates including age and sex information (each representing one case) were extracted from EARS-Net and, based on resistance patterns, SPs with defined antimicrobial resistance (SPDAR) were selected. SPDAR are listed in Table 2. Pathogens included in EARS-Net are selected in consultation with the EARS-Net disease-specific coordination committee, composed by officially nominated country representatives and external experts mainly representing collaborative institutions such as EUCAST and WHO. The European public health impact of the resistant infection, as well as availability of standardised laboratory methodology for species identification and susceptibility testing (in order to ensure reliable data) are amongst the criteria considered. Table 2. Bacteria and antibiotic resistance categories included in the study Bacteria Antibiotic resistance ¥ Acronym Colistin-resistant ColRACI Carbapenem-resistant (excluding isolates also resistant to colistin) CRACI Aminoglycoside- and fluoroquinolone-resistant# (excluding isolates also resistant to colistin and/or carbapenem) MDRACI Enterococcus faeca lis and E. faecium Vancomycin-resistant VRE Colistin-resistant ColREC Carbapenem-resistant (excluding isolates also resistant to colistin) CREC Third-generation cephalosporin-resistant* (excluding isolates also resistant to colistin and/or carbapenem) 3GCREC Colistin-resistant ColRKP Carbapenem-resistant (excluding isolates also resistant to colistin) CRKP Third-generation cephalosporin-resistant* (excluding isolates also resistant to colistin and/or carbapenem) 3GCRKP Colistin-resistant ColRPA Carbapenem-resistant (excluding isolates also resistant to colistin) CRPA Resistance to three or more antibiotic groups# (excluding isolates also resistant to colistin and/or carbapenem) MDRPA Staphy lococcus aureus Meticillin-resistant MRSA Penicillin-resistant (excluding isolates also resistant to macrolides) PRSP Penicillin- and macrolide-resistant (excluding isolates only resistant to penicillin) PMRSP Acinetobacter spp. Escherichia coli Klebsie lla pneum oniae Pseudom onas aeruginosa St reptococcus pneum oniae ¥ An isolate was considered resistant to an antimicrobial group when tested and interpreted as resistant (R) in accordance with the clinical breakpoint criteria used by the local laboratory * In 2015, most of the third-generation cephalosporin-resistant E. coli (88.6%) and K. pneumoniae (85.3%) isolates reported to EARS-Net produced an extended-spectrum β-lactamase (ESBL) (9). For more information on the antibiotics included in each antibiotic group, please refer to the EARS-Net protocol (5). # Resistances used as a marker of multidrug resistance 198 For each pathogen/resistance combination, unknown age-groups and sex data were re-distributed by imputation according to known cases where possible. When insufficient data was available (more than 40% of cases for an antibiotic resistance-bacterium combination with unknown age and/or sex), the cumulative EU age-group and sex distribution of the same antibiotic resistance-bacterium combination was applied for imputation. Addendum 4 provides more details of unknowns and the imputation methodology applied for each antibiotic resistance-bacterium combination in each country. b. Data modelling for estimating total SPDAR infections In order to obtain all SPDAR infections a multi-step adjustment was performed. A summary description is shown in Figure 1. Figure 1. Methodology for adjusting EARS-Net data in order to estimate the total number of SPDAR infections. i.Step 1: Country-coverage adjustment The primary data source was EARS-Net which is based on recruited laboratories in each Member State. EARS-Net is not a population-based surveillance network, the population coverage of the laboratories contributing data to EARS-Net varies between countries and the number of cases reported does not always reflect the total number of cases in a country. During the annual EARS-Net data call, a questionnaire on the estimated population coverage is distributed to the formally designated national Focal Points (NFP) for AMR and the Operational Contact Points (OCP) for AMR. The number of designated NFPs and OCPs per country varies, but represents those working closely with the national data collection and with good insight in geographical and demographical representativeness of EARS-Net. A limitation related to this country coverage correction approach is that case ascertainment of patients with bloodstream infections (BSIs) is strongly linked to diagnostic practices and the frequency with which blood cultures are taken. Therefore, variations in blood culture frequency or propensity to test BSIs could increase uncertainty when comparing the reported number of cases between countries and potentially underestimate the total number of cases when the blood culture frequency is low. Other limitations of the EARS-Net database considered for our study was the representativeness of the hospitals and laboratories participating: for countries reporting data from only a small number of hospitals and laboratories located in one specific geographical area, the sample may not be representative for the whole country. In addition, for countries where not all laboratories/hospitals participate in EARS-Net, the distribution of healthcare level of the sample origin might affect the patient case-mix, with the potential to both over- and underestimate the total number of cases when applying a general population coverage estimate. Methods aiming at improving the representativeness were explored, in particular the possibility of adjusting for the frequency of use of blood cultures. EARS-Net provides some information on the number of blood culture sets per 1,000 patient days as an indicator for case ascertainment of patients with bloodstream infections. However, this information is incomplete for many countries and the denominator (i.e. 1,000 patient days) was not always homogeneously estimated across countries. In 199 order to provide more information on blood culturing propensity, we provided the reported number of blood culture sets per 1,000 patient days for 2015 [3] and the 2015 EU LabCap Indicator 1.32 Blood culture test rate [12], see Addendum 4. Therefore, the estimation of the country coverage for EARS-Net was mainly based on the pathogen- specific EARS-Net country population coverage, which was generally calculated based on the national ratio of admissions in reporting hospitals to total admissions in national hospitals. In an effort to partially take into account the uncertainties discussed above, designated contact points in each Member State were given the possibility of providing a range of estimated national population coverage. The estimates were expressed in percentages of population covered and the resulting multiplication factor was derived (100/population covered). Table 3 shows the estimated population country coverage per organism for each participating countries. For each country, the total number of invasive infections due to each pathogen/resistance combination was then estimated by applying a factor based on this self-reported country coverage to the number of cases reported to EARS-Net. Table 3. Estimated population country coverage per organism. All numbers are percentages. ECDC is currently working with countries in standardising the sample frame and data collection methods, as well as evaluating the factors affecting the EARS-Net country coverage. These include (but not limited to): the population coverage, geographical representativeness and selection of Country S. pneumoniae S. aureus Enterococci E. coli K. pneumoniae P. aeruginosa Acinetobacter spp Austria 90 90 90 90 90 90 90 Belgium 87 24 24 24 23 24 8 Bulgaria 28-29-30 28-29-30 28-29-30 28-29-30 28-29-31 28-29-32 28-29-33 Cyprus 82.5-85-87.5 82.5-85-87.582.5-85-87.5 82.5-85-8782.5-85-87.5 82.5-85-87.5 82.5-85-87.5 Czech Republic 90 85 85 85 85 85 85 Germany 20-25-30 20-25-30 20-25-30 20-25-30 20-25-30 20-25-30 20-25-30 Denmark 100 100 100 100 100 100 100 Estonia 100 100 100 100 100 100 100 Greece NA 57 54 60 53 52 60 Spain 27.8-31.05-34.3 27.8-31.05-327.8-31.05-34 27.8-31.05 27.8-31.05-34.3 27.8-31.05-34.3 27.8-31.05-34.3 Finland 97-98-99 97-98-99 98-99-100 97-98-99 97-98-99 98-99-100 94-95-96 France 67.2 12.6-18-18 12.6-18-18 12.6-18-1812.6-18-18 12.6-18-18 12.6-18-18 Croatia 85-90-95 85-90-95 85-90-95 85-90-95 85-90-95 85-90-95 85-90-95 Hungary 90 90 90 90 90 90 90 Ireland 97 97 97 97 97 97 97 Iceland 100 100 100 100 100 100 100 Italy 10-15-20 10-15-20 10-15-20 10-15-20 10-15-20 10-15-20 10-15-20 Lithuania 90 90 90 90 90 90 90 Luxembourg 100 100 100 100 100 100 100 Latvia 90 90 90 90 90 90 90 Malta 95 95 95 95 95 95 95 Netherlands 65 65 65 65 65 65 65 Norway 100 100 100 100 100 100 100 Poland 14 14 14 14 14 14 14 Portugal 95 96.1 96 95.2 96.5 95.3 91.2 Romania 12-15-17 12-15-17 12-15-17 12-15-17 12-15-17 12-15-17 12-15-17 Sweden 75-77.5-80 75-77.5-80 75-77.5-80 75-77.5-8075-77.5-80 75-77.5-80 60 Slovenia 99.1 97.9 98.8 99.3 99.6 97.9 100 Slovakia 75 75 75 75 75 75 75 United Kingdom 21 26 12 12 12 12 12 200 surveillance sites/laboratories, patient case-mix, sampling (propensity to test) and laboratory capacity and procedures (AST methods). ii.Step 2: Estimation of number of other infection sites A complete picture of the burden of disease caused by infections with antibiotic-resistant bacteria requires the estimation of the number of all other types of infection. The ECDC PPS 2011-2012 focused on 29 EU/EEA countries and Croatia, and included data from a total of 273,753 patients in 1,149 hospitals. Selected antimicrobial susceptibility testing data were available for 85% of microorganisms reported in HAIs. PPS data were used to estimate the number of infections in other infection sites, except for S. pneumoniae. The EU/EEA total PPS infection site incidence for each SPDAR was calculated by applying the Rhame and Sudderth formula to the prevalence data [13]. We estimated the ratio from BSI to other infection sites from the incident EU/EEA cumulative number of infections in the PPS. Particularly, we computed the number of cases for the following infections sites (according to the EU/EEA case definitions [5]): • Bloodstream infection (BSI); • Respiratory infection (RESP); • Urinary tract infection (UTI); • Surgical site infection (SSI); • Other infection sites (OTH: excluding BSI, UTI, RESP and SSI). The OTH group included digestive tract infections, skin and soft tissue infections (SSTIs), eye, ear, nose or mouth infections, bone and joint infections, cardiovascular infections, reproductive tract infections and other less frequent infections, caused by the selected antibiotic-resistant bacteria. When PPS did not collect information on given SPDAR, proxies were chosen. This was the case for the following SPs: • PPS did not collect information on colistin resistance. Therefore, carbapenem resistance of the same pathogen was used instead. • PPS did not have enough cases of CREC; therefore, conversion factors of 3GCREC were used instead. • PPS did not collect information on MDR Acinetobacter spp. Therefore, carbapenem resistant Acinetobacter spp. was used instead. • PPS did not collect information on MDR P. aeruginosa. Therefore, carbapenem resistant P. aeruginosa was used instead. • PPS did not collect information on penicillin-resistant and combined penicillin- and macrolide- resistant S. pneumoniae. Therefore a review of the published literature was undertaken, described in paragraph 3. The PPS estimated ratio between BSIs and other infection sites, including 95% confidence interval (CI), were applied to the country-specific age-group and sex tables resulting from step 1. The CI of the conversion factors for each infection site were estimated by combining the CIs of the estimated infection site incidence of each SPDAR with the CIs of the incidence of BSI. The proportion of the CIs around BSI and the other infection site incidence were added and applied to the conversion factor. This approach ensures that all uncertainties are considered, but also entail very wide CIs. For more information on infection site conversion factors for each SPDAR, please refer to Addendum 1. iii.Step 3: Adjustment for secondary BSI Each infection leading to secondary BSI (S-BSI) retrieved through the PPS is expected to be reported as BSI in EARS-Net. Thus, the previous adjustment might lead to double counting of the infections, resulting in overestimation of the total number of AMR infections. Therefore, the percentage of S- BSIs from each of the other infection sites (reducing factors derived from the variable ‘origin of BSI’ in PPS data) was deducted from infections in other sites. This deduction was applied to the number of cases for each non-BSI infection site, similarly to the example for UTIs below: 201 (UTI)step3 = (UTI)step2 – ([BSI] * x) With x being the percentage of S-BSIs. For each country and for each SPDAR, the reducing factors were applied to age-group and sex adjusted cases obtained from step 2, in order to estimate the number of all infections for each SPDAR. When the initial number of cases is low, the resulting lower uncertainty bound after Step 3 can be negative. We assumed that in those cases the lower uncertainty bound is 0. For more information on S-BSI reducing factors for each SPDAR, please refer to Addendum 2. 202 Approach to estimate conversion factors for penicillin-resistant and combined penicillin- and macrolide-resistant S. pneumoniae The PPS 2011-2012 did not collect information on S. pneumoniae. Therefore, in order to estimate a BSI/other infection site conversion factor (step 2), a review of the published literature was undertaken. The search provided a number of studies focusing on penicillin-resistant S. pneumoniae infection sites in European countries. However, no studies were found specifically for penicillin/macrolide combined resistance. Conversion factors for the latter infections were assumed to be the same as for penicillin-resistant infections. No studies reported S. pneumoniae in SSIs or in UTIs. Table 4 summarises all the results of the literature search. ECDC report “Time to react” [6] used 2.7 as conversion between RESP/BSI. Vardhan et al. [7] report a number of penicillin-resistant S. pneumoniae infections by site in adults and in children. The latter did not experience any BSI and were not considered as a separate population. Isolates from chest were considered as “Respiratory (RESP)” infections and those from the following infection sites: eye, wound/burn, ear and sinus were all considered as “other (OTH)” infections’ category Hence, the conversion factors derived from this study are RESP/BSI: 8.33 and OTH/BSI: 0.54. A textbook [8] reported a respiratory infection to BSI conversion factor of 4. A large study in France [9] reported percentages of penicillin-resistant S. pneumoniae for each infection site in adults and in children, although the age group of the latter were not defined. We added the cerebral spine fluid (CSF) infections to BSIs and the middle ear fluid/sinus infections as part of the “other” category. Conversion factors for RESP/BSI was 2.97 and for other/BSI was 0.33 in adults. In children these factors change to 3.86 and 7.18, respectively. Infections resistant to erythromycin had almost the same conversion factors. However, erythromycin-resistant infections were not specified if they were also resistant to penicillin. Therefore, we decided to retain only the information on penicillin-resistant S. pneumoniae in adults. Hauser et al. [10] described the number of invasive and non-invasive penicillin-resistant S. pneumoniae infections in Switzerland. Assuming all invasive infections as BSI (and or CSF), we estimated a conversion factor OTH/BSI of 0.28. A study undergone in Iceland [11] found that a conversion factor for RESP/BSI of 8.07. Notably, no reducing factors (step 3) were applied for S. pneumoniae. Table 4. Results of the literature search Time to React (2007) [6] Vardham (2003) [7] Janoff (2015) [8] Demachy (2005) [9] Hauser (2016) [10] Hjalmarsdottir (2014) [11] RESP/BSI 2.7 8.33 4 2.97 NA 8.07 OTH/BSI NA 0.54 NA 0.33 0.28 NA 203 After expert opinion, it was considered that the publication from Demachy et al. [9] was the one with highest power and the following conversion factors were chosen: Penicillin-resistant and combined penicillin- and macrolide-resistant S. pneumoniae Ratio Lower CI Upper CI BSI 1 1 1 UTI 0 0 0 RESP 2.97 2.7 8.33 SSI 0 0 0 OTH 0.33 0.28 0.54 204 Limitations A number of limitations were identified and are listed here. Limitations related to the main data source, 2015 EARS-Net data: • EARS-Net data relies on blood culturing and diagnostic practices, which are heterogeneous across the EU/EEA. This variability mainly concerns the frequency of testing, where under- resources countries would test less and more severe/resistant infections. A potential effect could be the under-estimation of infection numbers and the over-representation of the resistance proportion. • EARS-Net surveillance is based on sentinel laboratories, which are assumed to be a representative sample of the country. However, in some countries participating laboratories might be concentrated in specific regions and/or in selected reference hospitals focused on high-level tertiary care. In addition, for countries where not all laboratories/hospitals participate in EARS-Net, the distribution of healthcare level of the sample origin might affect the patient case-mix, with the potential to both over- and underestimate the total number of cases when applying a general population coverage estimate. • In order to account for blood culturing propensity, stratification of countries according to the 2015 EU LabCap Indicator 1.32 (Blood culture test rate) could be explored, see Addendum 3 of this document. However, this information is incomplete for many countries and the denominator was not always homogeneously estimated across countries. • Countries were able to allocate a range estimates for the country coverage, in an attempt to include the resulting uncertainties in the final estimations. • EARS-Net collects antimicrobial susceptibility data of the first blood and/or cerebrospinal fluid isolate of every patient within the year (de-duplication of data). Therefore, re-hospitalised patients would not be included; however, it is important to note that data that are not de- duplicated are more likely to overestimate resistance rates and sequelae. Limitations related to using the PPS 2011-2012 data for converting BSI to other infections sites and to account for S-BSI: • In order to ensure an up-to-date epidemiological picture, we chose the latest available EARS- Net reported data, from 2015. The PPS with which we derive the BSI/non-BSI conversion factors and the reduction factors accounting for S-BSI was performed in 2011 and 2012 (depending on the country). The incidence of AMR infections might have changed between these years, although the extent to which this has an impact on the BSI/non-BSI ratio was deemed to be limited. • A number of EARS-Net infections can be considered predominately HAIs (e.g. colistin- resistant infections, Pseudomonas and Acinetobacter infections) or community-associated infections (CAIs) (e.g. Streptococcus pneumoniae), whereas other infections may be HAI or CAI (e.g. MRSA, Third-generation cephalosporin-resistant E. coli). We chose to apply the same PPS BSI/non-BSI conversion factors and the reduction factors accounting for S-BSI, irrespective of the fact of the infection is HAI or CAI. At the present stage, no published literature on the evidence for different conversion factors in CAIs was retrieved, and it was not possible to differentiate between HAI and CAI conversion factors. • The daily national prevalence of HAI in PPS is highly variable depending on the day of the measurement. Thus, the duration of different infection types may represent a potential limitation. Long-lasting infections have a higher probability of being registered in a cross- sectional study such as the PPS than infections lasting less time and/or those treated in a timely fashion. This might affect the ratio from BSI to other types of infections, potentially resulting in an under-estimation of non-BSI infections (i.e. in particular mild infections might be under-represented). We partially account for this limitation by applying and incidence approach to the estimation of the BSI/non-BSI conversion factors and the large uncertainty 205 intervals resulting from the Rhame and Sudderth formula estimation of the incidence.The estimation of non-BSIs might have been affected by the case-mix of patients, which could differ between hospitals. • The PPS study does not collect information on penicillin-resistant and combined penicillin- and macrolide-resistant S. pneumoniae. Therefore, conversion factors were derived from the review of the published literature. Retrieved evidence was limited and may be a source of uncertainty. 206 References 1. European Centre for Disease Prevention and Control. Point prevalence survey of healthcare- associated infections and antimicrobial use in European acute care hospitals. Stockholm: ECDC; 2013. Available from: http://ecdc.europa.eu/en/publications/Publications/healthcare-associated-infections- antimicrobial-use-PPS.pdf 2. Cassini A, Plachouras D, Eckmanns T, Abu Sin M, Blank HP, Ducomble T, et al. Burden of Six Healthcare-Associated Infections on European Population Health: Estimating Incidence-Based Disability-Adjusted Life Years through a Population Prevalence-Based Modelling Study. PLoS Med. 2016 Oct;13(10):e1002150. 3. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2015. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS- Net). Stockholm: ECDC; 2017. Available from: http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-europe-2015.pdf 4. European Centre for Disease Prevention and Control. EARS-Net Reporting Protocol. July 2015. Stockholm: ECDC; 2015. Available from: http://ecdc.europa.eu/en/activities/surveillance/EARS- Net/Documents/2015-EARS-Net-reporting-protocol.pdf 5. Brown LD, Cai TT, DasGupta A. Interval Estimation for a Binomial Proportion. Statist. Sci. 16 (2001), no. 2, 101--133. doi:10.1214/ss/1009213286. http://projecteuclid.org/euclid.ss/1009213286. 6. The bacterial challenge: time to react. A call to narrow the gap between multidrug-resistant bacteria in the EU and the development of new antibacterial agents. ECCD/EMEA Joint Technical Report, 2009. 7. Vardhan MS, Allen KD. Epidemiology of penicillin-resistant pneumococci in a Merseyside Health District over a 14-year period. J Infect. 2003;46(1):23-9. 8. Janoff EN, Musher DM. Streptococcus pneumoniae: Clinical syndromes. Mandell, Douglas, and Bennett`s Principles and Practice of Infectious Diseases, Eighth Edition. 2015 ISBN: 978-1-4557- 4801-3, Elsevier, Philadelphia. Page 2319 9. Demachy MC, Vernet-Garnier V, Cottin J, Cattier B, Chardon H, Chomarat M, et al. Antimicrobial resistance data on 16,756 Streptococcus pneumoniae isolates in 1999: A Pan-Regional Multicenter Surveillance Study in France. Microb Drug Resist. 2005 Winter;11(4):323-9. 10. Hauser C, Kronenberg A, Allemann A, Muhlemann K, Hilty M. Serotype/serogroup-specific antibiotic non-susceptibility of invasive and non-invasive Streptococcus pneumoniae, Switzerland, 2004 to 2014. Euro surveillance. 2016 May 26;21(21). 11. Hjalmarsdottir MA, Kristinsson KG. Epidemiology of penicillin-non-susceptible pneumococci in Iceland, 1995-2010. J Antimicrob Chemother. 2014 Apr;69(4):940-6. 12. European Centre for Disease Prevention and Control. European Centre for Disease Prevention and Control. EU Laboratory Capability Monitoring System (EULabCap) – Report on 2015 survey of EU/EEA country capabilities and capacities. Stockholm: ECDC; 2017. Available from: http://ecdc.europa.eu/en/publications/Publications/EULabCap_report-for-2015.pdf 13. Rhame FS, Sudderth WD. Incidence and prevalence as used in the analysis of the occurrence of nosocomial infections. Am J Epidemiol. 1981;113(1):1-11. 14. 207 Addendum 1 Infection site conversion factors for each SPDAR Colistin-/carbapenem-/multidrug-resistant Acinetobacter spp.* Ratio Lower CI Upper CI BSI 1.00 0.76 1.47 UTI 0.45 0.07 0.83 RESP 1.23 0.54 1.93 SSI 0.46 0.11 0.81 OTH 0.16 0.01 0.30 Colistin-/carbapenem/third generation cephalosporin-resistant E. coli* Ratio Lower CI Upper CI BSI 1.00 0.74 1.56 UTI 4.68 2.10 7.25 RESP 0.53 0.08 0.97 SSI 1.24 0.43 2.05 OTH 0.60 0.14 1.07 Vancomycin-resistant E. faecalis and E. faecium Ratio Lower CI Upper CI BSI 1.00 0.59 3.25 UTI 0.75 0.00 1.87 RESP 0.00 0.00 0.00 SSI 1.88 0.00 4.13 OTH 1.63 0.00 3.64 208 Colistin-/carbapenem-resistant K. pneumoniae* Third-generation cephalosporin- resistant K. pneumoniae Ratio Lower CI Upper CI Ratio Lower CI Upper CI BSI 1.00 0.72 1.62 BSI 1.00 0.78 1.34 UTI 0.74 0.13 1.35 UTI 1.52 0.79 2.29 RESP 0.64 0.07 1.20 RESP 0.94 0.44 1.47 SSI 0.37 0.00 0.75 SSI 0.43 0.16 0.72 OTH 0.68 0.09 1.27 OTH 0.50 0.21 0.81 Colistin-/carbapenem-/multidrug-resistant P. aeruginosa* Ratio Lower CI Upper CI BSI 1.00 0.70 1.75 UTI 1.38 0.21 2.55 RESP 4.06 1.38 6.73 SSI 0.91 0.13 1.68 OTH 0.67 0.06 1.27 Meticillin-resistant S. aureus Ratio Lower CI Upper CI BSI 1.00 0.80 1.34 UTI 0.25 0.03 0.47 RESP 1.65 0.86 2.45 SSI 1.77 0.97 2.57 OTH 1.62 0.89 2.36 *When PPS did not provide information on given SPDAR, proxies were chosen, as detailed in the corresponding paragraph 209 Addendum 2 Secondary BSI reducing factors for each SPDAR* Colistin-/carbapenem-/multidrug-resistant Acinetobacter spp. BSI 1 UTI 0.03 RESP 0.11 SSI 0.08 OTH 0.13 Colistin-/carbapenem-resistant E. coli Third-generation cephalosporin-resistant E. coli BSI 1 BSI 1 UTI 0.25 UTI 0.16 RESP 0.00 RESP 0.06 SSI 0.00 SSI 0.13 OTH 0.00 OTH 0.25 Vancomycin-resistant E. faecalis and E. faecium BSI 1 UTI 0.13 RESP 0.00 SSI 0.13 OTH 0.25 210 Colistin-/carbapenem-resistant K. pneumoniae Third-generation cephalosporin-resistant K. pneumoniae BSI 1 BSI 1 UTI 0.10 UTI 0.32 RESP 0.19 RESP 0.06 SSI 0.06 SSI 0.03 OTH 0.18 OTH 0.10 Colistin-/carbapenem-/multidrug-resistant P. aeruginosa BSI 1 UTI 0.00 RESP 0.08 SSI 0.16 OTH 0.12 Meticillin-resistant S. aureus BSI 1 UTI 0.00 RESP 0.11 SSI 0.09 OTH 0.11 *When PPS did not provide information on given SPDAR, proxies were chosen, as detailed in the corresponding paragraph 211 Addendum 3 Number of blood culture sets tested/1 000 hospital inpatient days reported by EARS-Net participating hospitals from your country. Country Number of blood culture tests tested/1000 hospital inpatient days reported Score 1.32 Austria 15.7 1 Belgium NA 0 Bulgaria 8.2 1 Croatia NA 0 Cyprus 41.4 2 Czech Republic 16.6 2 Denmark NA 0 Estonia 17.8 2 Finland NA 0 France 86.5 2 Germany 24.9 2 Greece NA 0 Hungary 8.4 1 Iceland 43.1 2 Ireland 52.9 2 Italy NA 0 Latvia 6.7 1 Lithuania NA 0 Luxembourg NA 0 Malta 22.7 2 Netherlands NA 0 Norway 56.9 2 Poland 32.4 2 Portugal 64.6 2 Romania NA 0 Slovakia 20.1 2 Slovenia 35.1 2 Spain NA 0 Sweden NA 0 United Kingdom 65.4 2 Score (will be calculated by the LabCap team): 0 = information not reported to EARS-Net 1 = low blood culture test utilisation rate/1000 patient days (first quartile) 2 = fair to high blood culture utilisation rate/1000 patient days (upper three quartiles) 212 Addendum 4 Imputation methodology applied for each antibiotic resistance-bacterium combination in each country for the redistribution of cases reported to EARS-Net with unknown age and/or sex cases 3GCREC CREC ColREC 3GCRKP CRKP ColRKP MDRACI CRACI ColRACI MDRPA CRPA ColRPA MRSA VRE PRSP PMRSP Austria                 Belgium                 Bulgaria                 Cyprus                 Czech Republic                 Germany                 Denmark                 Estonia                 Greece               NA NA Spain                 Finland                 France                 Croatia                 Hungary                 Ireland                 Iceland                 Italy                 Lithuania                 Luxembourg                 Latvia                 Malta                 Netherlands                 Norway                 Poland                 Portugal                 Romania                 Sweden                 Slovenia                 Slovakia                 United Kingdom                    Greece did not report data on S. pneumoniae isolates to EARS-Net in 2015 Less than 40% of reported cases with unknown age and/or sex: redistribution of unknown cases based on imputation from the country-specific known cases for the same antibiotic resistance-bacterium combination More than 40% of reported data with unknown age and/or sex: redistribution of unknown cases based on imputation from EU/EEA cumulative known cases for the same antibiotic resistance-bacterium combination No unknown cases reported 213 Burden of antimicrobial resistance GATHER checklist and further analysis on MRSA and attribution as healthcare-associated infections Written by Alessandro Cassini with contributions from Carl Suetens, Liselotte Diaz Högberg, Diamantis Plachouras, and Dominique Monnet 214 Contents List of abbreviations .............................................................................................. 215 1. Estimation of proportion of infections due to antimicrobial resistant organisms that are healthcare-associated ....................................................... 216 2. Further analysis on MRSA trends between 2007 and 2015 ................... 218 3. GATHER checklist ............................................................................................. 220 215 List of abbreviations 3GCREC third-generation cephalosporin-resistant E. coli 3GCRKP third-generation cephalosporin-resistant K. pneumoniae AMR antimicrobial resistance BSI bloodstream infection CAI Community-associated infections CI confidence interval ColRACI colistin-resistant Acinetobacter spp. ColREC colistin-resistant E. coli ColRKP colistin-resistant K. pneumoniae ColRPA colistin-resistant P. aeruginosa CRACI carbapenem-resistant Acinetobacter spp. CREC carbapenem-resistant E. coli CRKP carbapenem-resistant K. pneumoniae CRPA carbapenem-resistant P. aeruginosa CSF cerebral spine fluid DALY disability-adjusted life years EARS-Net European Antimicrobial Resistance Surveillance Network EEA European Economic Area EU European Union HAI healthcare-associated infection LOS length of stay MDR multidrug-resistant MDRACI multidrug-resistant Acinetobacter spp MDRPA multidrug-resistant P. aeruginosa MRSA meticillin-resistant Staphylococcus aureus MS Member State OECD Organisation for Economic Co-operation and Development OTH other infection site including digestive tract infections, skin and soft tissue infections (SSTI), eye, ear, nose or mouth infections, bone and joint infections, cardiovascular infections, reproductive tract infections and other less frequent infections PMRSP penicillin- and macrolide-resistant S. pneumoniae PPS point prevalence survey of healthcare-associated infections and antimicrobial use in acute care hospitals PRSP penicillin-resistant S. pneumoniae; RESP respiratory infections (including pneumonia, and low respiratory tract infection) S-BSI secondary BSI SP specified pathogens SPDAR specified pathogens with defined antimicrobial resistance SSI surgical site infection UTI urinary tract infection VRE vancomycin-resistant enterococci 216 Estimation of proportion of infections due to antimicrobial resistant organisms that are healthcare-associated All S. pneumoniae (penicillin-resistant, combined macrolide- and penicillin-resistant) were assumed to be 100% community-associated infections (CAIs), while the following EARS- Net pathogens were assumed to be 100% HAIs: • All infections resistant to carbapenems and/or colistin; • Acinetobacter spp.; • Pseudomonas aeruginosa; • Enterococcus faecalis and E. faecium. We estimated the proportion of HAIs and CAIs for the following infections due to antimicrobial resistant organisms: • Third-generation cephalosporin-resistant Klebsiella pneumoniae and Escherichia coli (excluding those resistant to colistin and/or carbapenem); • Meticillin-resistant Staphylococcus aureus. Information from EARS-Net was initially used to split HAIs from CAIs. EARS-Net information on date of hospital admission is available for a minority of cases, varying for each SP and across countries. In 2015 the proportion of all EARS-Net cases with information on date of hospitalisation was around 23%. Information on the time of admission (hour: minute) is not available. Therefore, for each group of infections due to antimicrobial resistant organisms, the EU/EEA cumulative number of cases notified to EARS-Net with information on date of hospitalisation was used to estimate the proportion of HAIs and CAIs. HAI was defined as patient with positive isolate on day 3 or more, based on date of hospital admission. CAI was defined as a patient with a positive isolate before day 3 of admission. However, as EARS-Net does not provide information on previous history of hospitalisation (e.g. readmission and patient transfer) the number is likely to underestimate the true proportion of HAIs. Therefore, for each specific pathogen/resistance combination, the resulting HAI/CAI proportion was further adjusted by applying the PPS percentage of HAIs present on hospital admission (assuming that a certain percentage of HAIs with recent discharge from a hospital [within 48 hours] was misclassified as CAI in EARS-Net). Therefore, considering that HAIEARS-Net = HAIcorrected – x% * HAIcorrected we used the following formula: HAIcorrected = HAIEARS-Net / (1 – x) With x being the percentage of HAIs present on hospital admission from the PPS database. The resulting HAI proportions were: • Third-generation cephalosporin-resistant Klebsiella pneumoniae (excluding those resistant to colistin and/or carbapenem): o 68% (66-70%) were considered HAIs • Third-generation cephalosporin-resistant Escherichia coli (excluding those resistant to colistin and/or carbapenem): o 43% (41-44%) were considered HAIs • Meticillin-resistant Staphylococcus aureus: o 68% (66-70%) were considered HAIs 217 Our estimation of the proportion of infections with antibiotic-resistant bacteria that were considered HAIs or CAIs was inherently limited by our a priori classification of infections caused by several bacterial species or any isolate resistant to colistin or to carbapenem as 100% HAI, given the limited availability and quality of the data on the likely individual place of acquisition of the infections reported to EARS-Net. This over-simplification has introduced a misclassification bias towards overestimating the HAI fraction of total burden of disease. Moreover, the data from EARS-Net do not distinguish between CAI and community onset infections. If not adjusted for, this might cause an underestimation of the true proportion of HAIs, as re-admissions with a HAI might be misclassified as CAI. We used the PPS percentage of HAIs present on hospital admission for each specific pathogen/resistance combination to adjust the number of CAIs reported from EARS-Net, hence limiting the impact of CAI misclassification. 218 Further analysis on MRSA trends between 2007 and 2015 As part of this study, the methodology developed to estimate the burden of AMR in 2015 was used with 2007 EARS-Net data in order to compare the epidemiological situation and trends across time. From 2007 to 2015, the proportion of Staphylococcus aureus isolates that were resistant to meticillin in the EU/EEA decreased form 26.6% to 16.8%. the 2007 population-weighted EU/EEA mean percentage was determined by applying population-based weights to each country’s data before calculating the arithmetic mean for all reporting countries. Country weightings were used to adjust for imbalances in reporting propensity and population coverage, as the total number of reported isolates by country in most cases does not reflect the population size. The weighting applied to each national data point represented the proportion of the country’s population out of the total population of all countries included in the calculation. Annual population data were retrieved from the Eurostat online database However, in our study we found that between 2007 and 2015 the incidence of MRSA increased by 23% (6-41%). In order to partly explore the reasons behind this apparent discrepancy, we analysed the age-specific incidence in 2007 and 2015, see Figure 1. Figure 1: age-group specific incidence rates of MRSA in 2007 and 2015. Median and 95% uncertainty intervals. From Figure 1 it seems that the increase was experiences mainly in infants (and children under 4 years old) and in the elderly population (starting from those over 55 years old). A number of reasons might explain the observed pattern: • Increase of participating laboratories reporting EARS-Net and consequent country coverage; • Increase in incidence of S. aureus 219 • Demographic increase in the elderly – ageing of the population which are more vulnerable and at higher chance of developing diseases, hence increasing the number of those at risk; • Improvement of the neonatal services, increasing the survival of at-risk infants, hence increasing a vulnerable population at risk for infections; The increase of MRSA incidence was also described in other studies: 1. Sarvikivi E, Ollgren J, Lyytikäinen O. Trends and outcome of healthcare-associated and community-onset bloodstream infections due to Staphylococcus aureus in Finland 2004-2015. European Scientific Conference on Applied Infectious Disease Epidemiology; 2017; Stockholm. 2. Swedres-Svarm 2016. Consumption of antibiotics and occurrence of resistance in Sweden. Solna/Uppsala ISSN1650-6332. 220 GATHER checklist Checklist of information that should be included in new reports of global health estimates Item # Checklist item Reported in manuscript and/or appendixes Objectives and funding 1 Define the indicator(s), populations (including age, sex, and geographic entities), and time period(s) for which estimates were made. Information in the Methods section under “Study design and outcome measure” (indicator) and under “Study population and estimation of incidence” (population including age, sex, geography and time period) 2 List the funding sources for the work. Statement available in the manuscript (“No specific funding was allocated for this study, which was conducted as part of routine work of ECDC and participating institutions.”) Data Inputs For all data inputs from multiple sources that are synthesized as part of the study: 3 Describe how the data were identified and how the data were accessed. Information available in the Methods section 4 Specify the inclusion and exclusion criteria. Identify all ad-hoc exclusions. Information available in the Methods section 5 Provide information on all included data sources and their main characteristics. For each data source used, report reference information or contact name/institution, population represented, data collection method, year(s) of data collection, sex and age range, diagnostic criteria or measurement method, and sample size, as relevant. Information available in the Methods section. Limitations related to data source and quality are available at the end of the Discussion section. 6 Identify and describe any categories of input data that have potentially important biases (e.g., based on characteristics listed in item 5). Information available in the Methods section. Limitations related to data source and quality are available at the end of the Discussion section. For data inputs that contribute to the analysis but were not synthesized as part of the study: 221 7 Describe and give sources for any other data inputs. Information available in the Methods section. Limitations related to data source and quality are available at the end of the Discussion section. For all data inputs: 8 Provide all data inputs in a file format from which data can be efficiently extracted (e.g., a spreadsheet rather than a PDF), including all relevant meta-data listed in item 5. For any data inputs that cannot be shared because of ethical or legal reasons, such as third-party ownership, provide a contact name or the name of the institution that retains the right to the data. Information available in the Methods section and in Supplementary appendixes. Case-based data is not shared for ethical reasons but can be requested to country experts (“Burden of AMR Collaborative Group”) Data analysis 9 Provide a conceptual overview of the data analysis method. A diagram may be helpful. Information available in the Methods section and in Supplementary appendixes. 10 Provide a detailed description of all steps of the analysis, including mathematical formulae. This description should cover, as relevant, data cleaning, data pre- processing, data adjustments and weighting of data sources, and mathematical or statistical model(s). Information available in the Methods section and in Supplementary appendixes. 11 Describe how candidate models were evaluated and how the final model(s) were selected. Information available in the Methods section and in Supplementary appendixes. 12 Provide the results of an evaluation of model performance, if done, as well as the results of any relevant sensitivity analysis. Information available in the Methods section and in Supplementary appendixes. 13 Describe methods for calculating uncertainty of the estimates. State which sources of uncertainty were, and were not, accounted for in the uncertainty analysis. Information available in the Methods section and in Supplementary appendixes. Limitations related to data source and quality are available at the end of the Discussion section. 14 State how analytic or statistical source code used to generate estimates can be accessed. Information available in the Methods section and in Supplementary appendixes. Results and Discussion 15 Provide published estimates in a file format from which data can be efficiently extracted. Information available in the Results and Discussion sections, and in Supplementary appendixes. 16 Report a quantitative measure of the uncertainty of the estimates (e.g. uncertainty intervals). Information available in the Results and Discussion sections, and in Supplementary appendixes. 17 Interpret results in light of existing evidence. If updating a previous set of estimates, describe the reasons for changes in estimates. Information available in the Discussion section and in Supplementary appendixes. 222 18 Discuss limitations of the estimates. Include a discussion of any modelling assumptions or data limitations that affect interpretation of the estimates. Information available in the Discussion section and in Supplementary appendixes. 223 Burden of antimicrobial resistance Country specific results Alessandro Cassini 224 Burden of antimicrobial resistance Country specific results Alessandro Cassini 17,706.86 20,562.69 23,408.62 2.5 % uncertainty Median 97.5% uncertainty 3GCREC third-generation cephalosporin-resistant E. coli 3GCRKP third-generation cephalosporin-resistant K. pneumoniae AMR antimicrobial resistance BSI bloodstream infection CAI Community-associated infections CI confidence interval ColRACI colistin-resistant Acinetobacter spp. ColREC colistin-resistant E. coli ColRKP colistin-resistant K. pneumoniae ColRPA colistin-resistant P. aeruginosa CRACI carbapenem-resistant Acinetobacter spp. CREC carbapenem-resistant E. coli CRKP carbapenem-resistant K. pneumoniae CRPA carbapenem-resistant P. aeruginosa CSF cerebral spine fluid DALY disability-adjusted life years EARS-Net European Antimicrobial Resistance Surveillance Network EEA European Economic Area EU European Union HAI healthcare-associated infection LOS length of stay MDR multidrug-resistant MDRACI multidrug-resistant Acinetobacter spp MDRPA multidrug-resistant P. aeruginosa MRSA meticillin-resistant Staphylococcus aureus MS Member State OECD Organisation for Economic Co-operation and Development OTH other infection site including digestive tract infections, skin and soft tissue infections (SSTI), eye, ear, nose or mouth infections, bone and joint infections, cardiovascular infections, reproductive tract infections and other less frequent infections PMRSP penicillin- and macrolide-resistant S. pneumoniae PPS point prevalence survey of healthcare-associated infections and antimicrobial use in acute care hospitals PRSP penicillin-resistant S. pneumoniae ; RESP respiratory infections (including pneumonia, and low respiratory tract infection) S-BSI secondary BSI SP specified pathogens SPDAR specified pathogens with defined antimicrobial resistance SSI surgical site infection UTI urinary tract infection VRE vancomycin-resistant enterococci Infection Colistin resistant Acinetobacter spp. 457.22 524.78 596.79 2,235.67 2,788.66 3,394.41 2,720.88 3,314.19 3,976.79 7.65 9.07 10.58 0.09 0.10 0.12 0.43 0.54 0.66 0.53 0.64 0.77 926.04 1,084.65 1,246.33 0.18 0.21 0.24 73.94 93.54 114.30 0.01 0.02 0.02 Carbapenem resistant Acinetobacter spp. (excluding those resistant to colistin) 10,137.61 11,356.05 12,639.81 51,131.87 60,714.17 71,088.35 61,885.46 72,062.11 83,259.70 6.93 7.86 8.87 1.97 2.21 2.46 9.95 11.81 13.83 12.04 14.02 16.20 24,063.67 27,342.65 30,793.69 4.68 5.32 5.99 1,947.02 2,362.70 2,809.51 0.38 0.46 0.55 Aminoglycosides and fluoroquinolones resistant Acinetobacter spp. (excluding those resistant to colistin and/or carbapenem) 665.79 747.07 831.99 3,235.13 3,912.01 4,654.25 3,926.24 4,663.60 5,459.70 5.93 6.90 7.89 0.13 0.15 0.16 0.63 0.76 0.91 0.76 0.91 1.06 1,775.87 2,012.55 2,251.84 0.35 0.39 0.44 140.54 172.08 205.62 0.03 0.03 0.04 Vancomycin resistant Enterococci (E. faecalis and E. faecium ) 2,297.49 2,699.67 3,215.58 21,742.25 25,509.67 30,074.34 24,033.96 28,223.26 33,244.92 6.18 6.70 7.33 0.45 0.53 0.63 4.23 4.96 5.85 4.68 5.49 6.47 13,205.65 16,145.93 19,333.86 2.57 3.14 3.76 891.10 1,080.55 1,291.67 0.17 0.21 0.25 Colistin resistant Escherichia coli 643.73 731.67 825.34 10,744.20 12,473.95 14,421.54 11,435.27 13,208.91 15,175.06 12.61 14.38 16.54 0.13 0.14 0.16 2.09 2.43 2.81 2.22 2.57 2.95 6,107.04 7,156.05 8,241.41 1.19 1.39 1.60 518.08 621.46 751.38 0.10 0.12 0.15 Carbapenem resistant Escherichia coli (excluding those resistant to colistin) 306.77 352.04 401.44 3,187.85 3,754.08 4,353.65 3,519.05 4,101.10 4,741.91 10.84 12.44 14.09 0.06 0.07 0.08 0.62 0.73 0.85 0.68 0.80 0.92 2,268.97 2,618.97 2,960.52 0.44 0.51 0.58 118.70 141.38 165.33 0.02 0.03 0.03 Third-generation cephalosporin resistant Escherichia coli (excluding those resistant to colistin and/or carbapenem) 24,348.48 27,655.43 31,161.25 143,743.01 163,372.77 185,130.96 168,565.98 191,127.06 214,981.67 4.70 5.14 5.64 4.74 5.38 6.06 27.97 31.78 36.02 32.79 37.18 41.83 255,376.87 297,415.94 341,063.79 49.68 57.86 66.35 7,786.52 9,065.55 10,607.13 1.51 1.76 2.06 Colistin resistant Klebsiella pneumoniae 2,041.86 2,364.62 2,716.36 35,076.83 41,708.08 48,711.50 36,976.93 44,035.45 51,345.52 15.68 17.93 20.20 0.40 0.46 0.53 6.82 8.11 9.48 7.19 8.57 9.99 6,223.13 7,450.28 8,714.97 1.21 1.45 1.70 1,362.46 1,634.56 1,922.23 0.27 0.32 0.37 Carbapenem resistant Klebsiella pneumoniae (excluding those resistant to colistin) 4,415.50 5,048.95 5,775.19 46,171.17 53,985.08 62,533.97 50,712.17 58,992.35 68,041.54 10.26 11.68 13.05 0.86 0.98 1.12 8.98 10.50 12.17 9.87 11.48 13.24 13,473.30 15,946.79 18,477.96 2.62 3.10 3.59 1,794.85 2,118.08 2,472.64 0.35 0.41 0.48 Third-generation cephalosporin resistant Klebsiella pneumoniae (excluding those resistant to colistin and/or carbapenem) 18,126.25 20,021.83 21,953.08 88,224.57 95,523.38 103,207.93 106,722.71 115,546.29 124,660.91 6.59 6.97 7.35 3.53 3.90 4.27 17.16 18.58 20.08 20.76 22.48 24.25 61,458.60 68,588.12 76,067.65 11.96 13.34 14.80 3,370.17 3,686.52 4,031.20 0.66 0.72 0.78 Colistin resistant Pseudomonas aeruginosa 414.44 496.03 585.54 1,930.83 2,510.29 3,157.62 2,373.82 3,007.09 3,706.76 8.69 10.67 12.84 0.08 0.10 0.11 0.38 0.49 0.61 0.46 0.59 0.72 1,043.43 1,261.88 1,475.72 0.20 0.25 0.29 65.52 84.47 107.50 0.01 0.02 0.02 Carbapenem resistant Pseudomonas aeruginosa (excluding those resistant to colistin) 20,316.09 23,189.72 26,234.73 96,716.06 116,604.32 139,420.87 118,131.39 139,831.71 164,327.31 8.64 10.02 11.29 3.95 4.51 5.10 18.82 22.69 27.12 22.98 27.20 31.97 53,209.86 61,892.13 70,983.70 10.35 12.04 13.81 3,397.79 4,155.29 5,087.37 0.66 0.81 0.99 Pseudomonas aeruginosa resistant to three or more antimicrobial groups (excluding those resistant to colistin and/or carbapenem) 2,449.52 2,815.97 3,249.53 10,669.81 13,319.44 16,346.41 13,381.34 16,141.82 19,304.91 6.68 7.92 9.16 0.48 0.55 0.63 2.08 2.59 3.18 2.60 3.14 3.76 7,735.67 9,028.27 10,425.40 1.50 1.76 2.03 456.30 572.31 703.19 0.09 0.11 0.14 Methicillin resistant Staphylococcus aureus 25,907.91 28,831.54 31,947.81 126,929.32 138,891.52 151,637.29 153,098.49 167,766.53 182,808.23 5.47 5.81 6.14 5.04 5.61 6.22 24.69 27.02 29.50 29.79 32.64 35.57 131,756.82 148,727.41 166,361.33 25.63 28.94 32.37 6,307.61 7,049.41 7,863.35 1.23 1.37 1.53 Penicillin and macrolides resistant Streptococcus pneumoniae (excluding those only resistant to penicillin) 1,097.16 1,261.59 1,509.49 2,957.32 3,341.28 3,900.33 4,077.11 4,601.09 5,374.64 8.44 9.05 9.79 0.21 0.25 0.29 0.58 0.65 0.76 0.79 0.90 1.05 1,942.77 2,181.52 2,448.96 0.38 0.42 0.48 89.50 100.45 112.65 0.02 0.02 0.02 Penicillin tesistant Streptococcus pneumoniae (excluding those resistant to macrolides) 1,651.03 1,856.81 2,104.56 5,581.19 6,057.78 6,617.21 7,276.05 7,918.61 8,658.90 8.78 9.20 9.67 0.32 0.36 0.41 1.09 1.18 1.29 1.42 1.54 1.68 2,580.71 2,836.19 3,118.64 0.50 0.55 0.61 159.83 171.84 184.92 0.03 0.03 0.04 Total 115,276.86 129,953.77 145,748.47 650,277.10 744,466.48 848,650.63 768,836.86 874,541.15 989,068.49 22.43 25.28 28.36 126.51 144.84 165.11 149.58 170.14 192.43 583,148.39 671,689.34 763,965.77 113.45 130.68 148.63 28,479.94 33,110.20 38,429.98 5.54 6.44 7.48 Model EU + EEA - Acinetobacter spp. CRACI BSI - model 36 5,839.88 6,461.52 7,126.11 41,501.12 49,674.89 58,656.88 47,930.71 56,135.57 65,351.08 5.20 6.01 6.89 1.14 1.26 1.39 8.07 9.66 11.41 9.33 10.92 12.71 8,599.72 9,339.76 10,191.59 1.67 1.82 1.98 1,563.08 1,913.83 2,293.42 0.30 0.37 0.45 EU + EEA - Acinetobacter spp. CRACI OTH - model 40 0.93 1.33 1.76 0.00 0.00 0.00 0.93 1.33 1.76 3.09E-03 3.76E-03 4.42E-03 1.81E-04 2.59E-04 3.42E-04 0.00 0.00 0.00 1.81E-04 2.59E-04 3.42E-04 269.13 356.11 449.34 0.05 0.07 0.09 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Acinetobacter spp. CRACI RESP - model 37 4,285.19 4,877.75 5,492.01 8,391.03 9,527.81 10,635.89 12,701.86 14,398.18 16,089.25 1.33 1.41 1.50 0.83 0.95 1.07 1.63 1.85 2.07 2.47 2.80 3.13 8,972.57 10,216.67 11,500.88 1.75 1.99 2.24 318.09 367.52 417.51 0.06 0.07 0.08 EU + EEA - Acinetobacter spp. CRACI SSI - model 39 5.49 7.48 9.79 1,239.73 1,511.48 1,795.58 1,245.84 1,519.07 1,807.47 0.40 0.43 0.47 1.07E-03 1.46E-03 1.90E-03 0.24 0.29 0.35 0.24 0.30 0.35 2,954.69 3,507.28 4,053.70 0.57 0.68 0.79 65.85 81.34 98.58 0.01 0.02 0.02 EU + EEA - Acinetobacter spp. CRACI UTI - model 38 6.12 7.97 10.14 0.00 0.00 0.00 6.12 7.97 10.14 1.68E-03 2.04E-03 2.43E-03 1.19E-03 1.55E-03 1.97E-03 0.00 0.00 0.00 1.19E-03 1.55E-03 1.97E-03 3,267.57 3,922.83 4,598.18 0.64 0.76 0.89 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Acinetobacter spp. ColRACI BSI - model 41 261.93 297.84 334.48 1,810.82 2,289.23 2,815.52 2,103.40 2,587.00 3,141.13 5.73 6.99 8.33 0.05 0.06 0.07 0.35 0.45 0.55 0.41 0.50 0.61 335.84 371.22 408.69 0.07 0.07 0.08 59.37 75.99 93.73 0.01 0.01 0.02 EU + EEA - Acinetobacter spp. ColRACI OTH - model 45 0.04 0.05 0.07 0.00 0.00 0.00 0.04 0.05 0.07 2.95E-03 3.73E-03 4.57E-03 6.90E-06 1.00E-05 1.43E-05 0.00 0.00 0.00 6.90E-06 1.00E-05 1.43E-05 9.94 13.80 18.56 1.93E-03 2.69E-03 3.61E-03 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Acinetobacter spp. ColRACI RESP - model 42 194.82 226.28 261.43 377.46 440.19 506.99 569.61 667.29 763.04 1.51 1.64 1.78 0.04 0.04 0.05 0.07 0.09 0.10 0.11 0.13 0.15 346.36 407.84 466.90 0.07 0.08 0.09 12.43 14.66 16.95 2.42E-03 2.85E-03 3.30E-03 EU + EEA - Acinetobacter spp. ColRACI SSI - model 44 0.20 0.29 0.40 47.39 59.24 71.90 47.61 59.54 72.15 0.40 0.43 0.47 3.94E-05 5.71E-05 7.78E-05 9.22E-03 0.01 0.01 9.26E-03 0.01 0.01 110.86 137.30 164.28 0.02 0.03 0.03 2.13 2.89 3.61 4.15E-04 5.62E-04 7.03E-04 EU + EEA - Acinetobacter spp. ColRACI UTI - model 43 0.23 0.31 0.41 0.00 0.00 0.00 0.23 0.31 0.41 1.61E-03 2.04E-03 2.47E-03 4.44E-05 6.11E-05 7.98E-05 0.00 0.00 0.00 4.44E-05 6.11E-05 7.98E-05 123.04 154.49 187.90 0.02 0.03 0.04 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Acinetobacter spp. MDRACI BSI - model 31 386.03 425.16 466.91 2,598.52 3,181.85 3,829.37 3,004.60 3,610.57 4,275.70 4.38 5.22 6.08 0.08 0.08 0.09 0.51 0.62 0.75 0.58 0.70 0.83 637.88 692.68 746.73 0.12 0.13 0.15 111.53 138.44 167.17 0.02 0.03 0.03 EU + EEA - Acinetobacter spp. MDRACI OTH - model 35 0.07 0.10 0.13 0.00 0.00 0.00 0.07 0.10 0.13 3.06E-03 3.75E-03 4.52E-03 1.29E-05 1.85E-05 2.46E-05 0.00 0.00 0.00 1.29E-05 1.85E-05 2.46E-05 19.47 25.45 32.22 3.79E-03 4.95E-03 6.27E-03 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Acinetobacter spp. MDRACI RESP - model 32 278.86 320.69 363.50 549.53 624.10 698.62 833.13 945.66 1,056.06 1.16 1.25 1.35 0.05 0.06 0.07 0.11 0.12 0.14 0.16 0.18 0.21 665.28 754.20 838.47 0.13 0.15 0.16 23.79 27.11 30.56 4.63E-03 5.27E-03 5.95E-03 EU + EEA - Acinetobacter spp. MDRACI SSI - model 34 0.40 0.54 0.72 87.09 106.07 126.25 88.00 106.69 127.09 0.39 0.42 0.45 7.71E-05 1.06E-04 1.40E-04 0.02 0.02 0.02 0.02 0.02 0.02 214.83 254.66 298.56 0.04 0.05 0.06 5.22 6.53 7.88 1.02E-03 1.27E-03 1.53E-03 EU + EEA - Acinetobacter spp. MDRACI UTI - model 33 0.44 0.58 0.74 0.00 0.00 0.00 0.44 0.58 0.74 1.67E-03 2.04E-03 2.46E-03 8.64E-05 1.13E-04 1.43E-04 0.00 0.00 0.00 8.64E-05 1.13E-04 1.43E-04 238.41 285.55 335.86 0.05 0.06 0.07 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Enterococcus faecalis and E. faecium VRE BSI - model 66 2,280.69 2,676.63 3,184.67 19,760.50 22,990.83 26,952.06 22,036.80 25,679.74 30,092.01 5.76 6.24 6.83 0.44 0.52 0.62 3.84 4.47 5.24 4.29 5.00 5.85 3,433.94 4,109.07 4,866.95 0.67 0.80 0.95 783.29 938.44 1,110.65 0.15 0.18 0.22 EU + EEA - Enterococcus faecalis and E. faecium VRE OTH - model 70 5.39 7.11 9.39 0.00 0.00 0.00 5.39 7.11 9.39 1.34E-03 1.64E-03 2.02E-03 1.05E-03 1.38E-03 1.83E-03 0.00 0.00 0.00 1.05E-03 1.38E-03 1.83E-03 3,564.88 4,350.09 5,195.14 0.69 0.85 1.01 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Enterococcus faecalis and E. faecium VRE RESP - model 67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Enterococcus faecalis and E. faecium VRE SSI - model 69 8.46 12.06 16.39 1,981.76 2,518.85 3,122.27 1,988.83 2,532.54 3,138.39 0.41 0.45 0.49 1.65E-03 2.35E-03 3.19E-03 0.39 0.49 0.61 0.39 0.49 0.61 4,558.85 5,607.00 6,762.02 0.89 1.09 1.32 107.81 142.11 181.02 0.02 0.03 0.04 EU + EEA - Enterococcus faecalis and E. faecium VRE UTI - model 68 2.94 3.88 5.13 0.00 0.00 0.00 2.94 3.88 5.13 1.52E-03 1.86E-03 2.23E-03 5.73E-04 7.54E-04 9.99E-04 0.00 0.00 0.00 5.73E-04 7.54E-04 9.99E-04 1,647.97 2,079.77 2,509.76 0.32 0.40 0.49 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Escherichia coli 3GCREC BSI - model 16 18,585.72 20,672.94 22,851.09 118,387.30 133,097.17 149,526.01 137,533.75 153,909.13 171,249.65 3.41 3.72 4.04 3.62 4.02 4.45 23.03 25.89 29.09 26.76 29.94 33.32 37,228.68 41,377.64 46,011.92 7.24 8.05 8.95 6,209.48 7,121.68 8,280.67 1.21 1.39 1.61 EU + EEA - Escherichia coli 3GCREC OTH - model 20 33.93 46.62 62.17 0.00 0.00 0.00 33.93 46.62 62.17 2.64E-03 3.36E-03 4.06E-03 6.60E-03 9.07E-03 0.01 0.00 0.00 0.00 6.60E-03 9.07E-03 0.01 11,110.58 14,027.11 17,124.26 2.16 2.73 3.33 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Escherichia coli 3GCREC RESP - model 17 5,389.03 6,492.06 7,669.89 10,555.71 12,559.28 14,823.00 15,864.13 19,005.76 22,379.93 0.91 1.01 1.16 1.05 1.26 1.49 2.05 2.44 2.88 3.09 3.70 4.35 15,131.89 18,784.60 22,459.11 2.94 3.65 4.37 548.65 673.87 817.49 0.11 0.13 0.16 EU + EEA - Escherichia coli 3GCREC SSI - model 19 69.64 93.85 126.82 14,800.00 17,716.31 20,781.95 14,864.02 17,815.60 20,838.64 0.37 0.40 0.43 0.01 0.02 0.02 2.88 3.45 4.04 2.89 3.47 4.05 37,482.37 44,320.65 51,360.92 7.29 8.62 9.99 1,028.38 1,270.01 1,508.97 0.20 0.25 0.29 EU + EEA - Escherichia coli 3GCREC UTI - model 18 270.15 349.95 451.28 0.00 0.00 0.00 270.15 349.95 451.28 1.59E-03 1.96E-03 2.39E-03 0.05 0.07 0.09 0.00 0.00 0.00 0.05 0.07 0.09 154,423.34 178,905.95 204,107.58 30.04 34.81 39.71 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Escherichia coli CREC BSI - model 21 228.03 256.99 288.23 2,890.06 3,397.54 3,936.56 3,142.82 3,649.62 4,213.92 9.13 10.51 11.91 0.04 0.05 0.06 0.56 0.66 0.77 0.61 0.71 0.82 316.85 348.29 378.97 0.06 0.07 0.07 104.82 124.53 145.32 0.02 0.02 0.03 EU + EEA - Escherichia coli CREC OTH - model 25 0.53 0.70 0.93 0.00 0.00 0.00 0.53 0.70 0.93 2.79E-03 3.50E-03 4.41E-03 1.03E-04 1.36E-04 1.81E-04 0.00 0.00 0.00 1.03E-04 1.36E-04 1.81E-04 168.22 200.37 234.66 0.03 0.04 0.05 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Escherichia coli CREC RESP - model 22 75.19 90.40 107.18 144.14 175.58 208.40 218.81 265.94 313.80 1.29 1.48 1.71 0.01 0.02 0.02 0.03 0.03 0.04 0.04 0.05 0.06 147.33 179.21 212.18 0.03 0.03 0.04 5.33 6.44 7.66 1.04E-03 1.25E-03 1.49E-03 EU + EEA - Escherichia coli CREC SSI - model 24 0.65 0.88 1.16 153.65 180.96 208.70 154.52 181.77 209.32 0.41 0.44 0.47 1.27E-04 1.71E-04 2.26E-04 0.03 0.04 0.04 0.03 0.04 0.04 350.63 414.14 477.36 0.07 0.08 0.09 8.55 10.42 12.35 1.66E-03 2.03E-03 2.40E-03 EU + EEA - Escherichia coli CREC UTI - model 23 2.37 3.07 3.94 0.00 0.00 0.00 2.37 3.07 3.94 1.67E-03 2.10E-03 2.55E-03 4.61E-04 5.98E-04 7.66E-04 0.00 0.00 0.00 4.61E-04 5.98E-04 7.66E-04 1,285.93 1,476.96 1,657.35 0.25 0.29 0.32 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Escherichia coli ColREC BSI - model 26 478.65 532.45 593.05 10,038.39 11,639.35 13,457.27 10,563.17 12,174.61 13,981.34 11.24 12.84 14.80 0.09 0.10 0.12 1.95 2.26 2.62 2.06 2.37 2.72 851.97 949.39 1,054.03 0.17 0.18 0.21 476.71 570.53 689.68 0.09 0.11 0.13 EU + EEA - Escherichia coli ColREC OTH - model 30 1.39 1.95 2.74 0.00 0.00 0.00 1.39 1.95 2.74 2.69E-03 3.51E-03 4.61E-03 2.71E-04 3.79E-04 5.33E-04 0.00 0.00 0.00 2.71E-04 3.79E-04 5.33E-04 451.69 552.64 669.78 0.09 0.11 0.13 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Escherichia coli ColREC RESP - model 27 155.64 186.51 215.51 302.23 361.29 415.13 459.48 548.14 627.34 0.98 1.12 1.28 0.03 0.04 0.04 0.06 0.07 0.08 0.09 0.11 0.12 395.23 487.71 586.76 0.08 0.09 0.11 13.98 17.60 21.38 2.72E-03 3.42E-03 4.16E-03 EU + EEA - Escherichia coli ColREC SSI - model 29 1.73 2.39 3.29 403.57 473.31 549.15 404.91 475.84 552.91 0.39 0.42 0.45 3.37E-04 4.65E-04 6.40E-04 0.08 0.09 0.11 0.08 0.09 0.11 967.84 1,138.67 1,328.46 0.19 0.22 0.26 27.39 33.34 40.33 5.33E-03 6.49E-03 7.85E-03 EU + EEA - Escherichia coli ColREC UTI - model 28 6.32 8.37 10.74 0.00 0.00 0.00 6.32 8.37 10.74 1.63E-03 2.09E-03 2.61E-03 1.23E-03 1.63E-03 2.09E-03 0.00 0.00 0.00 1.23E-03 1.63E-03 2.09E-03 3,440.31 4,027.64 4,602.38 0.67 0.78 0.90 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Klebsiella pneumoniae 3GCRKP BSI - model 1 11,361.18 12,394.50 13,452.19 72,431.36 77,722.21 83,340.90 84,112.69 90,092.50 96,381.25 4.83 5.08 5.34 2.21 2.41 2.62 14.09 15.12 16.21 16.36 17.53 18.75 16,574.99 17,739.39 19,006.58 3.22 3.45 3.70 2,735.80 2,956.27 3,205.88 0.53 0.58 0.62 EU + EEA - Klebsiella pneumoniae 3GCRKP OTH - model 5 18.84 23.83 29.87 0.00 0.00 0.00 18.84 23.83 29.87 2.77E-03 3.34E-03 4.02E-03 3.67E-03 4.64E-03 5.81E-03 0.00 0.00 0.00 3.67E-03 4.64E-03 5.81E-03 6,195.02 7,155.08 8,097.20 1.21 1.39 1.58 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Klebsiella pneumoniae 3GCRKP RESP - model 2 6,701.57 7,546.87 8,400.76 13,095.24 14,639.94 16,235.61 19,843.79 22,211.32 24,548.46 1.33 1.43 1.54 1.30 1.47 1.63 2.55 2.85 3.16 3.86 4.32 4.78 13,759.54 15,480.54 17,221.77 2.68 3.01 3.35 491.23 556.63 622.43 0.10 0.11 0.12 EU + EEA - Klebsiella pneumoniae 3GCRKP SSI - model 4 11.56 15.14 19.96 2,697.97 3,161.23 3,631.42 2,714.28 3,177.15 3,651.01 0.42 0.45 0.47 2.25E-03 2.95E-03 3.88E-03 0.52 0.62 0.71 0.53 0.62 0.71 6,166.97 7,129.19 8,083.67 1.20 1.39 1.57 143.14 173.62 202.89 0.03 0.03 0.04 EU + EEA - Klebsiella pneumoniae 3GCRKP UTI - model 3 33.11 41.49 50.31 0.00 0.00 0.00 33.11 41.49 50.31 1.63E-03 1.96E-03 2.31E-03 6.44E-03 8.07E-03 9.79E-03 0.00 0.00 0.00 6.44E-03 8.07E-03 9.79E-03 18,762.08 21,083.92 23,658.43 3.65 4.10 4.60 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Klebsiella pneumoniae CRKP BSI - model 6 3,449.19 3,872.75 4,365.28 43,729.02 50,988.85 58,934.05 47,292.27 54,820.25 63,050.45 8.60 9.84 11.00 0.67 0.75 0.85 8.51 9.92 11.47 9.20 10.67 12.27 5,029.69 5,579.32 6,245.01 0.98 1.09 1.21 1,692.19 1,989.03 2,315.29 0.33 0.39 0.45 EU + EEA - Klebsiella pneumoniae CRKP OTH - model 10 7.15 9.50 12.35 0.00 0.00 0.00 7.15 9.50 12.35 2.81E-03 3.51E-03 4.25E-03 1.39E-03 1.85E-03 2.40E-03 0.00 0.00 0.00 1.39E-03 1.85E-03 2.40E-03 2,175.49 2,724.87 3,150.61 0.42 0.53 0.61 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Klebsiella pneumoniae CRKP RESP - model 7 950.96 1,155.68 1,383.47 1,848.94 2,240.89 2,665.68 2,811.71 3,397.02 4,031.03 1.26 1.39 1.56 0.19 0.22 0.27 0.36 0.44 0.52 0.55 0.66 0.78 1,991.68 2,435.94 2,911.14 0.39 0.47 0.57 71.00 87.62 105.41 0.01 0.02 0.02 EU + EEA - Klebsiella pneumoniae CRKP SSI - model 9 2.68 3.70 4.89 593.20 755.34 934.23 595.52 758.25 938.51 0.40 0.44 0.48 5.21E-04 7.20E-04 9.51E-04 0.12 0.15 0.18 0.12 0.15 0.18 1,410.37 1,718.04 2,067.87 0.27 0.33 0.40 31.66 41.43 51.94 6.16E-03 8.06E-03 0.01 EU + EEA - Klebsiella pneumoniae CRKP UTI - model 8 5.52 7.33 9.20 0.00 0.00 0.00 5.52 7.33 9.20 1.71E-03 2.09E-03 2.50E-03 1.07E-03 1.43E-03 1.79E-03 0.00 0.00 0.00 1.07E-03 1.43E-03 1.79E-03 2,866.07 3,488.62 4,103.32 0.56 0.68 0.80 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Klebsiella pneumoniae ColRKP BSI - model 11 1,604.08 1,810.46 2,052.07 33,962.01 40,300.69 47,012.29 35,424.81 42,073.97 48,987.66 14.01 16.09 18.16 0.31 0.35 0.40 6.61 7.84 9.15 6.89 8.19 9.53 2,338.82 2,609.46 2,913.11 0.46 0.51 0.57 1,316.13 1,574.79 1,848.98 0.26 0.31 0.36 EU + EEA - Klebsiella pneumoniae ColRKP OTH - model 15 3.26 4.41 5.85 0.00 0.00 0.00 3.26 4.41 5.85 2.81E-03 3.52E-03 4.33E-03 6.34E-04 8.59E-04 1.14E-03 0.00 0.00 0.00 6.34E-04 8.59E-04 1.14E-03 1,008.28 1,264.71 1,518.48 0.20 0.25 0.30 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Klebsiella pneumoniae ColRKP RESP - model 12 430.77 544.67 651.66 846.69 1,059.98 1,264.10 1,277.06 1,604.27 1,910.26 1.27 1.40 1.55 0.08 0.11 0.13 0.16 0.21 0.25 0.25 0.31 0.37 902.44 1,144.59 1,372.14 0.18 0.22 0.27 32.43 41.14 49.39 6.31E-03 8.00E-03 9.61E-03 EU + EEA - Klebsiella pneumoniae ColRKP SSI - model 14 1.22 1.69 2.34 268.13 347.40 435.11 269.27 349.42 437.30 0.39 0.44 0.48 2.37E-04 3.30E-04 4.56E-04 0.05 0.07 0.08 0.05 0.07 0.09 649.02 802.75 976.06 0.13 0.16 0.19 13.90 18.63 23.86 2.70E-03 3.63E-03 4.64E-03 EU + EEA - Klebsiella pneumoniae ColRKP UTI - model 13 2.54 3.38 4.44 0.00 0.00 0.00 2.54 3.38 4.44 1.69E-03 2.09E-03 2.54E-03 4.93E-04 6.57E-04 8.65E-04 0.00 0.00 0.00 4.93E-04 6.57E-04 8.65E-04 1,324.57 1,628.76 1,935.19 0.26 0.32 0.38 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Pseudomonas aeruginosa CRPA BSI - model 51 5,844.74 6,500.84 7,287.13 45,552.59 55,274.57 66,218.66 52,137.77 61,723.63 73,112.51 6.15 7.19 8.14 1.14 1.26 1.42 8.86 10.75 12.88 10.14 12.01 14.22 7,809.76 8,568.92 9,596.63 1.52 1.67 1.87 1,588.89 1,946.31 2,395.54 0.31 0.38 0.47 EU + EEA - Pseudomonas aeruginosa CRPA OTH - model 55 12.46 16.13 20.62 0.00 0.00 0.00 12.46 16.13 20.62 3.03E-03 3.65E-03 4.31E-03 2.42E-03 3.14E-03 4.01E-03 0.00 0.00 0.00 2.42E-03 3.14E-03 4.01E-03 3,593.33 4,439.65 5,262.68 0.70 0.86 1.02 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Pseudomonas aeruginosa CRPA RESP - model 52 14,431.29 16,637.38 18,881.62 49,071.82 58,743.30 70,091.18 63,859.43 75,470.76 88,038.73 2.09 2.39 2.67 2.81 3.24 3.67 9.55 11.43 13.64 12.42 14.68 17.13 27,589.38 31,781.98 36,069.10 5.37 6.18 7.02 1,712.04 2,081.77 2,534.71 0.33 0.41 0.49 EU + EEA - Pseudomonas aeruginosa CRPA SSI - model 54 9.44 12.66 16.74 2,091.65 2,586.45 3,111.02 2,103.57 2,598.48 3,126.83 0.40 0.44 0.47 1.84E-03 2.46E-03 3.26E-03 0.41 0.50 0.61 0.41 0.51 0.61 4,923.99 5,957.66 7,003.61 0.96 1.16 1.36 96.86 127.22 157.12 0.02 0.02 0.03 EU + EEA - Pseudomonas aeruginosa CRPA UTI - model 53 18.15 22.71 28.61 0.00 0.00 0.00 18.15 22.71 28.61 1.71E-03 2.05E-03 2.40E-03 3.53E-03 4.42E-03 5.57E-03 0.00 0.00 0.00 3.53E-03 4.42E-03 5.57E-03 9,293.41 11,143.91 13,051.68 1.81 2.17 2.54 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Pseudomonas aeruginosa ColRPA BSI - model 56 119.66 137.94 161.31 914.78 1,185.34 1,504.30 1,041.49 1,323.02 1,635.93 6.18 7.68 9.37 0.02 0.03 0.03 0.18 0.23 0.29 0.20 0.26 0.32 151.40 172.99 196.20 0.03 0.03 0.04 30.45 39.29 50.31 5.92E-03 7.64E-03 9.79E-03 EU + EEA - Pseudomonas aeruginosa ColRPA OTH - model 60 0.24 0.33 0.45 0.00 0.00 0.00 0.24 0.33 0.45 3.01E-03 3.76E-03 4.57E-03 4.74E-05 6.49E-05 8.81E-05 0.00 0.00 0.00 4.74E-05 6.49E-05 8.81E-05 70.80 89.48 108.94 0.01 0.02 0.02 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Pseudomonas aeruginosa ColRPA RESP - model 57 294.01 357.03 422.80 972.53 1,268.63 1,583.68 1,287.83 1,626.68 1,999.75 2.08 2.52 2.95 0.06 0.07 0.08 0.19 0.25 0.31 0.25 0.32 0.39 545.94 649.51 752.39 0.11 0.13 0.15 33.15 42.57 53.87 6.45E-03 8.28E-03 0.01 EU + EEA - Pseudomonas aeruginosa ColRPA SSI - model 59 0.18 0.26 0.37 43.52 56.31 69.64 43.92 56.58 70.02 0.43 0.47 0.50 3.45E-05 5.05E-05 7.16E-05 8.47E-03 0.01 0.01 8.54E-03 0.01 0.01 96.59 121.57 146.60 0.02 0.02 0.03 1.92 2.61 3.32 3.74E-04 5.08E-04 6.46E-04 EU + EEA - Pseudomonas aeruginosa ColRPA UTI - model 58 0.34 0.46 0.61 0.00 0.00 0.00 0.34 0.46 0.61 1.62E-03 2.05E-03 2.50E-03 6.61E-05 9.03E-05 1.19E-04 0.00 0.00 0.00 6.61E-05 9.03E-05 1.19E-04 178.70 228.34 271.59 0.03 0.04 0.05 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Pseudomonas aeruginosa MDRPA BSI - model 46 694.79 787.00 893.39 4,931.01 6,157.65 7,532.02 5,725.34 6,949.49 8,341.16 4.65 5.59 6.54 0.14 0.15 0.17 0.96 1.20 1.47 1.11 1.35 1.62 1,112.08 1,248.68 1,387.51 0.22 0.24 0.27 210.45 263.24 320.68 0.04 0.05 0.06 EU + EEA - Pseudomonas aeruginosa MDRPA OTH - model 50 1.83 2.41 3.12 0.00 0.00 0.00 1.83 2.41 3.12 3.13E-03 3.74E-03 4.49E-03 3.56E-04 4.69E-04 6.07E-04 0.00 0.00 0.00 3.56E-04 4.69E-04 6.07E-04 515.66 646.55 775.73 0.10 0.13 0.15 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Pseudomonas aeruginosa MDRPA RESP - model 47 1,749.03 2,021.36 2,346.18 5,457.29 6,806.58 8,385.19 7,368.79 8,829.57 10,524.04 1.65 1.91 2.17 0.34 0.39 0.46 1.06 1.32 1.63 1.43 1.72 2.05 4,041.45 4,625.92 5,300.98 0.79 0.90 1.03 229.81 288.20 356.95 0.04 0.06 0.07 EU + EEA - Pseudomonas aeruginosa MDRPA SSI - model 49 1.35 1.87 2.52 281.51 355.21 429.19 282.86 357.02 432.30 0.37 0.41 0.45 2.62E-04 3.63E-04 4.91E-04 0.05 0.07 0.08 0.06 0.07 0.08 709.81 873.34 1,041.31 0.14 0.17 0.20 16.04 20.86 25.57 3.12E-03 4.06E-03 4.98E-03 EU + EEA - Pseudomonas aeruginosa MDRPA UTI - model 48 2.52 3.33 4.30 0.00 0.00 0.00 2.52 3.33 4.30 1.67E-03 2.04E-03 2.45E-03 4.91E-04 6.47E-04 8.37E-04 0.00 0.00 0.00 4.91E-04 6.47E-04 8.37E-04 1,356.67 1,633.79 1,919.87 0.26 0.32 0.37 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Staphylococcus aureus MRSA BSI - model 61 12,672.50 13,889.12 15,270.49 86,406.78 93,284.62 100,497.18 99,222.78 107,206.04 115,174.81 4.03 4.26 4.49 2.47 2.70 2.97 16.81 18.15 19.55 19.30 20.86 22.41 23,169.52 25,144.05 27,243.18 4.51 4.89 5.30 4,119.85 4,520.43 4,957.73 0.80 0.88 0.96 EU + EEA - Staphylococcus aureus MRSA OTH - model 65 95.76 121.75 150.83 0.00 0.00 0.00 95.76 121.75 150.83 2.67E-03 3.26E-03 3.88E-03 0.02 0.02 0.03 0.00 0.00 0.00 0.02 0.02 0.03 33,149.06 37,431.19 41,837.57 6.45 7.28 8.14 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Staphylococcus aureus MRSA RESP - model 62 13,064.24 14,720.16 16,394.84 25,533.71 28,448.38 31,710.93 38,704.84 43,173.97 47,941.89 1.05 1.13 1.21 2.54 2.86 3.19 4.97 5.53 6.17 7.53 8.40 9.33 33,803.92 38,223.85 42,991.15 6.58 7.44 8.36 1,205.20 1,373.00 1,578.92 0.23 0.27 0.31 EU + EEA - Staphylococcus aureus MRSA SSI - model 64 66.51 88.63 116.22 14,988.83 17,158.52 19,429.18 15,066.20 17,252.90 19,525.28 0.39 0.41 0.44 0.01 0.02 0.02 2.92 3.34 3.78 2.93 3.36 3.80 36,485.09 41,583.67 46,717.57 7.10 8.09 9.09 982.57 1,155.98 1,326.69 0.19 0.22 0.26 EU + EEA - Staphylococcus aureus MRSA UTI - model 63 8.91 11.88 15.42 0.00 0.00 0.00 8.91 11.88 15.42 1.50E-03 1.88E-03 2.28E-03 1.73E-03 2.31E-03 3.00E-03 0.00 0.00 0.00 1.73E-03 2.31E-03 3.00E-03 5,149.23 6,344.64 7,571.87 1.00 1.23 1.47 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Streptococcus pneumoniae PMRSP BSI - model 76 162.34 180.23 203.66 1,130.32 1,227.87 1,357.07 1,299.50 1,408.69 1,555.89 6.86 7.28 7.79 0.03 0.04 0.04 0.22 0.24 0.26 0.25 0.27 0.30 179.96 193.60 207.34 0.04 0.04 0.04 32.31 34.85 37.55 6.29E-03 6.78E-03 7.31E-03 EU + EEA - Streptococcus pneumoniae PMRSP OTH - model 80 0.26 0.33 0.40 0.00 0.00 0.00 0.26 0.33 0.40 1.58E-03 1.96E-03 2.32E-03 5.13E-05 6.38E-05 7.75E-05 0.00 0.00 0.00 5.13E-05 6.38E-05 7.75E-05 156.38 168.01 181.63 0.03 0.03 0.04 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Streptococcus pneumoniae PMRSP RESP - model 77 934.56 1,081.03 1,305.43 1,827.00 2,113.41 2,543.26 2,777.35 3,192.07 3,818.35 1.58 1.77 2.00 0.18 0.21 0.25 0.36 0.41 0.49 0.54 0.62 0.74 1,606.44 1,819.90 2,059.99 0.31 0.35 0.40 57.19 65.60 75.10 0.01 0.01 0.01 EU + EEA - Streptococcus pneumoniae PMRSP SSI - model 79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Streptococcus pneumoniae PMRSP UTI - model 78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Streptococcus pneumoniae PRSP BSI - model 71 460.51 497.71 533.82 3,235.66 3,388.30 3,535.87 3,722.93 3,884.84 4,039.47 7.01 7.28 7.58 0.09 0.10 0.10 0.63 0.66 0.69 0.72 0.76 0.79 522.74 533.68 544.14 0.10 0.10 0.11 92.52 96.08 99.42 0.02 0.02 0.02 EU + EEA - Streptococcus pneumoniae PRSP OTH - model 75 0.32 0.38 0.45 0.00 0.00 0.00 0.32 0.38 0.45 1.65E-03 1.96E-03 2.29E-03 6.23E-05 7.37E-05 8.75E-05 0.00 0.00 0.00 6.23E-05 7.37E-05 8.75E-05 181.24 193.16 207.92 0.04 0.04 0.04 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Streptococcus pneumoniae PRSP RESP - model 72 1,190.20 1,358.72 1,570.29 2,345.53 2,669.49 3,081.34 3,552.80 4,033.38 4,618.99 1.76 1.92 2.09 0.23 0.26 0.31 0.46 0.52 0.60 0.69 0.78 0.90 1,876.72 2,109.35 2,366.58 0.37 0.41 0.46 67.31 75.76 85.50 0.01 0.01 0.02 EU + EEA - Streptococcus pneumoniae PRSP SSI - model 74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 EU + EEA - Streptococcus pneumoniae PRSP UTI - model 73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total (Median & 95% UIs) 115,276.86 129,953.77 145,748.47 650,277.10 744,466.48 848,650.63 768,836.86 874,541.15 989,068.49 22.43 25.28 28.36 126.51 144.84 165.11 149.58 170.14 192.43 583,148.39 671,689.34 763,965.77 113.45 130.68 148.63 28,479.94 33,110.20 38,429.98 5.54 6.44 7.48 Total (average) Mortality per 100,000YLD YLL DALY DALY per Case YLD per 100,000 YLL per 100,000 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year 145.05 170.36 672,440.02 130.82 33,227.14 6.46 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 130,108.61 745,541.51 875,650.12 - 25.31 YLL per 100,000YLD YLL DALY DALY per Case YLD per 100,000 Infection Colistin resistant Acinetobacter spp. 0.71 1.12 1.66 2.43 6.27 10.58 3.27 7.40 12.07 3.92 6.92 9.71 0.01 0.01 0.02 0.03 0.07 0.12 0.04 0.09 0.14 1.97 3.32 4.67 0.02 0.04 0.05 0.12 0.30 0.50 0.00 0.00 0.01 Carbapenem resistant Acinetobacter spp. (excluding those resistant to colistin) 15.10 18.36 21.99 68.77 98.14 135.79 85.60 116.46 156.19 12.88 17.03 21.72 0.18 0.21 0.26 0.80 1.14 1.58 1.00 1.36 1.82 16.53 19.96 23.54 0.19 0.23 0.27 1.25 1.71 2.25 0.01 0.02 0.03 Aminoglycosides and fluoroquinolones resistant Acinetobacter spp. (excluding those resistant to colistin and/or carbapenem) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Vancomycin resistant Enterococci (E. faecalis and E. faecium ) 10.06 13.86 18.98 98.49 132.28 176.23 108.49 146.22 195.17 6.01 6.61 7.40 0.12 0.16 0.22 1.15 1.54 2.05 1.26 1.70 2.28 60.22 85.58 112.38 0.70 1.00 1.31 4.17 5.67 7.38 0.05 0.07 0.09 Colistin resistant Escherichia coli 0.15 0.25 0.39 1.94 3.80 6.32 2.11 4.05 6.64 2.24 3.68 5.02 0.00 0.00 0.00 0.02 0.04 0.07 0.02 0.05 0.08 5.15 8.76 12.32 0.06 0.10 0.14 0.39 0.76 1.26 0.00 0.01 0.01 Carbapenem resistant Escherichia coli (excluding those resistant to colistin) 0.54 0.90 1.39 5.23 10.06 16.49 5.87 10.98 17.76 6.67 9.99 13.31 0.01 0.01 0.02 0.06 0.12 0.19 0.07 0.13 0.21 5.11 8.65 12.30 0.06 0.10 0.14 0.25 0.48 0.78 0.00 0.01 0.01 Third-generation cephalosporin resistant Escherichia coli (excluding those resistant to colistin and/or carbapenem) 324.72 359.21 401.19 1,912.94 2,148.18 2,377.67 2,249.77 2,507.76 2,766.55 4.68 5.08 5.51 3.79 4.19 4.68 22.31 25.05 27.72 26.23 29.24 32.26 3,491.07 3,928.69 4,388.12 40.71 45.81 51.17 106.22 121.05 136.75 1.24 1.41 1.59 Colistin resistant Klebsiella pneumoniae 1.75 2.41 3.19 28.91 42.85 59.83 31.10 45.25 62.92 10.21 14.14 18.05 0.02 0.03 0.04 0.34 0.50 0.70 0.36 0.53 0.73 6.59 9.79 13.07 0.08 0.11 0.15 1.49 2.19 3.05 0.02 0.03 0.04 Carbapenem resistant Klebsiella pneumoniae (excluding those resistant to colistin) 4.88 6.53 8.60 48.50 69.73 93.21 54.39 76.17 101.29 7.66 10.37 12.82 0.06 0.08 0.10 0.57 0.81 1.09 0.63 0.89 1.18 16.77 22.82 29.00 0.20 0.27 0.34 2.28 3.08 3.98 0.03 0.04 0.05 Third-generation cephalosporin resistant Klebsiella pneumoniae (excluding those resistant to colistin and/or carbapenem) 86.79 95.99 106.24 425.99 460.42 494.72 514.85 556.26 598.94 6.26 6.59 6.93 1.01 1.12 1.24 4.97 5.37 5.77 6.00 6.49 6.98 312.24 347.04 382.12 3.64 4.05 4.46 17.32 18.87 20.46 0.20 0.22 0.24 Colistin resistant Pseudomonas aeruginosa 1.30 2.38 3.72 4.13 11.87 24.20 5.82 14.33 27.38 3.96 7.92 11.90 0.02 0.03 0.04 0.05 0.14 0.28 0.07 0.17 0.32 4.20 8.57 13.01 0.05 0.10 0.15 0.20 0.56 1.15 0.00 0.01 0.01 Carbapenem resistant Pseudomonas aeruginosa (excluding those resistant to colistin) 232.59 265.57 298.78 1,077.24 1,344.38 1,630.65 1,322.89 1,610.21 1,916.59 8.45 10.05 11.68 2.71 3.10 3.48 12.56 15.68 19.01 15.42 18.78 22.35 609.35 709.85 805.80 7.11 8.28 9.40 38.42 48.22 59.15 0.45 0.56 0.69 Pseudomonas aeruginosa resistant to three or more antimicrobial groups (excluding those resistant to colistin and/or carbapenem) 3.89 5.50 7.21 14.45 25.91 40.06 18.88 31.40 46.24 3.59 5.61 7.56 0.05 0.06 0.08 0.17 0.30 0.47 0.22 0.37 0.54 17.85 25.58 33.65 0.21 0.30 0.39 0.92 1.66 2.54 0.01 0.02 0.03 Methicillin resistant Staphylococcus aureus 208.98 230.38 253.15 1,049.75 1,135.65 1,215.94 1,262.98 1,365.34 1,463.25 4.74 4.97 5.19 2.44 2.69 2.95 12.24 13.24 14.18 14.73 15.92 17.06 1,273.64 1,397.96 1,525.10 14.85 16.30 17.78 62.18 67.63 72.91 0.73 0.79 0.85 Penicillin and macrolides resistant Streptococcus pneumoniae (excluding those only resistant to penicillin) 6.71 8.32 10.58 23.49 27.15 32.11 30.67 35.53 42.18 4.64 5.07 5.50 0.08 0.10 0.12 0.27 0.32 0.37 0.36 0.41 0.49 19.46 22.89 27.26 0.23 0.27 0.32 1.22 1.40 1.63 0.01 0.02 0.02 Penicillin tesistant Streptococcus pneumoniae (excluding those resistant to macrolides) 20.81 25.41 31.84 73.69 83.73 97.74 95.46 109.16 128.05 9.56 10.35 11.26 0.24 0.30 0.37 0.86 0.98 1.14 1.11 1.27 1.49 30.33 34.41 40.15 0.35 0.40 0.47 1.89 2.11 2.36 0.02 0.02 0.03 Total 918.98 1,036.20 1,168.92 4,835.97 5,600.42 6,411.54 5,792.14 6,636.51 7,541.23 10.72 12.08 13.63 56.39 65.30 74.76 67.54 77.38 87.93 5,870.48 6,633.87 7,422.48 68.45 77.35 86.55 238.30 275.70 316.17 2.78 3.21 3.69 Model Austria - Acinetobacter spp. ColRACI BSI - model 41 4.36E-01 6.38E-01 9.20E-01 1.78E+00 5.00E+00 8.67E+00 2.37E+00 5.64E+00 9.49E+00 2.17E+00 5.00E+00 7.62E+00 5.08E-03 7.44E-03 1.07E-02 2.07E-02 5.83E-02 1.01E-01 2.76E-02 6.57E-02 1.11E-01 9.04E-01 1.14E+00 1.44E+00 1.05E-02 1.33E-02 1.67E-02 8.43E-02 2.37E-01 4.12E-01 9.83E-04 2.76E-03 4.81E-03 Austria - Acinetobacter spp. ColRACI OTH - model 45 1.81E-05 1.29E-04 4.28E-04 0.00 0.00 0.00 1.81E-05 1.29E-04 4.28E-04 1.61E-03 3.81E-03 6.48E-03 2.12E-07 1.50E-06 4.99E-06 0.00 0.00 0.00 2.12E-07 1.50E-06 4.99E-06 6.71E-03 0.04 0.09 7.82E-05 4.38E-04 1.04E-03 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Acinetobacter spp. ColRACI RESP - model 42 0.27 0.48 0.73 0.52 0.95 1.41 0.77 1.43 2.08 0.99 1.15 1.32 3.19E-03 5.64E-03 8.56E-03 6.10E-03 0.01 0.02 8.93E-03 0.02 0.02 0.70 1.25 1.72 8.15E-03 0.01 0.02 0.02 0.04 0.07 2.89E-04 5.23E-04 7.77E-04 Austria - Acinetobacter spp. ColRACI SSI - model 44 1.45E-04 7.57E-04 2.22E-03 0.13 0.32 0.50 0.13 0.33 0.50 0.76 0.76 0.76 1.69E-06 8.82E-06 2.59E-05 1.53E-03 3.78E-03 5.88E-03 1.53E-03 3.79E-03 5.86E-03 0.17 0.43 0.66 2.02E-03 4.98E-03 7.75E-03 6.22E-03 0.02 0.02 7.26E-05 1.79E-04 2.79E-04 Austria - Acinetobacter spp. ColRACI UTI - model 43 2.53E-04 8.54E-04 2.24E-03 0.00 0.00 0.00 2.53E-04 8.54E-04 2.24E-03 8.07E-04 2.03E-03 3.55E-03 2.95E-06 9.96E-06 2.62E-05 0.00 0.00 0.00 2.95E-06 9.96E-06 2.62E-05 0.19 0.47 0.76 2.18E-03 5.50E-03 8.90E-03 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Acinetobacter spp. CRACI BSI - model 36 8.94 10.45 12.27 55.36 81.03 114.62 65.96 91.39 125.83 9.49 13.27 17.57 0.10 0.12 0.14 0.65 0.94 1.34 0.77 1.07 1.47 6.23 6.91 7.64 0.07 0.08 0.09 1.01 1.41 1.88 0.01 0.02 0.02 Austria - Acinetobacter spp. CRACI OTH - model 40 4.78E-04 8.93E-04 1.46E-03 0.00 0.00 0.00 4.78E-04 8.93E-04 1.46E-03 2.60E-03 3.71E-03 4.99E-03 5.58E-06 1.04E-05 1.71E-05 0.00 0.00 0.00 5.58E-06 1.04E-05 1.71E-05 0.14 0.24 0.35 1.67E-03 2.81E-03 4.08E-03 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Acinetobacter spp. CRACI RESP - model 37 6.15 7.90 9.70 12.27 15.58 19.20 18.49 23.53 28.38 2.81 3.14 3.48 0.07 0.09 0.11 0.14 0.18 0.22 0.22 0.27 0.33 6.17 7.51 8.82 0.07 0.09 0.10 0.22 0.27 0.32 2.54E-03 3.16E-03 3.79E-03 Austria - Acinetobacter spp. CRACI SSI - model 39 3.09E-03 5.26E-03 8.24E-03 1.14 1.53 1.97 1.14 1.53 1.97 0.57 0.62 0.66 3.60E-05 6.13E-05 9.60E-05 0.01 0.02 0.02 0.01 0.02 0.02 1.86 2.49 3.19 0.02 0.03 0.04 0.02 0.03 0.04 2.72E-04 3.92E-04 5.21E-04 Austria - Acinetobacter spp. CRACI UTI - model 38 3.71E-03 5.69E-03 8.48E-03 0.00 0.00 0.00 3.71E-03 5.69E-03 8.48E-03 1.45E-03 2.05E-03 2.69E-03 4.33E-05 6.64E-05 9.88E-05 0.00 0.00 0.00 4.33E-05 6.64E-05 9.88E-05 2.13 2.81 3.54 0.02 0.03 0.04 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Acinetobacter spp. MDRACI BSI - model 31 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Acinetobacter spp. MDRACI OTH - model 35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Acinetobacter spp. MDRACI RESP - model 32 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Acinetobacter spp. MDRACI SSI - model 34 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Acinetobacter spp. MDRACI UTI - model 33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Enterococcus faecalis and E. faecium VRE BSI - model 66 9.99 13.74 18.79 88.34 117.34 156.30 98.27 131.10 175.04 5.56 6.11 6.83 0.12 0.16 0.22 1.03 1.37 1.82 1.15 1.53 2.04 16.10 21.52 27.84 0.19 0.25 0.32 3.68 4.92 6.37 0.04 0.06 0.07 Austria - Enterococcus faecalis and E. faecium VRE OTH - model 70 0.02 0.04 0.06 0.00 0.00 0.00 0.02 0.04 0.06 1.13E-03 1.64E-03 2.24E-03 2.66E-04 4.39E-04 6.83E-04 0.00 0.00 0.00 2.66E-04 4.39E-04 6.83E-04 16.34 23.13 30.44 0.19 0.27 0.35 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Enterococcus faecalis and E. faecium VRE RESP - model 67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Enterococcus faecalis and E. faecium VRE SSI - model 69 0.04 0.06 0.10 10.15 14.94 19.93 10.18 15.06 20.05 0.45 0.51 0.56 4.09E-04 7.23E-04 1.22E-03 0.12 0.17 0.23 0.12 0.18 0.23 20.50 29.93 39.29 0.24 0.35 0.46 0.49 0.75 1.02 5.71E-03 8.77E-03 0.01 Austria - Enterococcus faecalis and E. faecium VRE UTI - model 68 0.01 0.02 0.03 0.00 0.00 0.00 0.01 0.02 0.03 1.30E-03 1.85E-03 2.54E-03 1.43E-04 2.36E-04 3.67E-04 0.00 0.00 0.00 1.43E-04 2.36E-04 3.67E-04 7.29 11.00 14.81 0.08 0.13 0.17 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Escherichia coli 3GCREC BSI - model 16 249.81 270.32 296.49 1,570.39 1,747.64 1,915.50 1,831.16 2,018.12 2,201.85 3.37 3.65 3.95 2.91 3.15 3.46 18.31 20.38 22.33 21.35 23.53 25.67 510.59 552.00 593.32 5.95 6.44 6.92 84.52 95.31 106.78 0.99 1.11 1.25 Austria - Escherichia coli 3GCREC OTH - model 20 0.46 0.61 0.80 0.00 0.00 0.00 0.46 0.61 0.80 2.67E-03 3.33E-03 4.08E-03 5.34E-03 7.10E-03 9.32E-03 0.00 0.00 0.00 5.34E-03 7.10E-03 9.32E-03 146.82 182.73 217.04 1.71 2.13 2.53 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Escherichia coli 3GCREC RESP - model 17 69.95 82.45 96.52 133.52 159.32 186.28 204.56 241.59 281.29 0.92 1.00 1.10 0.82 0.96 1.13 1.56 1.86 2.17 2.39 2.82 3.28 199.92 241.94 285.56 2.33 2.82 3.33 7.14 8.69 10.37 0.08 0.10 0.12 Austria - Escherichia coli 3GCREC SSI - model 19 0.87 1.23 1.66 209.04 241.21 275.89 209.96 242.84 276.89 0.39 0.42 0.44 0.01 0.01 0.02 2.44 2.81 3.22 2.45 2.83 3.23 508.32 583.54 655.96 5.93 6.80 7.65 14.56 17.04 19.60 0.17 0.20 0.23 Austria - Escherichia coli 3GCREC UTI - model 18 3.63 4.59 5.72 0.00 0.00 0.00 3.63 4.59 5.72 1.58E-03 1.95E-03 2.34E-03 0.04 0.05 0.07 0.00 0.00 0.00 0.04 0.05 0.07 2,125.42 2,368.48 2,636.24 24.78 27.62 30.74 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Escherichia coli ColREC BSI - model 26 0.12 0.18 0.26 1.76 3.45 5.78 1.90 3.62 5.98 1.82 3.21 4.50 1.42E-03 2.07E-03 3.02E-03 0.02 0.04 0.07 0.02 0.04 0.07 0.89 1.15 1.52 0.01 0.01 0.02 0.35 0.69 1.15 4.13E-03 8.08E-03 0.01 Austria - Escherichia coli ColREC OTH - model 30 6.34E-04 2.12E-03 5.45E-03 0.00 0.00 0.00 6.34E-04 2.12E-03 5.45E-03 1.22E-03 3.31E-03 7.13E-03 7.39E-06 2.47E-05 6.35E-05 0.00 0.00 0.00 7.39E-06 2.47E-05 6.35E-05 0.32 0.68 1.03 3.76E-03 7.91E-03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Escherichia coli ColREC RESP - model 27 0.02 0.06 0.10 0.04 0.11 0.17 0.07 0.17 0.26 0.24 0.28 0.32 2.88E-04 6.89E-04 1.13E-03 4.85E-04 1.23E-03 2.00E-03 7.94E-04 1.93E-03 3.08E-03 0.25 0.58 0.92 2.89E-03 6.81E-03 0.01 8.74E-03 0.02 0.03 1.02E-04 2.46E-04 3.99E-04 Austria - Escherichia coli ColREC SSI - model 29 6.49E-04 2.60E-03 7.03E-03 0.13 0.25 0.37 0.13 0.25 0.37 0.18 0.18 0.19 7.57E-06 3.04E-05 8.20E-05 1.57E-03 2.89E-03 4.26E-03 1.57E-03 2.93E-03 4.30E-03 0.74 1.37 2.01 8.67E-03 0.02 0.02 0.03 0.05 0.07 3.12E-04 5.75E-04 8.44E-04 Austria - Escherichia coli ColREC UTI - model 28 3.35E-03 9.42E-03 0.02 0.00 0.00 0.00 3.35E-03 9.42E-03 0.02 7.63E-04 1.98E-03 4.19E-03 3.90E-05 1.10E-04 2.68E-04 0.00 0.00 0.00 3.90E-05 1.10E-04 2.68E-04 2.95 4.98 6.84 0.03 0.06 0.08 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Escherichia coli CREC BSI - model 21 0.45 0.66 0.96 4.48 8.58 14.24 5.02 9.25 15.11 4.93 8.07 11.22 5.24E-03 7.70E-03 0.01 0.05 0.10 0.17 0.06 0.11 0.18 0.89 1.15 1.53 0.01 0.01 0.02 0.21 0.41 0.68 2.48E-03 4.76E-03 7.89E-03 Austria - Escherichia coli CREC OTH - model 25 6.24E-04 2.10E-03 5.42E-03 0.00 0.00 0.00 6.24E-04 2.10E-03 5.42E-03 1.18E-03 3.19E-03 7.07E-03 7.28E-06 2.45E-05 6.32E-05 0.00 0.00 0.00 7.28E-06 2.45E-05 6.32E-05 0.30 0.66 1.04 3.51E-03 7.73E-03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Escherichia coli CREC RESP - model 22 0.09 0.23 0.39 0.17 0.45 0.75 0.26 0.68 1.11 0.98 1.15 1.31 1.05E-03 2.65E-03 4.51E-03 1.94E-03 5.21E-03 8.70E-03 3.07E-03 7.92E-03 0.01 0.22 0.59 0.94 2.62E-03 6.86E-03 0.01 7.91E-03 0.02 0.04 9.22E-05 2.47E-04 4.10E-04 Austria - Escherichia coli CREC SSI - model 24 6.02E-04 2.52E-03 6.99E-03 0.58 1.03 1.51 0.59 1.04 1.51 0.76 0.76 0.76 7.02E-06 2.94E-05 8.15E-05 6.79E-03 0.01 0.02 6.86E-03 0.01 0.02 0.77 1.36 1.99 8.93E-03 0.02 0.02 0.03 0.05 0.07 3.22E-04 5.72E-04 8.35E-04 Austria - Escherichia coli CREC UTI - model 23 3.25E-03 9.25E-03 0.02 0.00 0.00 0.00 3.25E-03 9.25E-03 0.02 7.47E-04 1.99E-03 3.93E-03 3.79E-05 1.08E-04 2.65E-04 0.00 0.00 0.00 3.79E-05 1.08E-04 2.65E-04 2.93 4.88 6.79 0.03 0.06 0.08 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Klebsiella pneumoniae 3GCRKP BSI - model 1 54.91 59.72 65.42 350.51 374.81 398.33 406.56 434.38 462.35 4.57 4.79 5.00 0.64 0.70 0.76 4.09 4.37 4.64 4.74 5.06 5.39 86.05 90.74 95.47 1.00 1.06 1.11 14.09 15.14 16.23 0.16 0.18 0.19 Austria - Klebsiella pneumoniae 3GCRKP RESP - model 2 31.57 35.86 40.30 61.89 69.61 78.00 94.39 105.48 117.69 1.26 1.35 1.44 0.37 0.42 0.47 0.72 0.81 0.91 1.10 1.23 1.37 69.26 78.28 86.69 0.81 0.91 1.01 2.47 2.82 3.18 0.03 0.03 0.04 Austria - Klebsiella pneumoniae 3GCRKP UTI - model 3 0.16 0.21 0.26 0.00 0.00 0.00 0.16 0.21 0.26 1.59E-03 1.96E-03 2.39E-03 1.91E-03 2.44E-03 3.06E-03 0.00 0.00 0.00 1.91E-03 2.44E-03 3.06E-03 94.73 106.55 118.71 1.10 1.24 1.38 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Klebsiella pneumoniae 3GCRKP SSI - model 4 0.06 0.08 0.10 13.59 16.01 18.40 13.65 16.08 18.48 0.43 0.45 0.48 6.57E-04 8.88E-04 1.18E-03 0.16 0.19 0.21 0.16 0.19 0.22 30.83 35.53 40.37 0.36 0.41 0.47 0.76 0.91 1.06 8.86E-03 0.01 0.01 Austria - Klebsiella pneumoniae 3GCRKP OTH - model 5 0.09 0.12 0.15 0.00 0.00 0.00 0.09 0.12 0.15 2.69E-03 3.33E-03 4.10E-03 1.06E-03 1.39E-03 1.79E-03 0.00 0.00 0.00 1.06E-03 1.39E-03 1.79E-03 31.38 35.94 40.88 0.37 0.42 0.48 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Klebsiella pneumoniae ColRKP BSI - model 11 1.44 1.86 2.36 27.91 41.07 57.22 29.79 42.90 59.51 8.57 12.35 16.12 0.02 0.02 0.03 0.33 0.48 0.67 0.35 0.50 0.69 2.94 3.48 4.15 0.03 0.04 0.05 1.43 2.09 2.92 0.02 0.02 0.03 Austria - Klebsiella pneumoniae ColRKP OTH - model 15 2.48E-03 5.46E-03 0.01 0.00 0.00 0.00 2.48E-03 5.46E-03 0.01 1.83E-03 3.43E-03 5.58E-03 2.89E-05 6.36E-05 1.18E-04 0.00 0.00 0.00 2.89E-05 6.36E-05 1.18E-04 0.92 1.66 2.35 0.01 0.02 0.03 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Klebsiella pneumoniae ColRKP RESP - model 12 0.30 0.55 0.80 0.59 1.05 1.54 0.89 1.61 2.32 0.96 1.07 1.18 3.53E-03 6.37E-03 9.35E-03 6.89E-03 0.01 0.02 0.01 0.02 0.03 0.85 1.49 2.14 9.89E-03 0.02 0.02 0.03 0.05 0.08 3.52E-04 6.23E-04 9.23E-04 Austria - Klebsiella pneumoniae ColRKP SSI - model 14 9.48E-04 2.18E-03 4.23E-03 0.41 0.73 1.07 0.41 0.73 1.08 0.67 0.71 0.74 1.11E-05 2.54E-05 4.93E-05 4.82E-03 8.51E-03 0.01 4.84E-03 8.53E-03 0.01 0.57 1.03 1.50 6.61E-03 0.01 0.02 0.02 0.04 0.05 2.38E-04 4.34E-04 6.31E-04 Austria - Klebsiella pneumoniae ColRKP UTI - model 13 1.93E-03 4.35E-03 7.69E-03 0.00 0.00 0.00 1.93E-03 4.35E-03 7.69E-03 1.15E-03 2.07E-03 3.18E-03 2.26E-05 5.07E-05 8.97E-05 0.00 0.00 0.00 2.26E-05 5.07E-05 8.97E-05 1.31 2.13 2.92 0.02 0.02 0.03 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Klebsiella pneumoniae CRKP BSI - model 6 4.01 5.03 6.40 46.33 66.06 87.86 51.41 71.01 93.82 6.34 8.76 10.94 0.05 0.06 0.07 0.54 0.77 1.02 0.60 0.83 1.09 7.03 8.16 9.41 0.08 0.10 0.11 2.17 2.91 3.74 0.03 0.03 0.04 Austria - Klebsiella pneumoniae CRKP OTH - model 10 6.91E-03 0.01 0.02 0.00 0.00 0.00 6.91E-03 0.01 0.02 2.16E-03 3.48E-03 5.18E-03 8.06E-05 1.54E-04 2.58E-04 0.00 0.00 0.00 8.06E-05 1.54E-04 2.58E-04 2.56 3.83 5.11 0.03 0.04 0.06 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Klebsiella pneumoniae CRKP RESP - model 7 0.86 1.47 2.15 1.65 2.82 4.17 2.43 4.29 6.25 1.01 1.25 1.46 0.01 0.02 0.03 0.02 0.03 0.05 0.03 0.05 0.07 2.20 3.47 4.69 0.03 0.04 0.05 0.08 0.12 0.17 9.43E-04 1.45E-03 2.01E-03 Austria - Klebsiella pneumoniae CRKP SSI - model 9 2.47E-03 4.96E-03 8.81E-03 0.52 0.85 1.18 0.53 0.86 1.19 0.30 0.36 0.42 2.88E-05 5.78E-05 1.03E-04 6.12E-03 9.91E-03 0.01 6.15E-03 9.98E-03 0.01 1.50 2.39 3.33 0.02 0.03 0.04 0.03 0.05 0.07 3.65E-04 5.76E-04 7.90E-04 Austria - Klebsiella pneumoniae CRKP UTI - model 8 5.72E-03 0.01 0.02 0.00 0.00 0.00 5.72E-03 0.01 0.02 1.31E-03 2.07E-03 3.02E-03 6.67E-05 1.18E-04 1.92E-04 0.00 0.00 0.00 6.67E-05 1.18E-04 1.92E-04 3.48 4.97 6.46 0.04 0.06 0.08 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Pseudomonas aeruginosa ColRPA BSI - model 56 0.43 0.67 1.04 1.81 5.51 11.23 2.43 6.21 12.22 2.20 5.37 8.55 5.01E-03 7.80E-03 0.01 0.02 0.06 0.13 0.03 0.07 0.14 0.86 1.18 1.64 0.01 0.01 0.02 0.09 0.26 0.53 1.00E-03 3.05E-03 6.21E-03 Austria - Pseudomonas aeruginosa ColRPA OTH - model 60 4.64E-04 2.04E-03 5.24E-03 0.00 0.00 0.00 4.64E-04 2.04E-03 5.24E-03 1.54E-03 3.74E-03 6.51E-03 5.41E-06 2.38E-05 6.11E-05 0.00 0.00 0.00 5.41E-06 2.38E-05 6.11E-05 0.16 0.63 1.01 1.84E-03 7.30E-03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Pseudomonas aeruginosa ColRPA RESP - model 57 0.87 1.71 2.66 2.10 5.72 11.91 3.17 7.47 14.08 0.99 1.78 2.58 0.01 0.02 0.03 0.02 0.07 0.14 0.04 0.09 0.16 2.29 4.39 6.52 0.03 0.05 0.08 0.10 0.27 0.57 1.16E-03 3.16E-03 6.59E-03 Austria - Pseudomonas aeruginosa ColRPA SSI - model 59 3.09E-04 1.55E-03 4.50E-03 0.21 0.64 1.06 0.21 0.64 1.06 0.76 0.76 0.76 3.60E-06 1.80E-05 5.25E-05 2.50E-03 7.47E-03 0.01 2.50E-03 7.49E-03 0.01 0.28 0.84 1.40 3.29E-03 9.83E-03 0.02 0.01 0.03 0.05 1.18E-04 3.54E-04 5.86E-04 Austria - Pseudomonas aeruginosa ColRPA UTI - model 58 7.65E-04 2.80E-03 7.06E-03 0.00 0.00 0.00 7.65E-04 2.80E-03 7.06E-03 7.95E-04 1.94E-03 3.68E-03 8.92E-06 3.27E-05 8.23E-05 0.00 0.00 0.00 8.92E-06 3.27E-05 8.23E-05 0.61 1.54 2.45 7.10E-03 0.02 0.03 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Pseudomonas aeruginosa CRPA BSI - model 51 67.52 74.89 82.82 516.93 639.79 776.19 587.21 715.93 856.42 5.98 7.21 8.48 0.79 0.87 0.97 6.03 7.46 9.05 6.85 8.35 9.99 91.22 99.05 107.93 1.06 1.15 1.26 18.34 22.81 27.72 0.21 0.27 0.32 Austria - Pseudomonas aeruginosa CRPA OTH - model 55 0.14 0.18 0.23 0.00 0.00 0.00 0.14 0.18 0.23 2.94E-03 3.66E-03 4.34E-03 1.58E-03 2.12E-03 2.74E-03 0.00 0.00 0.00 1.58E-03 2.12E-03 2.74E-03 41.03 50.08 59.00 0.48 0.58 0.69 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Pseudomonas aeruginosa CRPA RESP - model 52 164.63 190.10 215.20 535.73 673.18 816.63 710.66 862.26 1,021.52 2.04 2.37 2.70 1.92 2.22 2.51 6.25 7.85 9.52 8.29 10.05 11.91 314.90 365.86 412.39 3.67 4.27 4.81 18.94 23.93 29.61 0.22 0.28 0.35 Austria - Pseudomonas aeruginosa CRPA SSI - model 54 0.10 0.14 0.20 24.59 31.41 37.82 24.68 31.59 38.08 0.42 0.46 0.50 1.20E-03 1.68E-03 2.30E-03 0.29 0.37 0.44 0.29 0.37 0.44 55.79 67.75 80.13 0.65 0.79 0.93 1.13 1.48 1.82 0.01 0.02 0.02 Austria - Pseudomonas aeruginosa CRPA UTI - model 53 0.20 0.26 0.32 0.00 0.00 0.00 0.20 0.26 0.32 1.67E-03 2.05E-03 2.45E-03 2.35E-03 2.99E-03 3.79E-03 0.00 0.00 0.00 2.35E-03 2.99E-03 3.79E-03 106.41 127.12 146.35 1.24 1.48 1.71 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Pseudomonas aeruginosa MDRPA BSI - model 46 1.17 1.54 1.97 6.33 11.82 18.27 7.77 13.36 20.02 2.20 3.76 5.24 0.01 0.02 0.02 0.07 0.14 0.21 0.09 0.16 0.23 2.94 3.59 4.28 0.03 0.04 0.05 0.40 0.76 1.15 4.67E-03 8.83E-03 0.01 Austria - Pseudomonas aeruginosa MDRPA OTH - model 50 2.98E-03 6.43E-03 0.01 0.00 0.00 0.00 2.98E-03 6.43E-03 0.01 2.17E-03 3.65E-03 5.39E-03 3.48E-05 7.50E-05 1.28E-04 0.00 0.00 0.00 3.48E-05 7.50E-05 1.28E-04 1.03 1.78 2.52 0.01 0.02 0.03 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Pseudomonas aeruginosa MDRPA RESP - model 47 2.71 3.93 5.21 7.33 12.68 19.82 10.31 16.61 24.22 0.89 1.27 1.66 0.03 0.05 0.06 0.09 0.15 0.23 0.12 0.19 0.28 9.57 13.16 17.03 0.11 0.15 0.20 0.47 0.81 1.26 5.48E-03 9.48E-03 0.01 Austria - Pseudomonas aeruginosa MDRPA SSI - model 49 2.25E-03 4.94E-03 9.70E-03 0.79 1.40 1.96 0.80 1.41 1.97 0.49 0.57 0.64 2.62E-05 5.76E-05 1.13E-04 9.24E-03 0.02 0.02 9.28E-03 0.02 0.02 1.46 2.48 3.51 0.02 0.03 0.04 0.05 0.09 0.13 6.13E-04 1.04E-03 1.47E-03 Austria - Pseudomonas aeruginosa MDRPA UTI - model 48 4.49E-03 9.08E-03 0.02 0.00 0.00 0.00 4.49E-03 9.08E-03 0.02 1.16E-03 1.99E-03 2.99E-03 5.24E-05 1.06E-04 1.81E-04 0.00 0.00 0.00 5.24E-05 1.06E-04 1.81E-04 2.85 4.57 6.30 0.03 0.05 0.07 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Staphylococcus aureus MRSA BSI - model 61 103.17 111.91 121.27 702.63 748.06 788.94 807.95 859.70 906.63 3.45 3.60 3.74 1.20 1.30 1.41 8.19 8.72 9.20 9.42 10.02 10.57 226.21 238.86 251.18 2.64 2.79 2.93 40.20 42.97 45.70 0.47 0.50 0.53 Austria - Staphylococcus aureus MRSA OTH - model 65 0.90 1.15 1.43 0.00 0.00 0.00 0.90 1.15 1.43 2.61E-03 3.27E-03 4.01E-03 0.01 0.01 0.02 0.00 0.00 0.00 0.01 0.01 0.02 319.76 350.79 383.58 3.73 4.09 4.47 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Staphylococcus aureus MRSA RESP - model 62 104.22 116.39 129.20 201.40 225.23 247.82 307.57 341.23 374.92 0.90 0.95 1.01 1.22 1.36 1.51 2.35 2.63 2.89 3.59 3.98 4.37 322.57 358.99 394.36 3.76 4.19 4.60 11.41 12.96 14.27 0.13 0.15 0.17 Austria - Staphylococcus aureus MRSA SSI - model 64 0.62 0.83 1.12 145.72 162.37 179.18 146.49 163.16 180.13 0.40 0.42 0.44 7.20E-03 9.65E-03 0.01 1.70 1.89 2.09 1.71 1.90 2.10 356.21 391.20 426.75 4.15 4.56 4.98 10.58 11.71 12.94 0.12 0.14 0.15 Austria - Staphylococcus aureus MRSA UTI - model 63 0.08 0.11 0.14 0.00 0.00 0.00 0.08 0.11 0.14 1.49E-03 1.87E-03 2.32E-03 9.38E-04 1.26E-03 1.65E-03 0.00 0.00 0.00 9.38E-04 1.26E-03 1.65E-03 48.89 58.12 69.23 0.57 0.68 0.81 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Streptococcus pneumoniae PMRSP BSI - model 76 1.98 2.30 2.68 14.28 15.50 16.72 16.54 17.83 19.06 3.72 4.02 4.29 0.02 0.03 0.03 0.17 0.18 0.19 0.19 0.21 0.22 4.44 4.44 4.44 0.05 0.05 0.05 0.74 0.80 0.86 8.62E-03 9.31E-03 0.01 Austria - Streptococcus pneumoniae PMRSP OTH - model 80 1.98E-03 3.09E-03 4.55E-03 0.00 0.00 0.00 1.98E-03 3.09E-03 4.55E-03 1.30E-03 1.93E-03 2.75E-03 2.31E-05 3.61E-05 5.31E-05 0.00 0.00 0.00 2.31E-05 3.61E-05 5.31E-05 1.40 1.59 1.79 0.02 0.02 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Streptococcus pneumoniae PMRSP RESP - model 77 4.72 6.02 7.90 9.21 11.65 15.40 14.13 17.70 23.12 0.92 1.05 1.20 0.06 0.07 0.09 0.11 0.14 0.18 0.16 0.21 0.27 13.62 16.86 21.03 0.16 0.20 0.25 0.48 0.61 0.77 5.59E-03 7.06E-03 8.99E-03 Austria - Streptococcus pneumoniae PMRSP SSI - model 79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Streptococcus pneumoniae PMRSP UTI - model 78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Streptococcus pneumoniae PRSP BSI - model 71 6.07 6.98 8.14 44.38 47.57 51.22 51.24 54.56 58.35 7.69 8.19 8.76 0.07 0.08 0.09 0.52 0.55 0.60 0.60 0.64 0.68 6.66 6.66 6.66 0.08 0.08 0.08 1.13 1.20 1.27 0.01 0.01 0.01 Austria - Streptococcus pneumoniae PRSP OTH - model 75 3.25E-03 4.64E-03 6.36E-03 0.00 0.00 0.00 3.25E-03 4.64E-03 6.36E-03 1.37E-03 1.94E-03 2.57E-03 3.79E-05 5.41E-05 7.42E-05 0.00 0.00 0.00 3.79E-05 5.41E-05 7.42E-05 2.16 2.39 2.62 0.03 0.03 0.03 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Streptococcus pneumoniae PRSP RESP - model 72 14.74 18.42 23.69 29.31 36.16 46.52 44.22 54.59 69.69 1.87 2.15 2.50 0.17 0.21 0.28 0.34 0.42 0.54 0.52 0.64 0.81 21.51 25.36 30.87 0.25 0.30 0.36 0.76 0.91 1.10 8.87E-03 0.01 0.01 Austria - Streptococcus pneumoniae PRSP SSI - model 74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Austria - Streptococcus pneumoniae PRSP UTI - model 73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total (Median & 95% UIs) 918.98 1,036.20 1,168.92 4,835.97 5,600.42 6,411.54 5,792.14 6,636.51 7,541.23 10.72 12.08 13.63 56.39 65.30 74.76 67.54 77.38 87.93 5,870.48 6,633.87 7,422.48 68.45 77.35 86.55 238.30 275.70 316.17 2.78 3.21 3.69 Total (average) Mortality per 100,000 YLL per 100,000YLD YLL DALY DALY per Case YLD per 100,000 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 YLLYLD DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year - YLL per 100,000YLD per 100,000DALY per CaseDALY 65.3912.101,037.52 5,608.35 6,645.87 - 3.2277.49 6,635.04 77.37 276.25 Infection Colistin resistant Acinetobacter spp. 6.56 10.09 14.98 21.70 55.30 95.93 29.52 65.25 108.57 3.13 5.40 7.70 0.06 0.09 0.13 0.19 0.49 0.85 0.26 0.58 0.97 22.56 37.09 53.19 0.20 0.33 0.47 1.30 3.30 5.73 0.01 0.03 0.05 Carbapenem resistant Acinetobacter spp. (excluding those resistant to colistin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Aminoglycosides and fluoroquinolones resistant Acinetobacter spp. (excluding those resistant to colistin and/or carbapenem) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Vancomycin resistant Enterococci (E. faecalis and E. faecium ) 3.94 6.56 11.08 37.60 63.05 97.72 41.94 69.48 107.23 5.98 6.44 6.92 0.04 0.06 0.10 0.33 0.56 0.87 0.37 0.62 0.95 21.59 42.45 65.68 0.19 0.38 0.58 1.64 2.72 4.20 0.01 0.02 0.04 Colistin resistant Escherichia coli 28.87 36.33 44.33 471.74 632.37 812.57 502.34 668.46 850.35 13.80 17.44 21.87 0.26 0.32 0.39 4.20 5.63 7.23 4.47 5.95 7.57 247.15 294.84 341.82 2.20 2.62 3.04 20.01 25.83 31.39 0.18 0.23 0.28 Carbapenem resistant Escherichia coli (excluding those resistant to colistin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Third-generation cephalosporin resistant Escherichia coli (excluding those resistant to colistin and/or carbapenem) 667.29 738.57 823.18 3,923.37 4,386.78 4,862.52 4,606.63 5,127.84 5,662.92 4.79 5.22 5.68 5.94 6.57 7.33 34.91 39.04 43.27 40.99 45.63 50.39 6,950.79 7,814.04 8,677.86 61.85 69.54 77.22 210.62 240.27 272.39 1.87 2.14 2.42 Colistin resistant Klebsiella pneumoniae 12.64 16.59 20.99 201.79 287.25 389.79 215.75 304.34 410.60 8.95 11.81 15.35 0.11 0.15 0.19 1.80 2.56 3.47 1.92 2.71 3.65 56.36 76.88 98.03 0.50 0.68 0.87 12.50 17.10 22.99 0.11 0.15 0.20 Carbapenem resistant Klebsiella pneumoniae (excluding those resistant to colistin) 7.28 11.02 15.66 73.67 119.22 181.17 82.31 130.27 194.79 11.19 15.83 21.49 0.06 0.10 0.14 0.66 1.06 1.61 0.73 1.16 1.73 15.72 25.51 35.69 0.14 0.23 0.32 2.18 3.44 5.00 0.02 0.03 0.04 Third-generation cephalosporin resistant Klebsiella pneumoniae (excluding those resistant to colistin and/or carbapenem) 213.46 240.78 270.33 1,054.88 1,155.68 1,251.32 1,275.22 1,395.27 1,510.54 4.30 4.58 4.85 1.90 2.14 2.41 9.39 10.28 11.14 11.35 12.42 13.44 1,131.00 1,271.81 1,415.44 10.06 11.32 12.60 63.34 69.57 75.77 0.56 0.62 0.67 Colistin resistant Pseudomonas aeruginosa 4.84 8.98 14.09 15.71 45.13 90.40 21.61 54.19 102.68 4.01 8.02 11.91 0.04 0.08 0.13 0.14 0.40 0.80 0.19 0.48 0.91 15.87 31.86 48.66 0.14 0.28 0.43 0.75 2.14 4.29 0.01 0.02 0.04 Carbapenem resistant Pseudomonas aeruginosa (excluding those resistant to colistin) 67.10 91.05 113.89 281.54 459.08 681.85 362.04 550.01 785.94 5.35 7.72 10.55 0.60 0.81 1.01 2.51 4.09 6.07 3.22 4.89 6.99 243.67 322.39 399.25 2.17 2.87 3.55 14.37 21.81 31.15 0.13 0.19 0.28 Pseudomonas aeruginosa resistant to three or more antimicrobial groups (excluding those resistant to colistin and/or carbapenem) 25.08 36.65 50.63 85.20 170.08 278.06 115.56 207.89 325.19 4.22 7.14 10.04 0.22 0.33 0.45 0.76 1.51 2.47 1.03 1.85 2.89 86.39 127.62 170.63 0.77 1.14 1.52 4.32 7.99 12.54 0.04 0.07 0.11 Methicillin resistant Staphylococcus aureus 525.89 576.88 628.13 2,603.98 2,789.26 2,979.37 3,145.59 3,364.92 3,593.66 5.88 6.17 6.44 4.68 5.13 5.59 23.17 24.82 26.51 27.99 29.94 31.98 2,554.81 2,800.31 3,044.61 22.74 24.92 27.09 122.15 132.94 144.02 1.09 1.18 1.28 Penicillin and macrolides resistant Streptococcus pneumoniae (excluding those only resistant to penicillin) 11.68 14.19 17.48 41.15 46.72 53.80 53.72 60.80 70.38 6.28 6.69 7.15 0.10 0.13 0.16 0.37 0.42 0.48 0.48 0.54 0.63 25.74 29.53 34.99 0.23 0.26 0.31 1.61 1.82 2.08 0.01 0.02 0.02 Penicillin tesistant Streptococcus pneumoniae (excluding those resistant to macrolides) 13.13 16.56 21.84 47.15 55.07 65.72 61.69 71.64 86.56 12.20 13.21 14.27 0.12 0.15 0.19 0.42 0.49 0.58 0.55 0.64 0.77 15.04 17.58 21.82 0.13 0.16 0.19 0.93 1.09 1.30 0.01 0.01 0.01 Total 1,587.77 1,804.25 2,046.61 8,859.50 10,264.98 11,840.22 10,513.91 12,070.36 13,809.39 14.13 16.06 18.21 78.84 91.35 105.37 93.56 107.41 122.89 11,386.69 12,891.92 14,407.66 101.33 114.72 128.21 455.70 530.04 612.86 4.06 4.72 5.45 Model Belgium - Acinetobacter spp. ColRACI BSI - model 41 4.04E+00 5.72E+00 8.21E+00 1.57E+01 4.40E+01 7.87E+01 2.09E+01 4.96E+01 8.50E+01 1.74E+00 3.87E+00 6.03E+00 3.60E-02 5.09E-02 7.31E-02 1.39E-01 3.92E-01 7.00E-01 1.86E-01 4.41E-01 7.57E-01 1.03E+01 1.27E+01 1.62E+01 9.12E-02 1.13E-01 1.44E-01 9.37E-01 2.63E+00 4.70E+00 8.34E-03 2.34E-02 4.18E-02 Belgium - Acinetobacter spp. ColRACI OTH - model 45 2.53E-04 1.59E-03 4.70E-03 0.00 0.00 0.00 2.53E-04 1.59E-03 4.70E-03 1.55E-03 3.70E-03 6.44E-03 2.26E-06 1.41E-05 4.18E-05 0.00 0.00 0.00 2.26E-06 1.41E-05 4.18E-05 0.08 0.45 0.97 7.33E-04 3.99E-03 8.65E-03 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Acinetobacter spp. ColRACI RESP - model 42 2.51 4.35 6.72 4.85 8.41 12.65 7.45 12.77 18.90 0.78 0.92 1.05 0.02 0.04 0.06 0.04 0.07 0.11 0.07 0.11 0.17 8.43 13.98 19.98 0.08 0.12 0.18 0.29 0.50 0.76 2.58E-03 4.47E-03 6.74E-03 Belgium - Acinetobacter spp. ColRACI SSI - model 44 1.79E-03 8.87E-03 0.03 1.17 2.84 4.59 1.18 2.85 4.60 0.60 0.61 0.61 1.59E-05 7.89E-05 2.38E-04 0.01 0.03 0.04 0.01 0.03 0.04 1.94 4.72 7.59 0.02 0.04 0.07 0.07 0.17 0.27 6.22E-04 1.51E-03 2.43E-03 Belgium - Acinetobacter spp. ColRACI UTI - model 43 2.62E-03 9.76E-03 0.02 0.00 0.00 0.00 2.62E-03 9.76E-03 0.02 8.17E-04 2.01E-03 3.63E-03 2.33E-05 8.68E-05 2.11E-04 0.00 0.00 0.00 2.33E-05 8.68E-05 2.11E-04 1.85 5.25 8.48 0.02 0.05 0.08 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Acinetobacter spp. CRACI BSI - model 36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Acinetobacter spp. CRACI OTH - model 40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Acinetobacter spp. CRACI RESP - model 37 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Acinetobacter spp. CRACI SSI - model 39 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Acinetobacter spp. CRACI UTI - model 38 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Acinetobacter spp. MDRACI BSI - model 31 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Acinetobacter spp. MDRACI OTH - model 35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Acinetobacter spp. MDRACI RESP - model 32 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Acinetobacter spp. MDRACI SSI - model 34 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Acinetobacter spp. MDRACI UTI - model 33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Enterococcus faecalis and E. faecium VRE BSI - model 66 3.92 6.51 10.96 34.65 55.65 86.03 38.97 62.03 95.47 5.65 5.95 6.25 0.03 0.06 0.10 0.31 0.50 0.77 0.35 0.55 0.85 6.61 10.46 16.05 0.06 0.09 0.14 1.50 2.39 3.66 0.01 0.02 0.03 Belgium - Enterococcus faecalis and E. faecium VRE OTH - model 70 6.75E-03 0.02 0.04 0.00 0.00 0.00 6.75E-03 0.02 0.04 7.64E-04 1.62E-03 2.77E-03 6.01E-05 1.65E-04 3.33E-04 0.00 0.00 0.00 6.01E-05 1.65E-04 3.33E-04 5.41 11.73 17.88 0.05 0.10 0.16 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Enterococcus faecalis and E. faecium VRE RESP - model 67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Enterococcus faecalis and E. faecium VRE SSI - model 69 9.68E-03 0.03 0.07 2.95 7.40 11.69 2.96 7.43 11.69 0.34 0.49 0.66 8.61E-05 2.64E-04 6.08E-04 0.03 0.07 0.10 0.03 0.07 0.10 7.19 14.87 23.18 0.06 0.13 0.21 0.13 0.34 0.54 1.16E-03 3.00E-03 4.79E-03 Belgium - Enterococcus faecalis and E. faecium VRE UTI - model 68 3.75E-03 9.57E-03 0.02 0.00 0.00 0.00 3.75E-03 9.57E-03 0.02 9.30E-04 1.86E-03 3.05E-03 3.33E-05 8.52E-05 1.83E-04 0.00 0.00 0.00 3.33E-05 8.52E-05 1.83E-04 2.38 5.39 8.57 0.02 0.05 0.08 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Escherichia coli 3GCREC BSI - model 16 511.73 556.25 609.90 3,243.84 3,593.45 3,959.25 3,769.97 4,151.16 4,549.11 3.48 3.78 4.09 4.55 4.95 5.43 28.87 31.98 35.23 33.55 36.94 40.48 1,023.21 1,099.03 1,178.15 9.11 9.78 10.48 168.48 189.76 213.90 1.50 1.69 1.90 Belgium - Escherichia coli 3GCREC OTH - model 20 0.90 1.21 1.58 0.00 0.00 0.00 0.90 1.21 1.58 2.73E-03 3.36E-03 4.05E-03 8.02E-03 0.01 0.01 0.00 0.00 0.00 8.02E-03 0.01 0.01 292.26 364.25 434.13 2.60 3.24 3.86 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Escherichia coli 3GCREC RESP - model 17 145.49 169.43 196.89 280.27 328.77 376.84 426.55 499.16 572.45 0.93 1.03 1.15 1.29 1.51 1.75 2.49 2.93 3.35 3.80 4.44 5.09 396.79 483.98 567.54 3.53 4.31 5.05 14.15 17.39 20.63 0.13 0.15 0.18 Belgium - Escherichia coli 3GCREC SSI - model 19 1.79 2.47 3.33 399.27 464.56 526.43 401.84 467.11 528.29 0.38 0.40 0.43 0.02 0.02 0.03 3.55 4.13 4.68 3.58 4.16 4.70 1,001.36 1,162.17 1,302.46 8.91 10.34 11.59 27.98 33.12 37.86 0.25 0.29 0.34 Belgium - Escherichia coli 3GCREC UTI - model 18 7.38 9.20 11.49 0.00 0.00 0.00 7.38 9.20 11.49 1.60E-03 1.96E-03 2.35E-03 0.07 0.08 0.10 0.00 0.00 0.00 0.07 0.08 0.10 4,237.16 4,704.61 5,195.58 37.71 41.87 46.24 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Escherichia coli ColREC BSI - model 26 22.04 26.71 31.90 440.69 592.34 763.33 464.46 618.73 789.30 12.28 15.59 19.66 0.20 0.24 0.28 3.92 5.27 6.79 4.13 5.51 7.02 35.21 39.47 43.68 0.31 0.35 0.39 18.46 23.87 28.99 0.16 0.21 0.26 Belgium - Escherichia coli ColREC OTH - model 30 0.05 0.08 0.11 0.00 0.00 0.00 0.05 0.08 0.11 2.40E-03 3.49E-03 4.69E-03 4.45E-04 6.98E-04 1.01E-03 0.00 0.00 0.00 4.45E-04 6.98E-04 1.01E-03 17.92 22.73 27.46 0.16 0.20 0.24 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Escherichia coli ColREC RESP - model 27 6.48 9.09 11.70 12.80 17.69 22.56 19.21 26.86 33.70 1.08 1.36 1.67 0.06 0.08 0.10 0.11 0.16 0.20 0.17 0.24 0.30 15.23 19.77 24.10 0.14 0.18 0.21 0.55 0.71 0.88 4.86E-03 6.32E-03 7.85E-03 Belgium - Escherichia coli ColREC SSI - model 29 0.06 0.10 0.14 18.25 22.34 26.68 18.38 22.45 26.76 0.44 0.48 0.53 5.73E-04 8.80E-04 1.28E-03 0.16 0.20 0.24 0.16 0.20 0.24 38.19 46.32 54.95 0.34 0.41 0.49 1.00 1.25 1.52 8.91E-03 0.01 0.01 Belgium - Escherichia coli ColREC UTI - model 28 0.23 0.35 0.47 0.00 0.00 0.00 0.23 0.35 0.47 1.45E-03 2.07E-03 2.77E-03 2.08E-03 3.09E-03 4.21E-03 0.00 0.00 0.00 2.08E-03 3.09E-03 4.21E-03 140.60 166.55 191.64 1.25 1.48 1.71 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Escherichia coli CREC BSI - model 21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Escherichia coli CREC OTH - model 25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Escherichia coli CREC RESP - model 22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Escherichia coli CREC SSI - model 24 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Escherichia coli CREC UTI - model 23 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Klebsiella pneumoniae 3GCRKP BSI - model 1 134.19 148.88 164.89 861.17 931.46 996.92 1,000.74 1,079.49 1,152.08 3.07 3.25 3.42 1.19 1.32 1.47 7.66 8.29 8.87 8.91 9.61 10.25 312.69 332.00 352.93 2.78 2.95 3.14 51.26 55.47 59.59 0.46 0.49 0.53 Belgium - Klebsiella pneumoniae 3GCRKP OTH - model 5 0.33 0.44 0.56 0.00 0.00 0.00 0.33 0.44 0.56 2.61E-03 3.33E-03 4.16E-03 2.92E-03 3.92E-03 5.03E-03 0.00 0.00 0.00 2.92E-03 3.92E-03 5.03E-03 112.84 132.04 152.33 1.00 1.18 1.36 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Klebsiella pneumoniae 3GCRKP RESP - model 2 78.16 90.42 103.52 150.73 173.06 195.20 230.41 263.15 297.40 0.85 0.92 0.99 0.70 0.80 0.92 1.34 1.54 1.74 2.05 2.34 2.65 250.40 287.19 321.97 2.23 2.56 2.87 8.89 10.33 11.77 0.08 0.09 0.10 Belgium - Klebsiella pneumoniae 3GCRKP UTI - model 3 0.58 0.76 0.97 0.00 0.00 0.00 0.58 0.76 0.97 1.52E-03 1.95E-03 2.39E-03 5.16E-03 6.76E-03 8.66E-03 0.00 0.00 0.00 5.16E-03 6.76E-03 8.66E-03 343.84 391.27 439.61 3.06 3.48 3.91 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Klebsiella pneumoniae 3GCRKP SSI - model 4 0.20 0.28 0.38 42.98 51.16 59.21 43.16 51.43 59.52 0.37 0.40 0.43 1.75E-03 2.48E-03 3.35E-03 0.38 0.46 0.53 0.38 0.46 0.53 111.22 129.32 148.58 0.99 1.15 1.32 3.19 3.77 4.41 0.03 0.03 0.04 Belgium - Klebsiella pneumoniae ColRKP BSI - model 11 10.32 12.83 15.70 195.81 277.63 376.44 207.36 290.94 392.20 7.93 10.57 13.83 0.09 0.11 0.14 1.74 2.47 3.35 1.85 2.59 3.49 23.61 27.58 31.88 0.21 0.25 0.28 12.11 16.47 22.11 0.11 0.15 0.20 Belgium - Klebsiella pneumoniae ColRKP OTH - model 15 0.02 0.04 0.07 0.00 0.00 0.00 0.02 0.04 0.07 2.11E-03 3.47E-03 5.05E-03 2.14E-04 3.92E-04 6.59E-04 0.00 0.00 0.00 2.14E-04 3.92E-04 6.59E-04 8.41 12.91 17.50 0.07 0.11 0.16 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Klebsiella pneumoniae ColRKP RESP - model 12 2.27 3.67 5.13 4.37 7.05 9.83 6.73 10.73 14.74 0.72 0.92 1.17 0.02 0.03 0.05 0.04 0.06 0.09 0.06 0.10 0.13 7.46 11.57 15.59 0.07 0.10 0.14 0.26 0.41 0.57 2.30E-03 3.69E-03 5.06E-03 Belgium - Klebsiella pneumoniae ColRKP SSI - model 14 8.60E-03 0.02 0.03 1.62 2.57 3.51 1.62 2.59 3.54 0.29 0.32 0.35 7.65E-05 1.51E-04 2.64E-04 0.01 0.02 0.03 0.01 0.02 0.03 5.23 8.09 11.07 0.05 0.07 0.10 0.13 0.22 0.31 1.17E-03 1.94E-03 2.79E-03 Belgium - Klebsiella pneumoniae ColRKP UTI - model 13 0.02 0.03 0.06 0.00 0.00 0.00 0.02 0.03 0.06 1.34E-03 2.06E-03 2.94E-03 1.78E-04 3.03E-04 4.94E-04 0.00 0.00 0.00 1.78E-04 3.03E-04 4.94E-04 11.65 16.73 22.00 0.10 0.15 0.20 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Klebsiella pneumoniae CRKP BSI - model 6 6.14 8.51 11.58 70.61 112.77 170.81 78.05 121.31 180.58 9.21 13.34 18.38 0.05 0.08 0.10 0.63 1.00 1.52 0.69 1.08 1.61 7.43 9.11 11.20 0.07 0.08 0.10 2.08 3.24 4.68 0.02 0.03 0.04 Belgium - Klebsiella pneumoniae CRKP OTH - model 10 5.32E-03 0.01 0.03 0.00 0.00 0.00 5.32E-03 0.01 0.03 1.68E-03 3.46E-03 6.03E-03 4.73E-05 1.27E-04 2.68E-04 0.00 0.00 0.00 4.73E-05 1.27E-04 2.68E-04 2.00 4.25 6.37 0.02 0.04 0.06 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Klebsiella pneumoniae CRKP RESP - model 7 1.13 2.48 4.02 2.27 4.82 7.86 3.44 7.30 11.65 1.46 1.88 2.41 0.01 0.02 0.04 0.02 0.04 0.07 0.03 0.06 0.10 1.91 3.88 5.85 0.02 0.03 0.05 0.07 0.14 0.22 6.17E-04 1.24E-03 1.94E-03 Belgium - Klebsiella pneumoniae CRKP SSI - model 9 1.74E-03 5.46E-03 0.01 0.80 1.63 2.49 0.81 1.63 2.51 0.51 0.60 0.69 1.55E-05 4.86E-05 1.03E-04 7.11E-03 0.01 0.02 7.18E-03 0.01 0.02 1.40 2.70 4.18 0.01 0.02 0.04 0.03 0.06 0.10 2.36E-04 5.44E-04 8.60E-04 Belgium - Klebsiella pneumoniae CRKP UTI - model 8 4.63E-03 0.01 0.02 0.00 0.00 0.00 4.63E-03 0.01 0.02 1.01E-03 1.96E-03 3.46E-03 4.12E-05 9.40E-05 1.94E-04 0.00 0.00 0.00 4.12E-05 9.40E-05 1.94E-04 2.97 5.57 8.08 0.03 0.05 0.07 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Pseudomonas aeruginosa ColRPA BSI - model 56 1.58 2.51 3.84 6.80 21.07 41.73 8.94 23.70 45.07 2.25 5.44 8.56 0.01 0.02 0.03 0.06 0.19 0.37 0.08 0.21 0.40 3.22 4.38 6.22 0.03 0.04 0.06 0.32 1.00 1.98 2.87E-03 8.90E-03 0.02 Belgium - Pseudomonas aeruginosa ColRPA OTH - model 60 1.65E-03 7.35E-03 0.02 0.00 0.00 0.00 1.65E-03 7.35E-03 0.02 1.52E-03 3.70E-03 6.59E-03 1.47E-05 6.54E-05 1.70E-04 0.00 0.00 0.00 1.47E-05 6.54E-05 1.70E-04 0.66 2.19 3.84 5.86E-03 0.02 0.03 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Pseudomonas aeruginosa ColRPA RESP - model 57 3.26 6.45 10.18 8.15 21.71 44.80 11.90 28.11 53.66 1.00 1.82 2.57 0.03 0.06 0.09 0.07 0.19 0.40 0.11 0.25 0.48 8.68 16.50 24.20 0.08 0.15 0.22 0.39 1.03 2.13 3.45E-03 9.18E-03 0.02 Belgium - Pseudomonas aeruginosa ColRPA SSI - model 59 1.10E-03 5.60E-03 0.02 0.76 2.35 3.86 0.76 2.36 3.90 0.76 0.76 0.76 9.75E-06 4.98E-05 1.48E-04 6.78E-03 0.02 0.03 6.79E-03 0.02 0.03 1.00 3.09 5.09 8.92E-03 0.03 0.05 0.04 0.11 0.18 3.21E-04 9.89E-04 1.63E-03 Belgium - Pseudomonas aeruginosa ColRPA UTI - model 58 3.12E-03 0.01 0.03 0.00 0.00 0.00 3.12E-03 0.01 0.03 8.06E-04 2.01E-03 3.60E-03 2.77E-05 9.25E-05 2.28E-04 0.00 0.00 0.00 2.77E-05 9.25E-05 2.28E-04 2.30 5.70 9.31 0.02 0.05 0.08 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Pseudomonas aeruginosa CRPA BSI - model 51 19.88 25.35 31.62 132.01 214.74 322.45 158.00 240.49 348.11 3.60 5.40 7.60 0.18 0.23 0.28 1.17 1.91 2.87 1.41 2.14 3.10 38.12 44.50 52.51 0.34 0.40 0.47 6.57 10.07 14.46 0.06 0.09 0.13 Belgium - Pseudomonas aeruginosa CRPA OTH - model 55 0.05 0.08 0.13 0.00 0.00 0.00 0.05 0.08 0.13 2.50E-03 3.60E-03 5.07E-03 4.24E-04 7.09E-04 1.17E-03 0.00 0.00 0.00 4.24E-04 7.09E-04 1.17E-03 14.67 22.46 30.28 0.13 0.20 0.27 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Pseudomonas aeruginosa CRPA RESP - model 52 47.07 65.44 81.84 139.07 227.85 337.33 193.35 292.77 415.34 1.27 1.78 2.36 0.42 0.58 0.73 1.24 2.03 3.00 1.72 2.61 3.70 128.37 166.71 203.31 1.14 1.48 1.81 7.12 10.71 15.33 0.06 0.10 0.14 Belgium - Pseudomonas aeruginosa CRPA SSI - model 54 0.03 0.06 0.12 10.46 16.49 22.07 10.57 16.56 22.18 0.49 0.54 0.58 3.04E-04 5.65E-04 1.03E-03 0.09 0.15 0.20 0.09 0.15 0.20 20.54 30.74 40.27 0.18 0.27 0.36 0.67 1.03 1.37 5.96E-03 9.13E-03 0.01 Belgium - Pseudomonas aeruginosa CRPA UTI - model 53 0.07 0.12 0.18 0.00 0.00 0.00 0.07 0.12 0.18 1.32E-03 2.04E-03 2.81E-03 6.30E-04 1.03E-03 1.59E-03 0.00 0.00 0.00 6.30E-04 1.03E-03 1.59E-03 41.97 57.98 72.88 0.37 0.52 0.65 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Pseudomonas aeruginosa MDRPA BSI - model 46 7.58 10.17 14.06 39.24 80.66 132.17 48.76 91.29 144.32 2.88 5.17 7.41 0.07 0.09 0.13 0.35 0.72 1.18 0.43 0.81 1.28 14.43 17.72 22.20 0.13 0.16 0.20 2.05 3.76 5.86 0.02 0.03 0.05 Belgium - Pseudomonas aeruginosa MDRPA OTH - model 50 0.01 0.03 0.06 0.00 0.00 0.00 0.01 0.03 0.06 2.15E-03 3.74E-03 5.56E-03 1.30E-04 3.02E-04 5.20E-04 0.00 0.00 0.00 1.30E-04 3.02E-04 5.20E-04 4.82 9.11 12.96 0.04 0.08 0.12 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Pseudomonas aeruginosa MDRPA RESP - model 47 17.45 26.37 36.38 44.24 86.64 141.92 65.03 113.72 176.71 1.12 1.73 2.38 0.16 0.23 0.32 0.39 0.77 1.26 0.58 1.01 1.57 45.85 65.85 86.50 0.41 0.59 0.77 2.17 4.04 6.41 0.02 0.04 0.06 Belgium - Pseudomonas aeruginosa MDRPA SSI - model 49 0.01 0.03 0.05 1.71 2.77 3.97 1.73 2.80 4.02 0.22 0.23 0.24 9.73E-05 2.29E-04 4.62E-04 0.02 0.02 0.04 0.02 0.02 0.04 7.46 12.20 17.32 0.07 0.11 0.15 0.11 0.19 0.28 9.39E-04 1.73E-03 2.46E-03 Belgium - Pseudomonas aeruginosa MDRPA UTI - model 48 0.02 0.05 0.08 0.00 0.00 0.00 0.02 0.05 0.08 1.19E-03 2.05E-03 3.11E-03 2.04E-04 4.05E-04 7.39E-04 0.00 0.00 0.00 2.04E-04 4.05E-04 7.39E-04 13.83 22.74 31.66 0.12 0.20 0.28 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Staphylococcus aureus MRSA BSI - model 61 258.69 280.12 302.16 1,782.31 1,883.47 1,986.72 2,052.89 2,162.82 2,279.44 4.33 4.54 4.71 2.30 2.49 2.69 15.86 16.76 17.68 18.27 19.25 20.28 453.21 477.54 501.95 4.03 4.25 4.47 80.06 85.68 91.38 0.71 0.76 0.81 Belgium - Staphylococcus aureus MRSA OTH - model 65 1.85 2.31 2.82 0.00 0.00 0.00 1.85 2.31 2.82 2.67E-03 3.28E-03 4.00E-03 0.02 0.02 0.03 0.00 0.00 0.00 0.02 0.02 0.03 642.57 702.29 765.50 5.72 6.25 6.81 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Staphylococcus aureus MRSA RESP - model 62 263.90 292.55 320.71 515.61 567.62 621.33 782.90 859.77 938.04 1.12 1.20 1.27 2.35 2.60 2.85 4.59 5.05 5.53 6.97 7.65 8.35 650.17 717.70 787.24 5.79 6.39 7.01 23.11 25.81 28.89 0.21 0.23 0.26 Belgium - Staphylococcus aureus MRSA SSI - model 64 1.29 1.69 2.17 306.06 338.17 371.32 307.80 339.81 373.08 0.42 0.43 0.45 0.01 0.02 0.02 2.72 3.01 3.30 2.74 3.02 3.32 715.48 786.21 854.27 6.37 7.00 7.60 18.98 21.45 23.76 0.17 0.19 0.21 Belgium - Staphylococcus aureus MRSA UTI - model 63 0.16 0.22 0.28 0.00 0.00 0.00 0.16 0.22 0.28 1.49E-03 1.87E-03 2.27E-03 1.45E-03 1.92E-03 2.49E-03 0.00 0.00 0.00 1.45E-03 1.92E-03 2.49E-03 93.38 116.58 135.64 0.83 1.04 1.21 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Streptococcus pneumoniae PMRSP BSI - model 76 3.42 3.91 4.46 24.80 26.54 28.33 28.69 30.45 32.28 4.99 5.30 5.61 0.03 0.03 0.04 0.22 0.24 0.25 0.26 0.27 0.29 5.75 5.75 5.75 0.05 0.05 0.05 0.97 1.04 1.10 8.66E-03 9.23E-03 9.80E-03 Belgium - Streptococcus pneumoniae PMRSP OTH - model 80 2.70E-03 3.97E-03 5.61E-03 0.00 0.00 0.00 2.70E-03 3.97E-03 5.61E-03 1.35E-03 1.94E-03 2.69E-03 2.40E-05 3.54E-05 4.99E-05 0.00 0.00 0.00 2.40E-05 3.54E-05 4.99E-05 1.84 2.05 2.30 0.02 0.02 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Streptococcus pneumoniae PMRSP RESP - model 77 8.26 10.27 13.01 16.35 20.17 25.47 25.02 30.35 38.10 1.29 1.40 1.53 0.07 0.09 0.12 0.15 0.18 0.23 0.22 0.27 0.34 18.15 21.73 26.95 0.16 0.19 0.24 0.64 0.79 0.98 5.70E-03 7.00E-03 8.76E-03 Belgium - Streptococcus pneumoniae PMRSP SSI - model 79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Streptococcus pneumoniae PMRSP UTI - model 78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Streptococcus pneumoniae PRSP BSI - model 71 3.84 4.58 5.42 28.78 31.52 34.07 33.42 36.05 38.80 9.69 10.45 11.25 0.03 0.04 0.05 0.26 0.28 0.30 0.30 0.32 0.35 3.45 3.45 3.45 0.03 0.03 0.03 0.57 0.62 0.67 5.03E-03 5.52E-03 5.96E-03 Belgium - Streptococcus pneumoniae PRSP OTH - model 75 1.36E-03 2.35E-03 3.62E-03 0.00 0.00 0.00 1.36E-03 2.35E-03 3.62E-03 1.14E-03 1.92E-03 2.86E-03 1.21E-05 2.09E-05 3.22E-05 0.00 0.00 0.00 1.21E-05 2.09E-05 3.22E-05 1.08 1.22 1.42 9.58E-03 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Streptococcus pneumoniae PRSP RESP - model 72 9.29 11.98 16.42 18.37 23.55 31.64 28.27 35.59 47.75 2.51 2.76 3.02 0.08 0.11 0.15 0.16 0.21 0.28 0.25 0.32 0.42 10.51 12.91 16.95 0.09 0.11 0.15 0.36 0.47 0.63 3.23E-03 4.14E-03 5.58E-03 Belgium - Streptococcus pneumoniae PRSP SSI - model 74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Belgium - Streptococcus pneumoniae PRSP UTI - model 73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total (Median & 95% UIs) 1,587.77 1,804.25 2,046.61 8,859.50 10,264.98 11,840.22 10,513.91 12,070.36 13,809.39 14.13 16.06 18.21 78.84 91.35 105.37 93.56 107.41 122.89 11,386.69 12,891.92 14,407.66 101.33 114.72 128.21 455.70 530.04 612.86 4.06 4.72 5.45 Total (average) Deaths per year DALY per 100,000 Cases per year Incidence per 100,000 - DALY per 100,000 Cases per year Incidence per 100,000 Deaths per yearDALY DALY per Case YLD per 100,000 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 Mortality per 100,000 1,807.69 10,292.81 12,100.51 - 16.09 4.7391.60 107.68 12,891.70 114.72 531.48 Mortality per 100,000YLL per 100,000 YLD YLL Infection Colistin resistant Acinetobacter spp. 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Acinetobacter spp. (excluding those resistant to colistin) 512.91 575.63 641.66 2,535.38 3,088.33 3,686.61 3,071.28 3,666.11 4,295.22 9.23 10.75 12.38 7.12 7.99 8.91 35.20 42.88 51.19 42.64 50.90 59.64 887.30 1,001.34 1,111.02 12.32 13.90 15.43 72.34 86.95 102.94 1.00 1.21 1.43 Aminoglycosides and fluoroquinolones resistant Acinetobacter spp. (excluding those resistant to colistin and/or carbapenem) 30.79 37.31 45.21 138.29 196.45 257.65 170.77 233.97 297.95 6.39 8.33 10.13 0.43 0.52 0.63 1.92 2.73 3.58 2.37 3.25 4.14 69.12 83.32 97.71 0.96 1.16 1.36 5.10 7.15 9.15 0.07 0.10 0.13 Vancomycin resistant Enterococci (E. faecalis and E. faecium ) 17.87 25.72 35.84 170.26 235.12 315.42 188.23 261.29 349.32 8.50 9.52 10.74 0.25 0.36 0.50 2.36 3.26 4.38 2.61 3.63 4.85 73.78 107.43 142.63 1.02 1.49 1.98 4.83 6.69 8.81 0.07 0.09 0.12 Colistin resistant Escherichia coli 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Escherichia coli (excluding those resistant to colistin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Third-generation cephalosporin resistant Escherichia coli (excluding those resistant to colistin and/or carbapenem) 195.26 226.07 260.52 1,162.07 1,339.75 1,543.63 1,359.34 1,568.36 1,791.68 5.57 6.11 6.67 2.71 3.14 3.62 16.13 18.60 21.43 18.87 21.78 24.88 1,789.47 2,052.35 2,320.28 24.85 28.50 32.22 53.37 62.05 71.37 0.74 0.86 0.99 Colistin resistant Klebsiella pneumoniae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Klebsiella pneumoniae (excluding those resistant to colistin) 8.17 13.15 19.85 82.56 142.89 229.17 91.63 156.21 245.40 15.63 23.98 33.43 0.11 0.18 0.28 1.15 1.98 3.18 1.27 2.17 3.41 12.28 20.58 29.18 0.17 0.29 0.41 1.68 2.73 4.10 0.02 0.04 0.06 Third-generation cephalosporin resistant Klebsiella pneumoniae (excluding those resistant to colistin and/or carbapenem) 380.33 436.18 500.65 1,893.69 2,090.75 2,326.96 2,285.91 2,525.80 2,806.04 10.29 11.01 11.79 5.28 6.06 6.95 26.29 29.03 32.31 31.74 35.07 38.96 832.20 935.35 1,039.62 11.55 12.99 14.43 45.83 49.97 54.71 0.64 0.69 0.76 Colistin resistant Pseudomonas aeruginosa 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Pseudomonas aeruginosa (excluding those resistant to colistin) 139.90 170.42 204.69 603.68 859.87 1,149.03 771.64 1,028.08 1,341.59 9.42 12.17 15.12 1.94 2.37 2.84 8.38 11.94 15.95 10.71 14.27 18.63 306.48 375.14 445.34 4.26 5.21 6.18 18.15 25.16 32.95 0.25 0.35 0.46 Pseudomonas aeruginosa resistant to three or more antimicrobial groups (excluding those resistant to colistin and/or carbapenem) 11.63 18.27 25.48 41.81 85.12 147.90 56.73 103.63 170.09 5.09 8.57 12.78 0.16 0.25 0.35 0.58 1.18 2.05 0.79 1.44 2.36 33.37 53.46 74.71 0.46 0.74 1.04 1.67 3.34 5.52 0.02 0.05 0.08 Methicillin resistant Staphylococcus aureus 172.48 191.41 214.14 831.65 896.90 968.85 1,008.13 1,088.32 1,176.85 8.96 9.38 9.80 2.39 2.66 2.97 11.55 12.45 13.45 14.00 15.11 16.34 554.12 602.77 654.78 7.69 8.37 9.09 24.99 26.95 28.98 0.35 0.37 0.40 Penicillin and macrolides resistant Streptococcus pneumoniae (excluding those only resistant to penicillin) 51.82 65.35 84.92 186.36 215.30 256.56 241.82 280.98 336.33 11.84 12.86 14.02 0.72 0.91 1.18 2.59 2.99 3.56 3.36 3.90 4.67 60.59 71.17 85.85 0.84 0.99 1.19 3.81 4.37 5.10 0.05 0.06 0.07 Penicillin tesistant Streptococcus pneumoniae (excluding those resistant to macrolides) 45.66 57.58 75.97 163.80 189.98 231.04 212.26 247.52 301.18 10.41 11.35 12.39 0.63 0.80 1.05 2.27 2.64 3.21 2.95 3.44 4.18 60.47 71.27 86.61 0.84 0.99 1.20 3.79 4.36 5.14 0.05 0.06 0.07 Total 1,566.81 1,817.08 2,108.93 7,809.54 9,340.44 11,112.82 9,457.75 11,160.29 13,111.65 21.75 25.23 29.28 108.43 129.69 154.30 131.32 154.96 182.05 4,679.17 5,374.19 6,087.71 64.97 74.62 84.53 235.55 279.72 328.78 3.27 3.88 4.57 Model Bulgaria - Acinetobacter spp. ColRACI BSI - model 41 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Acinetobacter spp. ColRACI OTH - model 45 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Acinetobacter spp. ColRACI RESP - model 42 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Acinetobacter spp. ColRACI SSI - model 44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Acinetobacter spp. ColRACI UTI - model 43 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Acinetobacter spp. CRACI BSI - model 36 296.17 328.53 361.68 2,062.37 2,547.40 3,078.02 2,376.63 2,877.90 3,412.30 6.95 8.34 9.82 4.11 4.56 5.02 28.64 35.37 42.74 33.00 39.96 47.38 322.21 345.59 369.93 4.47 4.80 5.14 58.70 71.35 85.34 0.82 0.99 1.18 Bulgaria - Acinetobacter spp. CRACI OTH - model 40 0.03 0.05 0.06 0.00 0.00 0.00 0.03 0.05 0.06 3.02E-03 3.75E-03 4.55E-03 4.54E-04 6.44E-04 8.94E-04 0.00 0.00 0.00 4.54E-04 6.44E-04 8.94E-04 9.22 12.38 15.71 0.13 0.17 0.22 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Acinetobacter spp. CRACI RESP - model 37 216.29 246.50 279.19 425.25 483.66 542.63 646.41 730.36 816.26 1.84 1.95 2.07 3.00 3.42 3.88 5.90 6.72 7.53 8.98 10.14 11.33 330.95 374.38 415.19 4.60 5.20 5.76 11.88 13.44 15.04 0.16 0.19 0.21 Bulgaria - Acinetobacter spp. CRACI SSI - model 39 0.20 0.27 0.36 47.77 57.27 65.96 47.99 57.52 66.22 0.43 0.46 0.48 2.73E-03 3.70E-03 4.94E-03 0.66 0.80 0.92 0.67 0.80 0.92 106.21 126.43 145.48 1.47 1.76 2.02 1.75 2.16 2.56 0.02 0.03 0.04 Bulgaria - Acinetobacter spp. CRACI UTI - model 38 0.22 0.29 0.37 0.00 0.00 0.00 0.22 0.29 0.37 1.67E-03 2.06E-03 2.45E-03 3.08E-03 4.03E-03 5.13E-03 0.00 0.00 0.00 3.08E-03 4.03E-03 5.13E-03 118.71 142.56 164.72 1.65 1.98 2.29 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Acinetobacter spp. MDRACI BSI - model 31 17.99 21.25 25.41 109.81 160.64 213.51 129.27 182.07 234.45 4.60 6.36 7.96 0.25 0.29 0.35 1.52 2.23 2.96 1.79 2.53 3.26 25.92 28.79 31.61 0.36 0.40 0.44 4.03 5.81 7.53 0.06 0.08 0.10 Bulgaria - Acinetobacter spp. MDRACI OTH - model 35 2.22E-03 3.88E-03 6.11E-03 0.00 0.00 0.00 2.22E-03 3.88E-03 6.11E-03 2.68E-03 3.72E-03 4.85E-03 3.08E-05 5.39E-05 8.48E-05 0.00 0.00 0.00 3.08E-05 5.39E-05 8.48E-05 0.68 1.05 1.49 9.42E-03 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Acinetobacter spp. MDRACI RESP - model 32 12.77 16.02 19.73 25.06 31.14 38.30 38.03 47.19 57.60 1.38 1.52 1.67 0.18 0.22 0.27 0.35 0.43 0.53 0.53 0.66 0.80 25.99 31.05 36.75 0.36 0.43 0.51 0.91 1.12 1.34 0.01 0.02 0.02 Bulgaria - Acinetobacter spp. MDRACI SSI - model 34 0.01 0.02 0.03 3.42 4.66 5.83 3.44 4.69 5.86 0.41 0.44 0.49 1.80E-04 3.04E-04 4.60E-04 0.05 0.06 0.08 0.05 0.07 0.08 7.77 10.53 13.09 0.11 0.15 0.18 0.15 0.22 0.28 2.14E-03 2.99E-03 3.84E-03 Bulgaria - Acinetobacter spp. MDRACI UTI - model 33 0.02 0.02 0.03 0.00 0.00 0.00 0.02 0.02 0.03 1.50E-03 2.05E-03 2.64E-03 2.19E-04 3.36E-04 4.77E-04 0.00 0.00 0.00 2.19E-04 3.36E-04 4.77E-04 8.76 11.90 14.77 0.12 0.17 0.21 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Enterococcus faecalis and E. faecium VRE BSI - model 66 17.78 25.57 35.60 160.46 220.73 296.27 178.34 246.76 329.95 8.15 9.14 10.32 0.25 0.35 0.49 2.23 3.06 4.11 2.48 3.43 4.58 19.92 27.02 35.39 0.28 0.38 0.49 4.52 6.18 8.10 0.06 0.09 0.11 Bulgaria - Enterococcus faecalis and E. faecium VRE OTH - model 70 0.03 0.05 0.08 0.00 0.00 0.00 0.03 0.05 0.08 1.12E-03 1.66E-03 2.32E-03 3.97E-04 6.62E-04 1.05E-03 0.00 0.00 0.00 3.97E-04 6.62E-04 1.05E-03 19.40 29.03 38.82 0.27 0.40 0.54 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Enterococcus faecalis and E. faecium VRE RESP - model 67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Enterococcus faecalis and E. faecium VRE SSI - model 69 0.04 0.08 0.13 9.80 14.39 19.15 9.86 14.46 19.26 0.35 0.38 0.42 6.00E-04 1.09E-03 1.75E-03 0.14 0.20 0.27 0.14 0.20 0.27 25.26 37.58 49.67 0.35 0.52 0.69 0.32 0.51 0.71 4.41E-03 7.11E-03 9.79E-03 Bulgaria - Enterococcus faecalis and E. faecium VRE UTI - model 68 0.02 0.03 0.04 0.00 0.00 0.00 0.02 0.03 0.04 1.26E-03 1.86E-03 2.51E-03 2.10E-04 3.51E-04 5.36E-04 0.00 0.00 0.00 2.10E-04 3.51E-04 5.36E-04 9.20 13.81 18.75 0.13 0.19 0.26 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Escherichia coli 3GCREC BSI - model 16 150.42 170.30 193.11 967.05 1,102.57 1,261.94 1,119.06 1,275.49 1,444.65 4.03 4.44 4.87 2.09 2.36 2.68 13.43 15.31 17.52 15.54 17.71 20.06 262.47 286.77 311.54 3.64 3.98 4.33 43.17 49.67 56.79 0.60 0.69 0.79 Bulgaria - Escherichia coli 3GCREC OTH - model 20 0.23 0.32 0.43 0.00 0.00 0.00 0.23 0.32 0.43 2.63E-03 3.34E-03 4.17E-03 3.24E-03 4.43E-03 6.04E-03 0.00 0.00 0.00 3.24E-03 4.43E-03 6.04E-03 74.87 95.58 116.97 1.04 1.33 1.62 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Escherichia coli 3GCREC RESP - model 17 42.29 52.39 62.97 81.63 101.40 122.84 124.37 153.75 184.78 1.12 1.21 1.32 0.59 0.73 0.87 1.13 1.41 1.71 1.73 2.13 2.57 102.37 126.92 152.25 1.42 1.76 2.11 3.68 4.58 5.51 0.05 0.06 0.08 Bulgaria - Escherichia coli 3GCREC SSI - model 19 0.46 0.64 0.89 113.39 135.78 158.85 113.82 136.39 158.70 0.42 0.45 0.48 6.36E-03 8.94E-03 0.01 1.57 1.89 2.21 1.58 1.89 2.20 259.79 303.95 351.93 3.61 4.22 4.89 6.52 7.81 9.07 0.09 0.11 0.13 Bulgaria - Escherichia coli 3GCREC UTI - model 18 1.86 2.41 3.11 0.00 0.00 0.00 1.86 2.41 3.11 1.57E-03 1.95E-03 2.41E-03 0.03 0.03 0.04 0.00 0.00 0.00 0.03 0.03 0.04 1,089.98 1,239.12 1,387.60 15.13 17.20 19.27 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Escherichia coli ColREC BSI - model 26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Escherichia coli ColREC OTH - model 30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Escherichia coli ColREC RESP - model 27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Escherichia coli ColREC SSI - model 29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Escherichia coli ColREC UTI - model 28 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Escherichia coli CREC BSI - model 21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Escherichia coli CREC OTH - model 25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Escherichia coli CREC RESP - model 22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Escherichia coli CREC SSI - model 24 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Escherichia coli CREC UTI - model 23 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Klebsiella pneumoniae 3GCRKP BSI - model 1 241.41 271.79 306.55 1,578.46 1,720.00 1,891.45 1,829.66 1,990.55 2,182.05 7.70 8.18 8.70 3.35 3.77 4.26 21.92 23.88 26.26 25.40 27.64 30.30 228.38 243.64 260.45 3.17 3.38 3.62 37.83 40.69 44.06 0.53 0.56 0.61 Bulgaria - Klebsiella pneumoniae 3GCRKP OTH - model 5 0.25 0.32 0.42 0.00 0.00 0.00 0.25 0.32 0.42 2.65E-03 3.36E-03 4.20E-03 3.45E-03 4.49E-03 5.85E-03 0.00 0.00 0.00 3.45E-03 4.49E-03 5.85E-03 82.49 97.28 110.82 1.15 1.35 1.54 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Klebsiella pneumoniae 3GCRKP RESP - model 2 138.09 163.30 192.69 272.89 319.76 375.94 413.03 483.19 562.95 2.08 2.30 2.52 1.92 2.27 2.68 3.79 4.44 5.22 5.73 6.71 7.82 185.11 210.90 236.70 2.57 2.93 3.29 6.60 7.59 8.64 0.09 0.11 0.12 Bulgaria - Klebsiella pneumoniae 3GCRKP SSI - model 4 0.15 0.20 0.28 42.34 50.99 59.56 42.53 51.19 59.91 0.50 0.53 0.57 2.04E-03 2.82E-03 3.92E-03 0.59 0.71 0.83 0.59 0.71 0.83 82.12 95.65 110.50 1.14 1.33 1.53 1.40 1.68 2.00 0.02 0.02 0.03 Bulgaria - Klebsiella pneumoniae 3GCRKP UTI - model 3 0.44 0.56 0.70 0.00 0.00 0.00 0.44 0.56 0.70 1.56E-03 1.96E-03 2.38E-03 6.06E-03 7.77E-03 9.75E-03 0.00 0.00 0.00 6.06E-03 7.77E-03 9.75E-03 254.10 287.89 321.15 3.53 4.00 4.46 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Klebsiella pneumoniae ColRKP BSI - model 11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Klebsiella pneumoniae ColRKP OTH - model 15 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Klebsiella pneumoniae ColRKP RESP - model 12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Klebsiella pneumoniae ColRKP SSI - model 14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Klebsiella pneumoniae ColRKP UTI - model 13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Klebsiella pneumoniae CRKP BSI - model 6 7.02 10.09 14.59 79.55 135.21 216.42 87.52 145.39 227.63 13.02 20.30 28.64 0.10 0.14 0.20 1.10 1.88 3.00 1.22 2.02 3.16 5.69 7.25 9.09 0.08 0.10 0.13 1.61 2.57 3.85 0.02 0.04 0.05 Bulgaria - Klebsiella pneumoniae CRKP OTH - model 10 4.38E-03 0.01 0.02 0.00 0.00 0.00 4.38E-03 0.01 0.02 1.46E-03 3.38E-03 6.04E-03 6.09E-05 1.59E-04 3.35E-04 0.00 0.00 0.00 6.09E-05 1.59E-04 3.35E-04 1.70 3.46 5.29 0.02 0.05 0.07 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Klebsiella pneumoniae CRKP RESP - model 7 1.15 3.04 5.22 2.24 6.01 10.16 3.34 9.14 15.12 1.84 2.90 4.01 0.02 0.04 0.07 0.03 0.08 0.14 0.05 0.13 0.21 1.42 3.12 4.81 0.02 0.04 0.07 0.05 0.11 0.17 6.95E-04 1.56E-03 2.43E-03 Bulgaria - Klebsiella pneumoniae CRKP SSI - model 9 1.32E-03 4.38E-03 9.51E-03 0.77 1.66 2.60 0.77 1.67 2.60 0.76 0.77 0.77 1.83E-05 6.09E-05 1.32E-04 0.01 0.02 0.04 0.01 0.02 0.04 1.00 2.18 3.39 0.01 0.03 0.05 0.02 0.05 0.08 2.57E-04 6.70E-04 1.11E-03 Bulgaria - Klebsiella pneumoniae CRKP UTI - model 8 3.61E-03 8.93E-03 0.02 0.00 0.00 0.00 3.61E-03 8.93E-03 0.02 9.79E-04 2.06E-03 3.37E-03 5.02E-05 1.24E-04 2.54E-04 0.00 0.00 0.00 5.02E-05 1.24E-04 2.54E-04 2.48 4.56 6.60 0.03 0.06 0.09 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Pseudomonas aeruginosa ColRPA BSI - model 56 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Pseudomonas aeruginosa ColRPA OTH - model 60 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Pseudomonas aeruginosa ColRPA RESP - model 57 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Pseudomonas aeruginosa ColRPA SSI - model 59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Pseudomonas aeruginosa ColRPA UTI - model 58 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Pseudomonas aeruginosa CRPA BSI - model 51 41.00 47.77 56.65 296.50 414.31 553.49 342.36 461.21 608.19 6.75 8.86 11.15 0.57 0.66 0.79 4.12 5.75 7.69 4.75 6.40 8.44 46.06 52.04 59.18 0.64 0.72 0.82 8.75 12.00 15.84 0.12 0.17 0.22 Bulgaria - Pseudomonas aeruginosa CRPA OTH - model 55 0.07 0.10 0.14 0.00 0.00 0.00 0.07 0.10 0.14 2.74E-03 3.63E-03 4.63E-03 9.26E-04 1.33E-03 1.90E-03 0.00 0.00 0.00 9.26E-04 1.33E-03 1.90E-03 19.60 26.57 32.67 0.27 0.37 0.45 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Pseudomonas aeruginosa CRPA RESP - model 52 98.68 122.34 147.60 295.65 430.61 577.18 417.52 551.61 714.61 2.29 2.89 3.51 1.37 1.70 2.05 4.10 5.98 8.01 5.80 7.66 9.92 160.77 193.28 227.14 2.23 2.68 3.15 9.00 12.63 16.45 0.12 0.18 0.23 Bulgaria - Pseudomonas aeruginosa CRPA SSI - model 54 0.05 0.08 0.12 11.53 14.95 18.35 11.60 15.03 18.46 0.38 0.42 0.46 6.73E-04 1.06E-03 1.60E-03 0.16 0.21 0.25 0.16 0.21 0.26 27.45 36.15 44.32 0.38 0.50 0.62 0.40 0.53 0.66 5.50E-03 7.39E-03 9.22E-03 Bulgaria - Pseudomonas aeruginosa CRPA UTI - model 53 0.10 0.14 0.19 0.00 0.00 0.00 0.10 0.14 0.19 1.57E-03 2.05E-03 2.61E-03 1.41E-03 1.89E-03 2.59E-03 0.00 0.00 0.00 1.41E-03 1.89E-03 2.59E-03 52.61 67.11 82.02 0.73 0.93 1.14 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Pseudomonas aeruginosa MDRPA BSI - model 46 3.58 5.06 6.99 18.59 39.40 69.72 23.29 44.76 75.42 3.32 6.03 9.33 0.05 0.07 0.10 0.26 0.55 0.97 0.32 0.62 1.05 5.55 7.43 9.49 0.08 0.10 0.13 0.76 1.53 2.56 0.01 0.02 0.04 Bulgaria - Pseudomonas aeruginosa MDRPA OTH - model 50 5.46E-03 0.01 0.03 0.00 0.00 0.00 5.46E-03 0.01 0.03 1.97E-03 3.79E-03 5.70E-03 7.57E-05 1.94E-04 3.86E-04 0.00 0.00 0.00 7.57E-05 1.94E-04 3.86E-04 1.94 3.80 5.72 0.03 0.05 0.08 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Pseudomonas aeruginosa MDRPA RESP - model 47 8.03 13.16 18.40 22.09 43.38 74.58 32.29 56.50 90.98 1.39 2.08 2.91 0.11 0.18 0.26 0.31 0.60 1.04 0.45 0.78 1.26 18.27 27.46 37.62 0.25 0.38 0.52 0.86 1.70 2.78 0.01 0.02 0.04 Bulgaria - Pseudomonas aeruginosa MDRPA SSI - model 49 3.16E-03 0.01 0.02 1.13 2.33 3.61 1.14 2.34 3.63 0.38 0.46 0.54 4.39E-05 1.41E-04 3.12E-04 0.02 0.03 0.05 0.02 0.03 0.05 2.48 5.12 7.93 0.03 0.07 0.11 0.05 0.11 0.18 6.93E-04 1.58E-03 2.55E-03 Bulgaria - Pseudomonas aeruginosa MDRPA UTI - model 48 8.16E-03 0.02 0.04 0.00 0.00 0.00 8.16E-03 0.02 0.04 1.03E-03 2.03E-03 3.23E-03 1.13E-04 2.69E-04 4.91E-04 0.00 0.00 0.00 1.13E-04 2.69E-04 4.91E-04 5.12 9.66 13.93 0.07 0.13 0.19 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Staphylococcus aureus MRSA BSI - model 61 85.33 93.28 103.30 594.41 631.90 673.50 682.97 725.20 774.40 6.77 7.07 7.37 1.18 1.30 1.43 8.25 8.77 9.35 9.48 10.07 10.75 97.73 102.75 107.79 1.36 1.43 1.50 17.40 18.46 19.59 0.24 0.26 0.27 Bulgaria - Staphylococcus aureus MRSA OTH - model 65 0.40 0.49 0.59 0.00 0.00 0.00 0.40 0.49 0.59 2.67E-03 3.26E-03 3.83E-03 5.58E-03 6.86E-03 8.22E-03 0.00 0.00 0.00 5.58E-03 6.86E-03 8.22E-03 139.54 151.56 165.81 1.94 2.10 2.30 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Staphylococcus aureus MRSA RESP - model 62 86.43 97.23 109.73 170.00 190.34 213.55 257.17 287.56 319.69 1.76 1.86 1.97 1.20 1.35 1.52 2.36 2.64 2.97 3.57 3.99 4.44 141.49 154.51 168.75 1.96 2.15 2.34 5.00 5.56 6.14 0.07 0.08 0.09 Bulgaria - Staphylococcus aureus MRSA SSI - model 64 0.28 0.36 0.46 67.24 74.66 81.80 67.57 75.01 82.11 0.43 0.44 0.46 3.87E-03 5.00E-03 6.36E-03 0.93 1.04 1.14 0.94 1.04 1.14 153.93 168.67 183.01 2.14 2.34 2.54 2.59 2.93 3.25 0.04 0.04 0.05 Bulgaria - Staphylococcus aureus MRSA UTI - model 63 0.04 0.05 0.06 0.00 0.00 0.00 0.04 0.05 0.06 1.51E-03 1.88E-03 2.26E-03 5.04E-04 6.60E-04 8.35E-04 0.00 0.00 0.00 5.04E-04 6.60E-04 8.35E-04 21.42 25.28 29.42 0.30 0.35 0.41 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Streptococcus pneumoniae PMRSP BSI - model 76 15.23 17.88 21.06 113.51 122.52 132.97 130.55 140.48 151.33 9.49 10.18 10.96 0.21 0.25 0.29 1.58 1.70 1.85 1.81 1.95 2.10 13.62 13.79 13.96 0.19 0.19 0.19 2.30 2.48 2.67 0.03 0.03 0.04 Bulgaria - Streptococcus pneumoniae PMRSP OTH - model 80 6.34E-03 9.63E-03 0.01 0.00 0.00 0.00 6.34E-03 9.63E-03 0.01 1.29E-03 1.95E-03 2.75E-03 8.80E-05 1.34E-04 1.94E-04 0.00 0.00 0.00 8.80E-05 1.34E-04 1.94E-04 4.28 4.93 5.68 0.06 0.07 0.08 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Streptococcus pneumoniae PMRSP RESP - model 77 36.58 47.46 63.84 72.85 92.78 123.59 111.27 140.49 184.98 2.35 2.67 3.06 0.51 0.66 0.89 1.01 1.29 1.72 1.54 1.95 2.57 42.70 52.45 66.22 0.59 0.73 0.92 1.51 1.88 2.43 0.02 0.03 0.03 Bulgaria - Streptococcus pneumoniae PMRSP SSI - model 79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Streptococcus pneumoniae PMRSP UTI - model 78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Streptococcus pneumoniae PRSP BSI - model 71 13.30 15.79 18.50 99.91 108.04 117.54 115.10 123.82 133.23 8.36 8.97 9.64 0.18 0.22 0.26 1.39 1.50 1.63 1.60 1.72 1.85 13.60 13.80 13.98 0.19 0.19 0.19 2.32 2.48 2.68 0.03 0.03 0.04 Bulgaria - Streptococcus pneumoniae PRSP OTH - model 75 6.09E-03 9.48E-03 0.01 0.00 0.00 0.00 6.09E-03 9.48E-03 0.01 1.26E-03 1.93E-03 2.76E-03 8.45E-05 1.32E-04 2.01E-04 0.00 0.00 0.00 8.45E-05 1.32E-04 2.01E-04 4.30 4.92 5.74 0.06 0.07 0.08 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Streptococcus pneumoniae PRSP RESP - model 72 32.36 41.78 57.45 63.89 81.93 113.49 97.15 123.69 167.93 2.05 2.38 2.75 0.45 0.58 0.80 0.89 1.14 1.58 1.35 1.72 2.33 42.57 52.54 66.89 0.59 0.73 0.93 1.47 1.88 2.47 0.02 0.03 0.03 Bulgaria - Streptococcus pneumoniae PRSP SSI - model 74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Bulgaria - Streptococcus pneumoniae PRSP UTI - model 73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total (Median & 95% UIs) 1,566.81 1,817.08 2,108.93 7,809.54 9,340.44 11,112.82 9,457.75 11,160.29 13,111.65 21.75 25.23 29.28 108.43 129.69 154.30 131.32 154.96 182.05 4,679.17 5,374.19 6,087.71 64.97 74.62 84.53 235.55 279.72 328.78 3.27 3.88 4.57 Total (average) - 130.20 155.52 5,376.59 74.65 280.14 3.89 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 1,823.84 9,377.19 11,201.03 - 25.32 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 Infection Colistin resistant Acinetobacter spp. 3.33 4.65 6.32 13.95 25.01 37.95 17.86 29.74 43.46 8.08 12.43 16.91 0.39 0.55 0.75 1.65 2.95 4.48 2.11 3.51 5.13 5.42 7.04 8.86 0.64 0.83 1.05 0.39 0.60 0.87 0.05 0.07 0.10 Carbapenem resistant Acinetobacter spp. (excluding those resistant to colistin) 73.42 89.27 109.01 345.68 479.94 647.03 427.32 569.19 749.74 7.77 10.10 12.74 8.67 10.54 12.87 40.81 56.66 76.39 50.45 67.20 88.52 146.20 166.60 188.04 17.26 19.67 22.20 11.62 14.60 17.71 1.37 1.72 2.09 Aminoglycosides and fluoroquinolones resistant Acinetobacter spp. (excluding those resistant to colistin and/or carbapenem) 2.03 3.30 5.00 6.78 17.23 30.52 9.33 20.65 34.95 9.25 17.12 24.83 0.24 0.39 0.59 0.80 2.03 3.60 1.10 2.44 4.13 2.09 3.55 5.15 0.25 0.42 0.61 0.12 0.29 0.52 0.01 0.03 0.06 Vancomycin resistant Enterococci (E. faecalis and E. faecium ) 6.01 8.67 12.43 59.58 83.73 116.31 65.92 92.40 127.49 6.15 7.27 8.84 0.71 1.02 1.47 7.03 9.89 13.73 7.78 10.91 15.05 33.32 48.67 65.24 3.93 5.75 7.70 2.40 3.29 4.40 0.28 0.39 0.52 Colistin resistant Escherichia coli 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Escherichia coli (excluding those resistant to colistin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Third-generation cephalosporin resistant Escherichia coli (excluding those resistant to colistin and/or carbapenem) 22.45 25.99 29.83 133.84 154.30 177.53 157.42 180.19 206.54 4.20 4.66 5.15 2.65 3.07 3.52 15.80 18.22 20.96 18.59 21.27 24.38 268.66 309.49 350.24 31.72 36.54 41.35 8.23 9.51 10.94 0.97 1.12 1.29 Colistin resistant Klebsiella pneumoniae 3.59 5.57 7.96 59.80 100.37 155.07 63.49 106.03 162.41 29.51 45.40 61.31 0.42 0.66 0.94 7.06 11.85 18.31 7.50 12.52 19.17 4.29 7.02 9.88 0.51 0.83 1.17 0.91 1.55 2.36 0.11 0.18 0.28 Carbapenem resistant Klebsiella pneumoniae (excluding those resistant to colistin) 4.98 6.38 8.08 49.82 67.45 89.34 55.43 73.84 96.62 7.54 9.51 11.63 0.59 0.75 0.95 5.88 7.96 10.55 6.54 8.72 11.41 18.54 24.41 30.67 2.19 2.88 3.62 2.47 3.26 4.22 0.29 0.38 0.50 Third-generation cephalosporin resistant Klebsiella pneumoniae (excluding those resistant to colistin and/or carbapenem) 14.06 16.34 18.88 70.37 79.39 88.28 85.19 95.82 106.24 4.60 4.86 5.13 1.66 1.93 2.23 8.31 9.37 10.42 10.06 11.31 12.54 71.66 83.10 94.12 8.46 9.81 11.11 4.04 4.55 5.08 0.48 0.54 0.60 Colistin resistant Pseudomonas aeruginosa 1.38 2.55 4.06 4.66 12.84 25.82 6.43 15.39 29.17 4.00 7.93 11.94 0.16 0.30 0.48 0.55 1.52 3.05 0.76 1.82 3.44 4.42 9.16 14.05 0.52 1.08 1.66 0.22 0.61 1.23 0.03 0.07 0.14 Carbapenem resistant Pseudomonas aeruginosa (excluding those resistant to colistin) 34.97 43.35 52.71 150.63 220.51 300.92 189.46 263.42 348.20 10.26 14.17 18.06 4.13 5.12 6.22 17.78 26.03 35.53 22.37 31.10 41.11 66.08 82.09 98.44 7.80 9.69 11.62 3.86 5.51 7.37 0.46 0.65 0.87 Pseudomonas aeruginosa resistant to three or more antimicrobial groups (excluding those resistant to colistin and/or carbapenem) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Methicillin resistant Staphylococcus aureus 71.25 80.76 90.83 360.50 393.64 430.88 433.94 474.77 518.26 5.20 5.53 5.91 8.41 9.53 10.72 42.56 46.47 50.87 51.23 56.05 61.19 394.24 439.06 483.95 46.55 51.84 57.14 19.30 21.10 23.15 2.28 2.49 2.73 Penicillin and macrolides resistant Streptococcus pneumoniae (excluding those only resistant to penicillin) 6.76 8.46 11.17 24.03 27.75 33.00 31.47 36.16 43.85 8.99 9.75 10.45 0.80 1.00 1.32 2.84 3.28 3.90 3.72 4.27 5.18 10.47 12.08 15.17 1.24 1.43 1.79 0.65 0.74 0.88 0.08 0.09 0.10 Penicillin tesistant Streptococcus pneumoniae (excluding those resistant to macrolides) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total 244.25 295.29 356.29 1,279.62 1,662.14 2,132.65 1,543.27 1,957.59 2,466.92 28.84 34.86 42.06 151.08 196.24 251.79 182.20 231.12 291.25 1,025.40 1,192.27 1,363.81 121.06 140.76 161.02 54.20 65.63 78.72 6.40 7.75 9.29 Model Cyprus - Acinetobacter spp. ColRACI BSI - model 41 2.01E+00 2.66E+00 3.49E+00 1.10E+01 2.07E+01 3.19E+01 1.35E+01 2.34E+01 3.48E+01 5.67E+00 9.67E+00 1.38E+01 2.38E-01 3.14E-01 4.12E-01 1.30E+00 2.44E+00 3.76E+00 1.60E+00 2.76E+00 4.11E+00 2.12E+00 2.42E+00 2.81E+00 2.50E-01 2.86E-01 3.32E-01 3.04E-01 4.94E-01 7.32E-01 3.59E-02 5.83E-02 8.64E-02 Cyprus - Acinetobacter spp. ColRACI OTH - model 45 1.43E-04 3.06E-04 6.09E-04 0.00 0.00 0.00 1.43E-04 3.06E-04 6.09E-04 2.26E-03 3.77E-03 5.29E-03 1.69E-05 3.61E-05 7.19E-05 0.00 0.00 0.00 1.69E-05 3.61E-05 7.19E-05 0.04 0.08 0.14 4.90E-03 9.82E-03 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Acinetobacter spp. ColRACI RESP - model 42 1.32 1.99 2.82 2.66 3.91 5.46 4.05 5.93 8.02 1.94 2.25 2.61 0.16 0.23 0.33 0.31 0.46 0.64 0.48 0.70 0.95 2.01 2.63 3.32 0.24 0.31 0.39 0.07 0.09 0.12 8.40E-03 0.01 0.01 Cyprus - Acinetobacter spp. ColRACI SSI - model 44 9.26E-04 1.82E-03 3.51E-03 0.28 0.45 0.61 0.29 0.45 0.62 0.47 0.50 0.53 1.09E-04 2.14E-04 4.15E-04 0.03 0.05 0.07 0.03 0.05 0.07 0.58 0.89 1.22 0.07 0.11 0.14 0.01 0.02 0.02 1.31E-03 1.87E-03 2.49E-03 Cyprus - Acinetobacter spp. ColRACI UTI - model 43 1.14E-03 2.04E-03 3.53E-03 0.00 0.00 0.00 1.14E-03 2.04E-03 3.53E-03 1.29E-03 2.04E-03 3.02E-03 1.34E-04 2.41E-04 4.17E-04 0.00 0.00 0.00 1.34E-04 2.41E-04 4.17E-04 0.67 1.02 1.37 0.08 0.12 0.16 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Acinetobacter spp. CRACI BSI - model 36 42.81 50.77 61.57 278.00 394.26 542.08 328.54 444.49 597.81 5.75 7.78 10.13 5.05 5.99 7.27 32.82 46.55 64.00 38.79 52.48 70.58 53.54 57.45 62.16 6.32 6.78 7.34 9.30 11.88 14.56 1.10 1.40 1.72 Cyprus - Acinetobacter spp. CRACI OTH - model 40 5.21E-03 7.69E-03 0.01 0.00 0.00 0.00 5.21E-03 7.69E-03 0.01 2.95E-03 3.74E-03 4.65E-03 6.15E-04 9.08E-04 1.28E-03 0.00 0.00 0.00 6.15E-04 9.08E-04 1.28E-03 1.48 2.05 2.70 0.17 0.24 0.32 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Acinetobacter spp. CRACI RESP - model 37 30.54 38.39 47.30 59.34 75.19 92.18 90.40 114.09 139.02 1.57 1.82 2.06 3.61 4.53 5.58 7.01 8.88 10.88 10.67 13.47 16.41 54.31 62.50 70.64 6.41 7.38 8.34 1.93 2.25 2.57 0.23 0.27 0.30 Cyprus - Acinetobacter spp. CRACI SSI - model 39 0.03 0.04 0.06 8.34 10.49 12.77 8.34 10.54 12.84 0.45 0.50 0.54 3.73E-03 5.29E-03 7.50E-03 0.98 1.24 1.51 0.99 1.24 1.52 17.55 21.08 24.88 2.07 2.49 2.94 0.39 0.48 0.58 0.05 0.06 0.07 Cyprus - Acinetobacter spp. CRACI UTI - model 38 0.04 0.05 0.06 0.00 0.00 0.00 0.04 0.05 0.06 1.60E-03 2.05E-03 2.50E-03 4.30E-03 5.63E-03 7.51E-03 0.00 0.00 0.00 4.30E-03 5.63E-03 7.51E-03 19.32 23.52 27.66 2.28 2.78 3.27 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Acinetobacter spp. MDRACI BSI - model 31 1.24 1.88 2.80 5.09 14.21 25.91 6.84 16.17 28.34 5.98 13.37 20.64 0.15 0.22 0.33 0.60 1.68 3.06 0.81 1.91 3.35 0.95 1.21 1.58 0.11 0.14 0.19 0.09 0.24 0.44 0.01 0.03 0.05 Cyprus - Acinetobacter spp. MDRACI OTH - model 35 2.03E-05 1.34E-04 4.20E-04 0.00 0.00 0.00 2.03E-05 1.34E-04 4.20E-04 1.54E-03 3.73E-03 6.45E-03 2.39E-06 1.58E-05 4.96E-05 0.00 0.00 0.00 2.39E-06 1.58E-05 4.96E-05 7.96E-03 0.04 0.09 9.40E-04 4.57E-03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Acinetobacter spp. MDRACI RESP - model 32 0.79 1.41 2.19 1.60 2.78 4.23 2.40 4.24 6.23 2.74 3.20 3.64 0.09 0.17 0.26 0.19 0.33 0.50 0.28 0.50 0.74 0.78 1.34 1.93 0.09 0.16 0.23 0.03 0.05 0.07 3.21E-03 5.56E-03 8.48E-03 Cyprus - Acinetobacter spp. MDRACI SSI - model 34 1.84E-04 8.19E-04 2.46E-03 0.09 0.24 0.38 0.09 0.24 0.38 0.53 0.53 0.53 2.17E-05 9.66E-05 2.90E-04 0.01 0.03 0.05 0.01 0.03 0.05 0.17 0.45 0.72 0.02 0.05 0.09 1.55E-03 4.06E-03 6.50E-03 1.83E-04 4.79E-04 7.67E-04 Cyprus - Acinetobacter spp. MDRACI UTI - model 33 2.74E-04 9.37E-04 2.26E-03 0.00 0.00 0.00 2.74E-04 9.37E-04 2.26E-03 7.80E-04 1.98E-03 3.60E-03 3.23E-05 1.11E-04 2.67E-04 0.00 0.00 0.00 3.23E-05 1.11E-04 2.67E-04 0.18 0.51 0.82 0.02 0.06 0.10 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Enterococcus faecalis and E. faecium VRE BSI - model 66 5.97 8.60 12.32 53.35 73.84 102.72 59.65 82.45 113.80 5.63 6.68 8.20 0.71 1.02 1.45 6.30 8.72 12.13 7.04 9.73 13.44 9.10 12.27 16.20 1.07 1.45 1.91 2.08 2.80 3.71 0.25 0.33 0.44 Cyprus - Enterococcus faecalis and E. faecium VRE OTH - model 70 0.01 0.02 0.04 0.00 0.00 0.00 0.01 0.02 0.04 1.07E-03 1.61E-03 2.28E-03 1.42E-03 2.46E-03 4.16E-03 0.00 0.00 0.00 1.42E-03 2.46E-03 4.16E-03 8.82 13.12 17.61 1.04 1.55 2.08 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Enterococcus faecalis and E. faecium VRE RESP - model 67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Enterococcus faecalis and E. faecium VRE SSI - model 69 0.02 0.04 0.06 6.23 9.89 13.59 6.25 9.92 13.64 0.52 0.58 0.64 2.20E-03 4.14E-03 7.15E-03 0.74 1.17 1.60 0.74 1.17 1.61 11.30 16.98 22.94 1.33 2.00 2.71 0.31 0.49 0.68 0.04 0.06 0.08 Cyprus - Enterococcus faecalis and E. faecium VRE UTI - model 68 6.71E-03 0.01 0.02 0.00 0.00 0.00 6.71E-03 0.01 0.02 1.27E-03 1.86E-03 2.58E-03 7.92E-04 1.37E-03 2.16E-03 0.00 0.00 0.00 7.92E-04 1.37E-03 2.16E-03 4.10 6.29 8.48 0.48 0.74 1.00 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Escherichia coli 3GCREC BSI - model 16 17.23 19.49 21.97 109.20 124.71 142.48 127.74 144.12 163.72 3.02 3.35 3.68 2.03 2.30 2.59 12.89 14.72 16.82 15.08 17.01 19.33 39.76 43.28 47.13 4.69 5.11 5.56 6.55 7.47 8.53 0.77 0.88 1.01 Cyprus - Escherichia coli 3GCREC OTH - model 20 0.03 0.05 0.06 0.00 0.00 0.00 0.03 0.05 0.06 2.69E-03 3.33E-03 4.17E-03 4.05E-03 5.72E-03 7.61E-03 0.00 0.00 0.00 4.05E-03 5.72E-03 7.61E-03 11.66 14.52 17.29 1.38 1.71 2.04 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Escherichia coli 3GCREC RESP - model 17 4.84 5.99 7.20 9.43 11.55 14.05 14.06 17.52 21.23 0.81 0.91 1.04 0.57 0.71 0.85 1.11 1.36 1.66 1.66 2.07 2.51 15.17 19.22 22.99 1.79 2.27 2.71 0.55 0.69 0.83 0.07 0.08 0.10 Cyprus - Escherichia coli 3GCREC SSI - model 19 0.07 0.10 0.14 15.21 18.04 21.00 15.30 18.14 21.07 0.37 0.40 0.42 7.78E-03 0.01 0.02 1.80 2.13 2.48 1.81 2.14 2.49 39.07 45.75 52.45 4.61 5.40 6.19 1.12 1.34 1.58 0.13 0.16 0.19 Cyprus - Escherichia coli 3GCREC UTI - model 18 0.29 0.36 0.46 0.00 0.00 0.00 0.29 0.36 0.46 1.57E-03 1.96E-03 2.37E-03 0.03 0.04 0.05 0.00 0.00 0.00 0.03 0.04 0.05 163.01 186.72 210.38 19.25 22.04 24.84 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Escherichia coli ColREC BSI - model 26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Escherichia coli ColREC OTH - model 30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Escherichia coli ColREC RESP - model 27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Escherichia coli ColREC SSI - model 29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Escherichia coli ColREC UTI - model 28 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Escherichia coli CREC BSI - model 21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Escherichia coli CREC OTH - model 25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Escherichia coli CREC RESP - model 22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Escherichia coli CREC SSI - model 24 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Escherichia coli CREC UTI - model 23 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Klebsiella pneumoniae 3GCRKP BSI - model 1 8.84 10.11 11.55 57.15 63.30 69.41 66.60 73.47 80.19 3.23 3.39 3.57 1.04 1.19 1.36 6.75 7.47 8.19 7.86 8.67 9.47 19.94 21.64 23.31 2.35 2.56 2.75 3.26 3.61 3.97 0.39 0.43 0.47 Cyprus - Klebsiella pneumoniae 3GCRKP OTH - model 5 0.02 0.03 0.04 0.00 0.00 0.00 0.02 0.03 0.04 2.46E-03 3.36E-03 4.35E-03 2.38E-03 3.37E-03 4.72E-03 0.00 0.00 0.00 2.38E-03 3.37E-03 4.72E-03 6.91 8.58 10.01 0.82 1.01 1.18 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Klebsiella pneumoniae 3GCRKP RESP - model 2 5.15 6.14 7.20 9.89 11.86 13.81 15.20 18.02 20.84 0.90 0.96 1.03 0.61 0.72 0.85 1.17 1.40 1.63 1.79 2.13 2.46 15.94 18.73 21.62 1.88 2.21 2.55 0.57 0.67 0.79 0.07 0.08 0.09 Cyprus - Klebsiella pneumoniae 3GCRKP SSI - model 4 0.01 0.02 0.03 3.33 4.23 5.07 3.34 4.25 5.10 0.47 0.50 0.52 1.41E-03 2.14E-03 3.09E-03 0.39 0.50 0.60 0.39 0.50 0.60 6.89 8.58 10.07 0.81 1.01 1.19 0.21 0.27 0.32 0.02 0.03 0.04 Cyprus - Klebsiella pneumoniae 3GCRKP UTI - model 3 0.04 0.05 0.07 0.00 0.00 0.00 0.04 0.05 0.07 1.43E-03 1.98E-03 2.48E-03 4.28E-03 5.89E-03 7.77E-03 0.00 0.00 0.00 4.28E-03 5.89E-03 7.77E-03 21.99 25.56 29.12 2.60 3.02 3.44 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Klebsiella pneumoniae ColRKP BSI - model 11 3.05 4.32 5.94 58.60 97.45 150.50 61.77 101.85 155.91 26.31 41.30 56.27 0.36 0.51 0.70 6.92 11.51 17.77 7.29 12.02 18.41 1.96 2.50 3.11 0.23 0.29 0.37 0.89 1.51 2.29 0.11 0.18 0.27 Cyprus - Klebsiella pneumoniae ColRKP OTH - model 15 1.52E-03 3.92E-03 7.93E-03 0.00 0.00 0.00 1.52E-03 3.92E-03 7.93E-03 1.55E-03 3.41E-03 6.32E-03 1.79E-04 4.63E-04 9.36E-04 0.00 0.00 0.00 1.79E-04 4.63E-04 9.36E-04 0.60 1.17 1.75 0.07 0.14 0.21 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Klebsiella pneumoniae ColRKP RESP - model 12 0.53 1.25 2.01 1.00 2.48 3.87 1.52 3.75 5.78 2.73 3.50 4.33 0.06 0.15 0.24 0.12 0.29 0.46 0.18 0.44 0.68 0.51 1.07 1.59 0.06 0.13 0.19 0.02 0.04 0.06 2.09E-03 4.56E-03 6.94E-03 Cyprus - Klebsiella pneumoniae ColRKP SSI - model 14 4.88E-04 1.47E-03 3.36E-03 0.19 0.43 0.70 0.20 0.43 0.70 0.47 0.59 0.70 5.76E-05 1.73E-04 3.97E-04 0.02 0.05 0.08 0.02 0.05 0.08 0.36 0.74 1.18 0.04 0.09 0.14 3.28E-03 6.67E-03 0.01 3.87E-04 7.88E-04 1.25E-03 Cyprus - Klebsiella pneumoniae ColRKP UTI - model 13 1.17E-03 3.02E-03 5.80E-03 0.00 0.00 0.00 1.17E-03 3.02E-03 5.80E-03 1.02E-03 2.02E-03 3.29E-03 1.38E-04 3.56E-04 6.85E-04 0.00 0.00 0.00 1.38E-04 3.56E-04 6.85E-04 0.86 1.55 2.25 0.10 0.18 0.27 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Klebsiella pneumoniae CRKP BSI - model 6 4.01 4.92 6.01 47.22 63.54 83.98 51.82 68.44 89.25 6.17 7.94 9.83 0.47 0.58 0.71 5.57 7.50 9.91 6.12 8.08 10.54 7.52 8.69 10.05 0.89 1.03 1.19 2.34 3.06 3.95 0.28 0.36 0.47 Cyprus - Klebsiella pneumoniae CRKP OTH - model 10 8.48E-03 0.01 0.02 0.00 0.00 0.00 8.48E-03 0.01 0.02 2.24E-03 3.46E-03 5.04E-03 1.00E-03 1.64E-03 2.80E-03 0.00 0.00 0.00 1.00E-03 1.64E-03 2.80E-03 2.81 4.08 5.38 0.33 0.48 0.64 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Klebsiella pneumoniae CRKP RESP - model 7 0.95 1.44 2.02 1.86 2.78 3.84 2.84 4.24 5.80 0.99 1.13 1.27 0.11 0.17 0.24 0.22 0.33 0.45 0.34 0.50 0.69 2.56 3.75 5.00 0.30 0.44 0.59 0.09 0.13 0.18 0.01 0.02 0.02 Cyprus - Klebsiella pneumoniae CRKP SSI - model 9 2.87E-03 5.36E-03 8.94E-03 0.74 1.13 1.52 0.75 1.13 1.52 0.37 0.44 0.53 3.38E-04 6.33E-04 1.06E-03 0.09 0.13 0.18 0.09 0.13 0.18 1.75 2.57 3.42 0.21 0.30 0.40 0.04 0.06 0.09 4.95E-03 7.41E-03 0.01 Cyprus - Klebsiella pneumoniae CRKP UTI - model 8 6.49E-03 0.01 0.02 0.00 0.00 0.00 6.49E-03 0.01 0.02 1.38E-03 2.07E-03 2.93E-03 7.66E-04 1.29E-03 2.04E-03 0.00 0.00 0.00 7.66E-04 1.29E-03 2.04E-03 3.90 5.32 6.83 0.46 0.63 0.81 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Pseudomonas aeruginosa ColRPA BSI - model 56 0.46 0.71 1.11 1.98 5.98 12.01 2.55 6.69 12.82 2.23 5.36 8.59 0.05 0.08 0.13 0.23 0.71 1.42 0.30 0.79 1.51 0.89 1.25 1.79 0.11 0.15 0.21 0.09 0.28 0.57 0.01 0.03 0.07 Cyprus - Pseudomonas aeruginosa ColRPA OTH - model 60 5.60E-04 2.20E-03 5.34E-03 0.00 0.00 0.00 5.60E-04 2.20E-03 5.34E-03 1.52E-03 3.59E-03 6.40E-03 6.61E-05 2.59E-04 6.31E-04 0.00 0.00 0.00 6.61E-05 2.59E-04 6.31E-04 0.22 0.65 1.09 0.03 0.08 0.13 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Pseudomonas aeruginosa ColRPA RESP - model 57 0.92 1.83 2.93 2.45 6.20 12.69 3.64 8.04 15.21 1.01 1.80 2.58 0.11 0.22 0.35 0.29 0.73 1.50 0.43 0.95 1.80 2.39 4.77 7.02 0.28 0.56 0.83 0.12 0.29 0.60 0.01 0.03 0.07 Cyprus - Pseudomonas aeruginosa ColRPA SSI - model 59 3.68E-04 1.68E-03 4.80E-03 0.23 0.66 1.12 0.23 0.66 1.13 0.76 0.76 0.76 4.34E-05 1.98E-04 5.66E-04 0.03 0.08 0.13 0.03 0.08 0.13 0.31 0.87 1.48 0.04 0.10 0.17 0.01 0.03 0.05 1.31E-03 3.71E-03 6.29E-03 Cyprus - Pseudomonas aeruginosa ColRPA UTI - model 58 8.50E-04 2.95E-03 7.62E-03 0.00 0.00 0.00 8.50E-04 2.95E-03 7.62E-03 8.36E-04 1.98E-03 3.72E-03 1.00E-04 3.48E-04 9.00E-04 0.00 0.00 0.00 1.00E-04 3.48E-04 9.00E-04 0.61 1.62 2.67 0.07 0.19 0.32 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Pseudomonas aeruginosa CRPA BSI - model 51 10.11 12.16 14.52 71.38 104.40 144.41 82.53 116.20 157.03 7.20 10.30 13.34 1.19 1.44 1.71 8.43 12.33 17.05 9.74 13.72 18.54 9.90 11.39 13.06 1.17 1.35 1.54 1.82 2.60 3.49 0.22 0.31 0.41 Cyprus - Pseudomonas aeruginosa CRPA OTH - model 55 0.01 0.02 0.03 0.00 0.00 0.00 0.01 0.02 0.03 2.73E-03 3.65E-03 4.72E-03 1.64E-03 2.48E-03 3.59E-03 0.00 0.00 0.00 1.64E-03 2.48E-03 3.59E-03 4.27 5.84 7.25 0.50 0.69 0.86 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Pseudomonas aeruginosa CRPA RESP - model 52 24.82 31.12 38.09 76.49 112.39 151.75 104.18 143.44 186.31 2.63 3.39 4.18 2.93 3.67 4.50 9.03 13.27 17.92 12.30 16.93 22.00 34.65 42.33 50.08 4.09 5.00 5.91 1.95 2.79 3.73 0.23 0.33 0.44 Cyprus - Pseudomonas aeruginosa CRPA SSI - model 54 0.01 0.02 0.03 2.76 3.72 4.76 2.73 3.73 4.78 0.43 0.48 0.53 1.19E-03 1.93E-03 2.96E-03 0.33 0.44 0.56 0.32 0.44 0.56 5.87 7.85 9.98 0.69 0.93 1.18 0.08 0.12 0.16 9.71E-03 0.01 0.02 Cyprus - Pseudomonas aeruginosa CRPA UTI - model 53 0.02 0.03 0.04 0.00 0.00 0.00 0.02 0.03 0.04 1.52E-03 2.03E-03 2.68E-03 2.35E-03 3.50E-03 5.02E-03 0.00 0.00 0.00 2.35E-03 3.50E-03 5.02E-03 11.39 14.67 18.07 1.34 1.73 2.13 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Pseudomonas aeruginosa MDRPA BSI - model 46 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Pseudomonas aeruginosa MDRPA OTH - model 50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Pseudomonas aeruginosa MDRPA RESP - model 47 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Pseudomonas aeruginosa MDRPA SSI - model 49 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Pseudomonas aeruginosa MDRPA UTI - model 48 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Staphylococcus aureus MRSA BSI - model 61 35.28 39.16 43.56 244.10 262.58 283.78 280.97 301.98 324.37 3.80 4.04 4.29 4.17 4.62 5.14 28.82 31.00 33.50 33.17 35.65 38.30 70.45 74.73 79.59 8.32 8.82 9.40 12.50 13.43 14.53 1.48 1.59 1.72 Cyprus - Staphylococcus aureus MRSA OTH - model 65 0.28 0.36 0.46 0.00 0.00 0.00 0.28 0.36 0.46 2.56E-03 3.25E-03 4.09E-03 0.03 0.04 0.05 0.00 0.00 0.00 0.03 0.04 0.05 98.59 110.27 121.80 11.64 13.02 14.38 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Staphylococcus aureus MRSA RESP - model 62 35.48 40.94 46.43 69.49 79.13 89.56 105.50 120.19 135.51 0.98 1.07 1.17 4.19 4.83 5.48 8.20 9.34 10.57 12.46 14.19 16.00 100.20 112.76 124.98 11.83 13.31 14.76 3.59 4.05 4.58 0.42 0.48 0.54 Cyprus - Staphylococcus aureus MRSA SSI - model 64 0.19 0.26 0.35 46.91 51.92 57.54 47.17 52.21 57.88 0.41 0.43 0.44 0.02 0.03 0.04 5.54 6.13 6.79 5.57 6.16 6.83 110.03 122.81 135.62 12.99 14.50 16.01 3.20 3.62 4.04 0.38 0.43 0.48 Cyprus - Staphylococcus aureus MRSA UTI - model 63 0.03 0.03 0.05 0.00 0.00 0.00 0.03 0.03 0.05 1.47E-03 1.85E-03 2.30E-03 2.98E-03 4.02E-03 5.47E-03 0.00 0.00 0.00 2.98E-03 4.02E-03 5.47E-03 14.98 18.50 21.97 1.77 2.18 2.59 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Streptococcus pneumoniae PMRSP BSI - model 76 1.93 2.29 2.73 14.47 15.73 16.84 16.76 18.04 19.27 7.16 7.71 8.21 0.23 0.27 0.32 1.71 1.86 1.99 1.98 2.13 2.28 2.32 2.34 2.37 0.27 0.28 0.28 0.39 0.42 0.45 0.05 0.05 0.05 Cyprus - Streptococcus pneumoniae PMRSP OTH - model 80 1.05E-03 1.58E-03 2.49E-03 0.00 0.00 0.00 1.05E-03 1.58E-03 2.49E-03 1.28E-03 1.94E-03 2.84E-03 1.24E-04 1.87E-04 2.94E-04 0.00 0.00 0.00 1.24E-04 1.87E-04 2.94E-04 0.73 0.82 0.97 0.09 0.10 0.11 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Streptococcus pneumoniae PMRSP RESP - model 77 4.83 6.16 8.45 9.56 12.01 16.16 14.72 18.12 24.58 1.83 2.03 2.24 0.57 0.73 1.00 1.13 1.42 1.91 1.74 2.14 2.90 7.42 8.92 11.83 0.88 1.05 1.40 0.26 0.32 0.43 0.03 0.04 0.05 Cyprus - Streptococcus pneumoniae PMRSP SSI - model 79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Streptococcus pneumoniae PMRSP UTI - model 78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Streptococcus pneumoniae PRSP BSI - model 71 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Streptococcus pneumoniae PRSP OTH - model 75 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Streptococcus pneumoniae PRSP RESP - model 72 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Streptococcus pneumoniae PRSP SSI - model 74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cyprus - Streptococcus pneumoniae PRSP UTI - model 73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total (Median & 95% UIs) 244.25 295.29 356.29 1,279.62 1,662.14 2,132.65 1,543.27 1,957.59 2,466.92 28.84 34.86 42.06 151.08 196.24 251.79 182.20 231.12 291.25 1,025.40 1,192.27 1,363.81 121.06 140.76 161.02 54.20 65.63 78.72 6.40 7.75 9.29 Total (average) Deaths per year DALY per 100,000 Cases per year Incidence per 100,000 - DALY per 100,000 Cases per year Incidence per 100,000 Deaths per yearDALY DALY per Case YLD per 100,000 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 Mortality per 100,000 296.65 1,673.16 1,969.81 - 35.02 7.78197.54 232.56 1,193.34 140.89 65.88 Mortality per 100,000YLL per 100,000 YLD YLL Infection Colistin resistant Acinetobacter spp. 4.05 5.19 6.51 17.84 27.69 39.42 22.37 32.85 45.18 4.87 6.84 9.02 0.04 0.05 0.06 0.17 0.26 0.37 0.21 0.31 0.43 11.04 14.15 17.28 0.10 0.13 0.16 0.82 1.23 1.70 0.01 0.01 0.02 Carbapenem resistant Acinetobacter spp. (excluding those resistant to colistin) 3.53 5.03 6.93 13.42 27.28 43.62 17.72 32.26 49.58 8.09 13.55 19.43 0.03 0.05 0.07 0.13 0.26 0.41 0.17 0.31 0.47 5.02 7.03 9.14 0.05 0.07 0.09 0.31 0.61 0.95 0.00 0.01 0.01 Aminoglycosides and fluoroquinolones resistant Acinetobacter spp. (excluding those resistant to colistin and/or carbapenem) 4.65 6.22 8.16 18.64 32.71 48.79 23.96 38.81 56.45 7.16 10.77 14.64 0.04 0.06 0.08 0.18 0.31 0.46 0.23 0.37 0.54 8.03 10.59 13.24 0.08 0.10 0.13 0.53 0.89 1.32 0.01 0.01 0.01 Vancomycin resistant Enterococci (E. faecalis and E. faecium ) 27.15 33.63 41.24 261.10 316.08 379.10 289.58 349.43 418.52 6.08 6.73 7.42 0.26 0.32 0.39 2.48 3.00 3.60 2.75 3.32 3.97 160.98 199.47 238.92 1.53 1.89 2.27 11.04 13.29 15.90 0.10 0.13 0.15 Colistin resistant Escherichia coli 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Escherichia coli (excluding those resistant to colistin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Third-generation cephalosporin resistant Escherichia coli (excluding those resistant to colistin and/or carbapenem) 293.04 330.59 368.99 1,763.72 1,986.27 2,228.42 2,069.13 2,316.46 2,584.17 4.18 4.55 4.93 2.78 3.14 3.50 16.74 18.85 21.15 19.63 21.98 24.52 3,574.16 4,042.98 4,526.25 33.92 38.36 42.95 110.71 125.98 143.28 1.05 1.20 1.36 Colistin resistant Klebsiella pneumoniae 12.10 14.28 16.81 202.11 252.90 304.61 215.97 266.96 321.08 12.54 15.35 17.93 0.11 0.14 0.16 1.92 2.40 2.89 2.05 2.53 3.05 42.99 51.92 61.42 0.41 0.49 0.58 9.50 11.69 14.20 0.09 0.11 0.13 Carbapenem resistant Klebsiella pneumoniae (excluding those resistant to colistin) 2.87 3.96 5.30 28.70 42.51 59.43 31.50 46.31 64.08 9.94 13.72 17.63 0.03 0.04 0.05 0.27 0.40 0.56 0.30 0.44 0.61 7.00 10.38 13.80 0.07 0.10 0.13 0.98 1.39 1.94 0.01 0.01 0.02 Third-generation cephalosporin resistant Klebsiella pneumoniae (excluding those resistant to colistin and/or carbapenem) 782.79 855.44 936.98 3,852.96 4,116.93 4,390.89 4,663.51 4,973.75 5,310.58 5.69 5.93 6.17 7.43 8.12 8.89 36.56 39.07 41.67 44.25 47.20 50.39 3,152.21 3,462.27 3,769.55 29.91 32.85 35.77 175.90 188.90 203.09 1.67 1.79 1.93 Colistin resistant Pseudomonas aeruginosa 1.75 2.71 3.94 5.78 13.21 23.71 7.94 15.97 26.95 2.16 4.03 6.21 0.02 0.03 0.04 0.05 0.13 0.22 0.08 0.15 0.26 11.56 18.12 25.08 0.11 0.17 0.24 0.58 1.23 2.08 0.01 0.01 0.02 Carbapenem resistant Pseudomonas aeruginosa (excluding those resistant to colistin) 112.98 130.32 149.29 528.00 659.08 815.23 647.22 789.31 958.99 6.58 7.92 9.28 1.07 1.24 1.42 5.01 6.25 7.74 6.14 7.49 9.10 381.80 444.03 508.51 3.62 4.21 4.83 24.01 30.31 37.68 0.23 0.29 0.36 Pseudomonas aeruginosa resistant to three or more antimicrobial groups (excluding those resistant to colistin and/or carbapenem) 103.63 119.60 138.27 450.44 573.88 704.24 558.63 692.44 833.33 5.95 7.20 8.41 0.98 1.13 1.31 4.27 5.45 6.68 5.30 6.57 7.91 364.93 425.26 487.28 3.46 4.04 4.62 21.37 27.42 33.89 0.20 0.26 0.32 Methicillin resistant Staphylococcus aureus 296.69 326.50 357.34 1,474.85 1,588.84 1,701.61 1,781.85 1,915.62 2,050.06 5.36 5.60 5.84 2.82 3.10 3.39 14.00 15.08 16.15 16.91 18.18 19.45 1,604.67 1,751.85 1,899.12 15.23 16.62 18.02 77.13 83.14 89.47 0.73 0.79 0.85 Penicillin and macrolides resistant Streptococcus pneumoniae (excluding those only resistant to penicillin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Penicillin tesistant Streptococcus pneumoniae (excluding those resistant to macrolides) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total 1,645.23 1,833.47 2,039.76 8,617.59 9,637.37 10,739.06 10,329.38 11,470.18 12,718.98 15.61 17.40 19.36 81.77 91.45 101.91 98.02 108.84 120.69 9,324.39 10,438.06 11,569.58 88.48 99.05 109.79 432.87 486.09 545.49 4.11 4.61 5.18 Model Czech Republic - Acinetobacter spp. ColRACI BSI - model 41 2.37E+00 2.96E+00 3.65E+00 1.41E+01 2.27E+01 3.31E+01 1.70E+01 2.56E+01 3.60E+01 3.44E+00 5.21E+00 7.19E+00 2.25E-02 2.81E-02 3.46E-02 1.34E-01 2.15E-01 3.14E-01 1.61E-01 2.43E-01 3.42E-01 4.31E+00 4.89E+00 5.53E+00 4.09E-02 4.64E-02 5.25E-02 6.49E-01 9.98E-01 1.41E+00 6.16E-03 9.47E-03 1.34E-02 Czech Republic - Acinetobacter spp. ColRACI OTH - model 45 2.65E-04 6.07E-04 1.07E-03 0.00 0.00 0.00 2.65E-04 6.07E-04 1.07E-03 2.40E-03 3.80E-03 5.37E-03 2.52E-06 5.76E-06 1.02E-05 0.00 0.00 0.00 2.52E-06 5.76E-06 1.02E-05 0.08 0.16 0.26 7.70E-04 1.56E-03 2.44E-03 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Acinetobacter spp. ColRACI RESP - model 42 1.68 2.23 2.85 3.24 4.33 5.47 4.90 6.57 8.27 1.08 1.24 1.39 0.02 0.02 0.03 0.03 0.04 0.05 0.05 0.06 0.08 4.09 5.31 6.49 0.04 0.05 0.06 0.15 0.19 0.24 1.39E-03 1.80E-03 2.24E-03 Czech Republic - Acinetobacter spp. ColRACI SSI - model 44 1.90E-03 3.74E-03 6.27E-03 0.45 0.68 0.89 0.46 0.69 0.90 0.34 0.38 0.43 1.81E-05 3.54E-05 5.95E-05 4.31E-03 6.48E-03 8.48E-03 4.34E-03 6.51E-03 8.54E-03 1.23 1.79 2.33 0.01 0.02 0.02 0.03 0.04 0.05 2.46E-04 3.82E-04 5.14E-04 Czech Republic - Acinetobacter spp. ColRACI UTI - model 43 2.24E-03 3.98E-03 6.44E-03 0.00 0.00 0.00 2.24E-03 3.98E-03 6.44E-03 1.32E-03 2.02E-03 2.80E-03 2.12E-05 3.78E-05 6.11E-05 0.00 0.00 0.00 2.12E-05 3.78E-05 6.11E-05 1.33 2.00 2.67 0.01 0.02 0.03 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Acinetobacter spp. CRACI BSI - model 36 2.13 2.87 3.89 10.27 22.39 36.69 12.96 25.20 39.96 5.43 10.41 15.71 0.02 0.03 0.04 0.10 0.21 0.35 0.12 0.24 0.38 2.06 2.45 2.86 0.02 0.02 0.03 0.24 0.50 0.79 2.26E-03 4.73E-03 7.53E-03 Czech Republic - Acinetobacter spp. CRACI OTH - model 40 8.61E-05 2.88E-04 6.77E-04 0.00 0.00 0.00 8.61E-05 2.88E-04 6.77E-04 1.86E-03 3.68E-03 5.78E-03 8.17E-07 2.73E-06 6.43E-06 0.00 0.00 0.00 8.17E-07 2.73E-06 6.43E-06 0.03 0.08 0.15 2.61E-04 7.65E-04 1.44E-03 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Acinetobacter spp. CRACI RESP - model 37 1.40 2.16 3.03 2.81 4.27 6.05 4.42 6.44 8.74 2.00 2.45 2.99 0.01 0.02 0.03 0.03 0.04 0.06 0.04 0.06 0.08 1.88 2.63 3.43 0.02 0.02 0.03 0.07 0.09 0.12 6.31E-04 8.98E-04 1.18E-03 Czech Republic - Acinetobacter spp. CRACI SSI - model 39 6.43E-04 1.84E-03 3.78E-03 0.35 0.61 0.87 0.35 0.61 0.87 0.66 0.69 0.73 6.10E-06 1.75E-05 3.59E-05 3.28E-03 5.80E-03 8.27E-03 3.29E-03 5.81E-03 8.30E-03 0.49 0.89 1.26 4.69E-03 8.41E-03 0.01 9.22E-03 0.02 0.03 8.75E-05 1.90E-04 2.85E-04 Czech Republic - Acinetobacter spp. CRACI UTI - model 38 8.90E-04 1.96E-03 3.71E-03 0.00 0.00 0.00 8.90E-04 1.96E-03 3.71E-03 1.05E-03 2.06E-03 3.22E-03 8.44E-06 1.86E-05 3.52E-05 0.00 0.00 0.00 8.44E-06 1.86E-05 3.52E-05 0.55 0.99 1.44 5.26E-03 9.38E-03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Acinetobacter spp. MDRACI BSI - model 31 2.75 3.57 4.53 14.45 26.82 41.08 17.72 30.29 45.20 5.01 8.29 11.77 0.03 0.03 0.04 0.14 0.25 0.39 0.17 0.29 0.43 3.16 3.66 4.21 0.03 0.03 0.04 0.41 0.72 1.10 3.87E-03 6.86E-03 0.01 Czech Republic - Acinetobacter spp. MDRACI OTH - model 35 1.67E-04 4.44E-04 9.27E-04 0.00 0.00 0.00 1.67E-04 4.44E-04 9.27E-04 2.16E-03 3.77E-03 5.54E-03 1.59E-06 4.21E-06 8.79E-06 0.00 0.00 0.00 1.59E-06 4.21E-06 8.79E-06 0.05 0.12 0.21 5.15E-04 1.14E-03 1.99E-03 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Acinetobacter spp. MDRACI RESP - model 32 1.89 2.65 3.62 3.77 5.24 6.84 5.83 7.86 10.38 1.71 1.99 2.33 0.02 0.03 0.03 0.04 0.05 0.06 0.06 0.07 0.10 3.03 3.96 4.98 0.03 0.04 0.05 0.11 0.14 0.18 1.00E-03 1.36E-03 1.73E-03 Czech Republic - Acinetobacter spp. MDRACI SSI - model 34 1.21E-03 2.71E-03 5.36E-03 0.41 0.65 0.87 0.41 0.65 0.87 0.44 0.49 0.53 1.15E-05 2.57E-05 5.09E-05 3.90E-03 6.13E-03 8.24E-03 3.92E-03 6.15E-03 8.26E-03 0.85 1.33 1.76 8.11E-03 0.01 0.02 0.01 0.02 0.03 1.32E-04 2.30E-04 3.26E-04 Czech Republic - Acinetobacter spp. MDRACI UTI - model 33 1.62E-03 2.98E-03 5.19E-03 0.00 0.00 0.00 1.62E-03 2.98E-03 5.19E-03 1.19E-03 2.04E-03 3.07E-03 1.54E-05 2.83E-05 4.92E-05 0.00 0.00 0.00 1.54E-05 2.83E-05 4.92E-05 0.92 1.52 2.08 8.75E-03 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Enterococcus faecalis and E. faecium VRE BSI - model 66 26.95 33.35 40.85 238.36 285.71 341.14 266.63 318.82 380.18 5.69 6.28 6.93 0.26 0.32 0.39 2.26 2.71 3.24 2.53 3.03 3.61 42.68 50.65 60.17 0.41 0.48 0.57 9.78 11.59 13.76 0.09 0.11 0.13 Czech Republic - Enterococcus faecalis and E. faecium VRE OTH - model 70 0.06 0.09 0.12 0.00 0.00 0.00 0.06 0.09 0.12 1.27E-03 1.65E-03 2.05E-03 6.08E-04 8.36E-04 1.12E-03 0.00 0.00 0.00 6.08E-04 8.36E-04 1.12E-03 42.73 53.80 64.11 0.41 0.51 0.61 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Enterococcus faecalis and E. faecium VRE RESP - model 67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Enterococcus faecalis and E. faecium VRE SSI - model 69 0.10 0.15 0.21 22.74 30.36 37.96 22.86 30.47 38.15 0.39 0.44 0.49 9.75E-04 1.40E-03 1.97E-03 0.22 0.29 0.36 0.22 0.29 0.36 55.32 69.35 83.10 0.52 0.66 0.79 1.26 1.70 2.14 0.01 0.02 0.02 Czech Republic - Enterococcus faecalis and E. faecium VRE UTI - model 68 0.03 0.05 0.06 0.00 0.00 0.00 0.03 0.05 0.06 1.47E-03 1.87E-03 2.32E-03 3.21E-04 4.54E-04 6.09E-04 0.00 0.00 0.00 3.21E-04 4.54E-04 6.09E-04 20.25 25.67 31.53 0.19 0.24 0.30 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Escherichia coli 3GCREC BSI - model 16 224.40 248.02 271.19 1,430.27 1,590.57 1,772.91 1,666.91 1,838.16 2,032.72 2.97 3.24 3.50 2.13 2.35 2.57 13.57 15.09 16.82 15.82 17.44 19.29 525.12 567.95 610.94 4.98 5.39 5.80 87.80 98.25 111.10 0.83 0.93 1.05 Czech Republic - Escherichia coli 3GCREC OTH - model 20 0.46 0.63 0.84 0.00 0.00 0.00 0.46 0.63 0.84 2.66E-03 3.34E-03 4.15E-03 4.32E-03 5.94E-03 8.01E-03 0.00 0.00 0.00 4.32E-03 5.94E-03 8.01E-03 151.07 188.26 229.16 1.43 1.79 2.17 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Escherichia coli 3GCREC RESP - model 17 63.56 75.92 89.24 121.34 146.45 171.50 184.80 222.53 259.34 0.82 0.88 0.98 0.60 0.72 0.85 1.15 1.39 1.63 1.75 2.11 2.46 204.27 250.99 296.25 1.94 2.38 2.81 7.27 9.05 10.74 0.07 0.09 0.10 Czech Republic - Escherichia coli 3GCREC SSI - model 19 0.88 1.27 1.73 212.11 249.26 284.01 213.21 250.39 285.27 0.39 0.42 0.44 8.36E-03 0.01 0.02 2.01 2.37 2.70 2.02 2.38 2.71 514.63 600.53 681.87 4.88 5.70 6.47 15.64 18.68 21.44 0.15 0.18 0.20 Czech Republic - Escherichia coli 3GCREC UTI - model 18 3.76 4.75 6.00 0.00 0.00 0.00 3.76 4.75 6.00 1.58E-03 1.95E-03 2.39E-03 0.04 0.05 0.06 0.00 0.00 0.00 0.04 0.05 0.06 2,179.07 2,435.25 2,708.02 20.68 23.11 25.70 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Escherichia coli ColREC BSI - model 26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Escherichia coli ColREC OTH - model 30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Escherichia coli ColREC RESP - model 27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Escherichia coli ColREC SSI - model 29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Escherichia coli ColREC UTI - model 28 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Escherichia coli CREC BSI - model 21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Escherichia coli CREC OTH - model 25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Escherichia coli CREC RESP - model 22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Escherichia coli CREC SSI - model 24 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Escherichia coli CREC UTI - model 23 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Klebsiella pneumoniae 3GCRKP BSI - model 1 491.60 532.04 579.51 3,162.45 3,342.49 3,526.28 3,679.25 3,875.67 4,090.94 4.12 4.28 4.42 4.66 5.05 5.50 30.01 31.72 33.46 34.91 36.78 38.82 864.95 907.50 950.27 8.21 8.61 9.02 142.83 151.56 160.93 1.36 1.44 1.53 Czech Republic - Klebsiella pneumoniae 3GCRKP RESP - model 2 288.02 319.38 352.44 556.42 616.46 682.55 846.75 936.11 1,032.79 1.15 1.20 1.27 2.73 3.03 3.34 5.28 5.85 6.48 8.03 8.88 9.80 705.78 778.27 855.71 6.70 7.39 8.12 25.06 27.97 31.26 0.24 0.27 0.30 Czech Republic - Klebsiella pneumoniae 3GCRKP UTI - model 3 1.66 2.08 2.53 0.00 0.00 0.00 1.66 2.08 2.53 1.59E-03 1.96E-03 2.34E-03 0.02 0.02 0.02 0.00 0.00 0.00 0.02 0.02 0.02 953.16 1,062.34 1,157.93 9.04 10.08 10.99 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Klebsiella pneumoniae 3GCRKP SSI - model 4 0.56 0.75 1.00 134.09 157.98 182.06 134.91 158.70 182.83 0.42 0.45 0.47 5.28E-03 7.10E-03 9.46E-03 1.27 1.50 1.73 1.28 1.51 1.73 312.55 354.21 401.80 2.97 3.36 3.81 8.01 9.37 10.89 0.08 0.09 0.10 Czech Republic - Klebsiella pneumoniae 3GCRKP OTH - model 5 0.95 1.20 1.49 0.00 0.00 0.00 0.95 1.20 1.49 2.72E-03 3.32E-03 3.99E-03 9.03E-03 0.01 0.01 0.00 0.00 0.00 9.03E-03 0.01 0.01 315.76 359.95 403.84 3.00 3.42 3.83 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Klebsiella pneumoniae ColRKP BSI - model 11 9.61 11.04 12.66 195.63 244.55 294.14 206.96 255.38 306.54 11.17 13.75 16.05 0.09 0.10 0.12 1.86 2.32 2.79 1.96 2.42 2.91 17.00 18.68 20.68 0.16 0.18 0.20 9.18 11.26 13.66 0.09 0.11 0.13 Czech Republic - Klebsiella pneumoniae ColRKP OTH - model 15 0.02 0.03 0.04 0.00 0.00 0.00 0.02 0.03 0.04 2.58E-03 3.48E-03 4.65E-03 1.93E-04 2.83E-04 4.13E-04 0.00 0.00 0.00 1.93E-04 2.83E-04 4.13E-04 6.67 8.65 10.56 0.06 0.08 0.10 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Klebsiella pneumoniae ColRKP RESP - model 12 2.44 3.17 4.06 4.77 6.13 7.70 7.25 9.29 11.68 1.00 1.19 1.42 0.02 0.03 0.04 0.05 0.06 0.07 0.07 0.09 0.11 6.12 7.86 9.74 0.06 0.07 0.09 0.22 0.28 0.35 2.07E-03 2.68E-03 3.33E-03 Czech Republic - Klebsiella pneumoniae ColRKP SSI - model 14 7.39E-03 0.01 0.02 1.72 2.23 2.77 1.73 2.24 2.78 0.37 0.41 0.45 7.01E-05 1.11E-04 1.65E-04 0.02 0.02 0.03 0.02 0.02 0.03 4.15 5.51 6.84 0.04 0.05 0.06 0.11 0.15 0.19 1.02E-03 1.41E-03 1.82E-03 Czech Republic - Klebsiella pneumoniae ColRKP UTI - model 13 0.02 0.02 0.03 0.00 0.00 0.00 0.02 0.02 0.03 1.57E-03 2.06E-03 2.64E-03 1.57E-04 2.16E-04 3.11E-04 0.00 0.00 0.00 1.57E-04 2.16E-04 3.11E-04 9.06 11.22 13.60 0.09 0.11 0.13 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Klebsiella pneumoniae CRKP BSI - model 6 2.38 3.05 3.97 27.55 40.31 56.27 29.83 43.19 59.66 8.31 11.65 15.11 0.02 0.03 0.04 0.26 0.38 0.53 0.28 0.41 0.57 3.10 3.76 4.46 0.03 0.04 0.04 0.93 1.31 1.83 8.86E-03 0.01 0.02 Czech Republic - Klebsiella pneumoniae CRKP OTH - model 10 2.60E-03 5.68E-03 0.01 0.00 0.00 0.00 2.60E-03 5.68E-03 0.01 1.98E-03 3.44E-03 5.49E-03 2.47E-05 5.39E-05 1.03E-04 0.00 0.00 0.00 2.47E-05 5.39E-05 1.03E-04 0.99 1.70 2.45 9.40E-03 0.02 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Klebsiella pneumoniae CRKP RESP - model 7 0.48 0.90 1.30 0.93 1.77 2.52 1.44 2.67 3.77 1.27 1.66 2.07 4.60E-03 8.51E-03 0.01 8.78E-03 0.02 0.02 0.01 0.03 0.04 0.94 1.60 2.20 8.88E-03 0.02 0.02 0.03 0.06 0.08 3.16E-04 5.47E-04 7.66E-04 Czech Republic - Klebsiella pneumoniae CRKP SSI - model 9 7.62E-04 2.22E-03 4.33E-03 0.23 0.43 0.63 0.23 0.43 0.63 0.35 0.39 0.43 7.23E-06 2.11E-05 4.11E-05 2.18E-03 4.09E-03 5.96E-03 2.19E-03 4.12E-03 5.98E-03 0.59 1.10 1.59 5.59E-03 0.01 0.02 9.36E-03 0.02 0.03 8.89E-05 1.88E-04 2.84E-04 Czech Republic - Klebsiella pneumoniae CRKP UTI - model 8 2.24E-03 4.60E-03 8.04E-03 0.00 0.00 0.00 2.24E-03 4.60E-03 8.04E-03 1.16E-03 2.07E-03 3.17E-03 2.13E-05 4.37E-05 7.63E-05 0.00 0.00 0.00 2.13E-05 4.37E-05 7.63E-05 1.39 2.22 3.10 0.01 0.02 0.03 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Pseudomonas aeruginosa ColRPA BSI - model 56 0.54 0.75 1.05 2.52 6.01 10.81 3.23 6.82 11.71 1.32 2.73 4.32 5.08E-03 7.10E-03 9.95E-03 0.02 0.06 0.10 0.03 0.06 0.11 1.95 2.51 3.17 0.02 0.02 0.03 0.25 0.56 0.94 2.38E-03 5.29E-03 8.91E-03 Czech Republic - Pseudomonas aeruginosa ColRPA OTH - model 60 1.79E-03 4.69E-03 9.17E-03 0.00 0.00 0.00 1.79E-03 4.69E-03 9.17E-03 1.90E-03 3.76E-03 5.77E-03 1.70E-05 4.45E-05 8.71E-05 0.00 0.00 0.00 1.70E-05 4.45E-05 8.71E-05 0.58 1.28 1.96 5.53E-03 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Pseudomonas aeruginosa ColRPA RESP - model 57 1.21 1.95 2.87 2.98 6.53 11.89 4.42 8.47 14.20 0.56 0.91 1.37 0.01 0.02 0.03 0.03 0.06 0.11 0.04 0.08 0.13 6.32 9.43 12.76 0.06 0.09 0.12 0.30 0.61 1.05 2.82E-03 5.78E-03 9.94E-03 Czech Republic - Pseudomonas aeruginosa ColRPA SSI - model 59 1.10E-03 3.34E-03 7.75E-03 0.29 0.67 1.02 0.29 0.67 1.02 0.27 0.39 0.51 1.04E-05 3.17E-05 7.36E-05 2.75E-03 6.37E-03 9.64E-03 2.77E-03 6.38E-03 9.67E-03 0.87 1.71 2.56 8.21E-03 0.02 0.02 0.03 0.06 0.09 2.96E-04 5.83E-04 8.73E-04 Czech Republic - Pseudomonas aeruginosa ColRPA UTI - model 58 2.86E-03 6.61E-03 0.01 0.00 0.00 0.00 2.86E-03 6.61E-03 0.01 1.06E-03 2.06E-03 3.30E-03 2.72E-05 6.27E-05 1.18E-04 0.00 0.00 0.00 2.72E-05 6.27E-05 1.18E-04 1.85 3.19 4.65 0.02 0.03 0.04 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Pseudomonas aeruginosa CRPA BSI - model 51 32.70 36.60 41.32 249.26 309.98 381.49 284.39 346.99 419.59 4.58 5.61 6.68 0.31 0.35 0.39 2.37 2.94 3.62 2.70 3.29 3.98 56.44 61.81 67.84 0.54 0.59 0.64 11.08 14.08 17.49 0.11 0.13 0.17 Czech Republic - Pseudomonas aeruginosa CRPA OTH - model 55 0.09 0.11 0.15 0.00 0.00 0.00 0.09 0.11 0.15 2.93E-03 3.67E-03 4.43E-03 8.17E-04 1.08E-03 1.39E-03 0.00 0.00 0.00 8.17E-04 1.08E-03 1.39E-03 25.67 31.44 36.94 0.24 0.30 0.35 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Pseudomonas aeruginosa CRPA RESP - model 52 80.01 93.35 107.49 264.16 330.28 410.90 347.96 423.15 516.08 1.59 1.86 2.11 0.76 0.89 1.02 2.51 3.13 3.90 3.30 4.02 4.90 199.11 228.53 260.23 1.89 2.17 2.47 12.07 15.11 18.83 0.11 0.14 0.18 Czech Republic - Pseudomonas aeruginosa CRPA SSI - model 54 0.06 0.09 0.12 14.58 18.82 22.84 14.66 18.90 22.97 0.41 0.44 0.48 6.05E-04 8.56E-04 1.17E-03 0.14 0.18 0.22 0.14 0.18 0.22 34.47 42.70 50.39 0.33 0.41 0.48 0.86 1.11 1.35 8.15E-03 0.01 0.01 Czech Republic - Pseudomonas aeruginosa CRPA UTI - model 53 0.12 0.16 0.21 0.00 0.00 0.00 0.12 0.16 0.21 1.64E-03 2.06E-03 2.46E-03 1.17E-03 1.54E-03 2.00E-03 0.00 0.00 0.00 1.17E-03 1.54E-03 2.00E-03 66.10 79.54 93.11 0.63 0.75 0.88 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Pseudomonas aeruginosa MDRPA BSI - model 46 29.84 33.71 38.13 207.82 265.87 324.85 239.10 299.46 360.36 4.09 5.05 5.98 0.28 0.32 0.36 1.97 2.52 3.08 2.27 2.84 3.42 53.99 59.34 65.15 0.51 0.56 0.62 9.81 12.64 15.57 0.09 0.12 0.15 Czech Republic - Pseudomonas aeruginosa MDRPA OTH - model 50 0.08 0.11 0.15 0.00 0.00 0.00 0.08 0.11 0.15 2.96E-03 3.75E-03 4.59E-03 7.79E-04 1.06E-03 1.42E-03 0.00 0.00 0.00 7.79E-04 1.06E-03 1.42E-03 23.67 29.92 36.01 0.22 0.28 0.34 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Pseudomonas aeruginosa MDRPA RESP - model 47 73.54 85.54 99.66 228.50 290.41 358.25 305.16 375.03 451.37 1.46 1.71 1.96 0.70 0.81 0.95 2.17 2.76 3.40 2.90 3.56 4.28 191.32 219.46 249.54 1.82 2.08 2.37 10.73 13.71 17.02 0.10 0.13 0.16 Czech Republic - Pseudomonas aeruginosa MDRPA SSI - model 49 0.06 0.09 0.12 14.12 17.59 21.14 14.18 17.69 21.25 0.40 0.44 0.47 5.75E-04 8.29E-04 1.16E-03 0.13 0.17 0.20 0.13 0.17 0.20 33.06 40.73 48.04 0.31 0.39 0.46 0.83 1.07 1.30 7.86E-03 0.01 0.01 Czech Republic - Pseudomonas aeruginosa MDRPA UTI - model 48 0.11 0.15 0.20 0.00 0.00 0.00 0.11 0.15 0.20 1.61E-03 2.04E-03 2.50E-03 1.08E-03 1.46E-03 1.91E-03 0.00 0.00 0.00 1.08E-03 1.46E-03 1.91E-03 62.90 75.82 88.53 0.60 0.72 0.84 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Staphylococcus aureus MRSA BSI - model 61 145.99 158.61 172.08 1,002.04 1,063.80 1,128.39 1,153.76 1,223.01 1,292.34 3.93 4.09 4.25 1.39 1.51 1.63 9.51 10.09 10.71 10.95 11.61 12.26 284.73 298.78 313.82 2.70 2.84 2.98 50.53 53.64 57.07 0.48 0.51 0.54 Czech Republic - Staphylococcus aureus MRSA OTH - model 65 1.16 1.44 1.77 0.00 0.00 0.00 1.16 1.44 1.77 2.70E-03 3.26E-03 3.93E-03 0.01 0.01 0.02 0.00 0.00 0.00 0.01 0.01 0.02 402.11 439.72 480.15 3.82 4.17 4.56 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Staphylococcus aureus MRSA RESP - model 62 148.64 165.27 181.98 288.21 320.67 350.04 441.46 485.61 531.52 1.02 1.08 1.14 1.41 1.57 1.73 2.73 3.04 3.32 4.19 4.61 5.04 408.76 449.84 490.92 3.88 4.27 4.66 14.59 16.17 17.83 0.14 0.15 0.17 Czech Republic - Staphylococcus aureus MRSA SSI - model 64 0.80 1.05 1.33 184.60 204.36 223.17 185.37 205.44 224.26 0.40 0.42 0.44 7.58E-03 9.94E-03 0.01 1.75 1.94 2.12 1.76 1.95 2.13 447.70 490.50 529.18 4.25 4.65 5.02 12.01 13.33 14.58 0.11 0.13 0.14 Czech Republic - Staphylococcus aureus MRSA UTI - model 63 0.10 0.13 0.18 0.00 0.00 0.00 0.10 0.13 0.18 1.50E-03 1.87E-03 2.28E-03 9.88E-04 1.28E-03 1.66E-03 0.00 0.00 0.00 9.88E-04 1.28E-03 1.66E-03 61.36 73.01 85.05 0.58 0.69 0.81 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Streptococcus pneumoniae PMRSP BSI - model 76 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Streptococcus pneumoniae PMRSP OTH - model 80 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Streptococcus pneumoniae PMRSP RESP - model 77 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Streptococcus pneumoniae PMRSP SSI - model 79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Streptococcus pneumoniae PMRSP UTI - model 78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Streptococcus pneumoniae PRSP BSI - model 71 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Streptococcus pneumoniae PRSP OTH - model 75 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Streptococcus pneumoniae PRSP RESP - model 72 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Streptococcus pneumoniae PRSP SSI - model 74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Czech Republic - Streptococcus pneumoniae PRSP UTI - model 73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total (Median & 95% UIs) 1,645.23 1,833.47 2,039.76 8,617.59 9,637.37 10,739.06 10,329.38 11,470.18 12,718.98 15.61 17.40 19.36 81.77 91.45 101.91 98.02 108.84 120.69 9,324.39 10,438.06 11,569.58 88.48 99.05 109.79 432.87 486.09 545.49 4.11 4.61 5.18 Total (average) - 91.54 108.96 10,443.14 99.10 486.73 4.62 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 1,835.95 9,647.06 11,483.01 - 17.42 YLL per 100,000YLD YLL DALY DALY per Case YLD per 100,000 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000YLL per 100,000YLD YLL DALY DALY per Case YLD per 100,000 Infection Colistin resistant Acinetobacter spp. 5.98 9.02 13.03 24.45 47.40 79.67 31.89 56.40 91.62 2.76 4.53 6.62 0.01 0.01 0.02 0.03 0.06 0.10 0.04 0.07 0.11 26.13 37.62 50.23 0.03 0.05 0.06 1.90 3.30 5.04 0.00 0.00 0.01 Carbapenem resistant Acinetobacter spp. (excluding those resistant to colistin) 67.99 81.36 96.34 329.26 434.42 548.22 402.81 516.36 641.25 4.58 5.60 6.69 0.08 0.10 0.12 0.41 0.54 0.68 0.50 0.64 0.79 233.11 277.53 324.74 0.29 0.34 0.40 18.76 24.14 30.64 0.02 0.03 0.04 Aminoglycosides and fluoroquinolones resistant Acinetobacter spp. (excluding those resistant to colistin and/or carbapenem) 9.36 14.21 21.17 38.02 75.01 127.45 49.32 89.10 144.73 4.36 7.05 10.26 0.01 0.02 0.03 0.05 0.09 0.16 0.06 0.11 0.18 25.71 37.76 50.86 0.03 0.05 0.06 1.88 3.23 4.92 0.00 0.00 0.01 Vancomycin resistant Enterococci (E. faecalis and E. faecium ) 396.93 476.90 564.90 3,760.51 4,511.91 5,322.80 4,158.96 4,986.88 5,888.96 5.64 6.24 6.83 0.49 0.59 0.70 4.63 5.56 6.56 5.12 6.14 7.25 2,483.18 3,088.59 3,700.08 3.06 3.80 4.56 167.77 205.46 245.73 0.21 0.25 0.30 Colistin resistant Escherichia coli 59.32 72.26 87.65 949.88 1,227.95 1,515.11 1,016.50 1,301.06 1,612.52 9.25 11.37 13.80 0.07 0.09 0.11 1.17 1.51 1.87 1.25 1.60 1.99 725.79 891.64 1,070.50 0.89 1.10 1.32 60.11 78.08 97.18 0.07 0.10 0.12 Carbapenem resistant Escherichia coli (excluding those resistant to colistin) 5.31 7.84 11.10 52.60 81.67 121.86 58.63 89.79 133.41 5.48 7.24 9.47 0.01 0.01 0.01 0.06 0.10 0.15 0.07 0.11 0.16 66.18 99.00 131.55 0.08 0.12 0.16 3.47 5.28 7.60 0.00 0.01 0.01 Third-generation cephalosporin resistant Escherichia coli (excluding those resistant to colistin and/or carbapenem) 2,126.51 2,420.26 2,796.12 12,654.65 14,408.43 16,325.01 14,804.04 16,833.12 19,020.70 4.33 4.77 5.24 2.62 2.98 3.44 15.59 17.74 20.11 18.23 20.73 23.43 24,000.61 28,391.89 32,720.22 29.56 34.97 40.30 734.98 867.92 1,011.37 0.91 1.07 1.25 Colistin resistant Klebsiella pneumoniae 28.93 37.18 46.90 487.37 645.98 850.83 518.54 683.57 892.26 12.97 16.53 20.72 0.04 0.05 0.06 0.60 0.80 1.05 0.64 0.84 1.10 95.27 125.61 155.89 0.12 0.15 0.19 21.10 27.49 35.00 0.03 0.03 0.04 Carbapenem resistant Klebsiella pneumoniae (excluding those resistant to colistin) 5.64 9.35 15.12 55.45 97.36 170.61 62.00 107.12 185.22 9.20 13.83 19.49 0.01 0.01 0.02 0.07 0.12 0.21 0.08 0.13 0.23 15.16 25.07 36.30 0.02 0.03 0.04 2.07 3.27 4.97 0.00 0.00 0.01 Third-generation cephalosporin resistant Klebsiella pneumoniae (excluding those resistant to colistin and/or carbapenem) 458.79 519.21 583.26 2,252.82 2,478.12 2,742.34 2,731.20 2,997.72 3,313.56 4.77 5.09 5.45 0.57 0.64 0.72 2.77 3.05 3.38 3.36 3.69 4.08 2,115.43 2,470.16 2,859.42 2.61 3.04 3.52 118.59 133.57 151.71 0.15 0.16 0.19 Colistin resistant Pseudomonas aeruginosa 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Pseudomonas aeruginosa (excluding those resistant to colistin) 1,294.68 1,508.57 1,739.67 6,025.29 7,597.87 9,338.91 7,424.97 9,118.69 10,970.13 7.39 8.80 10.20 1.59 1.86 2.14 7.42 9.36 11.50 9.14 11.23 13.51 3,872.69 4,628.24 5,387.34 4.77 5.70 6.63 241.23 310.73 389.36 0.30 0.38 0.48 Pseudomonas aeruginosa resistant to three or more antimicrobial groups (excluding those resistant to colistin and/or carbapenem) 114.98 142.70 174.00 500.71 675.09 887.98 624.04 817.30 1,048.42 5.85 7.39 9.09 0.14 0.18 0.21 0.62 0.83 1.09 0.77 1.01 1.29 396.25 490.57 592.89 0.49 0.60 0.73 22.60 31.22 40.14 0.03 0.04 0.05 Methicillin resistant Staphylococcus aureus 2,052.50 2,328.34 2,611.74 10,241.34 11,426.94 12,628.84 12,322.15 13,757.79 15,186.19 4.89 5.16 5.47 2.53 2.87 3.22 12.61 14.07 15.55 15.18 16.94 18.70 11,864.56 13,683.49 15,409.18 14.61 16.85 18.98 576.66 653.42 732.98 0.71 0.80 0.90 Penicillin and macrolides resistant Streptococcus pneumoniae (excluding those only resistant to penicillin) 18.39 26.42 41.41 67.02 86.34 118.83 87.04 112.95 158.62 4.98 5.80 6.74 0.02 0.03 0.05 0.08 0.11 0.15 0.11 0.14 0.20 50.10 64.99 86.60 0.06 0.08 0.11 3.22 3.95 4.90 0.00 0.00 0.01 Penicillin tesistant Streptococcus pneumoniae (excluding those resistant to macrolides) 130.99 167.95 220.36 459.44 544.58 662.36 595.77 713.54 875.95 11.04 12.04 13.25 0.16 0.21 0.27 0.57 0.67 0.82 0.73 0.88 1.08 163.60 196.65 232.91 0.20 0.24 0.29 10.29 11.81 13.54 0.01 0.01 0.02 Total 6,776.30 7,821.59 9,022.76 37,898.82 44,339.05 51,440.82 44,887.87 52,181.40 60,163.53 8.35 9.63 11.11 46.67 54.61 63.35 55.28 64.26 74.10 46,133.78 54,508.80 62,808.71 56.82 67.13 77.35 1,984.63 2,362.88 2,775.08 2.44 2.91 3.42 Model Germany - Acinetobacter spp. ColRACI BSI - model 41 3.53E+00 5.14E+00 7.28E+00 1.90E+01 3.88E+01 6.71E+01 2.39E+01 4.38E+01 7.35E+01 1.91E+00 3.47E+00 5.28E+00 4.35E-03 6.32E-03 8.96E-03 2.34E-02 4.77E-02 8.26E-02 2.95E-02 5.40E-02 9.05E-02 1.01E+01 1.29E+01 1.58E+01 1.25E-02 1.59E-02 1.95E-02 1.49E+00 2.67E+00 4.17E+00 1.83E-03 3.29E-03 5.13E-03 Germany - Acinetobacter spp. ColRACI OTH - model 45 6.36E-04 1.79E-03 3.46E-03 0.00 0.00 0.00 6.36E-04 1.79E-03 3.46E-03 2.24E-03 3.78E-03 5.59E-03 7.83E-07 2.21E-06 4.26E-06 0.00 0.00 0.00 7.83E-07 2.21E-06 4.26E-06 0.20 0.48 0.80 2.45E-04 5.92E-04 9.90E-04 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Acinetobacter spp. ColRACI RESP - model 42 2.44 3.86 5.71 4.74 7.38 10.72 7.21 11.29 16.22 0.61 0.79 1.04 3.01E-03 4.75E-03 7.03E-03 5.83E-03 9.09E-03 0.01 8.88E-03 0.01 0.02 9.85 13.99 18.65 0.01 0.02 0.02 0.34 0.50 0.68 4.23E-04 6.19E-04 8.35E-04 Germany - Acinetobacter spp. ColRACI SSI - model 44 3.92E-03 9.77E-03 0.02 0.72 1.26 1.90 0.73 1.28 1.90 0.24 0.26 0.29 4.82E-06 1.20E-05 2.50E-05 8.89E-04 1.56E-03 2.34E-03 8.97E-04 1.57E-03 2.34E-03 2.79 4.82 7.16 3.43E-03 5.94E-03 8.82E-03 0.07 0.13 0.20 8.62E-05 1.59E-04 2.46E-04 Germany - Acinetobacter spp. ColRACI UTI - model 43 5.35E-03 0.01 0.02 0.00 0.00 0.00 5.35E-03 0.01 0.02 1.16E-03 2.05E-03 3.08E-03 6.59E-06 1.35E-05 2.39E-05 0.00 0.00 0.00 6.59E-06 1.35E-05 2.39E-05 3.16 5.46 7.79 3.89E-03 6.73E-03 9.59E-03 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Acinetobacter spp. CRACI BSI - model 36 39.37 46.33 54.02 262.77 352.70 448.69 306.65 399.45 500.28 3.32 4.20 5.15 0.05 0.06 0.07 0.32 0.43 0.55 0.38 0.49 0.62 84.51 94.65 106.32 0.10 0.12 0.13 14.88 19.39 24.97 0.02 0.02 0.03 Germany - Acinetobacter spp. CRACI OTH - model 40 8.62E-03 0.01 0.02 0.00 0.00 0.00 8.62E-03 0.01 0.02 2.94E-03 3.73E-03 4.59E-03 1.06E-05 1.65E-05 2.38E-05 0.00 0.00 0.00 1.06E-05 1.65E-05 2.38E-05 2.48 3.60 4.80 3.05E-03 4.43E-03 5.91E-03 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Acinetobacter spp. CRACI RESP - model 37 28.50 34.87 42.08 55.26 66.97 80.93 84.76 102.00 122.14 0.89 0.99 1.08 0.04 0.04 0.05 0.07 0.08 0.10 0.10 0.13 0.15 86.96 103.74 121.60 0.11 0.13 0.15 3.09 3.73 4.40 3.81E-03 4.59E-03 5.42E-03 Germany - Acinetobacter spp. CRACI SSI - model 39 0.05 0.08 0.11 11.24 14.74 18.60 11.33 14.82 18.70 0.37 0.41 0.46 6.18E-05 9.24E-05 1.31E-04 0.01 0.02 0.02 0.01 0.02 0.02 28.01 35.65 43.81 0.03 0.04 0.05 0.78 1.02 1.28 9.65E-04 1.26E-03 1.57E-03 Germany - Acinetobacter spp. CRACI UTI - model 38 0.06 0.08 0.11 0.00 0.00 0.00 0.06 0.08 0.11 1.60E-03 2.03E-03 2.52E-03 7.18E-05 9.98E-05 1.37E-04 0.00 0.00 0.00 7.18E-05 9.98E-05 1.37E-04 31.16 39.90 48.21 0.04 0.05 0.06 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Acinetobacter spp. MDRACI BSI - model 31 5.73 8.06 11.79 29.84 60.97 106.86 37.22 68.87 115.25 3.06 5.36 8.12 7.06E-03 9.93E-03 0.01 0.04 0.08 0.13 0.05 0.08 0.14 10.17 12.81 16.22 0.01 0.02 0.02 1.47 2.59 4.04 1.80E-03 3.19E-03 4.98E-03 Germany - Acinetobacter spp. MDRACI OTH - model 35 6.28E-04 1.69E-03 3.53E-03 0.00 0.00 0.00 6.28E-04 1.69E-03 3.53E-03 2.11E-03 3.67E-03 5.48E-03 7.73E-07 2.08E-06 4.35E-06 0.00 0.00 0.00 7.73E-07 2.08E-06 4.35E-06 0.20 0.47 0.81 2.46E-04 5.80E-04 9.95E-04 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Acinetobacter spp. MDRACI RESP - model 32 3.62 6.12 9.33 7.13 12.07 17.66 11.04 18.25 26.51 0.96 1.28 1.65 4.45E-03 7.54E-03 0.01 8.78E-03 0.01 0.02 0.01 0.02 0.03 9.56 14.22 19.17 0.01 0.02 0.02 0.34 0.51 0.69 4.23E-04 6.27E-04 8.50E-04 Germany - Acinetobacter spp. MDRACI SSI - model 34 4.21E-03 9.93E-03 0.02 1.04 1.97 2.93 1.06 1.98 2.94 0.33 0.41 0.48 5.19E-06 1.22E-05 2.47E-05 1.29E-03 2.43E-03 3.61E-03 1.30E-03 2.44E-03 3.63E-03 2.70 4.85 6.73 3.32E-03 5.97E-03 8.29E-03 0.07 0.13 0.19 8.24E-05 1.60E-04 2.37E-04 Germany - Acinetobacter spp. MDRACI UTI - model 33 5.24E-03 0.01 0.02 0.00 0.00 0.00 5.24E-03 0.01 0.02 1.22E-03 2.03E-03 3.04E-03 6.45E-06 1.33E-05 2.47E-05 0.00 0.00 0.00 6.45E-06 1.33E-05 2.47E-05 3.09 5.41 7.93 3.81E-03 6.66E-03 9.76E-03 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Enterococcus faecalis and E. faecium VRE BSI - model 66 393.72 472.50 559.00 3,413.78 4,062.98 4,772.91 3,809.10 4,533.89 5,333.92 5.26 5.81 6.36 0.48 0.58 0.69 4.20 5.00 5.88 4.69 5.58 6.57 646.65 778.41 926.80 0.80 0.96 1.14 147.60 178.08 211.61 0.18 0.22 0.26 Germany - Enterococcus faecalis and E. faecium VRE OTH - model 70 1.01 1.36 1.79 0.00 0.00 0.00 1.01 1.36 1.79 1.31E-03 1.64E-03 2.01E-03 1.24E-03 1.67E-03 2.21E-03 0.00 0.00 0.00 1.24E-03 1.67E-03 2.21E-03 671.14 835.14 1,001.85 0.83 1.03 1.23 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Enterococcus faecalis and E. faecium VRE RESP - model 67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Enterococcus faecalis and E. faecium VRE SSI - model 69 1.65 2.31 3.13 346.73 448.93 549.89 348.30 450.90 552.28 0.38 0.42 0.46 2.03E-03 2.84E-03 3.85E-03 0.43 0.55 0.68 0.43 0.56 0.68 853.65 1,077.09 1,287.53 1.05 1.33 1.59 20.17 27.38 34.12 0.02 0.03 0.04 Germany - Enterococcus faecalis and E. faecium VRE UTI - model 68 0.55 0.74 0.97 0.00 0.00 0.00 0.55 0.74 0.97 1.51E-03 1.87E-03 2.24E-03 6.75E-04 9.13E-04 1.20E-03 0.00 0.00 0.00 6.75E-04 9.13E-04 1.20E-03 311.74 397.94 483.89 0.38 0.49 0.60 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Escherichia coli 3GCREC BSI - model 16 1,617.54 1,803.22 2,048.17 10,346.13 11,633.01 13,051.60 11,988.08 13,439.91 14,999.21 3.12 3.43 3.75 1.99 2.22 2.52 12.74 14.33 16.07 14.76 16.55 18.47 3,516.29 3,923.04 4,408.07 4.33 4.83 5.43 584.41 677.28 781.21 0.72 0.83 0.96 Germany - Escherichia coli 3GCREC OTH - model 20 3.15 4.48 6.00 0.00 0.00 0.00 3.15 4.48 6.00 2.63E-03 3.34E-03 4.19E-03 3.87E-03 5.52E-03 7.38E-03 0.00 0.00 0.00 3.87E-03 5.52E-03 7.38E-03 1,036.87 1,341.48 1,653.45 1.28 1.65 2.04 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Escherichia coli 3GCREC RESP - model 17 473.62 570.27 687.62 908.51 1,103.80 1,303.60 1,380.07 1,675.92 1,994.04 0.84 0.94 1.06 0.58 0.70 0.85 1.12 1.36 1.61 1.70 2.06 2.46 1,411.90 1,792.40 2,195.38 1.74 2.21 2.70 49.99 64.70 79.38 0.06 0.08 0.10 Germany - Escherichia coli 3GCREC SSI - model 19 6.56 8.99 12.47 1,400.01 1,671.62 1,969.81 1,407.08 1,679.51 1,979.59 0.37 0.40 0.43 8.07E-03 0.01 0.02 1.72 2.06 2.43 1.73 2.07 2.44 3,473.15 4,227.64 4,960.32 4.28 5.21 6.11 100.58 125.94 150.78 0.12 0.16 0.19 Germany - Escherichia coli 3GCREC UTI - model 18 25.66 33.30 41.86 0.00 0.00 0.00 25.66 33.30 41.86 1.54E-03 1.96E-03 2.37E-03 0.03 0.04 0.05 0.00 0.00 0.00 0.03 0.04 0.05 14,562.41 17,107.33 19,502.99 17.93 21.07 24.02 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Escherichia coli ColREC BSI - model 26 43.99 52.27 62.34 876.10 1,132.84 1,397.41 927.44 1,185.82 1,470.96 8.11 10.06 12.28 0.05 0.06 0.08 1.08 1.40 1.72 1.14 1.46 1.81 101.38 118.09 135.36 0.12 0.15 0.17 54.93 71.33 88.84 0.07 0.09 0.11 Germany - Escherichia coli ColREC OTH - model 30 0.16 0.24 0.36 0.00 0.00 0.00 0.16 0.24 0.36 2.56E-03 3.49E-03 4.69E-03 1.95E-04 2.98E-04 4.40E-04 0.00 0.00 0.00 1.95E-04 2.98E-04 4.40E-04 53.65 69.04 86.84 0.07 0.09 0.11 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Escherichia coli ColREC RESP - model 27 14.24 18.40 23.04 27.09 35.30 44.31 41.38 53.82 66.04 0.75 0.88 1.03 0.02 0.02 0.03 0.03 0.04 0.05 0.05 0.07 0.08 46.40 61.08 75.69 0.06 0.08 0.09 1.67 2.20 2.79 2.06E-03 2.71E-03 3.44E-03 Germany - Escherichia coli ColREC SSI - model 29 0.20 0.30 0.44 46.69 59.81 73.39 46.78 60.13 73.70 0.38 0.42 0.47 2.45E-04 3.70E-04 5.39E-04 0.06 0.07 0.09 0.06 0.07 0.09 112.57 142.26 170.66 0.14 0.18 0.21 3.51 4.55 5.55 4.32E-03 5.60E-03 6.83E-03 Germany - Escherichia coli ColREC UTI - model 28 0.74 1.04 1.47 0.00 0.00 0.00 0.74 1.04 1.47 1.54E-03 2.10E-03 2.77E-03 9.14E-04 1.29E-03 1.81E-03 0.00 0.00 0.00 9.14E-04 1.29E-03 1.81E-03 411.80 501.17 601.95 0.51 0.62 0.74 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Escherichia coli CREC BSI - model 21 4.13 5.67 7.74 47.03 72.49 108.62 51.86 78.41 116.98 4.47 6.02 8.01 5.08E-03 6.98E-03 9.53E-03 0.06 0.09 0.13 0.06 0.10 0.14 10.08 13.04 16.51 0.01 0.02 0.02 3.07 4.62 6.66 3.78E-03 5.69E-03 8.20E-03 Germany - Escherichia coli CREC OTH - model 25 0.01 0.03 0.05 0.00 0.00 0.00 0.01 0.03 0.05 2.00E-03 3.43E-03 5.71E-03 1.68E-05 3.27E-05 6.06E-05 0.00 0.00 0.00 1.68E-05 3.27E-05 6.06E-05 4.71 7.76 10.97 5.80E-03 9.56E-03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Escherichia coli CREC RESP - model 22 1.09 2.00 3.06 2.15 3.81 5.86 3.26 5.83 8.78 0.70 0.86 1.07 1.35E-03 2.47E-03 3.77E-03 2.65E-03 4.69E-03 7.21E-03 4.01E-03 7.18E-03 0.01 3.97 6.75 9.71 4.88E-03 8.32E-03 0.01 0.14 0.24 0.35 1.71E-04 2.98E-04 4.35E-04 Germany - Escherichia coli CREC SSI - model 24 0.01 0.03 0.06 3.41 5.37 7.38 3.45 5.41 7.41 0.31 0.34 0.38 1.82E-05 3.98E-05 7.52E-05 4.20E-03 6.61E-03 9.09E-03 4.24E-03 6.66E-03 9.13E-03 9.97 15.66 21.46 0.01 0.02 0.03 0.26 0.42 0.59 3.22E-04 5.23E-04 7.30E-04 Germany - Escherichia coli CREC UTI - model 23 0.06 0.11 0.20 0.00 0.00 0.00 0.06 0.11 0.20 1.21E-03 2.03E-03 3.22E-03 7.38E-05 1.36E-04 2.43E-04 0.00 0.00 0.00 7.38E-05 1.36E-04 2.43E-04 37.45 55.79 72.90 0.05 0.07 0.09 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Klebsiella pneumoniae 3GCRKP BSI - model 1 286.43 319.64 356.79 1,839.33 1,993.03 2,182.40 2,144.50 2,312.64 2,527.78 3.42 3.64 3.86 0.35 0.39 0.44 2.27 2.45 2.69 2.64 2.85 3.11 579.52 636.07 706.08 0.71 0.78 0.87 96.01 105.99 118.82 0.12 0.13 0.15 Germany - Klebsiella pneumoniae 3GCRKP OTH - model 5 0.63 0.86 1.15 0.00 0.00 0.00 0.63 0.86 1.15 2.63E-03 3.35E-03 4.19E-03 7.77E-04 1.06E-03 1.42E-03 0.00 0.00 0.00 7.77E-04 1.06E-03 1.42E-03 214.40 257.88 313.46 0.26 0.32 0.39 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Klebsiella pneumoniae 3GCRKP RESP - model 2 170.25 196.68 222.64 327.66 377.80 429.86 498.69 574.83 651.86 0.95 1.03 1.12 0.21 0.24 0.27 0.40 0.47 0.53 0.61 0.71 0.80 472.94 559.07 657.16 0.58 0.69 0.81 16.78 20.09 23.65 0.02 0.02 0.03 Germany - Klebsiella pneumoniae 3GCRKP SSI - model 4 0.38 0.54 0.78 85.83 107.29 130.08 86.27 107.90 130.86 0.40 0.42 0.45 4.62E-04 6.66E-04 9.59E-04 0.11 0.13 0.16 0.11 0.13 0.16 207.82 256.25 304.91 0.26 0.32 0.38 5.80 7.49 9.24 7.14E-03 9.22E-03 0.01 Germany - Klebsiella pneumoniae 3GCRKP UTI - model 3 1.11 1.48 1.90 0.00 0.00 0.00 1.11 1.48 1.90 1.53E-03 1.95E-03 2.41E-03 1.36E-03 1.83E-03 2.33E-03 0.00 0.00 0.00 1.36E-03 1.83E-03 2.33E-03 640.75 760.89 877.81 0.79 0.94 1.08 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Klebsiella pneumoniae ColRKP BSI - model 11 23.14 28.51 35.19 473.21 625.05 822.69 498.41 653.88 852.62 11.65 14.89 18.72 0.03 0.04 0.04 0.58 0.77 1.01 0.61 0.81 1.05 37.20 43.92 51.17 0.05 0.05 0.06 20.42 26.50 33.69 0.03 0.03 0.04 Germany - Klebsiella pneumoniae ColRKP OTH - model 15 0.05 0.07 0.11 0.00 0.00 0.00 0.05 0.07 0.11 2.46E-03 3.48E-03 4.71E-03 5.66E-05 9.13E-05 1.40E-04 0.00 0.00 0.00 5.66E-05 9.13E-05 1.40E-04 14.95 21.41 27.60 0.02 0.03 0.03 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Klebsiella pneumoniae ColRKP RESP - model 12 5.70 8.52 11.46 11.05 16.33 22.09 16.92 24.93 33.35 1.03 1.30 1.60 7.02E-03 0.01 0.01 0.01 0.02 0.03 0.02 0.03 0.04 13.73 19.36 24.65 0.02 0.02 0.03 0.49 0.69 0.89 6.10E-04 8.54E-04 1.10E-03 Germany - Klebsiella pneumoniae ColRKP SSI - model 14 0.02 0.03 0.05 3.11 4.60 6.05 3.13 4.63 6.09 0.29 0.34 0.39 2.00E-05 3.49E-05 5.59E-05 3.83E-03 5.67E-03 7.45E-03 3.86E-03 5.70E-03 7.50E-03 9.60 13.64 17.83 0.01 0.02 0.02 0.19 0.30 0.43 2.36E-04 3.74E-04 5.24E-04 Germany - Klebsiella pneumoniae ColRKP UTI - model 13 0.03 0.06 0.08 0.00 0.00 0.00 0.03 0.06 0.08 1.44E-03 2.07E-03 2.74E-03 4.29E-05 6.83E-05 1.03E-04 0.00 0.00 0.00 4.29E-05 6.83E-05 1.03E-04 19.80 27.28 34.64 0.02 0.03 0.04 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Klebsiella pneumoniae CRKP BSI - model 6 4.78 7.13 11.15 53.19 91.82 161.27 58.94 99.41 171.97 7.69 11.71 16.78 5.89E-03 8.78E-03 0.01 0.07 0.11 0.20 0.07 0.12 0.21 6.69 8.69 11.54 8.24E-03 0.01 0.01 1.97 3.07 4.66 2.42E-03 3.78E-03 5.74E-03 Germany - Klebsiella pneumoniae CRKP OTH - model 10 5.91E-03 0.01 0.03 0.00 0.00 0.00 5.91E-03 0.01 0.03 1.76E-03 3.41E-03 5.91E-03 7.28E-06 1.72E-05 3.43E-05 0.00 0.00 0.00 7.28E-06 1.72E-05 3.43E-05 2.14 4.27 6.46 2.63E-03 5.26E-03 7.96E-03 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Klebsiella pneumoniae CRKP RESP - model 7 0.85 2.20 3.91 1.61 4.29 7.44 2.39 6.44 11.28 1.06 1.66 2.24 1.04E-03 2.71E-03 4.82E-03 1.99E-03 5.28E-03 9.16E-03 2.95E-03 7.94E-03 0.01 2.13 3.88 5.93 2.62E-03 4.78E-03 7.31E-03 0.07 0.14 0.22 8.89E-05 1.71E-04 2.68E-04 Germany - Klebsiella pneumoniae CRKP SSI - model 9 2.41E-03 5.45E-03 0.01 0.65 1.24 1.91 0.66 1.24 1.91 0.45 0.45 0.46 2.97E-06 6.72E-06 1.48E-05 8.05E-04 1.53E-03 2.35E-03 8.08E-04 1.53E-03 2.36E-03 1.45 2.73 4.24 1.78E-03 3.37E-03 5.23E-03 0.03 0.06 0.09 4.00E-05 7.59E-05 1.15E-04 Germany - Klebsiella pneumoniae CRKP UTI - model 8 4.99E-03 0.01 0.02 0.00 0.00 0.00 4.99E-03 0.01 0.02 1.16E-03 2.06E-03 3.19E-03 6.15E-06 1.36E-05 2.57E-05 0.00 0.00 0.00 6.15E-06 1.36E-05 2.57E-05 2.76 5.50 8.13 3.40E-03 6.77E-03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Pseudomonas aeruginosa ColRPA BSI - model 56 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Pseudomonas aeruginosa ColRPA OTH - model 60 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Pseudomonas aeruginosa ColRPA RESP - model 57 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Pseudomonas aeruginosa ColRPA SSI - model 59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Pseudomonas aeruginosa ColRPA UTI - model 58 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Pseudomonas aeruginosa CRPA BSI - model 51 368.73 419.12 479.26 2,817.61 3,566.26 4,370.71 3,224.51 3,993.12 4,817.67 5.21 6.29 7.37 0.45 0.52 0.59 3.47 4.39 5.38 3.97 4.92 5.93 562.69 636.96 708.42 0.69 0.78 0.87 110.78 144.73 182.63 0.14 0.18 0.22 Germany - Pseudomonas aeruginosa CRPA OTH - model 55 0.86 1.19 1.59 0.00 0.00 0.00 0.86 1.19 1.59 2.96E-03 3.64E-03 4.39E-03 1.06E-03 1.47E-03 1.96E-03 0.00 0.00 0.00 1.06E-03 1.47E-03 1.96E-03 252.94 330.37 404.34 0.31 0.41 0.50 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Pseudomonas aeruginosa CRPA RESP - model 52 923.15 1,085.62 1,255.28 3,060.11 3,844.58 4,738.51 4,049.98 4,934.79 5,917.72 1.78 2.08 2.37 1.14 1.34 1.55 3.77 4.73 5.84 4.99 6.08 7.29 2,011.89 2,380.26 2,741.98 2.48 2.93 3.38 122.38 155.41 193.43 0.15 0.19 0.24 Germany - Pseudomonas aeruginosa CRPA SSI - model 54 0.67 0.95 1.32 147.58 187.03 229.69 148.37 187.89 230.93 0.39 0.42 0.45 8.28E-04 1.17E-03 1.62E-03 0.18 0.23 0.28 0.18 0.23 0.28 359.82 447.37 538.66 0.44 0.55 0.66 8.06 10.58 13.30 9.93E-03 0.01 0.02 Germany - Pseudomonas aeruginosa CRPA UTI - model 53 1.26 1.69 2.22 0.00 0.00 0.00 1.26 1.69 2.22 1.63E-03 2.05E-03 2.48E-03 1.55E-03 2.09E-03 2.73E-03 0.00 0.00 0.00 1.55E-03 2.09E-03 2.73E-03 685.35 833.27 993.94 0.84 1.03 1.22 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Pseudomonas aeruginosa MDRPA BSI - model 46 32.78 39.75 48.06 224.28 311.52 414.62 260.37 351.08 459.15 4.03 5.21 6.50 0.04 0.05 0.06 0.28 0.38 0.51 0.32 0.43 0.57 58.04 67.82 78.52 0.07 0.08 0.10 10.34 14.30 18.32 0.01 0.02 0.02 Germany - Pseudomonas aeruginosa MDRPA OTH - model 50 0.09 0.13 0.18 0.00 0.00 0.00 0.09 0.13 0.18 2.90E-03 3.75E-03 4.62E-03 1.06E-04 1.61E-04 2.27E-04 0.00 0.00 0.00 1.06E-04 1.61E-04 2.27E-04 25.66 34.84 44.98 0.03 0.04 0.06 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Pseudomonas aeruginosa MDRPA RESP - model 47 81.92 102.54 125.36 262.55 344.51 448.29 349.58 446.74 563.73 1.46 1.76 2.13 0.10 0.13 0.15 0.32 0.42 0.55 0.43 0.55 0.69 207.71 252.26 300.34 0.26 0.31 0.37 11.43 15.74 20.25 0.01 0.02 0.02 Germany - Pseudomonas aeruginosa MDRPA SSI - model 49 0.07 0.10 0.15 13.88 19.07 25.07 13.87 19.17 25.10 0.36 0.41 0.45 8.04E-05 1.23E-04 1.80E-04 0.02 0.02 0.03 0.02 0.02 0.03 35.74 47.07 59.24 0.04 0.06 0.07 0.83 1.18 1.57 1.02E-03 1.46E-03 1.93E-03 Germany - Pseudomonas aeruginosa MDRPA UTI - model 48 0.13 0.18 0.25 0.00 0.00 0.00 0.13 0.18 0.25 1.58E-03 2.04E-03 2.56E-03 1.54E-04 2.23E-04 3.04E-04 0.00 0.00 0.00 1.54E-04 2.23E-04 3.04E-04 69.10 88.57 109.80 0.09 0.11 0.14 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Staphylococcus aureus MRSA BSI - model 61 1,004.52 1,121.82 1,234.78 6,835.22 7,509.22 8,150.49 7,865.50 8,633.22 9,353.04 3.56 3.74 3.95 1.24 1.38 1.52 8.42 9.25 10.04 9.69 10.63 11.52 2,086.66 2,304.18 2,523.51 2.57 2.84 3.11 372.81 413.95 455.80 0.46 0.51 0.56 Germany - Staphylococcus aureus MRSA OTH - model 65 8.81 11.19 14.12 0.00 0.00 0.00 8.81 11.19 14.12 2.59E-03 3.28E-03 3.97E-03 0.01 0.01 0.02 0.00 0.00 0.00 0.01 0.01 0.02 2,991.82 3,446.10 3,854.62 3.68 4.24 4.75 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Staphylococcus aureus MRSA RESP - model 62 1,032.49 1,186.17 1,350.44 2,003.95 2,292.24 2,601.25 3,037.57 3,479.20 3,926.52 0.92 0.99 1.07 1.27 1.46 1.66 2.47 2.82 3.20 3.74 4.28 4.84 2,971.84 3,520.18 3,975.12 3.66 4.34 4.90 107.35 126.43 146.51 0.13 0.16 0.18 Germany - Staphylococcus aureus MRSA SSI - model 64 5.88 8.07 10.94 1,402.17 1,625.49 1,877.10 1,409.46 1,633.09 1,891.06 0.40 0.43 0.45 7.24E-03 9.94E-03 0.01 1.73 2.00 2.31 1.74 2.01 2.33 3,344.26 3,828.93 4,356.87 4.12 4.72 5.37 96.50 113.04 130.68 0.12 0.14 0.16 Germany - Staphylococcus aureus MRSA UTI - model 63 0.80 1.09 1.46 0.00 0.00 0.00 0.80 1.09 1.46 1.47E-03 1.87E-03 2.33E-03 9.88E-04 1.34E-03 1.79E-03 0.00 0.00 0.00 9.88E-04 1.34E-03 1.79E-03 469.97 584.09 699.07 0.58 0.72 0.86 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Streptococcus pneumoniae PMRSP BSI - model 76 5.58 7.22 9.21 41.90 48.61 56.96 48.41 55.90 64.97 4.09 4.59 5.12 6.87E-03 8.89E-03 0.01 0.05 0.06 0.07 0.06 0.07 0.08 11.24 12.17 13.15 0.01 0.01 0.02 1.96 2.19 2.44 2.41E-03 2.70E-03 3.00E-03 Germany - Streptococcus pneumoniae PMRSP OTH - model 80 5.13E-03 8.54E-03 0.01 0.00 0.00 0.00 5.13E-03 8.54E-03 0.01 1.24E-03 1.95E-03 2.74E-03 6.32E-06 1.05E-05 1.63E-05 0.00 0.00 0.00 6.32E-06 1.05E-05 1.63E-05 3.58 4.44 5.53 4.41E-03 5.47E-03 6.81E-03 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Streptococcus pneumoniae PMRSP RESP - model 77 12.81 19.19 32.18 25.13 37.73 61.87 38.63 57.03 93.64 0.88 1.20 1.62 0.02 0.02 0.04 0.03 0.05 0.08 0.05 0.07 0.12 35.28 48.38 67.92 0.04 0.06 0.08 1.26 1.75 2.47 1.56E-03 2.16E-03 3.04E-03 Germany - Streptococcus pneumoniae PMRSP SSI - model 79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Streptococcus pneumoniae PMRSP UTI - model 78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Streptococcus pneumoniae PRSP BSI - model 71 38.19 44.54 52.25 275.05 303.45 335.15 317.13 348.01 383.05 8.89 9.54 10.28 0.05 0.05 0.06 0.34 0.37 0.41 0.39 0.43 0.47 34.64 36.46 38.35 0.04 0.04 0.05 6.09 6.56 7.04 7.50E-03 8.08E-03 8.67E-03 Germany - Streptococcus pneumoniae PRSP OTH - model 75 0.02 0.03 0.03 0.00 0.00 0.00 0.02 0.03 0.03 1.46E-03 1.95E-03 2.51E-03 2.31E-05 3.17E-05 4.23E-05 0.00 0.00 0.00 2.31E-05 3.17E-05 4.23E-05 11.51 13.30 15.29 0.01 0.02 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Streptococcus pneumoniae PRSP RESP - model 72 92.78 123.39 168.07 184.39 241.13 327.21 278.62 365.51 492.87 2.14 2.50 2.97 0.11 0.15 0.21 0.23 0.30 0.40 0.34 0.45 0.61 117.45 146.88 179.26 0.14 0.18 0.22 4.21 5.26 6.50 5.18E-03 6.47E-03 8.00E-03 Germany - Streptococcus pneumoniae PRSP SSI - model 74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Germany - Streptococcus pneumoniae PRSP UTI - model 73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total (Median & 95% UIs) 6,776.30 7,821.59 9,022.76 37,898.82 44,339.05 51,440.82 44,887.87 52,181.40 60,163.53 8.35 9.63 11.11 46.67 54.61 63.35 55.28 64.26 74.10 46,133.78 54,508.80 62,808.71 56.82 67.13 77.35 1,984.63 2,362.88 2,775.08 2.44 2.91 3.42 Total (average) - 54.71 64.37 54,469.02 67.08 2,370.09 2.92 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 7,841.16 44,422.28 52,263.44 - 9.66 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 Infection Colistin resistant Acinetobacter spp. 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Acinetobacter spp. (excluding those resistant to colistin) 3.31 4.35 5.63 13.23 23.34 34.17 17.20 27.66 39.51 5.97 9.10 12.07 0.06 0.08 0.10 0.23 0.41 0.60 0.30 0.49 0.70 6.75 8.95 11.30 0.12 0.16 0.20 0.46 0.78 1.13 0.01 0.01 0.02 Aminoglycosides and fluoroquinolones resistant Acinetobacter spp. (excluding those resistant to colistin and/or carbapenem) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Vancomycin resistant Enterococci (E. faecalis and E. faecium ) 15.70 19.66 25.13 149.02 188.11 235.95 165.06 207.86 259.66 6.22 6.81 7.42 0.28 0.35 0.44 2.63 3.32 4.17 2.92 3.67 4.59 87.54 117.98 148.87 1.55 2.08 2.63 6.09 7.83 9.87 0.11 0.14 0.17 Colistin resistant Escherichia coli 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Escherichia coli (excluding those resistant to colistin) 1.07 1.84 2.88 10.44 20.32 31.43 11.82 22.18 33.87 14.32 22.30 29.66 0.02 0.03 0.05 0.18 0.36 0.56 0.21 0.39 0.60 4.59 7.90 11.07 0.08 0.14 0.20 0.21 0.41 0.64 0.00 0.01 0.01 Third-generation cephalosporin resistant Escherichia coli (excluding those resistant to colistin and/or carbapenem) 223.14 250.94 281.95 1,315.52 1,485.53 1,670.77 1,544.11 1,735.97 1,943.38 4.99 5.44 5.92 3.94 4.43 4.98 23.24 26.25 29.52 27.28 30.67 34.34 2,247.34 2,549.71 2,837.55 39.71 45.05 50.14 68.26 77.73 88.72 1.21 1.37 1.57 Colistin resistant Klebsiella pneumoniae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Klebsiella pneumoniae (excluding those resistant to colistin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Third-generation cephalosporin resistant Klebsiella pneumoniae (excluding those resistant to colistin and/or carbapenem) 53.53 60.28 67.46 265.30 288.86 313.87 321.35 349.03 378.63 4.90 5.16 5.44 0.95 1.07 1.19 4.69 5.10 5.55 5.68 6.17 6.69 252.26 280.89 309.77 4.46 4.96 5.47 14.01 15.31 16.66 0.25 0.27 0.29 Colistin resistant Pseudomonas aeruginosa 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Pseudomonas aeruginosa (excluding those resistant to colistin) 48.66 57.07 66.69 211.89 287.56 370.10 266.92 344.82 432.71 7.78 9.88 11.99 0.86 1.01 1.18 3.74 5.08 6.54 4.72 6.09 7.65 130.21 154.08 178.17 2.30 2.72 3.15 7.91 10.47 13.13 0.14 0.19 0.23 Pseudomonas aeruginosa resistant to three or more antimicrobial groups (excluding those resistant to colistin and/or carbapenem) 2.19 3.60 5.39 7.35 16.69 30.25 10.13 20.32 34.88 3.08 5.88 9.10 0.04 0.06 0.10 0.13 0.29 0.53 0.18 0.36 0.62 9.79 15.48 21.11 0.17 0.27 0.37 0.47 0.97 1.55 0.01 0.02 0.03 Methicillin resistant Staphylococcus aureus 30.36 34.85 39.33 151.30 166.02 181.60 182.77 201.01 220.10 5.39 5.74 6.11 0.54 0.62 0.69 2.67 2.93 3.21 3.23 3.55 3.89 161.57 180.10 198.31 2.85 3.18 3.50 7.72 8.47 9.25 0.14 0.15 0.16 Penicillin and macrolides resistant Streptococcus pneumoniae (excluding those only resistant to penicillin) 4.55 5.76 7.50 16.00 18.82 22.51 20.90 24.61 29.63 4.76 5.20 5.66 0.08 0.10 0.13 0.28 0.33 0.40 0.37 0.43 0.52 13.05 15.39 18.72 0.23 0.27 0.33 0.81 0.95 1.11 0.01 0.02 0.02 Penicillin tesistant Streptococcus pneumoniae (excluding those resistant to macrolides) 5.29 6.65 8.77 18.69 21.76 25.94 24.44 28.44 33.88 4.11 4.51 4.91 0.09 0.12 0.15 0.33 0.38 0.46 0.43 0.50 0.60 17.64 20.49 24.70 0.31 0.36 0.44 1.10 1.26 1.47 0.02 0.02 0.03 Total 387.79 445.00 510.74 2,158.73 2,517.01 2,916.60 2,564.70 2,961.91 3,406.25 6.85 7.86 9.02 38.14 44.47 51.53 45.31 52.33 60.18 2,930.74 3,350.95 3,759.56 51.78 59.21 66.43 107.06 124.17 143.53 1.89 2.19 2.54 Model Denmark - Acinetobacter spp. ColRACI BSI - model 41 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Acinetobacter spp. ColRACI OTH - model 45 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Acinetobacter spp. ColRACI RESP - model 42 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Acinetobacter spp. ColRACI SSI - model 44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Acinetobacter spp. ColRACI UTI - model 43 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Acinetobacter spp. CRACI BSI - model 36 1.98 2.48 3.16 10.24 19.16 28.73 12.82 21.61 31.64 4.12 6.98 9.65 0.04 0.04 0.06 0.18 0.34 0.51 0.23 0.38 0.56 2.68 3.10 3.61 0.05 0.05 0.06 0.36 0.63 0.94 6.32E-03 0.01 0.02 Denmark - Acinetobacter spp. CRACI OTH - model 40 1.67E-04 4.06E-04 7.91E-04 0.00 0.00 0.00 1.67E-04 4.06E-04 7.91E-04 2.19E-03 3.75E-03 5.47E-03 2.95E-06 7.17E-06 1.40E-05 0.00 0.00 0.00 2.95E-06 7.17E-06 1.40E-05 0.05 0.11 0.18 8.58E-04 1.99E-03 3.26E-03 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Acinetobacter spp. CRACI RESP - model 37 1.32 1.87 2.46 2.67 3.65 4.72 4.05 5.53 7.14 1.47 1.65 1.86 0.02 0.03 0.04 0.05 0.06 0.08 0.07 0.10 0.13 2.50 3.34 4.21 0.04 0.06 0.07 0.09 0.12 0.15 1.55E-03 2.12E-03 2.74E-03 Denmark - Acinetobacter spp. CRACI SSI - model 39 1.09E-03 2.33E-03 4.43E-03 0.32 0.53 0.72 0.32 0.53 0.73 0.38 0.46 0.55 1.93E-05 4.11E-05 7.84E-05 5.60E-03 9.30E-03 0.01 5.67E-03 9.33E-03 0.01 0.72 1.13 1.53 0.01 0.02 0.03 0.01 0.02 0.03 1.98E-04 3.57E-04 5.05E-04 Denmark - Acinetobacter spp. CRACI UTI - model 38 1.30E-03 2.56E-03 4.25E-03 0.00 0.00 0.00 1.30E-03 2.56E-03 4.25E-03 1.20E-03 2.05E-03 3.04E-03 2.30E-05 4.52E-05 7.51E-05 0.00 0.00 0.00 2.30E-05 4.52E-05 7.51E-05 0.80 1.27 1.77 0.01 0.02 0.03 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Acinetobacter spp. MDRACI BSI - model 31 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Acinetobacter spp. MDRACI OTH - model 35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Acinetobacter spp. MDRACI RESP - model 32 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Acinetobacter spp. MDRACI SSI - model 34 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Acinetobacter spp. MDRACI UTI - model 33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Enterococcus faecalis and E. faecium VRE BSI - model 66 15.60 19.49 24.88 135.43 167.54 208.32 151.34 187.11 231.67 5.78 6.31 6.85 0.28 0.34 0.44 2.39 2.96 3.68 2.67 3.31 4.09 23.93 29.60 36.88 0.42 0.52 0.65 5.43 6.78 8.45 0.10 0.12 0.15 Denmark - Enterococcus faecalis and E. faecium VRE OTH - model 70 0.03 0.05 0.08 0.00 0.00 0.00 0.03 0.05 0.08 1.20E-03 1.65E-03 2.24E-03 6.12E-04 9.13E-04 1.37E-03 0.00 0.00 0.00 6.12E-04 9.13E-04 1.37E-03 23.37 31.72 39.78 0.41 0.56 0.70 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Enterococcus faecalis and E. faecium VRE RESP - model 67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Enterococcus faecalis and E. faecium VRE SSI - model 69 0.05 0.08 0.13 13.59 20.57 27.63 13.66 20.67 27.87 0.44 0.50 0.56 9.56E-04 1.49E-03 2.30E-03 0.24 0.36 0.49 0.24 0.37 0.49 29.31 41.35 52.32 0.52 0.73 0.92 0.66 1.05 1.42 0.01 0.02 0.03 Denmark - Enterococcus faecalis and E. faecium VRE UTI - model 68 0.02 0.03 0.04 0.00 0.00 0.00 0.02 0.03 0.04 1.39E-03 1.86E-03 2.46E-03 3.28E-04 4.98E-04 7.49E-04 0.00 0.00 0.00 3.28E-04 4.98E-04 7.49E-04 10.93 15.30 19.88 0.19 0.27 0.35 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Escherichia coli 3GCREC BSI - model 16 171.26 188.83 208.24 1,086.16 1,215.02 1,358.68 1,262.53 1,402.97 1,558.38 3.61 3.94 4.28 3.03 3.34 3.68 19.19 21.47 24.01 22.31 24.79 27.53 332.12 356.84 385.75 5.87 6.30 6.82 54.78 61.66 69.98 0.97 1.09 1.24 Denmark - Escherichia coli 3GCREC OTH - model 20 0.29 0.39 0.52 0.00 0.00 0.00 0.29 0.39 0.52 2.66E-03 3.37E-03 4.06E-03 5.11E-03 6.96E-03 9.22E-03 0.00 0.00 0.00 5.11E-03 6.96E-03 9.22E-03 95.99 118.04 139.32 1.70 2.09 2.46 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Escherichia coli 3GCREC RESP - model 17 48.61 57.91 68.41 93.93 112.12 130.93 142.76 170.29 198.67 0.98 1.07 1.19 0.86 1.02 1.21 1.66 1.98 2.31 2.52 3.01 3.51 131.17 158.34 186.44 2.32 2.80 3.29 4.67 5.68 6.79 0.08 0.10 0.12 Denmark - Escherichia coli 3GCREC SSI - model 19 0.59 0.81 1.06 135.43 158.39 181.16 136.13 159.32 182.09 0.39 0.42 0.45 0.01 0.01 0.02 2.39 2.80 3.20 2.41 2.81 3.22 330.05 377.96 428.11 5.83 6.68 7.56 8.82 10.39 11.96 0.16 0.18 0.21 Denmark - Escherichia coli 3GCREC UTI - model 18 2.39 3.00 3.72 0.00 0.00 0.00 2.39 3.00 3.72 1.59E-03 1.96E-03 2.34E-03 0.04 0.05 0.07 0.00 0.00 0.00 0.04 0.05 0.07 1,358.01 1,538.52 1,697.93 23.99 27.18 30.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Escherichia coli ColREC BSI - model 26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Escherichia coli ColREC OTH - model 30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Escherichia coli ColREC RESP - model 27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Escherichia coli ColREC SSI - model 29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Escherichia coli ColREC UTI - model 28 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Escherichia coli CREC BSI - model 21 0.88 1.35 2.04 9.77 18.84 29.08 10.96 20.20 30.71 11.60 19.19 26.17 0.02 0.02 0.04 0.17 0.33 0.51 0.19 0.36 0.54 0.81 1.05 1.37 0.01 0.02 0.02 0.20 0.38 0.59 3.52E-03 6.79E-03 0.01 Denmark - Escherichia coli CREC OTH - model 25 5.12E-04 1.89E-03 5.00E-03 0.00 0.00 0.00 5.12E-04 1.89E-03 5.00E-03 1.19E-03 3.31E-03 7.16E-03 9.04E-06 3.34E-05 8.83E-05 0.00 0.00 0.00 9.04E-06 3.34E-05 8.83E-05 0.26 0.59 0.92 4.54E-03 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Escherichia coli CREC RESP - model 22 0.18 0.48 0.82 0.36 0.93 1.55 0.55 1.42 2.33 2.28 2.66 3.03 3.17E-03 8.42E-03 0.01 6.42E-03 0.02 0.03 9.77E-03 0.03 0.04 0.21 0.54 0.85 3.79E-03 9.50E-03 0.01 7.41E-03 0.02 0.03 1.31E-04 3.34E-04 5.57E-04 Denmark - Escherichia coli CREC SSI - model 24 5.21E-04 2.43E-03 6.52E-03 0.30 0.55 0.81 0.30 0.55 0.81 0.44 0.44 0.45 9.21E-06 4.30E-05 1.15E-04 5.25E-03 9.78E-03 0.01 5.29E-03 9.80E-03 0.01 0.67 1.25 1.83 0.01 0.02 0.03 6.06E-03 0.01 0.02 1.07E-04 1.99E-04 2.92E-04 Denmark - Escherichia coli CREC UTI - model 23 3.15E-03 8.32E-03 0.02 0.00 0.00 0.00 3.15E-03 8.32E-03 0.02 7.79E-04 1.95E-03 3.97E-03 5.56E-05 1.47E-04 3.56E-04 0.00 0.00 0.00 5.56E-05 1.47E-04 3.56E-04 2.64 4.47 6.10 0.05 0.08 0.11 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Klebsiella pneumoniae 3GCRKP BSI - model 1 33.57 37.41 41.56 217.01 233.47 251.25 252.66 270.80 290.76 3.52 3.70 3.88 0.59 0.66 0.73 3.83 4.13 4.44 4.46 4.78 5.14 69.67 73.32 77.81 1.23 1.30 1.37 11.34 12.23 13.19 0.20 0.22 0.23 Denmark - Klebsiella pneumoniae 3GCRKP RESP - model 2 19.71 22.55 25.48 38.16 43.45 49.01 58.31 65.97 73.88 0.98 1.04 1.12 0.35 0.40 0.45 0.67 0.77 0.87 1.03 1.17 1.31 56.38 63.18 70.43 1.00 1.12 1.24 2.00 2.28 2.56 0.04 0.04 0.05 Denmark - Klebsiella pneumoniae 3GCRKP UTI - model 3 0.13 0.17 0.22 0.00 0.00 0.00 0.13 0.17 0.22 1.56E-03 1.96E-03 2.42E-03 2.32E-03 2.99E-03 3.83E-03 0.00 0.00 0.00 2.32E-03 2.99E-03 3.83E-03 76.23 86.53 96.06 1.35 1.53 1.70 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Klebsiella pneumoniae 3GCRKP SSI - model 4 0.04 0.06 0.08 10.13 11.94 13.61 10.17 12.00 13.65 0.40 0.42 0.44 7.73E-04 1.08E-03 1.43E-03 0.18 0.21 0.24 0.18 0.21 0.24 24.79 28.75 32.36 0.44 0.51 0.57 0.67 0.80 0.92 0.01 0.01 0.02 Denmark - Klebsiella pneumoniae 3GCRKP OTH - model 5 0.07 0.10 0.12 0.00 0.00 0.00 0.07 0.10 0.12 2.65E-03 3.36E-03 4.14E-03 1.29E-03 1.73E-03 2.18E-03 0.00 0.00 0.00 1.29E-03 1.73E-03 2.18E-03 25.19 29.11 33.12 0.45 0.51 0.59 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Klebsiella pneumoniae ColRKP BSI - model 11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Klebsiella pneumoniae ColRKP OTH - model 15 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Klebsiella pneumoniae ColRKP RESP - model 12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Klebsiella pneumoniae ColRKP SSI - model 14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Klebsiella pneumoniae ColRKP UTI - model 13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Klebsiella pneumoniae CRKP BSI - model 6 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Klebsiella pneumoniae CRKP OTH - model 10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Klebsiella pneumoniae CRKP RESP - model 7 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Klebsiella pneumoniae CRKP SSI - model 9 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Klebsiella pneumoniae CRKP UTI - model 8 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Pseudomonas aeruginosa ColRPA BSI - model 56 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Pseudomonas aeruginosa ColRPA OTH - model 60 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Pseudomonas aeruginosa ColRPA RESP - model 57 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Pseudomonas aeruginosa ColRPA SSI - model 59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Pseudomonas aeruginosa ColRPA UTI - model 58 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Pseudomonas aeruginosa CRPA BSI - model 51 13.91 16.01 18.53 99.30 136.31 176.27 114.80 152.39 192.86 5.45 7.09 8.69 0.25 0.28 0.33 1.75 2.41 3.11 2.03 2.69 3.41 19.33 21.51 23.79 0.34 0.38 0.42 3.73 4.91 6.18 0.07 0.09 0.11 Denmark - Pseudomonas aeruginosa CRPA OTH - model 55 0.03 0.04 0.05 0.00 0.00 0.00 0.03 0.04 0.05 2.90E-03 3.66E-03 4.54E-03 4.97E-04 6.99E-04 9.45E-04 0.00 0.00 0.00 4.97E-04 6.99E-04 9.45E-04 8.60 10.87 13.08 0.15 0.19 0.23 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Pseudomonas aeruginosa CRPA RESP - model 52 34.65 40.93 47.99 107.62 144.72 185.94 147.06 185.77 231.82 1.92 2.34 2.80 0.61 0.72 0.85 1.90 2.56 3.29 2.60 3.28 4.10 67.79 79.36 91.07 1.20 1.40 1.61 3.93 5.23 6.54 0.07 0.09 0.12 Denmark - Pseudomonas aeruginosa CRPA SSI - model 54 0.02 0.03 0.05 4.97 6.53 7.88 4.99 6.56 7.90 0.41 0.45 0.49 3.57E-04 5.49E-04 8.02E-04 0.09 0.12 0.14 0.09 0.12 0.14 11.83 14.72 17.72 0.21 0.26 0.31 0.26 0.33 0.41 4.54E-03 5.85E-03 7.19E-03 Denmark - Pseudomonas aeruginosa CRPA UTI - model 53 0.04 0.06 0.07 0.00 0.00 0.00 0.04 0.06 0.07 1.61E-03 2.03E-03 2.52E-03 7.26E-04 9.91E-04 1.30E-03 0.00 0.00 0.00 7.26E-04 9.91E-04 1.30E-03 22.66 27.61 32.50 0.40 0.49 0.57 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Pseudomonas aeruginosa MDRPA BSI - model 46 0.70 1.02 1.49 3.29 8.03 14.31 4.28 9.01 15.35 2.06 4.25 6.63 0.01 0.02 0.03 0.06 0.14 0.25 0.08 0.16 0.27 1.69 2.15 2.70 0.03 0.04 0.05 0.21 0.45 0.72 3.67E-03 7.94E-03 0.01 Denmark - Pseudomonas aeruginosa MDRPA OTH - model 50 1.53E-03 3.91E-03 7.60E-03 0.00 0.00 0.00 1.53E-03 3.91E-03 7.60E-03 1.85E-03 3.71E-03 5.82E-03 2.71E-05 6.90E-05 1.34E-04 0.00 0.00 0.00 2.71E-05 6.90E-05 1.34E-04 0.56 1.11 1.66 9.90E-03 0.02 0.03 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Pseudomonas aeruginosa MDRPA RESP - model 47 1.48 2.57 3.88 3.89 8.33 15.44 5.68 10.97 19.01 0.82 1.40 2.21 0.03 0.05 0.07 0.07 0.15 0.27 0.10 0.19 0.34 5.26 7.95 10.66 0.09 0.14 0.19 0.25 0.49 0.78 4.43E-03 8.64E-03 0.01 Denmark - Pseudomonas aeruginosa MDRPA SSI - model 49 9.94E-04 2.97E-03 6.88E-03 0.16 0.33 0.50 0.16 0.33 0.51 0.20 0.23 0.25 1.76E-05 5.24E-05 1.21E-04 2.86E-03 5.82E-03 8.80E-03 2.88E-03 5.88E-03 9.03E-03 0.70 1.47 2.19 0.01 0.03 0.04 0.01 0.03 0.05 2.49E-04 5.84E-04 9.11E-04 Denmark - Pseudomonas aeruginosa MDRPA UTI - model 48 2.24E-03 5.40E-03 0.01 0.00 0.00 0.00 2.24E-03 5.40E-03 0.01 1.02E-03 2.00E-03 3.33E-03 3.96E-05 9.55E-05 1.84E-04 0.00 0.00 0.00 3.96E-05 9.55E-05 1.84E-04 1.58 2.80 3.91 0.03 0.05 0.07 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Staphylococcus aureus MRSA BSI - model 61 14.98 16.88 18.80 105.75 113.77 122.63 121.48 130.71 140.94 4.01 4.25 4.51 0.26 0.30 0.33 1.87 2.01 2.17 2.15 2.31 2.49 29.04 30.73 32.52 0.51 0.54 0.57 5.15 5.53 5.93 0.09 0.10 0.10 Denmark - Staphylococcus aureus MRSA OTH - model 65 0.11 0.15 0.19 0.00 0.00 0.00 0.11 0.15 0.19 2.49E-03 3.24E-03 4.08E-03 1.96E-03 2.58E-03 3.32E-03 0.00 0.00 0.00 1.96E-03 2.58E-03 3.32E-03 40.40 45.20 49.82 0.71 0.80 0.88 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Staphylococcus aureus MRSA RESP - model 62 15.18 17.70 20.18 29.72 34.27 38.90 45.16 52.04 58.77 1.03 1.12 1.22 0.27 0.31 0.36 0.53 0.61 0.69 0.80 0.92 1.04 41.01 46.46 51.42 0.72 0.82 0.91 1.47 1.67 1.89 0.03 0.03 0.03 Denmark - Staphylococcus aureus MRSA SSI - model 64 0.08 0.11 0.14 15.84 17.98 20.07 16.02 18.10 20.19 0.35 0.36 0.37 1.36E-03 1.89E-03 2.56E-03 0.28 0.32 0.35 0.28 0.32 0.36 45.08 50.25 55.64 0.80 0.89 0.98 1.11 1.27 1.43 0.02 0.02 0.03 Denmark - Staphylococcus aureus MRSA UTI - model 63 0.01 0.01 0.02 0.00 0.00 0.00 0.01 0.01 0.02 1.46E-03 1.89E-03 2.35E-03 1.79E-04 2.49E-04 3.30E-04 0.00 0.00 0.00 1.79E-04 2.49E-04 3.30E-04 6.03 7.46 8.91 0.11 0.13 0.16 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Streptococcus pneumoniae PMRSP BSI - model 76 1.33 1.58 1.88 9.85 10.78 11.65 11.37 12.36 13.30 3.79 4.12 4.43 0.02 0.03 0.03 0.17 0.19 0.21 0.20 0.22 0.24 3.00 3.00 3.00 0.05 0.05 0.05 0.50 0.54 0.58 8.78E-03 9.54E-03 0.01 Denmark - Streptococcus pneumoniae PMRSP OTH - model 80 1.18E-03 2.08E-03 3.20E-03 0.00 0.00 0.00 1.18E-03 2.08E-03 3.20E-03 1.08E-03 1.95E-03 2.95E-03 2.08E-05 3.68E-05 5.66E-05 0.00 0.00 0.00 2.08E-05 3.68E-05 5.66E-05 0.93 1.07 1.24 0.02 0.02 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Streptococcus pneumoniae PMRSP RESP - model 77 3.21 4.17 5.61 6.15 8.03 10.86 9.53 12.25 16.32 0.96 1.08 1.22 0.06 0.07 0.10 0.11 0.14 0.19 0.17 0.22 0.29 9.11 11.32 14.48 0.16 0.20 0.26 0.32 0.41 0.53 5.60E-03 7.18E-03 9.35E-03 Denmark - Streptococcus pneumoniae PMRSP SSI - model 79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Streptococcus pneumoniae PMRSP UTI - model 78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Streptococcus pneumoniae PRSP BSI - model 71 1.57 1.84 2.18 11.38 12.41 13.42 13.19 14.26 15.29 3.30 3.57 3.82 0.03 0.03 0.04 0.20 0.22 0.24 0.23 0.25 0.27 4.00 4.00 4.00 0.07 0.07 0.07 0.67 0.72 0.77 0.01 0.01 0.01 Denmark - Streptococcus pneumoniae PRSP OTH - model 75 1.73E-03 2.82E-03 4.03E-03 0.00 0.00 0.00 1.73E-03 2.82E-03 4.03E-03 1.25E-03 1.97E-03 2.81E-03 3.06E-05 4.97E-05 7.12E-05 0.00 0.00 0.00 3.06E-05 4.97E-05 7.12E-05 1.26 1.42 1.63 0.02 0.03 0.03 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Streptococcus pneumoniae PRSP RESP - model 72 3.72 4.81 6.59 7.31 9.35 12.52 11.24 14.17 18.59 0.81 0.94 1.08 0.07 0.08 0.12 0.13 0.17 0.22 0.20 0.25 0.33 12.38 15.07 19.07 0.22 0.27 0.34 0.43 0.54 0.70 7.63E-03 9.57E-03 0.01 Denmark - Streptococcus pneumoniae PRSP SSI - model 74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Denmark - Streptococcus pneumoniae PRSP UTI - model 73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total (Median & 95% UIs) 387.79 445.00 510.74 2,158.73 2,517.01 2,916.60 2,564.70 2,961.91 3,406.25 6.85 7.86 9.02 38.14 44.47 51.53 45.31 52.33 60.18 2,930.74 3,350.95 3,759.56 51.78 59.21 66.43 107.06 124.17 143.53 1.89 2.19 2.54 Total (average) - 44.60 52.48 3,347.53 59.15 124.51 2.20 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 445.70 2,524.26 2,969.96 - 7.87 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 Infection Colistin resistant Acinetobacter spp. 1.14 1.88 2.76 3.99 9.98 17.40 5.42 11.91 19.83 6.27 11.55 16.87 0.09 0.14 0.21 0.30 0.76 1.32 0.41 0.91 1.51 1.79 3.00 4.25 0.14 0.23 0.32 0.10 0.25 0.44 0.01 0.02 0.03 Carbapenem resistant Acinetobacter spp. (excluding those resistant to colistin) 2.00 2.98 4.24 7.47 16.07 26.85 9.86 19.06 30.16 5.37 9.47 13.87 0.15 0.23 0.32 0.57 1.22 2.04 0.75 1.45 2.29 4.19 5.97 7.77 0.32 0.45 0.59 0.27 0.52 0.80 0.02 0.04 0.06 Aminoglycosides and fluoroquinolones resistant Acinetobacter spp. (excluding those resistant to colistin and/or carbapenem) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Vancomycin resistant Enterococci (E. faecalis and E. faecium ) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Colistin resistant Escherichia coli 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Escherichia coli (excluding those resistant to colistin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Third-generation cephalosporin resistant Escherichia coli (excluding those resistant to colistin and/or carbapenem) 14.64 17.18 20.14 85.81 101.17 118.85 101.37 118.48 137.73 4.06 4.51 5.01 1.11 1.31 1.53 6.53 7.69 9.04 7.71 9.01 10.48 180.71 208.68 237.75 13.74 15.87 18.08 5.52 6.40 7.40 0.42 0.49 0.56 Colistin resistant Klebsiella pneumoniae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Klebsiella pneumoniae (excluding those resistant to colistin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Third-generation cephalosporin resistant Klebsiella pneumoniae (excluding those resistant to colistin and/or carbapenem) 18.48 20.82 23.60 91.00 99.64 109.19 109.83 120.51 132.15 5.41 5.77 6.13 1.41 1.58 1.80 6.92 7.58 8.30 8.35 9.17 10.05 76.12 85.92 96.07 5.79 6.53 7.31 4.24 4.66 5.11 0.32 0.35 0.39 Colistin resistant Pseudomonas aeruginosa 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Pseudomonas aeruginosa (excluding those resistant to colistin) 4.00 6.09 8.61 14.32 29.74 51.50 19.31 36.08 59.11 5.91 10.40 15.31 0.30 0.46 0.65 1.09 2.26 3.92 1.47 2.74 4.50 9.63 15.37 21.16 0.73 1.17 1.61 0.48 1.00 1.69 0.04 0.08 0.13 Pseudomonas aeruginosa resistant to three or more antimicrobial groups (excluding those resistant to colistin and/or carbapenem) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Methicillin resistant Staphylococcus aureus 5.67 6.77 8.01 29.09 33.31 37.70 35.20 40.10 45.21 5.30 5.69 6.13 0.43 0.51 0.61 2.21 2.53 2.87 2.68 3.05 3.44 31.06 35.96 40.96 2.36 2.74 3.12 1.51 1.71 1.92 0.11 0.13 0.15 Penicillin and macrolides resistant Streptococcus pneumoniae (excluding those only resistant to penicillin) 2.86 4.11 6.53 11.05 13.81 18.35 14.37 17.91 24.47 10.11 11.52 12.94 0.22 0.31 0.50 0.84 1.05 1.40 1.09 1.36 1.86 4.04 5.04 7.21 0.31 0.38 0.55 0.25 0.31 0.42 0.02 0.02 0.03 Penicillin tesistant Streptococcus pneumoniae (excluding those resistant to macrolides) 0.35 0.50 0.78 1.25 1.56 2.08 1.66 2.06 2.79 1.17 1.33 1.49 0.03 0.04 0.06 0.10 0.12 0.16 0.13 0.16 0.21 4.04 4.97 7.15 0.31 0.38 0.54 0.25 0.31 0.41 0.02 0.02 0.03 Total 49.14 60.33 74.67 243.98 305.28 381.90 297.01 366.13 451.45 3.74 4.59 5.68 18.56 23.22 29.05 22.59 27.85 34.33 311.60 364.92 422.32 23.70 27.75 32.12 12.61 15.16 18.19 0.96 1.15 1.38 Model Estonia - Acinetobacter spp. ColRACI BSI - model 41 7.17E-01 1.07E+00 1.54E+00 3.06 8.27 14.83 4.04E+00 9.37E+00 1.61E+01 4.07E+00 9.05E+00 1.41E+01 5.45E-02 8.14E-02 1.17E-01 0.23 0.63 1.13 3.07E-01 7.13E-01 1.23E+00 8.15E-01 1.04 1.31 6.20E-02 7.88E-02 9.93E-02 0.08 0.21 0.38 0.01 0.02 0.03 Estonia - Acinetobacter spp. ColRACI OTH - model 45 2.00E-05 1.19E-04 3.58E-04 0.00 0.00 0.00 2.00E-05 1.19E-04 3.58E-04 1.52E-03 3.67E-03 6.42E-03 1.52E-06 9.05E-06 2.73E-05 0.00 0.00 0.00 1.52E-06 9.05E-06 2.73E-05 7.27E-03 0.04 0.08 5.53E-04 2.75E-03 6.08E-03 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Acinetobacter spp. ColRACI RESP - model 42 0.42 0.81 1.22 0.88 1.58 2.36 1.32 2.40 3.50 1.84 2.14 2.45 0.03 0.06 0.09 0.07 0.12 0.18 0.10 0.18 0.27 0.66 1.13 1.59 0.05 0.09 0.12 0.02 0.04 0.06 1.70E-03 3.05E-03 4.55E-03 Estonia - Acinetobacter spp. ColRACI SSI - model 44 1.48E-04 7.21E-04 2.04E-03 0.05 0.13 0.21 0.05 0.14 0.21 0.36 0.36 0.36 1.13E-05 5.48E-05 1.55E-04 3.94E-03 0.01 0.02 3.94E-03 0.01 0.02 0.15 0.38 0.60 0.01 0.03 0.05 1.32E-03 3.42E-03 5.38E-03 1.00E-04 2.60E-04 4.09E-04 Estonia - Acinetobacter spp. ColRACI UTI - model 43 2.26E-04 7.50E-04 1.94E-03 0.00 0.00 0.00 2.26E-04 7.50E-04 1.94E-03 7.52E-04 1.97E-03 3.54E-03 1.72E-05 5.70E-05 1.48E-04 0.00 0.00 0.00 1.72E-05 5.70E-05 1.48E-04 0.16 0.42 0.67 0.01 0.03 0.05 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Acinetobacter spp. CRACI BSI - model 36 1.23 1.70 2.36 5.74 13.22 22.73 7.33 14.94 24.34 3.67 7.33 11.24 0.09 0.13 0.18 0.44 1.01 1.73 0.56 1.14 1.85 1.73 2.05 2.44 0.13 0.16 0.19 0.21 0.43 0.66 0.02 0.03 0.05 Estonia - Acinetobacter spp. CRACI OTH - model 40 8.97E-05 2.76E-04 5.94E-04 0.00 0.00 0.00 8.97E-05 2.76E-04 5.94E-04 1.94E-03 3.76E-03 5.71E-03 6.82E-06 2.10E-05 4.52E-05 0.00 0.00 0.00 6.82E-06 2.10E-05 4.52E-05 0.03 0.08 0.13 2.02E-03 5.83E-03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Acinetobacter spp. CRACI RESP - model 37 0.77 1.28 1.88 1.56 2.54 3.67 2.36 3.81 5.37 1.32 1.72 2.17 0.06 0.10 0.14 0.12 0.19 0.28 0.18 0.29 0.41 1.55 2.22 2.91 0.12 0.17 0.22 0.05 0.08 0.11 4.12E-03 6.07E-03 8.32E-03 Estonia - Acinetobacter spp. CRACI SSI - model 39 5.27E-04 1.52E-03 3.26E-03 0.17 0.31 0.44 0.17 0.32 0.45 0.38 0.41 0.45 4.01E-05 1.16E-04 2.48E-04 0.01 0.02 0.03 0.01 0.02 0.03 0.41 0.76 1.08 0.03 0.06 0.08 8.34E-03 0.02 0.03 6.34E-04 1.30E-03 1.94E-03 Estonia - Acinetobacter spp. CRACI UTI - model 38 6.95E-04 1.67E-03 3.12E-03 0.00 0.00 0.00 6.95E-04 1.67E-03 3.12E-03 1.04E-03 1.99E-03 3.19E-03 5.28E-05 1.27E-04 2.38E-04 0.00 0.00 0.00 5.28E-05 1.27E-04 2.38E-04 0.46 0.85 1.21 0.04 0.06 0.09 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Acinetobacter spp. MDRACI BSI - model 31 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Acinetobacter spp. MDRACI OTH - model 35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Acinetobacter spp. MDRACI RESP - model 32 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Acinetobacter spp. MDRACI SSI - model 34 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Acinetobacter spp. MDRACI UTI - model 33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Enterococcus faecalis and E. faecium VRE BSI - model 66 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Enterococcus faecalis and E. faecium VRE OTH - model 70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Enterococcus faecalis and E. faecium VRE RESP - model 67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Enterococcus faecalis and E. faecium VRE SSI - model 69 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Enterococcus faecalis and E. faecium VRE UTI - model 68 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Escherichia coli 3GCREC BSI - model 16 11.37 12.86 14.76 70.35 82.05 96.00 82.55 95.06 109.66 2.91 3.24 3.60 0.87 0.98 1.12 5.35 6.24 7.30 6.28 7.23 8.34 26.95 29.36 32.09 2.05 2.23 2.44 4.41 5.05 5.80 0.34 0.38 0.44 Estonia - Escherichia coli 3GCREC OTH - model 20 0.02 0.03 0.04 0.00 0.00 0.00 0.02 0.03 0.04 2.52E-03 3.36E-03 4.21E-03 1.73E-03 2.48E-03 3.39E-03 0.00 0.00 0.00 1.73E-03 2.48E-03 3.39E-03 7.51 9.72 11.85 0.57 0.74 0.90 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Escherichia coli 3GCREC RESP - model 17 3.01 3.98 4.93 5.94 7.65 9.53 9.01 11.61 14.25 0.80 0.89 1.00 0.23 0.30 0.37 0.45 0.58 0.72 0.69 0.88 1.08 10.41 13.03 15.85 0.79 0.99 1.21 0.37 0.47 0.58 0.03 0.04 0.04 Estonia - Escherichia coli 3GCREC SSI - model 19 0.05 0.07 0.09 9.52 11.47 13.32 9.60 11.53 13.46 0.35 0.37 0.40 3.46E-03 4.99E-03 6.86E-03 0.72 0.87 1.01 0.73 0.88 1.02 26.38 31.01 36.00 2.01 2.36 2.74 0.73 0.88 1.03 0.06 0.07 0.08 Estonia - Escherichia coli 3GCREC UTI - model 18 0.19 0.25 0.32 0.00 0.00 0.00 0.19 0.25 0.32 1.53E-03 1.97E-03 2.43E-03 0.01 0.02 0.02 0.00 0.00 0.00 0.01 0.02 0.02 109.46 125.56 141.95 8.32 9.55 10.80 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Escherichia coli ColREC BSI - model 26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Escherichia coli ColREC OTH - model 30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Escherichia coli ColREC RESP - model 27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Escherichia coli ColREC SSI - model 29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Escherichia coli ColREC UTI - model 28 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Escherichia coli CREC BSI - model 21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Escherichia coli CREC OTH - model 25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Escherichia coli CREC RESP - model 22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Escherichia coli CREC SSI - model 24 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Escherichia coli CREC UTI - model 23 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Klebsiella pneumoniae 3GCRKP BSI - model 1 11.67 12.89 14.53 75.12 81.03 87.86 87.04 94.00 101.88 3.95 4.19 4.42 0.89 0.98 1.10 5.71 6.16 6.68 6.62 7.15 7.75 21.08 22.48 23.94 1.60 1.71 1.82 3.46 3.75 4.05 0.26 0.28 0.31 Estonia - Klebsiella pneumoniae 3GCRKP OTH - model 5 0.02 0.03 0.04 0.00 0.00 0.00 0.02 0.03 0.04 2.56E-03 3.34E-03 4.22E-03 1.66E-03 2.24E-03 3.03E-03 0.00 0.00 0.00 1.66E-03 2.24E-03 3.03E-03 7.49 8.90 10.20 0.57 0.68 0.78 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Klebsiella pneumoniae 3GCRKP RESP - model 2 6.73 7.83 8.94 13.02 15.16 17.31 19.85 22.97 26.12 1.09 1.18 1.29 0.51 0.60 0.68 0.99 1.15 1.32 1.51 1.75 1.99 16.99 19.34 21.92 1.29 1.47 1.67 0.60 0.70 0.80 0.05 0.05 0.06 Estonia - Klebsiella pneumoniae 3GCRKP UTI - model 3 0.04 0.05 0.07 0.00 0.00 0.00 0.04 0.05 0.07 1.52E-03 1.96E-03 2.49E-03 2.91E-03 3.90E-03 5.12E-03 0.00 0.00 0.00 2.91E-03 3.90E-03 5.12E-03 23.17 26.37 29.72 1.76 2.01 2.26 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Klebsiella pneumoniae 3GCRKP SSI - model 4 0.01 0.02 0.03 2.87 3.44 4.02 2.88 3.46 4.04 0.37 0.39 0.41 9.92E-04 1.43E-03 2.00E-03 0.22 0.26 0.31 0.22 0.26 0.31 7.40 8.82 10.28 0.56 0.67 0.78 0.18 0.22 0.26 0.01 0.02 0.02 Estonia - Klebsiella pneumoniae ColRKP BSI - model 11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Klebsiella pneumoniae ColRKP OTH - model 15 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Klebsiella pneumoniae ColRKP RESP - model 12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Klebsiella pneumoniae ColRKP SSI - model 14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Klebsiella pneumoniae ColRKP UTI - model 13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Klebsiella pneumoniae CRKP BSI - model 6 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Klebsiella pneumoniae CRKP OTH - model 10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Klebsiella pneumoniae CRKP RESP - model 7 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Klebsiella pneumoniae CRKP SSI - model 9 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Klebsiella pneumoniae CRKP UTI - model 8 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Pseudomonas aeruginosa ColRPA BSI - model 56 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Pseudomonas aeruginosa ColRPA OTH - model 60 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Pseudomonas aeruginosa ColRPA RESP - model 57 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Pseudomonas aeruginosa ColRPA SSI - model 59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Pseudomonas aeruginosa ColRPA UTI - model 58 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Pseudomonas aeruginosa CRPA BSI - model 51 1.24 1.73 2.38 6.65 14.35 24.82 8.26 16.12 26.97 4.05 7.62 11.46 0.09 0.13 0.18 0.51 1.09 1.89 0.63 1.23 2.05 1.66 2.14 2.74 0.13 0.16 0.21 0.22 0.48 0.82 0.02 0.04 0.06 Estonia - Pseudomonas aeruginosa CRPA OTH - model 55 1.51E-03 3.76E-03 7.49E-03 0.00 0.00 0.00 1.51E-03 3.76E-03 7.49E-03 1.96E-03 3.60E-03 5.72E-03 1.14E-04 2.86E-04 5.70E-04 0.00 0.00 0.00 1.14E-04 2.86E-04 5.70E-04 0.54 1.09 1.61 0.04 0.08 0.12 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Pseudomonas aeruginosa CRPA RESP - model 52 2.76 4.34 6.20 7.46 14.98 26.09 10.83 19.54 31.53 1.60 2.50 3.54 0.21 0.33 0.47 0.57 1.14 1.98 0.82 1.49 2.40 5.18 7.90 10.69 0.39 0.60 0.81 0.25 0.50 0.85 0.02 0.04 0.06 Estonia - Pseudomonas aeruginosa CRPA SSI - model 54 1.03E-03 3.01E-03 6.21E-03 0.21 0.41 0.59 0.22 0.41 0.59 0.25 0.27 0.30 7.86E-05 2.29E-04 4.72E-04 0.02 0.03 0.04 0.02 0.03 0.05 0.80 1.51 2.16 0.06 0.11 0.16 7.20E-03 0.01 0.02 5.47E-04 1.03E-03 1.48E-03 Estonia - Pseudomonas aeruginosa CRPA UTI - model 53 2.21E-03 5.38E-03 0.01 0.00 0.00 0.00 2.21E-03 5.38E-03 0.01 1.05E-03 2.04E-03 3.20E-03 1.68E-04 4.09E-04 7.82E-04 0.00 0.00 0.00 1.68E-04 4.09E-04 7.82E-04 1.45 2.73 3.95 0.11 0.21 0.30 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Pseudomonas aeruginosa MDRPA BSI - model 46 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Pseudomonas aeruginosa MDRPA OTH - model 50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Pseudomonas aeruginosa MDRPA RESP - model 47 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Pseudomonas aeruginosa MDRPA SSI - model 49 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Pseudomonas aeruginosa MDRPA UTI - model 48 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Staphylococcus aureus MRSA BSI - model 61 2.81 3.30 3.83 19.71 22.11 24.65 22.86 25.41 28.14 3.87 4.14 4.45 0.21 0.25 0.29 1.50 1.68 1.87 1.74 1.93 2.14 5.68 6.15 6.61 0.43 0.47 0.50 1.00 1.10 1.22 0.08 0.08 0.09 Estonia - Staphylococcus aureus MRSA OTH - model 65 0.02 0.03 0.04 0.00 0.00 0.00 0.02 0.03 0.04 2.33E-03 3.26E-03 4.32E-03 1.58E-03 2.24E-03 3.04E-03 0.00 0.00 0.00 1.58E-03 2.24E-03 3.04E-03 7.79 9.06 10.37 0.59 0.69 0.79 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Staphylococcus aureus MRSA RESP - model 62 2.83 3.42 4.10 5.51 6.67 7.88 8.42 10.11 11.82 1.00 1.09 1.19 0.21 0.26 0.31 0.42 0.51 0.60 0.64 0.77 0.90 7.88 9.20 10.65 0.60 0.70 0.81 0.28 0.33 0.39 0.02 0.03 0.03 Estonia - Staphylococcus aureus MRSA SSI - model 64 0.01 0.02 0.03 3.86 4.54 5.17 3.89 4.56 5.20 0.43 0.45 0.48 1.00E-03 1.62E-03 2.48E-03 0.29 0.34 0.39 0.30 0.35 0.40 8.63 10.03 11.43 0.66 0.76 0.87 0.23 0.27 0.31 0.02 0.02 0.02 Estonia - Staphylococcus aureus MRSA UTI - model 63 1.79E-03 2.77E-03 4.09E-03 0.00 0.00 0.00 1.79E-03 2.77E-03 4.09E-03 1.32E-03 1.87E-03 2.52E-03 1.37E-04 2.10E-04 3.11E-04 0.00 0.00 0.00 1.37E-04 2.10E-04 3.11E-04 1.09 1.52 1.89 0.08 0.12 0.14 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Streptococcus pneumoniae PMRSP BSI - model 76 0.86 1.16 1.55 7.01 7.98 8.90 8.07 9.13 10.20 8.07 9.13 10.20 0.07 0.09 0.12 0.53 0.61 0.68 0.61 0.69 0.78 1.00 1.00 1.00 0.08 0.08 0.08 0.16 0.18 0.20 0.01 0.01 0.02 Estonia - Streptococcus pneumoniae PMRSP OTH - model 80 2.61E-04 6.52E-04 1.33E-03 0.00 0.00 0.00 2.61E-04 6.52E-04 1.33E-03 7.62E-04 1.86E-03 3.53E-03 1.98E-05 4.96E-05 1.01E-04 0.00 0.00 0.00 1.98E-05 4.96E-05 1.01E-04 0.29 0.35 0.46 0.02 0.03 0.03 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Streptococcus pneumoniae PMRSP RESP - model 77 2.00 2.95 4.98 4.04 5.83 9.44 6.30 8.78 14.27 2.04 2.39 2.74 0.15 0.22 0.38 0.31 0.44 0.72 0.48 0.67 1.09 2.75 3.69 5.76 0.21 0.28 0.44 0.09 0.13 0.21 6.95E-03 0.01 0.02 Estonia - Streptococcus pneumoniae PMRSP SSI - model 79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Streptococcus pneumoniae PMRSP UTI - model 78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Streptococcus pneumoniae PRSP BSI - model 71 0.10 0.14 0.18 0.80 0.90 1.01 0.92 1.05 1.17 0.92 1.05 1.17 7.79E-03 0.01 0.01 0.06 0.07 0.08 0.07 0.08 0.09 1.00 1.00 1.00 0.08 0.08 0.08 0.16 0.18 0.20 0.01 0.01 0.02 Estonia - Streptococcus pneumoniae PRSP OTH - model 75 2.42E-04 6.86E-04 1.36E-03 0.00 0.00 0.00 2.42E-04 6.86E-04 1.36E-03 6.96E-04 1.91E-03 3.61E-03 1.84E-05 5.22E-05 1.03E-04 0.00 0.00 0.00 1.84E-05 5.22E-05 1.03E-04 0.29 0.36 0.46 0.02 0.03 0.03 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Streptococcus pneumoniae PRSP RESP - model 72 0.25 0.36 0.60 0.46 0.65 1.06 0.73 1.02 1.62 0.24 0.28 0.32 0.02 0.03 0.05 0.03 0.05 0.08 0.06 0.08 0.12 2.76 3.61 5.70 0.21 0.27 0.43 0.09 0.13 0.21 6.98E-03 9.90E-03 0.02 Estonia - Streptococcus pneumoniae PRSP SSI - model 74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Estonia - Streptococcus pneumoniae PRSP UTI - model 73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total (Median & 95% UIs) 49.14 60.33 74.67 243.98 305.28 381.90 297.01 366.13 451.45 3.74 4.59 5.68 18.56 23.22 29.05 22.59 27.85 34.33 311.60 364.92 422.32 23.70 27.75 32.12 12.61 15.16 18.19 0.96 1.15 1.38 Total (average) - 23.37 27.99 356.56 27.12 15.23 1.16 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 60.74 307.34 368.08 - 4.62 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 Infection Colistin resistant Acinetobacter spp. 171.38 191.96 214.09 840.12 1,025.21 1,225.95 1,018.48 1,215.89 1,431.18 7.74 9.19 10.60 1.58 1.77 1.97 7.74 9.44 11.29 9.38 11.20 13.18 345.62 389.63 436.06 3.18 3.59 4.02 27.27 34.02 40.72 0.25 0.31 0.38 Carbapenem resistant Acinetobacter spp. (excluding those resistant to colistin) 1,604.23 1,751.22 1,894.28 7,975.81 9,413.80 10,671.56 9,613.21 11,169.66 12,536.01 6.85 7.81 8.67 14.77 16.13 17.45 73.46 86.70 98.28 88.54 102.87 115.45 3,800.84 4,215.18 4,606.36 35.00 38.82 42.42 310.17 371.21 430.10 2.86 3.42 3.96 Aminoglycosides and fluoroquinolones resistant Acinetobacter spp. (excluding those resistant to colistin and/or carbapenem) 17.23 19.14 21.34 83.15 100.75 118.44 101.24 120.12 138.87 6.22 7.14 8.07 0.16 0.18 0.20 0.77 0.93 1.09 0.93 1.11 1.28 44.49 49.89 55.23 0.41 0.46 0.51 3.56 4.32 5.09 0.03 0.04 0.05 Vancomycin resistant Enterococci (E. faecalis and E. faecium ) 95.72 110.78 128.76 899.48 1,043.80 1,204.88 1,002.45 1,155.16 1,331.12 6.27 6.77 7.29 0.88 1.02 1.19 8.28 9.61 11.10 9.23 10.64 12.26 545.96 655.43 770.85 5.03 6.04 7.10 37.02 43.70 51.61 0.34 0.40 0.48 Colistin resistant Escherichia coli 7.03 7.86 8.69 118.13 135.32 153.31 125.43 143.16 161.59 12.43 14.09 15.74 0.06 0.07 0.08 1.09 1.25 1.41 1.16 1.32 1.49 69.11 78.39 87.54 0.64 0.72 0.81 5.78 6.85 8.04 0.05 0.06 0.07 Carbapenem resistant Escherichia coli (excluding those resistant to colistin) 21.69 25.71 30.74 224.78 274.18 339.52 246.58 300.58 368.19 12.71 15.14 17.92 0.20 0.24 0.28 2.07 2.53 3.13 2.27 2.77 3.39 138.14 156.70 175.86 1.27 1.44 1.62 7.13 8.44 9.87 0.07 0.08 0.09 Third-generation cephalosporin resistant Escherichia coli (excluding those resistant to colistin and/or carbapenem) 231.58 257.13 284.27 1,367.01 1,529.18 1,705.64 1,606.96 1,787.34 1,983.88 4.65 5.04 5.45 2.13 2.37 2.62 12.59 14.08 15.71 14.80 16.46 18.27 2,499.83 2,829.91 3,136.03 23.02 26.06 28.88 75.84 86.78 98.63 0.70 0.80 0.91 Colistin resistant Klebsiella pneumoniae 347.43 391.45 439.44 5,942.01 6,936.69 7,971.62 6,318.30 7,324.17 8,377.90 15.80 17.97 20.24 3.20 3.61 4.05 54.72 63.89 73.42 58.19 67.45 77.16 1,050.15 1,211.57 1,371.30 9.67 11.16 12.63 233.50 271.40 314.40 2.15 2.50 2.90 Carbapenem resistant Klebsiella pneumoniae (excluding those resistant to colistin) 832.10 920.78 1,021.38 8,678.78 9,865.64 11,063.91 9,557.89 10,790.46 12,058.57 10.40 11.56 12.65 7.66 8.48 9.41 79.93 90.86 101.90 88.03 99.38 111.06 2,538.99 2,883.23 3,250.19 23.38 26.55 29.93 342.24 391.68 444.04 3.15 3.61 4.09 Third-generation cephalosporin resistant Klebsiella pneumoniae (excluding those resistant to colistin and/or carbapenem) 186.83 203.66 223.16 916.66 976.06 1,045.07 1,107.37 1,180.72 1,259.87 6.79 7.14 7.51 1.72 1.88 2.06 8.44 8.99 9.62 10.20 10.87 11.60 618.23 677.20 734.22 5.69 6.24 6.76 34.29 36.75 39.38 0.32 0.34 0.36 Colistin resistant Pseudomonas aeruginosa 18.51 20.87 23.48 143.11 184.99 229.97 164.37 206.03 250.13 6.38 7.79 9.29 0.17 0.19 0.22 1.32 1.70 2.12 1.51 1.90 2.30 78.58 93.58 108.24 0.72 0.86 1.00 5.05 6.59 8.09 0.05 0.06 0.07 Carbapenem resistant Pseudomonas aeruginosa (excluding those resistant to colistin) 1,292.83 1,438.21 1,592.97 6,091.59 7,270.50 8,566.85 7,437.71 8,707.90 10,095.84 8.47 9.76 11.05 11.91 13.25 14.67 56.10 66.96 78.90 68.50 80.20 92.98 2,880.38 3,241.79 3,581.90 26.53 29.86 32.99 220.15 267.87 318.31 2.03 2.47 2.93 Pseudomonas aeruginosa resistant to three or more antimicrobial groups (excluding those resistant to colistin and/or carbapenem) 30.37 34.28 38.58 133.01 162.69 195.31 165.47 197.08 231.52 6.27 7.34 8.44 0.28 0.32 0.36 1.22 1.50 1.80 1.52 1.82 2.13 102.04 118.70 134.82 0.94 1.09 1.24 6.02 7.57 9.30 0.06 0.07 0.09 Methicillin resistant Staphylococcus aureus 323.32 361.02 402.86 1,584.43 1,735.81 1,899.79 1,912.17 2,097.94 2,297.86 5.43 5.80 6.17 2.98 3.32 3.71 14.59 15.99 17.50 17.61 19.32 21.16 1,644.51 1,870.72 2,121.86 15.15 17.23 19.54 78.80 88.36 98.58 0.73 0.81 0.91 Penicillin and macrolides resistant Streptococcus pneumoniae (excluding those only resistant to penicillin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Penicillin tesistant Streptococcus pneumoniae (excluding those resistant to macrolides) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total 5,180.25 5,734.06 6,324.04 34,998.06 40,654.64 46,391.83 40,377.64 46,396.21 52,522.54 47.71 52.81 58.24 322.32 374.42 427.26 371.87 427.30 483.72 16,356.89 18,471.91 20,570.44 150.64 170.12 189.45 1,386.84 1,625.54 1,876.18 12.77 14.97 17.28 Model Greece - Acinetobacter spp. ColRACI BSI - model 41 99.00 109.74 121.07 681.85 843.96 1,019.25 786.89 952.57 1,132.59 5.78 7.09 8.36 0.91 1.01 1.12 6.28 7.77 9.39 7.25 8.77 10.43 126.41 134.72 143.98 1.16 1.24 1.33 21.92 27.80 33.60 0.20 0.26 0.31 Greece - Acinetobacter spp. ColRACI OTH - model 45 0.01 0.02 0.02 0.00 0.00 0.00 0.01 0.02 0.02 2.99E-03 3.76E-03 4.53E-03 1.16E-04 1.64E-04 2.26E-04 0.00 0.00 0.00 1.16E-04 1.64E-04 2.26E-04 3.53 4.79 6.22 0.03 0.04 0.06 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Acinetobacter spp. ColRACI RESP - model 42 72.21 81.99 92.71 140.57 160.15 181.68 213.71 241.99 273.33 1.56 1.66 1.77 0.67 0.76 0.85 1.29 1.47 1.67 1.97 2.23 2.52 129.14 146.03 163.69 1.19 1.34 1.51 4.57 5.25 5.94 0.04 0.05 0.05 Greece - Acinetobacter spp. ColRACI SSI - model 44 0.07 0.10 0.14 17.70 21.09 25.02 17.78 21.20 25.09 0.40 0.43 0.46 6.86E-04 9.66E-04 1.33E-03 0.16 0.19 0.23 0.16 0.20 0.23 40.97 49.13 58.25 0.38 0.45 0.54 0.77 0.97 1.18 7.13E-03 8.95E-03 0.01 Greece - Acinetobacter spp. ColRACI UTI - model 43 0.09 0.11 0.14 0.00 0.00 0.00 0.09 0.11 0.14 1.64E-03 2.03E-03 2.49E-03 7.83E-04 1.03E-03 1.32E-03 0.00 0.00 0.00 7.83E-04 1.03E-03 1.32E-03 45.57 54.96 63.93 0.42 0.51 0.59 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Acinetobacter spp. CRACI BSI - model 36 929.90 1,001.35 1,075.31 6,459.08 7,731.36 8,821.84 7,419.96 8,736.11 9,867.90 5.12 5.98 6.74 8.56 9.22 9.90 59.49 71.20 81.25 68.34 80.46 90.88 1,385.37 1,460.75 1,545.98 12.76 13.45 14.24 248.51 302.00 353.07 2.29 2.78 3.25 Greece - Acinetobacter spp. CRACI OTH - model 40 0.14 0.19 0.25 0.00 0.00 0.00 0.14 0.19 0.25 3.10E-03 3.76E-03 4.47E-03 1.31E-03 1.78E-03 2.34E-03 0.00 0.00 0.00 1.31E-03 1.78E-03 2.34E-03 40.72 51.64 63.65 0.38 0.48 0.59 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Acinetobacter spp. CRACI RESP - model 37 672.39 747.34 815.74 1,321.72 1,454.84 1,589.25 1,995.22 2,203.36 2,404.52 1.32 1.40 1.47 6.19 6.88 7.51 12.17 13.40 14.64 18.38 20.29 22.15 1,419.08 1,582.66 1,721.14 13.07 14.58 15.85 51.06 56.82 62.44 0.47 0.52 0.58 Greece - Acinetobacter spp. CRACI SSI - model 39 0.86 1.13 1.47 195.01 227.60 260.47 196.95 228.79 261.84 0.40 0.43 0.45 7.95E-03 0.01 0.01 1.80 2.10 2.40 1.81 2.11 2.41 453.31 531.78 603.55 4.17 4.90 5.56 10.60 12.39 14.60 0.10 0.11 0.13 Greece - Acinetobacter spp. CRACI UTI - model 38 0.94 1.20 1.50 0.00 0.00 0.00 0.94 1.20 1.50 1.70E-03 2.03E-03 2.41E-03 8.66E-03 0.01 0.01 0.00 0.00 0.00 8.66E-03 0.01 0.01 502.36 588.34 672.04 4.63 5.42 6.19 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Acinetobacter spp. MDRACI BSI - model 31 9.98 10.94 12.08 66.58 81.86 97.18 77.45 93.01 108.53 4.55 5.36 6.19 0.09 0.10 0.11 0.61 0.75 0.89 0.71 0.86 1.00 16.24 17.27 18.36 0.15 0.16 0.17 2.83 3.48 4.14 0.03 0.03 0.04 Greece - Acinetobacter spp. MDRACI OTH - model 35 1.65E-03 2.31E-03 3.07E-03 0.00 0.00 0.00 1.65E-03 2.31E-03 3.07E-03 3.07E-03 3.73E-03 4.49E-03 1.52E-05 2.13E-05 2.83E-05 0.00 0.00 0.00 1.52E-05 2.13E-05 2.83E-05 0.47 0.61 0.77 4.33E-03 5.66E-03 7.09E-03 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Acinetobacter spp. MDRACI RESP - model 32 7.23 8.17 9.22 14.16 15.88 17.67 21.35 24.07 26.71 1.22 1.29 1.37 0.07 0.08 0.08 0.13 0.15 0.16 0.20 0.22 0.25 16.60 18.70 20.77 0.15 0.17 0.19 0.60 0.67 0.76 5.48E-03 6.19E-03 6.98E-03 Greece - Acinetobacter spp. MDRACI SSI - model 34 0.01 0.01 0.02 2.41 3.01 3.60 2.42 3.03 3.61 0.44 0.48 0.51 9.35E-05 1.22E-04 1.64E-04 0.02 0.03 0.03 0.02 0.03 0.03 5.26 6.30 7.22 0.05 0.06 0.07 0.13 0.17 0.20 1.21E-03 1.53E-03 1.83E-03 Greece - Acinetobacter spp. MDRACI UTI - model 33 0.01 0.01 0.02 0.00 0.00 0.00 0.01 0.01 0.02 1.66E-03 2.03E-03 2.46E-03 9.83E-05 1.31E-04 1.67E-04 0.00 0.00 0.00 9.83E-05 1.31E-04 1.67E-04 5.91 7.00 8.11 0.05 0.06 0.07 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Enterococcus faecalis and E. faecium VRE BSI - model 66 95.01 109.84 127.53 816.57 941.25 1,082.36 918.74 1,051.73 1,207.43 5.85 6.32 6.80 0.88 1.01 1.17 7.52 8.67 9.97 8.46 9.69 11.12 142.53 165.91 194.92 1.31 1.53 1.80 32.55 38.00 44.63 0.30 0.35 0.41 Greece - Enterococcus faecalis and E. faecium VRE OTH - model 70 0.22 0.29 0.38 0.00 0.00 0.00 0.22 0.29 0.38 1.32E-03 1.65E-03 2.00E-03 2.06E-03 2.68E-03 3.49E-03 0.00 0.00 0.00 2.06E-03 2.68E-03 3.49E-03 147.57 176.99 208.81 1.36 1.63 1.92 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Enterococcus faecalis and E. faecium VRE RESP - model 67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Enterococcus faecalis and E. faecium VRE SSI - model 69 0.36 0.49 0.64 82.91 102.55 122.52 83.37 102.98 123.11 0.41 0.45 0.48 3.35E-03 4.50E-03 5.94E-03 0.76 0.94 1.13 0.77 0.95 1.13 187.70 228.11 266.63 1.73 2.10 2.46 4.47 5.70 6.98 0.04 0.05 0.06 Greece - Enterococcus faecalis and E. faecium VRE UTI - model 68 0.12 0.16 0.20 0.00 0.00 0.00 0.12 0.16 0.20 1.52E-03 1.87E-03 2.26E-03 1.08E-03 1.44E-03 1.88E-03 0.00 0.00 0.00 1.08E-03 1.44E-03 1.88E-03 68.15 84.42 100.49 0.63 0.78 0.93 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Escherichia coli 3GCREC BSI - model 16 177.73 193.30 210.52 1,125.83 1,246.33 1,383.99 1,311.18 1,440.82 1,589.68 3.37 3.64 3.92 1.64 1.78 1.94 10.37 11.48 12.75 12.08 13.27 14.64 368.12 395.57 423.74 3.39 3.64 3.90 60.34 68.30 77.17 0.56 0.63 0.71 Greece - Escherichia coli 3GCREC OTH - model 20 0.32 0.43 0.56 0.00 0.00 0.00 0.32 0.43 0.56 2.67E-03 3.35E-03 4.03E-03 2.99E-03 3.99E-03 5.20E-03 0.00 0.00 0.00 2.99E-03 3.99E-03 5.20E-03 106.27 130.68 155.69 0.98 1.20 1.43 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Escherichia coli 3GCREC RESP - model 17 50.22 59.17 67.84 96.71 114.76 130.90 147.62 173.73 197.76 0.90 0.99 1.10 0.46 0.54 0.62 0.89 1.06 1.21 1.36 1.60 1.82 142.18 174.68 202.45 1.31 1.61 1.86 5.09 6.29 7.38 0.05 0.06 0.07 Greece - Escherichia coli 3GCREC SSI - model 19 0.66 0.89 1.18 144.47 168.09 190.75 145.19 169.03 191.72 0.38 0.40 0.43 6.11E-03 8.20E-03 0.01 1.33 1.55 1.76 1.34 1.56 1.77 365.16 417.70 471.45 3.36 3.85 4.34 10.41 12.19 14.09 0.10 0.11 0.13 Greece - Escherichia coli 3GCREC UTI - model 18 2.64 3.33 4.17 0.00 0.00 0.00 2.64 3.33 4.17 1.57E-03 1.96E-03 2.36E-03 0.02 0.03 0.04 0.00 0.00 0.00 0.02 0.03 0.04 1,518.10 1,711.28 1,882.69 13.98 15.76 17.34 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Escherichia coli ColREC BSI - model 26 5.27 5.77 6.27 110.41 126.38 143.20 115.96 132.13 149.10 11.05 12.58 14.06 0.05 0.05 0.06 1.02 1.16 1.32 1.07 1.22 1.37 9.70 10.53 11.33 0.09 0.10 0.10 5.32 6.30 7.40 0.05 0.06 0.07 Greece - Escherichia coli ColREC OTH - model 30 0.02 0.02 0.03 0.00 0.00 0.00 0.02 0.02 0.03 2.76E-03 3.51E-03 4.52E-03 1.46E-04 1.95E-04 2.68E-04 0.00 0.00 0.00 1.46E-04 1.95E-04 2.68E-04 5.11 6.05 6.99 0.05 0.06 0.06 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Escherichia coli ColREC RESP - model 27 1.66 1.95 2.23 3.22 3.77 4.26 4.89 5.72 6.46 0.98 1.08 1.23 0.02 0.02 0.02 0.03 0.03 0.04 0.05 0.05 0.06 4.36 5.28 6.11 0.04 0.05 0.06 0.16 0.19 0.22 1.43E-03 1.74E-03 2.06E-03 Greece - Escherichia coli ColREC SSI - model 29 0.02 0.03 0.04 4.49 5.18 5.85 4.50 5.20 5.88 0.40 0.42 0.45 1.77E-04 2.42E-04 3.33E-04 0.04 0.05 0.05 0.04 0.05 0.05 10.63 12.39 13.93 0.10 0.11 0.13 0.30 0.37 0.42 2.78E-03 3.36E-03 3.84E-03 Greece - Escherichia coli ColREC UTI - model 28 0.07 0.09 0.12 0.00 0.00 0.00 0.07 0.09 0.12 1.64E-03 2.09E-03 2.61E-03 6.51E-04 8.45E-04 1.09E-03 0.00 0.00 0.00 6.51E-04 8.45E-04 1.09E-03 39.32 44.14 49.18 0.36 0.41 0.45 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Escherichia coli CREC BSI - model 21 16.44 18.88 21.97 204.45 248.73 308.67 220.97 268.31 328.84 10.69 12.80 15.25 0.15 0.17 0.20 1.88 2.29 2.84 2.04 2.47 3.03 19.33 20.95 22.70 0.18 0.19 0.21 6.34 7.47 8.72 0.06 0.07 0.08 Greece - Escherichia coli CREC OTH - model 25 0.03 0.04 0.06 0.00 0.00 0.00 0.03 0.04 0.06 2.69E-03 3.50E-03 4.50E-03 2.86E-04 3.83E-04 5.19E-04 0.00 0.00 0.00 2.86E-04 3.83E-04 5.19E-04 10.04 11.99 13.84 0.09 0.11 0.13 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Escherichia coli CREC RESP - model 22 5.03 6.54 8.39 9.85 12.85 16.10 14.93 19.40 24.23 1.54 1.82 2.12 0.05 0.06 0.08 0.09 0.12 0.15 0.14 0.18 0.22 8.75 10.69 12.56 0.08 0.10 0.12 0.31 0.38 0.46 2.89E-03 3.54E-03 4.20E-03 Greece - Escherichia coli CREC SSI - model 24 0.04 0.05 0.07 10.48 12.60 14.75 10.51 12.65 14.82 0.48 0.51 0.54 3.57E-04 4.84E-04 6.60E-04 0.10 0.12 0.14 0.10 0.12 0.14 21.29 24.63 27.93 0.20 0.23 0.26 0.48 0.59 0.69 4.46E-03 5.42E-03 6.37E-03 Greece - Escherichia coli CREC UTI - model 23 0.14 0.19 0.24 0.00 0.00 0.00 0.14 0.19 0.24 1.67E-03 2.10E-03 2.67E-03 1.32E-03 1.70E-03 2.24E-03 0.00 0.00 0.00 1.32E-03 1.70E-03 2.24E-03 78.74 88.43 98.83 0.73 0.81 0.91 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Klebsiella pneumoniae 3GCRKP BSI - model 1 117.69 126.76 136.91 756.39 797.27 847.06 877.66 925.28 977.51 5.00 5.23 5.46 1.08 1.17 1.26 6.97 7.34 7.80 8.08 8.52 9.00 169.10 176.97 185.23 1.56 1.63 1.71 27.90 29.54 31.35 0.26 0.27 0.29 Greece - Klebsiella pneumoniae 3GCRKP OTH - model 5 0.19 0.23 0.28 0.00 0.00 0.00 0.19 0.23 0.28 2.79E-03 3.34E-03 3.88E-03 1.73E-03 2.16E-03 2.62E-03 0.00 0.00 0.00 1.73E-03 2.16E-03 2.62E-03 62.30 70.16 78.01 0.57 0.65 0.72 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Klebsiella pneumoniae 3GCRKP RESP - model 2 68.50 76.11 85.28 133.59 148.29 163.88 202.38 224.13 247.28 1.37 1.47 1.58 0.63 0.70 0.79 1.23 1.37 1.51 1.86 2.06 2.28 137.86 152.63 167.52 1.27 1.41 1.54 4.94 5.51 6.08 0.05 0.05 0.06 Greece - Klebsiella pneumoniae 3GCRKP SSI - model 4 0.11 0.15 0.19 26.68 30.49 34.13 26.81 30.66 34.30 0.42 0.44 0.46 1.05E-03 1.36E-03 1.75E-03 0.25 0.28 0.31 0.25 0.28 0.32 61.82 69.53 77.08 0.57 0.64 0.71 1.46 1.71 1.95 0.01 0.02 0.02 Greece - Klebsiella pneumoniae 3GCRKP UTI - model 3 0.33 0.41 0.49 0.00 0.00 0.00 0.33 0.41 0.49 1.64E-03 1.97E-03 2.29E-03 3.04E-03 3.76E-03 4.55E-03 0.00 0.00 0.00 3.04E-03 3.76E-03 4.55E-03 187.16 207.92 226.38 1.72 1.91 2.08 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Klebsiella pneumoniae ColRKP BSI - model 11 274.83 302.81 334.76 5,759.99 6,713.95 7,706.77 6,062.12 7,012.88 8,009.28 14.13 16.15 18.26 2.53 2.79 3.08 53.05 61.83 70.98 55.83 64.59 73.76 401.37 435.01 466.70 3.70 4.01 4.30 225.76 261.89 303.12 2.08 2.41 2.79 Greece - Klebsiella pneumoniae ColRKP OTH - model 15 0.54 0.71 0.95 0.00 0.00 0.00 0.54 0.71 0.95 2.85E-03 3.51E-03 4.36E-03 4.97E-03 6.57E-03 8.78E-03 0.00 0.00 0.00 4.97E-03 6.57E-03 8.78E-03 168.93 202.52 237.77 1.56 1.87 2.19 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Klebsiella pneumoniae ColRKP RESP - model 12 71.44 87.11 102.65 139.02 168.60 199.55 211.98 255.56 301.37 1.28 1.40 1.52 0.66 0.80 0.95 1.28 1.55 1.84 1.95 2.35 2.78 152.74 183.14 212.38 1.41 1.69 1.96 5.50 6.59 7.72 0.05 0.06 0.07 Greece - Klebsiella pneumoniae ColRKP SSI - model 14 0.19 0.27 0.37 43.00 54.14 65.30 43.23 54.47 65.59 0.39 0.42 0.46 1.79E-03 2.51E-03 3.38E-03 0.40 0.50 0.60 0.40 0.50 0.60 105.03 128.18 152.62 0.97 1.18 1.41 2.24 2.92 3.56 0.02 0.03 0.03 Greece - Klebsiella pneumoniae ColRKP UTI - model 13 0.42 0.55 0.71 0.00 0.00 0.00 0.42 0.55 0.71 1.69E-03 2.10E-03 2.53E-03 3.89E-03 5.04E-03 6.53E-03 0.00 0.00 0.00 3.89E-03 5.04E-03 6.53E-03 222.08 262.71 301.82 2.05 2.42 2.78 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Klebsiella pneumoniae CRKP BSI - model 6 654.97 711.60 778.72 8,240.54 9,334.49 10,446.92 8,935.48 10,049.83 11,199.14 8.72 9.73 10.67 6.03 6.55 7.17 75.89 85.97 96.21 82.29 92.56 103.14 967.90 1,033.56 1,107.85 8.91 9.52 10.20 323.16 368.66 416.64 2.98 3.40 3.84 Greece - Klebsiella pneumoniae CRKP OTH - model 10 1.30 1.69 2.18 0.00 0.00 0.00 1.30 1.69 2.18 2.85E-03 3.52E-03 4.18E-03 0.01 0.02 0.02 0.00 0.00 0.00 0.01 0.02 0.02 403.49 482.12 560.05 3.72 4.44 5.16 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Klebsiella pneumoniae CRKP RESP - model 7 174.32 205.53 237.97 329.15 399.32 461.27 510.47 605.16 698.63 1.27 1.38 1.51 1.61 1.89 2.19 3.03 3.68 4.25 4.70 5.57 6.43 370.19 436.71 509.69 3.41 4.02 4.69 13.26 15.72 18.51 0.12 0.14 0.17 Greece - Klebsiella pneumoniae CRKP SSI - model 9 0.49 0.65 0.84 109.09 131.83 155.72 109.63 132.47 156.95 0.40 0.44 0.47 4.49E-03 5.97E-03 7.78E-03 1.00 1.21 1.43 1.01 1.22 1.45 256.31 304.98 357.62 2.36 2.81 3.29 5.82 7.31 8.88 0.05 0.07 0.08 Greece - Klebsiella pneumoniae CRKP UTI - model 8 1.02 1.31 1.67 0.00 0.00 0.00 1.02 1.31 1.67 1.69E-03 2.10E-03 2.52E-03 9.41E-03 0.01 0.02 0.00 0.00 0.00 9.41E-03 0.01 0.02 541.10 625.86 714.98 4.98 5.76 6.58 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Pseudomonas aeruginosa ColRPA BSI - model 56 18.39 20.71 23.27 136.18 176.06 219.12 157.30 196.93 239.07 5.93 7.29 8.76 0.17 0.19 0.21 1.25 1.62 2.02 1.45 1.81 2.20 24.30 26.89 29.61 0.22 0.25 0.27 4.74 6.16 7.55 0.04 0.06 0.07 Greece - Pseudomonas aeruginosa ColRPA OTH - model 60 0.04 0.05 0.07 0.00 0.00 0.00 0.04 0.05 0.07 2.97E-03 3.75E-03 4.53E-03 3.44E-04 4.64E-04 6.08E-04 0.00 0.00 0.00 3.44E-04 4.64E-04 6.08E-04 10.73 13.59 16.29 0.10 0.13 0.15 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Pseudomonas aeruginosa ColRPA RESP - model 57 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Pseudomonas aeruginosa ColRPA SSI - model 59 0.03 0.04 0.05 6.93 8.93 10.85 6.97 8.97 10.89 0.44 0.49 0.52 2.54E-04 3.59E-04 5.00E-04 0.06 0.08 0.10 0.06 0.08 0.10 15.02 18.45 22.02 0.14 0.17 0.20 0.32 0.43 0.53 2.92E-03 3.93E-03 4.90E-03 Greece - Pseudomonas aeruginosa ColRPA UTI - model 58 0.05 0.07 0.09 0.00 0.00 0.00 0.05 0.07 0.09 1.65E-03 2.05E-03 2.52E-03 4.96E-04 6.49E-04 8.38E-04 0.00 0.00 0.00 4.96E-04 6.49E-04 8.38E-04 28.53 34.65 40.32 0.26 0.32 0.37 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Pseudomonas aeruginosa CRPA BSI - model 51 371.40 404.83 442.37 2,867.61 3,444.75 4,066.36 3,269.62 3,846.17 4,490.63 6.01 7.01 8.00 3.42 3.73 4.07 26.41 31.73 37.45 30.11 35.42 41.36 509.25 549.94 591.81 4.69 5.06 5.45 102.50 125.36 149.42 0.94 1.15 1.38 Greece - Pseudomonas aeruginosa CRPA OTH - model 55 0.81 1.02 1.27 0.00 0.00 0.00 0.81 1.02 1.27 3.11E-03 3.66E-03 4.31E-03 7.43E-03 9.39E-03 0.01 0.00 0.00 0.00 7.43E-03 9.39E-03 0.01 236.42 279.18 322.82 2.18 2.57 2.97 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Pseudomonas aeruginosa CRPA RESP - model 52 920.02 1,031.56 1,148.31 3,090.91 3,664.42 4,313.30 4,032.98 4,698.61 5,415.43 2.06 2.31 2.59 8.47 9.50 10.58 28.47 33.75 39.72 37.14 43.27 49.87 1,813.27 2,036.45 2,237.55 16.70 18.76 20.61 110.80 134.16 159.01 1.02 1.24 1.46 Greece - Pseudomonas aeruginosa CRPA SSI - model 54 0.61 0.80 1.03 133.07 161.34 187.19 134.31 162.10 188.50 0.40 0.43 0.46 5.63E-03 7.37E-03 9.45E-03 1.23 1.49 1.72 1.24 1.49 1.74 321.44 376.22 429.72 2.96 3.46 3.96 6.85 8.34 9.88 0.06 0.08 0.09 Greece - Pseudomonas aeruginosa CRPA UTI - model 53 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Pseudomonas aeruginosa MDRPA BSI - model 46 8.74 9.63 10.69 62.01 75.70 90.39 71.67 85.39 100.52 4.34 5.16 6.00 0.08 0.09 0.10 0.57 0.70 0.83 0.66 0.79 0.93 15.13 16.49 18.08 0.14 0.15 0.17 2.79 3.49 4.26 0.03 0.03 0.04 Greece - Pseudomonas aeruginosa MDRPA OTH - model 50 0.02 0.03 0.04 0.00 0.00 0.00 0.02 0.03 0.04 3.01E-03 3.79E-03 4.53E-03 2.12E-04 2.89E-04 3.70E-04 0.00 0.00 0.00 2.12E-04 2.89E-04 3.70E-04 6.69 8.29 9.74 0.06 0.08 0.09 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Pseudomonas aeruginosa MDRPA RESP - model 47 21.55 24.55 27.76 67.24 82.23 99.26 89.97 106.82 125.23 1.53 1.76 1.99 0.20 0.23 0.26 0.62 0.76 0.91 0.83 0.98 1.15 53.12 61.17 68.99 0.49 0.56 0.64 2.99 3.79 4.69 0.03 0.03 0.04 Greece - Pseudomonas aeruginosa MDRPA SSI - model 49 0.02 0.02 0.03 3.76 4.77 5.65 3.78 4.79 5.68 0.39 0.42 0.45 1.57E-04 2.23E-04 3.05E-04 0.03 0.04 0.05 0.03 0.04 0.05 9.18 11.43 13.45 0.08 0.11 0.12 0.23 0.29 0.36 2.15E-03 2.70E-03 3.28E-03 Greece - Pseudomonas aeruginosa MDRPA UTI - model 48 0.03 0.04 0.06 0.00 0.00 0.00 0.03 0.04 0.06 1.62E-03 2.05E-03 2.49E-03 3.04E-04 3.99E-04 5.17E-04 0.00 0.00 0.00 3.04E-04 3.99E-04 5.17E-04 17.92 21.30 24.57 0.17 0.20 0.23 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Staphylococcus aureus MRSA BSI - model 61 158.15 173.82 189.69 1,080.13 1,165.94 1,258.36 1,240.69 1,340.29 1,444.79 4.01 4.26 4.51 1.46 1.60 1.75 9.95 10.74 11.59 11.43 12.34 13.31 288.28 314.70 346.01 2.66 2.90 3.19 51.44 56.51 61.92 0.47 0.52 0.57 Greece - Staphylococcus aureus MRSA OTH - model 65 1.21 1.53 1.92 0.00 0.00 0.00 1.21 1.53 1.92 2.65E-03 3.27E-03 3.93E-03 0.01 0.01 0.02 0.00 0.00 0.00 0.01 0.01 0.02 413.44 469.45 535.29 3.81 4.32 4.93 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Staphylococcus aureus MRSA RESP - model 62 163.02 184.40 209.55 318.67 358.22 402.61 483.58 543.15 611.02 1.03 1.13 1.22 1.50 1.70 1.93 2.93 3.30 3.71 4.45 5.00 5.63 417.62 482.50 549.39 3.85 4.44 5.06 14.90 17.36 19.88 0.14 0.16 0.18 Greece - Staphylococcus aureus MRSA SSI - model 64 0.83 1.11 1.51 185.63 211.65 238.82 186.59 212.81 239.93 0.38 0.41 0.43 7.62E-03 0.01 0.01 1.71 1.95 2.20 1.72 1.96 2.21 460.24 522.99 592.26 4.24 4.82 5.45 12.45 14.50 16.78 0.11 0.13 0.15 Greece - Staphylococcus aureus MRSA UTI - model 63 0.11 0.15 0.20 0.00 0.00 0.00 0.11 0.15 0.20 1.52E-03 1.88E-03 2.28E-03 1.01E-03 1.39E-03 1.83E-03 0.00 0.00 0.00 1.01E-03 1.39E-03 1.83E-03 64.92 81.08 98.91 0.60 0.75 0.91 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Streptococcus pneumoniae PMRSP BSI - model 76 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Streptococcus pneumoniae PMRSP OTH - model 80 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Streptococcus pneumoniae PMRSP RESP - model 77 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Streptococcus pneumoniae PMRSP SSI - model 79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Streptococcus pneumoniae PMRSP UTI - model 78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Streptococcus pneumoniae PRSP BSI - model 71 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Streptococcus pneumoniae PRSP OTH - model 75 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Streptococcus pneumoniae PRSP RESP - model 72 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Streptococcus pneumoniae PRSP SSI - model 74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Greece - Streptococcus pneumoniae PRSP UTI - model 73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total (Median & 95% UIs) 10,820.16 5,624.30 6,202.95 75,011.91 39,810.68 45,372.58 86,025.35 45,443.62 51,389.92 99.65 51.80 57.13 690.84 366.65 417.87 792.27 418.53 473.29 34,703.01 18,332.40 20,420.24 319.61 168.84 188.07 2,992.14 1,597.74 1,842.58 27.56 14.71 16.97 Total (average) - 374.80 427.65 18,476.06 170.16 1,627.22 14.99 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 5,738.92 40,695.70 46,434.62 - 52.85 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 Infection Colistin resistant Acinetobacter spp. 4.89 8.25 12.80 17.09 44.44 80.95 22.86 53.27 92.74 8.67 16.17 23.32 0.01 0.02 0.03 0.04 0.10 0.17 0.05 0.11 0.20 5.40 9.76 14.81 0.01 0.02 0.03 0.32 0.82 1.50 0.00 0.00 0.00 Carbapenem resistant Acinetobacter spp. (excluding those resistant to colistin) 180.13 207.71 240.65 867.44 1,119.60 1,370.43 1,055.15 1,329.96 1,595.48 6.67 7.96 9.25 0.39 0.45 0.52 1.87 2.41 2.95 2.27 2.86 3.43 424.90 493.97 566.39 0.91 1.06 1.22 33.70 43.11 53.21 0.07 0.09 0.11 Aminoglycosides and fluoroquinolones resistant Acinetobacter spp. (excluding those resistant to colistin and/or carbapenem) 12.47 15.65 19.18 56.99 82.20 111.23 70.93 98.11 129.24 3.25 4.27 5.47 0.03 0.03 0.04 0.12 0.18 0.24 0.15 0.21 0.28 55.03 69.34 84.84 0.12 0.15 0.18 4.31 6.02 7.98 0.01 0.01 0.02 Vancomycin resistant Enterococci (E. faecalis and E. faecium ) 26.54 36.41 48.95 257.16 344.31 457.94 280.07 380.62 504.32 4.96 5.68 6.58 0.06 0.08 0.11 0.55 0.74 0.99 0.60 0.82 1.09 188.35 258.58 332.47 0.41 0.56 0.72 13.31 17.45 22.08 0.03 0.04 0.05 Colistin resistant Escherichia coli 24.19 29.96 37.31 384.40 509.86 652.52 411.08 540.47 685.05 10.03 12.47 15.26 0.05 0.06 0.08 0.83 1.10 1.40 0.89 1.16 1.47 275.83 335.66 397.33 0.59 0.72 0.86 22.89 29.27 35.95 0.05 0.06 0.08 Carbapenem resistant Escherichia coli (excluding those resistant to colistin) 2.09 3.69 6.19 20.41 39.34 65.95 22.43 42.75 71.96 8.80 13.60 18.10 0.00 0.01 0.01 0.04 0.08 0.14 0.05 0.09 0.15 13.73 25.68 38.53 0.03 0.06 0.08 0.68 1.31 2.21 0.00 0.00 0.00 Third-generation cephalosporin resistant Escherichia coli (excluding those resistant to colistin and/or carbapenem) 1,331.90 1,505.38 1,693.97 7,966.45 8,934.44 10,031.55 9,324.17 10,432.11 11,648.62 4.12 4.54 4.99 2.87 3.24 3.65 17.15 19.23 21.60 20.07 22.46 25.08 15,795.33 18,425.79 21,045.18 34.01 39.67 45.31 491.11 567.70 656.87 1.06 1.22 1.41 Colistin resistant Klebsiella pneumoniae 10.12 14.10 18.83 171.21 251.04 359.76 182.33 265.48 375.04 15.13 20.64 26.15 0.02 0.03 0.04 0.37 0.54 0.77 0.39 0.57 0.81 26.94 38.88 51.80 0.06 0.08 0.11 6.03 8.58 11.98 0.01 0.02 0.03 Carbapenem resistant Klebsiella pneumoniae (excluding those resistant to colistin) 92.03 110.55 131.68 969.84 1,185.49 1,446.26 1,068.99 1,296.15 1,573.54 11.65 13.75 16.08 0.20 0.24 0.28 2.09 2.55 3.11 2.30 2.79 3.39 240.62 292.52 347.45 0.52 0.63 0.75 32.54 39.32 46.68 0.07 0.08 0.10 Third-generation cephalosporin resistant Klebsiella pneumoniae (excluding those resistant to colistin and/or carbapenem) 877.00 970.47 1,067.91 4,294.17 4,644.18 5,036.10 5,138.10 5,612.47 6,086.28 6.28 6.65 7.05 1.89 2.09 2.30 9.24 10.00 10.84 11.06 12.08 13.10 3,114.62 3,488.68 3,873.67 6.71 7.51 8.34 172.69 188.71 205.75 0.37 0.41 0.44 Colistin resistant Pseudomonas aeruginosa 45.28 60.45 77.84 182.59 302.44 443.10 235.46 363.74 516.21 8.68 12.45 16.62 0.10 0.13 0.17 0.39 0.65 0.95 0.51 0.78 1.11 95.35 128.49 162.14 0.21 0.28 0.35 5.21 8.44 12.27 0.01 0.02 0.03 Carbapenem resistant Pseudomonas aeruginosa (excluding those resistant to colistin) 1,566.19 1,774.54 1,995.55 7,341.51 8,958.79 10,795.89 8,992.85 10,726.53 12,686.88 8.12 9.51 11.01 3.37 3.82 4.30 15.81 19.29 23.24 19.36 23.09 27.31 4,316.79 5,003.83 5,713.88 9.29 10.77 12.30 271.81 339.18 414.12 0.59 0.73 0.89 Pseudomonas aeruginosa resistant to three or more antimicrobial groups (excluding those resistant to colistin and/or carbapenem) 60.79 75.92 92.57 255.63 357.99 478.22 323.43 435.11 566.32 5.26 6.85 8.72 0.13 0.16 0.20 0.55 0.77 1.03 0.70 0.94 1.22 223.62 280.84 340.69 0.48 0.60 0.73 12.69 18.01 23.66 0.03 0.04 0.05 Methicillin resistant Staphylococcus aureus 1,555.41 1,721.24 1,899.14 7,674.28 8,368.15 9,031.65 9,267.34 10,089.67 10,873.83 4.98 5.27 5.57 3.35 3.71 4.09 16.52 18.02 19.44 19.95 21.72 23.41 8,777.87 9,836.53 10,908.83 18.90 21.18 23.49 423.59 469.48 516.90 0.91 1.01 1.11 Penicillin and macrolides resistant Streptococcus pneumoniae (excluding those only resistant to penicillin) 667.87 786.04 944.03 2,292.55 2,561.82 2,915.47 2,984.40 3,351.45 3,833.22 8.26 8.86 9.50 1.44 1.69 2.03 4.94 5.52 6.28 6.43 7.22 8.25 1,107.92 1,239.86 1,394.22 2.39 2.67 3.00 69.34 75.58 82.93 0.15 0.16 0.18 Penicillin tesistant Streptococcus pneumoniae (excluding those resistant to macrolides) 791.07 896.36 1,022.20 2,681.46 2,906.46 3,189.51 3,495.34 3,805.93 4,182.98 8.42 8.81 9.26 1.70 1.93 2.20 5.77 6.26 6.87 7.53 8.19 9.01 1,294.94 1,416.61 1,565.03 2.79 3.05 3.37 80.36 86.26 93.16 0.17 0.19 0.20 Total 7,247.98 8,216.72 9,308.80 35,433.20 40,610.56 46,466.54 42,874.93 48,823.81 55,421.71 15.60 17.69 20.04 76.28 87.43 100.04 92.30 105.11 119.32 35,957.22 41,345.01 46,837.28 77.41 89.01 100.83 1,640.58 1,899.25 2,187.24 3.53 4.09 4.71 Model Spain - Acinetobacter spp. CRACI BSI - model 36 104.73 118.25 135.39 698.74 918.09 1,133.65 808.81 1,038.37 1,255.26 4.94 6.10 7.25 0.23 0.25 0.29 1.50 1.98 2.44 1.74 2.24 2.70 155.67 169.74 187.62 0.34 0.37 0.40 26.98 35.07 43.84 0.06 0.08 0.09 Spain - Acinetobacter spp. CRACI OTH - model 40 0.02 0.02 0.03 0.00 0.00 0.00 0.02 0.02 0.03 2.90E-03 3.76E-03 4.62E-03 3.28E-05 5.01E-05 7.23E-05 0.00 0.00 0.00 3.28E-05 5.01E-05 7.23E-05 4.49 6.25 8.26 9.67E-03 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Acinetobacter spp. CRACI RESP - model 37 75.18 89.16 104.85 147.48 174.14 203.34 224.90 263.91 306.33 1.33 1.43 1.53 0.16 0.19 0.23 0.32 0.37 0.44 0.48 0.57 0.66 157.28 184.69 212.54 0.34 0.40 0.46 5.67 6.66 7.68 0.01 0.01 0.02 Spain - Acinetobacter spp. CRACI SSI - model 39 0.10 0.13 0.19 21.22 27.38 33.44 21.32 27.50 33.67 0.40 0.44 0.47 2.09E-04 2.86E-04 4.04E-04 0.05 0.06 0.07 0.05 0.06 0.07 50.74 62.97 74.30 0.11 0.14 0.16 1.05 1.38 1.69 2.27E-03 2.98E-03 3.63E-03 Spain - Acinetobacter spp. CRACI UTI - model 38 0.11 0.14 0.19 0.00 0.00 0.00 0.11 0.14 0.19 1.62E-03 2.03E-03 2.50E-03 2.32E-04 3.05E-04 4.06E-04 0.00 0.00 0.00 2.32E-04 3.05E-04 4.06E-04 56.73 70.32 83.66 0.12 0.15 0.18 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Acinetobacter spp. ColRACI BSI - model 41 3.05 4.74 7.13 13.11 36.83 69.00 17.08 42.09 75.43 5.70 12.73 19.47 6.57E-03 0.01 0.02 0.03 0.08 0.15 0.04 0.09 0.16 2.45 3.32 4.52 5.28E-03 7.15E-03 9.72E-03 0.24 0.68 1.28 5.23E-04 1.47E-03 2.75E-03 Spain - Acinetobacter spp. ColRACI OTH - model 45 5.39E-05 3.88E-04 1.31E-03 0.00 0.00 0.00 5.39E-05 3.88E-04 1.31E-03 1.56E-03 3.75E-03 6.40E-03 1.16E-07 8.35E-07 2.82E-06 0.00 0.00 0.00 1.16E-07 8.35E-07 2.82E-06 0.02 0.12 0.27 4.19E-05 2.48E-04 5.89E-04 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Acinetobacter spp. ColRACI RESP - model 42 1.84 3.50 5.66 3.76 6.98 10.91 5.57 10.54 16.26 2.49 2.95 3.36 3.96E-03 7.54E-03 0.01 8.10E-03 0.02 0.02 0.01 0.02 0.04 2.00 3.63 5.49 4.30E-03 7.82E-03 0.01 0.07 0.13 0.20 1.50E-04 2.78E-04 4.35E-04 Spain - Acinetobacter spp. ColRACI SSI - model 44 4.79E-04 2.41E-03 6.87E-03 0.22 0.63 1.04 0.22 0.63 1.04 0.49 0.49 0.49 1.03E-06 5.19E-06 1.48E-05 4.65E-04 1.36E-03 2.24E-03 4.66E-04 1.37E-03 2.24E-03 0.44 1.30 2.14 9.56E-04 2.80E-03 4.60E-03 4.00E-03 0.01 0.02 8.61E-06 2.52E-05 4.14E-05 Spain - Acinetobacter spp. ColRACI UTI - model 43 7.15E-04 2.53E-03 6.57E-03 0.00 0.00 0.00 7.15E-04 2.53E-03 6.57E-03 8.40E-04 1.99E-03 3.58E-03 1.54E-06 5.45E-06 1.41E-05 0.00 0.00 0.00 1.54E-06 5.45E-06 1.41E-05 0.49 1.39 2.40 1.04E-03 2.99E-03 5.16E-03 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Acinetobacter spp. MDRACI BSI - model 31 7.28 8.92 10.75 44.68 66.03 90.78 53.65 75.15 100.70 2.27 3.14 4.15 0.02 0.02 0.02 0.10 0.14 0.20 0.12 0.16 0.22 20.80 23.75 27.49 0.04 0.05 0.06 3.37 4.80 6.44 7.26E-03 0.01 0.01 Spain - Acinetobacter spp. MDRACI OTH - model 35 1.63E-03 3.13E-03 5.44E-03 0.00 0.00 0.00 1.63E-03 3.13E-03 5.44E-03 2.52E-03 3.71E-03 5.05E-03 3.50E-06 6.74E-06 1.17E-05 0.00 0.00 0.00 3.50E-06 6.74E-06 1.17E-05 0.50 0.86 1.28 1.07E-03 1.85E-03 2.75E-03 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Acinetobacter spp. MDRACI RESP - model 32 5.16 6.68 8.36 9.95 12.83 16.03 14.87 19.56 24.08 0.64 0.75 0.87 0.01 0.01 0.02 0.02 0.03 0.03 0.03 0.04 0.05 20.18 26.06 31.50 0.04 0.06 0.07 0.73 0.94 1.16 1.57E-03 2.02E-03 2.50E-03 Spain - Acinetobacter spp. MDRACI SSI - model 34 0.01 0.02 0.03 2.36 3.35 4.41 2.39 3.37 4.43 0.33 0.38 0.44 2.26E-05 4.01E-05 6.46E-05 5.09E-03 7.22E-03 9.50E-03 5.14E-03 7.26E-03 9.55E-03 6.47 8.74 11.55 0.01 0.02 0.02 0.20 0.28 0.38 4.41E-04 6.06E-04 8.11E-04 Spain - Acinetobacter spp. MDRACI UTI - model 33 0.01 0.02 0.03 0.00 0.00 0.00 0.01 0.02 0.03 1.41E-03 2.00E-03 2.78E-03 2.60E-05 4.29E-05 6.53E-05 0.00 0.00 0.00 2.60E-05 4.29E-05 6.53E-05 7.08 9.93 13.02 0.02 0.02 0.03 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Enterococcus faecalis and E. faecium VRE BSI - model 66 26.31 36.05 48.39 230.67 306.83 409.06 253.39 342.76 454.97 4.58 5.25 6.11 0.06 0.08 0.10 0.50 0.66 0.88 0.55 0.74 0.98 50.47 65.67 82.67 0.11 0.14 0.18 11.55 15.02 18.93 0.02 0.03 0.04 Spain - Enterococcus faecalis and E. faecium VRE OTH - model 70 0.08 0.12 0.17 0.00 0.00 0.00 0.08 0.12 0.17 1.17E-03 1.65E-03 2.19E-03 1.62E-04 2.48E-04 3.70E-04 0.00 0.00 0.00 1.62E-04 2.48E-04 3.70E-04 48.86 70.25 90.82 0.11 0.15 0.20 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Enterococcus faecalis and E. faecium VRE RESP - model 67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Enterococcus faecalis and E. faecium VRE SSI - model 69 0.12 0.19 0.29 26.49 37.48 48.88 26.57 37.68 49.08 0.38 0.42 0.47 2.49E-04 4.08E-04 6.32E-04 0.06 0.08 0.11 0.06 0.08 0.11 64.90 89.62 115.79 0.14 0.19 0.25 1.76 2.42 3.15 3.79E-03 5.22E-03 6.78E-03 Spain - Enterococcus faecalis and E. faecium VRE UTI - model 68 0.04 0.06 0.09 0.00 0.00 0.00 0.04 0.06 0.09 1.37E-03 1.86E-03 2.39E-03 8.59E-05 1.31E-04 1.96E-04 0.00 0.00 0.00 8.59E-05 1.31E-04 1.96E-04 24.12 33.04 43.20 0.05 0.07 0.09 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Escherichia coli 3GCREC BSI - model 16 1,013.95 1,124.26 1,244.30 6,541.74 7,250.48 8,074.76 7,577.79 8,364.80 9,249.11 2.98 3.27 3.56 2.18 2.42 2.68 14.08 15.61 17.38 16.31 18.01 19.91 2,313.69 2,560.44 2,854.83 4.98 5.51 6.15 391.62 444.22 508.36 0.84 0.96 1.09 Spain - Escherichia coli 3GCREC OTH - model 20 2.02 2.86 3.96 0.00 0.00 0.00 2.02 2.86 3.96 2.63E-03 3.33E-03 4.22E-03 4.35E-03 6.15E-03 8.52E-03 0.00 0.00 0.00 4.35E-03 6.15E-03 8.52E-03 672.31 862.16 1,053.68 1.45 1.86 2.27 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Escherichia coli 3GCREC RESP - model 17 295.06 350.88 410.29 562.44 674.84 782.49 860.21 1,028.44 1,188.74 0.79 0.89 1.02 0.64 0.76 0.88 1.21 1.45 1.68 1.85 2.21 2.56 904.51 1,145.42 1,394.68 1.95 2.47 3.00 32.39 41.33 50.26 0.07 0.09 0.11 Spain - Escherichia coli 3GCREC SSI - model 19 4.17 5.77 7.92 862.27 1,009.11 1,174.30 867.45 1,014.42 1,179.31 0.34 0.37 0.40 8.98E-03 0.01 0.02 1.86 2.17 2.53 1.87 2.18 2.54 2,289.23 2,737.97 3,214.56 4.93 5.89 6.92 67.10 82.14 98.24 0.14 0.18 0.21 Spain - Escherichia coli 3GCREC UTI - model 18 16.69 21.60 27.50 0.00 0.00 0.00 16.69 21.60 27.50 1.53E-03 1.94E-03 2.42E-03 0.04 0.05 0.06 0.00 0.00 0.00 0.04 0.05 0.06 9,615.59 11,119.80 12,527.42 20.70 23.94 26.97 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Escherichia coli CREC BSI - model 21 1.73 2.71 4.42 19.18 36.35 61.01 20.82 38.81 65.37 7.12 11.68 15.95 3.73E-03 5.84E-03 9.51E-03 0.04 0.08 0.13 0.04 0.08 0.14 2.43 3.39 4.82 5.23E-03 7.31E-03 0.01 0.64 1.21 2.04 1.37E-03 2.60E-03 4.40E-03 Spain - Escherichia coli CREC OTH - model 25 1.60E-03 6.24E-03 0.02 0.00 0.00 0.00 1.60E-03 6.24E-03 0.02 1.12E-03 3.32E-03 7.52E-03 3.45E-06 1.34E-05 3.96E-05 0.00 0.00 0.00 3.45E-06 1.34E-05 3.96E-05 0.80 1.99 3.23 1.72E-03 4.28E-03 6.96E-03 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Escherichia coli CREC RESP - model 22 0.35 0.94 1.66 0.68 1.86 3.21 1.05 2.77 4.77 1.41 1.64 1.86 7.44E-04 2.02E-03 3.58E-03 1.46E-03 4.01E-03 6.91E-03 2.26E-03 5.97E-03 0.01 0.65 1.69 2.88 1.39E-03 3.65E-03 6.20E-03 0.02 0.06 0.11 4.84E-05 1.33E-04 2.30E-04 Spain - Escherichia coli CREC SSI - model 24 1.77E-03 7.74E-03 0.02 0.55 1.13 1.72 0.56 1.13 1.74 0.27 0.27 0.28 3.82E-06 1.67E-05 5.33E-05 1.19E-03 2.42E-03 3.71E-03 1.20E-03 2.44E-03 3.74E-03 2.04 4.16 6.37 4.40E-03 8.96E-03 0.01 0.02 0.04 0.06 3.96E-05 8.07E-05 1.23E-04 Spain - Escherichia coli CREC UTI - model 23 0.01 0.03 0.07 0.00 0.00 0.00 0.01 0.03 0.07 8.12E-04 2.03E-03 4.08E-03 2.18E-05 6.05E-05 1.46E-04 0.00 0.00 0.00 2.18E-05 6.05E-05 1.46E-04 7.81 14.44 21.23 0.02 0.03 0.05 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Escherichia coli ColREC BSI - model 26 18.21 21.78 26.40 358.21 475.92 610.19 378.93 498.24 631.85 8.86 11.13 13.72 0.04 0.05 0.06 0.77 1.02 1.31 0.82 1.07 1.36 39.11 44.56 50.86 0.08 0.10 0.11 21.10 26.97 33.11 0.05 0.06 0.07 Spain - Escherichia coli ColREC OTH - model 30 0.06 0.09 0.13 0.00 0.00 0.00 0.06 0.09 0.13 2.50E-03 3.52E-03 4.79E-03 1.29E-04 1.95E-04 2.87E-04 0.00 0.00 0.00 1.29E-04 1.95E-04 2.87E-04 20.25 25.99 31.80 0.04 0.06 0.07 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Escherichia coli ColREC RESP - model 27 5.57 7.59 10.06 10.82 14.66 19.05 16.37 22.34 29.02 0.83 0.97 1.14 0.01 0.02 0.02 0.02 0.03 0.04 0.04 0.05 0.06 17.30 22.78 28.54 0.04 0.05 0.06 0.62 0.82 1.03 1.34E-03 1.77E-03 2.23E-03 Spain - Escherichia coli ColREC SSI - model 29 0.07 0.11 0.17 15.36 19.28 23.28 15.45 19.40 23.49 0.34 0.36 0.39 1.56E-04 2.41E-04 3.56E-04 0.03 0.04 0.05 0.03 0.04 0.05 42.71 53.37 64.79 0.09 0.11 0.14 1.17 1.48 1.81 2.52E-03 3.19E-03 3.89E-03 Spain - Escherichia coli ColREC UTI - model 28 0.28 0.39 0.55 0.00 0.00 0.00 0.28 0.39 0.55 1.53E-03 2.10E-03 2.76E-03 5.92E-04 8.43E-04 1.19E-03 0.00 0.00 0.00 5.92E-04 8.43E-04 1.19E-03 156.47 188.96 221.35 0.34 0.41 0.48 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Klebsiella pneumoniae 3GCRKP BSI - model 1 551.27 600.45 652.67 3,532.69 3,776.05 4,060.83 4,047.27 4,375.52 4,700.07 4.61 4.85 5.10 1.19 1.29 1.41 7.61 8.13 8.74 8.71 9.42 10.12 848.11 904.21 965.04 1.83 1.95 2.08 140.07 151.14 162.77 0.30 0.33 0.35 Spain - Klebsiella pneumoniae 3GCRKP OTH - model 5 0.95 1.21 1.54 0.00 0.00 0.00 0.95 1.21 1.54 2.70E-03 3.34E-03 4.02E-03 2.06E-03 2.61E-03 3.32E-03 0.00 0.00 0.00 2.06E-03 2.61E-03 3.32E-03 314.92 363.72 417.72 0.68 0.78 0.90 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Klebsiella pneumoniae 3GCRKP RESP - model 2 322.52 365.96 410.08 628.32 712.22 793.79 953.94 1,076.94 1,199.75 1.26 1.36 1.47 0.69 0.79 0.88 1.35 1.53 1.71 2.05 2.32 2.58 697.68 788.95 887.12 1.50 1.70 1.91 25.01 28.47 32.21 0.05 0.06 0.07 Spain - Klebsiella pneumoniae 3GCRKP SSI - model 4 0.58 0.76 1.01 133.16 155.91 181.48 134.25 156.70 182.32 0.41 0.44 0.47 1.24E-03 1.65E-03 2.18E-03 0.29 0.34 0.39 0.29 0.34 0.39 311.25 359.11 408.37 0.67 0.77 0.88 7.62 9.10 10.77 0.02 0.02 0.02 Spain - Klebsiella pneumoniae 3GCRKP UTI - model 3 1.68 2.09 2.60 0.00 0.00 0.00 1.68 2.09 2.60 1.61E-03 1.95E-03 2.36E-03 3.61E-03 4.50E-03 5.61E-03 0.00 0.00 0.00 3.61E-03 4.50E-03 5.61E-03 942.67 1,072.69 1,195.42 2.03 2.31 2.57 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Klebsiella pneumoniae CRKP BSI - model 6 72.83 85.18 99.56 922.25 1,123.52 1,369.10 1,001.58 1,208.72 1,464.53 9.87 11.67 13.67 0.16 0.18 0.21 1.99 2.42 2.95 2.16 2.60 3.15 92.87 103.94 115.93 0.20 0.22 0.25 30.82 37.04 43.82 0.07 0.08 0.09 Spain - Klebsiella pneumoniae CRKP OTH - model 10 0.12 0.17 0.24 0.00 0.00 0.00 0.12 0.17 0.24 2.71E-03 3.50E-03 4.52E-03 2.62E-04 3.71E-04 5.21E-04 0.00 0.00 0.00 2.62E-04 3.71E-04 5.21E-04 37.73 49.32 61.48 0.08 0.11 0.13 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Klebsiella pneumoniae CRKP RESP - model 7 18.94 25.00 31.61 37.36 49.00 61.14 56.92 74.09 92.35 1.40 1.66 1.94 0.04 0.05 0.07 0.08 0.11 0.13 0.12 0.16 0.20 34.52 44.60 54.92 0.07 0.10 0.12 1.23 1.61 1.98 2.65E-03 3.46E-03 4.26E-03 Spain - Klebsiella pneumoniae CRKP SSI - model 9 0.04 0.07 0.10 10.23 12.97 16.01 10.29 13.04 16.24 0.38 0.42 0.47 9.41E-05 1.42E-04 2.09E-04 0.02 0.03 0.03 0.02 0.03 0.03 24.43 31.12 38.56 0.05 0.07 0.08 0.49 0.67 0.87 1.06E-03 1.44E-03 1.88E-03 Spain - Klebsiella pneumoniae CRKP UTI - model 8 0.09 0.13 0.18 0.00 0.00 0.00 0.09 0.13 0.18 1.61E-03 2.07E-03 2.65E-03 2.01E-04 2.84E-04 3.87E-04 0.00 0.00 0.00 2.01E-04 2.84E-04 3.87E-04 51.06 63.53 76.56 0.11 0.14 0.16 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Klebsiella pneumoniae ColRKP BSI - model 11 8.28 10.82 14.15 166.43 242.58 347.61 175.74 253.74 358.13 13.38 18.52 23.63 0.02 0.02 0.03 0.36 0.52 0.75 0.38 0.55 0.77 11.28 13.73 16.76 0.02 0.03 0.04 5.85 8.28 11.54 0.01 0.02 0.02 Spain - Klebsiella pneumoniae ColRKP OTH - model 15 0.01 0.02 0.04 0.00 0.00 0.00 0.01 0.02 0.04 2.00E-03 3.40E-03 5.30E-03 2.50E-05 4.76E-05 8.71E-05 0.00 0.00 0.00 2.50E-05 4.76E-05 8.71E-05 4.12 6.53 9.14 8.87E-03 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Klebsiella pneumoniae ColRKP RESP - model 12 1.82 3.23 4.59 3.62 6.31 9.02 5.40 9.54 13.69 1.30 1.59 1.91 3.92E-03 6.95E-03 9.88E-03 7.79E-03 0.01 0.02 0.01 0.02 0.03 3.57 5.90 8.35 7.70E-03 0.01 0.02 0.13 0.21 0.30 2.73E-04 4.57E-04 6.45E-04 Spain - Klebsiella pneumoniae ColRKP SSI - model 14 3.98E-03 8.61E-03 0.02 1.16 2.15 3.14 1.17 2.16 3.15 0.44 0.52 0.60 8.57E-06 1.85E-05 3.47E-05 2.51E-03 4.63E-03 6.75E-03 2.52E-03 4.65E-03 6.79E-03 2.41 4.16 5.92 5.19E-03 8.96E-03 0.01 0.05 0.09 0.14 1.06E-04 2.02E-04 2.99E-04 Spain - Klebsiella pneumoniae ColRKP UTI - model 13 9.42E-03 0.02 0.03 0.00 0.00 0.00 9.42E-03 0.02 0.03 1.27E-03 2.08E-03 3.08E-03 2.03E-05 3.74E-05 6.21E-05 0.00 0.00 0.00 2.03E-05 3.74E-05 6.21E-05 5.55 8.56 11.63 0.01 0.02 0.03 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Pseudomonas aeruginosa CRPA BSI - model 51 440.70 493.49 550.39 3,453.34 4,218.12 5,076.32 3,928.47 4,705.13 5,608.37 5.73 6.81 7.94 0.95 1.06 1.18 7.43 9.08 10.93 8.46 10.13 12.07 627.79 691.41 765.02 1.35 1.49 1.65 127.23 158.12 192.76 0.27 0.34 0.41 Spain - Pseudomonas aeruginosa CRPA OTH - model 55 0.99 1.29 1.64 0.00 0.00 0.00 0.99 1.29 1.64 3.02E-03 3.67E-03 4.30E-03 2.14E-03 2.78E-03 3.52E-03 0.00 0.00 0.00 2.14E-03 2.78E-03 3.52E-03 290.01 352.33 420.64 0.62 0.76 0.91 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Pseudomonas aeruginosa CRPA RESP - model 52 1,122.30 1,276.91 1,439.81 3,720.03 4,526.13 5,461.71 4,893.01 5,802.74 6,815.36 1.98 2.25 2.58 2.42 2.75 3.10 8.01 9.74 11.76 10.53 12.49 14.67 2,244.41 2,576.26 2,914.98 4.83 5.55 6.28 136.03 169.91 207.70 0.29 0.37 0.45 Spain - Pseudomonas aeruginosa CRPA SSI - model 54 0.76 1.02 1.37 168.14 214.54 257.86 168.93 215.54 259.17 0.40 0.45 0.48 1.63E-03 2.20E-03 2.96E-03 0.36 0.46 0.56 0.36 0.46 0.56 393.94 483.38 566.32 0.85 1.04 1.22 8.55 11.15 13.66 0.02 0.02 0.03 Spain - Pseudomonas aeruginosa CRPA UTI - model 53 1.45 1.82 2.34 0.00 0.00 0.00 1.45 1.82 2.34 1.70E-03 2.03E-03 2.44E-03 3.12E-03 3.92E-03 5.04E-03 0.00 0.00 0.00 3.12E-03 3.92E-03 5.04E-03 760.64 900.46 1,046.92 1.64 1.94 2.25 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Pseudomonas aeruginosa ColRPA BSI - model 56 13.17 16.87 21.68 87.23 143.32 211.16 102.15 160.53 232.60 6.09 9.03 12.29 0.03 0.04 0.05 0.19 0.31 0.45 0.22 0.35 0.50 14.48 17.67 21.33 0.03 0.04 0.05 2.51 3.96 5.78 5.40E-03 8.53E-03 0.01 Spain - Pseudomonas aeruginosa ColRPA OTH - model 60 0.02 0.03 0.05 0.00 0.00 0.00 0.02 0.03 0.05 2.51E-03 3.74E-03 5.03E-03 4.15E-05 7.32E-05 1.13E-04 0.00 0.00 0.00 4.15E-05 7.32E-05 1.13E-04 6.16 9.19 12.23 0.01 0.02 0.03 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Pseudomonas aeruginosa ColRPA RESP - model 57 32.05 43.47 55.99 91.98 154.04 225.13 129.88 198.02 276.65 2.21 2.99 3.86 0.07 0.09 0.12 0.20 0.33 0.48 0.28 0.43 0.60 49.57 66.18 82.30 0.11 0.14 0.18 2.60 4.30 6.24 5.59E-03 9.27E-03 0.01 Spain - Pseudomonas aeruginosa ColRPA SSI - model 59 0.01 0.03 0.04 3.38 5.08 6.81 3.39 5.10 6.84 0.37 0.41 0.46 2.96E-05 5.54E-05 9.42E-05 7.28E-03 0.01 0.01 7.29E-03 0.01 0.01 8.50 12.36 16.43 0.02 0.03 0.04 0.11 0.18 0.25 2.34E-04 3.82E-04 5.31E-04 Spain - Pseudomonas aeruginosa ColRPA UTI - model 58 0.03 0.05 0.07 0.00 0.00 0.00 0.03 0.05 0.07 1.39E-03 2.06E-03 2.79E-03 6.10E-05 1.01E-04 1.54E-04 0.00 0.00 0.00 6.10E-05 1.01E-04 1.54E-04 16.63 23.08 29.85 0.04 0.05 0.06 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Pseudomonas aeruginosa MDRPA BSI - model 46 17.81 21.32 25.45 115.14 165.88 220.47 136.05 187.23 244.05 3.62 4.83 6.22 0.04 0.05 0.05 0.25 0.36 0.47 0.29 0.40 0.53 33.45 38.82 44.68 0.07 0.08 0.10 5.84 8.29 10.79 0.01 0.02 0.02 Spain - Pseudomonas aeruginosa MDRPA OTH - model 50 0.05 0.07 0.11 0.00 0.00 0.00 0.05 0.07 0.11 2.68E-03 3.73E-03 4.73E-03 1.03E-04 1.60E-04 2.27E-04 0.00 0.00 0.00 1.03E-04 1.60E-04 2.27E-04 14.48 20.10 25.60 0.03 0.04 0.06 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Pseudomonas aeruginosa MDRPA RESP - model 47 42.83 54.36 66.78 132.58 181.58 244.35 179.29 237.11 308.55 1.30 1.63 2.05 0.09 0.12 0.14 0.29 0.39 0.53 0.39 0.51 0.66 117.50 144.26 173.11 0.25 0.31 0.37 6.36 9.02 11.94 0.01 0.02 0.03 Spain - Pseudomonas aeruginosa MDRPA SSI - model 49 0.04 0.06 0.09 7.91 10.53 13.40 7.97 10.59 13.47 0.34 0.39 0.44 7.78E-05 1.23E-04 1.88E-04 0.02 0.02 0.03 0.02 0.02 0.03 20.03 26.99 34.15 0.04 0.06 0.07 0.49 0.71 0.93 1.05E-03 1.53E-03 2.01E-03 Spain - Pseudomonas aeruginosa MDRPA UTI - model 48 0.07 0.10 0.15 0.00 0.00 0.00 0.07 0.10 0.15 1.53E-03 2.03E-03 2.62E-03 1.51E-04 2.21E-04 3.13E-04 0.00 0.00 0.00 1.51E-04 2.21E-04 3.13E-04 38.17 50.67 63.15 0.08 0.11 0.14 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Staphylococcus aureus MRSA BSI - model 61 761.03 832.78 912.99 5,184.36 5,571.43 5,953.14 5,975.92 6,406.69 6,823.75 3.65 3.85 4.05 1.64 1.79 1.97 11.16 11.99 12.82 12.87 13.79 14.69 1,552.57 1,664.13 1,789.30 3.34 3.58 3.85 274.63 298.69 324.48 0.59 0.64 0.70 Spain - Staphylococcus aureus MRSA OTH - model 65 6.28 8.01 9.93 0.00 0.00 0.00 6.28 8.01 9.93 2.64E-03 3.25E-03 3.95E-03 0.01 0.02 0.02 0.00 0.00 0.00 0.01 0.02 0.02 2,201.11 2,474.69 2,747.36 4.74 5.33 5.91 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Staphylococcus aureus MRSA RESP - model 62 783.26 873.81 967.55 1,518.81 1,696.81 1,870.89 2,306.86 2,568.97 2,828.28 0.94 1.02 1.09 1.69 1.88 2.08 3.27 3.65 4.03 4.97 5.53 6.09 2,236.29 2,528.80 2,843.26 4.81 5.44 6.12 79.30 90.84 102.73 0.17 0.20 0.22 Spain - Staphylococcus aureus MRSA SSI - model 64 4.28 5.86 7.64 971.12 1,099.92 1,207.62 977.71 1,105.23 1,210.85 0.38 0.40 0.42 9.21E-03 0.01 0.02 2.09 2.37 2.60 2.10 2.38 2.61 2,453.75 2,753.38 3,033.92 5.28 5.93 6.53 69.66 79.95 89.69 0.15 0.17 0.19 Spain - Staphylococcus aureus MRSA UTI - model 63 0.56 0.77 1.02 0.00 0.00 0.00 0.56 0.77 1.02 1.47E-03 1.86E-03 2.24E-03 1.22E-03 1.67E-03 2.19E-03 0.00 0.00 0.00 1.22E-03 1.67E-03 2.19E-03 334.15 415.53 495.00 0.72 0.89 1.07 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Streptococcus pneumoniae PMRSP BSI - model 76 190.38 212.46 237.61 1,358.55 1,442.88 1,531.27 1,569.76 1,656.73 1,749.74 6.66 7.02 7.37 0.41 0.46 0.51 2.92 3.11 3.30 3.38 3.57 3.77 230.91 236.08 240.72 0.50 0.51 0.52 40.67 42.48 44.46 0.09 0.09 0.10 Spain - Streptococcus pneumoniae PMRSP OTH - model 80 0.13 0.17 0.20 0.00 0.00 0.00 0.13 0.17 0.20 1.57E-03 1.97E-03 2.40E-03 2.84E-04 3.61E-04 4.41E-04 0.00 0.00 0.00 2.84E-04 3.61E-04 4.41E-04 78.74 85.20 94.46 0.17 0.18 0.20 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Streptococcus pneumoniae PMRSP RESP - model 77 477.36 573.41 706.21 934.00 1,118.94 1,384.20 1,414.51 1,694.55 2,083.27 1.60 1.84 2.12 1.03 1.23 1.52 2.01 2.41 2.98 3.05 3.65 4.49 798.26 918.58 1,059.04 1.72 1.98 2.28 28.67 33.10 38.47 0.06 0.07 0.08 Spain - Streptococcus pneumoniae PMRSP SSI - model 79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Streptococcus pneumoniae PMRSP UTI - model 78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Streptococcus pneumoniae PRSP BSI - model 71 220.74 240.27 261.00 1,564.33 1,629.37 1,704.15 1,798.81 1,869.78 1,947.31 6.73 6.97 7.23 0.48 0.52 0.56 3.37 3.51 3.67 3.87 4.03 4.19 263.82 268.16 272.83 0.57 0.58 0.59 46.52 48.32 50.05 0.10 0.10 0.11 Spain - Streptococcus pneumoniae PRSP OTH - model 75 0.16 0.19 0.23 0.00 0.00 0.00 0.16 0.19 0.23 1.65E-03 1.95E-03 2.30E-03 3.34E-04 4.06E-04 4.88E-04 0.00 0.00 0.00 3.34E-04 4.06E-04 4.88E-04 90.37 96.92 103.12 0.19 0.21 0.22 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Streptococcus pneumoniae PRSP RESP - model 72 570.17 655.91 760.97 1,117.13 1,277.10 1,485.36 1,696.37 1,935.96 2,235.43 1.69 1.84 2.03 1.23 1.41 1.64 2.41 2.75 3.20 3.65 4.17 4.81 940.74 1,051.53 1,189.08 2.03 2.26 2.56 33.84 37.94 43.11 0.07 0.08 0.09 Spain - Streptococcus pneumoniae PRSP SSI - model 74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Spain - Streptococcus pneumoniae PRSP UTI - model 73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total (Median & 95% UIs) 7,247.98 8,216.72 9,308.80 35,433.20 40,610.56 46,466.54 42,874.93 48,823.81 55,421.71 15.60 17.69 20.04 76.28 87.43 100.04 92.30 105.11 119.32 35,957.22 41,345.01 46,837.28 77.41 89.01 100.83 1,640.58 1,899.25 2,187.24 3.53 4.09 4.71 Total (average) - 87.56 105.29 41,350.08 89.02 1,902.48 4.10 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 8,236.05 40,669.84 48,905.89 - 17.73 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 Infection Colistin resistant Acinetobacter spp. 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Acinetobacter spp. (excluding those resistant to colistin) 1.50 2.42 3.62 5.09 12.61 22.70 6.99 15.05 25.73 7.80 14.15 21.12 0.03 0.04 0.07 0.09 0.23 0.41 0.13 0.28 0.47 1.85 3.13 4.50 0.03 0.06 0.08 0.10 0.26 0.46 0.00 0.00 0.01 Aminoglycosides and fluoroquinolones resistant Acinetobacter spp. (excluding those resistant to colistin and/or carbapenem) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Vancomycin resistant Enterococci (E. faecalis and E. faecium ) 0.29 0.57 1.15 2.92 5.90 10.95 3.27 6.47 11.96 4.71 4.89 5.09 0.01 0.01 0.02 0.05 0.11 0.20 0.06 0.12 0.22 1.78 5.13 9.25 0.03 0.09 0.17 0.17 0.35 0.65 0.00 0.01 0.01 Colistin resistant Escherichia coli 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Escherichia coli (excluding those resistant to colistin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Third-generation cephalosporin resistant Escherichia coli (excluding those resistant to colistin and/or carbapenem) 175.65 195.92 217.62 1,044.08 1,163.91 1,291.19 1,229.61 1,360.46 1,502.08 4.95 5.38 5.85 3.21 3.58 3.98 19.08 21.27 23.60 22.47 24.86 27.45 1,799.00 2,008.25 2,232.05 32.88 36.70 40.79 54.55 61.72 69.66 1.00 1.13 1.27 Colistin resistant Klebsiella pneumoniae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Klebsiella pneumoniae (excluding those resistant to colistin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Third-generation cephalosporin resistant Klebsiella pneumoniae (excluding those resistant to colistin and/or carbapenem) 18.50 20.97 24.05 92.19 101.66 111.35 111.37 122.59 134.21 6.29 6.70 7.15 0.34 0.38 0.44 1.68 1.86 2.04 2.04 2.24 2.45 66.96 75.72 84.51 1.22 1.38 1.54 3.76 4.14 4.53 0.07 0.08 0.08 Colistin resistant Pseudomonas aeruginosa 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Pseudomonas aeruginosa (excluding those resistant to colistin) 44.42 53.91 64.44 196.45 273.08 359.29 245.41 327.42 421.27 8.94 11.55 14.29 0.81 0.99 1.18 3.59 4.99 6.57 4.48 5.98 7.70 104.23 124.84 145.00 1.90 2.28 2.65 6.32 8.42 10.89 0.12 0.15 0.20 Pseudomonas aeruginosa resistant to three or more antimicrobial groups (excluding those resistant to colistin and/or carbapenem) 12.64 15.82 19.52 50.30 74.44 102.72 64.33 90.06 121.26 4.76 6.39 8.17 0.23 0.29 0.36 0.92 1.36 1.88 1.18 1.65 2.22 49.37 62.30 75.36 0.90 1.14 1.38 2.76 3.94 5.35 0.05 0.07 0.10 Methicillin resistant Staphylococcus aureus 59.07 66.86 75.46 285.86 312.22 340.65 347.33 378.93 413.22 7.73 8.23 8.78 1.08 1.22 1.38 5.22 5.71 6.23 6.35 6.93 7.55 214.76 239.50 263.46 3.92 4.38 4.81 9.87 10.84 11.87 0.18 0.20 0.22 Penicillin and macrolides resistant Streptococcus pneumoniae (excluding those only resistant to penicillin) 0.86 1.26 2.01 3.25 4.11 5.52 4.25 5.38 7.29 2.94 3.35 3.76 0.02 0.02 0.04 0.06 0.08 0.10 0.08 0.10 0.13 4.10 5.19 7.55 0.07 0.09 0.14 0.25 0.32 0.43 0.00 0.01 0.01 Penicillin tesistant Streptococcus pneumoniae (excluding those resistant to macrolides) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total 312.93 357.73 407.87 1,680.14 1,947.92 2,244.37 2,012.55 2,306.37 2,637.03 5.72 6.54 7.45 30.71 35.60 41.02 36.78 42.15 48.19 2,242.06 2,524.07 2,821.68 40.98 46.13 51.57 77.79 89.98 103.85 1.42 1.64 1.90 Model Finland - Acinetobacter spp. ColRACI BSI - model 41 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Acinetobacter spp. ColRACI OTH - model 45 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Acinetobacter spp. ColRACI RESP - model 42 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Acinetobacter spp. ColRACI SSI - model 44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Acinetobacter spp. ColRACI UTI - model 43 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Acinetobacter spp. CRACI BSI - model 36 0.93 1.39 1.97 3.82 10.36 19.30 5.13 11.74 20.87 5.06 11.03 17.62 0.02 0.03 0.04 0.07 0.19 0.35 0.09 0.21 0.38 0.85 1.07 1.37 0.02 0.02 0.03 0.08 0.21 0.39 1.43E-03 3.86E-03 7.15E-03 Finland - Acinetobacter spp. CRACI OTH - model 40 1.75E-05 1.27E-04 3.78E-04 0.00 0.00 0.00 1.75E-05 1.27E-04 3.78E-04 1.56E-03 3.67E-03 6.41E-03 3.20E-07 2.32E-06 6.91E-06 0.00 0.00 0.00 3.20E-07 2.32E-06 6.91E-06 5.90E-03 0.04 0.08 1.08E-04 6.95E-04 1.45E-03 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Acinetobacter spp. CRACI RESP - model 37 0.58 1.03 1.64 1.20 2.07 3.12 1.79 3.13 4.57 2.30 2.67 3.04 0.01 0.02 0.03 0.02 0.04 0.06 0.03 0.06 0.08 0.68 1.17 1.70 0.01 0.02 0.03 0.02 0.04 0.06 4.48E-04 7.70E-04 1.16E-03 Finland - Acinetobacter spp. CRACI SSI - model 39 1.38E-04 7.22E-04 2.10E-03 0.07 0.18 0.28 0.07 0.18 0.28 0.44 0.44 0.45 2.52E-06 1.32E-05 3.85E-05 1.24E-03 3.23E-03 5.10E-03 1.24E-03 3.25E-03 5.14E-03 0.15 0.40 0.63 2.80E-03 7.32E-03 0.01 1.38E-03 3.61E-03 5.68E-03 2.52E-05 6.59E-05 1.04E-04 Finland - Acinetobacter spp. CRACI UTI - model 38 2.53E-04 8.48E-04 2.06E-03 0.00 0.00 0.00 2.53E-04 8.48E-04 2.06E-03 8.67E-04 2.03E-03 3.71E-03 4.62E-06 1.55E-05 3.76E-05 0.00 0.00 0.00 4.62E-06 1.55E-05 3.76E-05 0.17 0.45 0.73 3.14E-03 8.22E-03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Acinetobacter spp. MDRACI BSI - model 31 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Acinetobacter spp. MDRACI OTH - model 35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Acinetobacter spp. MDRACI RESP - model 32 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Acinetobacter spp. MDRACI SSI - model 34 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Acinetobacter spp. MDRACI UTI - model 33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Enterococcus faecalis and E. faecium VRE BSI - model 66 0.29 0.56 1.13 2.61 4.83 9.03 2.96 5.39 10.02 4.11 4.28 4.48 5.29E-03 0.01 0.02 0.05 0.09 0.16 0.05 0.10 0.18 0.68 1.26 2.39 0.01 0.02 0.04 0.16 0.29 0.54 2.85E-03 5.27E-03 9.81E-03 Finland - Enterococcus faecalis and E. faecium VRE OTH - model 70 4.79E-04 2.05E-03 5.44E-03 0.00 0.00 0.00 4.79E-04 2.05E-03 5.44E-03 5.95E-04 1.55E-03 3.12E-03 8.75E-06 3.74E-05 9.95E-05 0.00 0.00 0.00 8.75E-06 3.74E-05 9.95E-05 0.41 1.43 2.43 7.50E-03 0.03 0.04 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Enterococcus faecalis and E. faecium VRE RESP - model 67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Enterococcus faecalis and E. faecium VRE SSI - model 69 6.22E-04 3.24E-03 0.01 0.31 1.07 1.92 0.31 1.08 1.93 0.60 0.61 0.61 1.14E-05 5.93E-05 1.97E-04 5.63E-03 0.02 0.04 5.62E-03 0.02 0.04 0.51 1.78 3.19 9.33E-03 0.03 0.06 0.02 0.06 0.11 3.36E-04 1.17E-03 2.10E-03 Finland - Enterococcus faecalis and E. faecium VRE UTI - model 68 2.28E-04 1.14E-03 3.00E-03 0.00 0.00 0.00 2.28E-04 1.14E-03 3.00E-03 7.21E-04 1.83E-03 3.33E-03 4.17E-06 2.08E-05 5.48E-05 0.00 0.00 0.00 4.17E-06 2.08E-05 5.48E-05 0.17 0.65 1.24 3.13E-03 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Escherichia coli 3GCREC BSI - model 16 134.39 147.48 161.22 864.63 954.75 1,052.46 1,009.37 1,102.61 1,208.01 3.59 3.90 4.22 2.46 2.70 2.95 15.80 17.45 19.23 18.45 20.15 22.08 263.78 282.48 302.12 4.82 5.16 5.52 43.69 48.81 54.58 0.80 0.89 1.00 Finland - Escherichia coli 3GCREC OTH - model 20 0.23 0.31 0.41 0.00 0.00 0.00 0.23 0.31 0.41 2.70E-03 3.33E-03 4.05E-03 4.12E-03 5.65E-03 7.48E-03 0.00 0.00 0.00 4.12E-03 5.65E-03 7.48E-03 74.85 93.22 111.17 1.37 1.70 2.03 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Escherichia coli 3GCREC RESP - model 17 38.67 45.13 52.24 74.32 87.54 99.90 112.79 132.87 151.15 0.97 1.07 1.19 0.71 0.82 0.95 1.36 1.60 1.83 2.06 2.43 2.76 104.08 124.49 144.34 1.90 2.28 2.64 3.73 4.47 5.23 0.07 0.08 0.10 Finland - Escherichia coli 3GCREC SSI - model 19 0.47 0.64 0.83 105.14 121.62 138.83 105.33 122.33 139.58 0.38 0.41 0.43 8.61E-03 0.01 0.02 1.92 2.22 2.54 1.93 2.24 2.55 260.91 299.73 342.53 4.77 5.48 6.26 7.13 8.43 9.85 0.13 0.15 0.18 Finland - Escherichia coli 3GCREC UTI - model 18 1.89 2.35 2.93 0.00 0.00 0.00 1.89 2.35 2.93 1.61E-03 1.96E-03 2.31E-03 0.03 0.04 0.05 0.00 0.00 0.00 0.03 0.04 0.05 1,095.37 1,208.33 1,331.90 20.02 22.08 24.34 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Escherichia coli ColREC BSI - model 26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Escherichia coli ColREC OTH - model 30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Escherichia coli ColREC RESP - model 27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Escherichia coli ColREC SSI - model 29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Escherichia coli ColREC UTI - model 28 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Escherichia coli CREC BSI - model 21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Escherichia coli CREC OTH - model 25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Escherichia coli CREC RESP - model 22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Escherichia coli CREC SSI - model 24 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Escherichia coli CREC UTI - model 23 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Klebsiella pneumoniae 3GCRKP BSI - model 1 11.75 13.05 14.68 75.63 82.28 89.01 87.94 95.29 102.63 4.54 4.82 5.11 0.21 0.24 0.27 1.38 1.50 1.63 1.61 1.74 1.88 18.57 19.77 21.00 0.34 0.36 0.38 3.05 3.30 3.56 0.06 0.06 0.06 Finland - Klebsiella pneumoniae 3GCRKP OTH - model 5 0.02 0.03 0.04 0.00 0.00 0.00 0.02 0.03 0.04 2.56E-03 3.36E-03 4.28E-03 3.46E-04 4.80E-04 6.48E-04 0.00 0.00 0.00 3.46E-04 4.80E-04 6.48E-04 6.68 7.86 9.10 0.12 0.14 0.17 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Klebsiella pneumoniae 3GCRKP RESP - model 2 6.69 7.84 9.26 13.17 15.29 17.59 19.97 23.12 26.72 1.24 1.35 1.49 0.12 0.14 0.17 0.24 0.28 0.32 0.36 0.42 0.49 14.95 17.10 19.41 0.27 0.31 0.35 0.53 0.61 0.71 9.71E-03 0.01 0.01 Finland - Klebsiella pneumoniae 3GCRKP SSI - model 4 0.01 0.02 0.02 3.39 4.08 4.75 3.41 4.10 4.76 0.50 0.52 0.55 1.96E-04 2.99E-04 4.13E-04 0.06 0.07 0.09 0.06 0.07 0.09 6.60 7.79 9.00 0.12 0.14 0.16 0.18 0.23 0.26 3.36E-03 4.12E-03 4.84E-03 Finland - Klebsiella pneumoniae 3GCRKP UTI - model 3 0.03 0.05 0.06 0.00 0.00 0.00 0.03 0.05 0.06 1.50E-03 1.97E-03 2.41E-03 6.20E-04 8.33E-04 1.08E-03 0.00 0.00 0.00 6.20E-04 8.33E-04 1.08E-03 20.16 23.20 26.01 0.37 0.42 0.48 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Klebsiella pneumoniae ColRKP BSI - model 11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Klebsiella pneumoniae ColRKP OTH - model 15 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Klebsiella pneumoniae ColRKP RESP - model 12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Klebsiella pneumoniae ColRKP SSI - model 14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Klebsiella pneumoniae ColRKP UTI - model 13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Klebsiella pneumoniae CRKP BSI - model 6 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Klebsiella pneumoniae CRKP OTH - model 10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Klebsiella pneumoniae CRKP RESP - model 7 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Klebsiella pneumoniae CRKP SSI - model 9 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Klebsiella pneumoniae CRKP UTI - model 8 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Pseudomonas aeruginosa ColRPA BSI - model 56 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Pseudomonas aeruginosa ColRPA OTH - model 60 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Pseudomonas aeruginosa ColRPA RESP - model 57 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Pseudomonas aeruginosa ColRPA SSI - model 59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Pseudomonas aeruginosa ColRPA UTI - model 58 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Pseudomonas aeruginosa CRPA BSI - model 51 12.92 15.06 17.77 92.86 128.72 167.47 107.08 143.80 184.60 6.30 8.31 10.42 0.24 0.28 0.32 1.70 2.35 3.06 1.96 2.63 3.37 15.54 17.33 19.44 0.28 0.32 0.36 2.93 3.95 5.09 0.05 0.07 0.09 Finland - Pseudomonas aeruginosa CRPA OTH - model 55 0.02 0.03 0.04 0.00 0.00 0.00 0.02 0.03 0.04 2.83E-03 3.63E-03 4.56E-03 4.09E-04 5.79E-04 7.88E-04 0.00 0.00 0.00 4.09E-04 5.79E-04 7.88E-04 6.83 8.81 10.71 0.12 0.16 0.20 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Pseudomonas aeruginosa CRPA RESP - model 52 31.43 38.75 46.53 99.33 138.93 185.20 133.99 178.09 229.92 2.21 2.77 3.38 0.57 0.71 0.85 1.82 2.54 3.38 2.45 3.25 4.20 54.38 64.25 73.81 0.99 1.17 1.35 3.20 4.22 5.49 0.06 0.08 0.10 Finland - Pseudomonas aeruginosa CRPA SSI - model 54 0.02 0.03 0.04 4.26 5.43 6.62 4.28 5.46 6.66 0.43 0.46 0.49 3.05E-04 4.63E-04 6.53E-04 0.08 0.10 0.12 0.08 0.10 0.12 9.58 12.00 14.46 0.18 0.22 0.26 0.19 0.25 0.31 3.41E-03 4.54E-03 5.69E-03 Finland - Pseudomonas aeruginosa CRPA UTI - model 53 0.03 0.05 0.06 0.00 0.00 0.00 0.03 0.05 0.06 1.59E-03 2.04E-03 2.57E-03 5.85E-04 8.39E-04 1.09E-03 0.00 0.00 0.00 5.85E-04 8.39E-04 1.09E-03 17.90 22.45 26.58 0.33 0.41 0.49 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Pseudomonas aeruginosa MDRPA BSI - model 46 3.68 4.45 5.37 23.36 34.63 48.28 27.56 39.10 53.05 3.23 4.49 5.82 0.07 0.08 0.10 0.43 0.63 0.88 0.50 0.71 0.97 7.50 8.69 9.96 0.14 0.16 0.18 1.28 1.81 2.49 0.02 0.03 0.05 Finland - Pseudomonas aeruginosa MDRPA OTH - model 50 0.01 0.02 0.02 0.00 0.00 0.00 0.01 0.02 0.02 2.60E-03 3.72E-03 4.95E-03 1.83E-04 3.00E-04 4.30E-04 0.00 0.00 0.00 1.83E-04 3.00E-04 4.30E-04 3.20 4.41 5.72 0.06 0.08 0.10 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Pseudomonas aeruginosa MDRPA RESP - model 47 8.92 11.31 14.07 25.43 37.64 51.60 35.23 48.74 65.30 1.20 1.53 1.93 0.16 0.21 0.26 0.46 0.69 0.94 0.64 0.89 1.19 26.11 32.09 38.04 0.48 0.59 0.70 1.38 1.97 2.65 0.03 0.04 0.05 Finland - Pseudomonas aeruginosa MDRPA SSI - model 49 7.42E-03 0.01 0.02 1.51 2.17 2.84 1.52 2.18 2.85 0.33 0.36 0.40 1.36E-04 2.32E-04 3.77E-04 0.03 0.04 0.05 0.03 0.04 0.05 4.32 5.99 7.60 0.08 0.11 0.14 0.11 0.15 0.20 1.95E-03 2.82E-03 3.73E-03 Finland - Pseudomonas aeruginosa MDRPA UTI - model 48 0.01 0.02 0.03 0.00 0.00 0.00 0.01 0.02 0.03 1.42E-03 2.04E-03 2.68E-03 2.67E-04 4.13E-04 5.98E-04 0.00 0.00 0.00 2.67E-04 4.13E-04 5.98E-04 8.25 11.12 14.04 0.15 0.20 0.26 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Staphylococcus aureus MRSA BSI - model 61 29.03 32.62 36.62 204.20 220.40 237.86 234.97 253.01 272.27 5.85 6.20 6.60 0.53 0.60 0.67 3.73 4.03 4.35 4.29 4.62 4.98 38.49 40.86 43.32 0.70 0.75 0.79 6.81 7.33 7.92 0.12 0.13 0.14 Finland - Staphylococcus aureus MRSA OTH - model 65 0.15 0.20 0.25 0.00 0.00 0.00 0.15 0.20 0.25 2.50E-03 3.31E-03 4.07E-03 2.71E-03 3.62E-03 4.63E-03 0.00 0.00 0.00 2.71E-03 3.62E-03 4.63E-03 53.48 60.08 66.46 0.98 1.10 1.21 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Staphylococcus aureus MRSA RESP - model 62 29.78 33.88 38.36 58.44 66.14 74.75 88.82 99.88 112.48 1.51 1.63 1.77 0.54 0.62 0.70 1.07 1.21 1.37 1.62 1.83 2.06 54.61 61.34 67.86 1.00 1.12 1.24 1.94 2.20 2.48 0.04 0.04 0.05 Finland - Staphylococcus aureus MRSA SSI - model 64 0.10 0.14 0.20 23.22 25.69 28.04 23.38 25.82 28.20 0.37 0.38 0.40 1.87E-03 2.64E-03 3.60E-03 0.42 0.47 0.51 0.43 0.47 0.52 60.22 67.17 73.74 1.10 1.23 1.35 1.12 1.30 1.47 0.02 0.02 0.03 Finland - Staphylococcus aureus MRSA UTI - model 63 0.01 0.02 0.03 0.00 0.00 0.00 0.01 0.02 0.03 1.48E-03 1.87E-03 2.36E-03 2.50E-04 3.39E-04 4.71E-04 0.00 0.00 0.00 2.50E-04 3.39E-04 4.71E-04 7.96 10.04 12.08 0.15 0.18 0.22 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Streptococcus pneumoniae PMRSP BSI - model 76 0.25 0.35 0.46 2.07 2.36 2.63 2.39 2.70 3.01 2.34 2.65 2.95 4.59E-03 6.37E-03 8.40E-03 0.04 0.04 0.05 0.04 0.05 0.05 1.01 1.02 1.03 0.02 0.02 0.02 0.16 0.18 0.21 2.94E-03 3.36E-03 3.75E-03 Finland - Streptococcus pneumoniae PMRSP OTH - model 80 2.60E-04 6.91E-04 1.38E-03 0.00 0.00 0.00 2.60E-04 6.91E-04 1.38E-03 7.08E-04 1.93E-03 3.64E-03 4.75E-06 1.26E-05 2.52E-05 0.00 0.00 0.00 4.75E-06 1.26E-05 2.52E-05 0.29 0.36 0.47 5.34E-03 6.59E-03 8.60E-03 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Streptococcus pneumoniae PMRSP RESP - model 77 0.61 0.91 1.54 1.19 1.75 2.88 1.86 2.68 4.28 0.60 0.70 0.81 0.01 0.02 0.03 0.02 0.03 0.05 0.03 0.05 0.08 2.79 3.81 6.05 0.05 0.07 0.11 0.09 0.14 0.23 1.69E-03 2.50E-03 4.12E-03 Finland - Streptococcus pneumoniae PMRSP SSI - model 79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Streptococcus pneumoniae PMRSP UTI - model 78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Streptococcus pneumoniae PRSP BSI - model 71 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Streptococcus pneumoniae PRSP OTH - model 75 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Streptococcus pneumoniae PRSP RESP - model 72 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Streptococcus pneumoniae PRSP SSI - model 74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Finland - Streptococcus pneumoniae PRSP UTI - model 73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total (Median & 95% UIs) 312.93 357.73 407.87 1,680.14 1,947.92 2,244.37 2,012.55 2,306.37 2,637.03 5.72 6.54 7.45 30.71 35.60 41.02 36.78 42.15 48.19 2,242.06 2,524.07 2,821.68 40.98 46.13 51.57 77.79 89.98 103.85 1.42 1.64 1.90 Total (average) - 35.66 42.21 2,525.84 46.16 90.26 1.65 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 358.76 1,951.01 2,309.77 - 6.56 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 Infection Colistin resistant Acinetobacter spp. 10.48 18.42 31.29 36.96 96.74 193.85 49.59 114.91 221.26 10.05 18.59 27.47 0.02 0.03 0.05 0.06 0.15 0.29 0.07 0.17 0.33 9.42 18.31 30.71 0.01 0.03 0.05 0.58 1.52 3.04 0.00 0.00 0.00 Carbapenem resistant Acinetobacter spp. (excluding those resistant to colistin) 164.25 192.97 229.19 807.57 1,029.49 1,282.49 977.46 1,221.64 1,499.06 6.74 8.14 9.67 0.25 0.29 0.34 1.21 1.55 1.93 1.47 1.84 2.25 376.59 444.76 519.41 0.57 0.67 0.78 30.98 38.20 46.44 0.05 0.06 0.07 Aminoglycosides and fluoroquinolones resistant Acinetobacter spp. (excluding those resistant to colistin and/or carbapenem) 73.97 93.78 119.59 351.48 494.04 674.26 432.93 587.94 783.36 6.04 7.95 9.97 0.11 0.14 0.18 0.53 0.74 1.01 0.65 0.88 1.18 175.69 221.89 273.51 0.26 0.33 0.41 13.65 18.78 24.72 0.02 0.03 0.04 Vancomycin resistant Enterococci (E. faecalis and E. faecium ) 61.17 82.51 109.81 586.53 771.81 1,025.66 650.00 854.43 1,127.19 7.33 8.16 9.18 0.09 0.12 0.17 0.88 1.16 1.54 0.98 1.29 1.70 296.30 396.07 505.22 0.45 0.60 0.76 20.19 26.45 33.90 0.03 0.04 0.05 Colistin resistant Escherichia coli 23.84 31.91 42.69 395.89 553.44 768.54 421.65 585.86 806.42 11.74 15.75 20.25 0.04 0.05 0.06 0.60 0.83 1.16 0.63 0.88 1.21 211.32 290.90 378.43 0.32 0.44 0.57 17.76 25.20 34.73 0.03 0.04 0.05 Carbapenem resistant Escherichia coli (excluding those resistant to colistin) 12.87 16.63 22.26 132.28 176.12 236.27 144.47 192.63 257.65 8.53 10.69 13.00 0.02 0.03 0.03 0.20 0.26 0.36 0.22 0.29 0.39 105.14 144.24 190.08 0.16 0.22 0.29 5.44 7.63 10.52 0.01 0.01 0.02 Third-generation cephalosporin resistant Escherichia coli (excluding those resistant to colistin and/or carbapenem) 4,838.69 5,459.70 6,249.17 28,517.09 32,168.33 36,673.30 33,508.72 37,620.40 42,742.00 4.92 5.39 5.89 7.28 8.21 9.40 42.89 48.38 55.16 50.40 56.58 64.29 47,961.12 55,957.55 64,194.76 72.13 84.16 96.55 1,475.20 1,703.78 1,967.39 2.22 2.56 2.96 Colistin resistant Klebsiella pneumoniae 113.54 141.65 177.03 1,966.60 2,514.54 3,141.77 2,102.80 2,658.21 3,302.61 18.03 21.72 26.05 0.17 0.21 0.27 2.96 3.78 4.73 3.16 4.00 4.97 284.18 367.73 459.27 0.43 0.55 0.69 64.07 80.43 100.70 0.10 0.12 0.15 Carbapenem resistant Klebsiella pneumoniae (excluding those resistant to colistin) 50.72 67.22 87.26 524.71 715.83 939.36 581.97 784.23 1,022.05 10.61 13.29 15.99 0.08 0.10 0.13 0.79 1.08 1.41 0.88 1.18 1.54 128.08 183.99 250.28 0.19 0.28 0.38 17.37 24.45 33.72 0.03 0.04 0.05 Third-generation cephalosporin resistant Klebsiella pneumoniae (excluding those resistant to colistin and/or carbapenem) 4,138.74 4,573.06 5,076.61 20,093.84 21,885.65 23,873.94 24,286.06 26,475.68 28,928.40 6.33 6.66 7.03 6.22 6.88 7.64 30.22 32.92 35.91 36.53 39.82 43.51 14,478.03 16,487.78 18,464.21 21.78 24.80 27.77 797.93 884.58 977.33 1.20 1.33 1.47 Colistin resistant Pseudomonas aeruginosa 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Pseudomonas aeruginosa (excluding those resistant to colistin) 4,878.90 5,771.95 6,751.41 23,030.85 29,005.17 36,114.77 28,241.26 34,716.98 42,322.08 8.44 10.11 11.76 7.34 8.68 10.15 34.64 43.62 54.32 42.48 52.22 63.65 12,756.98 15,234.18 17,913.90 19.19 22.91 26.94 800.72 1,024.90 1,296.94 1.20 1.54 1.95 Pseudomonas aeruginosa resistant to three or more antimicrobial groups (excluding those resistant to colistin and/or carbapenem) 870.94 1,036.02 1,231.13 3,864.03 4,908.67 6,141.49 4,764.64 5,947.88 7,289.07 7.27 8.62 10.04 1.31 1.56 1.85 5.81 7.38 9.24 7.17 8.95 10.96 2,545.95 3,036.34 3,573.66 3.83 4.57 5.37 151.17 192.67 239.06 0.23 0.29 0.36 Methicillin resistant Staphylococcus aureus 5,335.81 6,003.83 6,661.74 26,424.83 28,900.05 31,481.46 31,795.87 34,915.84 38,104.46 5.30 5.63 5.99 8.03 9.03 10.02 39.74 43.47 47.35 47.82 52.51 57.31 28,174.64 31,998.99 36,149.02 42.38 48.13 54.37 1,347.31 1,513.19 1,687.73 2.03 2.28 2.54 Penicillin and macrolides resistant Streptococcus pneumoniae (excluding those only resistant to penicillin) 6.28 7.90 10.50 22.14 25.86 31.26 28.93 33.76 40.78 4.43 4.80 5.20 0.01 0.01 0.02 0.03 0.04 0.05 0.04 0.05 0.06 19.36 22.80 28.18 0.03 0.03 0.04 1.21 1.41 1.68 0.00 0.00 0.00 Penicillin tesistant Streptococcus pneumoniae (excluding those resistant to macrolides) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total 20,580.20 23,497.54 26,799.68 106,754.80 123,245.73 142,578.41 127,986.35 146,710.40 168,446.37 30.95 35.34 40.31 160.56 185.36 214.44 192.49 220.66 253.35 107,522.80 124,805.54 142,930.63 161.72 187.71 214.97 4,743.59 5,543.20 6,457.89 7.13 8.34 9.71 Model France - Acinetobacter spp. ColRACI BSI - model 41 6.55E+00 1.04E+01 1.73E+01 2.87E+01 7.98E+01 1.64E+02 3.75E+01 8.97E+01 1.78E+02 6.50E+00 1.46E+01 2.30E+01 9.86E-03 1.57E-02 2.61E-02 4.32E-02 1.20E-01 2.47E-01 5.64E-02 1.35E-01 2.67E-01 4.46E+00 6.18E+00 9.41E+00 6.71E-03 9.30E-03 1.42E-02 4.50E-01 1.25E+00 2.57E+00 6.77E-04 1.88E-03 3.87E-03 France - Acinetobacter spp. ColRACI OTH - model 45 9.50E-05 8.20E-04 2.82E-03 0.00 0.00 0.00 9.50E-05 8.20E-04 2.82E-03 1.62E-03 3.73E-03 6.49E-03 1.43E-07 1.23E-06 4.25E-06 0.00 0.00 0.00 1.43E-07 1.23E-06 4.25E-06 0.03 0.23 0.59 4.59E-05 3.47E-04 8.86E-04 0.00 0.00 0.00 0.00 0.00 0.00 France - Acinetobacter spp. ColRACI RESP - model 42 3.92 7.99 13.92 7.82 15.58 27.02 11.71 23.81 41.14 2.97 3.44 3.93 5.90E-03 0.01 0.02 0.01 0.02 0.04 0.02 0.04 0.06 3.44 6.88 11.47 5.17E-03 0.01 0.02 0.12 0.24 0.42 1.84E-04 3.67E-04 6.36E-04 France - Acinetobacter spp. ColRACI SSI - model 44 8.94E-04 4.36E-03 0.01 0.42 1.34 2.48 0.42 1.34 2.50 0.58 0.58 0.58 1.34E-06 6.56E-06 2.16E-05 6.25E-04 2.02E-03 3.73E-03 6.26E-04 2.02E-03 3.76E-03 0.72 2.33 4.32 1.09E-03 3.51E-03 6.49E-03 6.51E-03 0.02 0.04 9.79E-06 3.16E-05 5.85E-05 France - Acinetobacter spp. ColRACI UTI - model 43 1.10E-03 4.82E-03 0.01 0.00 0.00 0.00 1.10E-03 4.82E-03 0.01 8.05E-04 2.02E-03 3.67E-03 1.66E-06 7.25E-06 2.01E-05 0.00 0.00 0.00 1.66E-06 7.25E-06 2.01E-05 0.77 2.69 4.92 1.16E-03 4.04E-03 7.39E-03 0.00 0.00 0.00 0.00 0.00 0.00 France - Acinetobacter spp. CRACI BSI - model 36 95.49 110.36 127.69 657.26 845.48 1,059.92 757.91 954.76 1,177.04 5.03 6.27 7.61 0.14 0.17 0.19 0.99 1.27 1.59 1.14 1.44 1.77 136.55 152.40 168.64 0.21 0.23 0.25 25.13 31.08 37.98 0.04 0.05 0.06 France - Acinetobacter spp. CRACI OTH - model 40 0.01 0.02 0.03 0.00 0.00 0.00 0.01 0.02 0.03 2.93E-03 3.76E-03 4.54E-03 2.19E-05 3.35E-05 4.78E-05 0.00 0.00 0.00 2.19E-05 3.35E-05 4.78E-05 4.13 5.97 7.78 6.21E-03 8.97E-03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 France - Acinetobacter spp. CRACI RESP - model 37 68.57 82.34 101.11 132.98 161.72 194.72 201.99 244.32 293.83 1.35 1.47 1.62 0.10 0.12 0.15 0.20 0.24 0.29 0.30 0.37 0.44 140.03 165.71 195.39 0.21 0.25 0.29 4.98 5.98 7.02 7.50E-03 8.99E-03 0.01 France - Acinetobacter spp. CRACI SSI - model 39 0.08 0.12 0.17 17.33 22.30 27.85 17.46 22.40 27.99 0.35 0.39 0.43 1.24E-04 1.84E-04 2.56E-04 0.03 0.03 0.04 0.03 0.03 0.04 45.52 57.17 69.43 0.07 0.09 0.10 0.87 1.15 1.44 1.31E-03 1.73E-03 2.16E-03 France - Acinetobacter spp. CRACI UTI - model 38 0.09 0.13 0.18 0.00 0.00 0.00 0.09 0.13 0.18 1.58E-03 2.04E-03 2.50E-03 1.40E-04 1.94E-04 2.64E-04 0.00 0.00 0.00 1.40E-04 1.94E-04 2.64E-04 50.37 63.51 78.18 0.08 0.10 0.12 0.00 0.00 0.00 0.00 0.00 0.00 France - Acinetobacter spp. MDRACI BSI - model 31 43.58 53.37 66.93 281.59 401.13 553.45 332.30 454.86 610.81 4.33 5.99 7.74 0.07 0.08 0.10 0.42 0.60 0.83 0.50 0.68 0.92 66.29 76.00 88.87 0.10 0.11 0.13 10.83 15.04 19.97 0.02 0.02 0.03 France - Acinetobacter spp. MDRACI OTH - model 35 5.78E-03 0.01 0.02 0.00 0.00 0.00 5.78E-03 0.01 0.02 2.61E-03 3.73E-03 4.94E-03 8.70E-06 1.65E-05 2.62E-05 0.00 0.00 0.00 8.70E-06 1.65E-05 2.62E-05 1.82 2.99 4.35 2.74E-03 4.49E-03 6.54E-03 0.00 0.00 0.00 0.00 0.00 0.00 France - Acinetobacter spp. MDRACI RESP - model 32 30.30 40.28 52.45 60.08 78.47 101.69 90.73 118.50 153.26 1.23 1.43 1.67 0.05 0.06 0.08 0.09 0.12 0.15 0.14 0.18 0.23 65.57 82.71 102.25 0.10 0.12 0.15 2.32 2.99 3.74 3.49E-03 4.50E-03 5.63E-03 France - Acinetobacter spp. MDRACI SSI - model 34 0.03 0.06 0.09 9.81 14.44 19.12 9.85 14.51 19.18 0.47 0.52 0.56 5.10E-05 8.73E-05 1.40E-04 0.01 0.02 0.03 0.01 0.02 0.03 19.68 28.26 36.47 0.03 0.04 0.05 0.50 0.75 1.01 7.50E-04 1.13E-03 1.52E-03 France - Acinetobacter spp. MDRACI UTI - model 33 0.04 0.06 0.10 0.00 0.00 0.00 0.04 0.06 0.10 1.50E-03 2.05E-03 2.66E-03 6.24E-05 9.67E-05 1.43E-04 0.00 0.00 0.00 6.24E-05 9.67E-05 1.43E-04 22.32 31.92 41.57 0.03 0.05 0.06 0.00 0.00 0.00 0.00 0.00 0.00 France - Enterococcus faecalis and E. faecium VRE BSI - model 66 60.81 81.95 108.99 538.41 703.92 934.63 601.57 785.96 1,035.42 6.89 7.65 8.62 0.09 0.12 0.16 0.81 1.06 1.41 0.90 1.18 1.56 79.85 102.42 129.46 0.12 0.15 0.19 18.08 23.42 29.74 0.03 0.04 0.04 France - Enterococcus faecalis and E. faecium VRE OTH - model 70 0.12 0.17 0.26 0.00 0.00 0.00 0.12 0.17 0.26 1.25E-03 1.65E-03 2.13E-03 1.73E-04 2.59E-04 3.84E-04 0.00 0.00 0.00 1.73E-04 2.59E-04 3.84E-04 77.65 106.17 135.53 0.12 0.16 0.20 0.00 0.00 0.00 0.00 0.00 0.00 France - Enterococcus faecalis and E. faecium VRE RESP - model 67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 France - Enterococcus faecalis and E. faecium VRE SSI - model 69 0.19 0.29 0.43 48.12 67.89 91.02 48.25 68.20 91.37 0.44 0.50 0.55 2.79E-04 4.33E-04 6.49E-04 0.07 0.10 0.14 0.07 0.10 0.14 101.77 136.91 174.39 0.15 0.21 0.26 2.11 3.04 4.16 3.17E-03 4.57E-03 6.26E-03 France - Enterococcus faecalis and E. faecium VRE UTI - model 68 0.06 0.09 0.14 0.00 0.00 0.00 0.06 0.09 0.14 1.43E-03 1.88E-03 2.34E-03 9.52E-05 1.43E-04 2.05E-04 0.00 0.00 0.00 9.52E-05 1.43E-04 2.05E-04 37.03 50.58 65.84 0.06 0.08 0.10 0.00 0.00 0.00 0.00 0.00 0.00 France - Escherichia coli 3GCREC BSI - model 16 3,706.37 4,089.37 4,609.55 23,700.15 26,396.43 29,848.04 27,557.10 30,472.32 34,314.09 3.60 3.92 4.26 5.57 6.15 6.93 35.65 39.70 44.89 41.45 45.83 51.61 7,087.64 7,776.64 8,664.30 10.66 11.70 13.03 1,188.16 1,349.40 1,539.38 1.79 2.03 2.32 France - Escherichia coli 3GCREC OTH - model 20 6.45 8.80 11.54 0.00 0.00 0.00 6.45 8.80 11.54 2.69E-03 3.35E-03 4.05E-03 9.69E-03 0.01 0.02 0.00 0.00 0.00 9.69E-03 0.01 0.02 2,004.89 2,672.47 3,245.33 3.02 4.02 4.88 0.00 0.00 0.00 0.00 0.00 0.00 France - Escherichia coli 3GCREC RESP - model 17 1,061.00 1,278.32 1,520.76 2,073.30 2,479.77 2,905.21 3,135.91 3,762.93 4,391.38 0.95 1.07 1.20 1.60 1.92 2.29 3.12 3.73 4.37 4.72 5.66 6.60 2,841.65 3,520.04 4,214.31 4.27 5.29 6.34 102.04 126.41 152.35 0.15 0.19 0.23 France - Escherichia coli 3GCREC SSI - model 19 12.97 17.76 23.61 2,743.64 3,292.13 3,920.05 2,757.35 3,310.90 3,941.29 0.37 0.40 0.43 0.02 0.03 0.04 4.13 4.95 5.90 4.15 4.98 5.93 7,017.92 8,332.04 9,700.87 10.56 12.53 14.59 185.01 227.97 275.66 0.28 0.34 0.41 France - Escherichia coli 3GCREC UTI - model 18 51.91 65.45 83.71 0.00 0.00 0.00 51.91 65.45 83.71 1.60E-03 1.96E-03 2.34E-03 0.08 0.10 0.13 0.00 0.00 0.00 0.08 0.10 0.13 29,009.03 33,656.37 38,369.95 43.63 50.62 57.71 0.00 0.00 0.00 0.00 0.00 0.00 France - Escherichia coli ColREC BSI - model 26 18.42 23.29 30.01 370.75 516.09 716.86 390.64 539.87 742.24 10.32 14.07 18.20 0.03 0.04 0.05 0.56 0.78 1.08 0.59 0.81 1.12 32.19 38.35 46.97 0.05 0.06 0.07 16.48 23.24 32.00 0.02 0.03 0.05 France - Escherichia coli ColREC OTH - model 30 0.04 0.08 0.14 0.00 0.00 0.00 0.04 0.08 0.14 2.14E-03 3.44E-03 5.28E-03 6.35E-05 1.16E-04 2.04E-04 0.00 0.00 0.00 6.35E-05 1.16E-04 2.04E-04 15.29 22.86 30.83 0.02 0.03 0.05 0.00 0.00 0.00 0.00 0.00 0.00 France - Escherichia coli ColREC RESP - model 27 5.13 8.12 11.83 10.06 15.75 22.64 15.55 23.88 34.33 0.99 1.21 1.53 7.71E-03 0.01 0.02 0.02 0.02 0.03 0.02 0.04 0.05 12.58 19.63 28.01 0.02 0.03 0.04 0.46 0.71 1.03 6.91E-04 1.07E-03 1.54E-03 France - Escherichia coli ColREC SSI - model 29 0.05 0.10 0.17 15.08 21.60 29.04 15.21 21.70 29.17 0.43 0.47 0.51 7.71E-05 1.46E-04 2.49E-04 0.02 0.03 0.04 0.02 0.03 0.04 32.21 46.41 61.35 0.05 0.07 0.09 0.82 1.25 1.71 1.23E-03 1.88E-03 2.57E-03 France - Escherichia coli ColREC UTI - model 28 0.20 0.33 0.54 0.00 0.00 0.00 0.20 0.33 0.54 1.33E-03 2.05E-03 2.98E-03 3.04E-04 5.02E-04 8.13E-04 0.00 0.00 0.00 3.04E-04 5.02E-04 8.13E-04 119.06 163.65 211.26 0.18 0.25 0.32 0.00 0.00 0.00 0.00 0.00 0.00 France - Escherichia coli CREC BSI - model 21 9.86 12.10 15.65 120.21 158.82 212.36 129.53 170.82 227.29 7.07 9.00 11.01 0.01 0.02 0.02 0.18 0.24 0.32 0.19 0.26 0.34 15.61 19.26 23.87 0.02 0.03 0.04 4.88 6.77 9.28 7.34E-03 0.01 0.01 France - Escherichia coli CREC OTH - model 25 0.02 0.04 0.07 0.00 0.00 0.00 0.02 0.04 0.07 2.23E-03 3.45E-03 5.45E-03 3.11E-05 5.71E-05 1.07E-04 0.00 0.00 0.00 3.11E-05 5.71E-05 1.07E-04 7.28 11.19 15.61 0.01 0.02 0.02 0.00 0.00 0.00 0.00 0.00 0.00 France - Escherichia coli CREC RESP - model 22 2.86 4.27 6.18 5.55 8.29 11.85 8.27 12.56 17.87 1.10 1.29 1.53 4.30E-03 6.42E-03 9.30E-03 8.34E-03 0.01 0.02 0.01 0.02 0.03 6.28 9.81 14.07 9.45E-03 0.01 0.02 0.21 0.35 0.52 3.17E-04 5.28E-04 7.75E-04 France - Escherichia coli CREC SSI - model 24 0.03 0.05 0.09 6.52 9.01 12.06 6.55 9.06 12.15 0.36 0.40 0.45 3.86E-05 7.16E-05 1.32E-04 9.80E-03 0.01 0.02 9.85E-03 0.01 0.02 15.87 22.71 30.48 0.02 0.03 0.05 0.35 0.51 0.73 5.29E-04 7.72E-04 1.10E-03 France - Escherichia coli CREC UTI - model 23 0.10 0.17 0.27 0.00 0.00 0.00 0.10 0.17 0.27 1.36E-03 2.07E-03 3.10E-03 1.54E-04 2.51E-04 4.05E-04 0.00 0.00 0.00 1.54E-04 2.51E-04 4.05E-04 60.10 81.28 106.06 0.09 0.12 0.16 0.00 0.00 0.00 0.00 0.00 0.00 France - Klebsiella pneumoniae 3GCRKP BSI - model 1 2,597.66 2,823.82 3,097.94 16,503.69 17,790.67 19,214.48 19,138.66 20,631.37 22,296.37 4.63 4.85 5.08 3.91 4.25 4.66 24.82 26.76 28.90 28.79 31.03 33.53 3,907.42 4,253.05 4,600.98 5.88 6.40 6.92 649.39 710.15 774.22 0.98 1.07 1.16 France - Klebsiella pneumoniae 3GCRKP OTH - model 5 4.53 5.81 7.33 0.00 0.00 0.00 4.53 5.81 7.33 2.72E-03 3.35E-03 4.06E-03 6.81E-03 8.75E-03 0.01 0.00 0.00 0.00 6.81E-03 8.75E-03 0.01 1,488.72 1,727.53 1,975.97 2.24 2.60 2.97 0.00 0.00 0.00 0.00 0.00 0.00 France - Klebsiella pneumoniae 3GCRKP RESP - model 2 1,525.99 1,729.79 1,954.20 2,975.42 3,355.84 3,800.88 4,517.25 5,085.74 5,747.97 1.29 1.37 1.47 2.30 2.60 2.94 4.48 5.05 5.72 6.79 7.65 8.65 3,207.66 3,713.78 4,219.08 4.82 5.59 6.35 115.68 133.64 154.79 0.17 0.20 0.23 France - Klebsiella pneumoniae 3GCRKP SSI - model 4 2.66 3.61 4.82 614.73 739.14 858.57 617.74 742.73 864.41 0.40 0.43 0.47 4.00E-03 5.43E-03 7.25E-03 0.92 1.11 1.29 0.93 1.12 1.30 1,446.85 1,717.37 1,963.95 2.18 2.58 2.95 32.87 40.79 48.31 0.05 0.06 0.07 France - Klebsiella pneumoniae 3GCRKP UTI - model 3 7.89 10.02 12.32 0.00 0.00 0.00 7.89 10.02 12.32 1.64E-03 1.97E-03 2.34E-03 0.01 0.02 0.02 0.00 0.00 0.00 0.01 0.02 0.02 4,427.38 5,076.06 5,704.22 6.66 7.63 8.58 0.00 0.00 0.00 0.00 0.00 0.00 France - Klebsiella pneumoniae ColRKP BSI - model 11 90.17 109.18 131.80 1,910.17 2,433.40 3,030.80 2,023.15 2,544.94 3,146.17 16.17 19.56 23.56 0.14 0.16 0.20 2.87 3.66 4.56 3.04 3.83 4.73 112.50 130.23 150.01 0.17 0.20 0.23 62.14 77.65 96.86 0.09 0.12 0.15 France - Klebsiella pneumoniae ColRKP OTH - model 15 0.13 0.22 0.32 0.00 0.00 0.00 0.13 0.22 0.32 2.49E-03 3.51E-03 4.75E-03 2.03E-04 3.26E-04 4.87E-04 0.00 0.00 0.00 2.03E-04 3.26E-04 4.87E-04 44.21 62.03 81.49 0.07 0.09 0.12 0.00 0.00 0.00 0.00 0.00 0.00 France - Klebsiella pneumoniae ColRKP RESP - model 12 23.07 32.01 44.53 44.54 62.89 85.00 67.47 94.56 129.80 1.46 1.69 1.95 0.03 0.05 0.07 0.07 0.09 0.13 0.10 0.14 0.20 40.48 56.17 73.63 0.06 0.08 0.11 1.44 2.02 2.69 2.17E-03 3.04E-03 4.04E-03 France - Klebsiella pneumoniae ColRKP SSI - model 14 0.05 0.08 0.13 11.88 18.25 25.98 11.93 18.34 26.07 0.40 0.47 0.53 7.62E-05 1.25E-04 1.93E-04 0.02 0.03 0.04 0.02 0.03 0.04 27.50 39.15 53.11 0.04 0.06 0.08 0.48 0.76 1.16 7.28E-04 1.14E-03 1.74E-03 France - Klebsiella pneumoniae ColRKP UTI - model 13 0.11 0.16 0.24 0.00 0.00 0.00 0.11 0.16 0.24 1.51E-03 2.07E-03 2.69E-03 1.67E-04 2.45E-04 3.67E-04 0.00 0.00 0.00 1.67E-04 2.45E-04 3.67E-04 59.48 80.16 101.03 0.09 0.12 0.15 0.00 0.00 0.00 0.00 0.00 0.00 France - Klebsiella pneumoniae CRKP BSI - model 6 41.30 51.85 65.41 502.09 678.03 884.61 549.49 730.77 944.24 8.91 11.25 13.56 0.06 0.08 0.10 0.76 1.02 1.33 0.83 1.10 1.42 53.25 65.20 80.23 0.08 0.10 0.12 16.62 23.09 31.62 0.02 0.03 0.05 France - Klebsiella pneumoniae CRKP OTH - model 10 0.06 0.11 0.20 0.00 0.00 0.00 0.06 0.11 0.20 2.20E-03 3.48E-03 5.30E-03 8.73E-05 1.61E-04 2.94E-04 0.00 0.00 0.00 8.73E-05 1.61E-04 2.94E-04 19.42 31.03 44.43 0.03 0.05 0.07 0.00 0.00 0.00 0.00 0.00 0.00 France - Klebsiella pneumoniae CRKP RESP - model 7 9.29 15.14 21.44 18.16 29.44 41.72 27.89 44.87 64.38 1.33 1.61 1.93 0.01 0.02 0.03 0.03 0.04 0.06 0.04 0.07 0.10 16.40 28.04 40.71 0.02 0.04 0.06 0.59 1.00 1.48 8.93E-04 1.50E-03 2.23E-03 France - Klebsiella pneumoniae CRKP SSI - model 9 0.02 0.04 0.08 4.46 8.35 13.03 4.49 8.39 13.09 0.35 0.42 0.49 3.08E-05 6.30E-05 1.14E-04 6.71E-03 0.01 0.02 6.75E-03 0.01 0.02 11.88 19.73 28.83 0.02 0.03 0.04 0.16 0.36 0.62 2.36E-04 5.47E-04 9.30E-04 France - Klebsiella pneumoniae CRKP UTI - model 8 0.05 0.08 0.14 0.00 0.00 0.00 0.05 0.08 0.14 1.34E-03 2.02E-03 3.08E-03 6.82E-05 1.22E-04 2.10E-04 0.00 0.00 0.00 6.82E-05 1.22E-04 2.10E-04 27.13 39.99 56.07 0.04 0.06 0.08 0.00 0.00 0.00 0.00 0.00 0.00 France - Pseudomonas aeruginosa ColRPA BSI - model 56 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 France - Pseudomonas aeruginosa ColRPA OTH - model 60 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 France - Pseudomonas aeruginosa ColRPA RESP - model 57 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 France - Pseudomonas aeruginosa ColRPA SSI - model 59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 France - Pseudomonas aeruginosa ColRPA UTI - model 58 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 France - Pseudomonas aeruginosa CRPA BSI - model 51 1,392.96 1,608.46 1,846.87 10,780.43 13,671.34 17,161.57 12,301.64 15,267.37 18,814.63 5.98 7.28 8.54 2.10 2.42 2.78 16.21 20.56 25.81 18.50 22.96 28.30 1,845.46 2,108.01 2,391.14 2.78 3.17 3.60 377.49 479.83 610.14 0.57 0.72 0.92 France - Pseudomonas aeruginosa CRPA OTH - model 55 2.89 3.94 5.26 0.00 0.00 0.00 2.89 3.94 5.26 2.96E-03 3.66E-03 4.34E-03 4.35E-03 5.93E-03 7.92E-03 0.00 0.00 0.00 4.35E-03 5.93E-03 7.92E-03 852.65 1,078.40 1,335.76 1.28 1.62 2.01 0.00 0.00 0.00 0.00 0.00 0.00 France - Pseudomonas aeruginosa CRPA RESP - model 52 3,476.77 4,150.82 4,887.65 11,775.71 14,727.94 18,208.62 15,455.20 18,831.06 22,746.91 2.08 2.41 2.75 5.23 6.24 7.35 17.71 22.15 27.39 23.25 28.32 34.21 6,669.68 7,828.58 9,123.13 10.03 11.77 13.72 401.68 516.51 650.88 0.60 0.78 0.98 France - Pseudomonas aeruginosa CRPA SSI - model 54 2.20 3.11 4.34 474.72 605.89 744.58 477.45 609.00 747.99 0.37 0.41 0.46 3.31E-03 4.68E-03 6.52E-03 0.71 0.91 1.12 0.72 0.92 1.12 1,168.17 1,468.75 1,785.32 1.76 2.21 2.69 21.55 28.57 35.91 0.03 0.04 0.05 France - Pseudomonas aeruginosa CRPA UTI - model 53 4.08 5.61 7.30 0.00 0.00 0.00 4.08 5.61 7.30 1.66E-03 2.05E-03 2.47E-03 6.14E-03 8.44E-03 0.01 0.00 0.00 0.00 6.14E-03 8.44E-03 0.01 2,221.02 2,750.44 3,278.55 3.34 4.14 4.93 0.00 0.00 0.00 0.00 0.00 0.00 France - Pseudomonas aeruginosa MDRPA BSI - model 46 251.80 290.44 333.91 1,821.28 2,271.31 2,846.41 2,087.20 2,562.57 3,157.94 5.11 6.12 7.22 0.38 0.44 0.50 2.74 3.42 4.28 3.14 3.85 4.75 370.43 420.14 471.95 0.56 0.63 0.71 69.07 88.39 109.15 0.10 0.13 0.16 France - Pseudomonas aeruginosa MDRPA OTH - model 50 0.59 0.80 1.08 0.00 0.00 0.00 0.59 0.80 1.08 3.03E-03 3.73E-03 4.49E-03 8.91E-04 1.21E-03 1.62E-03 0.00 0.00 0.00 8.91E-04 1.21E-03 1.62E-03 172.84 215.88 264.35 0.26 0.32 0.40 0.00 0.00 0.00 0.00 0.00 0.00 France - Pseudomonas aeruginosa MDRPA RESP - model 47 617.27 743.03 893.84 1,952.53 2,520.72 3,152.09 2,585.43 3,266.22 3,985.09 1.79 2.09 2.37 0.93 1.12 1.34 2.94 3.79 4.74 3.89 4.91 5.99 1,326.84 1,561.74 1,826.84 2.00 2.35 2.75 77.47 98.21 122.44 0.12 0.15 0.18 France - Pseudomonas aeruginosa MDRPA SSI - model 49 0.43 0.63 0.85 90.21 116.64 142.99 90.56 117.17 143.51 0.37 0.40 0.45 6.44E-04 9.45E-04 1.27E-03 0.14 0.18 0.22 0.14 0.18 0.22 232.92 291.32 352.76 0.35 0.44 0.53 4.63 6.06 7.47 6.96E-03 9.12E-03 0.01 France - Pseudomonas aeruginosa MDRPA UTI - model 48 0.85 1.11 1.45 0.00 0.00 0.00 0.85 1.11 1.45 1.68E-03 2.05E-03 2.45E-03 1.28E-03 1.67E-03 2.19E-03 0.00 0.00 0.00 1.28E-03 1.67E-03 2.19E-03 442.93 547.26 657.76 0.67 0.82 0.99 0.00 0.00 0.00 0.00 0.00 0.00 France - Staphylococcus aureus MRSA BSI - model 61 2,612.97 2,895.78 3,173.65 18,026.27 19,438.54 20,846.50 20,661.21 22,340.22 23,968.00 3.91 4.13 4.38 3.93 4.36 4.77 27.11 29.24 31.35 31.08 33.60 36.05 4,943.56 5,398.80 5,873.52 7.44 8.12 8.83 880.88 970.19 1,064.74 1.32 1.46 1.60 France - Staphylococcus aureus MRSA OTH - model 65 20.50 26.06 33.25 0.00 0.00 0.00 20.50 26.06 33.25 2.60E-03 3.23E-03 3.93E-03 0.03 0.04 0.05 0.00 0.00 0.00 0.03 0.04 0.05 7,039.04 8,083.11 9,176.02 10.59 12.16 13.80 0.00 0.00 0.00 0.00 0.00 0.00 France - Staphylococcus aureus MRSA RESP - model 62 2,686.04 3,060.54 3,426.78 5,297.17 5,921.51 6,623.23 7,984.01 8,988.88 10,065.35 1.01 1.09 1.18 4.04 4.60 5.15 7.97 8.91 9.96 12.01 13.52 15.14 7,179.17 8,224.06 9,361.24 10.80 12.37 14.08 254.94 296.39 337.42 0.38 0.45 0.51 France - Staphylococcus aureus MRSA SSI - model 64 14.47 18.92 24.66 3,101.39 3,540.00 4,011.72 3,128.32 3,558.16 4,034.47 0.37 0.40 0.42 0.02 0.03 0.04 4.66 5.32 6.03 4.71 5.35 6.07 7,905.63 8,925.26 10,082.37 11.89 13.42 15.16 211.48 246.60 285.57 0.32 0.37 0.43 France - Staphylococcus aureus MRSA UTI - model 63 1.84 2.52 3.39 0.00 0.00 0.00 1.84 2.52 3.39 1.49E-03 1.86E-03 2.26E-03 2.77E-03 3.79E-03 5.10E-03 0.00 0.00 0.00 2.77E-03 3.79E-03 5.10E-03 1,107.24 1,367.76 1,655.88 1.67 2.06 2.49 0.00 0.00 0.00 0.00 0.00 0.00 France - Streptococcus pneumoniae PMRSP BSI - model 76 1.83 2.19 2.59 13.60 14.78 16.02 15.75 16.99 18.20 3.52 3.80 4.07 2.75E-03 3.29E-03 3.89E-03 0.02 0.02 0.02 0.02 0.03 0.03 4.47 4.47 4.47 6.72E-03 6.72E-03 6.72E-03 0.74 0.81 0.87 1.12E-03 1.21E-03 1.31E-03 France - Streptococcus pneumoniae PMRSP OTH - model 80 1.77E-03 3.08E-03 4.74E-03 0.00 0.00 0.00 1.77E-03 3.08E-03 4.74E-03 1.15E-03 1.95E-03 2.88E-03 2.67E-06 4.63E-06 7.13E-06 0.00 0.00 0.00 2.67E-06 4.63E-06 7.13E-06 1.39 1.58 1.83 2.09E-03 2.38E-03 2.75E-03 0.00 0.00 0.00 0.00 0.00 0.00 France - Streptococcus pneumoniae PMRSP RESP - model 77 4.45 5.71 7.91 8.54 11.08 15.24 13.18 16.76 22.57 0.91 1.00 1.12 6.69E-03 8.59E-03 0.01 0.01 0.02 0.02 0.02 0.03 0.03 13.50 16.75 21.87 0.02 0.03 0.03 0.47 0.61 0.81 7.05E-04 9.13E-04 1.22E-03 France - Streptococcus pneumoniae PMRSP SSI - model 79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 France - Streptococcus pneumoniae PMRSP UTI - model 78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 France - Streptococcus pneumoniae PRSP BSI - model 71 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 France - Streptococcus pneumoniae PRSP OTH - model 75 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 France - Streptococcus pneumoniae PRSP RESP - model 72 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 France - Streptococcus pneumoniae PRSP SSI - model 74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 France - Streptococcus pneumoniae PRSP UTI - model 73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total (Median & 95% UIs) 20,580.20 23,497.54 26,799.68 106,754.80 123,245.73 142,578.41 127,986.35 146,710.40 168,446.37 30.95 35.34 40.31 160.56 185.36 214.44 192.49 220.66 253.35 107,522.80 124,805.54 142,930.63 161.72 187.71 214.97 4,743.59 5,543.20 6,457.89 7.13 8.34 9.71 Total (average) - 185.76 221.16 125,011.54 188.02 5,551.56 8.35 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 23,539.73 123,505.38 147,045.12 - 35.40 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 Infection Colistin resistant Acinetobacter spp. 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Acinetobacter spp. (excluding those resistant to colistin) 233.98 261.48 288.46 1,151.96 1,401.48 1,635.75 1,401.00 1,663.77 1,911.05 7.08 8.17 9.25 5.54 6.19 6.83 27.26 33.17 38.71 33.16 39.38 45.23 534.10 600.12 668.28 12.64 14.20 15.82 42.80 52.48 62.06 1.01 1.24 1.47 Aminoglycosides and fluoroquinolones resistant Acinetobacter spp. (excluding those resistant to colistin and/or carbapenem) 2.27 3.00 3.85 9.09 15.87 22.73 11.64 18.85 26.29 3.88 5.66 7.38 0.05 0.07 0.09 0.22 0.38 0.54 0.28 0.45 0.62 7.35 10.05 12.84 0.17 0.24 0.30 0.51 0.87 1.23 0.01 0.02 0.03 Vancomycin resistant Enterococci (E. faecalis and E. faecium ) 20.42 25.56 32.03 191.53 237.84 293.31 211.88 263.28 324.35 6.34 7.00 7.71 0.48 0.60 0.76 4.53 5.63 6.94 5.01 6.23 7.68 113.41 145.38 179.36 2.68 3.44 4.24 7.65 9.50 11.78 0.18 0.22 0.28 Colistin resistant Escherichia coli 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Escherichia coli (excluding those resistant to colistin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Third-generation cephalosporin resistant Escherichia coli (excluding those resistant to colistin and/or carbapenem) 105.10 118.23 133.11 619.33 697.55 785.36 728.10 816.70 917.22 5.39 5.93 6.51 2.49 2.80 3.15 14.66 16.51 18.59 17.23 19.33 21.71 969.54 1,103.25 1,240.19 22.95 26.11 29.35 29.26 33.69 38.32 0.69 0.80 0.91 Colistin resistant Klebsiella pneumoniae 0.69 1.22 1.98 10.72 21.83 36.83 11.49 23.03 38.67 12.49 20.73 29.14 0.02 0.03 0.05 0.25 0.52 0.87 0.27 0.55 0.92 1.47 3.28 5.29 0.03 0.08 0.13 0.36 0.73 1.23 0.01 0.02 0.03 Carbapenem resistant Klebsiella pneumoniae (excluding those resistant to colistin) 7.21 9.06 11.06 75.66 97.20 122.35 83.90 106.36 132.65 10.25 12.51 14.87 0.17 0.21 0.26 1.79 2.30 2.90 1.99 2.52 3.14 20.32 26.52 32.77 0.48 0.63 0.78 2.77 3.56 4.48 0.07 0.08 0.11 Third-generation cephalosporin resistant Klebsiella pneumoniae (excluding those resistant to colistin and/or carbapenem) 245.25 271.61 299.42 1,202.87 1,299.04 1,397.17 1,454.22 1,571.00 1,688.08 8.21 8.66 9.13 5.80 6.43 7.09 28.47 30.74 33.07 34.42 37.18 39.95 676.61 740.55 804.46 16.01 17.53 19.04 36.95 39.80 42.53 0.87 0.94 1.01 Colistin resistant Pseudomonas aeruginosa 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Pseudomonas aeruginosa (excluding those resistant to colistin) 310.30 353.02 395.85 1,447.00 1,783.90 2,153.34 1,773.64 2,137.48 2,539.59 9.39 10.98 12.68 7.34 8.35 9.37 34.25 42.22 50.96 41.98 50.59 60.10 750.78 860.21 969.10 17.77 20.36 22.94 46.87 57.94 70.40 1.11 1.37 1.67 Pseudomonas aeruginosa resistant to three or more antimicrobial groups (excluding those resistant to colistin and/or carbapenem) 14.68 20.88 27.55 57.57 97.63 149.89 74.57 118.31 175.34 6.80 10.07 13.43 0.35 0.49 0.65 1.36 2.31 3.55 1.76 2.80 4.15 36.94 51.93 67.43 0.87 1.23 1.60 1.98 3.25 4.84 0.05 0.08 0.11 Methicillin resistant Staphylococcus aureus 149.11 165.46 182.16 734.02 792.88 855.17 886.47 957.83 1,032.02 5.88 6.15 6.45 3.53 3.92 4.31 17.37 18.76 20.24 20.98 22.67 24.42 723.30 800.68 878.41 17.12 18.95 20.79 34.40 37.58 41.10 0.81 0.89 0.97 Penicillin and macrolides resistant Streptococcus pneumoniae (excluding those only resistant to penicillin) 5.78 8.58 13.68 22.87 28.84 39.61 29.65 37.25 52.15 19.20 21.83 24.53 0.14 0.20 0.32 0.54 0.68 0.94 0.70 0.88 1.23 4.31 5.50 8.42 0.10 0.13 0.20 0.27 0.34 0.47 0.01 0.01 0.01 Penicillin tesistant Streptococcus pneumoniae (excluding those resistant to macrolides) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total 1,094.78 1,238.10 1,389.15 5,522.62 6,474.07 7,491.50 6,666.56 7,713.86 8,837.41 25.91 29.30 32.88 130.70 153.22 177.30 157.78 182.56 209.15 3,838.12 4,347.46 4,866.55 90.84 102.89 115.18 203.82 239.74 278.43 4.82 5.67 6.59 Model Croatia - Acinetobacter spp. ColRACI BSI - model 41 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Acinetobacter spp. ColRACI OTH - model 45 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Acinetobacter spp. ColRACI RESP - model 42 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Acinetobacter spp. ColRACI SSI - model 44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Acinetobacter spp. ColRACI UTI - model 43 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Acinetobacter spp. CRACI BSI - model 36 135.00 148.94 162.47 931.65 1,150.62 1,354.40 1,079.92 1,300.59 1,505.01 5.29 6.27 7.22 3.20 3.52 3.85 22.05 27.23 32.05 25.56 30.78 35.62 193.06 206.99 221.77 4.57 4.90 5.25 34.35 42.75 50.97 0.81 1.01 1.21 Croatia - Acinetobacter spp. CRACI OTH - model 40 0.02 0.03 0.04 0.00 0.00 0.00 0.02 0.03 0.04 3.04E-03 3.72E-03 4.43E-03 4.69E-04 6.57E-04 8.92E-04 0.00 0.00 0.00 4.69E-04 6.57E-04 8.92E-04 5.74 7.49 9.30 0.14 0.18 0.22 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Acinetobacter spp. CRACI RESP - model 37 98.70 112.18 125.52 193.46 218.39 243.56 293.95 330.35 367.76 1.39 1.47 1.56 2.34 2.65 2.97 4.58 5.17 5.76 6.96 7.82 8.70 199.58 224.45 250.98 4.72 5.31 5.94 7.11 8.08 9.14 0.17 0.19 0.22 Croatia - Acinetobacter spp. CRACI SSI - model 39 0.12 0.16 0.22 26.85 32.47 37.79 26.97 32.63 38.03 0.40 0.43 0.46 2.84E-03 3.80E-03 5.11E-03 0.64 0.77 0.89 0.64 0.77 0.90 64.65 75.96 88.35 1.53 1.80 2.09 1.34 1.65 1.94 0.03 0.04 0.05 Croatia - Acinetobacter spp. CRACI UTI - model 38 0.13 0.17 0.22 0.00 0.00 0.00 0.13 0.17 0.22 1.66E-03 2.03E-03 2.43E-03 3.14E-03 4.07E-03 5.15E-03 0.00 0.00 0.00 3.14E-03 4.07E-03 5.15E-03 71.07 85.22 97.87 1.68 2.02 2.32 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Acinetobacter spp. MDRACI BSI - model 31 1.36 1.70 2.13 6.99 12.85 18.62 8.62 14.52 20.56 2.61 4.22 5.74 0.03 0.04 0.05 0.17 0.30 0.44 0.20 0.34 0.49 2.88 3.46 4.07 0.07 0.08 0.10 0.39 0.70 1.00 9.20E-03 0.02 0.02 Croatia - Acinetobacter spp. MDRACI OTH - model 35 1.70E-04 4.56E-04 8.67E-04 0.00 0.00 0.00 1.70E-04 4.56E-04 8.67E-04 2.13E-03 3.74E-03 5.48E-03 4.01E-06 1.08E-05 2.05E-05 0.00 0.00 0.00 4.01E-06 1.08E-05 2.05E-05 0.06 0.12 0.21 1.33E-03 2.94E-03 4.87E-03 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Acinetobacter spp. MDRACI RESP - model 32 0.91 1.30 1.70 1.76 2.47 3.32 2.68 3.78 4.93 0.89 1.00 1.14 0.02 0.03 0.04 0.04 0.06 0.08 0.06 0.09 0.12 2.75 3.78 4.80 0.07 0.09 0.11 0.10 0.14 0.18 2.31E-03 3.20E-03 4.20E-03 Croatia - Acinetobacter spp. MDRACI SSI - model 34 1.09E-03 2.70E-03 4.89E-03 0.34 0.55 0.79 0.34 0.55 0.79 0.37 0.43 0.50 2.59E-05 6.39E-05 1.16E-04 7.99E-03 0.01 0.02 8.02E-03 0.01 0.02 0.79 1.28 1.79 0.02 0.03 0.04 0.02 0.03 0.05 4.69E-04 8.20E-04 1.17E-03 Croatia - Acinetobacter spp. MDRACI UTI - model 33 1.45E-03 2.81E-03 4.90E-03 0.00 0.00 0.00 1.45E-03 2.81E-03 4.90E-03 1.23E-03 2.02E-03 3.05E-03 3.44E-05 6.65E-05 1.16E-04 0.00 0.00 0.00 3.44E-05 6.65E-05 1.16E-04 0.86 1.41 1.97 0.02 0.03 0.05 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Enterococcus faecalis and E. faecium VRE BSI - model 66 20.28 25.35 31.74 176.28 217.61 267.67 196.48 242.84 298.54 5.98 6.59 7.26 0.48 0.60 0.75 4.17 5.15 6.33 4.65 5.75 7.07 30.01 36.85 45.38 0.71 0.87 1.07 6.86 8.42 10.39 0.16 0.20 0.25 Croatia - Enterococcus faecalis and E. faecium VRE OTH - model 70 0.04 0.06 0.09 0.00 0.00 0.00 0.04 0.06 0.09 1.25E-03 1.66E-03 2.08E-03 1.05E-03 1.52E-03 2.13E-03 0.00 0.00 0.00 1.05E-03 1.52E-03 2.13E-03 30.16 39.33 48.33 0.71 0.93 1.14 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Enterococcus faecalis and E. faecium VRE RESP - model 67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Enterococcus faecalis and E. faecium VRE SSI - model 69 0.07 0.11 0.15 15.25 20.23 25.64 15.33 20.34 25.67 0.36 0.40 0.45 1.71E-03 2.53E-03 3.56E-03 0.36 0.48 0.61 0.36 0.48 0.61 38.89 50.55 62.28 0.92 1.20 1.47 0.79 1.09 1.38 0.02 0.03 0.03 Croatia - Enterococcus faecalis and E. faecium VRE UTI - model 68 0.02 0.03 0.05 0.00 0.00 0.00 0.02 0.03 0.05 1.44E-03 1.88E-03 2.38E-03 5.80E-04 8.24E-04 1.16E-03 0.00 0.00 0.00 5.80E-04 8.24E-04 1.16E-03 14.35 18.64 23.37 0.34 0.44 0.55 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Escherichia coli 3GCREC BSI - model 16 80.44 88.98 98.54 515.78 576.40 645.15 599.60 666.21 742.36 3.94 4.33 4.71 1.90 2.11 2.33 12.21 13.64 15.27 14.19 15.77 17.57 142.20 153.97 166.33 3.37 3.64 3.94 23.47 26.73 30.10 0.56 0.63 0.71 Croatia - Escherichia coli 3GCREC OTH - model 20 0.12 0.17 0.22 0.00 0.00 0.00 0.12 0.17 0.22 2.64E-03 3.33E-03 4.04E-03 2.93E-03 4.03E-03 5.21E-03 0.00 0.00 0.00 2.93E-03 4.03E-03 5.21E-03 41.80 51.13 61.82 0.99 1.21 1.46 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Escherichia coli 3GCREC RESP - model 17 23.26 27.44 32.25 44.93 53.22 62.64 68.35 80.74 94.88 1.05 1.18 1.34 0.55 0.65 0.76 1.06 1.26 1.48 1.62 1.91 2.25 56.51 68.60 81.26 1.34 1.62 1.92 2.01 2.47 2.96 0.05 0.06 0.07 Croatia - Escherichia coli 3GCREC SSI - model 19 0.26 0.35 0.47 58.62 67.94 77.57 59.00 68.28 78.14 0.39 0.42 0.44 6.24E-03 8.24E-03 0.01 1.39 1.61 1.84 1.40 1.62 1.85 141.64 163.06 186.32 3.35 3.86 4.41 3.78 4.48 5.26 0.09 0.11 0.12 Croatia - Escherichia coli 3GCREC UTI - model 18 1.02 1.30 1.62 0.00 0.00 0.00 1.02 1.30 1.62 1.59E-03 1.96E-03 2.33E-03 0.02 0.03 0.04 0.00 0.00 0.00 0.02 0.03 0.04 587.39 666.49 744.46 13.90 15.77 17.62 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Escherichia coli ColREC BSI - model 26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Escherichia coli ColREC OTH - model 30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Escherichia coli ColREC RESP - model 27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Escherichia coli ColREC SSI - model 29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Escherichia coli ColREC UTI - model 28 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Escherichia coli CREC BSI - model 21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Escherichia coli CREC OTH - model 25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Escherichia coli CREC RESP - model 22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Escherichia coli CREC SSI - model 24 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Escherichia coli CREC UTI - model 23 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Klebsiella pneumoniae 3GCRKP BSI - model 1 154.24 169.15 184.43 995.63 1,066.34 1,137.54 1,156.21 1,235.59 1,315.52 6.11 6.41 6.71 3.65 4.00 4.36 23.56 25.24 26.92 27.36 29.24 31.13 182.60 193.03 202.18 4.32 4.57 4.78 30.22 32.27 34.16 0.72 0.76 0.81 Croatia - Klebsiella pneumoniae 3GCRKP RESP - model 2 90.31 101.59 113.94 177.06 198.58 221.37 267.05 300.42 333.29 1.67 1.80 1.94 2.14 2.40 2.70 4.19 4.70 5.24 6.32 7.11 7.89 150.27 166.40 182.19 3.56 3.94 4.31 5.39 5.99 6.61 0.13 0.14 0.16 Croatia - Klebsiella pneumoniae 3GCRKP UTI - model 3 0.37 0.44 0.53 0.00 0.00 0.00 0.37 0.44 0.53 1.65E-03 1.96E-03 2.28E-03 8.68E-03 0.01 0.01 0.00 0.00 0.00 8.68E-03 0.01 0.01 207.26 227.91 248.92 4.91 5.39 5.89 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Klebsiella pneumoniae 3GCRKP OTH - model 5 0.21 0.26 0.31 0.00 0.00 0.00 0.21 0.26 0.31 2.81E-03 3.35E-03 3.91E-03 4.91E-03 6.07E-03 7.42E-03 0.00 0.00 0.00 4.91E-03 6.07E-03 7.42E-03 68.56 77.00 86.01 1.62 1.82 2.04 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Klebsiella pneumoniae 3GCRKP SSI - model 4 0.13 0.16 0.21 30.18 34.12 38.26 30.38 34.29 38.43 0.43 0.45 0.47 2.98E-03 3.86E-03 4.93E-03 0.71 0.81 0.91 0.72 0.81 0.91 67.91 76.21 85.17 1.61 1.80 2.02 1.34 1.55 1.76 0.03 0.04 0.04 Croatia - Klebsiella pneumoniae ColRKP BSI - model 11 0.62 0.94 1.44 10.56 21.18 35.67 11.26 22.10 36.98 10.82 18.81 26.98 0.01 0.02 0.03 0.25 0.50 0.84 0.27 0.52 0.88 0.84 1.17 1.62 0.02 0.03 0.04 0.35 0.71 1.19 8.32E-03 0.02 0.03 Croatia - Klebsiella pneumoniae ColRKP OTH - model 15 3.92E-04 1.63E-03 4.87E-03 0.00 0.00 0.00 3.92E-04 1.63E-03 4.87E-03 1.24E-03 3.24E-03 7.10E-03 9.27E-06 3.86E-05 1.15E-04 0.00 0.00 0.00 9.27E-06 3.86E-05 1.15E-04 0.15 0.55 0.97 3.53E-03 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Klebsiella pneumoniae ColRKP RESP - model 12 0.07 0.28 0.53 0.14 0.55 1.00 0.21 0.84 1.51 1.40 1.64 1.88 1.68E-03 6.62E-03 0.01 3.27E-03 0.01 0.02 4.92E-03 0.02 0.04 0.13 0.51 0.90 3.08E-03 0.01 0.02 4.60E-03 0.02 0.03 1.09E-04 4.37E-04 7.84E-04 Croatia - Klebsiella pneumoniae ColRKP SSI - model 14 1.12E-04 6.33E-04 1.98E-03 0.03 0.09 0.17 0.03 0.09 0.17 0.27 0.27 0.27 2.65E-06 1.50E-05 4.70E-05 5.93E-04 2.23E-03 3.99E-03 5.96E-04 2.24E-03 4.06E-03 0.09 0.35 0.62 2.19E-03 8.25E-03 0.01 8.32E-04 3.14E-03 5.60E-03 1.97E-05 7.42E-05 1.33E-04 Croatia - Klebsiella pneumoniae ColRKP UTI - model 13 3.23E-04 1.29E-03 3.27E-03 0.00 0.00 0.00 3.23E-04 1.29E-03 3.27E-03 7.62E-04 1.95E-03 4.02E-03 7.64E-06 3.04E-05 7.75E-05 0.00 0.00 0.00 7.64E-06 3.04E-05 7.75E-05 0.26 0.71 1.18 6.16E-03 0.02 0.03 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Klebsiella pneumoniae CRKP BSI - model 6 5.80 6.99 8.27 71.97 91.79 115.12 78.79 98.86 122.70 8.48 10.49 12.57 0.14 0.17 0.20 1.70 2.17 2.72 1.86 2.34 2.90 8.21 9.48 10.78 0.19 0.22 0.26 2.63 3.35 4.20 0.06 0.08 0.10 Croatia - Klebsiella pneumoniae CRKP OTH - model 10 8.88E-03 0.02 0.02 0.00 0.00 0.00 8.88E-03 0.02 0.02 2.32E-03 3.51E-03 5.05E-03 2.10E-04 3.65E-04 5.88E-04 0.00 0.00 0.00 2.10E-04 3.65E-04 5.88E-04 3.18 4.45 5.76 0.08 0.11 0.14 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Klebsiella pneumoniae CRKP RESP - model 7 1.39 2.03 2.73 2.78 3.96 5.24 4.17 6.01 7.92 1.32 1.49 1.70 0.03 0.05 0.06 0.07 0.09 0.12 0.10 0.14 0.19 2.78 4.04 5.21 0.07 0.10 0.12 0.10 0.14 0.19 2.37E-03 3.42E-03 4.55E-03 Croatia - Klebsiella pneumoniae CRKP SSI - model 9 3.27E-03 5.76E-03 9.40E-03 0.92 1.45 1.99 0.93 1.46 1.99 0.44 0.52 0.59 7.74E-05 1.36E-04 2.22E-04 0.02 0.03 0.05 0.02 0.03 0.05 1.96 2.82 3.67 0.05 0.07 0.09 0.04 0.06 0.09 9.07E-04 1.49E-03 2.10E-03 Croatia - Klebsiella pneumoniae CRKP UTI - model 8 7.37E-03 0.01 0.02 0.00 0.00 0.00 7.37E-03 0.01 0.02 1.39E-03 2.10E-03 2.90E-03 1.75E-04 2.80E-04 4.33E-04 0.00 0.00 0.00 1.75E-04 2.80E-04 4.33E-04 4.19 5.73 7.34 0.10 0.14 0.17 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Pseudomonas aeruginosa ColRPA BSI - model 56 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Pseudomonas aeruginosa ColRPA OTH - model 60 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Pseudomonas aeruginosa ColRPA RESP - model 57 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Pseudomonas aeruginosa ColRPA SSI - model 59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Pseudomonas aeruginosa ColRPA UTI - model 58 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Pseudomonas aeruginosa CRPA BSI - model 51 88.11 99.18 110.23 685.69 849.43 1,020.77 782.55 949.29 1,130.63 6.67 7.93 9.24 2.09 2.35 2.61 16.23 20.10 24.16 18.52 22.47 26.76 108.78 119.36 129.71 2.57 2.82 3.07 22.19 27.52 33.22 0.53 0.65 0.79 Croatia - Pseudomonas aeruginosa CRPA OTH - model 55 0.17 0.22 0.28 0.00 0.00 0.00 0.17 0.22 0.28 3.02E-03 3.66E-03 4.25E-03 3.98E-03 5.26E-03 6.61E-03 0.00 0.00 0.00 3.98E-03 5.26E-03 6.61E-03 50.28 60.87 71.16 1.19 1.44 1.68 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Pseudomonas aeruginosa CRPA RESP - model 52 221.64 253.12 284.71 731.07 898.91 1,091.06 960.27 1,151.90 1,366.58 2.31 2.61 2.97 5.25 5.99 6.74 17.30 21.27 25.82 22.73 27.26 32.34 389.82 443.27 492.83 9.23 10.49 11.66 23.38 28.83 35.28 0.55 0.68 0.84 Croatia - Pseudomonas aeruginosa CRPA SSI - model 54 0.13 0.18 0.23 30.24 35.56 41.51 30.40 35.75 41.70 0.40 0.43 0.47 3.10E-03 4.16E-03 5.48E-03 0.72 0.84 0.98 0.72 0.85 0.99 69.41 82.63 96.84 1.64 1.96 2.29 1.29 1.59 1.89 0.03 0.04 0.04 Croatia - Pseudomonas aeruginosa CRPA UTI - model 53 0.25 0.32 0.40 0.00 0.00 0.00 0.25 0.32 0.40 1.70E-03 2.06E-03 2.44E-03 5.94E-03 7.46E-03 9.47E-03 0.00 0.00 0.00 5.94E-03 7.46E-03 9.47E-03 132.49 154.08 178.56 3.14 3.65 4.23 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Pseudomonas aeruginosa MDRPA BSI - model 46 4.37 5.83 7.65 26.74 46.15 71.19 31.70 51.93 77.67 4.72 7.29 9.90 0.10 0.14 0.18 0.63 1.09 1.68 0.75 1.23 1.84 5.86 7.19 8.77 0.14 0.17 0.21 0.91 1.52 2.26 0.02 0.04 0.05 Croatia - Pseudomonas aeruginosa MDRPA OTH - model 50 6.80E-03 0.01 0.02 0.00 0.00 0.00 6.80E-03 0.01 0.02 2.44E-03 3.72E-03 5.24E-03 1.61E-04 3.25E-04 5.19E-04 0.00 0.00 0.00 1.61E-04 3.25E-04 5.19E-04 2.30 3.71 5.10 0.05 0.09 0.12 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Pseudomonas aeruginosa MDRPA RESP - model 47 10.29 15.01 19.83 29.82 49.83 76.40 41.83 64.68 95.31 1.77 2.44 3.16 0.24 0.36 0.47 0.71 1.18 1.81 0.99 1.53 2.26 19.45 26.75 34.09 0.46 0.63 0.81 1.03 1.66 2.49 0.02 0.04 0.06 Croatia - Pseudomonas aeruginosa MDRPA SSI - model 49 4.76E-03 0.01 0.02 1.01 1.65 2.29 1.02 1.67 2.32 0.31 0.33 0.36 1.13E-04 2.46E-04 4.50E-04 0.02 0.04 0.05 0.02 0.04 0.05 3.09 5.02 6.91 0.07 0.12 0.16 0.04 0.07 0.09 9.76E-04 1.60E-03 2.24E-03 Croatia - Pseudomonas aeruginosa MDRPA UTI - model 48 0.01 0.02 0.03 0.00 0.00 0.00 0.01 0.02 0.03 1.26E-03 2.01E-03 2.89E-03 2.43E-04 4.36E-04 7.12E-04 0.00 0.00 0.00 2.43E-04 4.36E-04 7.12E-04 6.23 9.27 12.56 0.15 0.22 0.30 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Staphylococcus aureus MRSA BSI - model 61 73.49 80.16 87.51 505.16 538.81 574.76 581.32 618.43 658.39 4.35 4.54 4.74 1.74 1.90 2.07 11.96 12.75 13.60 13.76 14.64 15.58 128.36 136.26 144.89 3.04 3.22 3.43 22.74 24.48 26.39 0.54 0.58 0.62 Croatia - Staphylococcus aureus MRSA OTH - model 65 0.52 0.66 0.81 0.00 0.00 0.00 0.52 0.66 0.81 2.62E-03 3.25E-03 3.98E-03 0.01 0.02 0.02 0.00 0.00 0.00 0.01 0.02 0.02 180.10 201.90 222.27 4.26 4.78 5.26 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Staphylococcus aureus MRSA RESP - model 62 74.69 84.10 93.15 146.90 163.01 180.21 222.30 247.16 272.06 1.13 1.20 1.28 1.77 1.99 2.20 3.48 3.86 4.27 5.26 5.85 6.44 185.36 205.12 226.26 4.39 4.85 5.35 6.60 7.38 8.32 0.16 0.17 0.20 Croatia - Staphylococcus aureus MRSA SSI - model 64 0.36 0.48 0.61 81.96 91.06 100.19 82.28 91.53 100.67 0.39 0.41 0.42 8.62E-03 0.01 0.01 1.94 2.16 2.37 1.95 2.17 2.38 201.68 223.91 245.61 4.77 5.30 5.81 5.06 5.71 6.39 0.12 0.14 0.15 Croatia - Staphylococcus aureus MRSA UTI - model 63 0.05 0.06 0.08 0.00 0.00 0.00 0.05 0.06 0.08 1.53E-03 1.88E-03 2.29E-03 1.14E-03 1.48E-03 1.92E-03 0.00 0.00 0.00 1.14E-03 1.48E-03 1.92E-03 27.79 33.48 39.39 0.66 0.79 0.93 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Streptococcus pneumoniae PMRSP BSI - model 76 1.76 2.43 3.23 14.59 16.69 18.97 16.90 19.12 21.69 15.35 17.30 19.30 0.04 0.06 0.08 0.35 0.40 0.45 0.40 0.45 0.51 1.07 1.11 1.16 0.03 0.03 0.03 0.17 0.20 0.23 4.13E-03 4.72E-03 5.37E-03 Croatia - Streptococcus pneumoniae PMRSP OTH - model 80 2.86E-04 7.36E-04 1.53E-03 0.00 0.00 0.00 2.86E-04 7.36E-04 1.53E-03 7.76E-04 1.85E-03 3.51E-03 6.77E-06 1.74E-05 3.61E-05 0.00 0.00 0.00 6.77E-06 1.74E-05 3.61E-05 0.31 0.39 0.54 7.25E-03 9.33E-03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Streptococcus pneumoniae PMRSP RESP - model 77 4.02 6.15 10.45 8.27 12.15 20.63 12.75 18.13 30.47 3.85 4.53 5.23 0.10 0.15 0.25 0.20 0.29 0.49 0.30 0.43 0.72 2.94 3.99 6.72 0.07 0.09 0.16 0.10 0.15 0.25 2.34E-03 3.44E-03 5.84E-03 Croatia - Streptococcus pneumoniae PMRSP SSI - model 79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Streptococcus pneumoniae PMRSP UTI - model 78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Streptococcus pneumoniae PRSP BSI - model 71 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Streptococcus pneumoniae PRSP OTH - model 75 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Streptococcus pneumoniae PRSP RESP - model 72 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Streptococcus pneumoniae PRSP SSI - model 74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Croatia - Streptococcus pneumoniae PRSP UTI - model 73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total (Median & 95% UIs) 1,094.78 1,238.10 1,389.15 5,522.62 6,474.07 7,491.50 6,666.56 7,713.86 8,837.41 25.91 29.30 32.88 130.70 153.22 177.30 157.78 182.56 209.15 3,838.12 4,347.46 4,866.55 90.84 102.89 115.18 203.82 239.74 278.43 4.82 5.67 6.59 Total (average) - 153.48 182.82 4,347.31 102.89 239.96 5.68 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 1,239.78 6,484.89 7,724.67 - 29.34 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 Infection Colistin resistant Acinetobacter spp. 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Acinetobacter spp. (excluding those resistant to colistin) 310.09 341.22 375.20 1,509.77 1,826.14 2,136.89 1,835.02 2,165.80 2,491.25 6.52 7.45 8.39 3.15 3.46 3.81 15.32 18.53 21.68 18.62 21.98 25.28 774.15 860.35 946.80 7.85 8.73 9.61 62.51 74.96 88.22 0.63 0.76 0.90 Aminoglycosides and fluoroquinolones resistant Acinetobacter spp. (excluding those resistant to colistin and/or carbapenem) 45.30 51.52 58.85 212.77 270.68 328.86 261.18 322.64 384.73 6.14 7.36 8.61 0.46 0.52 0.60 2.16 2.75 3.34 2.65 3.27 3.90 114.05 129.61 146.50 1.16 1.32 1.49 8.79 11.13 13.61 0.09 0.11 0.14 Vancomycin resistant Enterococci (E. faecalis and E. faecium ) 28.01 34.24 42.38 265.80 329.24 394.15 292.85 363.53 437.22 5.53 6.06 6.67 0.28 0.35 0.43 2.70 3.34 4.00 2.97 3.69 4.44 179.10 228.37 279.45 1.82 2.32 2.84 12.61 15.66 18.73 0.13 0.16 0.19 Colistin resistant Escherichia coli 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Escherichia coli (excluding those resistant to colistin) 1.92 3.27 4.92 18.16 35.22 57.32 20.55 38.56 62.15 22.76 35.49 47.57 0.02 0.03 0.05 0.18 0.36 0.58 0.21 0.39 0.63 5.17 8.65 12.28 0.05 0.09 0.12 0.23 0.45 0.73 0.00 0.00 0.01 Third-generation cephalosporin resistant Escherichia coli (excluding those resistant to colistin and/or carbapenem) 259.27 291.12 324.12 1,541.46 1,724.47 1,921.94 1,814.62 2,015.39 2,247.60 5.28 5.71 6.16 2.63 2.95 3.29 15.64 17.50 19.50 18.41 20.45 22.81 2,516.61 2,820.71 3,123.08 25.53 28.62 31.69 76.09 85.76 96.81 0.77 0.87 0.98 Colistin resistant Klebsiella pneumoniae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Klebsiella pneumoniae (excluding those resistant to colistin) 1.01 1.75 2.79 9.98 18.79 31.34 11.19 20.56 33.56 12.83 19.57 26.60 0.01 0.02 0.03 0.10 0.19 0.32 0.11 0.21 0.34 1.57 3.28 5.09 0.02 0.03 0.05 0.23 0.43 0.71 0.00 0.00 0.01 Third-generation cephalosporin resistant Klebsiella pneumoniae (excluding those resistant to colistin and/or carbapenem) 298.48 323.97 350.13 1,464.50 1,556.13 1,649.60 1,772.85 1,881.26 1,988.84 6.58 6.84 7.13 3.03 3.29 3.55 14.86 15.79 16.74 17.99 19.09 20.18 1,039.64 1,131.76 1,230.49 10.55 11.48 12.49 57.32 61.42 65.84 0.58 0.62 0.67 Colistin resistant Pseudomonas aeruginosa 2.12 3.91 6.08 6.38 18.58 38.34 9.19 22.45 43.51 5.52 11.82 18.64 0.02 0.04 0.06 0.06 0.19 0.39 0.09 0.23 0.44 4.29 8.51 12.88 0.04 0.09 0.13 0.18 0.54 1.11 0.00 0.01 0.01 Carbapenem resistant Pseudomonas aeruginosa (excluding those resistant to colistin) 866.53 964.16 1,065.39 4,096.11 4,857.62 5,707.05 4,991.98 5,822.40 6,740.55 9.56 10.94 12.49 8.79 9.78 10.81 41.56 49.29 57.91 50.65 59.08 68.39 2,096.64 2,356.96 2,630.92 21.27 23.92 26.69 132.30 159.57 191.71 1.34 1.62 1.95 Pseudomonas aeruginosa resistant to three or more antimicrobial groups (excluding those resistant to colistin and/or carbapenem) 59.77 71.86 85.02 252.41 340.71 437.65 318.01 412.44 519.44 7.01 8.80 10.67 0.61 0.73 0.86 2.56 3.46 4.44 3.23 4.18 5.27 167.51 206.26 243.86 1.70 2.09 2.47 9.59 13.06 16.98 0.10 0.13 0.17 Methicillin resistant Staphylococcus aureus 415.07 458.12 503.10 2,081.78 2,239.54 2,404.91 2,506.29 2,698.09 2,892.11 5.29 5.53 5.77 4.21 4.65 5.10 21.12 22.72 24.40 25.43 27.38 29.34 2,271.74 2,493.50 2,706.84 23.05 25.30 27.47 109.44 118.74 127.88 1.11 1.20 1.30 Penicillin and macrolides resistant Streptococcus pneumoniae (excluding those only resistant to penicillin) 3.78 4.93 6.79 13.45 16.31 19.96 17.67 21.24 26.28 5.50 6.07 6.67 0.04 0.05 0.07 0.14 0.17 0.20 0.18 0.22 0.27 9.34 11.37 14.53 0.09 0.12 0.15 0.58 0.70 0.85 0.01 0.01 0.01 Penicillin tesistant Streptococcus pneumoniae (excluding those resistant to macrolides) 4.82 6.59 10.02 18.10 21.93 28.47 23.53 28.56 37.89 7.19 8.26 9.39 0.05 0.07 0.10 0.18 0.22 0.29 0.24 0.29 0.38 9.36 11.29 14.86 0.09 0.11 0.15 0.58 0.70 0.86 0.01 0.01 0.01 Total 2,296.17 2,556.67 2,834.78 11,490.67 13,255.37 15,156.49 13,874.92 15,812.92 17,905.14 23.30 25.94 28.76 116.59 134.50 153.79 140.78 160.45 181.68 9,189.16 10,270.61 11,367.59 93.24 104.21 115.34 470.46 543.11 624.03 4.77 5.51 6.33 Model Hungary - Acinetobacter spp. ColRACI BSI - model 41 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Acinetobacter spp. ColRACI OTH - model 45 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Acinetobacter spp. ColRACI RESP - model 42 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Acinetobacter spp. ColRACI SSI - model 44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Acinetobacter spp. ColRACI UTI - model 43 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Acinetobacter spp. CRACI BSI - model 36 179.24 194.50 212.61 1,216.21 1,495.21 1,766.69 1,409.08 1,688.58 1,962.07 4.84 5.68 6.51 1.82 1.97 2.16 12.34 15.17 17.93 14.30 17.13 19.91 280.60 297.37 315.56 2.85 3.02 3.20 50.10 60.84 72.40 0.51 0.62 0.73 Hungary - Acinetobacter spp. CRACI OTH - model 40 0.03 0.04 0.05 0.00 0.00 0.00 0.03 0.04 0.05 3.07E-03 3.72E-03 4.44E-03 2.94E-04 3.97E-04 5.23E-04 0.00 0.00 0.00 2.94E-04 3.97E-04 5.23E-04 8.14 10.53 13.13 0.08 0.11 0.13 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Acinetobacter spp. CRACI RESP - model 37 130.45 146.21 161.92 254.59 284.68 317.03 386.54 430.47 475.39 1.27 1.34 1.41 1.32 1.48 1.64 2.58 2.89 3.22 3.92 4.37 4.82 289.66 321.91 354.29 2.94 3.27 3.59 10.32 11.58 12.85 0.10 0.12 0.13 Hungary - Acinetobacter spp. CRACI SSI - model 39 0.17 0.23 0.30 38.96 46.26 53.17 39.17 46.46 53.44 0.40 0.43 0.46 1.75E-03 2.32E-03 3.05E-03 0.40 0.47 0.54 0.40 0.47 0.54 92.73 108.85 123.85 0.94 1.10 1.26 2.10 2.54 2.98 0.02 0.03 0.03 Hungary - Acinetobacter spp. CRACI UTI - model 38 0.19 0.25 0.31 0.00 0.00 0.00 0.19 0.25 0.31 1.70E-03 2.04E-03 2.40E-03 1.97E-03 2.52E-03 3.14E-03 0.00 0.00 0.00 1.97E-03 2.52E-03 3.14E-03 103.02 121.68 139.98 1.05 1.23 1.42 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Acinetobacter spp. MDRACI BSI - model 31 26.30 29.49 33.35 170.11 220.39 270.91 199.06 250.32 301.91 4.47 5.56 6.67 0.27 0.30 0.34 1.73 2.24 2.75 2.02 2.54 3.06 41.83 44.89 48.59 0.42 0.46 0.49 6.96 9.00 11.15 0.07 0.09 0.11 Hungary - Acinetobacter spp. MDRACI OTH - model 35 3.95E-03 5.85E-03 8.35E-03 0.00 0.00 0.00 3.95E-03 5.85E-03 8.35E-03 2.86E-03 3.73E-03 4.66E-03 4.00E-05 5.94E-05 8.47E-05 0.00 0.00 0.00 4.00E-05 5.94E-05 8.47E-05 1.13 1.57 2.08 0.01 0.02 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Acinetobacter spp. MDRACI RESP - model 32 18.95 21.95 25.39 36.74 42.83 48.95 56.14 64.78 73.70 1.24 1.33 1.43 0.19 0.22 0.26 0.37 0.43 0.50 0.57 0.66 0.75 42.63 48.53 54.85 0.43 0.49 0.56 1.52 1.74 1.99 0.02 0.02 0.02 Hungary - Acinetobacter spp. MDRACI SSI - model 34 0.02 0.03 0.05 5.92 7.46 9.00 5.95 7.50 9.06 0.42 0.46 0.50 2.41E-04 3.51E-04 5.02E-04 0.06 0.08 0.09 0.06 0.08 0.09 13.64 16.33 19.20 0.14 0.17 0.19 0.31 0.39 0.48 3.12E-03 3.98E-03 4.84E-03 Hungary - Acinetobacter spp. MDRACI UTI - model 33 0.03 0.04 0.05 0.00 0.00 0.00 0.03 0.04 0.05 1.56E-03 2.03E-03 2.53E-03 2.68E-04 3.75E-04 4.98E-04 0.00 0.00 0.00 2.68E-04 3.75E-04 4.98E-04 14.82 18.29 21.78 0.15 0.19 0.22 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Enterococcus faecalis and E. faecium VRE BSI - model 66 27.79 33.92 41.91 236.18 289.83 344.97 262.97 323.77 387.61 5.07 5.56 6.12 0.28 0.34 0.43 2.40 2.94 3.50 2.67 3.29 3.93 47.46 58.32 69.35 0.48 0.59 0.70 10.89 13.34 15.81 0.11 0.14 0.16 Hungary - Enterococcus faecalis and E. faecium VRE OTH - model 70 0.07 0.10 0.14 0.00 0.00 0.00 0.07 0.10 0.14 1.27E-03 1.64E-03 2.11E-03 7.11E-04 1.03E-03 1.44E-03 0.00 0.00 0.00 7.11E-04 1.03E-03 1.44E-03 48.05 61.57 76.05 0.49 0.62 0.77 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Enterococcus faecalis and E. faecium VRE RESP - model 67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Enterococcus faecalis and E. faecium VRE SSI - model 69 0.11 0.17 0.24 29.62 39.41 49.18 29.77 39.60 49.39 0.46 0.50 0.54 1.14E-03 1.71E-03 2.48E-03 0.30 0.40 0.50 0.30 0.40 0.50 61.32 79.29 97.84 0.62 0.80 0.99 1.72 2.32 2.92 0.02 0.02 0.03 Hungary - Enterococcus faecalis and E. faecium VRE UTI - model 68 0.04 0.05 0.08 0.00 0.00 0.00 0.04 0.05 0.08 1.44E-03 1.87E-03 2.35E-03 3.89E-04 5.50E-04 7.64E-04 0.00 0.00 0.00 3.89E-04 5.50E-04 7.64E-04 22.27 29.18 36.21 0.23 0.30 0.37 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Escherichia coli 3GCREC BSI - model 16 199.25 219.31 239.95 1,279.11 1,416.24 1,566.13 1,491.13 1,635.06 1,807.91 3.83 4.14 4.47 2.02 2.23 2.43 12.98 14.37 15.89 15.13 16.59 18.34 369.33 395.73 424.08 3.75 4.02 4.30 61.32 68.32 76.54 0.62 0.69 0.78 Hungary - Escherichia coli 3GCREC OTH - model 20 0.33 0.43 0.57 0.00 0.00 0.00 0.33 0.43 0.57 2.73E-03 3.36E-03 4.07E-03 3.34E-03 4.40E-03 5.81E-03 0.00 0.00 0.00 3.34E-03 4.40E-03 5.81E-03 106.22 130.28 155.77 1.08 1.32 1.58 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Escherichia coli 3GCREC RESP - model 17 56.36 67.16 78.27 108.25 130.30 151.07 165.49 197.66 229.25 1.05 1.13 1.22 0.57 0.68 0.79 1.10 1.32 1.53 1.68 2.01 2.33 144.23 175.53 202.42 1.46 1.78 2.05 5.19 6.29 7.34 0.05 0.06 0.07 Hungary - Escherichia coli 3GCREC SSI - model 19 0.65 0.89 1.16 154.09 177.93 204.74 154.98 178.92 205.71 0.41 0.43 0.45 6.55E-03 8.98E-03 0.01 1.56 1.81 2.08 1.57 1.82 2.09 367.79 416.09 469.57 3.73 4.22 4.76 9.58 11.15 12.93 0.10 0.11 0.13 Hungary - Escherichia coli 3GCREC UTI - model 18 2.69 3.33 4.17 0.00 0.00 0.00 2.69 3.33 4.17 1.61E-03 1.97E-03 2.36E-03 0.03 0.03 0.04 0.00 0.00 0.00 0.03 0.03 0.04 1,529.03 1,703.08 1,871.24 15.51 17.28 18.99 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Escherichia coli ColREC BSI - model 26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Escherichia coli ColREC OTH - model 30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Escherichia coli ColREC RESP - model 27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Escherichia coli ColREC SSI - model 29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Escherichia coli ColREC UTI - model 28 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Escherichia coli CREC BSI - model 21 1.59 2.41 3.50 16.97 32.62 53.16 19.02 35.11 56.63 18.40 30.52 42.01 0.02 0.02 0.04 0.17 0.33 0.54 0.19 0.36 0.57 0.89 1.15 1.50 9.05E-03 0.01 0.02 0.22 0.41 0.68 2.19E-03 4.20E-03 6.85E-03 Hungary - Escherichia coli CREC OTH - model 25 5.84E-04 2.07E-03 5.47E-03 0.00 0.00 0.00 5.84E-04 2.07E-03 5.47E-03 1.19E-03 3.31E-03 7.23E-03 5.93E-06 2.10E-05 5.55E-05 0.00 0.00 0.00 5.93E-06 2.10E-05 5.55E-05 0.29 0.66 1.04 2.94E-03 6.73E-03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Escherichia coli CREC RESP - model 22 0.33 0.84 1.39 0.66 1.63 2.73 1.00 2.47 4.06 3.65 4.25 4.84 3.33E-03 8.53E-03 0.01 6.74E-03 0.02 0.03 0.01 0.03 0.04 0.25 0.59 0.93 2.51E-03 5.94E-03 9.41E-03 8.44E-03 0.02 0.03 8.56E-05 2.09E-04 3.52E-04 Hungary - Escherichia coli CREC SSI - model 24 6.11E-04 2.61E-03 7.23E-03 0.52 0.97 1.43 0.52 0.97 1.44 0.71 0.71 0.71 6.20E-06 2.65E-05 7.33E-05 5.29E-03 9.82E-03 0.01 5.31E-03 9.85E-03 0.01 0.74 1.37 2.02 7.47E-03 0.01 0.02 6.62E-03 0.01 0.02 6.72E-05 1.25E-04 1.84E-04 Hungary - Escherichia coli CREC UTI - model 23 3.42E-03 9.52E-03 0.02 0.00 0.00 0.00 3.42E-03 9.52E-03 0.02 7.95E-04 1.98E-03 3.88E-03 3.47E-05 9.66E-05 2.12E-04 0.00 0.00 0.00 3.47E-05 9.66E-05 2.12E-04 3.01 4.89 6.79 0.03 0.05 0.07 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Klebsiella pneumoniae 3GCRKP BSI - model 1 187.36 201.52 215.91 1,203.38 1,267.34 1,332.20 1,399.79 1,469.49 1,538.92 4.80 4.97 5.16 1.90 2.04 2.19 12.21 12.86 13.52 14.20 14.91 15.61 282.85 295.35 309.55 2.87 3.00 3.14 46.65 49.34 52.34 0.47 0.50 0.53 Hungary - Klebsiella pneumoniae 3GCRKP OTH - model 5 0.32 0.39 0.48 0.00 0.00 0.00 0.32 0.39 0.48 2.76E-03 3.36E-03 3.99E-03 3.21E-03 3.98E-03 4.92E-03 0.00 0.00 0.00 3.21E-03 3.98E-03 4.92E-03 104.40 117.49 130.77 1.06 1.19 1.33 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Klebsiella pneumoniae 3GCRKP RESP - model 2 110.07 121.13 132.59 214.36 234.96 256.28 325.23 356.62 387.22 1.33 1.40 1.47 1.12 1.23 1.35 2.18 2.38 2.60 3.30 3.62 3.93 231.83 254.73 279.15 2.35 2.58 2.83 8.20 9.18 10.18 0.08 0.09 0.10 Hungary - Klebsiella pneumoniae 3GCRKP SSI - model 4 0.19 0.25 0.32 46.76 53.84 61.13 46.96 54.08 61.39 0.44 0.47 0.49 1.90E-03 2.52E-03 3.20E-03 0.47 0.55 0.62 0.48 0.55 0.62 102.62 116.04 129.69 1.04 1.18 1.32 2.48 2.91 3.32 0.03 0.03 0.03 Hungary - Klebsiella pneumoniae 3GCRKP UTI - model 3 0.55 0.68 0.83 0.00 0.00 0.00 0.55 0.68 0.83 1.64E-03 1.96E-03 2.33E-03 5.60E-03 6.93E-03 8.47E-03 0.00 0.00 0.00 5.60E-03 6.93E-03 8.47E-03 317.94 348.14 381.34 3.23 3.53 3.87 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Klebsiella pneumoniae ColRKP BSI - model 11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Klebsiella pneumoniae ColRKP OTH - model 15 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Klebsiella pneumoniae ColRKP RESP - model 12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Klebsiella pneumoniae ColRKP SSI - model 14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Klebsiella pneumoniae ColRKP UTI - model 13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Klebsiella pneumoniae CRKP BSI - model 6 0.86 1.34 2.05 9.67 17.85 29.69 10.74 19.20 31.19 10.37 16.75 23.45 8.78E-03 0.01 0.02 0.10 0.18 0.30 0.11 0.19 0.32 0.87 1.16 1.54 8.87E-03 0.01 0.02 0.22 0.40 0.67 2.22E-03 4.10E-03 6.82E-03 Hungary - Klebsiella pneumoniae CRKP OTH - model 10 3.89E-04 1.69E-03 4.99E-03 0.00 0.00 0.00 3.89E-04 1.69E-03 4.99E-03 1.18E-03 3.25E-03 7.18E-03 3.95E-06 1.71E-05 5.06E-05 0.00 0.00 0.00 3.95E-06 1.71E-05 5.06E-05 0.18 0.56 0.93 1.79E-03 5.65E-03 9.47E-03 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Klebsiella pneumoniae CRKP RESP - model 7 0.14 0.40 0.73 0.27 0.81 1.42 0.41 1.23 2.12 2.06 2.42 2.74 1.42E-03 4.10E-03 7.43E-03 2.77E-03 8.17E-03 0.01 4.20E-03 0.01 0.02 0.17 0.51 0.85 1.76E-03 5.18E-03 8.58E-03 6.17E-03 0.02 0.03 6.26E-05 1.85E-04 3.25E-04 Hungary - Klebsiella pneumoniae CRKP SSI - model 9 1.08E-04 6.27E-04 1.99E-03 0.03 0.13 0.24 0.04 0.13 0.24 0.40 0.40 0.40 1.10E-06 6.37E-06 2.02E-05 3.50E-04 1.35E-03 2.41E-03 3.59E-04 1.36E-03 2.44E-03 0.09 0.33 0.60 8.81E-04 3.40E-03 6.07E-03 7.81E-04 3.01E-03 5.38E-03 7.93E-06 3.06E-05 5.46E-05 Hungary - Klebsiella pneumoniae CRKP UTI - model 8 3.78E-04 1.36E-03 3.57E-03 0.00 0.00 0.00 3.78E-04 1.36E-03 3.57E-03 7.28E-04 2.02E-03 3.94E-03 3.83E-06 1.38E-05 3.62E-05 0.00 0.00 0.00 3.83E-06 1.38E-05 3.62E-05 0.26 0.72 1.17 2.62E-03 7.31E-03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Pseudomonas aeruginosa ColRPA BSI - model 56 0.68 1.07 1.64 2.91 8.90 18.03 3.86 9.99 19.41 3.59 8.57 14.08 6.89E-03 0.01 0.02 0.03 0.09 0.18 0.04 0.10 0.20 0.85 1.17 1.63 8.61E-03 0.01 0.02 0.08 0.26 0.52 8.53E-04 2.60E-03 5.28E-03 Hungary - Pseudomonas aeruginosa ColRPA OTH - model 60 5.38E-04 2.11E-03 5.09E-03 0.00 0.00 0.00 5.38E-04 2.11E-03 5.09E-03 1.55E-03 3.74E-03 6.49E-03 5.46E-06 2.14E-05 5.17E-05 0.00 0.00 0.00 5.46E-06 2.14E-05 5.17E-05 0.19 0.62 1.02 1.96E-03 6.26E-03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Pseudomonas aeruginosa ColRPA RESP - model 57 1.44 2.83 4.42 3.38 9.43 19.90 5.25 12.20 23.66 1.61 2.93 4.23 0.01 0.03 0.04 0.03 0.10 0.20 0.05 0.12 0.24 2.38 4.38 6.47 0.02 0.04 0.07 0.10 0.27 0.57 9.91E-04 2.76E-03 5.82E-03 Hungary - Pseudomonas aeruginosa ColRPA SSI - model 59 2.74E-04 1.48E-03 4.49E-03 0.08 0.25 0.42 0.08 0.25 0.42 0.31 0.31 0.32 2.78E-06 1.50E-05 4.56E-05 7.96E-04 2.56E-03 4.25E-03 8.20E-04 2.57E-03 4.28E-03 0.25 0.81 1.34 2.55E-03 8.18E-03 0.01 2.26E-03 7.26E-03 0.01 2.30E-05 7.36E-05 1.22E-04 Hungary - Pseudomonas aeruginosa ColRPA UTI - model 58 7.38E-04 2.70E-03 6.56E-03 0.00 0.00 0.00 7.38E-04 2.70E-03 6.56E-03 8.08E-04 1.92E-03 3.62E-03 7.49E-06 2.74E-05 6.65E-05 0.00 0.00 0.00 7.49E-06 2.74E-05 6.65E-05 0.62 1.53 2.42 6.28E-03 0.02 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Pseudomonas aeruginosa CRPA BSI - model 51 247.78 270.21 297.43 1,940.23 2,296.16 2,700.44 2,179.75 2,562.87 2,989.59 6.82 7.86 9.07 2.51 2.74 3.02 19.69 23.30 27.40 22.12 26.00 30.33 304.44 327.17 353.52 3.09 3.32 3.59 62.22 74.91 89.20 0.63 0.76 0.91 Hungary - Pseudomonas aeruginosa CRPA OTH - model 55 0.48 0.61 0.75 0.00 0.00 0.00 0.48 0.61 0.75 3.08E-03 3.65E-03 4.31E-03 4.83E-03 6.16E-03 7.61E-03 0.00 0.00 0.00 4.83E-03 6.16E-03 7.61E-03 140.40 166.15 191.96 1.42 1.69 1.95 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Pseudomonas aeruginosa CRPA RESP - model 52 617.22 692.01 765.53 2,068.71 2,458.18 2,886.10 2,723.50 3,154.34 3,628.11 2.31 2.61 2.92 6.26 7.02 7.77 20.99 24.94 29.28 27.63 32.01 36.81 1,091.39 1,217.63 1,345.72 11.07 12.35 13.65 66.24 79.95 96.96 0.67 0.81 0.98 Hungary - Pseudomonas aeruginosa CRPA SSI - model 54 0.37 0.48 0.61 87.17 103.28 120.51 87.56 103.72 121.04 0.43 0.46 0.49 3.72E-03 4.84E-03 6.22E-03 0.88 1.05 1.22 0.89 1.05 1.23 192.45 224.57 260.70 1.95 2.28 2.65 3.85 4.71 5.55 0.04 0.05 0.06 Hungary - Pseudomonas aeruginosa CRPA UTI - model 53 0.69 0.86 1.06 0.00 0.00 0.00 0.69 0.86 1.06 1.71E-03 2.05E-03 2.41E-03 6.99E-03 8.74E-03 0.01 0.00 0.00 0.00 6.99E-03 8.74E-03 0.01 367.97 421.44 479.03 3.73 4.28 4.86 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Pseudomonas aeruginosa MDRPA BSI - model 46 17.30 20.17 23.31 114.92 158.27 204.25 134.05 178.60 225.63 4.85 6.21 7.67 0.18 0.20 0.24 1.17 1.61 2.07 1.36 1.81 2.29 25.43 28.68 32.27 0.26 0.29 0.33 4.39 6.03 7.87 0.04 0.06 0.08 Hungary - Pseudomonas aeruginosa MDRPA OTH - model 50 0.04 0.05 0.07 0.00 0.00 0.00 0.04 0.05 0.07 2.79E-03 3.73E-03 4.70E-03 3.69E-04 5.35E-04 7.55E-04 0.00 0.00 0.00 3.69E-04 5.35E-04 7.55E-04 10.77 14.47 17.59 0.11 0.15 0.18 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Pseudomonas aeruginosa MDRPA RESP - model 47 42.36 51.53 61.47 131.65 173.78 222.50 178.02 225.02 282.68 1.78 2.14 2.50 0.43 0.52 0.62 1.34 1.76 2.26 1.81 2.28 2.87 87.95 106.33 125.15 0.89 1.08 1.27 4.93 6.62 8.60 0.05 0.07 0.09 Hungary - Pseudomonas aeruginosa MDRPA SSI - model 49 0.03 0.04 0.06 5.84 8.66 10.90 5.85 8.69 10.96 0.38 0.44 0.50 2.64E-04 4.20E-04 6.42E-04 0.06 0.09 0.11 0.06 0.09 0.11 14.59 19.78 24.12 0.15 0.20 0.24 0.27 0.40 0.51 2.72E-03 4.06E-03 5.17E-03 Hungary - Pseudomonas aeruginosa MDRPA UTI - model 48 0.05 0.07 0.11 0.00 0.00 0.00 0.05 0.07 0.11 1.51E-03 2.04E-03 2.63E-03 5.26E-04 7.53E-04 1.07E-03 0.00 0.00 0.00 5.26E-04 7.53E-04 1.07E-03 28.76 37.00 44.73 0.29 0.38 0.45 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Staphylococcus aureus MRSA BSI - model 61 204.14 222.46 241.24 1,404.30 1,491.28 1,581.59 1,613.63 1,714.08 1,812.11 3.87 4.03 4.19 2.07 2.26 2.45 14.25 15.13 16.05 16.37 17.39 18.39 404.63 425.32 445.11 4.11 4.32 4.52 71.35 76.37 80.97 0.72 0.77 0.82 Hungary - Staphylococcus aureus MRSA OTH - model 65 1.66 2.05 2.51 0.00 0.00 0.00 1.66 2.05 2.51 2.70E-03 3.28E-03 3.92E-03 0.02 0.02 0.03 0.00 0.00 0.00 0.02 0.02 0.03 564.42 628.05 682.77 5.73 6.37 6.93 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Staphylococcus aureus MRSA RESP - model 62 207.98 231.91 257.16 407.01 448.65 494.39 618.90 680.82 746.66 1.01 1.07 1.12 2.11 2.35 2.61 4.13 4.55 5.02 6.28 6.91 7.58 580.41 638.86 699.08 5.89 6.48 7.09 20.71 23.01 25.61 0.21 0.23 0.26 Hungary - Staphylococcus aureus MRSA SSI - model 64 1.13 1.50 1.93 270.47 299.60 328.93 271.94 300.94 330.59 0.41 0.43 0.45 0.01 0.02 0.02 2.74 3.04 3.34 2.76 3.05 3.35 635.27 697.43 757.98 6.45 7.08 7.69 17.38 19.36 21.30 0.18 0.20 0.22 Hungary - Staphylococcus aureus MRSA UTI - model 63 0.15 0.19 0.25 0.00 0.00 0.00 0.15 0.19 0.25 1.49E-03 1.88E-03 2.28E-03 1.50E-03 1.96E-03 2.55E-03 0.00 0.00 0.00 1.50E-03 1.96E-03 2.55E-03 87.01 103.83 121.90 0.88 1.05 1.24 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Streptococcus pneumoniae PMRSP BSI - model 76 1.10 1.37 1.67 8.36 9.30 10.24 9.67 10.66 11.66 4.36 4.80 5.25 0.01 0.01 0.02 0.08 0.09 0.10 0.10 0.11 0.12 2.22 2.22 2.22 0.02 0.02 0.02 0.36 0.40 0.44 3.64E-03 4.05E-03 4.46E-03 Hungary - Streptococcus pneumoniae PMRSP OTH - model 80 7.57E-04 1.51E-03 2.57E-03 0.00 0.00 0.00 7.57E-04 1.51E-03 2.57E-03 9.89E-04 1.94E-03 3.17E-03 7.68E-06 1.54E-05 2.61E-05 0.00 0.00 0.00 7.68E-06 1.54E-05 2.61E-05 0.67 0.79 0.95 6.83E-03 8.04E-03 9.60E-03 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Streptococcus pneumoniae PMRSP RESP - model 77 2.67 3.56 5.13 5.10 7.02 9.72 7.99 10.58 14.62 1.14 1.27 1.42 0.03 0.04 0.05 0.05 0.07 0.10 0.08 0.11 0.15 6.44 8.35 11.36 0.07 0.08 0.12 0.22 0.30 0.41 2.23E-03 3.05E-03 4.20E-03 Hungary - Streptococcus pneumoniae PMRSP SSI - model 79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Streptococcus pneumoniae PMRSP UTI - model 78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Streptococcus pneumoniae PRSP BSI - model 71 1.42 1.83 2.33 11.28 12.69 14.03 13.01 14.53 16.06 5.86 6.55 7.23 0.01 0.02 0.02 0.11 0.13 0.14 0.13 0.15 0.16 2.22 2.22 2.22 0.02 0.02 0.02 0.36 0.40 0.44 3.64E-03 4.06E-03 4.46E-03 Hungary - Streptococcus pneumoniae PRSP OTH - model 75 8.23E-04 1.51E-03 2.66E-03 0.00 0.00 0.00 8.23E-04 1.51E-03 2.66E-03 1.05E-03 1.94E-03 3.18E-03 8.35E-06 1.53E-05 2.70E-05 0.00 0.00 0.00 8.35E-06 1.53E-05 2.70E-05 0.67 0.79 0.95 6.84E-03 8.02E-03 9.62E-03 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Streptococcus pneumoniae PRSP RESP - model 72 3.40 4.77 7.70 6.82 9.24 14.44 10.52 14.03 21.82 1.33 1.71 2.15 0.03 0.05 0.08 0.07 0.09 0.15 0.11 0.14 0.22 6.46 8.28 11.69 0.07 0.08 0.12 0.22 0.30 0.42 2.25E-03 3.01E-03 4.23E-03 Hungary - Streptococcus pneumoniae PRSP SSI - model 74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Hungary - Streptococcus pneumoniae PRSP UTI - model 73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total (Median & 95% UIs) 2,296.17 2,556.67 2,834.78 11,490.67 13,255.37 15,156.49 13,874.92 15,812.92 17,905.14 23.30 25.94 28.76 116.59 134.50 153.79 140.78 160.45 181.68 9,189.16 10,270.61 11,367.59 93.24 104.21 115.34 470.46 543.11 624.03 4.77 5.51 6.33 Total (average) - - 160.84 10,270.46 104.21 544.36 5.52 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 2,558.99 13,292.76 15,851.75 25.96 134.88 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 Infection Colistin resistant Acinetobacter spp. 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Acinetobacter spp. (excluding those resistant to colistin) 7.28 8.99 11.04 32.08 48.54 65.89 40.37 57.46 76.02 8.07 10.94 13.94 0.16 0.19 0.24 0.69 1.05 1.42 0.87 1.24 1.64 12.36 15.43 18.37 0.27 0.33 0.40 0.93 1.35 1.78 0.02 0.03 0.04 Aminoglycosides and fluoroquinolones resistant Acinetobacter spp. (excluding those resistant to colistin and/or carbapenem) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Vancomycin resistant Enterococci (E. faecalis and E. faecium ) 151.85 178.31 208.15 1,430.17 1,670.34 1,955.75 1,592.95 1,848.81 2,163.73 6.62 7.12 7.66 3.28 3.85 4.50 30.90 36.08 42.25 34.41 39.94 46.74 836.27 1,001.78 1,173.54 18.07 21.64 25.35 56.45 66.35 77.73 1.22 1.43 1.68 Colistin resistant Escherichia coli 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Escherichia coli (excluding those resistant to colistin) 1.77 3.00 4.66 17.06 33.14 52.73 19.13 36.13 56.70 22.78 35.63 47.28 0.04 0.06 0.10 0.37 0.72 1.14 0.41 0.78 1.22 4.75 8.01 11.44 0.10 0.17 0.25 0.22 0.42 0.67 0.00 0.01 0.01 Third-generation cephalosporin resistant Escherichia coli (excluding those resistant to colistin and/or carbapenem) 191.54 213.70 236.50 1,146.66 1,268.18 1,402.65 1,344.06 1,482.28 1,628.82 4.70 5.13 5.58 4.14 4.62 5.11 24.77 27.40 30.30 29.04 32.02 35.19 2,051.92 2,302.37 2,567.52 44.33 49.74 55.47 62.50 71.03 80.27 1.35 1.53 1.73 Colistin resistant Klebsiella pneumoniae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Klebsiella pneumoniae (excluding those resistant to colistin) 0.97 1.50 2.20 9.50 15.86 24.45 10.65 17.38 26.45 6.05 8.81 12.08 0.02 0.03 0.05 0.21 0.34 0.53 0.23 0.38 0.57 3.70 6.02 8.50 0.08 0.13 0.18 0.51 0.81 1.20 0.01 0.02 0.03 Third-generation cephalosporin resistant Klebsiella pneumoniae (excluding those resistant to colistin and/or carbapenem) 49.97 55.54 61.50 246.35 267.45 287.67 298.61 323.39 346.23 5.74 6.05 6.35 1.08 1.20 1.33 5.32 5.78 6.21 6.45 6.99 7.48 199.90 221.41 242.30 4.32 4.78 5.23 11.13 12.09 13.01 0.24 0.26 0.28 Colistin resistant Pseudomonas aeruginosa 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Pseudomonas aeruginosa (excluding those resistant to colistin) 48.17 57.39 66.96 216.34 292.03 373.06 269.29 348.84 435.17 8.45 10.79 13.06 1.04 1.24 1.45 4.67 6.31 8.06 5.82 7.54 9.40 122.04 142.70 163.37 2.64 3.08 3.53 7.66 9.76 12.16 0.17 0.21 0.26 Pseudomonas aeruginosa resistant to three or more antimicrobial groups (excluding those resistant to colistin and/or carbapenem) 1.99 3.59 5.65 6.11 16.51 33.32 8.56 20.03 38.14 5.58 11.23 17.18 0.04 0.08 0.12 0.13 0.36 0.72 0.18 0.43 0.82 4.01 7.98 11.93 0.09 0.17 0.26 0.18 0.48 0.96 0.00 0.01 0.02 Methicillin resistant Staphylococcus aureus 208.93 227.69 246.67 1,028.67 1,097.22 1,163.36 1,242.77 1,324.80 1,403.29 5.50 5.75 6.01 4.51 4.92 5.33 22.22 23.70 25.13 26.85 28.62 30.32 1,082.96 1,182.35 1,281.80 23.40 25.54 27.69 51.87 56.25 60.48 1.12 1.22 1.31 Penicillin and macrolides resistant Streptococcus pneumoniae (excluding those only resistant to penicillin) 0.65 0.94 1.51 2.40 3.00 4.06 3.15 3.93 5.39 2.15 2.44 2.73 0.01 0.02 0.03 0.05 0.06 0.09 0.07 0.08 0.12 4.18 5.18 7.69 0.09 0.11 0.17 0.26 0.32 0.44 0.01 0.01 0.01 Penicillin tesistant Streptococcus pneumoniae (excluding those resistant to macrolides) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total 663.13 750.65 844.83 4,135.35 4,712.28 5,362.94 4,829.53 5,463.04 6,179.93 14.33 16.22 18.25 89.34 101.80 115.86 104.33 118.02 133.51 4,322.08 4,893.24 5,486.45 93.37 105.71 118.52 191.69 218.87 248.69 4.14 4.73 5.37 Model Ireland - Acinetobacter spp. CRACI BSI - model 36 4.32 5.12 6.25 25.59 40.04 55.32 30.74 45.09 60.80 5.84 8.44 11.16 0.09 0.11 0.13 0.55 0.87 1.20 0.66 0.97 1.31 4.76 5.34 5.97 0.10 0.12 0.13 0.74 1.10 1.48 0.02 0.02 0.03 Ireland - Acinetobacter spp. CRACI OTH - model 40 3.65E-04 7.12E-04 1.18E-03 0.00 0.00 0.00 3.65E-04 7.12E-04 1.18E-03 2.50E-03 3.78E-03 5.23E-03 7.89E-06 1.54E-05 2.56E-05 0.00 0.00 0.00 7.89E-06 1.54E-05 2.56E-05 0.11 0.19 0.28 2.46E-03 4.19E-03 6.11E-03 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Acinetobacter spp. CRACI RESP - model 37 2.96 3.85 4.78 5.79 7.48 9.25 8.92 11.34 13.90 1.74 1.96 2.19 0.06 0.08 0.10 0.13 0.16 0.20 0.19 0.25 0.30 4.60 5.79 6.85 0.10 0.13 0.15 0.16 0.21 0.25 3.52E-03 4.50E-03 5.41E-03 Ireland - Acinetobacter spp. CRACI SSI - model 39 2.18E-03 4.09E-03 6.72E-03 0.70 1.02 1.31 0.71 1.02 1.32 0.48 0.53 0.58 4.71E-05 8.84E-05 1.45E-04 0.02 0.02 0.03 0.02 0.02 0.03 1.33 1.92 2.45 0.03 0.04 0.05 0.02 0.04 0.05 5.21E-04 8.16E-04 1.10E-03 Ireland - Acinetobacter spp. CRACI UTI - model 38 2.62E-03 4.37E-03 6.55E-03 0.00 0.00 0.00 2.62E-03 4.37E-03 6.55E-03 1.37E-03 2.04E-03 2.78E-03 5.66E-05 9.43E-05 1.41E-04 0.00 0.00 0.00 5.66E-05 9.43E-05 1.41E-04 1.55 2.18 2.82 0.03 0.05 0.06 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Acinetobacter spp. ColRACI BSI - model 41 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Acinetobacter spp. ColRACI OTH - model 45 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Acinetobacter spp. ColRACI RESP - model 42 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Acinetobacter spp. ColRACI SSI - model 44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Acinetobacter spp. ColRACI UTI - model 43 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Acinetobacter spp. MDRACI BSI - model 31 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Acinetobacter spp. MDRACI OTH - model 35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Acinetobacter spp. MDRACI RESP - model 32 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Acinetobacter spp. MDRACI SSI - model 34 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Acinetobacter spp. MDRACI UTI - model 33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Enterococcus faecalis and E. faecium VRE BSI - model 66 150.80 176.89 206.22 1,307.89 1,514.03 1,764.99 1,469.26 1,691.07 1,971.15 6.20 6.67 7.17 3.26 3.82 4.45 28.25 32.71 38.13 31.74 36.53 42.58 218.20 253.95 296.47 4.71 5.49 6.40 50.05 58.04 67.61 1.08 1.25 1.46 Ireland - Enterococcus faecalis and E. faecium VRE OTH - model 70 0.33 0.44 0.57 0.00 0.00 0.00 0.33 0.44 0.57 1.33E-03 1.64E-03 2.02E-03 7.24E-03 9.56E-03 0.01 0.00 0.00 0.00 7.24E-03 9.56E-03 0.01 226.85 271.50 315.57 4.90 5.87 6.82 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Enterococcus faecalis and E. faecium VRE RESP - model 67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Enterococcus faecalis and E. faecium VRE SSI - model 69 0.54 0.74 1.06 122.28 156.32 190.77 123.17 157.05 191.70 0.42 0.45 0.49 0.01 0.02 0.02 2.64 3.38 4.12 2.66 3.39 4.14 284.64 347.61 410.07 6.15 7.51 8.86 6.40 8.30 10.12 0.14 0.18 0.22 Ireland - Enterococcus faecalis and E. faecium VRE UTI - model 68 0.18 0.24 0.30 0.00 0.00 0.00 0.18 0.24 0.30 1.56E-03 1.88E-03 2.21E-03 3.99E-03 5.24E-03 6.56E-03 0.00 0.00 0.00 3.99E-03 5.24E-03 6.56E-03 106.59 128.72 151.43 2.30 2.78 3.27 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Escherichia coli 3GCREC BSI - model 16 146.80 161.05 175.35 946.19 1,036.63 1,138.59 1,098.28 1,198.11 1,304.48 3.40 3.71 4.01 3.17 3.48 3.79 20.44 22.39 24.60 23.73 25.88 28.18 301.40 322.67 347.53 6.51 6.97 7.51 50.02 55.94 62.79 1.08 1.21 1.36 Ireland - Escherichia coli 3GCREC OTH - model 20 0.26 0.35 0.48 0.00 0.00 0.00 0.26 0.35 0.48 2.69E-03 3.32E-03 4.09E-03 5.69E-03 7.64E-03 0.01 0.00 0.00 0.00 5.69E-03 7.64E-03 0.01 87.76 106.33 127.30 1.90 2.30 2.75 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Escherichia coli 3GCREC RESP - model 17 41.85 48.84 56.30 81.33 94.64 108.77 123.87 143.45 164.31 0.92 1.01 1.14 0.90 1.06 1.22 1.76 2.04 2.35 2.68 3.10 3.55 117.42 141.56 166.21 2.54 3.06 3.59 4.16 5.09 6.02 0.09 0.11 0.13 Ireland - Escherichia coli 3GCREC SSI - model 19 0.54 0.73 0.98 119.14 136.91 155.29 119.57 137.64 156.16 0.38 0.40 0.43 0.01 0.02 0.02 2.57 2.96 3.35 2.58 2.97 3.37 296.25 342.05 385.08 6.40 7.39 8.32 8.32 10.00 11.46 0.18 0.22 0.25 Ireland - Escherichia coli 3GCREC UTI - model 18 2.09 2.73 3.39 0.00 0.00 0.00 2.09 2.73 3.39 1.60E-03 1.97E-03 2.36E-03 0.05 0.06 0.07 0.00 0.00 0.00 0.05 0.06 0.07 1,249.08 1,389.76 1,541.40 26.98 30.02 33.30 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Escherichia coli CREC BSI - model 21 1.47 2.21 3.32 15.99 30.68 48.93 17.73 32.87 51.62 18.41 30.63 41.66 0.03 0.05 0.07 0.35 0.66 1.06 0.38 0.71 1.12 0.82 1.08 1.42 0.02 0.02 0.03 0.20 0.39 0.62 4.39E-03 8.43E-03 0.01 Ireland - Escherichia coli CREC OTH - model 25 5.58E-04 1.87E-03 5.49E-03 0.00 0.00 0.00 5.58E-04 1.87E-03 5.49E-03 1.15E-03 3.17E-03 7.32E-03 1.20E-05 4.03E-05 1.19E-04 0.00 0.00 0.00 1.20E-05 4.03E-05 1.19E-04 0.28 0.62 0.97 6.10E-03 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Escherichia coli CREC RESP - model 22 0.30 0.78 1.31 0.59 1.54 2.48 0.91 2.33 3.73 3.65 4.28 4.90 6.50E-03 0.02 0.03 0.01 0.03 0.05 0.02 0.05 0.08 0.21 0.55 0.86 4.55E-03 0.01 0.02 7.48E-03 0.02 0.03 1.62E-04 4.24E-04 6.80E-04 Ireland - Escherichia coli CREC SSI - model 24 5.81E-04 2.52E-03 6.48E-03 0.49 0.91 1.33 0.49 0.92 1.33 0.71 0.71 0.71 1.26E-05 5.44E-05 1.40E-04 0.01 0.02 0.03 0.01 0.02 0.03 0.69 1.29 1.87 0.01 0.03 0.04 6.20E-03 0.01 0.02 1.34E-04 2.50E-04 3.64E-04 Ireland - Escherichia coli CREC UTI - model 23 3.17E-03 8.94E-03 0.02 0.00 0.00 0.00 3.17E-03 8.94E-03 0.02 8.35E-04 2.01E-03 4.05E-03 6.84E-05 1.93E-04 4.49E-04 0.00 0.00 0.00 6.84E-05 1.93E-04 4.49E-04 2.75 4.48 6.32 0.06 0.10 0.14 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Escherichia coli ColREC BSI - model 26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Escherichia coli ColREC OTH - model 30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Escherichia coli ColREC RESP - model 27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Escherichia coli ColREC SSI - model 29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Escherichia coli ColREC UTI - model 28 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Klebsiella pneumoniae 3GCRKP BSI - model 1 31.45 34.52 37.90 201.45 216.53 230.63 234.86 251.32 266.22 4.14 4.34 4.53 0.68 0.75 0.82 4.35 4.68 4.98 5.07 5.43 5.75 54.78 57.86 60.91 1.18 1.25 1.32 8.99 9.66 10.30 0.19 0.21 0.22 Ireland - Klebsiella pneumoniae 3GCRKP OTH - model 5 0.06 0.08 0.10 0.00 0.00 0.00 0.06 0.08 0.10 2.73E-03 3.32E-03 4.03E-03 1.30E-03 1.65E-03 2.06E-03 0.00 0.00 0.00 1.30E-03 1.65E-03 2.06E-03 19.97 22.96 25.81 0.43 0.50 0.56 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Klebsiella pneumoniae 3GCRKP RESP - model 2 18.32 20.76 23.27 35.61 40.10 44.63 54.27 60.99 67.27 1.14 1.23 1.31 0.40 0.45 0.50 0.77 0.87 0.96 1.17 1.32 1.45 44.49 49.77 54.90 0.96 1.08 1.19 1.60 1.79 1.98 0.03 0.04 0.04 Ireland - Klebsiella pneumoniae 3GCRKP SSI - model 4 0.04 0.05 0.06 9.28 10.83 12.41 9.32 10.87 12.47 0.45 0.48 0.50 7.81E-04 1.06E-03 1.39E-03 0.20 0.23 0.27 0.20 0.23 0.27 19.86 22.73 25.66 0.43 0.49 0.55 0.54 0.64 0.73 0.01 0.01 0.02 Ireland - Klebsiella pneumoniae 3GCRKP UTI - model 3 0.10 0.13 0.17 0.00 0.00 0.00 0.10 0.13 0.17 1.54E-03 1.95E-03 2.36E-03 2.25E-03 2.86E-03 3.59E-03 0.00 0.00 0.00 2.25E-03 2.86E-03 3.59E-03 60.81 68.09 75.02 1.31 1.47 1.62 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Klebsiella pneumoniae CRKP BSI - model 6 0.82 1.16 1.63 9.13 15.02 23.08 10.12 16.20 24.56 5.01 7.43 10.28 0.02 0.03 0.04 0.20 0.32 0.50 0.22 0.35 0.53 1.76 2.16 2.65 0.04 0.05 0.06 0.49 0.77 1.13 0.01 0.02 0.02 Ireland - Klebsiella pneumoniae CRKP OTH - model 10 1.24E-03 3.20E-03 7.06E-03 0.00 0.00 0.00 1.24E-03 3.20E-03 7.06E-03 1.60E-03 3.33E-03 6.08E-03 2.67E-05 6.91E-05 1.52E-04 0.00 0.00 0.00 2.67E-05 6.91E-05 1.52E-04 0.47 1.00 1.53 0.01 0.02 0.03 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Klebsiella pneumoniae CRKP RESP - model 7 0.14 0.33 0.55 0.28 0.65 1.08 0.44 0.98 1.58 0.76 1.07 1.47 3.12E-03 7.19E-03 0.01 6.15E-03 0.01 0.02 9.53E-03 0.02 0.03 0.45 0.91 1.40 9.69E-03 0.02 0.03 0.02 0.03 0.05 3.39E-04 7.08E-04 1.10E-03 Ireland - Klebsiella pneumoniae CRKP SSI - model 9 4.08E-04 1.25E-03 2.72E-03 0.09 0.19 0.29 0.09 0.19 0.30 0.29 0.30 0.32 8.82E-06 2.71E-05 5.88E-05 1.85E-03 4.15E-03 6.36E-03 1.86E-03 4.17E-03 6.41E-03 0.29 0.64 0.97 6.25E-03 0.01 0.02 5.52E-03 0.01 0.02 1.19E-04 3.01E-04 4.96E-04 Ireland - Klebsiella pneumoniae CRKP UTI - model 8 1.13E-03 2.58E-03 5.27E-03 0.00 0.00 0.00 1.13E-03 2.58E-03 5.27E-03 1.02E-03 2.03E-03 3.50E-03 2.45E-05 5.57E-05 1.14E-04 0.00 0.00 0.00 2.45E-05 5.57E-05 1.14E-04 0.73 1.31 1.95 0.02 0.03 0.04 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Klebsiella pneumoniae ColRKP BSI - model 11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Klebsiella pneumoniae ColRKP OTH - model 15 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Klebsiella pneumoniae ColRKP RESP - model 12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Klebsiella pneumoniae ColRKP SSI - model 14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Klebsiella pneumoniae ColRKP UTI - model 13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Pseudomonas aeruginosa CRPA BSI - model 51 13.77 16.10 18.67 101.29 137.88 176.47 116.60 154.08 193.42 5.94 7.74 9.48 0.30 0.35 0.40 2.19 2.98 3.81 2.52 3.33 4.18 18.14 19.88 21.99 0.39 0.43 0.47 3.52 4.57 5.68 0.08 0.10 0.12 Ireland - Pseudomonas aeruginosa CRPA OTH - model 55 0.03 0.04 0.05 0.00 0.00 0.00 0.03 0.04 0.05 2.89E-03 3.66E-03 4.43E-03 5.82E-04 7.94E-04 1.02E-03 0.00 0.00 0.00 5.82E-04 7.94E-04 1.02E-03 8.16 10.06 12.04 0.18 0.22 0.26 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Pseudomonas aeruginosa CRPA RESP - model 52 34.32 41.17 48.14 109.99 147.60 188.62 147.51 188.09 233.62 2.07 2.56 3.06 0.74 0.89 1.04 2.38 3.19 4.07 3.19 4.06 5.05 63.64 73.66 83.12 1.37 1.59 1.80 3.89 4.86 6.07 0.08 0.11 0.13 Ireland - Pseudomonas aeruginosa CRPA SSI - model 54 0.02 0.03 0.04 5.06 6.55 7.97 5.10 6.58 8.03 0.44 0.48 0.52 4.30E-04 6.20E-04 8.68E-04 0.11 0.14 0.17 0.11 0.14 0.17 10.98 13.64 16.28 0.24 0.29 0.35 0.25 0.33 0.41 5.36E-03 7.07E-03 8.78E-03 Ireland - Pseudomonas aeruginosa CRPA UTI - model 53 0.04 0.05 0.07 0.00 0.00 0.00 0.04 0.05 0.07 1.63E-03 2.05E-03 2.51E-03 8.39E-04 1.12E-03 1.46E-03 0.00 0.00 0.00 8.39E-04 1.12E-03 1.46E-03 21.13 25.46 29.94 0.46 0.55 0.65 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Pseudomonas aeruginosa ColRPA BSI - model 56 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Pseudomonas aeruginosa ColRPA OTH - model 60 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Pseudomonas aeruginosa ColRPA RESP - model 57 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Pseudomonas aeruginosa ColRPA SSI - model 59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Pseudomonas aeruginosa ColRPA UTI - model 58 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Pseudomonas aeruginosa MDRPA BSI - model 46 0.67 1.01 1.60 2.81 8.00 15.77 3.66 9.00 17.23 3.64 8.11 12.85 0.01 0.02 0.03 0.06 0.17 0.34 0.08 0.19 0.37 0.79 1.12 1.55 0.02 0.02 0.03 0.08 0.23 0.45 1.75E-03 4.98E-03 9.82E-03 Ireland - Pseudomonas aeruginosa MDRPA OTH - model 50 4.92E-04 1.92E-03 4.59E-03 0.00 0.00 0.00 4.92E-04 1.92E-03 4.59E-03 1.59E-03 3.80E-03 6.46E-03 1.06E-05 4.14E-05 9.91E-05 0.00 0.00 0.00 1.06E-05 4.14E-05 9.91E-05 0.17 0.55 0.95 3.57E-03 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Pseudomonas aeruginosa MDRPA RESP - model 47 1.32 2.57 4.03 3.23 8.27 17.16 4.81 10.78 20.50 1.63 2.80 4.00 0.03 0.06 0.09 0.07 0.18 0.37 0.10 0.23 0.44 2.23 4.13 5.92 0.05 0.09 0.13 0.09 0.24 0.49 2.01E-03 5.15E-03 0.01 Ireland - Pseudomonas aeruginosa MDRPA SSI - model 49 2.69E-04 1.42E-03 4.17E-03 0.08 0.24 0.39 0.08 0.25 0.40 0.31 0.31 0.32 5.81E-06 3.07E-05 9.00E-05 1.72E-03 5.27E-03 8.53E-03 1.73E-03 5.30E-03 8.57E-03 0.26 0.78 1.26 5.52E-03 0.02 0.03 2.30E-03 7.03E-03 0.01 4.97E-05 1.52E-04 2.46E-04 Ireland - Pseudomonas aeruginosa MDRPA UTI - model 48 7.77E-04 2.63E-03 6.53E-03 0.00 0.00 0.00 7.77E-04 2.63E-03 6.53E-03 8.43E-04 1.96E-03 3.76E-03 1.68E-05 5.67E-05 1.41E-04 0.00 0.00 0.00 1.68E-05 5.67E-05 1.41E-04 0.57 1.41 2.24 0.01 0.03 0.05 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Staphylococcus aureus MRSA BSI - model 61 102.28 110.40 119.11 702.34 740.38 777.90 809.44 850.68 892.20 4.06 4.23 4.40 2.21 2.38 2.57 15.17 15.99 16.81 17.49 18.38 19.27 191.93 201.27 211.66 4.15 4.35 4.57 33.89 36.13 38.38 0.73 0.78 0.83 Ireland - Staphylococcus aureus MRSA OTH - model 65 0.79 0.97 1.17 0.00 0.00 0.00 0.79 0.97 1.17 2.70E-03 3.27E-03 3.91E-03 0.02 0.02 0.03 0.00 0.00 0.00 0.02 0.02 0.03 271.19 297.01 323.58 5.86 6.42 6.99 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Staphylococcus aureus MRSA RESP - model 62 105.26 115.53 125.36 205.03 224.12 241.46 310.66 339.67 365.08 1.05 1.12 1.19 2.27 2.50 2.71 4.43 4.84 5.22 6.71 7.34 7.89 275.10 304.53 331.14 5.94 6.58 7.15 9.79 10.98 12.03 0.21 0.24 0.26 Ireland - Staphylococcus aureus MRSA SSI - model 64 0.53 0.70 0.91 121.30 132.73 144.00 121.81 133.39 144.72 0.39 0.40 0.42 0.01 0.02 0.02 2.62 2.87 3.11 2.63 2.88 3.13 303.65 330.11 358.52 6.56 7.13 7.75 8.19 9.15 10.07 0.18 0.20 0.22 Ireland - Staphylococcus aureus MRSA UTI - model 63 0.07 0.09 0.12 0.00 0.00 0.00 0.07 0.09 0.12 1.52E-03 1.88E-03 2.25E-03 1.52E-03 1.98E-03 2.54E-03 0.00 0.00 0.00 1.52E-03 1.98E-03 2.54E-03 41.09 49.43 56.90 0.89 1.07 1.23 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Streptococcus pneumoniae PMRSP BSI - model 76 0.19 0.26 0.34 1.52 1.72 1.93 1.76 1.98 2.21 1.71 1.93 2.15 4.13E-03 5.54E-03 7.37E-03 0.03 0.04 0.04 0.04 0.04 0.05 1.03 1.03 1.03 0.02 0.02 0.02 0.16 0.18 0.21 3.52E-03 3.99E-03 4.48E-03 Ireland - Streptococcus pneumoniae PMRSP OTH - model 80 2.60E-04 6.79E-04 1.40E-03 0.00 0.00 0.00 2.60E-04 6.79E-04 1.40E-03 7.28E-04 1.86E-03 3.65E-03 5.61E-06 1.47E-05 3.02E-05 0.00 0.00 0.00 5.61E-06 1.47E-05 3.02E-05 0.30 0.36 0.47 6.46E-03 7.83E-03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Streptococcus pneumoniae PMRSP RESP - model 77 0.46 0.68 1.17 0.89 1.28 2.12 1.39 1.95 3.18 0.44 0.51 0.58 9.90E-03 0.01 0.03 0.02 0.03 0.05 0.03 0.04 0.07 2.85 3.79 6.18 0.06 0.08 0.13 0.10 0.14 0.23 2.06E-03 2.97E-03 4.92E-03 Ireland - Streptococcus pneumoniae PMRSP SSI - model 79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Streptococcus pneumoniae PMRSP UTI - model 78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Streptococcus pneumoniae PRSP BSI - model 71 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Streptococcus pneumoniae PRSP OTH - model 75 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Streptococcus pneumoniae PRSP RESP - model 72 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Streptococcus pneumoniae PRSP SSI - model 74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Ireland - Streptococcus pneumoniae PRSP UTI - model 73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total (Median & 95% UIs) 663.13 750.65 844.83 4,135.35 4,712.28 5,362.94 4,829.53 5,463.04 6,179.93 14.33 16.22 18.25 89.34 101.80 115.86 104.33 118.02 133.51 4,322.08 4,893.24 5,486.45 93.37 105.71 118.52 191.69 218.87 248.69 4.14 4.73 5.37 Total (average) - 102.03 118.26 4,898.90 105.83 219.18 4.73 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 751.71 4,722.69 5,474.41 - 16.24 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 Infection Colistin resistant Acinetobacter spp. 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Acinetobacter spp. (excluding those resistant to colistin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Aminoglycosides and fluoroquinolones resistant Acinetobacter spp. (excluding those resistant to colistin and/or carbapenem) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Vancomycin resistant Enterococci (E. faecalis and E. faecium ) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Colistin resistant Escherichia coli 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Escherichia coli (excluding those resistant to colistin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Third-generation cephalosporin resistant Escherichia coli (excluding those resistant to colistin and/or carbapenem) 1.03 1.51 2.12 5.84 8.51 11.89 7.06 10.03 13.85 2.68 3.59 4.70 0.31 0.46 0.65 1.78 2.59 3.61 2.14 3.05 4.21 16.67 22.36 28.15 5.07 6.79 8.55 0.50 0.69 0.89 0.15 0.21 0.27 Colistin resistant Klebsiella pneumoniae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Klebsiella pneumoniae (excluding those resistant to colistin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Third-generation cephalosporin resistant Klebsiella pneumoniae (excluding those resistant to colistin and/or carbapenem) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Colistin resistant Pseudomonas aeruginosa 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Pseudomonas aeruginosa (excluding those resistant to colistin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Pseudomonas aeruginosa resistant to three or more antimicrobial groups (excluding those resistant to colistin and/or carbapenem) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Methicillin resistant Staphylococcus aureus 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Penicillin and macrolides resistant Streptococcus pneumoniae (excluding those only resistant to penicillin) 1.09 1.57 2.52 4.16 5.21 7.06 5.43 6.77 9.38 3.86 4.38 4.90 0.33 0.48 0.77 1.27 1.58 2.14 1.65 2.06 2.85 4.04 4.97 7.23 1.23 1.51 2.20 0.25 0.31 0.42 0.08 0.09 0.13 Penicillin tesistant Streptococcus pneumoniae (excluding those resistant to macrolides) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total 2.12 3.08 4.65 10.01 13.72 18.95 12.49 16.80 23.23 0.64 0.94 1.41 3.04 4.17 5.76 3.80 5.11 7.06 20.72 27.33 35.38 6.30 8.30 10.75 0.75 1.00 1.31 0.23 0.30 0.40 Model Iceland - Acinetobacter spp. ColRACI BSI - model 41 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Acinetobacter spp. ColRACI OTH - model 45 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Acinetobacter spp. ColRACI RESP - model 42 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Acinetobacter spp. ColRACI SSI - model 44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Acinetobacter spp. ColRACI UTI - model 43 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Acinetobacter spp. CRACI BSI - model 36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Acinetobacter spp. CRACI OTH - model 40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Acinetobacter spp. CRACI RESP - model 37 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Acinetobacter spp. CRACI SSI - model 39 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Acinetobacter spp. CRACI UTI - model 38 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Acinetobacter spp. MDRACI BSI - model 31 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Acinetobacter spp. MDRACI OTH - model 35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Acinetobacter spp. MDRACI RESP - model 32 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Acinetobacter spp. MDRACI SSI - model 34 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Acinetobacter spp. MDRACI UTI - model 33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Enterococcus faecalis and E. faecium VRE BSI - model 66 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Enterococcus faecalis and E. faecium VRE OTH - model 70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Enterococcus faecalis and E. faecium VRE RESP - model 67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Enterococcus faecalis and E. faecium VRE SSI - model 69 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Enterococcus faecalis and E. faecium VRE UTI - model 68 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Escherichia coli 3GCREC BSI - model 16 0.83 1.12 1.53 5.00 7.14 9.96 6.01 8.27 11.34 2.01 2.65 3.47 0.25 0.34 0.46 1.52 2.17 3.03 1.82 2.51 3.45 2.70 3.14 3.69 0.82 0.95 1.12 0.41 0.55 0.70 0.12 0.17 0.21 Iceland - Escherichia coli 3GCREC OTH - model 20 1.59E-03 3.40E-03 6.09E-03 0.00 0.00 0.00 1.59E-03 3.40E-03 6.09E-03 1.94E-03 3.30E-03 4.89E-03 4.83E-04 1.03E-03 1.85E-03 0.00 0.00 0.00 4.83E-04 1.03E-03 1.85E-03 0.61 1.05 1.52 0.18 0.32 0.46 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Escherichia coli 3GCREC RESP - model 17 0.17 0.35 0.54 0.35 0.67 1.01 0.54 1.02 1.54 0.47 0.72 1.00 0.05 0.11 0.16 0.11 0.20 0.31 0.16 0.31 0.47 0.89 1.39 1.92 0.27 0.42 0.58 0.03 0.05 0.07 9.39E-03 0.02 0.02 Iceland - Escherichia coli 3GCREC SSI - model 19 3.12E-03 6.91E-03 0.01 0.50 0.71 0.93 0.50 0.71 0.93 0.20 0.21 0.23 9.48E-04 2.10E-03 3.71E-03 0.15 0.21 0.28 0.15 0.22 0.28 2.34 3.34 4.33 0.71 1.01 1.32 0.06 0.09 0.12 0.02 0.03 0.04 Iceland - Escherichia coli 3GCREC UTI - model 18 0.01 0.03 0.04 0.00 0.00 0.00 0.01 0.03 0.04 1.16E-03 1.94E-03 2.87E-03 4.37E-03 7.95E-03 0.01 0.00 0.00 0.00 4.37E-03 7.95E-03 0.01 10.14 13.45 16.68 3.08 4.09 5.07 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Escherichia coli ColREC BSI - model 26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Escherichia coli ColREC OTH - model 30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Escherichia coli ColREC RESP - model 27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Escherichia coli ColREC SSI - model 29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Escherichia coli ColREC UTI - model 28 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Escherichia coli CREC BSI - model 21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Escherichia coli CREC OTH - model 25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Escherichia coli CREC RESP - model 22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Escherichia coli CREC SSI - model 24 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Escherichia coli CREC UTI - model 23 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Klebsiella pneumoniae 3GCRKP BSI - model 1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Klebsiella pneumoniae 3GCRKP OTH - model 5 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Klebsiella pneumoniae 3GCRKP RESP - model 2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Klebsiella pneumoniae 3GCRKP SSI - model 4 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Klebsiella pneumoniae 3GCRKP UTI - model 3 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Klebsiella pneumoniae ColRKP BSI - model 11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Klebsiella pneumoniae ColRKP OTH - model 15 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Klebsiella pneumoniae ColRKP RESP - model 12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Klebsiella pneumoniae ColRKP SSI - model 14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Klebsiella pneumoniae ColRKP UTI - model 13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Klebsiella pneumoniae CRKP BSI - model 6 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Klebsiella pneumoniae CRKP OTH - model 10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Klebsiella pneumoniae CRKP RESP - model 7 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Klebsiella pneumoniae CRKP SSI - model 9 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Klebsiella pneumoniae CRKP UTI - model 8 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Pseudomonas aeruginosa ColRPA BSI - model 56 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Pseudomonas aeruginosa ColRPA OTH - model 60 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Pseudomonas aeruginosa ColRPA RESP - model 57 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Pseudomonas aeruginosa ColRPA SSI - model 59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Pseudomonas aeruginosa ColRPA UTI - model 58 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Pseudomonas aeruginosa CRPA BSI - model 51 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Pseudomonas aeruginosa CRPA OTH - model 55 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Pseudomonas aeruginosa CRPA RESP - model 52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Pseudomonas aeruginosa CRPA SSI - model 54 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Pseudomonas aeruginosa CRPA UTI - model 53 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Pseudomonas aeruginosa MDRPA BSI - model 46 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Pseudomonas aeruginosa MDRPA OTH - model 50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Pseudomonas aeruginosa MDRPA RESP - model 47 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Pseudomonas aeruginosa MDRPA SSI - model 49 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Pseudomonas aeruginosa MDRPA UTI - model 48 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Staphylococcus aureus MRSA BSI - model 61 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Staphylococcus aureus MRSA OTH - model 65 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Staphylococcus aureus MRSA RESP - model 62 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Staphylococcus aureus MRSA SSI - model 64 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Staphylococcus aureus MRSA UTI - model 63 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Streptococcus pneumoniae PMRSP BSI - model 76 0.33 0.44 0.58 2.65 3.03 3.39 3.07 3.46 3.86 3.07 3.46 3.86 0.10 0.13 0.18 0.81 0.92 1.03 0.93 1.05 1.17 1.00 1.00 1.00 0.30 0.30 0.30 0.16 0.18 0.20 0.05 0.05 0.06 Iceland - Streptococcus pneumoniae PMRSP OTH - model 80 2.32E-04 6.78E-04 1.32E-03 0.00 0.00 0.00 2.32E-04 6.78E-04 1.32E-03 7.50E-04 1.93E-03 3.57E-03 7.04E-05 2.06E-04 4.01E-04 0.00 0.00 0.00 7.04E-05 2.06E-04 4.01E-04 0.29 0.35 0.45 0.09 0.11 0.14 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Streptococcus pneumoniae PMRSP RESP - model 77 0.77 1.13 1.94 1.51 2.18 3.67 2.37 3.31 5.52 0.79 0.92 1.04 0.23 0.34 0.59 0.46 0.66 1.12 0.72 1.00 1.68 2.76 3.62 5.77 0.84 1.10 1.75 0.09 0.13 0.22 0.03 0.04 0.07 Iceland - Streptococcus pneumoniae PMRSP SSI - model 79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Streptococcus pneumoniae PMRSP UTI - model 78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Streptococcus pneumoniae PRSP BSI - model 71 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Streptococcus pneumoniae PRSP OTH - model 75 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Streptococcus pneumoniae PRSP RESP - model 72 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Streptococcus pneumoniae PRSP SSI - model 74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Iceland - Streptococcus pneumoniae PRSP UTI - model 73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total (Median & 95% UIs) 2.12 3.08 4.65 10.01 13.72 18.95 12.49 16.80 23.23 0.64 0.94 1.41 3.04 4.17 5.76 3.80 5.11 7.06 20.72 27.33 35.38 6.30 8.30 10.75 0.75 1.00 1.31 0.23 0.30 0.40 Total (average) - 4.24 5.20 27.54 8.37 1.01 0.31 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 3.17 13.96 17.13 - 0.96 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 Infection Colistin resistant Acinetobacter spp. 122.94 153.39 189.59 579.02 817.56 1,085.03 713.50 971.89 1,265.67 6.38 8.21 10.10 0.20 0.25 0.31 0.95 1.34 1.78 1.17 1.60 2.08 281.73 357.97 436.99 0.46 0.59 0.72 22.37 30.77 40.75 0.04 0.05 0.07 Carbapenem resistant Acinetobacter spp. (excluding those resistant to colistin) 3,848.26 4,414.09 4,991.46 19,315.09 23,532.41 27,711.84 23,329.24 27,969.97 32,449.30 6.40 7.36 8.35 6.33 7.26 8.21 31.77 38.71 45.58 38.37 46.01 53.37 9,770.46 11,410.09 13,106.23 16.07 18.77 21.56 789.46 976.44 1,175.05 1.30 1.61 1.93 Aminoglycosides and fluoroquinolones resistant Acinetobacter spp. (excluding those resistant to colistin and/or carbapenem) 60.17 70.38 81.64 294.27 364.90 442.53 357.31 435.39 520.51 3.89 4.59 5.39 0.10 0.12 0.13 0.48 0.60 0.73 0.59 0.72 0.86 226.34 288.83 359.24 0.37 0.48 0.59 17.87 24.48 32.23 0.03 0.04 0.05 Vancomycin resistant Enterococci (E. faecalis and E. faecium ) 516.65 651.96 811.84 4,907.99 6,186.34 7,659.62 5,384.80 6,831.01 8,439.87 5.57 6.25 7.05 0.85 1.07 1.34 8.07 10.18 12.60 8.86 11.24 13.88 3,186.35 4,190.98 5,248.14 5.24 6.89 8.63 217.79 281.27 356.24 0.36 0.46 0.59 Colistin resistant Escherichia coli 173.12 205.49 241.27 2,877.51 3,477.76 4,143.86 3,054.49 3,683.32 4,369.91 11.40 13.37 15.57 0.28 0.34 0.40 4.73 5.72 6.82 5.02 6.06 7.19 1,740.76 2,149.90 2,634.70 2.86 3.54 4.33 144.84 185.53 236.66 0.24 0.31 0.39 Carbapenem resistant Escherichia coli (excluding those resistant to colistin) 75.83 98.70 128.94 783.87 1,042.96 1,425.08 861.66 1,140.06 1,528.26 11.27 14.35 17.81 0.12 0.16 0.21 1.29 1.72 2.34 1.42 1.88 2.51 522.53 638.20 760.92 0.86 1.05 1.25 27.36 33.62 42.13 0.05 0.06 0.07 Third-generation cephalosporin resistant Escherichia coli (excluding those resistant to colistin and/or carbapenem) 6,972.23 8,131.30 9,355.87 41,429.12 48,116.17 56,147.84 48,647.39 56,308.85 65,145.23 4.44 4.93 5.43 11.47 13.37 15.39 68.14 79.14 92.36 80.02 92.62 107.15 75,454.48 92,178.96 109,552.34 124.11 151.62 180.20 2,332.84 2,825.53 3,409.85 3.84 4.65 5.61 Colistin resistant Klebsiella pneumoniae 1,264.92 1,490.77 1,748.46 22,073.91 26,233.98 31,088.92 23,400.34 27,727.18 32,761.23 15.57 17.88 20.25 2.08 2.45 2.88 36.31 43.15 51.14 38.49 45.61 53.89 3,917.41 4,754.92 5,639.23 6.44 7.82 9.28 862.15 1,039.24 1,229.36 1.42 1.71 2.02 Carbapenem resistant Klebsiella pneumoniae (excluding those resistant to colistin) 2,757.85 3,233.62 3,721.76 28,944.34 34,149.32 39,976.25 31,788.08 37,393.79 43,543.67 9.81 11.04 12.33 4.54 5.32 6.12 47.61 56.17 65.76 52.29 61.51 71.62 8,941.81 10,840.47 12,717.78 14.71 17.83 20.92 1,181.96 1,425.11 1,689.62 1.94 2.34 2.78 Third-generation cephalosporin resistant Klebsiella pneumoniae (excluding those resistant to colistin and/or carbapenem) 3,227.41 3,695.03 4,208.36 15,693.72 17,584.74 19,849.57 18,991.66 21,303.20 23,997.88 6.53 7.08 7.70 5.31 6.08 6.92 25.81 28.92 32.65 31.24 35.04 39.47 10,941.77 12,572.01 14,384.70 18.00 20.68 23.66 590.78 669.57 750.71 0.97 1.10 1.23 Colistin resistant Pseudomonas aeruginosa 178.93 228.62 289.42 826.99 1,140.02 1,606.30 1,020.14 1,369.14 1,884.08 8.29 10.66 13.48 0.29 0.38 0.48 1.36 1.88 2.64 1.68 2.25 3.10 448.84 581.04 723.80 0.74 0.96 1.19 27.98 38.81 52.78 0.05 0.06 0.09 Carbapenem resistant Pseudomonas aeruginosa (excluding those resistant to colistin) 4,496.72 5,270.27 6,072.92 21,551.99 26,500.58 32,143.76 26,328.34 31,786.16 38,022.58 8.60 9.97 11.48 7.40 8.67 9.99 35.45 43.59 52.87 43.31 52.28 62.54 11,998.76 14,207.39 16,643.73 19.74 23.37 27.38 769.46 950.83 1,186.92 1.27 1.56 1.95 Pseudomonas aeruginosa resistant to three or more antimicrobial groups (excluding those resistant to colistin and/or carbapenem) 442.58 539.51 642.46 1,934.83 2,532.87 3,198.92 2,407.10 3,074.30 3,819.15 5.51 6.70 7.97 0.73 0.89 1.06 3.18 4.17 5.26 3.96 5.06 6.28 1,650.03 2,036.26 2,453.92 2.71 3.35 4.04 97.07 128.19 164.14 0.16 0.21 0.27 Methicillin resistant Staphylococcus aureus 7,658.44 8,772.65 10,095.06 37,715.16 42,387.01 47,572.19 45,565.05 51,188.16 57,428.68 5.47 5.91 6.42 12.60 14.43 16.60 62.04 69.72 78.25 74.95 84.20 94.46 38,324.20 44,877.93 51,912.59 63.04 73.82 85.39 1,844.27 2,123.09 2,414.77 3.03 3.49 3.97 Penicillin and macrolides resistant Streptococcus pneumoniae (excluding those only resistant to penicillin) 77.06 113.96 188.11 278.31 368.33 522.29 361.46 482.88 700.69 7.32 8.51 9.89 0.13 0.19 0.31 0.46 0.61 0.86 0.59 0.79 1.15 141.16 190.32 264.79 0.23 0.31 0.44 8.98 11.42 14.85 0.01 0.02 0.02 Penicillin tesistant Streptococcus pneumoniae (excluding those resistant to macrolides) 183.02 227.42 291.49 614.77 730.14 879.80 798.61 957.63 1,163.32 9.59 10.38 11.37 0.30 0.37 0.48 1.01 1.20 1.45 1.31 1.58 1.91 262.68 308.30 368.16 0.43 0.51 0.61 16.08 18.34 21.17 0.03 0.03 0.03 Total 32,056.11 37,297.16 43,058.64 199,820.89 235,165.11 275,453.79 233,009.16 272,622.93 317,040.02 52.73 61.35 70.83 328.68 386.81 453.08 383.27 448.43 521.49 167,809.32 201,583.57 237,207.25 276.02 331.58 390.17 8,951.28 10,762.23 12,817.23 14.72 17.70 21.08 Model Italy - Acinetobacter spp. CRACI BSI - model 36 2,197.61 2,484.65 2,786.44 15,592.39 19,160.62 22,711.43 17,964.48 21,666.00 25,268.12 4.80 5.60 6.45 3.61 4.09 4.58 25.65 31.52 37.36 29.55 35.64 41.56 3,431.55 3,843.46 4,301.01 5.64 6.32 7.07 631.02 786.05 951.80 1.04 1.29 1.57 Italy - Acinetobacter spp. CRACI OTH - model 40 0.42 0.58 0.80 0.00 0.00 0.00 0.42 0.58 0.80 3.10E-03 3.76E-03 4.45E-03 6.86E-04 9.57E-04 1.32E-03 0.00 0.00 0.00 6.86E-04 9.57E-04 1.32E-03 116.22 156.41 196.85 0.19 0.26 0.32 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Acinetobacter spp. CRACI RESP - model 37 1,645.35 1,922.34 2,195.60 3,217.07 3,742.16 4,237.00 4,854.77 5,667.12 6,409.21 1.21 1.32 1.43 2.71 3.16 3.61 5.29 6.16 6.97 7.99 9.32 10.54 3,648.05 4,281.89 4,900.69 6.00 7.04 8.06 130.32 154.00 178.04 0.21 0.25 0.29 Italy - Acinetobacter spp. CRACI SSI - model 39 2.33 3.15 4.28 505.63 629.63 763.41 507.02 632.92 766.84 0.39 0.43 0.47 3.83E-03 5.19E-03 7.03E-03 0.83 1.04 1.26 0.83 1.04 1.26 1,225.22 1,479.02 1,742.89 2.02 2.43 2.87 28.12 36.39 45.21 0.05 0.06 0.07 Italy - Acinetobacter spp. CRACI UTI - model 38 2.55 3.36 4.34 0.00 0.00 0.00 2.55 3.36 4.34 1.68E-03 2.05E-03 2.44E-03 4.19E-03 5.52E-03 7.13E-03 0.00 0.00 0.00 4.19E-03 5.52E-03 7.13E-03 1,349.42 1,649.31 1,964.80 2.22 2.71 3.23 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Acinetobacter spp. ColRACI BSI - model 41 71.07 86.31 105.05 463.43 668.05 899.77 545.32 755.04 996.52 4.72 6.32 7.94 0.12 0.14 0.17 0.76 1.10 1.48 0.90 1.24 1.64 101.64 120.35 139.86 0.17 0.20 0.23 17.88 24.87 33.35 0.03 0.04 0.05 Italy - Acinetobacter spp. ColRACI OTH - model 45 0.01 0.02 0.03 0.00 0.00 0.00 0.01 0.02 0.03 2.65E-03 3.76E-03 4.75E-03 1.81E-05 2.93E-05 4.43E-05 0.00 0.00 0.00 1.81E-05 2.93E-05 4.43E-05 3.13 4.82 6.81 5.15E-03 7.93E-03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Acinetobacter spp. ColRACI RESP - model 42 51.73 66.86 84.21 101.44 129.98 160.02 153.88 197.10 243.58 1.27 1.46 1.69 0.09 0.11 0.14 0.17 0.21 0.26 0.25 0.32 0.40 104.68 134.58 163.49 0.17 0.22 0.27 3.78 4.84 5.94 6.22E-03 7.96E-03 9.77E-03 Italy - Acinetobacter spp. ColRACI SSI - model 44 0.06 0.10 0.15 14.15 19.54 25.23 14.23 19.63 25.39 0.39 0.42 0.46 9.73E-05 1.61E-04 2.45E-04 0.02 0.03 0.04 0.02 0.03 0.04 33.85 46.29 59.52 0.06 0.08 0.10 0.72 1.06 1.46 1.18E-03 1.75E-03 2.39E-03 Italy - Acinetobacter spp. ColRACI UTI - model 43 0.07 0.11 0.15 0.00 0.00 0.00 0.07 0.11 0.15 1.52E-03 2.03E-03 2.60E-03 1.14E-04 1.73E-04 2.46E-04 0.00 0.00 0.00 1.14E-04 1.73E-04 2.46E-04 38.43 51.93 67.30 0.06 0.09 0.11 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Acinetobacter spp. MDRACI BSI - model 31 34.64 39.69 45.40 234.99 293.11 357.00 272.48 332.93 399.65 2.83 3.40 4.04 0.06 0.07 0.07 0.39 0.48 0.59 0.45 0.55 0.66 81.79 97.49 116.87 0.13 0.16 0.19 14.06 19.41 25.80 0.02 0.03 0.04 Italy - Acinetobacter spp. MDRACI OTH - model 35 8.91E-03 0.01 0.02 0.00 0.00 0.00 8.91E-03 0.01 0.02 2.77E-03 3.73E-03 4.85E-03 1.46E-05 2.38E-05 3.79E-05 0.00 0.00 0.00 1.46E-05 2.38E-05 3.79E-05 2.53 3.91 5.53 4.16E-03 6.42E-03 9.09E-03 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Acinetobacter spp. MDRACI RESP - model 32 25.42 30.51 35.97 49.10 58.61 68.79 74.51 89.10 103.89 0.73 0.83 0.94 0.04 0.05 0.06 0.08 0.10 0.11 0.12 0.15 0.17 84.61 108.07 134.12 0.14 0.18 0.22 3.00 3.89 4.87 4.93E-03 6.40E-03 8.02E-03 Italy - Acinetobacter spp. MDRACI SSI - model 34 0.05 0.08 0.12 10.18 13.18 16.74 10.25 13.27 16.82 0.32 0.35 0.39 8.27E-05 1.30E-04 2.02E-04 0.02 0.02 0.03 0.02 0.02 0.03 27.51 37.71 48.35 0.05 0.06 0.08 0.82 1.17 1.56 1.35E-03 1.92E-03 2.56E-03 Italy - Acinetobacter spp. MDRACI UTI - model 33 0.06 0.08 0.12 0.00 0.00 0.00 0.06 0.08 0.12 1.55E-03 2.02E-03 2.60E-03 9.24E-05 1.38E-04 2.05E-04 0.00 0.00 0.00 9.24E-05 1.38E-04 2.05E-04 29.91 41.65 54.38 0.05 0.07 0.09 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Enterococcus faecalis and E. faecium VRE BSI - model 66 512.54 646.05 803.31 4,434.34 5,532.04 6,795.47 4,907.43 6,169.80 7,567.52 5.17 5.80 6.54 0.84 1.06 1.32 7.29 9.10 11.18 8.07 10.15 12.45 832.03 1,058.52 1,327.58 1.37 1.74 2.18 190.70 242.17 303.81 0.31 0.40 0.50 Italy - Enterococcus faecalis and E. faecium VRE OTH - model 70 1.33 1.84 2.59 0.00 0.00 0.00 1.33 1.84 2.59 1.30E-03 1.64E-03 2.06E-03 2.19E-03 3.02E-03 4.26E-03 0.00 0.00 0.00 2.19E-03 3.02E-03 4.26E-03 867.22 1,132.41 1,380.43 1.43 1.86 2.27 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Enterococcus faecalis and E. faecium VRE RESP - model 67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Enterococcus faecalis and E. faecium VRE SSI - model 69 2.07 3.06 4.51 473.65 654.30 864.14 475.33 658.36 868.32 0.40 0.45 0.50 3.40E-03 5.03E-03 7.42E-03 0.78 1.08 1.42 0.78 1.08 1.43 1,085.97 1,456.15 1,846.49 1.79 2.40 3.04 27.09 39.09 52.44 0.04 0.06 0.09 Italy - Enterococcus faecalis and E. faecium VRE UTI - model 68 0.71 1.01 1.43 0.00 0.00 0.00 0.71 1.01 1.43 1.49E-03 1.87E-03 2.30E-03 1.17E-03 1.67E-03 2.35E-03 0.00 0.00 0.00 1.17E-03 1.67E-03 2.35E-03 401.13 543.89 693.63 0.66 0.89 1.14 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Escherichia coli 3GCREC BSI - model 16 5,280.83 6,033.34 6,855.80 33,916.01 38,834.30 45,030.80 39,416.51 44,932.84 51,542.39 3.21 3.55 3.88 8.69 9.92 11.28 55.79 63.88 74.07 64.83 73.91 84.78 10,940.86 12,713.67 14,501.06 18.00 20.91 23.85 1,835.80 2,206.40 2,635.90 3.02 3.63 4.34 Italy - Escherichia coli 3GCREC OTH - model 20 10.58 14.76 20.40 0.00 0.00 0.00 10.58 14.76 20.40 2.73E-03 3.35E-03 4.16E-03 0.02 0.02 0.03 0.00 0.00 0.00 0.02 0.02 0.03 3,321.97 4,409.72 5,460.09 5.46 7.25 8.98 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Escherichia coli 3GCREC RESP - model 17 1,579.93 1,946.66 2,297.82 3,039.18 3,761.74 4,474.03 4,639.63 5,705.94 6,754.94 0.86 0.97 1.11 2.60 3.20 3.78 5.00 6.19 7.36 7.63 9.39 11.11 4,574.24 5,874.01 7,315.00 7.52 9.66 12.03 164.93 210.02 266.57 0.27 0.35 0.44 Italy - Escherichia coli 3GCREC SSI - model 19 20.77 29.23 40.60 4,473.94 5,520.13 6,643.01 4,500.55 5,547.99 6,686.25 0.37 0.40 0.44 0.03 0.05 0.07 7.36 9.08 10.93 7.40 9.13 11.00 11,238.00 13,789.50 16,615.15 18.48 22.68 27.33 332.12 409.11 507.38 0.55 0.67 0.83 Italy - Escherichia coli 3GCREC UTI - model 18 80.12 107.32 141.25 0.00 0.00 0.00 80.12 107.32 141.25 1.54E-03 1.95E-03 2.39E-03 0.13 0.18 0.23 0.00 0.00 0.00 0.13 0.18 0.23 45,379.41 55,392.06 65,661.04 74.64 91.11 108.00 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Escherichia coli CREC BSI - model 21 57.36 71.48 91.45 713.91 947.25 1,299.83 772.80 1,017.47 1,366.95 9.50 12.17 15.16 0.09 0.12 0.15 1.17 1.56 2.14 1.27 1.67 2.25 72.13 83.90 97.56 0.12 0.14 0.16 24.33 29.67 37.26 0.04 0.05 0.06 Italy - Escherichia coli CREC OTH - model 25 0.12 0.17 0.25 0.00 0.00 0.00 0.12 0.17 0.25 2.63E-03 3.49E-03 4.64E-03 1.97E-04 2.87E-04 4.13E-04 0.00 0.00 0.00 1.97E-04 2.87E-04 4.13E-04 39.61 50.03 62.05 0.07 0.08 0.10 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Escherichia coli CREC RESP - model 22 17.66 26.07 35.91 34.39 50.70 70.14 52.47 76.47 105.15 1.36 1.73 2.16 0.03 0.04 0.06 0.06 0.08 0.12 0.09 0.13 0.17 33.90 44.13 55.11 0.06 0.07 0.09 1.21 1.58 1.97 1.99E-03 2.61E-03 3.24E-03 Italy - Escherichia coli CREC SSI - model 24 0.15 0.22 0.30 35.56 45.01 55.11 35.74 45.19 54.88 0.40 0.44 0.49 2.41E-04 3.61E-04 4.97E-04 0.06 0.07 0.09 0.06 0.07 0.09 81.21 101.86 120.65 0.13 0.17 0.20 1.82 2.36 2.90 2.99E-03 3.89E-03 4.76E-03 Italy - Escherichia coli CREC UTI - model 23 0.54 0.75 1.02 0.00 0.00 0.00 0.54 0.75 1.02 1.60E-03 2.09E-03 2.64E-03 8.89E-04 1.24E-03 1.68E-03 0.00 0.00 0.00 8.89E-04 1.24E-03 1.68E-03 295.68 358.27 425.54 0.49 0.59 0.70 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Escherichia coli ColREC BSI - model 26 127.90 148.61 170.69 2,685.27 3,238.68 3,856.43 2,817.47 3,387.72 4,013.44 10.16 11.92 13.88 0.21 0.24 0.28 4.42 5.33 6.34 4.63 5.57 6.60 239.79 283.74 336.88 0.39 0.47 0.55 133.21 170.04 217.04 0.22 0.28 0.36 Italy - Escherichia coli ColREC OTH - model 30 0.41 0.58 0.87 0.00 0.00 0.00 0.41 0.58 0.87 2.62E-03 3.50E-03 4.75E-03 6.67E-04 9.56E-04 1.43E-03 0.00 0.00 0.00 6.67E-04 9.56E-04 1.43E-03 128.27 168.00 214.02 0.21 0.28 0.35 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Escherichia coli ColREC RESP - model 27 42.52 53.11 65.16 82.65 102.03 121.82 124.77 154.89 185.63 0.88 1.04 1.24 0.07 0.09 0.11 0.14 0.17 0.20 0.21 0.25 0.31 113.49 149.04 186.48 0.19 0.25 0.31 4.07 5.33 6.79 6.70E-03 8.77E-03 0.01 Italy - Escherichia coli ColREC SSI - model 29 0.50 0.72 1.07 109.58 137.05 165.61 110.05 137.65 166.49 0.36 0.40 0.45 8.25E-04 1.19E-03 1.76E-03 0.18 0.23 0.27 0.18 0.23 0.27 271.72 344.32 418.12 0.45 0.57 0.69 7.55 10.15 12.83 0.01 0.02 0.02 Italy - Escherichia coli ColREC UTI - model 28 1.79 2.47 3.48 0.00 0.00 0.00 1.79 2.47 3.48 1.58E-03 2.07E-03 2.66E-03 2.95E-03 4.07E-03 5.72E-03 0.00 0.00 0.00 2.95E-03 4.07E-03 5.72E-03 987.49 1,204.79 1,479.19 1.62 1.98 2.43 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Klebsiella pneumoniae 3GCRKP BSI - model 1 2,017.76 2,265.71 2,548.33 12,844.56 14,249.69 15,951.80 14,921.13 16,538.30 18,471.74 4.81 5.17 5.58 3.32 3.73 4.19 21.13 23.44 26.24 24.54 27.20 30.38 2,883.16 3,197.63 3,536.19 4.74 5.26 5.82 476.53 533.96 591.81 0.78 0.88 0.97 Italy - Klebsiella pneumoniae 3GCRKP OTH - model 5 3.43 4.42 5.72 0.00 0.00 0.00 3.43 4.42 5.72 2.75E-03 3.36E-03 4.03E-03 5.64E-03 7.27E-03 9.40E-03 0.00 0.00 0.00 5.64E-03 7.27E-03 9.40E-03 1,123.28 1,325.62 1,545.42 1.85 2.18 2.54 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Klebsiella pneumoniae 3GCRKP RESP - model 2 1,198.12 1,414.46 1,641.01 2,358.44 2,747.63 3,202.52 3,567.82 4,162.37 4,812.36 1.31 1.46 1.64 1.97 2.33 2.70 3.88 4.52 5.27 5.87 6.85 7.92 2,452.03 2,853.01 3,281.20 4.03 4.69 5.40 87.42 102.67 118.57 0.14 0.17 0.20 Italy - Klebsiella pneumoniae 3GCRKP SSI - model 4 2.12 2.83 3.75 490.73 587.43 695.25 493.29 590.49 698.51 0.41 0.45 0.48 3.48E-03 4.65E-03 6.17E-03 0.81 0.97 1.14 0.81 0.97 1.15 1,125.84 1,322.81 1,581.85 1.85 2.18 2.60 26.83 32.94 40.34 0.04 0.05 0.07 Italy - Klebsiella pneumoniae 3GCRKP UTI - model 3 5.99 7.62 9.56 0.00 0.00 0.00 5.99 7.62 9.56 1.63E-03 1.96E-03 2.33E-03 9.85E-03 0.01 0.02 0.00 0.00 0.00 9.85E-03 0.01 0.02 3,357.46 3,872.93 4,440.03 5.52 6.37 7.30 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Klebsiella pneumoniae CRKP BSI - model 6 2,136.76 2,463.07 2,803.93 27,362.27 32,172.48 37,565.39 29,592.92 34,647.55 40,226.68 8.22 9.27 10.37 3.51 4.05 4.61 45.01 52.92 61.79 48.68 56.99 66.17 3,237.93 3,748.65 4,208.80 5.33 6.17 6.92 1,110.93 1,335.34 1,579.12 1.83 2.20 2.60 Italy - Klebsiella pneumoniae CRKP OTH - model 10 4.80 6.46 8.56 0.00 0.00 0.00 4.80 6.46 8.56 2.82E-03 3.50E-03 4.31E-03 7.89E-03 0.01 0.01 0.00 0.00 0.00 7.89E-03 0.01 0.01 1,468.12 1,863.37 2,227.63 2.41 3.06 3.66 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Klebsiella pneumoniae CRKP RESP - model 7 610.89 756.72 899.22 1,187.56 1,464.67 1,760.91 1,791.00 2,220.40 2,648.78 1.19 1.32 1.46 1.00 1.24 1.48 1.95 2.41 2.90 2.95 3.65 4.36 1,371.24 1,684.07 2,011.76 2.26 2.77 3.31 49.00 60.45 72.71 0.08 0.10 0.12 Italy - Klebsiella pneumoniae CRKP SSI - model 9 1.77 2.49 3.53 394.51 512.17 649.94 395.74 514.50 653.13 0.40 0.44 0.48 2.91E-03 4.10E-03 5.81E-03 0.65 0.84 1.07 0.65 0.85 1.07 939.57 1,170.50 1,427.97 1.55 1.93 2.35 22.03 29.32 37.79 0.04 0.05 0.06 Italy - Klebsiella pneumoniae CRKP UTI - model 8 3.63 4.88 6.52 0.00 0.00 0.00 3.63 4.88 6.52 1.67E-03 2.07E-03 2.53E-03 5.96E-03 8.03E-03 0.01 0.00 0.00 0.00 5.96E-03 8.03E-03 0.01 1,924.96 2,373.88 2,841.61 3.17 3.90 4.67 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Klebsiella pneumoniae ColRKP BSI - model 11 991.41 1,138.24 1,317.89 21,368.55 25,338.32 29,977.40 22,417.38 26,478.49 31,229.21 13.91 16.05 18.21 1.63 1.87 2.17 35.15 41.68 49.31 36.87 43.55 51.37 1,461.83 1,652.59 1,872.91 2.40 2.72 3.08 832.65 1,000.39 1,181.06 1.37 1.65 1.94 Italy - Klebsiella pneumoniae ColRKP OTH - model 15 2.05 2.85 3.74 0.00 0.00 0.00 2.05 2.85 3.74 2.78E-03 3.52E-03 4.35E-03 3.37E-03 4.68E-03 6.16E-03 0.00 0.00 0.00 3.37E-03 4.68E-03 6.16E-03 643.51 809.76 989.66 1.06 1.33 1.63 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Klebsiella pneumoniae ColRKP RESP - model 12 269.06 346.42 422.49 530.85 670.22 821.16 804.10 1,017.02 1,233.17 1.25 1.38 1.55 0.44 0.57 0.69 0.87 1.10 1.35 1.32 1.67 2.03 571.23 736.52 899.87 0.94 1.21 1.48 20.51 26.64 32.39 0.03 0.04 0.05 Italy - Klebsiella pneumoniae ColRKP SSI - model 14 0.78 1.11 1.48 174.51 225.45 290.36 175.18 226.67 292.26 0.40 0.44 0.48 1.28E-03 1.82E-03 2.44E-03 0.29 0.37 0.48 0.29 0.37 0.48 400.84 516.04 639.40 0.66 0.85 1.05 9.00 12.21 15.91 0.01 0.02 0.03 Italy - Klebsiella pneumoniae ColRKP UTI - model 13 1.63 2.15 2.85 0.00 0.00 0.00 1.63 2.15 2.85 1.69E-03 2.10E-03 2.56E-03 2.68E-03 3.54E-03 4.69E-03 0.00 0.00 0.00 2.68E-03 3.54E-03 4.69E-03 840.01 1,040.01 1,237.39 1.38 1.71 2.04 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Pseudomonas aeruginosa CRPA BSI - model 51 1,284.24 1,467.02 1,669.36 10,260.64 12,409.92 15,179.89 11,637.31 13,870.39 16,740.78 6.11 7.15 8.28 2.11 2.41 2.75 16.88 20.41 24.97 19.14 22.81 27.54 1,696.83 1,947.55 2,209.51 2.79 3.20 3.63 358.12 441.32 550.71 0.59 0.73 0.91 Italy - Pseudomonas aeruginosa CRPA OTH - model 55 2.83 3.73 4.78 0.00 0.00 0.00 2.83 3.73 4.78 3.06E-03 3.65E-03 4.34E-03 4.66E-03 6.14E-03 7.87E-03 0.00 0.00 0.00 4.66E-03 6.14E-03 7.87E-03 832.04 1,024.92 1,219.63 1.37 1.69 2.01 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Pseudomonas aeruginosa CRPA RESP - model 52 3,203.50 3,791.26 4,388.13 10,804.56 13,474.68 16,212.37 14,195.10 17,287.90 20,513.42 2.08 2.37 2.71 5.27 6.24 7.22 17.77 22.16 26.67 23.35 28.44 33.74 6,223.54 7,282.21 8,471.98 10.24 11.98 13.94 388.05 478.41 597.99 0.64 0.79 0.98 Italy - Pseudomonas aeruginosa CRPA SSI - model 54 2.18 2.97 4.03 486.79 615.97 751.50 489.14 618.84 756.98 0.41 0.45 0.49 3.58E-03 4.88E-03 6.63E-03 0.80 1.01 1.24 0.80 1.02 1.25 1,123.48 1,386.63 1,655.40 1.85 2.28 2.72 23.29 31.10 38.22 0.04 0.05 0.06 Italy - Pseudomonas aeruginosa CRPA UTI - model 53 3.96 5.30 6.61 0.00 0.00 0.00 3.96 5.30 6.61 1.72E-03 2.05E-03 2.40E-03 6.51E-03 8.71E-03 0.01 0.00 0.00 0.00 6.51E-03 8.71E-03 0.01 2,122.87 2,566.08 3,087.21 3.49 4.22 5.08 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Pseudomonas aeruginosa ColRPA BSI - model 56 51.67 63.06 78.79 386.47 536.22 754.12 441.84 599.94 828.01 5.83 7.67 9.69 0.08 0.10 0.13 0.64 0.88 1.24 0.73 0.99 1.36 65.69 78.88 95.60 0.11 0.13 0.16 13.03 18.13 24.67 0.02 0.03 0.04 Italy - Pseudomonas aeruginosa ColRPA OTH - model 60 0.11 0.15 0.22 0.00 0.00 0.00 0.11 0.15 0.22 2.83E-03 3.71E-03 4.67E-03 1.76E-04 2.54E-04 3.65E-04 0.00 0.00 0.00 1.76E-04 2.54E-04 3.65E-04 31.05 41.80 55.07 0.05 0.07 0.09 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Pseudomonas aeruginosa ColRPA RESP - model 57 126.92 165.07 209.92 421.91 577.01 817.53 559.35 741.92 1,020.73 2.02 2.52 3.27 0.21 0.27 0.35 0.69 0.95 1.34 0.92 1.22 1.68 232.08 298.01 366.83 0.38 0.49 0.60 14.13 19.42 26.38 0.02 0.03 0.04 Italy - Pseudomonas aeruginosa ColRPA SSI - model 59 0.07 0.12 0.18 18.61 26.78 34.66 18.69 26.90 34.81 0.43 0.47 0.51 1.23E-04 1.98E-04 3.04E-04 0.03 0.04 0.06 0.03 0.04 0.06 40.64 56.99 71.92 0.07 0.09 0.12 0.82 1.26 1.74 1.35E-03 2.07E-03 2.85E-03 Italy - Pseudomonas aeruginosa ColRPA UTI - model 58 0.15 0.21 0.30 0.00 0.00 0.00 0.15 0.21 0.30 1.55E-03 2.04E-03 2.61E-03 2.47E-04 3.53E-04 4.98E-04 0.00 0.00 0.00 2.47E-04 3.53E-04 4.98E-04 79.37 105.36 134.38 0.13 0.17 0.22 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Pseudomonas aeruginosa MDRPA BSI - model 46 124.83 149.52 175.81 886.48 1,158.77 1,465.22 1,024.93 1,310.93 1,628.30 3.84 4.72 5.66 0.21 0.25 0.29 1.46 1.91 2.41 1.69 2.16 2.68 234.50 277.04 320.33 0.39 0.46 0.53 43.98 58.21 74.70 0.07 0.10 0.12 Italy - Pseudomonas aeruginosa MDRPA OTH - model 50 0.38 0.55 0.73 0.00 0.00 0.00 0.38 0.55 0.73 3.03E-03 3.75E-03 4.49E-03 6.30E-04 9.04E-04 1.21E-03 0.00 0.00 0.00 6.30E-04 9.04E-04 1.21E-03 110.41 146.85 181.71 0.18 0.24 0.30 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Pseudomonas aeruginosa MDRPA RESP - model 47 316.54 388.27 464.35 991.37 1,301.30 1,643.63 1,323.89 1,688.87 2,098.57 1.33 1.61 1.91 0.52 0.64 0.76 1.63 2.14 2.70 2.18 2.78 3.45 854.91 1,044.22 1,256.83 1.41 1.72 2.07 49.40 64.86 82.91 0.08 0.11 0.14 Italy - Pseudomonas aeruginosa MDRPA SSI - model 49 0.28 0.42 0.59 56.98 72.80 90.07 57.35 73.20 90.57 0.33 0.37 0.40 4.55E-04 6.94E-04 9.77E-04 0.09 0.12 0.15 0.09 0.12 0.15 155.17 198.69 248.53 0.26 0.33 0.41 3.68 5.12 6.53 6.06E-03 8.42E-03 0.01 Italy - Pseudomonas aeruginosa MDRPA UTI - model 48 0.55 0.75 0.98 0.00 0.00 0.00 0.55 0.75 0.98 1.64E-03 2.05E-03 2.50E-03 9.10E-04 1.23E-03 1.61E-03 0.00 0.00 0.00 9.10E-04 1.23E-03 1.61E-03 295.04 369.46 446.53 0.49 0.61 0.73 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Staphylococcus aureus MRSA BSI - model 61 3,754.16 4,226.31 4,746.59 25,666.29 28,364.97 31,346.41 29,534.31 32,604.82 35,956.78 4.03 4.33 4.69 6.18 6.95 7.81 42.22 46.66 51.56 48.58 53.63 59.14 6,717.11 7,520.15 8,359.43 11.05 12.37 13.75 1,199.90 1,352.58 1,506.38 1.97 2.22 2.48 Italy - Staphylococcus aureus MRSA OTH - model 65 27.96 36.53 47.18 0.00 0.00 0.00 27.96 36.53 47.18 2.63E-03 3.24E-03 3.92E-03 0.05 0.06 0.08 0.00 0.00 0.00 0.05 0.06 0.08 9,617.43 11,343.18 13,231.13 15.82 18.66 21.76 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Staphylococcus aureus MRSA RESP - model 62 3,853.80 4,479.30 5,261.58 7,545.08 8,694.19 10,007.97 11,467.00 13,189.14 15,179.54 1.04 1.15 1.27 6.34 7.37 8.65 12.41 14.30 16.46 18.86 21.69 24.97 9,687.17 11,487.03 13,302.64 15.93 18.89 21.88 349.21 414.08 482.85 0.57 0.68 0.79 Italy - Staphylococcus aureus MRSA SSI - model 64 19.82 26.88 34.57 4,503.78 5,327.85 6,217.80 4,533.08 5,354.04 6,240.04 0.40 0.43 0.46 0.03 0.04 0.06 7.41 8.76 10.23 7.46 8.81 10.26 10,751.95 12,569.28 14,579.36 17.69 20.67 23.98 295.16 356.43 425.53 0.49 0.59 0.70 Italy - Staphylococcus aureus MRSA UTI - model 63 2.70 3.64 5.14 0.00 0.00 0.00 2.70 3.64 5.14 1.50E-03 1.88E-03 2.30E-03 4.44E-03 5.99E-03 8.46E-03 0.00 0.00 0.00 4.44E-03 5.99E-03 8.46E-03 1,550.54 1,958.29 2,440.03 2.55 3.22 4.01 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Streptococcus pneumoniae PMRSP BSI - model 76 23.37 30.00 39.26 169.83 204.63 248.09 195.79 234.81 285.56 5.96 6.74 7.66 0.04 0.05 0.06 0.28 0.34 0.41 0.32 0.39 0.47 30.67 34.86 39.35 0.05 0.06 0.06 5.43 6.27 7.28 8.93E-03 0.01 0.01 Italy - Streptococcus pneumoniae PMRSP OTH - model 80 0.02 0.02 0.04 0.00 0.00 0.00 0.02 0.02 0.04 1.25E-03 1.95E-03 2.81E-03 2.54E-05 4.03E-05 6.47E-05 0.00 0.00 0.00 2.54E-05 4.03E-05 6.47E-05 9.92 12.81 16.88 0.02 0.02 0.03 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Streptococcus pneumoniae PMRSP RESP - model 77 53.67 83.93 148.80 108.49 163.70 274.20 165.65 248.04 415.09 1.36 1.76 2.23 0.09 0.14 0.24 0.18 0.27 0.45 0.27 0.41 0.68 100.57 142.65 208.55 0.17 0.23 0.34 3.55 5.15 7.57 5.84E-03 8.47E-03 0.01 Italy - Streptococcus pneumoniae PMRSP SSI - model 79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Streptococcus pneumoniae PMRSP UTI - model 78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Streptococcus pneumoniae PRSP BSI - model 71 51.58 58.29 66.73 357.24 396.75 443.31 409.58 455.29 507.94 7.70 8.22 8.82 0.08 0.10 0.11 0.59 0.65 0.73 0.67 0.75 0.84 51.59 55.41 59.67 0.08 0.09 0.10 9.21 9.97 10.82 0.02 0.02 0.02 Italy - Streptococcus pneumoniae PRSP OTH - model 75 0.03 0.04 0.05 0.00 0.00 0.00 0.03 0.04 0.05 1.57E-03 1.96E-03 2.38E-03 5.21E-05 6.64E-05 8.64E-05 0.00 0.00 0.00 5.21E-05 6.64E-05 8.64E-05 18.16 20.71 24.04 0.03 0.03 0.04 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Streptococcus pneumoniae PRSP RESP - model 72 131.40 169.09 224.70 257.54 333.40 436.49 388.99 502.30 655.33 1.89 2.16 2.55 0.22 0.28 0.37 0.42 0.55 0.72 0.64 0.83 1.08 192.94 232.19 284.46 0.32 0.38 0.47 6.88 8.37 10.35 0.01 0.01 0.02 Italy - Streptococcus pneumoniae PRSP SSI - model 74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Italy - Streptococcus pneumoniae PRSP UTI - model 73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total (Median & 95% UIs) 32,056.11 37,297.16 43,058.64 199,820.89 235,165.11 275,453.79 233,009.16 272,622.93 317,040.02 52.73 61.35 70.83 328.68 386.81 453.08 383.27 448.43 521.49 167,809.32 201,583.57 237,207.25 276.02 331.58 390.17 8,951.28 10,762.23 12,817.23 14.72 17.70 21.08 Total (average) - 387.76 449.25 201,845.48 332.01 10,785.46 17.74 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 37,384.89 235,742.11 273,127.00 - 61.49 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 Infection Colistin resistant Acinetobacter spp. 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Acinetobacter spp. (excluding those resistant to colistin) 75.41 83.58 92.50 372.67 449.84 527.43 450.90 533.16 617.38 6.97 8.02 9.06 2.58 2.86 3.17 12.76 15.40 18.05 15.44 18.25 21.13 176.55 196.51 217.08 6.04 6.73 7.43 14.17 17.27 20.14 0.49 0.59 0.69 Aminoglycosides and fluoroquinolones resistant Acinetobacter spp. (excluding those resistant to colistin and/or carbapenem) 6.35 7.46 8.65 29.41 39.04 48.56 36.27 46.49 56.61 3.75 4.64 5.50 0.22 0.26 0.30 1.01 1.34 1.66 1.24 1.59 1.94 25.51 29.95 34.40 0.87 1.03 1.18 1.97 2.58 3.19 0.07 0.09 0.11 Vancomycin resistant Enterococci (E. faecalis and E. faecium ) 6.50 8.01 9.90 62.67 75.69 91.56 69.22 83.77 101.30 4.13 4.71 5.34 0.22 0.27 0.34 2.15 2.59 3.13 2.37 2.87 3.47 53.76 68.52 84.16 1.84 2.35 2.88 3.74 4.67 5.71 0.13 0.16 0.20 Colistin resistant Escherichia coli 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Escherichia coli (excluding those resistant to colistin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Third-generation cephalosporin resistant Escherichia coli (excluding those resistant to colistin and/or carbapenem) 70.49 78.95 88.64 410.82 469.36 522.30 490.04 547.94 606.75 5.23 5.66 6.12 2.41 2.70 3.03 14.06 16.07 17.88 16.77 18.76 20.77 687.20 772.65 858.82 23.52 26.45 29.40 20.74 23.66 26.60 0.71 0.81 0.91 Colistin resistant Klebsiella pneumoniae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Klebsiella pneumoniae (excluding those resistant to colistin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Third-generation cephalosporin resistant Klebsiella pneumoniae (excluding those resistant to colistin and/or carbapenem) 78.63 86.62 95.73 385.44 415.69 447.15 466.56 502.27 539.45 4.97 5.21 5.46 2.69 2.97 3.28 13.19 14.23 15.31 15.97 17.19 18.47 359.04 399.21 438.45 12.29 13.67 15.01 20.12 21.80 23.62 0.69 0.75 0.81 Colistin resistant Pseudomonas aeruginosa 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Pseudomonas aeruginosa (excluding those resistant to colistin) 18.27 21.83 26.01 79.91 109.92 143.95 99.55 131.85 167.91 4.84 6.28 7.68 0.63 0.75 0.89 2.74 3.76 4.93 3.41 4.51 5.75 78.18 94.11 110.63 2.68 3.22 3.79 4.70 6.45 8.38 0.16 0.22 0.29 Pseudomonas aeruginosa resistant to three or more antimicrobial groups (excluding those resistant to colistin and/or carbapenem) 5.48 7.45 9.86 21.67 35.12 53.40 27.94 42.47 61.99 4.96 7.43 10.15 0.19 0.26 0.34 0.74 1.20 1.83 0.96 1.45 2.12 19.59 25.71 31.80 0.67 0.88 1.09 1.08 1.63 2.30 0.04 0.06 0.08 Methicillin resistant Staphylococcus aureus 38.13 42.24 46.77 187.18 202.33 217.27 226.38 244.80 262.53 5.62 5.90 6.18 1.31 1.45 1.60 6.41 6.93 7.44 7.75 8.38 8.99 194.32 213.15 231.73 6.65 7.30 7.93 9.20 9.99 10.79 0.32 0.34 0.37 Penicillin and macrolides resistant Streptococcus pneumoniae (excluding those only resistant to penicillin) 1.04 1.38 1.93 3.72 4.46 5.61 4.91 5.83 7.46 3.04 3.36 3.69 0.04 0.05 0.07 0.13 0.15 0.19 0.17 0.20 0.26 4.67 5.62 7.40 0.16 0.19 0.25 0.29 0.35 0.44 0.01 0.01 0.01 Penicillin tesistant Streptococcus pneumoniae (excluding those resistant to macrolides) 8.88 10.95 14.00 31.22 35.83 42.22 40.73 46.77 55.54 6.21 6.68 7.17 0.30 0.37 0.48 1.07 1.23 1.45 1.39 1.60 1.90 19.62 22.78 27.62 0.67 0.78 0.95 1.22 1.40 1.66 0.04 0.05 0.06 Total 309.17 348.47 394.00 1,584.69 1,837.29 2,099.45 1,912.49 2,185.36 2,476.93 10.58 11.93 13.49 54.25 62.89 71.87 65.47 74.81 84.79 1,618.44 1,828.20 2,042.07 55.40 62.58 69.90 77.23 89.81 102.83 2.64 3.07 3.52 Model Lithuania - Acinetobacter spp. CRACI BSI - model 36 43.53 47.63 52.27 300.84 368.71 436.88 346.39 416.10 486.59 5.19 6.12 7.05 1.49 1.63 1.79 10.30 12.62 14.96 11.86 14.24 16.66 63.88 67.89 72.07 2.19 2.32 2.47 11.32 14.03 16.49 0.39 0.48 0.56 Lithuania - Acinetobacter spp. CRACI OTH - model 40 6.43E-03 8.95E-03 0.01 0.00 0.00 0.00 6.43E-03 8.95E-03 0.01 3.02E-03 3.75E-03 4.49E-03 2.20E-04 3.06E-04 4.19E-04 0.00 0.00 0.00 2.20E-04 3.06E-04 4.19E-04 1.81 2.42 3.05 0.06 0.08 0.10 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Acinetobacter spp. CRACI RESP - model 37 31.79 35.83 40.08 62.58 69.88 77.33 95.15 105.70 117.45 1.35 1.43 1.53 1.09 1.23 1.37 2.14 2.39 2.65 3.26 3.62 4.02 66.26 73.68 81.23 2.27 2.52 2.78 2.39 2.66 2.96 0.08 0.09 0.10 Lithuania - Acinetobacter spp. CRACI SSI - model 39 0.04 0.05 0.07 9.26 11.25 13.21 9.30 11.30 13.26 0.43 0.45 0.48 1.40E-03 1.80E-03 2.45E-03 0.32 0.38 0.45 0.32 0.39 0.45 21.18 24.87 28.61 0.73 0.85 0.98 0.46 0.58 0.69 0.02 0.02 0.02 Lithuania - Acinetobacter spp. CRACI UTI - model 38 0.04 0.06 0.07 0.00 0.00 0.00 0.04 0.06 0.07 1.64E-03 2.05E-03 2.46E-03 1.51E-03 1.94E-03 2.45E-03 0.00 0.00 0.00 1.51E-03 1.94E-03 2.45E-03 23.42 27.65 32.12 0.80 0.95 1.10 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Acinetobacter spp. ColRACI BSI - model 41 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Acinetobacter spp. ColRACI OTH - model 45 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Acinetobacter spp. ColRACI RESP - model 42 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Acinetobacter spp. ColRACI SSI - model 44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Acinetobacter spp. ColRACI UTI - model 43 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Acinetobacter spp. MDRACI BSI - model 31 3.68 4.25 4.84 23.24 31.58 39.77 27.45 35.83 44.14 2.67 3.45 4.19 0.13 0.15 0.17 0.80 1.08 1.36 0.94 1.23 1.51 9.53 10.38 11.29 0.33 0.36 0.39 1.55 2.06 2.58 0.05 0.07 0.09 Lithuania - Acinetobacter spp. MDRACI OTH - model 35 8.35E-04 1.35E-03 2.04E-03 0.00 0.00 0.00 8.35E-04 1.35E-03 2.04E-03 2.74E-03 3.74E-03 4.83E-03 2.86E-05 4.62E-05 6.99E-05 0.00 0.00 0.00 2.86E-05 4.62E-05 6.99E-05 0.24 0.37 0.52 8.26E-03 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Acinetobacter spp. MDRACI RESP - model 32 2.66 3.19 3.77 5.15 6.13 7.17 7.80 9.31 10.83 0.75 0.83 0.92 0.09 0.11 0.13 0.18 0.21 0.25 0.27 0.32 0.37 9.57 11.23 12.92 0.33 0.38 0.44 0.34 0.41 0.47 0.01 0.01 0.02 Lithuania - Acinetobacter spp. MDRACI SSI - model 34 5.02E-03 7.96E-03 0.01 1.01 1.33 1.62 1.02 1.34 1.63 0.32 0.35 0.38 1.72E-04 2.73E-04 4.04E-04 0.03 0.05 0.06 0.03 0.05 0.06 2.96 3.79 4.55 0.10 0.13 0.16 0.08 0.11 0.14 2.85E-03 3.89E-03 4.76E-03 Lithuania - Acinetobacter spp. MDRACI UTI - model 33 5.54E-03 8.44E-03 0.01 0.00 0.00 0.00 5.54E-03 8.44E-03 0.01 1.51E-03 2.05E-03 2.67E-03 1.90E-04 2.89E-04 4.13E-04 0.00 0.00 0.00 1.90E-04 2.89E-04 4.13E-04 3.21 4.19 5.12 0.11 0.14 0.18 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Enterococcus faecalis and E. faecium VRE BSI - model 66 6.43 7.92 9.76 55.91 67.02 80.90 62.39 75.01 90.51 3.80 4.34 4.93 0.22 0.27 0.33 1.91 2.29 2.77 2.14 2.57 3.10 14.14 17.35 21.12 0.48 0.59 0.72 3.23 3.97 4.83 0.11 0.14 0.17 Lithuania - Enterococcus faecalis and E. faecium VRE OTH - model 70 0.02 0.03 0.04 0.00 0.00 0.00 0.02 0.03 0.04 1.27E-03 1.63E-03 2.11E-03 7.20E-04 1.03E-03 1.43E-03 0.00 0.00 0.00 7.20E-04 1.03E-03 1.43E-03 14.37 18.50 22.59 0.49 0.63 0.77 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Enterococcus faecalis and E. faecium VRE RESP - model 67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Enterococcus faecalis and E. faecium VRE SSI - model 69 0.03 0.05 0.08 6.75 8.67 10.66 6.80 8.72 10.72 0.33 0.37 0.40 1.15E-03 1.73E-03 2.57E-03 0.23 0.30 0.36 0.23 0.30 0.37 18.56 23.85 29.49 0.64 0.82 1.01 0.51 0.70 0.88 0.02 0.02 0.03 Lithuania - Enterococcus faecalis and E. faecium VRE UTI - model 68 0.01 0.02 0.02 0.00 0.00 0.00 0.01 0.02 0.02 1.45E-03 1.86E-03 2.40E-03 4.04E-04 5.61E-04 7.95E-04 0.00 0.00 0.00 4.04E-04 5.61E-04 7.95E-04 6.69 8.82 10.95 0.23 0.30 0.37 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Escherichia coli 3GCREC BSI - model 16 54.09 59.53 65.80 338.61 385.53 425.87 401.40 444.65 487.61 3.79 4.11 4.44 1.85 2.04 2.25 11.59 13.20 14.58 13.74 15.22 16.69 100.74 108.44 116.73 3.45 3.71 4.00 16.64 18.79 20.93 0.57 0.64 0.72 Lithuania - Escherichia coli 3GCREC OTH - model 20 0.09 0.12 0.15 0.00 0.00 0.00 0.09 0.12 0.15 2.72E-03 3.33E-03 4.01E-03 3.06E-03 4.10E-03 5.24E-03 0.00 0.00 0.00 3.06E-03 4.10E-03 5.24E-03 28.96 35.94 42.35 0.99 1.23 1.45 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Escherichia coli 3GCREC RESP - model 17 15.39 18.14 21.22 30.04 35.12 41.18 45.44 53.26 62.26 1.03 1.13 1.23 0.53 0.62 0.73 1.03 1.20 1.41 1.56 1.82 2.13 40.17 47.64 55.61 1.38 1.63 1.90 1.41 1.71 2.04 0.05 0.06 0.07 Lithuania - Escherichia coli 3GCREC SSI - model 19 0.18 0.24 0.32 42.17 48.71 55.26 42.37 49.00 55.59 0.41 0.43 0.45 6.21E-03 8.26E-03 0.01 1.44 1.67 1.89 1.45 1.68 1.90 99.96 114.60 129.65 3.42 3.92 4.44 2.68 3.16 3.63 0.09 0.11 0.12 Lithuania - Escherichia coli 3GCREC UTI - model 18 0.74 0.91 1.14 0.00 0.00 0.00 0.74 0.91 1.14 1.59E-03 1.96E-03 2.37E-03 0.03 0.03 0.04 0.00 0.00 0.00 0.03 0.03 0.04 417.36 466.02 514.48 14.29 15.95 17.61 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Escherichia coli CREC BSI - model 21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Escherichia coli CREC OTH - model 25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Escherichia coli CREC RESP - model 22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Escherichia coli CREC SSI - model 24 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Escherichia coli CREC UTI - model 23 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Escherichia coli ColREC BSI - model 26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Escherichia coli ColREC OTH - model 30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Escherichia coli ColREC RESP - model 27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Escherichia coli ColREC SSI - model 29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Escherichia coli ColREC UTI - model 28 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Klebsiella pneumoniae 3GCRKP BSI - model 1 49.51 53.84 58.50 315.84 336.81 358.98 367.34 390.54 414.61 3.60 3.75 3.90 1.69 1.84 2.00 10.81 11.53 12.29 12.57 13.37 14.19 98.69 104.40 109.89 3.38 3.57 3.76 16.30 17.43 18.70 0.56 0.60 0.64 Lithuania - Klebsiella pneumoniae 3GCRKP OTH - model 5 0.11 0.14 0.18 0.00 0.00 0.00 0.11 0.14 0.18 2.70E-03 3.34E-03 4.13E-03 3.68E-03 4.71E-03 6.05E-03 0.00 0.00 0.00 3.68E-03 4.71E-03 6.05E-03 35.91 41.49 46.89 1.23 1.42 1.61 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Klebsiella pneumoniae 3GCRKP RESP - model 2 28.76 32.32 36.64 55.64 62.51 69.66 84.87 94.91 105.71 0.99 1.06 1.13 0.98 1.11 1.25 1.90 2.14 2.38 2.91 3.25 3.62 80.42 90.02 100.14 2.75 3.08 3.43 2.87 3.24 3.63 0.10 0.11 0.12 Lithuania - Klebsiella pneumoniae 3GCRKP SSI - model 4 0.06 0.09 0.12 13.96 16.36 18.52 14.05 16.45 18.65 0.38 0.40 0.42 2.17E-03 2.93E-03 3.94E-03 0.48 0.56 0.63 0.48 0.56 0.64 35.60 40.91 46.12 1.22 1.40 1.58 0.95 1.13 1.29 0.03 0.04 0.04 Lithuania - Klebsiella pneumoniae 3GCRKP UTI - model 3 0.18 0.24 0.30 0.00 0.00 0.00 0.18 0.24 0.30 1.59E-03 1.96E-03 2.36E-03 6.32E-03 8.19E-03 0.01 0.00 0.00 0.00 6.32E-03 8.19E-03 0.01 108.42 122.39 135.41 3.71 4.19 4.64 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Klebsiella pneumoniae CRKP BSI - model 6 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Klebsiella pneumoniae CRKP OTH - model 10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Klebsiella pneumoniae CRKP RESP - model 7 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Klebsiella pneumoniae CRKP SSI - model 9 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Klebsiella pneumoniae CRKP UTI - model 8 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Klebsiella pneumoniae ColRKP BSI - model 11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Klebsiella pneumoniae ColRKP OTH - model 15 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Klebsiella pneumoniae ColRKP RESP - model 12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Klebsiella pneumoniae ColRKP SSI - model 14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Klebsiella pneumoniae ColRKP UTI - model 13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Pseudomonas aeruginosa CRPA BSI - model 51 5.24 6.12 7.11 36.82 51.40 67.53 42.52 57.49 74.21 3.28 4.40 5.50 0.18 0.21 0.24 1.26 1.76 2.31 1.46 1.97 2.54 11.82 13.09 14.69 0.40 0.45 0.50 2.17 2.99 3.88 0.07 0.10 0.13 Lithuania - Pseudomonas aeruginosa CRPA OTH - model 55 0.02 0.02 0.03 0.00 0.00 0.00 0.02 0.02 0.03 2.78E-03 3.66E-03 4.63E-03 5.83E-04 8.20E-04 1.17E-03 0.00 0.00 0.00 5.83E-04 8.20E-04 1.17E-03 5.06 6.62 8.29 0.17 0.23 0.28 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Pseudomonas aeruginosa CRPA RESP - model 52 12.97 15.63 18.79 40.35 54.84 71.84 54.25 70.61 89.02 1.17 1.46 1.74 0.44 0.54 0.64 1.38 1.88 2.46 1.86 2.42 3.05 40.80 48.35 56.02 1.40 1.66 1.92 2.34 3.20 4.17 0.08 0.11 0.14 Lithuania - Pseudomonas aeruginosa CRPA SSI - model 54 0.01 0.02 0.03 2.74 3.68 4.59 2.74 3.70 4.60 0.38 0.41 0.44 4.21E-04 6.58E-04 9.73E-04 0.09 0.13 0.16 0.09 0.13 0.16 6.81 9.01 11.18 0.23 0.31 0.38 0.19 0.26 0.33 6.38E-03 8.87E-03 0.01 Lithuania - Pseudomonas aeruginosa CRPA UTI - model 53 0.02 0.03 0.05 0.00 0.00 0.00 0.02 0.03 0.05 1.58E-03 2.04E-03 2.56E-03 8.39E-04 1.17E-03 1.61E-03 0.00 0.00 0.00 8.39E-04 1.17E-03 1.61E-03 13.69 17.04 20.45 0.47 0.58 0.70 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Pseudomonas aeruginosa ColRPA BSI - model 56 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Pseudomonas aeruginosa ColRPA OTH - model 60 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Pseudomonas aeruginosa ColRPA RESP - model 57 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Pseudomonas aeruginosa ColRPA SSI - model 59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Pseudomonas aeruginosa ColRPA UTI - model 58 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Pseudomonas aeruginosa MDRPA BSI - model 46 1.65 2.09 2.72 9.63 16.49 25.03 11.67 18.59 27.23 3.28 5.25 7.25 0.06 0.07 0.09 0.33 0.56 0.86 0.40 0.64 0.93 3.04 3.57 4.13 0.10 0.12 0.14 0.49 0.75 1.09 0.02 0.03 0.04 Lithuania - Pseudomonas aeruginosa MDRPA OTH - model 50 3.86E-03 6.73E-03 0.01 0.00 0.00 0.00 3.86E-03 6.73E-03 0.01 2.51E-03 3.73E-03 5.15E-03 1.32E-04 2.30E-04 3.67E-04 0.00 0.00 0.00 1.32E-04 2.30E-04 3.67E-04 1.23 1.81 2.41 0.04 0.06 0.08 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Pseudomonas aeruginosa MDRPA RESP - model 47 3.82 5.34 7.11 11.33 17.57 26.97 15.55 22.80 33.32 1.28 1.74 2.42 0.13 0.18 0.24 0.39 0.60 0.92 0.53 0.78 1.14 10.34 13.26 16.11 0.35 0.45 0.55 0.54 0.82 1.13 0.02 0.03 0.04 Lithuania - Pseudomonas aeruginosa MDRPA SSI - model 49 2.80E-03 5.12E-03 9.02E-03 0.71 1.06 1.40 0.71 1.07 1.41 0.40 0.43 0.47 9.59E-05 1.75E-04 3.09E-04 0.02 0.04 0.05 0.02 0.04 0.05 1.65 2.46 3.23 0.06 0.08 0.11 0.04 0.07 0.09 1.49E-03 2.27E-03 2.94E-03 Lithuania - Pseudomonas aeruginosa MDRPA UTI - model 48 5.73E-03 9.30E-03 0.01 0.00 0.00 0.00 5.73E-03 9.30E-03 0.01 1.34E-03 2.05E-03 2.80E-03 1.96E-04 3.18E-04 4.92E-04 0.00 0.00 0.00 1.96E-04 3.18E-04 4.92E-04 3.32 4.61 5.92 0.11 0.16 0.20 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Staphylococcus aureus MRSA BSI - model 61 18.79 20.56 22.50 129.08 138.00 146.45 148.61 158.74 168.26 4.16 4.36 4.55 0.64 0.70 0.77 4.42 4.72 5.01 5.09 5.43 5.76 34.46 36.38 38.49 1.18 1.25 1.32 6.11 6.54 6.99 0.21 0.22 0.24 Lithuania - Staphylococcus aureus MRSA OTH - model 65 0.14 0.18 0.21 0.00 0.00 0.00 0.14 0.18 0.21 2.66E-03 3.26E-03 3.93E-03 4.77E-03 6.01E-03 7.34E-03 0.00 0.00 0.00 4.77E-03 6.01E-03 7.34E-03 48.70 53.81 58.13 1.67 1.84 1.99 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Staphylococcus aureus MRSA RESP - model 62 19.09 21.36 23.87 37.40 41.56 45.94 56.82 62.96 69.06 1.08 1.15 1.23 0.65 0.73 0.82 1.28 1.42 1.57 1.95 2.16 2.36 49.49 54.47 59.77 1.69 1.86 2.05 1.76 1.96 2.16 0.06 0.07 0.07 Lithuania - Staphylococcus aureus MRSA SSI - model 64 0.10 0.13 0.17 20.69 22.77 24.87 20.79 22.91 24.97 0.37 0.38 0.40 3.28E-03 4.34E-03 5.70E-03 0.71 0.78 0.85 0.71 0.78 0.85 54.40 59.59 64.93 1.86 2.04 2.22 1.33 1.49 1.64 0.05 0.05 0.06 Lithuania - Staphylococcus aureus MRSA UTI - model 63 0.01 0.02 0.02 0.00 0.00 0.00 0.01 0.02 0.02 1.51E-03 1.87E-03 2.29E-03 4.23E-04 5.65E-04 7.46E-04 0.00 0.00 0.00 4.23E-04 5.65E-04 7.46E-04 7.27 8.89 10.41 0.25 0.30 0.36 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Streptococcus pneumoniae PMRSP BSI - model 76 0.31 0.38 0.47 2.30 2.56 2.82 2.68 2.95 3.22 2.41 2.65 2.90 0.01 0.01 0.02 0.08 0.09 0.10 0.09 0.10 0.11 1.11 1.11 1.11 0.04 0.04 0.04 0.18 0.20 0.22 6.13E-03 6.84E-03 7.52E-03 Lithuania - Streptococcus pneumoniae PMRSP OTH - model 80 3.94E-04 7.35E-04 1.22E-03 0.00 0.00 0.00 3.94E-04 7.35E-04 1.22E-03 1.03E-03 1.91E-03 3.06E-03 1.35E-05 2.52E-05 4.16E-05 0.00 0.00 0.00 1.35E-05 2.52E-05 4.16E-05 0.33 0.39 0.46 0.01 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Streptococcus pneumoniae PMRSP RESP - model 77 0.73 0.99 1.46 1.42 1.90 2.79 2.23 2.89 4.24 0.63 0.70 0.78 0.02 0.03 0.05 0.05 0.07 0.10 0.08 0.10 0.15 3.23 4.12 5.83 0.11 0.14 0.20 0.11 0.15 0.22 3.79E-03 5.08E-03 7.44E-03 Lithuania - Streptococcus pneumoniae PMRSP SSI - model 79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Streptococcus pneumoniae PMRSP UTI - model 78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Streptococcus pneumoniae PRSP BSI - model 71 2.59 3.01 3.48 18.92 20.44 22.05 21.88 23.47 25.07 4.93 5.29 5.65 0.09 0.10 0.12 0.65 0.70 0.75 0.75 0.80 0.86 4.44 4.44 4.44 0.15 0.15 0.15 0.74 0.80 0.86 0.03 0.03 0.03 Lithuania - Streptococcus pneumoniae PRSP OTH - model 75 1.90E-03 3.06E-03 4.48E-03 0.00 0.00 0.00 1.90E-03 3.06E-03 4.48E-03 1.23E-03 1.92E-03 2.81E-03 6.50E-05 1.05E-04 1.53E-04 0.00 0.00 0.00 6.50E-05 1.05E-04 1.53E-04 1.40 1.58 1.81 0.05 0.05 0.06 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Streptococcus pneumoniae PRSP RESP - model 72 6.29 7.94 10.52 12.29 15.39 20.17 18.85 23.29 30.47 1.28 1.40 1.52 0.22 0.27 0.36 0.42 0.53 0.69 0.65 0.80 1.04 13.78 16.76 21.37 0.47 0.57 0.73 0.48 0.60 0.80 0.02 0.02 0.03 Lithuania - Streptococcus pneumoniae PRSP SSI - model 74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Lithuania - Streptococcus pneumoniae PRSP UTI - model 73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total (Median & 95% UIs) 309.17 348.47 394.00 1,584.69 1,837.29 2,099.45 1,912.49 2,185.36 2,476.93 10.58 11.93 13.49 54.25 62.89 71.87 65.47 74.81 84.79 1,618.44 1,828.20 2,042.07 55.40 62.58 69.90 77.23 89.81 102.83 2.64 3.07 3.52 Total (average) - 62.95 74.91 1,828.61 62.60 89.85 3.08 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 349.35 1,838.94 2,188.28 - 11.96 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 Infection Colistin resistant Acinetobacter spp. 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Acinetobacter spp. (excluding those resistant to colistin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Aminoglycosides and fluoroquinolones resistant Acinetobacter spp. (excluding those resistant to colistin and/or carbapenem) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Vancomycin resistant Enterococci (E. faecalis and E. faecium ) 0.10 0.18 0.37 0.86 1.75 3.16 0.96 1.93 3.49 1.42 1.48 1.53 0.02 0.03 0.07 0.15 0.31 0.56 0.17 0.34 0.62 1.76 5.06 9.04 0.31 0.90 1.61 0.17 0.35 0.63 0.03 0.06 0.11 Colistin resistant Escherichia coli 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Escherichia coli (excluding those resistant to colistin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Third-generation cephalosporin resistant Escherichia coli (excluding those resistant to colistin and/or carbapenem) 24.27 28.38 32.43 145.46 171.00 196.61 171.28 199.40 227.14 4.27 4.80 5.37 4.31 5.04 5.76 25.84 30.37 34.92 30.42 35.42 40.35 280.78 328.68 378.56 49.88 58.38 67.25 8.63 10.27 12.00 1.53 1.82 2.13 Colistin resistant Klebsiella pneumoniae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Klebsiella pneumoniae (excluding those resistant to colistin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Third-generation cephalosporin resistant Klebsiella pneumoniae (excluding those resistant to colistin and/or carbapenem) 11.66 13.63 15.80 58.94 65.99 73.61 71.00 79.58 88.76 4.68 5.02 5.37 2.07 2.42 2.81 10.47 11.72 13.08 12.61 14.14 15.77 56.99 66.20 75.41 10.12 11.76 13.40 3.25 3.63 4.04 0.58 0.64 0.72 Colistin resistant Pseudomonas aeruginosa 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Pseudomonas aeruginosa (excluding those resistant to colistin) 2.57 3.90 5.45 9.14 19.75 33.02 12.34 23.59 37.93 4.15 7.04 9.98 0.46 0.69 0.97 1.62 3.51 5.87 2.19 4.19 6.74 9.69 15.35 21.17 1.72 2.73 3.76 0.49 1.05 1.73 0.09 0.19 0.31 Pseudomonas aeruginosa resistant to three or more antimicrobial groups (excluding those resistant to colistin and/or carbapenem) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Methicillin resistant Staphylococcus aureus 13.93 16.27 18.91 69.96 78.31 87.15 84.19 94.55 104.79 6.25 6.74 7.31 2.47 2.89 3.36 12.43 13.91 15.48 14.95 16.79 18.61 64.39 71.96 79.73 11.44 12.78 14.16 3.11 3.41 3.74 0.55 0.61 0.66 Penicillin and macrolides resistant Streptococcus pneumoniae (excluding those only resistant to penicillin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Penicillin tesistant Streptococcus pneumoniae (excluding those resistant to macrolides) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total 52.52 62.36 72.97 284.36 336.80 393.55 339.76 399.05 462.11 9.33 11.08 12.96 50.51 59.83 69.91 60.35 70.88 82.09 413.62 487.25 563.92 73.47 86.55 100.17 15.64 18.71 22.13 2.78 3.32 3.93 Model Luxembourg - Acinetobacter spp. CRACI BSI - model 36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Acinetobacter spp. CRACI OTH - model 40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Acinetobacter spp. CRACI RESP - model 37 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Acinetobacter spp. CRACI SSI - model 39 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Acinetobacter spp. CRACI UTI - model 38 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Acinetobacter spp. ColRACI BSI - model 41 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Acinetobacter spp. ColRACI OTH - model 45 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Acinetobacter spp. ColRACI RESP - model 42 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Acinetobacter spp. ColRACI SSI - model 44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Acinetobacter spp. ColRACI UTI - model 43 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Acinetobacter spp. MDRACI BSI - model 31 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Acinetobacter spp. MDRACI OTH - model 35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Acinetobacter spp. MDRACI RESP - model 32 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Acinetobacter spp. MDRACI SSI - model 34 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Acinetobacter spp. MDRACI UTI - model 33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Enterococcus faecalis and E. faecium VRE BSI - model 66 0.09 0.18 0.35 0.77 1.43 2.60 0.86 1.61 2.92 1.24 1.29 1.34 0.02 0.03 0.06 0.14 0.25 0.46 0.15 0.29 0.52 0.67 1.24 2.28 0.12 0.22 0.40 0.15 0.28 0.52 0.03 0.05 0.09 Luxembourg - Enterococcus faecalis and E. faecium VRE OTH - model 70 4.22E-04 2.03E-03 5.95E-03 0.00 0.00 0.00 4.22E-04 2.03E-03 5.95E-03 5.50E-04 1.55E-03 3.20E-03 7.49E-05 3.61E-04 1.06E-03 0.00 0.00 0.00 7.49E-05 3.61E-04 1.06E-03 0.38 1.39 2.43 0.07 0.25 0.43 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Enterococcus faecalis and E. faecium VRE RESP - model 67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Enterococcus faecalis and E. faecium VRE SSI - model 69 6.37E-04 3.24E-03 0.01 0.10 0.32 0.56 0.10 0.33 0.56 0.18 0.18 0.19 1.13E-04 5.75E-04 1.90E-03 0.02 0.06 0.10 0.02 0.06 0.10 0.53 1.78 3.09 0.09 0.32 0.55 0.02 0.06 0.11 3.41E-03 0.01 0.02 Luxembourg - Enterococcus faecalis and E. faecium VRE UTI - model 68 2.16E-04 1.04E-03 3.03E-03 0.00 0.00 0.00 2.16E-04 1.04E-03 3.03E-03 7.07E-04 1.75E-03 3.44E-03 3.84E-05 1.84E-04 5.38E-04 0.00 0.00 0.00 3.84E-05 1.84E-04 5.38E-04 0.17 0.65 1.25 0.03 0.11 0.22 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Escherichia coli 3GCREC BSI - model 16 18.77 21.26 23.79 117.96 136.90 155.85 138.11 158.22 177.91 3.06 3.42 3.78 3.33 3.78 4.23 20.95 24.32 27.68 24.53 28.11 31.60 42.19 46.11 50.40 7.49 8.19 8.95 6.81 7.99 9.23 1.21 1.42 1.64 Luxembourg - Escherichia coli 3GCREC OTH - model 20 0.04 0.05 0.07 0.00 0.00 0.00 0.04 0.05 0.07 2.48E-03 3.31E-03 4.25E-03 6.29E-03 8.93E-03 0.01 0.00 0.00 0.00 6.29E-03 8.93E-03 0.01 11.51 15.23 19.03 2.04 2.70 3.38 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Escherichia coli 3GCREC RESP - model 17 5.11 6.57 7.90 9.96 12.70 15.48 15.16 19.25 23.25 0.81 0.94 1.09 0.91 1.17 1.40 1.77 2.26 2.75 2.69 3.42 4.13 15.70 20.41 25.46 2.79 3.63 4.52 0.56 0.74 0.92 0.10 0.13 0.16 Luxembourg - Escherichia coli 3GCREC SSI - model 19 0.07 0.10 0.15 17.54 21.40 25.28 17.68 21.50 25.39 0.40 0.44 0.49 0.01 0.02 0.03 3.12 3.80 4.49 3.14 3.82 4.51 40.93 48.69 57.25 7.27 8.65 10.17 1.26 1.54 1.85 0.22 0.27 0.33 Luxembourg - Escherichia coli 3GCREC UTI - model 18 0.29 0.39 0.52 0.00 0.00 0.00 0.29 0.39 0.52 1.50E-03 1.95E-03 2.53E-03 0.05 0.07 0.09 0.00 0.00 0.00 0.05 0.07 0.09 170.45 198.24 226.43 30.28 35.21 40.22 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Escherichia coli CREC BSI - model 21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Escherichia coli CREC OTH - model 25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Escherichia coli CREC RESP - model 22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Escherichia coli CREC SSI - model 24 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Escherichia coli CREC UTI - model 23 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Escherichia coli ColREC BSI - model 26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Escherichia coli ColREC OTH - model 30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Escherichia coli ColREC RESP - model 27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Escherichia coli ColREC SSI - model 29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Escherichia coli ColREC UTI - model 28 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Klebsiella pneumoniae 3GCRKP BSI - model 1 7.34 8.44 9.62 48.39 53.04 58.15 56.12 61.44 67.25 3.33 3.55 3.77 1.30 1.50 1.71 8.60 9.42 10.33 9.97 10.91 11.95 16.09 17.30 18.68 2.86 3.07 3.32 2.65 2.89 3.16 0.47 0.51 0.56 Luxembourg - Klebsiella pneumoniae 3GCRKP OTH - model 5 0.02 0.02 0.03 0.00 0.00 0.00 0.02 0.02 0.03 2.43E-03 3.34E-03 4.30E-03 2.82E-03 4.03E-03 5.62E-03 0.00 0.00 0.00 2.82E-03 4.03E-03 5.62E-03 5.61 6.85 8.14 1.00 1.22 1.45 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Klebsiella pneumoniae 3GCRKP RESP - model 2 4.26 5.11 6.08 8.14 9.82 11.65 12.44 14.94 17.60 0.92 1.00 1.09 0.76 0.91 1.08 1.45 1.74 2.07 2.21 2.65 3.13 12.58 14.95 17.09 2.24 2.66 3.04 0.45 0.54 0.63 0.08 0.10 0.11 Luxembourg - Klebsiella pneumoniae 3GCRKP SSI - model 4 8.95E-03 0.01 0.02 2.40 3.13 3.80 2.41 3.14 3.82 0.42 0.46 0.50 1.59E-03 2.52E-03 3.88E-03 0.43 0.56 0.68 0.43 0.56 0.68 5.38 6.83 8.15 0.96 1.21 1.45 0.15 0.20 0.25 0.03 0.04 0.04 Luxembourg - Klebsiella pneumoniae 3GCRKP UTI - model 3 0.03 0.04 0.05 0.00 0.00 0.00 0.03 0.04 0.05 1.42E-03 1.96E-03 2.58E-03 5.09E-03 7.04E-03 9.49E-03 0.00 0.00 0.00 5.09E-03 7.04E-03 9.49E-03 17.33 20.27 23.36 3.08 3.60 4.15 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Klebsiella pneumoniae CRKP BSI - model 6 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Klebsiella pneumoniae CRKP OTH - model 10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Klebsiella pneumoniae CRKP RESP - model 7 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Klebsiella pneumoniae CRKP SSI - model 9 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Klebsiella pneumoniae CRKP UTI - model 8 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Klebsiella pneumoniae ColRKP BSI - model 11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Klebsiella pneumoniae ColRKP OTH - model 15 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Klebsiella pneumoniae ColRKP RESP - model 12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Klebsiella pneumoniae ColRKP SSI - model 14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Klebsiella pneumoniae ColRKP UTI - model 13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Pseudomonas aeruginosa CRPA BSI - model 51 0.79 1.09 1.52 4.18 8.91 15.08 5.18 9.93 16.34 2.48 4.74 7.07 0.14 0.19 0.27 0.74 1.58 2.68 0.92 1.76 2.90 1.71 2.14 2.73 0.30 0.38 0.48 0.22 0.47 0.79 0.04 0.08 0.14 Luxembourg - Pseudomonas aeruginosa CRPA OTH - model 55 1.51E-03 3.80E-03 7.31E-03 0.00 0.00 0.00 1.51E-03 3.80E-03 7.31E-03 1.90E-03 3.69E-03 5.65E-03 2.69E-04 6.76E-04 1.30E-03 0.00 0.00 0.00 2.69E-04 6.76E-04 1.30E-03 0.53 1.08 1.61 0.09 0.19 0.29 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Pseudomonas aeruginosa CRPA RESP - model 52 1.77 2.79 3.91 4.44 9.85 16.51 6.63 12.65 20.12 1.02 1.62 2.19 0.31 0.50 0.69 0.79 1.75 2.93 1.18 2.25 3.57 5.17 7.95 10.81 0.92 1.41 1.92 0.24 0.52 0.86 0.04 0.09 0.15 Luxembourg - Pseudomonas aeruginosa CRPA SSI - model 54 9.93E-04 2.89E-03 6.36E-03 0.52 1.00 1.44 0.52 1.00 1.44 0.64 0.68 0.72 1.76E-04 5.13E-04 1.13E-03 0.09 0.18 0.26 0.09 0.18 0.26 0.71 1.47 2.11 0.13 0.26 0.38 0.03 0.05 0.08 4.57E-03 9.42E-03 0.01 Luxembourg - Pseudomonas aeruginosa CRPA UTI - model 53 2.35E-03 5.39E-03 0.01 0.00 0.00 0.00 2.35E-03 5.39E-03 0.01 1.09E-03 2.05E-03 3.23E-03 4.18E-04 9.57E-04 1.83E-03 0.00 0.00 0.00 4.18E-04 9.57E-04 1.83E-03 1.57 2.70 3.91 0.28 0.48 0.70 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Pseudomonas aeruginosa ColRPA BSI - model 56 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Pseudomonas aeruginosa ColRPA OTH - model 60 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Pseudomonas aeruginosa ColRPA RESP - model 57 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Pseudomonas aeruginosa ColRPA SSI - model 59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Pseudomonas aeruginosa ColRPA UTI - model 58 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Pseudomonas aeruginosa MDRPA BSI - model 46 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Pseudomonas aeruginosa MDRPA OTH - model 50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Pseudomonas aeruginosa MDRPA RESP - model 47 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Pseudomonas aeruginosa MDRPA SSI - model 49 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Pseudomonas aeruginosa MDRPA UTI - model 48 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Staphylococcus aureus MRSA BSI - model 61 6.95 7.90 9.12 48.69 53.44 58.70 55.96 61.37 66.94 4.65 4.98 5.37 1.23 1.40 1.62 8.65 9.49 10.43 9.94 10.90 11.89 11.57 12.28 13.07 2.05 2.18 2.32 2.05 2.20 2.38 0.36 0.39 0.42 Luxembourg - Staphylococcus aureus MRSA OTH - model 65 0.04 0.06 0.08 0.00 0.00 0.00 0.04 0.06 0.08 2.59E-03 3.26E-03 4.10E-03 7.97E-03 0.01 0.01 0.00 0.00 0.00 7.97E-03 0.01 0.01 16.11 18.12 20.07 2.86 3.22 3.57 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Staphylococcus aureus MRSA RESP - model 62 6.91 8.26 9.65 13.60 16.14 18.71 20.48 24.34 27.97 1.18 1.32 1.48 1.23 1.47 1.71 2.42 2.87 3.32 3.64 4.32 4.97 16.29 18.44 20.58 2.89 3.28 3.66 0.58 0.67 0.75 0.10 0.12 0.13 Luxembourg - Staphylococcus aureus MRSA SSI - model 64 0.03 0.04 0.06 7.67 8.73 9.73 7.70 8.77 9.79 0.42 0.44 0.45 5.36E-03 7.63E-03 0.01 1.36 1.55 1.73 1.37 1.56 1.74 18.01 20.11 22.39 3.20 3.57 3.98 0.47 0.54 0.61 0.08 0.10 0.11 Luxembourg - Staphylococcus aureus MRSA UTI - model 63 3.90E-03 5.64E-03 7.77E-03 0.00 0.00 0.00 3.90E-03 5.64E-03 7.77E-03 1.42E-03 1.87E-03 2.34E-03 6.93E-04 1.00E-03 1.38E-03 0.00 0.00 0.00 6.93E-04 1.00E-03 1.38E-03 2.41 3.01 3.61 0.43 0.54 0.64 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Streptococcus pneumoniae PMRSP BSI - model 76 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Streptococcus pneumoniae PMRSP OTH - model 80 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Streptococcus pneumoniae PMRSP RESP - model 77 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Streptococcus pneumoniae PMRSP SSI - model 79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Streptococcus pneumoniae PMRSP UTI - model 78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Streptococcus pneumoniae PRSP BSI - model 71 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Streptococcus pneumoniae PRSP OTH - model 75 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Streptococcus pneumoniae PRSP RESP - model 72 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Streptococcus pneumoniae PRSP SSI - model 74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Luxembourg - Streptococcus pneumoniae PRSP UTI - model 73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total (Median & 95% UIs) 52.52 62.36 72.97 284.36 336.80 393.55 339.76 399.05 462.11 9.33 11.08 12.96 50.51 59.83 69.91 60.35 70.88 82.09 413.62 487.25 563.92 73.47 86.55 100.17 15.64 18.71 22.13 2.78 3.32 3.93 Total (average) - 59.86 70.97 487.79 86.65 18.75 3.33 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 62.49 337.01 399.50 - 11.10 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 Infection Colistin resistant Acinetobacter spp. 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Acinetobacter spp. (excluding those resistant to colistin) 58.01 66.05 74.24 285.01 355.62 427.28 345.10 422.13 498.05 7.49 8.85 10.26 2.92 3.33 3.74 14.35 17.91 21.51 17.38 21.25 25.08 123.23 139.69 156.01 6.20 7.03 7.86 9.92 12.23 14.60 0.50 0.62 0.73 Aminoglycosides and fluoroquinolones resistant Acinetobacter spp. (excluding those resistant to colistin and/or carbapenem) 5.05 6.69 9.16 19.59 35.37 52.44 25.40 42.06 60.59 6.07 9.29 12.39 0.25 0.34 0.46 0.99 1.78 2.64 1.28 2.12 3.05 9.90 13.30 16.92 0.50 0.67 0.85 0.66 1.13 1.66 0.03 0.06 0.08 Vancomycin resistant Enterococci (E. faecalis and E. faecium ) 6.24 8.89 12.58 58.92 82.29 110.99 65.00 91.33 123.53 7.86 8.81 10.48 0.31 0.45 0.63 2.97 4.14 5.59 3.27 4.60 6.22 27.15 39.82 52.98 1.37 2.00 2.67 1.87 2.54 3.33 0.09 0.13 0.17 Colistin resistant Escherichia coli 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Escherichia coli (excluding those resistant to colistin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Third-generation cephalosporin resistant Escherichia coli (excluding those resistant to colistin and/or carbapenem) 28.28 32.61 37.44 165.87 192.33 220.28 196.34 225.24 255.89 5.45 6.02 6.62 1.42 1.64 1.89 8.35 9.68 11.09 9.89 11.34 12.88 262.12 299.25 337.90 13.20 15.07 17.01 7.75 9.00 10.21 0.39 0.45 0.51 Colistin resistant Klebsiella pneumoniae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Klebsiella pneumoniae (excluding those resistant to colistin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Third-generation cephalosporin resistant Klebsiella pneumoniae (excluding those resistant to colistin and/or carbapenem) 68.84 77.90 87.91 340.07 372.39 404.82 411.59 450.77 490.57 7.46 7.84 8.25 3.47 3.92 4.43 17.12 18.75 20.38 20.72 22.70 24.70 210.28 233.48 257.02 10.59 11.76 12.94 11.58 12.57 13.56 0.58 0.63 0.68 Colistin resistant Pseudomonas aeruginosa 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Pseudomonas aeruginosa (excluding those resistant to colistin) 9.49 14.74 20.33 35.23 74.70 126.63 48.03 89.11 145.52 13.06 23.18 33.64 0.48 0.74 1.02 1.77 3.76 6.38 2.42 4.49 7.33 10.67 17.06 23.30 0.54 0.86 1.17 0.53 1.13 1.92 0.03 0.06 0.10 Pseudomonas aeruginosa resistant to three or more antimicrobial groups (excluding those resistant to colistin and/or carbapenem) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Methicillin resistant Staphylococcus aureus 26.05 30.21 34.81 127.72 142.21 157.97 154.89 172.48 191.33 9.01 9.58 10.12 1.31 1.52 1.75 6.43 7.16 7.95 7.80 8.68 9.63 82.43 93.32 103.87 4.15 4.70 5.23 3.78 4.21 4.66 0.19 0.21 0.23 Penicillin and macrolides resistant Streptococcus pneumoniae (excluding those only resistant to penicillin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Penicillin tesistant Streptococcus pneumoniae (excluding those resistant to macrolides) 4.17 5.42 7.61 14.86 17.83 22.18 19.30 23.22 29.42 6.01 6.69 7.33 0.21 0.27 0.38 0.75 0.90 1.12 0.97 1.17 1.48 9.35 11.31 15.04 0.47 0.57 0.76 0.58 0.70 0.87 0.03 0.04 0.04 Total 206.13 242.50 284.08 1,047.26 1,272.73 1,522.59 1,265.66 1,516.34 1,794.90 10.38 12.21 14.30 52.73 64.08 76.66 63.73 76.35 90.37 735.13 847.23 963.04 37.01 42.66 48.49 36.67 43.50 50.81 1.85 2.19 2.56 Model Latvia - Acinetobacter spp. CRACI BSI - model 36 33.86 37.81 42.23 230.60 292.67 355.33 266.03 330.81 394.55 5.58 6.80 8.06 1.70 1.90 2.13 11.61 14.74 17.89 13.39 16.66 19.87 45.36 48.49 51.79 2.28 2.44 2.61 7.99 9.99 12.02 0.40 0.50 0.61 Latvia - Acinetobacter spp. CRACI OTH - model 40 4.45E-03 6.35E-03 8.83E-03 0.00 0.00 0.00 4.45E-03 6.35E-03 8.83E-03 2.97E-03 3.74E-03 4.53E-03 2.24E-04 3.20E-04 4.45E-04 0.00 0.00 0.00 2.24E-04 3.20E-04 4.45E-04 1.28 1.70 2.20 0.06 0.09 0.11 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Acinetobacter spp. CRACI RESP - model 37 24.09 28.16 31.90 47.77 54.88 62.33 72.37 83.15 93.77 1.49 1.59 1.70 1.21 1.42 1.61 2.41 2.76 3.14 3.64 4.19 4.72 45.88 52.18 58.06 2.31 2.63 2.92 1.63 1.87 2.13 0.08 0.09 0.11 Latvia - Acinetobacter spp. CRACI SSI - model 39 0.03 0.04 0.05 6.64 8.07 9.63 6.67 8.11 9.67 0.42 0.46 0.49 1.37E-03 1.88E-03 2.54E-03 0.33 0.41 0.48 0.34 0.41 0.49 14.68 17.62 20.71 0.74 0.89 1.04 0.30 0.37 0.45 0.02 0.02 0.02 Latvia - Acinetobacter spp. CRACI UTI - model 38 0.03 0.04 0.05 0.00 0.00 0.00 0.03 0.04 0.05 1.64E-03 2.05E-03 2.51E-03 1.50E-03 2.03E-03 2.65E-03 0.00 0.00 0.00 1.50E-03 2.03E-03 2.65E-03 16.03 19.69 23.26 0.81 0.99 1.17 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Acinetobacter spp. ColRACI BSI - model 41 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Acinetobacter spp. ColRACI OTH - model 45 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Acinetobacter spp. ColRACI RESP - model 42 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Acinetobacter spp. ColRACI SSI - model 44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Acinetobacter spp. ColRACI UTI - model 43 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Acinetobacter spp. MDRACI BSI - model 31 3.01 3.84 5.05 15.29 29.12 44.03 18.92 32.92 48.50 4.19 7.18 10.03 0.15 0.19 0.25 0.77 1.47 2.22 0.95 1.66 2.44 3.98 4.62 5.41 0.20 0.23 0.27 0.51 0.93 1.40 0.03 0.05 0.07 Latvia - Acinetobacter spp. MDRACI OTH - model 35 2.25E-04 5.76E-04 1.19E-03 0.00 0.00 0.00 2.25E-04 5.76E-04 1.19E-03 2.12E-03 3.70E-03 5.53E-03 1.13E-05 2.90E-05 5.99E-05 0.00 0.00 0.00 1.13E-05 2.90E-05 5.99E-05 0.07 0.16 0.27 3.56E-03 8.06E-03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Acinetobacter spp. MDRACI RESP - model 32 2.04 2.84 4.09 3.88 5.58 7.50 6.05 8.47 11.18 1.52 1.70 1.90 0.10 0.14 0.21 0.20 0.28 0.38 0.30 0.43 0.56 3.66 4.98 6.36 0.18 0.25 0.32 0.13 0.18 0.23 6.51E-03 8.97E-03 0.01 Latvia - Acinetobacter spp. MDRACI SSI - model 34 1.49E-03 3.42E-03 6.85E-03 0.42 0.67 0.90 0.42 0.67 0.91 0.36 0.40 0.45 7.53E-05 1.72E-04 3.45E-04 0.02 0.03 0.05 0.02 0.03 0.05 1.04 1.68 2.32 0.05 0.08 0.12 0.02 0.03 0.04 7.81E-04 1.33E-03 1.85E-03 Latvia - Acinetobacter spp. MDRACI UTI - model 33 1.84E-03 3.72E-03 6.37E-03 0.00 0.00 0.00 1.84E-03 3.72E-03 6.37E-03 1.14E-03 2.04E-03 3.03E-03 9.26E-05 1.87E-04 3.20E-04 0.00 0.00 0.00 9.26E-05 1.87E-04 3.20E-04 1.14 1.86 2.56 0.06 0.09 0.13 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Enterococcus faecalis and E. faecium VRE BSI - model 66 6.20 8.83 12.49 54.87 75.89 102.44 60.91 84.88 114.92 7.48 8.34 9.92 0.31 0.44 0.63 2.76 3.82 5.16 3.07 4.27 5.79 7.48 10.11 13.22 0.38 0.51 0.67 1.72 2.31 3.01 0.09 0.12 0.15 Latvia - Enterococcus faecalis and E. faecium VRE OTH - model 70 0.01 0.02 0.03 0.00 0.00 0.00 0.01 0.02 0.03 1.08E-03 1.66E-03 2.36E-03 5.25E-04 8.87E-04 1.43E-03 0.00 0.00 0.00 5.25E-04 8.87E-04 1.43E-03 7.27 10.79 14.17 0.37 0.54 0.71 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Enterococcus faecalis and E. faecium VRE RESP - model 67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Enterococcus faecalis and E. faecium VRE SSI - model 69 0.01 0.03 0.05 4.05 6.39 8.54 4.07 6.42 8.57 0.38 0.46 0.55 7.45E-04 1.47E-03 2.55E-03 0.20 0.32 0.43 0.20 0.32 0.43 9.00 13.85 18.62 0.45 0.70 0.94 0.14 0.23 0.31 7.21E-03 0.01 0.02 Latvia - Enterococcus faecalis and E. faecium VRE UTI - model 68 5.65E-03 9.42E-03 0.02 0.00 0.00 0.00 5.65E-03 9.42E-03 0.02 1.27E-03 1.88E-03 2.55E-03 2.84E-04 4.74E-04 7.64E-04 0.00 0.00 0.00 2.84E-04 4.74E-04 7.64E-04 3.40 5.08 6.96 0.17 0.26 0.35 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Escherichia coli 3GCREC BSI - model 16 21.85 24.55 27.61 138.48 159.17 181.82 162.51 183.98 207.65 3.96 4.40 4.84 1.10 1.24 1.39 6.97 8.01 9.15 8.18 9.26 10.46 38.55 41.83 45.34 1.94 2.11 2.28 6.32 7.24 8.15 0.32 0.36 0.41 Latvia - Escherichia coli 3GCREC OTH - model 20 0.03 0.05 0.06 0.00 0.00 0.00 0.03 0.05 0.06 2.62E-03 3.33E-03 4.14E-03 1.63E-03 2.33E-03 3.09E-03 0.00 0.00 0.00 1.63E-03 2.33E-03 3.09E-03 11.02 13.93 16.77 0.55 0.70 0.84 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Escherichia coli 3GCREC RESP - model 17 6.06 7.57 9.20 11.71 14.72 17.66 17.77 22.33 26.78 1.09 1.20 1.32 0.31 0.38 0.46 0.59 0.74 0.89 0.89 1.12 1.35 15.15 18.62 22.08 0.76 0.94 1.11 0.54 0.67 0.80 0.03 0.03 0.04 Latvia - Escherichia coli 3GCREC SSI - model 19 0.07 0.09 0.13 15.68 18.43 20.79 15.76 18.53 20.95 0.39 0.42 0.45 3.38E-03 4.70E-03 6.43E-03 0.79 0.93 1.05 0.79 0.93 1.05 37.87 44.19 50.05 1.91 2.22 2.52 0.90 1.09 1.26 0.05 0.06 0.06 Latvia - Escherichia coli 3GCREC UTI - model 18 0.27 0.35 0.44 0.00 0.00 0.00 0.27 0.35 0.44 1.57E-03 1.96E-03 2.40E-03 0.01 0.02 0.02 0.00 0.00 0.00 0.01 0.02 0.02 159.53 180.69 203.66 8.03 9.10 10.25 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Escherichia coli CREC BSI - model 21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Escherichia coli CREC OTH - model 25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Escherichia coli CREC RESP - model 22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Escherichia coli CREC SSI - model 24 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Escherichia coli CREC UTI - model 23 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Escherichia coli ColREC BSI - model 26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Escherichia coli ColREC OTH - model 30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Escherichia coli ColREC RESP - model 27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Escherichia coli ColREC SSI - model 29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Escherichia coli ColREC UTI - model 28 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Klebsiella pneumoniae 3GCRKP BSI - model 1 43.67 48.57 53.78 283.23 305.86 328.45 329.13 354.76 380.53 5.54 5.79 6.07 2.20 2.45 2.71 14.26 15.40 16.54 16.57 17.86 19.16 57.96 61.10 64.38 2.92 3.08 3.24 9.54 10.22 10.91 0.48 0.51 0.55 Latvia - Klebsiella pneumoniae 3GCRKP OTH - model 5 0.06 0.08 0.10 0.00 0.00 0.00 0.06 0.08 0.10 2.71E-03 3.36E-03 4.06E-03 3.21E-03 4.10E-03 5.16E-03 0.00 0.00 0.00 3.21E-03 4.10E-03 5.16E-03 21.11 24.26 27.28 1.06 1.22 1.37 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Klebsiella pneumoniae 3GCRKP RESP - model 2 24.95 29.06 33.78 48.30 56.61 65.03 73.71 85.81 98.37 1.53 1.63 1.73 1.26 1.46 1.70 2.43 2.85 3.27 3.71 4.32 4.95 46.45 52.68 58.77 2.34 2.65 2.96 1.65 1.89 2.14 0.08 0.10 0.11 Latvia - Klebsiella pneumoniae 3GCRKP SSI - model 4 0.04 0.05 0.07 8.54 9.93 11.33 8.59 9.98 11.38 0.40 0.41 0.44 1.86E-03 2.57E-03 3.49E-03 0.43 0.50 0.57 0.43 0.50 0.57 20.71 24.07 27.13 1.04 1.21 1.37 0.39 0.46 0.52 0.02 0.02 0.03 Latvia - Klebsiella pneumoniae 3GCRKP UTI - model 3 0.11 0.14 0.17 0.00 0.00 0.00 0.11 0.14 0.17 1.55E-03 1.95E-03 2.38E-03 5.49E-03 6.99E-03 8.79E-03 0.00 0.00 0.00 5.49E-03 6.99E-03 8.79E-03 64.04 71.37 79.47 3.22 3.59 4.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Klebsiella pneumoniae CRKP BSI - model 6 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Klebsiella pneumoniae CRKP OTH - model 10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Klebsiella pneumoniae CRKP RESP - model 7 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Klebsiella pneumoniae CRKP SSI - model 9 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Klebsiella pneumoniae CRKP UTI - model 8 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Klebsiella pneumoniae ColRKP BSI - model 11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Klebsiella pneumoniae ColRKP OTH - model 15 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Klebsiella pneumoniae ColRKP RESP - model 12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Klebsiella pneumoniae ColRKP SSI - model 14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Klebsiella pneumoniae ColRKP UTI - model 13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Pseudomonas aeruginosa CRPA BSI - model 51 2.98 4.09 5.50 16.64 36.30 60.77 21.31 40.15 65.69 8.88 16.98 25.36 0.15 0.21 0.28 0.84 1.83 3.06 1.07 2.02 3.31 1.88 2.38 2.99 0.09 0.12 0.15 0.26 0.55 0.92 0.01 0.03 0.05 Latvia - Pseudomonas aeruginosa CRPA OTH - model 55 1.77E-03 4.31E-03 8.35E-03 0.00 0.00 0.00 1.77E-03 4.31E-03 8.35E-03 1.98E-03 3.72E-03 5.78E-03 8.90E-05 2.17E-04 4.20E-04 0.00 0.00 0.00 8.90E-05 2.17E-04 4.20E-04 0.56 1.21 1.79 0.03 0.06 0.09 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Pseudomonas aeruginosa CRPA RESP - model 52 6.51 10.64 14.80 18.08 37.44 64.44 26.20 47.99 78.38 3.61 5.59 7.63 0.33 0.54 0.75 0.91 1.89 3.24 1.32 2.42 3.95 5.67 8.81 11.79 0.29 0.44 0.59 0.27 0.57 0.98 0.01 0.03 0.05 Latvia - Pseudomonas aeruginosa CRPA SSI - model 54 1.08E-03 3.12E-03 7.37E-03 0.51 0.96 1.42 0.52 0.97 1.43 0.56 0.60 0.64 5.45E-05 1.57E-04 3.71E-04 0.03 0.05 0.07 0.03 0.05 0.07 0.83 1.61 2.36 0.04 0.08 0.12 7.49E-03 0.01 0.02 3.77E-04 7.30E-04 1.07E-03 Latvia - Pseudomonas aeruginosa CRPA UTI - model 53 2.54E-03 5.98E-03 0.01 0.00 0.00 0.00 2.54E-03 5.98E-03 0.01 1.00E-03 2.03E-03 3.32E-03 1.28E-04 3.01E-04 5.84E-04 0.00 0.00 0.00 1.28E-04 3.01E-04 5.84E-04 1.73 3.06 4.37 0.09 0.15 0.22 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Pseudomonas aeruginosa ColRPA BSI - model 56 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Pseudomonas aeruginosa ColRPA OTH - model 60 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Pseudomonas aeruginosa ColRPA RESP - model 57 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Pseudomonas aeruginosa ColRPA SSI - model 59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Pseudomonas aeruginosa ColRPA UTI - model 58 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Pseudomonas aeruginosa MDRPA BSI - model 46 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Pseudomonas aeruginosa MDRPA OTH - model 50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Pseudomonas aeruginosa MDRPA RESP - model 47 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Pseudomonas aeruginosa MDRPA SSI - model 49 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Pseudomonas aeruginosa MDRPA UTI - model 48 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Staphylococcus aureus MRSA BSI - model 61 12.98 14.76 16.87 91.11 99.80 109.44 104.71 114.65 125.32 6.79 7.20 7.58 0.65 0.74 0.85 4.59 5.02 5.51 5.27 5.77 6.31 14.86 15.91 16.97 0.75 0.80 0.85 2.62 2.86 3.13 0.13 0.14 0.16 Latvia - Staphylococcus aureus MRSA OTH - model 65 0.06 0.08 0.10 0.00 0.00 0.00 0.06 0.08 0.10 2.46E-03 3.27E-03 4.24E-03 2.78E-03 3.87E-03 5.07E-03 0.00 0.00 0.00 2.78E-03 3.87E-03 5.07E-03 20.68 23.46 26.27 1.04 1.18 1.32 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Staphylococcus aureus MRSA RESP - model 62 12.97 15.32 17.75 25.65 30.00 34.81 39.12 45.29 52.10 1.76 1.90 2.04 0.65 0.77 0.89 1.29 1.51 1.75 1.97 2.28 2.62 20.80 23.96 26.99 1.05 1.21 1.36 0.74 0.86 0.99 0.04 0.04 0.05 Latvia - Staphylococcus aureus MRSA SSI - model 64 0.04 0.05 0.08 10.96 12.41 13.73 11.00 12.45 13.79 0.46 0.48 0.50 1.88E-03 2.74E-03 4.02E-03 0.55 0.62 0.69 0.55 0.63 0.69 23.06 26.07 28.85 1.16 1.31 1.45 0.42 0.49 0.55 0.02 0.02 0.03 Latvia - Staphylococcus aureus MRSA UTI - model 63 4.95E-03 7.21E-03 0.01 0.00 0.00 0.00 4.95E-03 7.21E-03 0.01 1.35E-03 1.87E-03 2.41E-03 2.49E-04 3.63E-04 5.17E-04 0.00 0.00 0.00 2.49E-04 3.63E-04 5.17E-04 3.04 3.92 4.77 0.15 0.20 0.24 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Streptococcus pneumoniae PMRSP BSI - model 76 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Streptococcus pneumoniae PMRSP OTH - model 80 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Streptococcus pneumoniae PMRSP RESP - model 77 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Streptococcus pneumoniae PMRSP SSI - model 79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Streptococcus pneumoniae PMRSP UTI - model 78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Streptococcus pneumoniae PRSP BSI - model 71 1.20 1.50 1.86 9.19 10.25 11.25 10.62 11.76 12.83 4.78 5.30 5.78 0.06 0.08 0.09 0.46 0.52 0.57 0.53 0.59 0.65 2.22 2.22 2.22 0.11 0.11 0.11 0.36 0.40 0.44 0.02 0.02 0.02 Latvia - Streptococcus pneumoniae PRSP OTH - model 75 7.67E-04 1.53E-03 2.57E-03 0.00 0.00 0.00 7.67E-04 1.53E-03 2.57E-03 9.84E-04 1.93E-03 3.17E-03 3.86E-05 7.71E-05 1.30E-04 0.00 0.00 0.00 3.86E-05 7.71E-05 1.30E-04 0.67 0.79 0.95 0.03 0.04 0.05 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Streptococcus pneumoniae PRSP RESP - model 72 2.97 3.92 5.75 5.67 7.59 10.93 8.68 11.47 16.59 1.23 1.39 1.54 0.15 0.20 0.29 0.29 0.38 0.55 0.44 0.58 0.84 6.46 8.30 11.87 0.33 0.42 0.60 0.22 0.30 0.43 0.01 0.01 0.02 Latvia - Streptococcus pneumoniae PRSP SSI - model 74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Latvia - Streptococcus pneumoniae PRSP UTI - model 73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total (Median & 95% UIs) 206.13 242.50 284.08 1,047.26 1,272.73 1,522.59 1,265.66 1,516.34 1,794.90 10.38 12.21 14.30 52.73 64.08 76.66 63.73 76.35 90.37 735.13 847.23 963.04 37.01 42.66 48.49 36.67 43.50 50.81 1.85 2.19 2.56 Total (average) - 64.27 76.52 847.97 42.70 43.59 2.19 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 243.29 1,276.47 1,519.76 - 12.25 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 Infection Colistin resistant Acinetobacter spp. 0.52 0.84 1.26 1.84 4.58 7.96 2.55 5.44 9.09 3.19 5.39 7.68 0.12 0.19 0.29 0.43 1.07 1.85 0.59 1.27 2.12 1.84 3.11 4.46 0.43 0.73 1.04 0.11 0.27 0.48 0.03 0.06 0.11 Carbapenem resistant Acinetobacter spp. (excluding those resistant to colistin) 3.25 4.82 6.82 12.40 25.42 42.71 16.46 30.06 48.64 8.28 14.14 21.08 0.76 1.12 1.59 2.89 5.92 9.95 3.83 7.00 11.33 4.45 6.31 8.27 1.04 1.47 1.93 0.28 0.55 0.84 0.07 0.13 0.20 Aminoglycosides and fluoroquinolones resistant Acinetobacter spp. (excluding those resistant to colistin and/or carbapenem) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Vancomycin resistant Enterococci (E. faecalis and E. faecium ) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Colistin resistant Escherichia coli 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Escherichia coli (excluding those resistant to colistin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Third-generation cephalosporin resistant Escherichia coli (excluding those resistant to colistin and/or carbapenem) 16.19 18.69 21.33 96.74 110.43 124.80 113.56 129.03 145.33 4.00 4.50 5.05 3.77 4.35 4.97 22.53 25.72 29.07 26.45 30.05 33.85 195.78 228.91 261.33 45.60 53.32 60.87 5.98 7.09 8.22 1.39 1.65 1.91 Colistin resistant Klebsiella pneumoniae 0.91 1.34 1.89 14.39 23.73 34.30 15.45 25.03 35.88 8.15 12.35 16.20 0.21 0.31 0.44 3.35 5.53 7.99 3.60 5.83 8.36 3.72 6.22 8.71 0.87 1.45 2.03 0.85 1.40 2.04 0.20 0.33 0.47 Carbapenem resistant Klebsiella pneumoniae (excluding those resistant to colistin) 2.85 4.02 5.46 28.96 43.26 62.87 32.00 47.38 67.80 11.23 15.78 20.51 0.66 0.94 1.27 6.74 10.07 14.64 7.45 11.04 15.79 6.27 9.22 12.27 1.46 2.15 2.86 0.84 1.24 1.74 0.20 0.29 0.41 Third-generation cephalosporin resistant Klebsiella pneumoniae (excluding those resistant to colistin and/or carbapenem) 10.20 12.39 15.09 52.13 60.31 69.47 63.02 72.77 83.59 6.70 7.37 8.11 2.38 2.89 3.51 12.14 14.05 16.18 14.68 16.95 19.47 33.85 41.02 48.27 7.88 9.56 11.24 1.94 2.23 2.57 0.45 0.52 0.60 Colistin resistant Pseudomonas aeruginosa 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Pseudomonas aeruginosa (excluding those resistant to colistin) 8.39 11.05 14.28 33.34 56.32 80.57 43.40 67.23 93.77 6.29 9.26 12.12 1.95 2.57 3.33 7.77 13.12 18.77 10.11 15.66 21.84 23.92 32.47 41.10 5.57 7.56 9.57 1.32 2.20 3.15 0.31 0.51 0.73 Pseudomonas aeruginosa resistant to three or more antimicrobial groups (excluding those resistant to colistin and/or carbapenem) 0.32 0.58 0.91 0.91 2.58 5.17 1.31 3.17 5.95 0.97 1.85 2.67 0.07 0.14 0.21 0.21 0.60 1.20 0.31 0.74 1.39 4.04 8.09 12.23 0.94 1.88 2.85 0.18 0.52 1.03 0.04 0.12 0.24 Methicillin resistant Staphylococcus aureus 35.82 40.83 46.19 182.20 201.22 221.67 219.50 242.19 265.91 4.28 4.54 4.81 8.34 9.51 10.76 42.44 46.87 51.63 51.12 56.41 61.93 242.85 272.20 300.89 56.56 63.40 70.08 11.87 13.10 14.29 2.76 3.05 3.33 Penicillin and macrolides resistant Streptococcus pneumoniae (excluding those only resistant to penicillin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Penicillin tesistant Streptococcus pneumoniae (excluding those resistant to macrolides) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total 78.45 94.56 113.23 422.92 527.84 649.52 507.25 622.31 755.97 18.27 22.02 26.37 98.50 122.94 151.28 118.15 144.94 176.08 516.72 607.56 697.54 120.35 141.51 162.47 23.38 28.61 34.36 5.45 6.66 8.00 Model Malta - Acinetobacter spp. CRACI BSI - model 36 1.94 2.73 3.80 9.65 20.79 36.30 12.30 23.30 39.36 5.63 10.88 17.16 0.45 0.64 0.88 2.25 4.84 8.45 2.86 5.43 9.17 1.84 2.18 2.58 0.43 0.51 0.60 0.22 0.45 0.70 0.05 0.10 0.16 Malta - Acinetobacter spp. CRACI OTH - model 40 8.50E-05 2.67E-04 6.02E-04 0.00 0.00 0.00 8.50E-05 2.67E-04 6.02E-04 1.93E-03 3.77E-03 5.91E-03 1.98E-05 6.22E-05 1.40E-04 0.00 0.00 0.00 1.98E-05 6.22E-05 1.40E-04 0.03 0.08 0.13 6.45E-03 0.02 0.03 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Acinetobacter spp. CRACI RESP - model 37 1.30 2.09 3.01 2.48 4.11 5.64 3.88 6.24 8.51 2.01 2.60 3.22 0.30 0.49 0.70 0.58 0.96 1.31 0.90 1.45 1.98 1.68 2.38 3.08 0.39 0.55 0.72 0.06 0.08 0.11 0.01 0.02 0.03 Malta - Acinetobacter spp. CRACI SSI - model 39 5.91E-04 1.58E-03 3.43E-03 0.28 0.52 0.76 0.28 0.52 0.76 0.63 0.66 0.68 1.38E-04 3.67E-04 7.99E-04 0.06 0.12 0.18 0.06 0.12 0.18 0.42 0.79 1.15 0.10 0.18 0.27 8.53E-03 0.02 0.03 1.99E-03 4.11E-03 6.27E-03 Malta - Acinetobacter spp. CRACI UTI - model 38 7.19E-04 1.75E-03 3.36E-03 0.00 0.00 0.00 7.19E-04 1.75E-03 3.36E-03 1.05E-03 2.04E-03 3.14E-03 1.67E-04 4.08E-04 7.84E-04 0.00 0.00 0.00 1.67E-04 4.08E-04 7.84E-04 0.48 0.89 1.32 0.11 0.21 0.31 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Acinetobacter spp. ColRACI BSI - model 41 0.32 0.47 0.68 1.36 3.64 6.52 1.85 4.14 7.12 1.81 3.86 6.01 0.08 0.11 0.16 0.32 0.85 1.52 0.43 0.96 1.66 0.86 1.07 1.36 0.20 0.25 0.32 0.08 0.22 0.39 0.02 0.05 0.09 Malta - Acinetobacter spp. ColRACI OTH - model 45 1.89E-05 1.23E-04 4.08E-04 0.00 0.00 0.00 1.89E-05 1.23E-04 4.08E-04 1.56E-03 3.65E-03 6.39E-03 4.41E-06 2.86E-05 9.49E-05 0.00 0.00 0.00 4.41E-06 2.86E-05 9.49E-05 6.41E-03 0.04 0.08 1.49E-03 8.61E-03 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Acinetobacter spp. ColRACI RESP - model 42 0.20 0.36 0.57 0.39 0.70 1.06 0.60 1.07 1.59 0.78 0.91 1.05 0.05 0.08 0.13 0.09 0.16 0.25 0.14 0.25 0.37 0.66 1.18 1.66 0.15 0.27 0.39 0.02 0.04 0.06 5.38E-03 9.72E-03 0.01 Malta - Acinetobacter spp. ColRACI SSI - model 44 1.49E-04 7.27E-04 2.21E-03 0.10 0.24 0.38 0.10 0.24 0.38 0.60 0.61 0.61 3.47E-05 1.69E-04 5.15E-04 0.02 0.06 0.09 0.02 0.06 0.09 0.16 0.40 0.63 0.04 0.09 0.15 5.68E-03 0.01 0.02 1.32E-03 3.31E-03 5.28E-03 Malta - Acinetobacter spp. ColRACI UTI - model 43 2.33E-04 7.96E-04 2.02E-03 0.00 0.00 0.00 2.33E-04 7.96E-04 2.02E-03 7.70E-04 1.98E-03 3.64E-03 5.43E-05 1.85E-04 4.70E-04 0.00 0.00 0.00 5.43E-05 1.85E-04 4.70E-04 0.16 0.44 0.73 0.04 0.10 0.17 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Acinetobacter spp. MDRACI BSI - model 31 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Acinetobacter spp. MDRACI OTH - model 35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Acinetobacter spp. MDRACI RESP - model 32 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Acinetobacter spp. MDRACI SSI - model 34 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Acinetobacter spp. MDRACI UTI - model 33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Enterococcus faecalis and E. faecium VRE BSI - model 66 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Enterococcus faecalis and E. faecium VRE OTH - model 70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Enterococcus faecalis and E. faecium VRE RESP - model 67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Enterococcus faecalis and E. faecium VRE SSI - model 69 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Enterococcus faecalis and E. faecium VRE UTI - model 68 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Escherichia coli 3GCREC BSI - model 16 12.48 14.03 15.68 79.85 90.15 101.16 92.88 104.08 116.16 2.93 3.25 3.62 2.91 3.27 3.65 18.60 21.00 23.56 21.63 24.24 27.06 29.33 32.02 34.88 6.83 7.46 8.12 4.76 5.55 6.37 1.11 1.29 1.48 Malta - Escherichia coli 3GCREC OTH - model 20 0.02 0.04 0.05 0.00 0.00 0.00 0.02 0.04 0.05 2.51E-03 3.34E-03 4.24E-03 5.63E-03 8.21E-03 0.01 0.00 0.00 0.00 5.63E-03 8.21E-03 0.01 8.11 10.57 12.92 1.89 2.46 3.01 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Escherichia coli 3GCREC RESP - model 17 3.43 4.29 5.14 6.67 8.26 9.93 10.16 12.56 14.97 0.74 0.89 1.04 0.80 1.00 1.20 1.55 1.92 2.31 2.37 2.93 3.49 11.01 14.15 17.10 2.56 3.30 3.98 0.40 0.51 0.63 0.09 0.12 0.15 Malta - Escherichia coli 3GCREC SSI - model 19 0.05 0.07 0.10 10.22 12.02 13.71 10.29 12.09 13.79 0.33 0.36 0.39 0.01 0.02 0.02 2.38 2.80 3.19 2.40 2.82 3.21 27.92 33.80 39.43 6.50 7.87 9.18 0.82 1.03 1.22 0.19 0.24 0.28 Malta - Escherichia coli 3GCREC UTI - model 18 0.21 0.27 0.36 0.00 0.00 0.00 0.21 0.27 0.36 1.49E-03 1.96E-03 2.51E-03 0.05 0.06 0.08 0.00 0.00 0.00 0.05 0.06 0.08 119.41 138.38 156.99 27.81 32.23 36.56 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Escherichia coli CREC BSI - model 21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Escherichia coli CREC OTH - model 25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Escherichia coli CREC RESP - model 22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Escherichia coli CREC SSI - model 24 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Escherichia coli CREC UTI - model 23 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Escherichia coli ColREC BSI - model 26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Escherichia coli ColREC OTH - model 30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Escherichia coli ColREC RESP - model 27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Escherichia coli ColREC SSI - model 29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Escherichia coli ColREC UTI - model 28 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Klebsiella pneumoniae 3GCRKP BSI - model 1 6.50 7.74 9.26 43.33 48.75 55.12 50.50 56.58 63.62 4.86 5.29 5.77 1.51 1.80 2.16 10.09 11.35 12.84 11.76 13.18 14.82 9.79 10.71 11.79 2.28 2.50 2.75 1.59 1.79 2.01 0.37 0.42 0.47 Malta - Klebsiella pneumoniae 3GCRKP OTH - model 5 9.02E-03 0.01 0.02 0.00 0.00 0.00 9.02E-03 0.01 0.02 2.30E-03 3.31E-03 4.67E-03 2.10E-03 3.23E-03 4.90E-03 0.00 0.00 0.00 2.10E-03 3.23E-03 4.90E-03 3.26 4.23 5.32 0.76 0.99 1.24 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Klebsiella pneumoniae 3GCRKP RESP - model 2 3.67 4.60 5.76 6.97 9.09 11.18 10.66 13.68 16.74 1.30 1.48 1.69 0.85 1.07 1.34 1.62 2.12 2.61 2.48 3.19 3.90 7.40 9.23 11.10 1.72 2.15 2.58 0.26 0.33 0.41 0.06 0.08 0.10 Malta - Klebsiella pneumoniae 3GCRKP SSI - model 4 5.01E-03 8.71E-03 0.02 1.83 2.47 3.16 1.83 2.47 3.18 0.54 0.59 0.64 1.17E-03 2.03E-03 3.50E-03 0.43 0.57 0.74 0.43 0.58 0.74 3.25 4.20 5.22 0.76 0.98 1.22 0.09 0.12 0.15 0.02 0.03 0.04 Malta - Klebsiella pneumoniae 3GCRKP UTI - model 3 0.02 0.02 0.04 0.00 0.00 0.00 0.02 0.02 0.04 1.34E-03 1.95E-03 2.68E-03 3.71E-03 5.66E-03 8.38E-03 0.00 0.00 0.00 3.71E-03 5.66E-03 8.38E-03 10.15 12.65 14.85 2.36 2.95 3.46 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Klebsiella pneumoniae CRKP BSI - model 6 2.38 3.11 4.07 27.73 41.03 59.48 30.31 44.23 63.09 9.36 13.34 17.50 0.55 0.72 0.95 6.46 9.56 13.85 7.06 10.30 14.70 2.79 3.31 3.91 0.65 0.77 0.91 0.80 1.17 1.64 0.19 0.27 0.38 Malta - Klebsiella pneumoniae CRKP OTH - model 10 2.38E-03 5.12E-03 9.82E-03 0.00 0.00 0.00 2.38E-03 5.12E-03 9.82E-03 1.94E-03 3.41E-03 5.81E-03 5.54E-04 1.19E-03 2.29E-03 0.00 0.00 0.00 5.54E-04 1.19E-03 2.29E-03 0.90 1.54 2.18 0.21 0.36 0.51 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Klebsiella pneumoniae CRKP RESP - model 7 0.47 0.90 1.37 0.97 1.74 2.66 1.43 2.65 3.96 1.47 1.92 2.39 0.11 0.21 0.32 0.23 0.41 0.62 0.33 0.62 0.92 0.78 1.38 2.01 0.18 0.32 0.47 0.03 0.05 0.07 6.54E-03 0.01 0.02 Malta - Klebsiella pneumoniae CRKP SSI - model 9 7.68E-04 1.98E-03 4.06E-03 0.26 0.49 0.73 0.26 0.49 0.73 0.40 0.51 0.61 1.79E-04 4.62E-04 9.45E-04 0.06 0.11 0.17 0.06 0.11 0.17 0.52 0.97 1.40 0.12 0.22 0.33 8.09E-03 0.02 0.03 1.88E-03 4.00E-03 6.22E-03 Malta - Klebsiella pneumoniae CRKP UTI - model 8 1.93E-03 4.07E-03 7.12E-03 0.00 0.00 0.00 1.93E-03 4.07E-03 7.12E-03 1.12E-03 2.03E-03 3.27E-03 4.48E-04 9.47E-04 1.66E-03 0.00 0.00 0.00 4.48E-04 9.47E-04 1.66E-03 1.28 2.01 2.78 0.30 0.47 0.65 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Klebsiella pneumoniae ColRKP BSI - model 11 0.77 1.03 1.40 13.94 22.74 32.79 14.85 23.75 33.90 6.86 10.80 14.38 0.18 0.24 0.33 3.25 5.30 7.64 3.46 5.53 7.89 1.78 2.23 2.74 0.41 0.52 0.64 0.82 1.34 1.95 0.19 0.31 0.45 Malta - Klebsiella pneumoniae ColRKP OTH - model 15 1.14E-03 3.28E-03 7.34E-03 0.00 0.00 0.00 1.14E-03 3.28E-03 7.34E-03 1.59E-03 3.44E-03 6.37E-03 2.66E-04 7.65E-04 1.71E-03 0.00 0.00 0.00 2.66E-04 7.65E-04 1.71E-03 0.47 1.02 1.53 0.11 0.24 0.36 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Klebsiella pneumoniae ColRKP RESP - model 12 0.14 0.30 0.47 0.26 0.58 0.89 0.41 0.88 1.35 0.77 0.93 1.11 0.03 0.07 0.11 0.06 0.14 0.21 0.10 0.21 0.31 0.45 0.95 1.43 0.10 0.22 0.33 0.02 0.03 0.05 3.66E-03 7.98E-03 0.01 Malta - Klebsiella pneumoniae ColRKP SSI - model 14 4.46E-04 1.26E-03 2.95E-03 0.19 0.40 0.62 0.19 0.40 0.62 0.52 0.61 0.70 1.04E-04 2.94E-04 6.87E-04 0.04 0.09 0.14 0.04 0.09 0.15 0.32 0.65 1.01 0.07 0.15 0.24 0.01 0.02 0.04 2.68E-03 5.44E-03 8.47E-03 Malta - Klebsiella pneumoniae ColRKP UTI - model 13 1.11E-03 2.72E-03 5.55E-03 0.00 0.00 0.00 1.11E-03 2.72E-03 5.55E-03 9.91E-04 2.06E-03 3.60E-03 2.58E-04 6.33E-04 1.29E-03 0.00 0.00 0.00 2.58E-04 6.33E-04 1.29E-03 0.70 1.36 2.01 0.16 0.32 0.47 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Pseudomonas aeruginosa CRPA BSI - model 51 2.45 3.09 3.89 16.18 26.67 38.33 19.26 29.65 41.84 4.34 6.58 8.80 0.57 0.72 0.91 3.77 6.21 8.93 4.49 6.91 9.75 3.77 4.52 5.32 0.88 1.05 1.24 0.63 1.04 1.47 0.15 0.24 0.34 Malta - Pseudomonas aeruginosa CRPA OTH - model 55 4.50E-03 8.31E-03 0.01 0.00 0.00 0.00 4.50E-03 8.31E-03 0.01 2.36E-03 3.62E-03 5.13E-03 1.05E-03 1.94E-03 3.09E-03 0.00 0.00 0.00 1.05E-03 1.94E-03 3.09E-03 1.48 2.30 3.08 0.35 0.54 0.72 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Pseudomonas aeruginosa CRPA RESP - model 52 5.93 7.94 10.35 16.19 28.06 40.06 23.17 35.96 49.71 1.52 2.16 2.71 1.38 1.85 2.41 3.77 6.54 9.33 5.40 8.38 11.58 12.76 16.80 20.99 2.97 3.91 4.89 0.65 1.09 1.58 0.15 0.25 0.37 Malta - Pseudomonas aeruginosa CRPA SSI - model 54 3.31E-03 6.43E-03 0.01 0.96 1.59 2.18 0.96 1.60 2.19 0.42 0.52 0.61 7.72E-04 1.50E-03 2.64E-03 0.22 0.37 0.51 0.22 0.37 0.51 2.01 3.09 4.20 0.47 0.72 0.98 0.04 0.07 0.10 9.69E-03 0.02 0.02 Malta - Pseudomonas aeruginosa CRPA UTI - model 53 6.49E-03 0.01 0.02 0.00 0.00 0.00 6.49E-03 0.01 0.02 1.28E-03 2.03E-03 2.90E-03 1.51E-03 2.69E-03 4.42E-03 0.00 0.00 0.00 1.51E-03 2.69E-03 4.42E-03 3.89 5.75 7.51 0.91 1.34 1.75 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Pseudomonas aeruginosa ColRPA BSI - model 56 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Pseudomonas aeruginosa ColRPA OTH - model 60 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Pseudomonas aeruginosa ColRPA RESP - model 57 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Pseudomonas aeruginosa ColRPA SSI - model 59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Pseudomonas aeruginosa ColRPA UTI - model 58 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Pseudomonas aeruginosa MDRPA BSI - model 46 0.11 0.16 0.26 0.40 1.19 2.39 0.54 1.36 2.61 0.54 1.24 1.88 0.02 0.04 0.06 0.09 0.28 0.56 0.12 0.32 0.61 0.80 1.11 1.56 0.19 0.26 0.36 0.08 0.24 0.48 0.02 0.06 0.11 Malta - Pseudomonas aeruginosa MDRPA OTH - model 50 5.09E-04 2.06E-03 4.93E-03 0.00 0.00 0.00 5.09E-04 2.06E-03 4.93E-03 1.52E-03 3.72E-03 6.38E-03 1.19E-04 4.79E-04 1.15E-03 0.00 0.00 0.00 1.19E-04 4.79E-04 1.15E-03 0.17 0.58 1.00 0.04 0.14 0.23 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Pseudomonas aeruginosa MDRPA RESP - model 47 0.21 0.41 0.64 0.47 1.25 2.55 0.73 1.65 3.09 0.24 0.42 0.59 0.05 0.10 0.15 0.11 0.29 0.59 0.17 0.38 0.72 2.21 4.12 6.08 0.51 0.96 1.42 0.09 0.25 0.51 0.02 0.06 0.12 Malta - Pseudomonas aeruginosa MDRPA SSI - model 49 2.83E-04 1.47E-03 4.52E-03 0.05 0.14 0.23 0.05 0.15 0.24 0.18 0.18 0.19 6.59E-05 3.43E-04 1.05E-03 0.01 0.03 0.05 0.01 0.03 0.06 0.27 0.80 1.29 0.06 0.19 0.30 9.59E-03 0.03 0.05 2.23E-03 6.70E-03 0.01 Malta - Pseudomonas aeruginosa MDRPA UTI - model 48 6.95E-04 2.63E-03 6.57E-03 0.00 0.00 0.00 6.95E-04 2.63E-03 6.57E-03 8.09E-04 1.86E-03 3.63E-03 1.62E-04 6.12E-04 1.53E-03 0.00 0.00 0.00 1.62E-04 6.12E-04 1.53E-03 0.60 1.47 2.30 0.14 0.34 0.54 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Staphylococcus aureus MRSA BSI - model 61 17.56 19.70 21.94 121.53 131.59 142.71 140.30 151.35 163.36 3.10 3.27 3.46 4.09 4.59 5.11 28.31 30.65 33.24 32.68 35.25 38.05 43.28 46.27 48.97 10.08 10.78 11.41 7.69 8.32 8.92 1.79 1.94 2.08 Malta - Staphylococcus aureus MRSA OTH - model 65 0.17 0.22 0.28 0.00 0.00 0.00 0.17 0.22 0.28 2.55E-03 3.29E-03 4.03E-03 0.04 0.05 0.07 0.00 0.00 0.00 0.04 0.05 0.07 61.33 68.39 75.77 14.29 15.93 17.65 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Staphylococcus aureus MRSA RESP - model 62 17.96 20.73 23.72 34.39 39.90 45.50 52.60 60.70 68.60 0.80 0.87 0.93 4.18 4.83 5.52 8.01 9.29 10.60 12.25 14.14 15.98 61.76 69.96 77.90 14.39 16.29 18.14 2.19 2.52 2.84 0.51 0.59 0.66 Malta - Staphylococcus aureus MRSA SSI - model 64 0.11 0.16 0.22 26.28 29.73 33.46 26.41 29.90 33.63 0.37 0.39 0.41 0.03 0.04 0.05 6.12 6.92 7.79 6.15 6.96 7.83 67.49 76.20 84.58 15.72 17.75 19.70 1.99 2.26 2.54 0.46 0.53 0.59 Malta - Staphylococcus aureus MRSA UTI - model 63 0.01 0.02 0.03 0.00 0.00 0.00 0.01 0.02 0.03 1.42E-03 1.87E-03 2.37E-03 3.46E-03 4.92E-03 6.73E-03 0.00 0.00 0.00 3.46E-03 4.92E-03 6.73E-03 8.98 11.38 13.67 2.09 2.65 3.18 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Streptococcus pneumoniae PMRSP BSI - model 76 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Streptococcus pneumoniae PMRSP OTH - model 80 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Streptococcus pneumoniae PMRSP RESP - model 77 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Streptococcus pneumoniae PMRSP SSI - model 79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Streptococcus pneumoniae PMRSP UTI - model 78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Streptococcus pneumoniae PRSP BSI - model 71 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Streptococcus pneumoniae PRSP OTH - model 75 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Streptococcus pneumoniae PRSP RESP - model 72 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Streptococcus pneumoniae PRSP SSI - model 74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Malta - Streptococcus pneumoniae PRSP UTI - model 73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total (Median & 95% UIs) 78.45 94.56 113.23 422.92 527.84 649.52 507.25 622.31 755.97 18.27 22.02 26.37 98.50 122.94 151.28 118.15 144.94 176.08 516.72 607.56 697.54 120.35 141.51 162.47 23.38 28.61 34.36 5.45 6.66 8.00 Total (average) - 123.30 145.40 606.94 141.36 28.66 6.68 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 94.90 529.36 624.26 - 22.10 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 Infection Colistin resistant Acinetobacter spp. 4.54 6.94 9.95 16.94 37.07 62.49 21.15 43.95 71.30 7.91 14.09 21.30 0.03 0.04 0.06 0.10 0.22 0.37 0.13 0.26 0.42 6.52 9.21 12.05 0.04 0.05 0.07 0.42 0.79 1.24 0.00 0.00 0.01 Carbapenem resistant Acinetobacter spp. (excluding those resistant to colistin) 3.64 5.41 7.63 13.82 28.87 47.17 18.00 34.36 53.64 4.32 7.30 10.41 0.02 0.03 0.05 0.08 0.17 0.28 0.11 0.20 0.32 9.59 13.85 18.37 0.06 0.08 0.11 0.60 1.19 1.86 0.00 0.01 0.01 Aminoglycosides and fluoroquinolones resistant Acinetobacter spp. (excluding those resistant to colistin and/or carbapenem) 2.91 4.12 5.55 11.47 21.57 33.75 14.96 25.72 38.83 5.34 8.34 11.55 0.02 0.02 0.03 0.07 0.13 0.20 0.09 0.15 0.23 6.43 9.24 11.94 0.04 0.05 0.07 0.42 0.78 1.21 0.00 0.00 0.01 Vancomycin resistant Enterococci (E. faecalis and E. faecium ) 6.42 9.28 13.53 63.49 90.27 128.82 70.54 99.43 140.82 5.57 6.15 6.88 0.04 0.05 0.08 0.38 0.53 0.76 0.42 0.59 0.83 38.97 62.51 90.07 0.23 0.37 0.53 2.89 4.21 6.27 0.02 0.02 0.04 Colistin resistant Escherichia coli 21.50 25.06 29.13 355.22 435.40 520.82 377.41 460.06 549.30 11.24 13.37 15.49 0.13 0.15 0.17 2.10 2.58 3.08 2.23 2.72 3.25 229.42 265.04 302.69 1.36 1.57 1.79 19.13 23.35 27.92 0.11 0.14 0.17 Carbapenem resistant Escherichia coli (excluding those resistant to colistin) 1.04 1.74 2.72 9.63 18.11 29.27 10.95 19.82 31.58 8.69 13.26 18.08 0.01 0.01 0.02 0.06 0.11 0.17 0.06 0.12 0.19 7.06 12.00 17.28 0.04 0.07 0.10 0.32 0.60 0.98 0.00 0.00 0.01 Third-generation cephalosporin resistant Escherichia coli (excluding those resistant to colistin and/or carbapenem) 312.03 352.48 393.50 1,871.90 2,098.90 2,344.43 2,189.15 2,449.98 2,727.98 5.16 5.59 6.04 1.85 2.09 2.33 11.08 12.42 13.87 12.95 14.50 16.14 3,115.24 3,503.37 3,899.09 18.43 20.73 23.07 93.11 107.10 121.02 0.55 0.63 0.72 Colistin resistant Klebsiella pneumoniae 5.43 7.04 8.95 89.86 123.98 164.06 96.14 131.03 172.34 11.05 14.58 18.10 0.03 0.04 0.05 0.53 0.73 0.97 0.57 0.78 1.02 19.78 27.09 34.34 0.12 0.16 0.20 4.45 6.03 7.86 0.03 0.04 0.05 Carbapenem resistant Klebsiella pneumoniae (excluding those resistant to colistin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Third-generation cephalosporin resistant Klebsiella pneumoniae (excluding those resistant to colistin and/or carbapenem) 90.71 99.78 110.00 446.24 480.59 514.85 539.78 580.67 622.29 5.16 5.43 5.72 0.54 0.59 0.65 2.64 2.84 3.05 3.19 3.44 3.68 399.02 444.33 490.19 2.36 2.63 2.90 22.35 24.39 26.34 0.13 0.14 0.16 Colistin resistant Pseudomonas aeruginosa 2.20 3.49 5.18 7.83 17.39 30.41 10.66 20.91 34.82 2.28 4.11 6.28 0.01 0.02 0.03 0.05 0.10 0.18 0.06 0.12 0.21 14.91 23.67 32.29 0.09 0.14 0.19 0.78 1.62 2.65 0.00 0.01 0.02 Carbapenem resistant Pseudomonas aeruginosa (excluding those resistant to colistin) 61.84 73.93 88.15 272.29 377.60 497.80 339.93 451.31 576.06 6.66 8.51 10.37 0.37 0.44 0.52 1.61 2.23 2.95 2.01 2.67 3.41 194.09 236.36 279.81 1.15 1.40 1.66 11.70 16.30 21.52 0.07 0.10 0.13 Pseudomonas aeruginosa resistant to three or more antimicrobial groups (excluding those resistant to colistin and/or carbapenem) 12.76 16.48 20.68 49.77 77.89 111.25 64.86 94.28 130.30 4.30 5.95 7.71 0.08 0.10 0.12 0.29 0.46 0.66 0.38 0.56 0.77 55.66 71.05 86.25 0.33 0.42 0.51 3.10 4.59 6.21 0.02 0.03 0.04 Methicillin resistant Staphylococcus aureus 59.55 67.22 76.61 293.66 321.54 353.47 355.48 389.18 426.28 7.60 8.05 8.50 0.35 0.40 0.45 1.74 1.90 2.09 2.10 2.30 2.52 225.17 249.03 273.31 1.33 1.47 1.62 10.56 11.53 12.56 0.06 0.07 0.07 Penicillin and macrolides resistant Streptococcus pneumoniae (excluding those only resistant to penicillin) 12.20 15.85 21.35 44.50 52.12 64.30 58.20 67.86 83.97 6.24 7.05 7.96 0.07 0.09 0.13 0.26 0.31 0.38 0.34 0.40 0.50 26.52 31.32 39.41 0.16 0.19 0.23 1.67 1.93 2.35 0.01 0.01 0.01 Penicillin tesistant Streptococcus pneumoniae (excluding those resistant to macrolides) 5.47 6.92 9.00 19.40 22.47 26.88 25.34 29.41 35.35 3.74 4.04 4.35 0.03 0.04 0.05 0.11 0.13 0.16 0.15 0.17 0.21 19.94 23.55 29.06 0.12 0.14 0.17 1.25 1.46 1.73 0.01 0.01 0.01 Total 602.23 695.73 801.92 3,566.04 4,203.77 4,929.77 4,192.56 4,897.96 5,694.86 3.56 4.12 4.74 21.10 24.87 29.17 24.81 28.98 33.70 4,368.31 4,981.61 5,616.15 25.85 29.48 33.23 172.75 205.87 241.72 1.02 1.22 1.43 Model Netherlands - Acinetobacter spp. CRACI BSI - model 36 2.25 3.10 4.32 10.58 23.76 39.90 13.50 26.92 43.29 2.90 5.64 8.47 0.01 0.02 0.03 0.06 0.14 0.24 0.08 0.16 0.26 4.00 4.80 5.76 0.02 0.03 0.03 0.46 0.98 1.56 2.71E-03 5.78E-03 9.26E-03 Netherlands - Acinetobacter spp. CRACI OTH - model 40 1.82E-04 5.98E-04 1.35E-03 0.00 0.00 0.00 1.82E-04 5.98E-04 1.35E-03 1.89E-03 3.72E-03 5.92E-03 1.07E-06 3.54E-06 8.01E-06 0.00 0.00 0.00 1.07E-06 3.54E-06 8.01E-06 0.06 0.16 0.31 3.32E-04 9.59E-04 1.82E-03 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Acinetobacter spp. CRACI RESP - model 37 1.38 2.30 3.29 2.92 4.53 6.42 4.17 6.86 9.48 1.12 1.32 1.54 8.19E-03 0.01 0.02 0.02 0.03 0.04 0.02 0.04 0.06 3.58 5.20 6.81 0.02 0.03 0.04 0.13 0.19 0.25 7.67E-04 1.10E-03 1.50E-03 Netherlands - Acinetobacter spp. CRACI SSI - model 39 1.29E-03 3.52E-03 7.29E-03 0.32 0.58 0.85 0.32 0.59 0.86 0.30 0.34 0.38 7.61E-06 2.08E-05 4.31E-05 1.89E-03 3.44E-03 5.01E-03 1.90E-03 3.46E-03 5.09E-03 0.93 1.74 2.59 5.52E-03 0.01 0.02 0.02 0.03 0.05 9.51E-05 1.86E-04 2.73E-04 Netherlands - Acinetobacter spp. CRACI UTI - model 38 1.52E-03 3.84E-03 7.69E-03 0.00 0.00 0.00 1.52E-03 3.84E-03 7.69E-03 1.01E-03 2.05E-03 3.27E-03 8.99E-06 2.27E-05 4.55E-05 0.00 0.00 0.00 8.99E-06 2.27E-05 4.55E-05 1.02 1.95 2.90 6.03E-03 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Acinetobacter spp. ColRACI BSI - model 41 2.75 3.95 5.62 13.00 30.57 53.11 15.27 34.44 57.77 5.57 10.96 17.33 0.02 0.02 0.03 0.08 0.18 0.31 0.09 0.20 0.34 2.69 3.18 3.77 0.02 0.02 0.02 0.32 0.64 1.04 1.89E-03 3.79E-03 6.13E-03 Netherlands - Acinetobacter spp. ColRACI OTH - model 45 1.15E-04 3.73E-04 8.12E-04 0.00 0.00 0.00 1.15E-04 3.73E-04 8.12E-04 1.91E-03 3.69E-03 5.88E-03 6.79E-07 2.21E-06 4.81E-06 0.00 0.00 0.00 6.79E-07 2.21E-06 4.81E-06 0.04 0.11 0.19 2.19E-04 6.35E-04 1.15E-03 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Acinetobacter spp. ColRACI RESP - model 42 1.78 2.98 4.31 3.60 5.85 8.43 5.53 8.85 12.57 1.90 2.58 3.30 0.01 0.02 0.03 0.02 0.03 0.05 0.03 0.05 0.07 2.44 3.45 4.49 0.01 0.02 0.03 0.09 0.12 0.17 5.10E-04 7.25E-04 9.91E-04 Netherlands - Acinetobacter spp. ColRACI SSI - model 44 8.49E-04 2.40E-03 5.17E-03 0.34 0.65 0.95 0.35 0.65 0.96 0.45 0.55 0.66 5.02E-06 1.42E-05 3.06E-05 2.04E-03 3.84E-03 5.65E-03 2.05E-03 3.85E-03 5.66E-03 0.65 1.18 1.70 3.84E-03 6.98E-03 0.01 0.01 0.03 0.04 8.12E-05 1.58E-04 2.34E-04 Netherlands - Acinetobacter spp. ColRACI UTI - model 43 9.90E-04 2.55E-03 4.74E-03 0.00 0.00 0.00 9.90E-04 2.55E-03 4.74E-03 1.01E-03 2.03E-03 3.21E-03 5.86E-06 1.51E-05 2.81E-05 0.00 0.00 0.00 5.86E-06 1.51E-05 2.81E-05 0.71 1.29 1.91 4.21E-03 7.65E-03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Acinetobacter spp. MDRACI BSI - model 31 1.77 2.34 3.14 8.84 17.48 28.20 11.07 19.83 31.00 3.57 6.27 9.17 0.01 0.01 0.02 0.05 0.10 0.17 0.07 0.12 0.18 2.69 3.18 3.77 0.02 0.02 0.02 0.32 0.63 1.00 1.90E-03 3.75E-03 5.93E-03 Netherlands - Acinetobacter spp. MDRACI OTH - model 35 1.00E-04 3.63E-04 8.30E-04 0.00 0.00 0.00 1.00E-04 3.63E-04 8.30E-04 1.87E-03 3.72E-03 5.97E-03 5.94E-07 2.15E-06 4.91E-06 0.00 0.00 0.00 5.94E-07 2.15E-06 4.91E-06 0.03 0.10 0.19 2.00E-04 6.11E-04 1.11E-03 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Acinetobacter spp. MDRACI RESP - model 32 1.14 1.77 2.40 2.27 3.46 4.63 3.53 5.25 6.90 1.33 1.52 1.74 6.75E-03 0.01 0.01 0.01 0.02 0.03 0.02 0.03 0.04 2.39 3.46 4.43 0.01 0.02 0.03 0.08 0.12 0.16 4.92E-04 7.36E-04 9.71E-04 Netherlands - Acinetobacter spp. MDRACI SSI - model 34 8.41E-04 2.35E-03 5.14E-03 0.36 0.63 0.92 0.36 0.64 0.93 0.43 0.54 0.64 4.98E-06 1.39E-05 3.04E-05 2.10E-03 3.75E-03 5.46E-03 2.12E-03 3.76E-03 5.48E-03 0.69 1.18 1.66 4.07E-03 7.01E-03 9.83E-03 0.01 0.03 0.04 8.15E-05 1.56E-04 2.34E-04 Netherlands - Acinetobacter spp. MDRACI UTI - model 33 1.02E-03 2.53E-03 4.86E-03 0.00 0.00 0.00 1.02E-03 2.53E-03 4.86E-03 1.03E-03 2.00E-03 3.22E-03 6.01E-06 1.50E-05 2.87E-05 0.00 0.00 0.00 6.01E-06 1.50E-05 2.87E-05 0.63 1.31 1.89 3.74E-03 7.75E-03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Enterococcus faecalis and E. faecium VRE BSI - model 66 6.38 9.19 13.37 56.26 78.03 111.05 63.26 87.09 122.94 5.06 5.58 6.26 0.04 0.05 0.08 0.33 0.46 0.66 0.37 0.52 0.73 11.15 15.64 23.20 0.07 0.09 0.14 2.54 3.57 5.33 0.02 0.02 0.03 Netherlands - Enterococcus faecalis and E. faecium VRE OTH - model 70 0.01 0.03 0.05 0.00 0.00 0.00 0.01 0.03 0.05 9.86E-04 1.59E-03 2.52E-03 8.12E-05 1.56E-04 2.89E-04 0.00 0.00 0.00 8.12E-05 1.56E-04 2.89E-04 9.94 17.00 24.11 0.06 0.10 0.14 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Enterococcus faecalis and E. faecium VRE RESP - model 67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Enterococcus faecalis and E. faecium VRE SSI - model 69 0.02 0.04 0.09 7.24 12.25 17.77 7.26 12.30 17.81 0.51 0.57 0.62 1.24E-04 2.63E-04 5.25E-04 0.04 0.07 0.11 0.04 0.07 0.11 13.05 21.82 31.12 0.08 0.13 0.18 0.35 0.63 0.94 2.10E-03 3.75E-03 5.57E-03 Netherlands - Enterococcus faecalis and E. faecium VRE UTI - model 68 7.44E-03 0.01 0.03 0.00 0.00 0.00 7.44E-03 0.01 0.03 1.11E-03 1.87E-03 2.80E-03 4.40E-05 8.62E-05 1.61E-04 0.00 0.00 0.00 4.40E-05 8.62E-05 1.61E-04 4.83 8.05 11.65 0.03 0.05 0.07 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Escherichia coli 3GCREC BSI - model 16 239.51 265.65 290.64 1,548.14 1,716.16 1,897.92 1,792.74 1,980.31 2,179.07 3.73 4.04 4.36 1.42 1.57 1.72 9.16 10.15 11.23 10.61 11.72 12.89 457.06 490.76 530.03 2.70 2.90 3.14 74.61 84.85 95.09 0.44 0.50 0.56 Netherlands - Escherichia coli 3GCREC OTH - model 20 0.40 0.54 0.71 0.00 0.00 0.00 0.40 0.54 0.71 2.70E-03 3.35E-03 4.15E-03 2.39E-03 3.17E-03 4.23E-03 0.00 0.00 0.00 2.39E-03 3.17E-03 4.23E-03 131.16 162.13 192.32 0.78 0.96 1.14 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Escherichia coli 3GCREC RESP - model 17 68.08 81.05 95.53 131.88 157.36 185.24 199.88 238.45 280.44 1.01 1.10 1.20 0.40 0.48 0.57 0.78 0.93 1.10 1.18 1.41 1.66 180.17 216.71 254.57 1.07 1.28 1.51 6.38 7.80 9.30 0.04 0.05 0.06 Netherlands - Escherichia coli 3GCREC SSI - model 19 0.81 1.10 1.44 191.88 225.38 261.27 192.91 226.54 262.58 0.41 0.44 0.46 4.77E-03 6.53E-03 8.51E-03 1.14 1.33 1.55 1.14 1.34 1.55 449.46 518.75 589.03 2.66 3.07 3.49 12.12 14.44 16.63 0.07 0.09 0.10 Netherlands - Escherichia coli 3GCREC UTI - model 18 3.22 4.14 5.17 0.00 0.00 0.00 3.22 4.14 5.17 1.56E-03 1.95E-03 2.38E-03 0.02 0.02 0.03 0.00 0.00 0.00 0.02 0.02 0.03 1,897.39 2,115.01 2,333.14 11.23 12.51 13.80 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Escherichia coli CREC BSI - model 21 0.87 1.27 1.92 9.02 16.71 27.04 10.17 17.94 28.59 6.99 11.35 15.93 5.12E-03 7.49E-03 0.01 0.05 0.10 0.16 0.06 0.11 0.17 1.23 1.59 2.11 7.29E-03 9.41E-03 0.01 0.30 0.56 0.90 1.78E-03 3.29E-03 5.34E-03 Netherlands - Escherichia coli CREC OTH - model 25 9.66E-04 2.87E-03 8.01E-03 0.00 0.00 0.00 9.66E-04 2.87E-03 8.01E-03 1.23E-03 3.18E-03 7.40E-03 5.71E-06 1.70E-05 4.74E-05 0.00 0.00 0.00 5.71E-06 1.70E-05 4.74E-05 0.43 0.92 1.45 2.57E-03 5.45E-03 8.59E-03 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Escherichia coli CREC RESP - model 22 0.17 0.45 0.75 0.33 0.88 1.46 0.50 1.34 2.18 1.42 1.63 1.87 1.02E-03 2.68E-03 4.46E-03 1.95E-03 5.22E-03 8.63E-03 2.98E-03 7.94E-03 0.01 0.31 0.82 1.30 1.84E-03 4.88E-03 7.71E-03 0.01 0.03 0.05 6.48E-05 1.74E-04 2.87E-04 Netherlands - Escherichia coli CREC SSI - model 24 8.29E-04 3.55E-03 9.83E-03 0.28 0.52 0.77 0.28 0.52 0.77 0.27 0.27 0.28 4.91E-06 2.10E-05 5.81E-05 1.63E-03 3.06E-03 4.53E-03 1.64E-03 3.09E-03 4.55E-03 1.02 1.91 2.82 6.04E-03 0.01 0.02 9.19E-03 0.02 0.03 5.44E-05 1.02E-04 1.50E-04 Netherlands - Escherichia coli CREC UTI - model 23 4.50E-03 0.01 0.03 0.00 0.00 0.00 4.50E-03 0.01 0.03 7.61E-04 1.97E-03 4.04E-03 2.66E-05 7.59E-05 1.70E-04 0.00 0.00 0.00 2.66E-05 7.59E-05 1.70E-04 4.06 6.75 9.59 0.02 0.04 0.06 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Escherichia coli ColREC BSI - model 26 16.20 18.32 20.86 330.51 405.15 484.68 347.40 423.05 505.12 9.90 11.90 13.87 0.10 0.11 0.12 1.96 2.40 2.87 2.06 2.50 2.99 32.74 35.63 38.83 0.19 0.21 0.23 17.62 21.50 25.72 0.10 0.13 0.15 Netherlands - Escherichia coli ColREC OTH - model 30 0.05 0.07 0.10 0.00 0.00 0.00 0.05 0.07 0.10 2.56E-03 3.50E-03 4.75E-03 2.91E-04 4.20E-04 5.99E-04 0.00 0.00 0.00 2.91E-04 4.20E-04 5.99E-04 16.61 20.40 23.91 0.10 0.12 0.14 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Escherichia coli ColREC RESP - model 27 4.97 6.27 7.63 9.74 12.03 14.78 14.69 18.31 22.23 0.92 1.03 1.14 0.03 0.04 0.05 0.06 0.07 0.09 0.09 0.11 0.13 14.54 17.83 21.55 0.09 0.11 0.13 0.51 0.64 0.78 3.05E-03 3.79E-03 4.63E-03 Netherlands - Escherichia coli ColREC SSI - model 29 0.06 0.09 0.12 14.97 18.23 21.36 15.04 18.32 21.45 0.41 0.44 0.46 3.62E-04 5.27E-04 7.36E-04 0.09 0.11 0.13 0.09 0.11 0.13 35.45 42.00 48.64 0.21 0.25 0.29 0.99 1.20 1.42 5.86E-03 7.12E-03 8.42E-03 Netherlands - Escherichia coli ColREC UTI - model 28 0.22 0.31 0.40 0.00 0.00 0.00 0.22 0.31 0.40 1.57E-03 2.08E-03 2.68E-03 1.33E-03 1.83E-03 2.40E-03 0.00 0.00 0.00 1.33E-03 1.83E-03 2.40E-03 130.08 149.18 169.75 0.77 0.88 1.00 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Klebsiella pneumoniae 3GCRKP BSI - model 1 57.21 61.91 67.60 364.49 387.78 410.84 424.04 449.83 476.15 3.70 3.87 4.06 0.34 0.37 0.40 2.16 2.29 2.43 2.51 2.66 2.82 109.61 116.14 122.60 0.65 0.69 0.73 18.08 19.42 20.71 0.11 0.11 0.12 Netherlands - Klebsiella pneumoniae 3GCRKP OTH - model 5 0.11 0.15 0.20 0.00 0.00 0.00 0.11 0.15 0.20 2.65E-03 3.34E-03 4.11E-03 6.79E-04 9.08E-04 1.16E-03 0.00 0.00 0.00 6.79E-04 9.08E-04 1.16E-03 39.29 45.83 52.76 0.23 0.27 0.31 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Klebsiella pneumoniae 3GCRKP RESP - model 2 33.10 37.35 41.73 63.96 72.02 80.22 97.53 109.53 121.68 1.02 1.09 1.17 0.20 0.22 0.25 0.38 0.43 0.47 0.58 0.65 0.72 89.13 100.41 111.56 0.53 0.59 0.66 3.14 3.62 4.06 0.02 0.02 0.02 Netherlands - Klebsiella pneumoniae 3GCRKP SSI - model 4 0.07 0.10 0.13 17.79 20.79 23.80 17.88 20.89 23.93 0.43 0.46 0.48 4.29E-04 5.72E-04 7.71E-04 0.11 0.12 0.14 0.11 0.12 0.14 39.36 45.60 52.01 0.23 0.27 0.31 1.13 1.36 1.57 6.68E-03 8.03E-03 9.29E-03 Netherlands - Klebsiella pneumoniae 3GCRKP UTI - model 3 0.21 0.27 0.33 0.00 0.00 0.00 0.21 0.27 0.33 1.60E-03 1.96E-03 2.37E-03 1.23E-03 1.58E-03 1.98E-03 0.00 0.00 0.00 1.23E-03 1.58E-03 1.98E-03 121.63 136.36 151.25 0.72 0.81 0.89 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Klebsiella pneumoniae CRKP BSI - model 6 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Klebsiella pneumoniae CRKP OTH - model 10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Klebsiella pneumoniae CRKP RESP - model 7 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Klebsiella pneumoniae CRKP SSI - model 9 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Klebsiella pneumoniae CRKP UTI - model 8 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Klebsiella pneumoniae ColRKP BSI - model 11 4.44 5.42 6.68 87.17 119.52 157.87 92.41 124.95 163.89 9.66 12.96 16.25 0.03 0.03 0.04 0.52 0.71 0.93 0.55 0.74 0.97 8.35 9.67 11.15 0.05 0.06 0.07 4.31 5.80 7.55 0.03 0.03 0.04 Netherlands - Klebsiella pneumoniae ColRKP OTH - model 15 7.64E-03 0.02 0.03 0.00 0.00 0.00 7.64E-03 0.02 0.03 2.16E-03 3.46E-03 5.34E-03 4.52E-05 9.13E-05 1.62E-04 0.00 0.00 0.00 4.52E-05 9.13E-05 1.62E-04 2.89 4.58 6.03 0.02 0.03 0.04 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Klebsiella pneumoniae ColRKP RESP - model 12 0.97 1.58 2.21 1.88 3.03 4.18 2.89 4.63 6.38 0.99 1.12 1.27 5.75E-03 9.33E-03 0.01 0.01 0.02 0.02 0.02 0.03 0.04 2.64 4.09 5.49 0.02 0.02 0.03 0.09 0.15 0.20 5.61E-04 8.68E-04 1.19E-03 Netherlands - Klebsiella pneumoniae ColRKP SSI - model 14 3.14E-03 5.95E-03 0.01 0.81 1.43 2.02 0.82 1.43 2.02 0.40 0.49 0.57 1.86E-05 3.52E-05 6.04E-05 4.80E-03 8.44E-03 0.01 4.85E-03 8.48E-03 0.01 1.91 2.86 3.89 0.01 0.02 0.02 0.05 0.08 0.11 2.75E-04 4.59E-04 6.45E-04 Netherlands - Klebsiella pneumoniae ColRKP UTI - model 13 6.91E-03 0.01 0.02 0.00 0.00 0.00 6.91E-03 0.01 0.02 1.36E-03 2.08E-03 3.11E-03 4.09E-05 7.18E-05 1.17E-04 0.00 0.00 0.00 4.09E-05 7.18E-05 1.17E-04 4.00 5.89 7.78 0.02 0.03 0.05 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Pseudomonas aeruginosa CRPA BSI - model 51 17.93 20.90 24.39 129.14 179.10 235.34 149.27 199.83 256.82 4.63 6.05 7.46 0.11 0.12 0.14 0.76 1.06 1.39 0.88 1.18 1.52 29.24 33.03 37.15 0.17 0.20 0.22 5.49 7.69 10.04 0.03 0.05 0.06 Netherlands - Pseudomonas aeruginosa CRPA OTH - model 55 0.04 0.06 0.09 0.00 0.00 0.00 0.04 0.06 0.09 2.78E-03 3.68E-03 4.69E-03 2.46E-04 3.61E-04 5.12E-04 0.00 0.00 0.00 2.46E-04 3.61E-04 5.12E-04 12.76 16.70 20.69 0.08 0.10 0.12 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Pseudomonas aeruginosa CRPA RESP - model 52 43.78 52.83 63.47 135.74 188.11 249.15 183.12 240.89 305.66 1.60 1.99 2.41 0.26 0.31 0.38 0.80 1.11 1.47 1.08 1.43 1.81 101.61 121.58 142.81 0.60 0.72 0.85 5.79 8.01 10.70 0.03 0.05 0.06 Netherlands - Pseudomonas aeruginosa CRPA SSI - model 54 0.03 0.05 0.07 7.41 10.39 13.32 7.44 10.45 13.38 0.42 0.46 0.50 1.79E-04 2.78E-04 4.31E-04 0.04 0.06 0.08 0.04 0.06 0.08 17.17 22.60 27.84 0.10 0.13 0.16 0.42 0.60 0.78 2.49E-03 3.55E-03 4.60E-03 Netherlands - Pseudomonas aeruginosa CRPA UTI - model 53 0.06 0.09 0.12 0.00 0.00 0.00 0.06 0.09 0.12 1.52E-03 2.04E-03 2.65E-03 3.53E-04 5.10E-04 7.17E-04 0.00 0.00 0.00 3.53E-04 5.10E-04 7.17E-04 33.31 42.45 51.32 0.20 0.25 0.30 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Pseudomonas aeruginosa ColRPA BSI - model 56 0.68 0.98 1.38 3.62 8.12 14.17 4.57 9.11 15.35 1.44 2.81 4.38 4.03E-03 5.81E-03 8.16E-03 0.02 0.05 0.08 0.03 0.05 0.09 2.54 3.30 4.15 0.02 0.02 0.02 0.36 0.76 1.24 2.14E-03 4.49E-03 7.35E-03 Netherlands - Pseudomonas aeruginosa ColRPA OTH - model 60 2.48E-03 6.11E-03 0.01 0.00 0.00 0.00 2.48E-03 6.11E-03 0.01 1.91E-03 3.77E-03 5.70E-03 1.47E-05 3.62E-05 7.17E-05 0.00 0.00 0.00 1.47E-05 3.62E-05 7.17E-05 0.87 1.69 2.52 5.14E-03 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Pseudomonas aeruginosa ColRPA RESP - model 57 1.51 2.49 3.76 3.80 8.37 14.88 5.67 10.88 18.08 0.56 0.91 1.38 8.93E-03 0.01 0.02 0.02 0.05 0.09 0.03 0.06 0.11 8.00 12.12 16.13 0.05 0.07 0.10 0.38 0.78 1.28 2.22E-03 4.63E-03 7.58E-03 Netherlands - Pseudomonas aeruginosa ColRPA SSI - model 59 1.49E-03 4.47E-03 9.64E-03 0.41 0.89 1.36 0.41 0.90 1.37 0.28 0.39 0.51 8.83E-06 2.65E-05 5.70E-05 2.41E-03 5.29E-03 8.03E-03 2.43E-03 5.33E-03 8.08E-03 1.17 2.28 3.43 6.95E-03 0.01 0.02 0.04 0.08 0.12 2.50E-04 4.86E-04 7.31E-04 Netherlands - Pseudomonas aeruginosa ColRPA UTI - model 58 3.51E-03 8.35E-03 0.02 0.00 0.00 0.00 3.51E-03 8.35E-03 0.02 1.02E-03 2.00E-03 3.30E-03 2.08E-05 4.94E-05 9.18E-05 0.00 0.00 0.00 2.08E-05 4.94E-05 9.18E-05 2.34 4.28 6.06 0.01 0.03 0.04 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Pseudomonas aeruginosa MDRPA BSI - model 46 3.78 4.63 5.64 22.34 35.83 51.65 26.65 40.38 56.18 2.83 4.09 5.41 0.02 0.03 0.03 0.13 0.21 0.31 0.16 0.24 0.33 8.55 9.91 11.32 0.05 0.06 0.07 1.39 2.11 2.80 8.25E-03 0.01 0.02 Netherlands - Pseudomonas aeruginosa MDRPA OTH - model 50 0.01 0.02 0.03 0.00 0.00 0.00 0.01 0.02 0.03 2.66E-03 3.72E-03 4.96E-03 6.82E-05 1.10E-04 1.66E-04 0.00 0.00 0.00 6.82E-05 1.10E-04 1.66E-04 3.63 5.06 6.51 0.02 0.03 0.04 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Pseudomonas aeruginosa MDRPA RESP - model 47 8.95 11.79 14.96 25.23 38.93 55.54 35.97 50.71 69.98 1.05 1.39 1.77 0.05 0.07 0.09 0.15 0.23 0.33 0.21 0.30 0.41 29.18 36.52 43.69 0.17 0.22 0.26 1.56 2.26 3.14 9.23E-03 0.01 0.02 Netherlands - Pseudomonas aeruginosa MDRPA SSI - model 49 8.42E-03 0.01 0.02 2.19 3.13 4.06 2.20 3.15 4.08 0.41 0.47 0.52 4.98E-05 8.46E-05 1.32E-04 0.01 0.02 0.02 0.01 0.02 0.02 4.84 6.76 8.64 0.03 0.04 0.05 0.15 0.21 0.28 8.78E-04 1.26E-03 1.64E-03 Netherlands - Pseudomonas aeruginosa MDRPA UTI - model 48 0.02 0.03 0.04 0.00 0.00 0.00 0.02 0.03 0.04 1.44E-03 2.05E-03 2.75E-03 9.70E-05 1.54E-04 2.31E-04 0.00 0.00 0.00 9.70E-05 1.54E-04 2.31E-04 9.45 12.80 16.09 0.06 0.08 0.10 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Staphylococcus aureus MRSA BSI - model 61 29.46 32.72 36.75 205.36 221.80 239.28 236.78 254.86 273.38 5.67 5.99 6.28 0.17 0.19 0.22 1.22 1.31 1.42 1.40 1.51 1.62 40.15 42.49 45.04 0.24 0.25 0.27 7.11 7.63 8.19 0.04 0.05 0.05 Netherlands - Staphylococcus aureus MRSA OTH - model 65 0.16 0.20 0.26 0.00 0.00 0.00 0.16 0.20 0.26 2.55E-03 3.25E-03 4.04E-03 9.27E-04 1.21E-03 1.54E-03 0.00 0.00 0.00 9.27E-04 1.21E-03 1.54E-03 56.04 62.60 68.83 0.33 0.37 0.41 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Staphylococcus aureus MRSA RESP - model 62 29.82 34.13 39.38 58.72 66.55 77.49 88.82 100.76 115.76 1.47 1.58 1.72 0.18 0.20 0.23 0.35 0.39 0.46 0.53 0.60 0.68 57.53 63.79 70.64 0.34 0.38 0.42 2.04 2.30 2.58 0.01 0.01 0.02 Netherlands - Staphylococcus aureus MRSA SSI - model 64 0.10 0.15 0.20 29.59 33.19 36.70 29.71 33.33 36.85 0.46 0.48 0.50 6.19E-04 8.89E-04 1.18E-03 0.18 0.20 0.22 0.18 0.20 0.22 63.05 69.82 76.47 0.37 0.41 0.45 1.41 1.60 1.79 8.36E-03 9.49E-03 0.01 Netherlands - Staphylococcus aureus MRSA UTI - model 63 0.01 0.02 0.03 0.00 0.00 0.00 0.01 0.02 0.03 1.47E-03 1.87E-03 2.33E-03 8.32E-05 1.13E-04 1.56E-04 0.00 0.00 0.00 8.32E-05 1.13E-04 1.56E-04 8.41 10.32 12.32 0.05 0.06 0.07 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Streptococcus pneumoniae PMRSP BSI - model 76 3.60 4.42 5.36 27.15 29.92 32.72 31.49 34.38 37.59 5.11 5.58 6.10 0.02 0.03 0.03 0.16 0.18 0.19 0.19 0.20 0.22 6.16 6.16 6.16 0.04 0.04 0.04 1.01 1.11 1.20 6.00E-03 6.56E-03 7.09E-03 Netherlands - Streptococcus pneumoniae PMRSP OTH - model 80 2.37E-03 4.22E-03 6.79E-03 0.00 0.00 0.00 2.37E-03 4.22E-03 6.79E-03 1.12E-03 1.93E-03 2.92E-03 1.40E-05 2.50E-05 4.02E-05 0.00 0.00 0.00 1.40E-05 2.50E-05 4.02E-05 1.91 2.18 2.58 0.01 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Streptococcus pneumoniae PMRSP RESP - model 77 8.59 11.42 15.99 17.35 22.20 31.58 26.71 33.48 46.37 1.13 1.47 1.85 0.05 0.07 0.09 0.10 0.13 0.19 0.16 0.20 0.27 18.45 22.98 30.66 0.11 0.14 0.18 0.65 0.83 1.15 3.85E-03 4.89E-03 6.81E-03 Netherlands - Streptococcus pneumoniae PMRSP SSI - model 79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Streptococcus pneumoniae PMRSP UTI - model 78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Streptococcus pneumoniae PRSP BSI - model 71 1.61 1.90 2.24 11.85 12.84 13.94 13.69 14.75 15.85 2.96 3.19 3.43 9.50E-03 0.01 0.01 0.07 0.08 0.08 0.08 0.09 0.09 4.62 4.62 4.62 0.03 0.03 0.03 0.77 0.83 0.90 4.54E-03 4.92E-03 5.33E-03 Netherlands - Streptococcus pneumoniae PRSP OTH - model 75 1.82E-03 3.23E-03 5.01E-03 0.00 0.00 0.00 1.82E-03 3.23E-03 5.01E-03 1.12E-03 1.97E-03 2.97E-03 1.07E-05 1.91E-05 2.97E-05 0.00 0.00 0.00 1.07E-05 1.91E-05 2.97E-05 1.44 1.64 1.91 8.50E-03 9.72E-03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Streptococcus pneumoniae PRSP RESP - model 72 3.86 5.02 6.76 7.55 9.62 12.95 11.64 14.65 19.50 0.77 0.85 0.92 0.02 0.03 0.04 0.04 0.06 0.08 0.07 0.09 0.12 13.89 17.29 22.53 0.08 0.10 0.13 0.49 0.63 0.83 2.89E-03 3.70E-03 4.91E-03 Netherlands - Streptococcus pneumoniae PRSP SSI - model 74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Netherlands - Streptococcus pneumoniae PRSP UTI - model 73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total (Median & 95% UIs) 602.23 695.73 801.92 3,566.04 4,203.77 4,929.77 4,192.56 4,897.96 5,694.86 3.56 4.12 4.74 21.10 24.87 29.17 24.81 28.98 33.70 4,368.31 4,981.61 5,616.15 25.85 29.48 33.23 172.75 205.87 241.72 1.02 1.22 1.43 Total (average) - 24.94 29.07 4,982.94 29.48 206.31 1.22 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 698.40 4,215.35 4,913.75 - 4.13 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 Infection Colistin resistant Acinetobacter spp. 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Acinetobacter spp. (excluding those resistant to colistin) 3.33 4.40 5.77 14.13 23.99 35.88 17.99 28.32 40.67 6.33 9.43 12.63 0.06 0.09 0.11 0.27 0.46 0.69 0.35 0.55 0.79 6.84 8.97 11.27 0.13 0.17 0.22 0.48 0.79 1.14 0.01 0.02 0.02 Aminoglycosides and fluoroquinolones resistant Acinetobacter spp. (excluding those resistant to colistin and/or carbapenem) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Vancomycin resistant Enterococci (E. faecalis and E. faecium ) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Colistin resistant Escherichia coli 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Escherichia coli (excluding those resistant to colistin) 0.22 0.38 0.59 2.09 3.99 6.52 2.38 4.39 7.01 3.00 4.48 5.87 0.00 0.01 0.01 0.04 0.08 0.13 0.05 0.08 0.14 4.58 7.82 11.19 0.09 0.15 0.22 0.23 0.43 0.70 0.00 0.01 0.01 Third-generation cephalosporin resistant Escherichia coli (excluding those resistant to colistin and/or carbapenem) 136.48 153.20 170.25 810.20 907.38 1,015.70 949.98 1,061.23 1,184.78 5.26 5.72 6.20 2.64 2.97 3.30 15.68 17.56 19.66 18.39 20.54 22.93 1,320.91 1,483.51 1,646.22 25.57 28.71 31.86 39.90 45.27 50.80 0.77 0.88 0.98 Colistin resistant Klebsiella pneumoniae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Klebsiella pneumoniae (excluding those resistant to colistin) 0.92 1.59 2.56 8.81 17.21 28.31 10.03 18.79 30.31 12.70 19.73 26.64 0.02 0.03 0.05 0.17 0.33 0.55 0.19 0.36 0.59 1.40 2.95 4.60 0.03 0.06 0.09 0.20 0.39 0.64 0.00 0.01 0.01 Third-generation cephalosporin resistant Klebsiella pneumoniae (excluding those resistant to colistin and/or carbapenem) 27.03 30.31 33.80 134.00 146.11 158.66 161.96 176.54 190.84 5.19 5.52 5.85 0.52 0.59 0.65 2.59 2.83 3.07 3.13 3.42 3.69 117.75 132.48 147.54 2.28 2.56 2.86 6.63 7.27 7.95 0.13 0.14 0.15 Colistin resistant Pseudomonas aeruginosa 0.31 0.56 0.89 0.92 2.55 5.17 1.30 3.11 5.94 0.97 1.92 2.86 0.01 0.01 0.02 0.02 0.05 0.10 0.03 0.06 0.11 3.86 7.66 11.66 0.07 0.15 0.23 0.18 0.51 1.04 0.00 0.01 0.02 Carbapenem resistant Pseudomonas aeruginosa (excluding those resistant to colistin) 24.24 29.33 34.98 106.60 148.64 194.84 132.80 177.90 226.17 6.14 7.92 9.86 0.47 0.57 0.68 2.06 2.88 3.77 2.57 3.44 4.38 82.20 100.15 117.47 1.59 1.94 2.27 4.91 6.82 8.98 0.10 0.13 0.17 Pseudomonas aeruginosa resistant to three or more antimicrobial groups (excluding those resistant to colistin and/or carbapenem) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Methicillin resistant Staphylococcus aureus 21.44 24.60 28.22 106.47 117.73 130.18 128.90 142.36 156.87 6.66 7.20 7.77 0.41 0.48 0.55 2.06 2.28 2.52 2.49 2.76 3.04 91.68 101.97 112.82 1.77 1.97 2.18 4.38 4.82 5.28 0.08 0.09 0.10 Penicillin and macrolides resistant Streptococcus pneumoniae (excluding those only resistant to penicillin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Penicillin tesistant Streptococcus pneumoniae (excluding those resistant to macrolides) 19.17 23.04 28.39 67.53 76.26 88.07 88.12 99.35 115.47 8.34 8.98 9.72 0.37 0.45 0.55 1.31 1.48 1.70 1.71 1.92 2.24 31.59 36.05 42.19 0.61 0.70 0.82 1.98 2.22 2.53 0.04 0.04 0.05 Total 233.15 267.41 305.44 1,250.75 1,443.85 1,663.33 1,493.47 1,711.97 1,958.06 4.51 5.18 5.91 24.21 27.95 32.19 28.91 33.14 37.90 1,660.81 1,881.57 2,104.97 32.15 36.42 40.74 58.87 68.53 79.07 1.14 1.33 1.53 Model Norway - Acinetobacter spp. CRACI BSI - model 36 2.00 2.53 3.24 11.04 19.63 30.02 13.52 22.11 32.43 4.35 7.14 9.98 0.04 0.05 0.06 0.21 0.38 0.58 0.26 0.43 0.63 2.71 3.12 3.57 0.05 0.06 0.07 0.37 0.64 0.95 7.15E-03 0.01 0.02 Norway - Acinetobacter spp. CRACI OTH - model 40 1.61E-04 4.08E-04 7.75E-04 0.00 0.00 0.00 1.61E-04 4.08E-04 7.75E-04 2.26E-03 3.73E-03 5.40E-03 3.12E-06 7.90E-06 1.50E-05 0.00 0.00 0.00 3.12E-06 7.90E-06 1.50E-05 0.05 0.11 0.18 9.92E-04 2.20E-03 3.57E-03 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Acinetobacter spp. CRACI RESP - model 37 1.32 1.87 2.52 2.62 3.66 4.91 4.00 5.51 7.29 1.40 1.66 1.97 0.03 0.04 0.05 0.05 0.07 0.10 0.08 0.11 0.14 2.52 3.35 4.20 0.05 0.06 0.08 0.09 0.12 0.15 1.71E-03 2.33E-03 3.00E-03 Norway - Acinetobacter spp. CRACI SSI - model 39 1.00E-03 2.32E-03 4.39E-03 0.47 0.70 0.95 0.47 0.70 0.95 0.58 0.62 0.66 1.94E-05 4.50E-05 8.50E-05 9.10E-03 0.01 0.02 9.12E-03 0.01 0.02 0.76 1.13 1.58 0.01 0.02 0.03 0.02 0.03 0.04 3.84E-04 5.92E-04 8.31E-04 Norway - Acinetobacter spp. CRACI UTI - model 38 1.23E-03 2.49E-03 4.14E-03 0.00 0.00 0.00 1.23E-03 2.49E-03 4.14E-03 1.18E-03 2.01E-03 3.05E-03 2.38E-05 4.82E-05 8.02E-05 0.00 0.00 0.00 2.38E-05 4.82E-05 8.02E-05 0.80 1.25 1.74 0.02 0.02 0.03 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Acinetobacter spp. ColRACI BSI - model 41 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Acinetobacter spp. ColRACI OTH - model 45 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Acinetobacter spp. ColRACI RESP - model 42 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Acinetobacter spp. ColRACI SSI - model 44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Acinetobacter spp. ColRACI UTI - model 43 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Acinetobacter spp. MDRACI BSI - model 31 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Acinetobacter spp. MDRACI OTH - model 35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Acinetobacter spp. MDRACI RESP - model 32 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Acinetobacter spp. MDRACI SSI - model 34 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Acinetobacter spp. MDRACI UTI - model 33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Enterococcus faecalis and E. faecium VRE BSI - model 66 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Enterococcus faecalis and E. faecium VRE OTH - model 70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Enterococcus faecalis and E. faecium VRE RESP - model 67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Enterococcus faecalis and E. faecium VRE SSI - model 69 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Enterococcus faecalis and E. faecium VRE UTI - model 68 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Escherichia coli 3GCREC BSI - model 16 105.02 115.38 125.91 672.15 743.98 828.01 780.66 860.08 953.00 3.82 4.14 4.49 2.03 2.23 2.44 13.01 14.40 16.03 15.11 16.65 18.45 193.50 207.59 221.90 3.75 4.02 4.29 32.02 35.88 39.92 0.62 0.69 0.77 Norway - Escherichia coli 3GCREC OTH - model 20 0.17 0.23 0.29 0.00 0.00 0.00 0.17 0.23 0.29 2.72E-03 3.35E-03 4.06E-03 3.35E-03 4.47E-03 5.69E-03 0.00 0.00 0.00 3.35E-03 4.47E-03 5.69E-03 56.77 68.72 82.33 1.10 1.33 1.59 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Escherichia coli 3GCREC RESP - model 17 29.56 35.38 41.30 57.00 68.61 79.13 86.61 103.86 120.05 1.03 1.13 1.24 0.57 0.68 0.80 1.10 1.33 1.53 1.68 2.01 2.32 75.88 92.15 106.70 1.47 1.78 2.07 2.73 3.31 3.86 0.05 0.06 0.07 Norway - Escherichia coli 3GCREC SSI - model 19 0.35 0.47 0.61 81.05 94.79 108.56 81.15 95.32 109.29 0.41 0.43 0.46 6.75E-03 9.12E-03 0.01 1.57 1.83 2.10 1.57 1.84 2.12 190.68 220.04 247.06 3.69 4.26 4.78 5.15 6.09 7.03 0.10 0.12 0.14 Norway - Escherichia coli 3GCREC UTI - model 18 1.38 1.74 2.14 0.00 0.00 0.00 1.38 1.74 2.14 1.59E-03 1.95E-03 2.34E-03 0.03 0.03 0.04 0.00 0.00 0.00 0.03 0.03 0.04 804.08 895.02 988.24 15.56 17.32 19.13 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Escherichia coli CREC BSI - model 21 0.18 0.28 0.40 1.80 3.40 5.62 2.04 3.68 5.92 2.22 3.62 4.94 3.57E-03 5.35E-03 7.80E-03 0.03 0.07 0.11 0.04 0.07 0.11 0.80 1.03 1.35 0.02 0.02 0.03 0.19 0.37 0.60 3.75E-03 7.09E-03 0.01 Norway - Escherichia coli CREC OTH - model 25 6.15E-04 1.87E-03 4.91E-03 0.00 0.00 0.00 6.15E-04 1.87E-03 4.91E-03 1.23E-03 3.29E-03 7.28E-03 1.19E-05 3.61E-05 9.51E-05 0.00 0.00 0.00 1.19E-05 3.61E-05 9.51E-05 0.29 0.61 0.93 5.52E-03 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Escherichia coli CREC RESP - model 22 0.04 0.09 0.16 0.07 0.18 0.30 0.11 0.27 0.45 0.44 0.52 0.58 7.06E-04 1.83E-03 3.11E-03 1.37E-03 3.43E-03 5.81E-03 2.04E-03 5.31E-03 8.76E-03 0.21 0.53 0.86 4.16E-03 0.01 0.02 7.63E-03 0.02 0.03 1.48E-04 3.69E-04 6.25E-04 Norway - Escherichia coli CREC SSI - model 24 5.82E-04 2.34E-03 6.38E-03 0.23 0.42 0.61 0.23 0.42 0.61 0.34 0.34 0.34 1.13E-05 4.54E-05 1.24E-04 4.36E-03 8.09E-03 0.01 4.38E-03 8.14E-03 0.01 0.67 1.25 1.82 0.01 0.02 0.04 0.02 0.04 0.07 4.67E-04 8.68E-04 1.27E-03 Norway - Escherichia coli CREC UTI - model 23 2.83E-03 8.57E-03 0.02 0.00 0.00 0.00 2.83E-03 8.57E-03 0.02 7.49E-04 1.99E-03 4.04E-03 5.49E-05 1.66E-04 3.83E-04 0.00 0.00 0.00 5.49E-05 1.66E-04 3.83E-04 2.61 4.40 6.22 0.05 0.09 0.12 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Escherichia coli ColREC BSI - model 26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Escherichia coli ColREC OTH - model 30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Escherichia coli ColREC RESP - model 27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Escherichia coli ColREC SSI - model 29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Escherichia coli ColREC UTI - model 28 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Klebsiella pneumoniae 3GCRKP BSI - model 1 17.04 18.80 20.85 109.61 118.10 127.04 127.53 136.97 146.63 3.73 3.95 4.16 0.33 0.36 0.40 2.12 2.29 2.46 2.47 2.65 2.84 32.68 34.70 36.88 0.63 0.67 0.71 5.36 5.79 6.25 0.10 0.11 0.12 Norway - Klebsiella pneumoniae 3GCRKP OTH - model 5 0.03 0.05 0.06 0.00 0.00 0.00 0.03 0.05 0.06 2.56E-03 3.34E-03 4.19E-03 6.57E-04 8.80E-04 1.17E-03 0.00 0.00 0.00 6.57E-04 8.80E-04 1.17E-03 11.69 13.67 15.58 0.23 0.26 0.30 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Klebsiella pneumoniae 3GCRKP RESP - model 2 9.88 11.35 12.75 19.26 21.96 24.54 29.18 33.37 36.92 1.03 1.11 1.21 0.19 0.22 0.25 0.37 0.43 0.47 0.56 0.65 0.71 26.07 29.93 33.52 0.50 0.58 0.65 0.93 1.08 1.22 0.02 0.02 0.02 Norway - Klebsiella pneumoniae 3GCRKP SSI - model 4 0.02 0.03 0.04 5.13 6.04 7.09 5.16 6.07 7.12 0.43 0.45 0.47 3.89E-04 5.52E-04 7.73E-04 0.10 0.12 0.14 0.10 0.12 0.14 11.60 13.56 15.76 0.22 0.26 0.30 0.33 0.40 0.48 6.41E-03 7.78E-03 9.21E-03 Norway - Klebsiella pneumoniae 3GCRKP UTI - model 3 0.06 0.08 0.10 0.00 0.00 0.00 0.06 0.08 0.10 1.53E-03 1.98E-03 2.43E-03 1.20E-03 1.55E-03 1.96E-03 0.00 0.00 0.00 1.20E-03 1.55E-03 1.96E-03 35.71 40.63 45.80 0.69 0.79 0.89 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Klebsiella pneumoniae CRKP BSI - model 6 0.82 1.22 1.89 8.56 16.38 26.83 9.66 17.59 28.19 10.24 16.92 23.45 0.02 0.02 0.04 0.17 0.32 0.52 0.19 0.34 0.55 0.79 1.05 1.43 0.02 0.02 0.03 0.19 0.37 0.61 3.73E-03 7.17E-03 0.01 Norway - Klebsiella pneumoniae CRKP OTH - model 10 3.95E-04 1.54E-03 4.34E-03 0.00 0.00 0.00 3.95E-04 1.54E-03 4.34E-03 1.27E-03 3.38E-03 7.39E-03 7.65E-06 2.98E-05 8.40E-05 0.00 0.00 0.00 7.65E-06 2.98E-05 8.40E-05 0.16 0.50 0.84 3.14E-03 9.70E-03 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Klebsiella pneumoniae CRKP RESP - model 7 0.10 0.36 0.66 0.22 0.71 1.26 0.34 1.07 1.90 2.06 2.41 2.77 2.02E-03 7.05E-03 0.01 4.17E-03 0.01 0.02 6.51E-03 0.02 0.04 0.13 0.45 0.76 2.61E-03 8.66E-03 0.01 4.87E-03 0.02 0.03 9.43E-05 3.11E-04 5.54E-04 Norway - Klebsiella pneumoniae CRKP SSI - model 9 9.89E-05 5.57E-04 1.70E-03 0.03 0.12 0.22 0.04 0.12 0.22 0.40 0.40 0.40 1.91E-06 1.08E-05 3.29E-05 6.71E-04 2.39E-03 4.17E-03 6.79E-04 2.41E-03 4.21E-03 0.09 0.31 0.54 1.69E-03 6.03E-03 0.01 7.84E-04 2.80E-03 4.87E-03 1.52E-05 5.42E-05 9.43E-05 Norway - Klebsiella pneumoniae CRKP UTI - model 8 3.87E-04 1.21E-03 3.29E-03 0.00 0.00 0.00 3.87E-04 1.21E-03 3.29E-03 7.85E-04 2.04E-03 4.04E-03 7.48E-06 2.34E-05 6.36E-05 0.00 0.00 0.00 7.48E-06 2.34E-05 6.36E-05 0.23 0.64 1.04 4.50E-03 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Klebsiella pneumoniae ColRKP BSI - model 11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Klebsiella pneumoniae ColRKP OTH - model 15 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Klebsiella pneumoniae ColRKP RESP - model 12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Klebsiella pneumoniae ColRKP SSI - model 14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Klebsiella pneumoniae ColRKP UTI - model 13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Pseudomonas aeruginosa CRPA BSI - model 51 6.94 8.20 9.60 49.78 69.97 92.79 57.51 78.08 101.52 4.29 5.64 7.12 0.13 0.16 0.19 0.96 1.35 1.80 1.11 1.51 1.96 12.45 13.91 15.64 0.24 0.27 0.30 2.22 3.20 4.26 0.04 0.06 0.08 Norway - Pseudomonas aeruginosa CRPA OTH - model 55 0.02 0.03 0.04 0.00 0.00 0.00 0.02 0.03 0.04 2.81E-03 3.65E-03 4.63E-03 3.39E-04 5.04E-04 6.98E-04 0.00 0.00 0.00 3.39E-04 5.04E-04 6.98E-04 5.33 7.09 8.79 0.10 0.14 0.17 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Pseudomonas aeruginosa CRPA RESP - model 52 17.25 21.04 25.26 54.07 74.84 97.22 72.48 95.91 119.72 1.49 1.86 2.29 0.33 0.41 0.49 1.05 1.45 1.88 1.40 1.86 2.32 43.33 51.45 59.73 0.84 1.00 1.16 2.51 3.38 4.40 0.05 0.07 0.09 Norway - Pseudomonas aeruginosa CRPA SSI - model 54 0.01 0.02 0.03 2.75 3.83 4.83 2.77 3.85 4.84 0.35 0.40 0.45 2.45E-04 3.90E-04 5.93E-04 0.05 0.07 0.09 0.05 0.07 0.09 7.30 9.63 11.75 0.14 0.19 0.23 0.17 0.25 0.32 3.38E-03 4.75E-03 6.10E-03 Norway - Pseudomonas aeruginosa CRPA UTI - model 53 0.03 0.04 0.05 0.00 0.00 0.00 0.03 0.04 0.05 1.56E-03 2.06E-03 2.59E-03 4.85E-04 7.11E-04 9.67E-04 0.00 0.00 0.00 4.85E-04 7.11E-04 9.67E-04 13.78 18.07 21.56 0.27 0.35 0.42 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Pseudomonas aeruginosa ColRPA BSI - model 56 0.10 0.15 0.24 0.40 1.21 2.37 0.54 1.37 2.57 0.54 1.31 2.05 1.93E-03 2.95E-03 4.61E-03 7.80E-03 0.02 0.05 0.01 0.03 0.05 0.77 1.05 1.46 0.01 0.02 0.03 0.08 0.24 0.47 1.56E-03 4.70E-03 9.16E-03 Norway - Pseudomonas aeruginosa ColRPA OTH - model 60 4.13E-04 1.88E-03 4.73E-03 0.00 0.00 0.00 4.13E-04 1.88E-03 4.73E-03 1.49E-03 3.70E-03 6.50E-03 8.00E-06 3.64E-05 9.16E-05 0.00 0.00 0.00 8.00E-06 3.64E-05 9.16E-05 0.17 0.55 0.91 3.31E-03 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Pseudomonas aeruginosa ColRPA RESP - model 57 0.21 0.40 0.63 0.47 1.21 2.58 0.72 1.60 3.14 0.25 0.43 0.62 3.97E-03 7.79E-03 0.01 9.13E-03 0.02 0.05 0.01 0.03 0.06 2.10 3.94 5.90 0.04 0.08 0.11 0.09 0.24 0.52 1.83E-03 4.69E-03 0.01 Norway - Pseudomonas aeruginosa ColRPA SSI - model 59 2.51E-04 1.39E-03 4.07E-03 0.04 0.13 0.22 0.05 0.14 0.22 0.18 0.18 0.19 4.86E-06 2.69E-05 7.88E-05 8.63E-04 2.59E-03 4.17E-03 8.80E-04 2.62E-03 4.24E-03 0.25 0.74 1.19 4.75E-03 0.01 0.02 8.84E-03 0.03 0.04 1.71E-04 5.15E-04 8.29E-04 Norway - Pseudomonas aeruginosa ColRPA UTI - model 58 7.43E-04 2.60E-03 6.30E-03 0.00 0.00 0.00 7.43E-04 2.60E-03 6.30E-03 8.10E-04 1.97E-03 3.70E-03 1.44E-05 5.03E-05 1.22E-04 0.00 0.00 0.00 1.44E-05 5.03E-05 1.22E-04 0.58 1.38 2.20 0.01 0.03 0.04 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Pseudomonas aeruginosa MDRPA BSI - model 46 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Pseudomonas aeruginosa MDRPA OTH - model 50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Pseudomonas aeruginosa MDRPA RESP - model 47 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Pseudomonas aeruginosa MDRPA SSI - model 49 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Pseudomonas aeruginosa MDRPA UTI - model 48 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Staphylococcus aureus MRSA BSI - model 61 10.57 11.99 13.46 74.36 80.93 88.43 85.65 92.95 100.81 4.97 5.35 5.74 0.20 0.23 0.26 1.44 1.57 1.71 1.66 1.80 1.95 16.34 17.38 18.58 0.32 0.34 0.36 2.89 3.12 3.37 0.06 0.06 0.07 Norway - Staphylococcus aureus MRSA OTH - model 65 0.06 0.08 0.10 0.00 0.00 0.00 0.06 0.08 0.10 2.55E-03 3.23E-03 4.03E-03 1.23E-03 1.61E-03 2.03E-03 0.00 0.00 0.00 1.23E-03 1.61E-03 2.03E-03 23.16 25.66 28.38 0.45 0.50 0.55 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Staphylococcus aureus MRSA RESP - model 62 10.75 12.46 14.57 20.98 24.34 27.91 31.99 36.80 42.05 1.27 1.41 1.56 0.21 0.24 0.28 0.41 0.47 0.54 0.62 0.71 0.81 23.30 26.15 29.15 0.45 0.51 0.56 0.82 0.94 1.06 0.02 0.02 0.02 Norway - Staphylococcus aureus MRSA SSI - model 64 0.04 0.06 0.08 11.13 12.45 13.84 11.19 12.51 13.90 0.41 0.44 0.46 8.24E-04 1.19E-03 1.57E-03 0.22 0.24 0.27 0.22 0.24 0.27 25.50 28.52 31.56 0.49 0.55 0.61 0.67 0.76 0.85 0.01 0.01 0.02 Norway - Staphylococcus aureus MRSA UTI - model 63 5.66E-03 7.97E-03 0.01 0.00 0.00 0.00 5.66E-03 7.97E-03 0.01 1.44E-03 1.89E-03 2.38E-03 1.10E-04 1.54E-04 2.11E-04 0.00 0.00 0.00 1.10E-04 1.54E-04 2.11E-04 3.38 4.26 5.14 0.07 0.08 0.10 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Streptococcus pneumoniae PMRSP BSI - model 76 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Streptococcus pneumoniae PMRSP OTH - model 80 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Streptococcus pneumoniae PMRSP RESP - model 77 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Streptococcus pneumoniae PMRSP SSI - model 79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Streptococcus pneumoniae PMRSP UTI - model 78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Streptococcus pneumoniae PRSP BSI - model 71 5.61 6.39 7.32 40.60 43.50 46.47 46.91 49.85 53.05 6.70 7.12 7.58 0.11 0.12 0.14 0.79 0.84 0.90 0.91 0.96 1.03 7.00 7.00 7.00 0.14 0.14 0.14 1.18 1.26 1.34 0.02 0.02 0.03 Norway - Streptococcus pneumoniae PRSP OTH - model 75 3.32E-03 4.87E-03 6.64E-03 0.00 0.00 0.00 3.32E-03 4.87E-03 6.64E-03 1.37E-03 1.95E-03 2.61E-03 6.43E-05 9.42E-05 1.29E-04 0.00 0.00 0.00 6.43E-05 9.42E-05 1.29E-04 2.26 2.48 2.77 0.04 0.05 0.05 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Streptococcus pneumoniae PRSP RESP - model 72 13.56 16.64 21.06 26.93 32.76 41.60 41.21 49.50 62.42 1.63 1.86 2.14 0.26 0.32 0.41 0.52 0.63 0.81 0.80 0.96 1.21 22.32 26.56 32.42 0.43 0.51 0.63 0.80 0.95 1.20 0.02 0.02 0.02 Norway - Streptococcus pneumoniae PRSP SSI - model 74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Norway - Streptococcus pneumoniae PRSP UTI - model 73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total (Median & 95% UIs) 233.15 267.41 305.44 1,250.75 1,443.85 1,663.33 1,493.47 1,711.97 1,958.06 4.51 5.18 5.91 24.21 27.95 32.19 28.91 33.14 37.90 1,660.81 1,881.57 2,104.97 32.15 36.42 40.74 58.87 68.53 79.07 1.14 1.33 1.53 Total (average) - 28.03 33.22 1,881.69 36.42 68.65 1.33 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 268.11 1,448.21 1,716.32 - 5.19 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 Infection Colistin resistant Acinetobacter spp. 6.37 10.32 15.22 22.29 53.89 96.33 30.36 64.18 109.72 4.87 8.84 12.95 0.02 0.03 0.04 0.06 0.14 0.25 0.08 0.17 0.29 12.66 21.36 30.57 0.03 0.06 0.08 0.74 1.79 3.20 0.00 0.00 0.01 Carbapenem resistant Acinetobacter spp. (excluding those resistant to colistin) 1,249.15 1,375.21 1,524.03 6,105.86 7,386.49 8,681.89 7,377.78 8,765.98 10,121.98 6.54 7.56 8.60 3.29 3.62 4.01 16.07 19.44 22.84 19.41 23.06 26.63 3,066.24 3,427.95 3,775.21 8.07 9.02 9.93 242.41 300.01 352.94 0.64 0.79 0.93 Aminoglycosides and fluoroquinolones resistant Acinetobacter spp. (excluding those resistant to colistin and/or carbapenem) 243.64 277.60 316.14 1,154.54 1,449.11 1,768.35 1,407.18 1,727.10 2,064.00 5.49 6.61 7.74 0.64 0.73 0.83 3.04 3.81 4.65 3.70 4.54 5.43 677.34 770.60 865.34 1.78 2.03 2.28 53.58 65.83 80.31 0.14 0.17 0.21 Vancomycin resistant Enterococci (E. faecalis and E. faecium ) 318.92 378.50 452.85 2,975.53 3,532.04 4,152.77 3,302.09 3,910.32 4,578.31 7.67 8.23 8.83 0.84 1.00 1.19 7.83 9.29 10.93 8.69 10.29 12.05 1,505.25 1,830.82 2,159.62 3.96 4.82 5.68 99.69 119.17 141.37 0.26 0.31 0.37 Colistin resistant Escherichia coli 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Escherichia coli (excluding those resistant to colistin) 19.16 27.66 38.94 183.46 296.03 439.81 206.36 323.94 474.28 15.80 23.14 30.84 0.05 0.07 0.10 0.48 0.78 1.16 0.54 0.85 1.25 77.19 112.03 146.25 0.20 0.29 0.38 3.63 5.81 8.18 0.01 0.02 0.02 Third-generation cephalosporin resistant Escherichia coli (excluding those resistant to colistin and/or carbapenem) 1,020.18 1,131.03 1,267.57 6,013.89 6,701.32 7,449.35 7,076.91 7,829.74 8,657.23 5.63 6.10 6.59 2.68 2.98 3.34 15.82 17.63 19.60 18.62 20.60 22.78 9,170.41 10,248.90 11,319.62 24.13 26.97 29.78 276.85 311.77 350.77 0.73 0.82 0.92 Colistin resistant Klebsiella pneumoniae 62.73 77.23 93.14 1,054.53 1,364.11 1,718.54 1,126.60 1,442.02 1,805.72 13.57 16.94 20.68 0.17 0.20 0.25 2.77 3.59 4.52 2.96 3.79 4.75 201.56 251.67 301.72 0.53 0.66 0.79 44.38 55.98 69.34 0.12 0.15 0.18 Carbapenem resistant Klebsiella pneumoniae (excluding those resistant to colistin) 9.15 12.73 17.19 89.23 133.49 186.09 100.69 146.21 201.50 5.34 7.26 9.34 0.02 0.03 0.05 0.23 0.35 0.49 0.26 0.38 0.53 43.29 62.97 84.57 0.11 0.17 0.22 5.65 8.46 11.70 0.01 0.02 0.03 Third-generation cephalosporin resistant Klebsiella pneumoniae (excluding those resistant to colistin and/or carbapenem) 3,595.65 3,935.98 4,276.89 17,656.84 18,834.92 20,144.00 21,300.64 22,775.65 24,302.88 7.61 7.97 8.33 9.46 10.36 11.25 46.46 49.56 53.00 56.05 59.93 63.95 10,713.03 11,678.08 12,652.19 28.19 30.73 33.29 589.55 631.34 675.45 1.55 1.66 1.78 Colistin resistant Pseudomonas aeruginosa 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Pseudomonas aeruginosa (excluding those resistant to colistin) 1,921.88 2,149.52 2,381.24 8,889.39 10,849.65 12,844.07 10,885.31 13,015.71 15,107.61 9.52 11.08 12.69 5.06 5.66 6.27 23.39 28.55 33.80 28.64 34.25 39.75 4,558.16 5,177.74 5,796.59 11.99 13.62 15.25 283.41 350.71 418.84 0.75 0.92 1.10 Pseudomonas aeruginosa resistant to three or more antimicrobial groups (excluding those resistant to colistin and/or carbapenem) 180.81 227.78 280.27 749.80 1,077.34 1,448.41 958.12 1,304.37 1,711.32 5.73 7.51 9.38 0.48 0.60 0.74 1.97 2.83 3.81 2.52 3.43 4.50 617.91 769.63 921.48 1.63 2.03 2.42 35.26 49.12 64.55 0.09 0.13 0.17 Methicillin resistant Staphylococcus aureus 1,408.49 1,528.69 1,658.16 6,849.43 7,328.95 7,783.41 8,319.53 8,859.44 9,399.38 6.77 7.05 7.34 3.71 4.02 4.36 18.02 19.28 20.48 21.89 23.31 24.73 5,965.19 6,463.03 6,964.73 15.70 17.01 18.33 281.73 302.30 323.75 0.74 0.80 0.85 Penicillin and macrolides resistant Streptococcus pneumoniae (excluding those only resistant to penicillin) 114.15 150.09 217.18 422.23 499.54 636.12 549.64 648.74 836.13 8.63 9.69 11.00 0.30 0.39 0.57 1.11 1.31 1.67 1.45 1.71 2.20 188.86 219.13 267.10 0.50 0.58 0.70 11.82 13.50 15.81 0.03 0.04 0.04 Penicillin tesistant Streptococcus pneumoniae (excluding those resistant to macrolides) 12.02 17.02 27.10 45.71 56.55 76.79 59.44 73.59 101.75 5.87 6.68 7.47 0.03 0.04 0.07 0.12 0.15 0.20 0.16 0.19 0.27 29.09 35.44 52.56 0.08 0.09 0.14 1.79 2.21 3.00 0.00 0.01 0.01 Total 10,162.29 11,299.37 12,565.91 52,212.72 59,563.43 67,425.94 62,700.66 70,886.98 79,471.80 26.74 29.73 33.06 137.38 156.72 177.41 164.98 186.52 209.11 36,826.17 41,069.36 45,337.54 96.90 108.06 119.29 1,930.50 2,218.00 2,519.22 5.08 5.84 6.63 Model Poland - Acinetobacter spp. CRACI BSI - model 36 722.44 783.46 861.09 4,923.96 6,049.56 7,191.49 5,668.90 6,839.15 7,978.79 4.84 5.76 6.68 1.90 2.06 2.27 12.96 15.92 18.92 14.92 18.00 20.99 1,115.93 1,184.86 1,253.98 2.94 3.12 3.30 193.35 243.62 289.81 0.51 0.64 0.76 Poland - Acinetobacter spp. CRACI OTH - model 40 0.11 0.16 0.21 0.00 0.00 0.00 0.11 0.16 0.21 3.04E-03 3.75E-03 4.48E-03 2.92E-04 4.13E-04 5.58E-04 0.00 0.00 0.00 2.92E-04 4.13E-04 5.58E-04 31.87 41.75 52.12 0.08 0.11 0.14 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Acinetobacter spp. CRACI RESP - model 37 525.16 589.70 660.25 1,025.22 1,148.25 1,267.02 1,550.60 1,736.15 1,917.41 1.28 1.35 1.45 1.38 1.55 1.74 2.70 3.02 3.33 4.08 4.57 5.05 1,141.72 1,285.27 1,406.69 3.00 3.38 3.70 40.78 46.27 51.19 0.11 0.12 0.13 Poland - Acinetobacter spp. CRACI SSI - model 39 0.68 0.92 1.23 156.67 188.68 223.37 157.42 189.54 224.32 0.41 0.44 0.47 1.78E-03 2.42E-03 3.22E-03 0.41 0.50 0.59 0.41 0.50 0.59 371.99 434.17 498.40 0.98 1.14 1.31 8.28 10.11 11.94 0.02 0.03 0.03 Poland - Acinetobacter spp. CRACI UTI - model 38 0.76 0.98 1.25 0.00 0.00 0.00 0.76 0.98 1.25 1.68E-03 2.04E-03 2.46E-03 1.99E-03 2.58E-03 3.29E-03 0.00 0.00 0.00 1.99E-03 2.58E-03 3.29E-03 404.73 481.89 564.02 1.06 1.27 1.48 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Acinetobacter spp. ColRACI BSI - model 41 3.91 5.79 8.57 17.02 44.32 81.86 22.42 50.03 89.22 3.20 6.92 10.79 0.01 0.02 0.02 0.04 0.12 0.22 0.06 0.13 0.23 5.80 7.33 9.32 0.02 0.02 0.02 0.57 1.48 2.72 1.49E-03 3.88E-03 7.16E-03 Poland - Acinetobacter spp. ColRACI OTH - model 45 1.38E-04 8.16E-04 2.75E-03 0.00 0.00 0.00 1.38E-04 8.16E-04 2.75E-03 1.58E-03 3.60E-03 6.29E-03 3.63E-07 2.15E-06 7.22E-06 0.00 0.00 0.00 3.63E-07 2.15E-06 7.22E-06 0.05 0.25 0.57 1.19E-04 6.50E-04 1.49E-03 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Acinetobacter spp. ColRACI RESP - model 42 2.46 4.52 6.62 4.99 8.85 13.31 7.65 13.42 19.33 1.40 1.64 1.88 6.48E-03 0.01 0.02 0.01 0.02 0.04 0.02 0.04 0.05 4.66 8.11 11.39 0.01 0.02 0.03 0.17 0.29 0.44 4.37E-04 7.74E-04 1.17E-03 Poland - Acinetobacter spp. ColRACI SSI - model 44 1.06E-03 5.07E-03 0.01 0.28 0.72 1.16 0.29 0.73 1.16 0.27 0.27 0.28 2.80E-06 1.33E-05 3.86E-05 7.32E-04 1.91E-03 3.06E-03 7.54E-04 1.92E-03 3.06E-03 1.03 2.68 4.30 2.70E-03 7.04E-03 0.01 9.25E-03 0.02 0.04 2.43E-05 6.34E-05 1.02E-04 Poland - Acinetobacter spp. ColRACI UTI - model 43 1.50E-03 5.69E-03 0.01 0.00 0.00 0.00 1.50E-03 5.69E-03 0.01 8.02E-04 2.02E-03 3.57E-03 3.94E-06 1.50E-05 3.56E-05 0.00 0.00 0.00 3.94E-06 1.50E-05 3.56E-05 1.13 2.99 4.99 2.97E-03 7.88E-03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Acinetobacter spp. MDRACI BSI - model 31 141.19 158.62 179.56 926.18 1,181.17 1,461.57 1,074.83 1,340.36 1,622.54 4.03 5.02 6.01 0.37 0.42 0.47 2.44 3.11 3.85 2.83 3.53 4.27 249.51 266.34 286.64 0.66 0.70 0.75 42.62 53.09 65.67 0.11 0.14 0.17 Poland - Acinetobacter spp. MDRACI OTH - model 35 0.02 0.04 0.05 0.00 0.00 0.00 0.02 0.04 0.05 2.85E-03 3.72E-03 4.57E-03 6.20E-05 9.22E-05 1.31E-04 0.00 0.00 0.00 6.20E-05 9.22E-05 1.31E-04 6.99 9.45 12.12 0.02 0.02 0.03 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Acinetobacter spp. MDRACI RESP - model 32 102.12 118.51 135.96 199.04 231.36 263.92 302.51 349.69 398.08 1.12 1.21 1.31 0.27 0.31 0.36 0.52 0.61 0.69 0.80 0.92 1.05 253.56 288.84 324.44 0.67 0.76 0.85 9.06 10.41 11.85 0.02 0.03 0.03 Poland - Acinetobacter spp. MDRACI SSI - model 34 0.14 0.21 0.28 29.32 36.59 42.86 29.65 36.79 43.04 0.34 0.38 0.41 3.80E-04 5.43E-04 7.37E-04 0.08 0.10 0.11 0.08 0.10 0.11 78.68 97.16 113.66 0.21 0.26 0.30 1.89 2.33 2.79 4.98E-03 6.13E-03 7.33E-03 Poland - Acinetobacter spp. MDRACI UTI - model 33 0.16 0.22 0.29 0.00 0.00 0.00 0.16 0.22 0.29 1.63E-03 2.05E-03 2.52E-03 4.33E-04 5.88E-04 7.73E-04 0.00 0.00 0.00 4.33E-04 5.88E-04 7.73E-04 88.58 108.81 128.48 0.23 0.29 0.34 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Enterococcus faecalis and E. faecium VRE BSI - model 66 316.99 375.90 449.43 2,741.77 3,235.36 3,795.41 3,066.80 3,610.97 4,217.56 7.24 7.76 8.32 0.83 0.99 1.18 7.21 8.51 9.99 8.07 9.50 11.10 392.04 462.87 546.76 1.03 1.22 1.44 89.57 105.81 125.14 0.24 0.28 0.33 Poland - Enterococcus faecalis and E. faecium VRE OTH - model 70 0.62 0.82 1.05 0.00 0.00 0.00 0.62 0.82 1.05 1.35E-03 1.65E-03 2.02E-03 1.64E-03 2.15E-03 2.76E-03 0.00 0.00 0.00 1.64E-03 2.15E-03 2.76E-03 403.94 497.09 581.34 1.06 1.31 1.53 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Enterococcus faecalis and E. faecium VRE RESP - model 67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Enterococcus faecalis and E. faecium VRE SSI - model 69 0.98 1.35 1.80 233.75 296.68 357.37 234.33 298.10 359.12 0.43 0.47 0.51 2.57E-03 3.55E-03 4.74E-03 0.62 0.78 0.94 0.62 0.78 0.94 519.76 636.52 752.66 1.37 1.67 1.98 10.12 13.37 16.24 0.03 0.04 0.04 Poland - Enterococcus faecalis and E. faecium VRE UTI - model 68 0.33 0.44 0.57 0.00 0.00 0.00 0.33 0.44 0.57 1.53E-03 1.86E-03 2.28E-03 8.67E-04 1.15E-03 1.50E-03 0.00 0.00 0.00 8.67E-04 1.15E-03 1.50E-03 189.52 234.34 278.86 0.50 0.62 0.73 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Escherichia coli 3GCREC BSI - model 16 784.96 853.96 942.04 5,022.45 5,534.58 6,113.11 5,844.02 6,385.93 7,001.25 4.10 4.44 4.78 2.07 2.25 2.48 13.22 14.56 16.08 15.38 16.80 18.42 1,344.17 1,440.47 1,540.66 3.54 3.79 4.05 223.77 248.74 277.88 0.59 0.65 0.73 Poland - Escherichia coli 3GCREC OTH - model 20 1.18 1.58 2.05 0.00 0.00 0.00 1.18 1.58 2.05 2.71E-03 3.31E-03 4.01E-03 3.11E-03 4.16E-03 5.40E-03 0.00 0.00 0.00 3.11E-03 4.16E-03 5.40E-03 393.33 475.18 562.16 1.03 1.25 1.48 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Escherichia coli 3GCREC RESP - model 17 221.99 260.16 304.19 425.64 506.42 588.27 653.48 766.91 887.96 1.11 1.21 1.34 0.58 0.68 0.80 1.12 1.33 1.55 1.72 2.02 2.34 526.54 631.62 730.30 1.39 1.66 1.92 19.00 22.63 26.65 0.05 0.06 0.07 Poland - Escherichia coli 3GCREC SSI - model 19 2.43 3.24 4.23 565.81 660.32 747.97 568.61 663.24 750.92 0.41 0.43 0.46 6.39E-03 8.54E-03 0.01 1.49 1.74 1.97 1.50 1.75 1.98 1,341.54 1,528.26 1,709.28 3.53 4.02 4.50 34.08 40.39 46.24 0.09 0.11 0.12 Poland - Escherichia coli 3GCREC UTI - model 18 9.63 12.08 15.05 0.00 0.00 0.00 9.63 12.08 15.05 1.60E-03 1.96E-03 2.39E-03 0.03 0.03 0.04 0.00 0.00 0.00 0.03 0.03 0.04 5,564.83 6,173.37 6,777.22 14.64 16.24 17.83 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Escherichia coli CREC BSI - model 21 15.42 20.39 27.46 171.24 273.75 407.37 190.17 294.32 431.15 13.24 19.86 26.87 0.04 0.05 0.07 0.45 0.72 1.07 0.50 0.77 1.13 12.36 14.93 18.37 0.03 0.04 0.05 3.38 5.39 7.58 8.89E-03 0.01 0.02 Poland - Escherichia coli CREC OTH - model 25 0.01 0.03 0.06 0.00 0.00 0.00 0.01 0.03 0.06 1.72E-03 3.34E-03 6.13E-03 3.25E-05 7.53E-05 1.58E-04 0.00 0.00 0.00 3.25E-05 7.53E-05 1.58E-04 5.10 8.80 12.37 0.01 0.02 0.03 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Escherichia coli CREC RESP - model 22 3.66 7.08 11.10 7.16 14.05 21.29 11.11 21.20 31.62 2.17 2.81 3.42 9.62E-03 0.02 0.03 0.02 0.04 0.06 0.03 0.06 0.08 4.14 7.52 10.86 0.01 0.02 0.03 0.15 0.27 0.39 3.87E-04 7.10E-04 1.04E-03 Poland - Escherichia coli CREC SSI - model 24 0.01 0.04 0.07 5.06 8.22 11.15 5.00 8.27 11.21 0.39 0.47 0.54 3.48E-05 9.47E-05 1.89E-04 0.01 0.02 0.03 0.01 0.02 0.03 11.50 17.64 23.37 0.03 0.05 0.06 0.10 0.16 0.21 2.72E-04 4.18E-04 5.53E-04 Poland - Escherichia coli CREC UTI - model 23 0.06 0.13 0.24 0.00 0.00 0.00 0.06 0.13 0.24 1.07E-03 2.05E-03 3.48E-03 1.63E-04 3.34E-04 6.34E-04 0.00 0.00 0.00 1.63E-04 3.34E-04 6.34E-04 44.10 63.15 81.28 0.12 0.17 0.21 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Escherichia coli ColREC BSI - model 26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Escherichia coli ColREC OTH - model 30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Escherichia coli ColREC RESP - model 27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Escherichia coli ColREC SSI - model 29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Escherichia coli ColREC UTI - model 28 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Klebsiella pneumoniae 3GCRKP BSI - model 1 2,259.71 2,444.68 2,635.00 14,574.84 15,409.07 16,339.72 16,868.12 17,850.32 18,873.23 5.61 5.85 6.08 5.95 6.43 6.93 38.35 40.54 42.99 44.38 46.97 49.66 2,918.33 3,053.53 3,191.64 7.68 8.03 8.40 481.13 510.34 540.16 1.27 1.34 1.42 Poland - Klebsiella pneumoniae 3GCRKP OTH - model 5 3.36 4.06 5.06 0.00 0.00 0.00 3.36 4.06 5.06 2.82E-03 3.36E-03 4.02E-03 8.83E-03 0.01 0.01 0.00 0.00 0.00 8.83E-03 0.01 0.01 1,073.52 1,211.48 1,349.04 2.82 3.19 3.55 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Klebsiella pneumoniae 3GCRKP RESP - model 2 1,324.86 1,477.69 1,625.12 2,594.16 2,873.09 3,181.65 3,933.26 4,358.67 4,789.44 1.56 1.65 1.75 3.49 3.89 4.28 6.83 7.56 8.37 10.35 11.47 12.60 2,390.80 2,642.22 2,876.89 6.29 6.95 7.57 85.48 94.92 105.29 0.22 0.25 0.28 Poland - Klebsiella pneumoniae 3GCRKP SSI - model 4 2.01 2.55 3.29 487.85 552.75 622.62 490.19 555.58 626.72 0.44 0.47 0.49 5.28E-03 6.70E-03 8.65E-03 1.28 1.45 1.64 1.29 1.46 1.65 1,074.84 1,192.83 1,339.51 2.83 3.14 3.52 22.95 26.08 30.00 0.06 0.07 0.08 Poland - Klebsiella pneumoniae 3GCRKP UTI - model 3 5.72 7.01 8.42 0.00 0.00 0.00 5.72 7.01 8.42 1.66E-03 1.96E-03 2.31E-03 0.02 0.02 0.02 0.00 0.00 0.00 0.02 0.02 0.02 3,255.54 3,578.03 3,895.10 8.57 9.41 10.25 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Klebsiella pneumoniae CRKP BSI - model 6 7.59 9.80 12.76 85.24 125.79 174.57 95.25 135.53 185.62 4.35 6.05 7.86 0.02 0.03 0.03 0.22 0.33 0.46 0.25 0.36 0.49 18.79 22.53 26.95 0.05 0.06 0.07 5.37 7.93 10.93 0.01 0.02 0.03 Poland - Klebsiella pneumoniae CRKP OTH - model 10 0.02 0.04 0.07 0.00 0.00 0.00 0.02 0.04 0.07 1.94E-03 3.49E-03 5.60E-03 4.19E-05 9.48E-05 1.83E-04 0.00 0.00 0.00 4.19E-05 9.48E-05 1.83E-04 6.52 10.64 15.47 0.02 0.03 0.04 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Klebsiella pneumoniae CRKP RESP - model 7 1.52 2.85 4.29 2.76 5.45 8.19 4.19 8.34 12.42 0.69 0.87 1.08 4.01E-03 7.49E-03 0.01 7.27E-03 0.01 0.02 0.01 0.02 0.03 5.64 9.60 13.66 0.01 0.03 0.04 0.19 0.35 0.50 5.02E-04 9.15E-04 1.30E-03 Poland - Klebsiella pneumoniae CRKP SSI - model 9 5.27E-03 0.01 0.03 1.22 2.26 3.33 1.22 2.27 3.34 0.30 0.34 0.39 1.39E-05 3.50E-05 7.17E-05 3.22E-03 5.95E-03 8.76E-03 3.21E-03 5.96E-03 8.79E-03 3.68 6.58 9.52 9.68E-03 0.02 0.03 0.09 0.18 0.27 2.37E-04 4.67E-04 7.02E-04 Poland - Klebsiella pneumoniae CRKP UTI - model 8 0.01 0.03 0.05 0.00 0.00 0.00 0.01 0.03 0.05 1.16E-03 2.06E-03 3.23E-03 3.74E-05 7.27E-05 1.30E-04 0.00 0.00 0.00 3.74E-05 7.27E-05 1.30E-04 8.66 13.62 18.97 0.02 0.04 0.05 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Klebsiella pneumoniae ColRKP BSI - model 11 50.36 59.87 70.14 1,023.20 1,320.64 1,662.11 1,082.62 1,381.09 1,726.62 12.09 15.22 18.70 0.13 0.16 0.18 2.69 3.47 4.37 2.85 3.63 4.54 80.98 90.38 100.61 0.21 0.24 0.26 42.96 54.01 66.84 0.11 0.14 0.18 Poland - Klebsiella pneumoniae ColRKP OTH - model 15 0.09 0.15 0.22 0.00 0.00 0.00 0.09 0.15 0.22 2.45E-03 3.52E-03 4.85E-03 2.47E-04 3.84E-04 5.88E-04 0.00 0.00 0.00 2.47E-04 3.84E-04 5.88E-04 30.64 41.66 53.14 0.08 0.11 0.14 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Klebsiella pneumoniae ColRKP RESP - model 12 12.16 17.05 22.52 23.91 33.16 43.57 36.36 50.31 65.77 1.12 1.32 1.55 0.03 0.04 0.06 0.06 0.09 0.11 0.10 0.13 0.17 28.40 38.01 47.33 0.07 0.10 0.12 1.01 1.37 1.73 2.67E-03 3.59E-03 4.54E-03 Poland - Klebsiella pneumoniae ColRKP SSI - model 14 0.03 0.06 0.09 7.41 10.31 12.87 7.46 10.36 12.94 0.36 0.39 0.42 9.02E-05 1.48E-04 2.28E-04 0.02 0.03 0.03 0.02 0.03 0.03 19.08 26.70 33.31 0.05 0.07 0.09 0.41 0.60 0.77 1.08E-03 1.59E-03 2.04E-03 Poland - Klebsiella pneumoniae ColRKP UTI - model 13 0.08 0.11 0.16 0.00 0.00 0.00 0.08 0.11 0.16 1.50E-03 2.08E-03 2.71E-03 2.01E-04 2.98E-04 4.24E-04 0.00 0.00 0.00 2.01E-04 2.98E-04 4.24E-04 42.46 54.92 67.33 0.11 0.14 0.18 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Pseudomonas aeruginosa CRPA BSI - model 51 544.16 602.08 660.45 4,208.30 5,158.37 6,132.59 4,784.01 5,765.36 6,752.00 6.82 8.01 9.24 1.43 1.58 1.74 11.07 13.57 16.14 12.59 15.17 17.77 661.62 721.26 781.08 1.74 1.90 2.06 132.90 165.73 198.88 0.35 0.44 0.52 Poland - Pseudomonas aeruginosa CRPA OTH - model 55 1.02 1.34 1.70 0.00 0.00 0.00 1.02 1.34 1.70 3.06E-03 3.68E-03 4.33E-03 2.68E-03 3.52E-03 4.48E-03 0.00 0.00 0.00 2.68E-03 3.52E-03 4.48E-03 302.44 366.56 416.25 0.80 0.96 1.10 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Pseudomonas aeruginosa CRPA RESP - model 52 1,374.41 1,543.16 1,715.30 4,500.35 5,474.13 6,459.58 5,917.22 7,028.92 8,098.19 2.29 2.62 2.97 3.62 4.06 4.51 11.84 14.40 17.00 15.57 18.49 21.31 2,388.97 2,671.59 2,967.88 6.29 7.03 7.81 143.12 175.69 208.94 0.38 0.46 0.55 Poland - Pseudomonas aeruginosa CRPA SSI - model 54 0.78 1.04 1.37 180.73 217.15 251.89 181.55 218.20 253.29 0.41 0.44 0.47 2.05E-03 2.74E-03 3.60E-03 0.48 0.57 0.66 0.48 0.57 0.67 413.37 494.92 566.37 1.09 1.30 1.49 7.40 9.28 11.02 0.02 0.02 0.03 Poland - Pseudomonas aeruginosa CRPA UTI - model 53 1.51 1.90 2.43 0.00 0.00 0.00 1.51 1.90 2.43 1.69E-03 2.05E-03 2.42E-03 3.97E-03 5.01E-03 6.39E-03 0.00 0.00 0.00 3.97E-03 5.01E-03 6.39E-03 791.75 923.41 1,065.01 2.08 2.43 2.80 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Pseudomonas aeruginosa ColRPA BSI - model 56 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Pseudomonas aeruginosa ColRPA OTH - model 60 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Pseudomonas aeruginosa ColRPA RESP - model 57 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Pseudomonas aeruginosa ColRPA SSI - model 59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Pseudomonas aeruginosa ColRPA UTI - model 58 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Pseudomonas aeruginosa MDRPA BSI - model 46 51.87 63.81 76.75 342.42 498.99 669.47 406.96 562.20 745.41 3.93 5.26 6.66 0.14 0.17 0.20 0.90 1.31 1.76 1.07 1.48 1.96 94.52 107.08 121.57 0.25 0.28 0.32 15.99 22.53 29.77 0.04 0.06 0.08 Poland - Pseudomonas aeruginosa MDRPA OTH - model 50 0.13 0.20 0.29 0.00 0.00 0.00 0.13 0.20 0.29 2.79E-03 3.75E-03 4.84E-03 3.43E-04 5.39E-04 7.60E-04 0.00 0.00 0.00 3.43E-04 5.39E-04 7.60E-04 39.63 54.48 69.47 0.10 0.14 0.18 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Pseudomonas aeruginosa MDRPA RESP - model 47 128.52 163.34 202.60 385.13 546.13 737.67 528.50 709.29 923.78 1.43 1.80 2.21 0.34 0.43 0.53 1.01 1.44 1.94 1.39 1.87 2.43 326.12 397.37 469.75 0.86 1.05 1.24 17.96 24.81 32.53 0.05 0.07 0.09 Poland - Pseudomonas aeruginosa MDRPA SSI - model 49 0.10 0.15 0.23 22.25 32.23 41.26 22.35 32.40 41.45 0.38 0.44 0.51 2.51E-04 4.05E-04 6.16E-04 0.06 0.08 0.11 0.06 0.09 0.11 54.87 73.29 92.06 0.14 0.19 0.24 1.31 1.79 2.25 3.46E-03 4.70E-03 5.92E-03 Poland - Pseudomonas aeruginosa MDRPA UTI - model 48 0.19 0.28 0.39 0.00 0.00 0.00 0.19 0.28 0.39 1.49E-03 2.04E-03 2.63E-03 4.91E-04 7.33E-04 1.03E-03 0.00 0.00 0.00 4.91E-04 7.33E-04 1.03E-03 102.78 137.40 168.63 0.27 0.36 0.44 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Staphylococcus aureus MRSA BSI - model 61 689.10 741.99 801.34 4,742.39 5,013.47 5,271.13 5,486.50 5,756.50 6,042.00 5.02 5.22 5.42 1.81 1.95 2.11 12.48 13.19 13.87 14.44 15.15 15.90 1,055.06 1,102.88 1,150.65 2.78 2.90 3.03 187.34 197.76 209.20 0.49 0.52 0.55 Poland - Staphylococcus aureus MRSA OTH - model 65 4.29 5.30 6.39 0.00 0.00 0.00 4.29 5.30 6.39 2.73E-03 3.25E-03 3.89E-03 0.01 0.01 0.02 0.00 0.00 0.00 0.01 0.01 0.02 1,500.25 1,626.76 1,751.19 3.95 4.28 4.61 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Staphylococcus aureus MRSA RESP - model 62 711.71 777.05 844.88 1,381.52 1,515.67 1,641.62 2,099.15 2,293.44 2,475.21 1.31 1.38 1.46 1.87 2.04 2.22 3.64 3.99 4.32 5.52 6.03 6.51 1,521.26 1,660.27 1,805.96 4.00 4.37 4.75 54.14 59.76 65.40 0.14 0.16 0.17 Poland - Staphylococcus aureus MRSA SSI - model 64 3.01 3.86 4.92 725.53 799.81 870.66 729.21 803.70 875.16 0.43 0.44 0.46 7.92E-03 0.01 0.01 1.91 2.10 2.29 1.92 2.11 2.30 1,663.73 1,804.40 1,948.39 4.38 4.75 5.13 40.26 44.78 49.15 0.11 0.12 0.13 Poland - Staphylococcus aureus MRSA UTI - model 63 0.39 0.50 0.63 0.00 0.00 0.00 0.39 0.50 0.63 1.56E-03 1.87E-03 2.24E-03 1.02E-03 1.32E-03 1.65E-03 0.00 0.00 0.00 1.02E-03 1.32E-03 1.65E-03 224.89 268.72 308.53 0.59 0.71 0.81 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Streptococcus pneumoniae PMRSP BSI - model 76 33.57 41.97 52.52 260.58 287.73 316.52 299.45 329.84 361.66 6.99 7.70 8.44 0.09 0.11 0.14 0.69 0.76 0.83 0.79 0.87 0.95 42.86 42.86 42.86 0.11 0.11 0.11 7.16 7.72 8.31 0.02 0.02 0.02 Poland - Streptococcus pneumoniae PMRSP OTH - model 80 0.02 0.03 0.04 0.00 0.00 0.00 0.02 0.03 0.04 1.20E-03 1.91E-03 2.87E-03 4.81E-05 7.66E-05 1.15E-04 0.00 0.00 0.00 4.81E-05 7.66E-05 1.15E-04 13.36 15.21 17.45 0.04 0.04 0.05 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Streptococcus pneumoniae PMRSP RESP - model 77 80.56 108.09 164.61 161.65 211.81 319.60 250.17 318.87 474.42 1.64 1.99 2.56 0.21 0.28 0.43 0.43 0.56 0.84 0.66 0.84 1.25 132.65 161.06 206.78 0.35 0.42 0.54 4.66 5.78 7.50 0.01 0.02 0.02 Poland - Streptococcus pneumoniae PMRSP SSI - model 79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Streptococcus pneumoniae PMRSP UTI - model 78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Streptococcus pneumoniae PRSP BSI - model 71 3.55 4.79 6.30 28.89 32.79 36.77 33.31 37.73 41.91 4.66 5.28 5.87 9.35E-03 0.01 0.02 0.08 0.09 0.10 0.09 0.10 0.11 7.14 7.14 7.14 0.02 0.02 0.02 1.13 1.28 1.44 2.98E-03 3.38E-03 3.79E-03 Poland - Streptococcus pneumoniae PRSP OTH - model 75 1.96E-03 4.74E-03 9.48E-03 0.00 0.00 0.00 1.96E-03 4.74E-03 9.48E-03 7.72E-04 1.88E-03 3.67E-03 5.16E-06 1.25E-05 2.49E-05 0.00 0.00 0.00 5.16E-06 1.25E-05 2.49E-05 2.07 2.49 3.26 5.43E-03 6.55E-03 8.58E-03 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Streptococcus pneumoniae PRSP RESP - model 72 8.46 12.23 20.78 16.81 23.76 40.03 26.13 35.85 59.83 1.20 1.39 1.60 0.02 0.03 0.05 0.04 0.06 0.11 0.07 0.09 0.16 19.89 25.81 42.16 0.05 0.07 0.11 0.66 0.93 1.56 1.74E-03 2.45E-03 4.09E-03 Poland - Streptococcus pneumoniae PRSP SSI - model 74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Poland - Streptococcus pneumoniae PRSP UTI - model 73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total (Median & 95% UIs) 10,162.29 11,299.37 12,565.91 52,212.72 59,563.43 67,425.94 62,700.66 70,886.98 79,471.80 26.74 29.73 33.06 137.38 156.72 177.41 164.98 186.52 209.11 36,826.17 41,069.36 45,337.54 96.90 108.06 119.29 1,930.50 2,218.00 2,519.22 5.08 5.84 6.63 Total (average) - 156.83 186.60 41,076.10 108.08 2,219.88 5.84 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 11,313.14 59,604.27 70,917.41 - 29.77 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 Infection Colistin resistant Acinetobacter spp. 5.22 6.69 8.29 22.05 35.25 50.91 27.95 42.03 58.13 6.65 9.32 12.25 0.05 0.06 0.08 0.21 0.34 0.49 0.27 0.41 0.56 10.33 13.15 15.95 0.10 0.13 0.15 0.72 1.13 1.55 0.01 0.01 0.01 Carbapenem resistant Acinetobacter spp. (excluding those resistant to colistin) 190.43 211.50 232.95 944.07 1,131.38 1,317.73 1,142.70 1,342.32 1,537.58 5.95 6.87 7.77 1.84 2.04 2.25 9.10 10.91 12.70 11.01 12.94 14.82 518.02 578.28 635.88 4.99 5.57 6.13 41.93 50.68 59.29 0.40 0.49 0.57 Aminoglycosides and fluoroquinolones resistant Acinetobacter spp. (excluding those resistant to colistin and/or carbapenem) 2.12 3.32 4.98 7.13 17.37 30.31 9.93 20.66 34.65 10.12 18.43 26.84 0.02 0.03 0.05 0.07 0.17 0.29 0.10 0.20 0.33 1.99 3.27 4.70 0.02 0.03 0.05 0.11 0.27 0.47 0.00 0.00 0.00 Vancomycin resistant Enterococci (E. faecalis and E. faecium ) 82.57 99.22 116.83 787.19 931.73 1,097.86 868.78 1,031.11 1,214.94 5.91 6.58 7.25 0.80 0.96 1.13 7.59 8.98 10.58 8.37 9.94 11.71 495.79 605.57 716.40 4.78 5.84 6.91 33.83 40.35 47.71 0.33 0.39 0.46 Colistin resistant Escherichia coli 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Escherichia coli (excluding those resistant to colistin) 5.47 7.27 9.59 54.03 77.47 104.57 60.05 84.71 113.37 12.21 16.35 21.13 0.05 0.07 0.09 0.52 0.75 1.01 0.58 0.82 1.09 32.04 41.31 50.76 0.31 0.40 0.49 1.56 2.19 2.90 0.02 0.02 0.03 Third-generation cephalosporin resistant Escherichia coli (excluding those resistant to colistin and/or carbapenem) 464.10 519.27 576.82 2,800.09 3,107.39 3,477.27 3,285.82 3,624.68 4,039.62 3.94 4.28 4.65 4.47 5.01 5.56 26.99 29.95 33.52 31.67 34.94 38.94 5,890.48 6,754.39 7,599.84 56.78 65.10 73.25 182.89 210.48 242.31 1.76 2.03 2.34 Colistin resistant Klebsiella pneumoniae 0.99 1.49 2.10 15.38 25.93 38.67 16.30 27.37 40.79 8.81 13.43 18.33 0.01 0.01 0.02 0.15 0.25 0.37 0.16 0.26 0.39 3.75 6.12 8.53 0.04 0.06 0.08 0.82 1.36 2.00 0.01 0.01 0.02 Carbapenem resistant Klebsiella pneumoniae (excluding those resistant to colistin) 54.23 62.18 70.59 568.66 667.21 772.66 625.72 729.18 837.80 9.48 10.71 11.93 0.52 0.60 0.68 5.48 6.43 7.45 6.03 7.03 8.08 183.24 210.45 238.84 1.77 2.03 2.30 24.70 28.60 32.82 0.24 0.28 0.32 Third-generation cephalosporin resistant Klebsiella pneumoniae (excluding those resistant to colistin and/or carbapenem) 663.34 725.09 788.31 3,261.20 3,478.45 3,690.54 3,939.60 4,203.28 4,464.47 5.27 5.52 5.80 6.39 6.99 7.60 31.43 33.53 35.57 37.97 40.51 43.03 2,842.12 3,142.56 3,436.49 27.39 30.29 33.12 158.99 171.66 184.92 1.53 1.65 1.78 Colistin resistant Pseudomonas aeruginosa 8.02 11.16 14.92 30.43 56.11 88.64 40.33 67.23 102.56 7.67 12.30 17.35 0.08 0.11 0.14 0.29 0.54 0.85 0.39 0.65 0.99 16.95 24.17 31.43 0.16 0.23 0.30 0.90 1.62 2.51 0.01 0.02 0.02 Carbapenem resistant Pseudomonas aeruginosa (excluding those resistant to colistin) 543.51 610.89 678.87 2,511.59 3,085.29 3,663.15 3,095.19 3,697.41 4,305.79 7.29 8.61 9.85 5.24 5.89 6.54 24.21 29.74 35.31 29.83 35.64 41.50 1,670.15 1,901.37 2,131.29 16.10 18.33 20.54 104.37 129.06 155.27 1.01 1.24 1.50 Pseudomonas aeruginosa resistant to three or more antimicrobial groups (excluding those resistant to colistin and/or carbapenem) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Methicillin resistant Staphylococcus aureus 1,520.11 1,663.80 1,814.19 7,634.02 8,157.09 8,707.45 9,176.47 9,817.87 10,473.09 4.51 4.73 4.97 14.65 16.04 17.49 73.58 78.62 83.93 88.45 94.63 100.95 9,588.43 10,577.74 11,558.01 92.42 101.96 111.40 468.54 510.92 554.22 4.52 4.92 5.34 Penicillin and macrolides resistant Streptococcus pneumoniae (excluding those only resistant to penicillin) 39.35 45.03 52.62 135.08 147.61 163.07 176.15 192.67 213.38 6.82 7.21 7.64 0.38 0.43 0.51 1.30 1.42 1.57 1.70 1.86 2.06 79.57 86.99 96.83 0.77 0.84 0.93 4.95 5.35 5.81 0.05 0.05 0.06 Penicillin tesistant Streptococcus pneumoniae (excluding those resistant to macrolides) 42.50 49.26 57.91 146.84 162.27 180.79 191.12 211.39 236.58 8.53 9.06 9.62 0.41 0.47 0.56 1.42 1.56 1.74 1.84 2.04 2.28 68.67 75.97 87.05 0.66 0.73 0.84 4.27 4.67 5.15 0.04 0.05 0.05 Total 3,621.96 4,016.17 4,428.98 18,917.76 21,080.58 23,383.62 22,656.12 25,091.92 27,672.77 34.91 38.71 42.69 182.34 203.19 225.39 218.38 241.85 266.73 21,401.52 24,021.33 26,611.99 206.28 231.53 256.51 1,028.59 1,158.34 1,296.95 9.91 11.16 12.50 Model Portugal - Acinetobacter spp. CRACI BSI - model 36 110.10 120.81 131.97 762.51 926.12 1,087.97 879.90 1,046.50 1,209.40 4.40 5.23 6.01 1.06 1.16 1.27 7.35 8.93 10.49 8.48 10.09 11.66 188.74 200.47 212.44 1.82 1.93 2.05 33.52 41.06 48.46 0.32 0.40 0.47 Portugal - Acinetobacter spp. CRACI OTH - model 40 0.02 0.03 0.03 0.00 0.00 0.00 0.02 0.03 0.03 2.97E-03 3.75E-03 4.47E-03 1.80E-04 2.54E-04 3.30E-04 0.00 0.00 0.00 1.80E-04 2.54E-04 3.30E-04 5.33 7.07 8.74 0.05 0.07 0.08 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Acinetobacter spp. CRACI RESP - model 37 80.07 90.34 100.53 156.25 175.27 195.00 237.25 265.48 293.00 1.15 1.23 1.31 0.77 0.87 0.97 1.51 1.69 1.88 2.29 2.56 2.82 192.97 216.37 236.85 1.86 2.09 2.28 6.90 7.77 8.65 0.07 0.07 0.08 Portugal - Acinetobacter spp. CRACI SSI - model 39 0.11 0.15 0.21 25.31 29.98 34.76 25.41 30.15 34.94 0.39 0.41 0.44 1.09E-03 1.49E-03 1.99E-03 0.24 0.29 0.34 0.24 0.29 0.34 61.72 73.18 83.64 0.59 0.71 0.81 1.50 1.85 2.19 0.01 0.02 0.02 Portugal - Acinetobacter spp. CRACI UTI - model 38 0.13 0.17 0.21 0.00 0.00 0.00 0.13 0.17 0.21 1.67E-03 2.05E-03 2.49E-03 1.22E-03 1.60E-03 2.03E-03 0.00 0.00 0.00 1.22E-03 1.60E-03 2.03E-03 69.25 81.18 94.21 0.67 0.78 0.91 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Acinetobacter spp. ColRACI BSI - model 41 3.09 3.82 4.69 17.41 29.00 42.98 21.06 32.89 46.64 4.77 7.22 9.91 0.03 0.04 0.05 0.17 0.28 0.41 0.20 0.32 0.45 4.04 4.55 5.14 0.04 0.04 0.05 0.57 0.92 1.30 5.52E-03 8.89E-03 0.01 Portugal - Acinetobacter spp. ColRACI OTH - model 45 2.64E-04 5.60E-04 1.02E-03 0.00 0.00 0.00 2.64E-04 5.60E-04 1.02E-03 2.27E-03 3.70E-03 5.11E-03 2.55E-06 5.40E-06 9.86E-06 0.00 0.00 0.00 2.55E-06 5.40E-06 9.86E-06 0.09 0.16 0.24 8.37E-04 1.50E-03 2.28E-03 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Acinetobacter spp. ColRACI RESP - model 42 2.13 2.85 3.59 4.21 5.63 7.10 6.47 8.51 10.66 1.54 1.72 1.93 0.02 0.03 0.03 0.04 0.05 0.07 0.06 0.08 0.10 3.82 4.93 5.93 0.04 0.05 0.06 0.13 0.18 0.22 1.30E-03 1.72E-03 2.10E-03 Portugal - Acinetobacter spp. ColRACI SSI - model 44 1.77E-03 3.47E-03 6.07E-03 0.42 0.62 0.82 0.42 0.62 0.83 0.35 0.37 0.40 1.71E-05 3.35E-05 5.85E-05 4.03E-03 5.96E-03 7.95E-03 4.05E-03 6.00E-03 8.00E-03 1.13 1.67 2.22 0.01 0.02 0.02 0.02 0.03 0.04 1.53E-04 2.53E-04 3.45E-04 Portugal - Acinetobacter spp. ColRACI UTI - model 43 2.06E-03 3.74E-03 6.03E-03 0.00 0.00 0.00 2.06E-03 3.74E-03 6.03E-03 1.28E-03 2.08E-03 2.97E-03 1.99E-05 3.60E-05 5.82E-05 0.00 0.00 0.00 1.99E-05 3.60E-05 5.82E-05 1.25 1.84 2.42 0.01 0.02 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Acinetobacter spp. MDRACI BSI - model 31 1.27 1.89 2.82 5.38 14.33 25.78 7.28 16.16 28.04 6.54 14.38 22.29 0.01 0.02 0.03 0.05 0.14 0.25 0.07 0.16 0.27 0.90 1.13 1.45 8.70E-03 0.01 0.01 0.08 0.22 0.40 8.12E-04 2.16E-03 3.89E-03 Portugal - Acinetobacter spp. MDRACI OTH - model 35 1.86E-05 1.25E-04 3.97E-04 0.00 0.00 0.00 1.86E-05 1.25E-04 3.97E-04 1.58E-03 3.69E-03 6.51E-03 1.79E-07 1.21E-06 3.83E-06 0.00 0.00 0.00 1.79E-07 1.21E-06 3.83E-06 6.18E-03 0.04 0.09 5.96E-05 3.72E-04 8.42E-04 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Acinetobacter spp. MDRACI RESP - model 32 0.85 1.43 2.16 1.65 2.80 4.15 2.55 4.26 6.23 3.00 3.46 3.96 8.15E-03 0.01 0.02 0.02 0.03 0.04 0.02 0.04 0.06 0.73 1.23 1.76 7.03E-03 0.01 0.02 0.03 0.04 0.06 2.49E-04 4.22E-04 6.26E-04 Portugal - Acinetobacter spp. MDRACI SSI - model 34 1.62E-04 7.95E-04 2.20E-03 0.10 0.24 0.38 0.10 0.24 0.38 0.58 0.58 0.58 1.56E-06 7.66E-06 2.12E-05 9.59E-04 2.32E-03 3.66E-03 9.59E-04 2.33E-03 3.67E-03 0.17 0.42 0.66 1.67E-03 4.04E-03 6.37E-03 1.56E-03 3.77E-03 5.95E-03 1.50E-05 3.63E-05 5.74E-05 Portugal - Acinetobacter spp. MDRACI UTI - model 33 2.41E-04 8.46E-04 2.13E-03 0.00 0.00 0.00 2.41E-04 8.46E-04 2.13E-03 7.90E-04 1.96E-03 3.72E-03 2.32E-06 8.15E-06 2.05E-05 0.00 0.00 0.00 2.32E-06 8.15E-06 2.05E-05 0.18 0.46 0.75 1.73E-03 4.40E-03 7.19E-03 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Enterococcus faecalis and E. faecium VRE BSI - model 66 81.95 98.36 115.67 715.88 842.46 990.18 796.75 940.95 1,106.45 5.53 6.14 6.78 0.79 0.95 1.11 6.90 8.12 9.54 7.68 9.07 10.66 130.06 153.32 180.76 1.25 1.48 1.74 29.74 35.04 41.22 0.29 0.34 0.40 Portugal - Enterococcus faecalis and E. faecium VRE OTH - model 70 0.20 0.27 0.35 0.00 0.00 0.00 0.20 0.27 0.35 1.31E-03 1.65E-03 2.01E-03 1.92E-03 2.59E-03 3.38E-03 0.00 0.00 0.00 1.92E-03 2.59E-03 3.38E-03 132.68 164.16 192.21 1.28 1.58 1.85 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Enterococcus faecalis and E. faecium VRE RESP - model 67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Enterococcus faecalis and E. faecium VRE SSI - model 69 0.32 0.45 0.62 71.32 89.27 107.68 71.72 89.75 107.95 0.38 0.43 0.47 3.12E-03 4.30E-03 5.96E-03 0.69 0.86 1.04 0.69 0.87 1.04 171.78 210.10 249.76 1.66 2.03 2.41 4.10 5.31 6.50 0.04 0.05 0.06 Portugal - Enterococcus faecalis and E. faecium VRE UTI - model 68 0.11 0.15 0.19 0.00 0.00 0.00 0.11 0.15 0.19 1.55E-03 1.87E-03 2.30E-03 1.02E-03 1.41E-03 1.86E-03 0.00 0.00 0.00 1.02E-03 1.41E-03 1.86E-03 61.27 77.99 93.67 0.59 0.75 0.90 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Escherichia coli 3GCREC BSI - model 16 354.87 389.14 425.50 2,278.69 2,502.81 2,783.29 2,653.81 2,890.12 3,196.92 2.83 3.06 3.30 3.42 3.75 4.10 21.96 24.12 26.83 25.58 27.86 30.81 871.37 948.27 1,028.08 8.40 9.14 9.91 144.75 164.50 188.06 1.40 1.59 1.81 Portugal - Escherichia coli 3GCREC OTH - model 20 0.76 1.04 1.41 0.00 0.00 0.00 0.76 1.04 1.41 2.59E-03 3.34E-03 4.13E-03 7.31E-03 0.01 0.01 0.00 0.00 0.00 7.31E-03 0.01 0.01 249.80 313.85 378.16 2.41 3.03 3.64 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Escherichia coli 3GCREC RESP - model 17 100.75 119.00 136.93 193.58 228.36 263.50 296.81 347.19 398.03 0.76 0.83 0.94 0.97 1.15 1.32 1.87 2.20 2.54 2.86 3.35 3.84 340.93 417.38 492.96 3.29 4.02 4.75 12.22 14.97 17.93 0.12 0.14 0.17 Portugal - Escherichia coli 3GCREC SSI - model 19 1.53 2.12 2.87 327.82 376.22 430.48 328.25 378.35 433.14 0.36 0.38 0.41 0.01 0.02 0.03 3.16 3.63 4.15 3.16 3.65 4.17 850.50 995.02 1,144.37 8.20 9.59 11.03 25.92 31.02 36.32 0.25 0.30 0.35 Portugal - Escherichia coli 3GCREC UTI - model 18 6.19 7.97 10.12 0.00 0.00 0.00 6.19 7.97 10.12 1.53E-03 1.97E-03 2.41E-03 0.06 0.08 0.10 0.00 0.00 0.00 0.06 0.08 0.10 3,577.88 4,079.86 4,556.27 34.49 39.32 43.92 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Escherichia coli CREC BSI - model 21 4.28 5.35 6.89 49.65 71.04 96.00 54.49 76.37 102.16 10.32 13.94 18.06 0.04 0.05 0.07 0.48 0.68 0.93 0.53 0.74 0.98 4.71 5.50 6.31 0.05 0.05 0.06 1.41 1.96 2.59 0.01 0.02 0.02 Portugal - Escherichia coli CREC OTH - model 25 5.81E-03 0.01 0.02 0.00 0.00 0.00 5.81E-03 0.01 0.02 2.08E-03 3.43E-03 5.42E-03 5.60E-05 1.06E-04 1.75E-04 0.00 0.00 0.00 5.60E-05 1.06E-04 1.75E-04 2.23 3.18 4.09 0.02 0.03 0.04 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Escherichia coli CREC RESP - model 22 1.15 1.84 2.59 2.31 3.63 5.02 3.44 5.46 7.54 1.49 1.97 2.59 0.01 0.02 0.02 0.02 0.03 0.05 0.03 0.05 0.07 1.80 2.78 3.71 0.02 0.03 0.04 0.06 0.10 0.14 6.24E-04 9.56E-04 1.31E-03 Portugal - Escherichia coli CREC SSI - model 24 7.16E-03 0.01 0.02 2.07 2.80 3.55 2.09 2.82 3.57 0.39 0.43 0.47 6.90E-05 1.31E-04 2.28E-04 0.02 0.03 0.03 0.02 0.03 0.03 4.82 6.55 8.26 0.05 0.06 0.08 0.08 0.13 0.17 8.19E-04 1.24E-03 1.68E-03 Portugal - Escherichia coli CREC UTI - model 23 0.03 0.05 0.08 0.00 0.00 0.00 0.03 0.05 0.08 1.29E-03 2.07E-03 3.07E-03 2.74E-04 4.61E-04 7.32E-04 0.00 0.00 0.00 2.74E-04 4.61E-04 7.32E-04 18.48 23.30 28.39 0.18 0.22 0.27 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Escherichia coli ColREC BSI - model 26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Escherichia coli ColREC OTH - model 30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Escherichia coli ColREC RESP - model 27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Escherichia coli ColREC SSI - model 29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Escherichia coli ColREC UTI - model 28 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Klebsiella pneumoniae 3GCRKP BSI - model 1 416.62 449.31 484.87 2,672.70 2,819.52 2,963.21 3,100.74 3,268.83 3,438.33 3.82 3.98 4.15 4.02 4.33 4.67 25.76 27.18 28.56 29.89 31.51 33.14 779.06 821.97 864.55 7.51 7.92 8.33 128.99 137.28 146.39 1.24 1.32 1.41 Portugal - Klebsiella pneumoniae 3GCRKP OTH - model 5 0.84 1.09 1.34 0.00 0.00 0.00 0.84 1.09 1.34 2.71E-03 3.35E-03 4.01E-03 8.12E-03 0.01 0.01 0.00 0.00 0.00 8.12E-03 0.01 0.01 283.61 325.03 366.27 2.73 3.13 3.53 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Klebsiella pneumoniae 3GCRKP RESP - model 2 243.87 272.12 298.88 471.83 525.44 574.72 719.27 797.32 869.10 1.05 1.12 1.20 2.35 2.62 2.88 4.55 5.06 5.54 6.93 7.69 8.38 632.41 709.56 784.21 6.10 6.84 7.56 22.54 25.53 28.38 0.22 0.25 0.27 Portugal - Klebsiella pneumoniae 3GCRKP SSI - model 4 0.51 0.68 0.90 116.67 133.50 152.61 117.25 134.15 153.38 0.39 0.42 0.44 4.92E-03 6.58E-03 8.65E-03 1.12 1.29 1.47 1.13 1.29 1.48 281.45 320.80 361.22 2.71 3.09 3.48 7.46 8.85 10.15 0.07 0.09 0.10 Portugal - Klebsiella pneumoniae 3GCRKP UTI - model 3 1.50 1.90 2.32 0.00 0.00 0.00 1.50 1.90 2.32 1.63E-03 1.97E-03 2.34E-03 0.01 0.02 0.02 0.00 0.00 0.00 0.01 0.02 0.02 865.60 965.21 1,060.24 8.34 9.30 10.22 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Klebsiella pneumoniae CRKP BSI - model 6 43.01 48.08 53.45 540.00 631.55 729.72 586.27 679.39 778.04 7.95 9.03 10.08 0.41 0.46 0.52 5.20 6.09 7.03 5.65 6.55 7.50 70.16 75.53 81.03 0.68 0.73 0.78 23.34 26.92 30.84 0.22 0.26 0.30 Portugal - Klebsiella pneumoniae CRKP OTH - model 10 0.09 0.12 0.17 0.00 0.00 0.00 0.09 0.12 0.17 2.79E-03 3.52E-03 4.35E-03 8.84E-04 1.19E-03 1.61E-03 0.00 0.00 0.00 8.84E-04 1.19E-03 1.61E-03 29.78 35.39 41.22 0.29 0.34 0.40 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Klebsiella pneumoniae CRKP RESP - model 7 11.02 13.83 16.78 21.49 26.71 32.40 32.09 40.56 48.87 1.16 1.28 1.40 0.11 0.13 0.16 0.21 0.26 0.31 0.31 0.39 0.47 26.28 31.86 37.83 0.25 0.31 0.36 0.95 1.15 1.36 9.16E-03 0.01 0.01 Portugal - Klebsiella pneumoniae CRKP SSI - model 9 0.03 0.05 0.06 7.16 8.96 10.54 7.20 9.00 10.59 0.37 0.40 0.44 3.32E-04 4.56E-04 6.03E-04 0.07 0.09 0.10 0.07 0.09 0.10 18.30 22.29 26.18 0.18 0.21 0.25 0.41 0.52 0.63 3.99E-03 5.04E-03 6.08E-03 Portugal - Klebsiella pneumoniae CRKP UTI - model 8 0.07 0.10 0.12 0.00 0.00 0.00 0.07 0.10 0.12 1.69E-03 2.10E-03 2.58E-03 6.92E-04 9.19E-04 1.19E-03 0.00 0.00 0.00 6.92E-04 9.19E-04 1.19E-03 38.72 45.37 52.59 0.37 0.44 0.51 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Klebsiella pneumoniae ColRKP BSI - model 11 0.84 1.15 1.56 14.99 25.07 37.33 15.75 26.18 38.93 7.68 12.03 16.62 8.12E-03 0.01 0.02 0.14 0.24 0.36 0.15 0.25 0.38 1.76 2.19 2.69 0.02 0.02 0.03 0.79 1.31 1.93 7.66E-03 0.01 0.02 Portugal - Klebsiella pneumoniae ColRKP OTH - model 15 1.25E-03 3.24E-03 7.05E-03 0.00 0.00 0.00 1.25E-03 3.24E-03 7.05E-03 1.66E-03 3.29E-03 6.12E-03 1.21E-05 3.13E-05 6.79E-05 0.00 0.00 0.00 1.21E-05 3.13E-05 6.79E-05 0.49 1.02 1.51 4.69E-03 9.83E-03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Klebsiella pneumoniae ColRKP RESP - model 12 0.15 0.33 0.52 0.29 0.63 0.99 0.45 0.96 1.51 0.85 1.05 1.30 1.45E-03 3.19E-03 5.00E-03 2.75E-03 6.10E-03 9.57E-03 4.30E-03 9.28E-03 0.01 0.44 0.91 1.41 4.26E-03 8.76E-03 0.01 0.02 0.03 0.05 1.54E-04 3.13E-04 4.91E-04 Portugal - Klebsiella pneumoniae ColRKP SSI - model 14 4.79E-04 1.33E-03 3.01E-03 0.10 0.23 0.35 0.10 0.23 0.35 0.28 0.35 0.41 4.61E-06 1.28E-05 2.90E-05 9.89E-04 2.21E-03 3.35E-03 9.94E-04 2.22E-03 3.37E-03 0.32 0.66 0.99 3.07E-03 6.37E-03 9.57E-03 6.06E-03 0.01 0.02 5.84E-05 1.44E-04 2.27E-04 Portugal - Klebsiella pneumoniae ColRKP UTI - model 13 1.12E-03 2.66E-03 5.20E-03 0.00 0.00 0.00 1.12E-03 2.66E-03 5.20E-03 1.03E-03 2.04E-03 3.42E-03 1.08E-05 2.56E-05 5.01E-05 0.00 0.00 0.00 1.08E-05 2.56E-05 5.01E-05 0.73 1.33 1.92 7.08E-03 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Pseudomonas aeruginosa CRPA BSI - model 51 154.36 170.82 188.74 1,183.70 1,448.04 1,726.48 1,348.19 1,618.79 1,906.91 5.12 6.14 7.07 1.49 1.65 1.82 11.41 13.96 16.64 12.99 15.60 18.38 243.47 264.50 287.52 2.35 2.55 2.77 48.29 60.14 72.73 0.47 0.58 0.70 Portugal - Pseudomonas aeruginosa CRPA OTH - model 55 0.38 0.49 0.61 0.00 0.00 0.00 0.38 0.49 0.61 3.02E-03 3.63E-03 4.34E-03 3.62E-03 4.68E-03 5.89E-03 0.00 0.00 0.00 3.62E-03 4.68E-03 5.89E-03 110.09 134.29 155.62 1.06 1.29 1.50 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Pseudomonas aeruginosa CRPA RESP - model 52 387.95 438.51 488.15 1,265.74 1,560.71 1,846.81 1,683.57 2,000.53 2,307.14 1.77 2.04 2.32 3.74 4.23 4.71 12.20 15.04 17.80 16.23 19.28 22.24 877.59 980.11 1,090.13 8.46 9.45 10.51 52.52 64.45 77.18 0.51 0.62 0.74 Portugal - Pseudomonas aeruginosa CRPA SSI - model 54 0.29 0.39 0.51 62.15 76.55 89.86 62.52 76.91 90.26 0.40 0.42 0.45 2.78E-03 3.74E-03 4.88E-03 0.60 0.74 0.87 0.60 0.74 0.87 151.30 182.26 211.08 1.46 1.76 2.03 3.56 4.47 5.35 0.03 0.04 0.05 Portugal - Pseudomonas aeruginosa CRPA UTI - model 53 0.54 0.69 0.86 0.00 0.00 0.00 0.54 0.69 0.86 1.68E-03 2.06E-03 2.43E-03 5.19E-03 6.70E-03 8.31E-03 0.00 0.00 0.00 5.19E-03 6.70E-03 8.31E-03 287.70 340.21 386.93 2.77 3.28 3.73 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Pseudomonas aeruginosa ColRPA BSI - model 56 2.43 3.17 4.15 14.04 26.93 42.14 17.07 30.06 45.98 5.17 8.88 12.82 0.02 0.03 0.04 0.14 0.26 0.41 0.16 0.29 0.44 2.77 3.40 4.17 0.03 0.03 0.04 0.41 0.77 1.19 3.99E-03 7.42E-03 0.01 Portugal - Pseudomonas aeruginosa ColRPA OTH - model 60 3.02E-03 6.28E-03 0.01 0.00 0.00 0.00 3.02E-03 6.28E-03 0.01 2.14E-03 3.71E-03 5.36E-03 2.91E-05 6.06E-05 1.05E-04 0.00 0.00 0.00 2.91E-05 6.06E-05 1.05E-04 1.01 1.70 2.42 9.74E-03 0.02 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Pseudomonas aeruginosa ColRPA RESP - model 57 5.57 7.97 10.73 15.78 28.11 45.00 22.64 36.08 55.06 2.07 2.95 4.01 0.05 0.08 0.10 0.15 0.27 0.43 0.22 0.35 0.53 9.15 12.41 15.88 0.09 0.12 0.15 0.47 0.81 1.26 4.48E-03 7.80E-03 0.01 Portugal - Pseudomonas aeruginosa ColRPA SSI - model 59 2.05E-03 4.71E-03 9.17E-03 0.62 1.07 1.49 0.62 1.08 1.50 0.42 0.47 0.51 1.97E-05 4.54E-05 8.84E-05 5.94E-03 0.01 0.01 5.97E-03 0.01 0.01 1.33 2.31 3.12 0.01 0.02 0.03 0.02 0.04 0.06 1.88E-04 3.96E-04 5.85E-04 Portugal - Pseudomonas aeruginosa ColRPA UTI - model 58 4.41E-03 8.60E-03 0.01 0.00 0.00 0.00 4.41E-03 8.60E-03 0.01 1.19E-03 2.00E-03 3.03E-03 4.25E-05 8.29E-05 1.44E-04 0.00 0.00 0.00 4.25E-05 8.29E-05 1.44E-04 2.69 4.34 5.84 0.03 0.04 0.06 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Pseudomonas aeruginosa MDRPA BSI - model 46 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Pseudomonas aeruginosa MDRPA OTH - model 50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Pseudomonas aeruginosa MDRPA RESP - model 47 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Pseudomonas aeruginosa MDRPA SSI - model 49 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Pseudomonas aeruginosa MDRPA UTI - model 48 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Staphylococcus aureus MRSA BSI - model 61 748.90 805.09 869.86 5,119.85 5,390.26 5,689.33 5,888.91 6,193.00 6,522.76 3.29 3.43 3.59 7.22 7.76 8.38 49.35 51.96 54.84 56.76 59.69 62.87 1,715.34 1,803.08 1,899.90 16.53 17.38 18.31 302.39 323.97 346.83 2.91 3.12 3.34 Portugal - Staphylococcus aureus MRSA OTH - model 65 6.92 8.67 10.74 0.00 0.00 0.00 6.92 8.67 10.74 2.66E-03 3.26E-03 4.00E-03 0.07 0.08 0.10 0.00 0.00 0.00 0.07 0.08 0.10 2,389.05 2,660.89 2,916.67 23.03 25.65 28.11 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Staphylococcus aureus MRSA RESP - model 62 758.95 842.92 924.04 1,477.93 1,620.37 1,760.88 2,235.24 2,462.49 2,674.89 0.85 0.91 0.97 7.32 8.12 8.91 14.25 15.62 16.97 21.54 23.74 25.78 2,442.56 2,710.84 2,987.62 23.54 26.13 28.80 86.99 97.51 108.39 0.84 0.94 1.04 Portugal - Staphylococcus aureus MRSA SSI - model 64 4.71 6.30 8.47 1,036.24 1,146.46 1,257.24 1,044.78 1,152.90 1,263.63 0.37 0.39 0.41 0.05 0.06 0.08 9.99 11.05 12.12 10.07 11.11 12.18 2,685.84 2,961.90 3,235.76 25.89 28.55 31.19 79.16 89.44 98.99 0.76 0.86 0.95 Portugal - Staphylococcus aureus MRSA UTI - model 63 0.61 0.82 1.08 0.00 0.00 0.00 0.61 0.82 1.08 1.49E-03 1.87E-03 2.29E-03 5.89E-03 7.91E-03 0.01 0.00 0.00 0.00 5.89E-03 7.91E-03 0.01 355.62 441.03 518.05 3.43 4.25 4.99 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Streptococcus pneumoniae PMRSP BSI - model 76 11.13 12.31 13.51 79.76 83.68 87.56 91.96 95.95 99.96 5.47 5.70 5.94 0.11 0.12 0.13 0.77 0.81 0.84 0.89 0.92 0.96 16.82 16.82 16.82 0.16 0.16 0.16 2.91 3.03 3.15 0.03 0.03 0.03 Portugal - Streptococcus pneumoniae PMRSP OTH - model 80 9.29E-03 0.01 0.01 0.00 0.00 0.00 9.29E-03 0.01 0.01 1.56E-03 1.97E-03 2.38E-03 8.95E-05 1.14E-04 1.41E-04 0.00 0.00 0.00 8.95E-05 1.14E-04 1.41E-04 5.59 6.02 6.45 0.05 0.06 0.06 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Streptococcus pneumoniae PMRSP RESP - model 77 28.21 32.71 39.10 55.32 63.93 75.51 84.18 96.71 113.41 1.35 1.51 1.70 0.27 0.32 0.38 0.53 0.62 0.73 0.81 0.93 1.09 57.17 64.15 73.56 0.55 0.62 0.71 2.04 2.31 2.66 0.02 0.02 0.03 Portugal - Streptococcus pneumoniae PMRSP SSI - model 79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Streptococcus pneumoniae PMRSP UTI - model 78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Streptococcus pneumoniae PRSP BSI - model 71 12.09 13.54 15.06 86.86 92.05 96.63 100.54 105.52 110.56 6.83 7.17 7.51 0.12 0.13 0.15 0.84 0.89 0.93 0.97 1.02 1.07 14.72 14.72 14.72 0.14 0.14 0.14 2.53 2.65 2.77 0.02 0.03 0.03 Portugal - Streptococcus pneumoniae PRSP OTH - model 75 7.84E-03 0.01 0.01 0.00 0.00 0.00 7.84E-03 0.01 0.01 1.47E-03 1.95E-03 2.49E-03 7.56E-05 9.90E-05 1.28E-04 0.00 0.00 0.00 7.56E-05 9.90E-05 1.28E-04 4.85 5.27 5.74 0.05 0.05 0.06 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Streptococcus pneumoniae PRSP RESP - model 72 30.40 35.72 42.83 59.98 70.23 84.16 90.57 105.85 126.01 1.70 1.89 2.11 0.29 0.34 0.41 0.58 0.68 0.81 0.87 1.02 1.21 49.10 55.99 66.59 0.47 0.54 0.64 1.74 2.02 2.38 0.02 0.02 0.02 Portugal - Streptococcus pneumoniae PRSP SSI - model 74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Portugal - Streptococcus pneumoniae PRSP UTI - model 73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total (Median & 95% UIs) 3,621.96 4,016.17 4,428.98 18,917.76 21,080.58 23,383.62 22,656.12 25,091.92 27,672.77 34.91 38.71 42.69 182.34 203.19 225.39 218.38 241.85 266.73 21,401.52 24,021.33 26,611.99 206.28 231.53 256.51 1,028.59 1,158.34 1,296.95 9.91 11.16 12.50 Total (average) - 203.32 242.07 24,027.46 231.59 1,160.11 11.18 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 4,019.65 21,094.33 25,113.98 - 38.74 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 Infection Colistin resistant Acinetobacter spp. 46.17 61.57 81.10 202.22 325.58 484.55 253.90 388.09 557.86 7.74 10.98 14.61 0.23 0.31 0.41 1.02 1.64 2.44 1.28 1.95 2.81 79.63 104.74 133.45 0.40 0.53 0.67 5.73 8.91 12.74 0.03 0.04 0.06 Carbapenem resistant Acinetobacter spp. (excluding those resistant to colistin) 1,370.64 1,542.53 1,720.42 6,919.58 8,270.35 9,617.31 8,313.24 9,811.36 11,311.03 8.03 9.15 10.39 6.90 7.76 8.66 34.82 41.62 48.40 41.84 49.38 56.92 2,783.42 3,182.06 3,584.39 14.01 16.01 18.04 227.74 275.43 323.61 1.15 1.39 1.63 Aminoglycosides and fluoroquinolones resistant Acinetobacter spp. (excluding those resistant to colistin and/or carbapenem) 44.70 58.81 76.75 199.36 307.87 443.98 250.04 367.41 513.78 7.59 10.41 13.57 0.22 0.30 0.39 1.00 1.55 2.23 1.26 1.85 2.59 78.99 105.05 133.13 0.40 0.53 0.67 5.94 8.81 12.30 0.03 0.04 0.06 Vancomycin resistant Enterococci (E. faecalis and E. faecium ) 136.43 181.82 235.76 1,306.09 1,705.85 2,195.25 1,434.63 1,885.40 2,427.19 7.45 8.51 9.96 0.69 0.92 1.19 6.57 8.58 11.05 7.22 9.49 12.21 634.24 856.75 1,119.39 3.19 4.31 5.63 41.42 55.84 74.23 0.21 0.28 0.37 Colistin resistant Escherichia coli 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Escherichia coli (excluding those resistant to colistin) 38.95 51.67 67.18 408.97 549.02 719.22 451.64 601.73 778.45 10.09 12.45 15.56 0.20 0.26 0.34 2.06 2.76 3.62 2.27 3.03 3.92 292.85 383.26 481.57 1.47 1.93 2.42 15.39 20.49 27.45 0.08 0.10 0.14 Third-generation cephalosporin resistant Escherichia coli (excluding those resistant to colistin and/or carbapenem) 505.64 582.74 666.36 2,968.40 3,418.86 3,903.35 3,498.48 4,003.58 4,574.33 6.16 6.67 7.24 2.54 2.93 3.35 14.94 17.21 19.64 17.61 20.15 23.02 4,161.60 4,815.42 5,536.68 20.94 24.23 27.86 123.33 143.85 168.98 0.62 0.72 0.85 Colistin resistant Klebsiella pneumoniae 98.28 121.73 147.99 1,658.12 2,154.32 2,677.87 1,772.17 2,277.25 2,813.84 16.16 19.40 22.67 0.49 0.61 0.74 8.34 10.84 13.48 8.92 11.46 14.16 279.36 355.98 438.42 1.41 1.79 2.21 60.89 77.76 97.27 0.31 0.39 0.49 Carbapenem resistant Klebsiella pneumoniae (excluding those resistant to colistin) 337.16 409.91 503.20 3,311.48 4,123.68 5,119.40 3,665.10 4,535.67 5,584.90 12.65 14.69 16.98 1.70 2.06 2.53 16.67 20.75 25.76 18.44 22.83 28.11 889.66 1,085.93 1,282.98 4.48 5.46 6.46 106.16 128.33 155.13 0.53 0.65 0.78 Third-generation cephalosporin resistant Klebsiella pneumoniae (excluding those resistant to colistin and/or carbapenem) 1,078.51 1,262.50 1,472.81 5,288.99 6,006.92 6,944.57 6,408.99 7,265.10 8,371.60 8.43 9.24 10.15 5.43 6.35 7.41 26.62 30.23 34.95 32.25 36.56 42.13 2,868.54 3,242.05 3,634.86 14.44 16.32 18.29 156.87 173.23 191.19 0.79 0.87 0.96 Colistin resistant Pseudomonas aeruginosa 11.39 24.94 42.74 38.97 118.77 264.23 54.58 142.81 297.38 5.66 12.22 18.69 0.06 0.13 0.22 0.20 0.60 1.33 0.27 0.72 1.50 22.65 54.89 91.98 0.11 0.28 0.46 1.12 3.43 7.62 0.01 0.02 0.04 Carbapenem resistant Pseudomonas aeruginosa (excluding those resistant to colistin) 1,140.79 1,344.67 1,566.95 5,279.39 6,784.31 8,502.33 6,510.58 8,130.10 9,993.43 8.98 11.00 12.99 5.74 6.77 7.89 26.57 34.14 42.79 32.76 40.92 50.29 2,754.54 3,279.14 3,837.11 13.86 16.50 19.31 172.87 219.25 275.97 0.87 1.10 1.39 Pseudomonas aeruginosa resistant to three or more antimicrobial groups (excluding those resistant to colistin and/or carbapenem) 25.67 47.87 80.03 91.18 215.62 443.65 120.92 262.76 510.57 5.82 10.77 18.31 0.13 0.24 0.40 0.46 1.09 2.23 0.61 1.32 2.57 60.48 108.19 161.62 0.30 0.54 0.81 3.16 6.61 11.81 0.02 0.03 0.06 Methicillin resistant Staphylococcus aureus 1,558.93 1,747.58 1,945.11 7,510.08 8,277.00 9,075.98 9,124.16 10,026.32 10,981.09 6.98 7.35 7.70 7.85 8.79 9.79 37.79 41.65 45.68 45.92 50.46 55.26 6,343.63 7,106.78 7,884.42 31.92 35.77 39.68 291.56 323.98 357.35 1.47 1.63 1.80 Penicillin and macrolides resistant Streptococcus pneumoniae (excluding those only resistant to penicillin) 33.51 48.59 78.20 122.90 160.06 227.32 159.00 208.75 299.70 8.71 9.72 10.81 0.17 0.24 0.39 0.62 0.81 1.14 0.80 1.05 1.51 51.06 70.92 105.63 0.26 0.36 0.53 3.32 4.30 5.96 0.02 0.02 0.03 Penicillin tesistant Streptococcus pneumoniae (excluding those resistant to macrolides) 167.44 209.84 261.49 575.93 680.17 799.33 751.91 890.51 1,059.24 8.31 8.99 9.69 0.84 1.06 1.32 2.90 3.42 4.02 3.78 4.48 5.33 267.23 325.96 396.66 1.34 1.64 2.00 16.93 19.72 22.90 0.09 0.10 0.12 Total 6,594.20 7,696.78 8,946.11 35,881.65 43,098.38 51,418.34 42,769.33 50,796.86 60,074.39 33.19 38.73 45.02 180.58 216.89 258.77 215.24 255.64 302.33 21,567.89 25,077.12 28,822.30 108.54 126.20 145.05 1,232.43 1,469.94 1,744.51 6.20 7.40 8.78 Model Romania - Acinetobacter spp. CRACI BSI - model 36 782.82 875.49 966.03 5,627.61 6,782.35 7,936.10 6,440.41 7,657.52 8,879.08 6.05 7.03 8.12 3.94 4.41 4.86 28.32 34.13 39.94 32.41 38.54 44.68 995.14 1,086.96 1,179.94 5.01 5.47 5.94 183.78 224.02 264.10 0.92 1.13 1.33 Romania - Acinetobacter spp. CRACI OTH - model 40 0.11 0.15 0.20 0.00 0.00 0.00 0.11 0.15 0.20 3.08E-03 3.74E-03 4.41E-03 5.69E-04 7.77E-04 1.03E-03 0.00 0.00 0.00 5.69E-04 7.77E-04 1.03E-03 32.07 41.36 52.45 0.16 0.21 0.26 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Acinetobacter spp. CRACI RESP - model 37 586.34 665.09 751.88 1,142.33 1,301.29 1,461.13 1,721.65 1,965.11 2,209.11 1.54 1.65 1.77 2.95 3.35 3.78 5.75 6.55 7.35 8.66 9.89 11.12 1,039.45 1,189.83 1,344.91 5.23 5.99 6.77 37.29 42.84 49.11 0.19 0.22 0.25 Romania - Acinetobacter spp. CRACI SSI - model 39 0.65 0.87 1.12 149.64 186.71 220.08 150.35 187.64 221.45 0.43 0.46 0.49 3.28E-03 4.36E-03 5.65E-03 0.75 0.94 1.11 0.76 0.94 1.11 337.01 406.28 476.09 1.70 2.04 2.40 6.68 8.57 10.40 0.03 0.04 0.05 Romania - Acinetobacter spp. CRACI UTI - model 38 0.72 0.93 1.19 0.00 0.00 0.00 0.72 0.93 1.19 1.70E-03 2.04E-03 2.44E-03 3.63E-03 4.69E-03 5.97E-03 0.00 0.00 0.00 3.63E-03 4.69E-03 5.97E-03 379.75 457.63 531.01 1.91 2.30 2.67 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Acinetobacter spp. ColRACI BSI - model 41 27.15 35.05 45.39 161.02 268.10 409.16 192.96 304.00 447.64 5.62 8.54 11.84 0.14 0.18 0.23 0.81 1.35 2.06 0.97 1.53 2.25 29.70 36.01 42.95 0.15 0.18 0.22 4.57 7.32 10.65 0.02 0.04 0.05 Romania - Acinetobacter spp. ColRACI OTH - model 45 2.44E-03 4.98E-03 8.73E-03 0.00 0.00 0.00 2.44E-03 4.98E-03 8.73E-03 2.49E-03 3.73E-03 5.09E-03 1.23E-05 2.51E-05 4.39E-05 0.00 0.00 0.00 1.23E-05 2.51E-05 4.39E-05 0.74 1.36 2.14 3.74E-03 6.85E-03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Acinetobacter spp. ColRACI RESP - model 42 18.99 26.46 35.60 37.35 51.76 67.71 57.06 78.31 102.47 1.74 2.01 2.29 0.10 0.13 0.18 0.19 0.26 0.34 0.29 0.39 0.52 29.28 39.03 50.10 0.15 0.20 0.25 1.04 1.40 1.82 5.24E-03 7.05E-03 9.15E-03 Romania - Acinetobacter spp. ColRACI SSI - model 44 0.02 0.03 0.05 3.84 5.72 7.67 3.86 5.75 7.69 0.38 0.43 0.47 7.71E-05 1.43E-04 2.37E-04 0.02 0.03 0.04 0.02 0.03 0.04 9.31 13.48 18.09 0.05 0.07 0.09 0.12 0.20 0.27 6.15E-04 9.83E-04 1.37E-03 Romania - Acinetobacter spp. ColRACI UTI - model 43 0.02 0.03 0.05 0.00 0.00 0.00 0.02 0.03 0.05 1.38E-03 2.05E-03 2.82E-03 9.08E-05 1.52E-04 2.38E-04 0.00 0.00 0.00 9.08E-05 1.52E-04 2.38E-04 10.60 14.87 20.17 0.05 0.07 0.10 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Acinetobacter spp. MDRACI BSI - model 31 26.27 33.48 42.28 158.59 251.99 370.95 190.01 286.13 405.47 5.50 8.02 10.83 0.13 0.17 0.21 0.80 1.27 1.87 0.96 1.44 2.04 30.01 35.89 42.96 0.15 0.18 0.22 4.73 7.14 10.10 0.02 0.04 0.05 Romania - Acinetobacter spp. MDRACI OTH - model 35 2.40E-03 5.08E-03 8.72E-03 0.00 0.00 0.00 2.40E-03 5.08E-03 8.72E-03 2.39E-03 3.75E-03 5.22E-03 1.21E-05 2.56E-05 4.39E-05 0.00 0.00 0.00 1.21E-05 2.56E-05 4.39E-05 0.75 1.36 2.07 3.79E-03 6.84E-03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Acinetobacter spp. MDRACI RESP - model 32 18.39 25.28 34.36 36.48 49.48 64.31 55.73 74.82 99.49 1.64 1.91 2.22 0.09 0.13 0.17 0.18 0.25 0.32 0.28 0.38 0.50 29.25 39.24 49.61 0.15 0.20 0.25 1.05 1.41 1.82 5.27E-03 7.09E-03 9.17E-03 Romania - Acinetobacter spp. MDRACI SSI - model 34 0.01 0.03 0.05 4.29 6.40 8.72 4.29 6.42 8.77 0.44 0.48 0.51 7.05E-05 1.41E-04 2.37E-04 0.02 0.03 0.04 0.02 0.03 0.04 9.11 13.46 18.14 0.05 0.07 0.09 0.16 0.26 0.38 8.12E-04 1.33E-03 1.90E-03 Romania - Acinetobacter spp. MDRACI UTI - model 33 0.02 0.03 0.05 0.00 0.00 0.00 0.02 0.03 0.05 1.35E-03 2.03E-03 2.80E-03 8.75E-05 1.52E-04 2.44E-04 0.00 0.00 0.00 8.75E-05 1.52E-04 2.44E-04 9.86 15.11 20.34 0.05 0.08 0.10 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Enterococcus faecalis and E. faecium VRE BSI - model 66 135.65 180.62 233.87 1,201.62 1,552.04 1,984.01 1,329.38 1,730.49 2,214.45 7.01 7.99 9.37 0.68 0.91 1.18 6.05 7.81 9.98 6.69 8.71 11.14 163.46 215.05 284.67 0.82 1.08 1.43 37.30 49.29 64.97 0.19 0.25 0.33 Romania - Enterococcus faecalis and E. faecium VRE OTH - model 70 0.25 0.37 0.56 0.00 0.00 0.00 0.25 0.37 0.56 1.21E-03 1.63E-03 2.18E-03 1.24E-03 1.88E-03 2.81E-03 0.00 0.00 0.00 1.24E-03 1.88E-03 2.81E-03 171.44 231.46 300.30 0.86 1.16 1.51 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Enterococcus faecalis and E. faecium VRE RESP - model 67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Enterococcus faecalis and E. faecium VRE SSI - model 69 0.40 0.62 1.02 104.46 153.80 211.24 104.87 154.32 211.88 0.44 0.52 0.58 2.00E-03 3.12E-03 5.15E-03 0.53 0.77 1.06 0.53 0.78 1.07 220.37 299.39 387.69 1.11 1.51 1.95 4.11 6.54 9.27 0.02 0.03 0.05 Romania - Enterococcus faecalis and E. faecium VRE UTI - model 68 0.13 0.20 0.31 0.00 0.00 0.00 0.13 0.20 0.31 1.38E-03 1.87E-03 2.43E-03 6.61E-04 1.03E-03 1.56E-03 0.00 0.00 0.00 6.61E-04 1.03E-03 1.56E-03 78.97 110.85 146.74 0.40 0.56 0.74 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Escherichia coli 3GCREC BSI - model 16 385.57 436.20 491.72 2,480.37 2,825.89 3,199.99 2,890.24 3,263.57 3,698.56 4.51 4.89 5.31 1.94 2.20 2.47 12.48 14.22 16.10 14.55 16.42 18.61 599.67 667.38 743.73 3.02 3.36 3.74 100.24 115.33 134.59 0.50 0.58 0.68 Romania - Escherichia coli 3GCREC OTH - model 20 0.56 0.76 1.02 0.00 0.00 0.00 0.56 0.76 1.02 2.65E-03 3.34E-03 4.14E-03 2.81E-03 3.83E-03 5.15E-03 0.00 0.00 0.00 2.81E-03 3.83E-03 5.15E-03 178.80 228.69 274.41 0.90 1.15 1.38 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Escherichia coli 3GCREC RESP - model 17 113.97 138.57 164.25 223.99 268.99 317.71 337.85 408.13 479.96 1.22 1.33 1.45 0.57 0.70 0.83 1.13 1.35 1.60 1.70 2.05 2.42 248.74 306.29 364.04 1.25 1.54 1.83 8.92 11.00 13.28 0.04 0.06 0.07 Romania - Escherichia coli 3GCREC SSI - model 19 1.14 1.54 2.04 264.04 323.97 385.66 265.44 325.45 387.45 0.42 0.45 0.48 5.74E-03 7.73E-03 0.01 1.33 1.63 1.94 1.34 1.64 1.95 611.77 720.09 836.45 3.08 3.62 4.21 14.16 17.53 21.12 0.07 0.09 0.11 Romania - Escherichia coli 3GCREC UTI - model 18 4.40 5.68 7.34 0.00 0.00 0.00 4.40 5.68 7.34 1.59E-03 1.98E-03 2.39E-03 0.02 0.03 0.04 0.00 0.00 0.00 0.02 0.03 0.04 2,522.63 2,892.96 3,318.05 12.70 14.56 16.70 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Escherichia coli CREC BSI - model 21 29.68 37.51 47.23 369.87 492.58 645.57 403.12 531.01 685.77 8.41 10.46 13.20 0.15 0.19 0.24 1.86 2.48 3.25 2.03 2.67 3.45 42.44 50.73 61.35 0.21 0.26 0.31 13.71 18.04 24.21 0.07 0.09 0.12 Romania - Escherichia coli CREC OTH - model 25 0.06 0.10 0.17 0.00 0.00 0.00 0.06 0.10 0.17 2.26E-03 3.48E-03 5.10E-03 3.00E-04 5.24E-04 8.63E-04 0.00 0.00 0.00 3.00E-04 5.24E-04 8.63E-04 21.43 29.81 39.21 0.11 0.15 0.20 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Escherichia coli CREC RESP - model 22 8.87 13.48 18.90 17.25 26.28 35.64 26.42 39.89 53.89 1.22 1.49 1.83 0.04 0.07 0.10 0.09 0.13 0.18 0.13 0.20 0.27 18.01 26.60 35.53 0.09 0.13 0.18 0.64 0.95 1.27 3.21E-03 4.78E-03 6.41E-03 Romania - Escherichia coli CREC SSI - model 24 0.07 0.13 0.21 21.84 30.17 38.01 21.77 30.28 37.94 0.46 0.49 0.53 3.65E-04 6.41E-04 1.08E-03 0.11 0.15 0.19 0.11 0.15 0.19 44.86 61.12 78.13 0.23 0.31 0.39 1.04 1.50 1.97 5.24E-03 7.54E-03 9.90E-03 Romania - Escherichia coli CREC UTI - model 23 0.27 0.44 0.67 0.00 0.00 0.00 0.27 0.44 0.67 1.34E-03 2.06E-03 2.94E-03 1.36E-03 2.23E-03 3.37E-03 0.00 0.00 0.00 1.36E-03 2.23E-03 3.37E-03 166.12 215.01 267.36 0.84 1.08 1.35 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Escherichia coli ColREC BSI - model 26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Escherichia coli ColREC OTH - model 30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Escherichia coli ColREC RESP - model 27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Escherichia coli ColREC SSI - model 29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Escherichia coli ColREC UTI - model 28 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Klebsiella pneumoniae 3GCRKP BSI - model 1 682.93 782.03 900.54 4,380.52 4,912.66 5,632.98 5,097.63 5,689.37 6,488.20 6.26 6.82 7.48 3.44 3.94 4.53 22.05 24.72 28.35 25.65 28.63 32.65 778.89 837.10 901.80 3.92 4.21 4.54 128.25 139.91 152.65 0.65 0.70 0.77 Romania - Klebsiella pneumoniae 3GCRKP OTH - model 5 0.89 1.12 1.43 0.00 0.00 0.00 0.89 1.12 1.43 2.74E-03 3.31E-03 3.99E-03 4.47E-03 5.64E-03 7.22E-03 0.00 0.00 0.00 4.47E-03 5.64E-03 7.22E-03 289.97 339.76 387.52 1.46 1.71 1.95 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Klebsiella pneumoniae 3GCRKP RESP - model 2 392.62 476.69 567.44 770.29 930.34 1,118.57 1,170.13 1,408.01 1,685.62 1.70 1.92 2.14 1.98 2.40 2.86 3.88 4.68 5.63 5.89 7.09 8.48 638.88 732.10 826.93 3.22 3.68 4.16 22.81 26.39 30.25 0.11 0.13 0.15 Romania - Klebsiella pneumoniae 3GCRKP SSI - model 4 0.54 0.71 0.96 138.17 163.92 193.02 138.81 164.65 193.90 0.46 0.49 0.52 2.73E-03 3.59E-03 4.83E-03 0.70 0.82 0.97 0.70 0.83 0.98 289.89 334.31 388.48 1.46 1.68 1.96 5.81 6.94 8.29 0.03 0.03 0.04 Romania - Klebsiella pneumoniae 3GCRKP UTI - model 3 1.53 1.95 2.43 0.00 0.00 0.00 1.53 1.95 2.43 1.64E-03 1.95E-03 2.31E-03 7.72E-03 9.81E-03 0.01 0.00 0.00 0.00 7.72E-03 9.81E-03 0.01 870.90 998.78 1,130.14 4.38 5.03 5.69 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Klebsiella pneumoniae CRKP BSI - model 6 248.38 289.33 342.00 3,098.58 3,834.75 4,745.70 3,357.42 4,126.72 5,051.82 10.54 12.22 14.13 1.25 1.46 1.72 15.59 19.30 23.88 16.90 20.77 25.42 296.32 338.50 378.55 1.49 1.70 1.91 99.53 119.84 144.64 0.50 0.60 0.73 Romania - Klebsiella pneumoniae CRKP OTH - model 10 0.50 0.68 0.93 0.00 0.00 0.00 0.50 0.68 0.93 2.78E-03 3.51E-03 4.47E-03 2.49E-03 3.43E-03 4.69E-03 0.00 0.00 0.00 2.49E-03 3.43E-03 4.69E-03 154.32 195.76 238.60 0.78 0.99 1.20 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Klebsiella pneumoniae CRKP RESP - model 7 87.72 119.11 159.21 169.32 232.73 303.49 263.01 351.23 460.93 1.69 2.00 2.34 0.44 0.60 0.80 0.85 1.17 1.53 1.32 1.77 2.32 140.50 175.97 212.79 0.71 0.89 1.07 4.96 6.35 7.83 0.02 0.03 0.04 Romania - Klebsiella pneumoniae CRKP SSI - model 9 0.18 0.26 0.37 43.58 56.20 70.21 43.78 56.51 70.54 0.41 0.46 0.50 9.26E-04 1.32E-03 1.87E-03 0.22 0.28 0.35 0.22 0.28 0.35 97.16 123.77 154.26 0.49 0.62 0.78 1.66 2.14 2.67 8.37E-03 0.01 0.01 Romania - Klebsiella pneumoniae CRKP UTI - model 8 0.38 0.52 0.69 0.00 0.00 0.00 0.38 0.52 0.69 1.64E-03 2.09E-03 2.58E-03 1.92E-03 2.64E-03 3.47E-03 0.00 0.00 0.00 1.92E-03 2.64E-03 3.47E-03 201.37 251.93 298.77 1.01 1.27 1.50 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Klebsiella pneumoniae ColRKP BSI - model 11 78.49 93.39 111.11 1,607.40 2,082.62 2,584.28 1,701.54 2,177.16 2,683.81 14.44 17.45 20.43 0.40 0.47 0.56 8.09 10.48 13.01 8.56 10.96 13.51 107.27 124.56 144.31 0.54 0.63 0.73 58.90 74.95 93.61 0.30 0.38 0.47 Romania - Klebsiella pneumoniae ColRKP OTH - model 15 0.14 0.21 0.31 0.00 0.00 0.00 0.14 0.21 0.31 2.57E-03 3.48E-03 4.73E-03 6.99E-04 1.06E-03 1.54E-03 0.00 0.00 0.00 6.99E-04 1.06E-03 1.54E-03 45.47 60.72 77.12 0.23 0.31 0.39 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Klebsiella pneumoniae ColRKP RESP - model 12 19.49 27.88 36.23 38.76 54.46 70.83 58.31 82.39 106.62 1.31 1.50 1.72 0.10 0.14 0.18 0.20 0.27 0.36 0.29 0.41 0.54 40.08 54.87 70.48 0.20 0.28 0.35 1.43 1.98 2.56 7.20E-03 9.94E-03 0.01 Romania - Klebsiella pneumoniae ColRKP SSI - model 14 0.05 0.08 0.12 11.95 17.25 22.77 12.08 17.34 22.87 0.40 0.45 0.51 2.54E-04 4.04E-04 5.95E-04 0.06 0.09 0.11 0.06 0.09 0.12 27.72 38.33 49.04 0.14 0.19 0.25 0.56 0.83 1.11 2.81E-03 4.19E-03 5.57E-03 Romania - Klebsiella pneumoniae ColRKP UTI - model 13 0.11 0.16 0.23 0.00 0.00 0.00 0.11 0.16 0.23 1.59E-03 2.09E-03 2.71E-03 5.42E-04 8.11E-04 1.15E-03 0.00 0.00 0.00 5.42E-04 8.11E-04 1.15E-03 58.82 77.49 97.46 0.30 0.39 0.49 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Pseudomonas aeruginosa CRPA BSI - model 51 322.69 372.54 433.26 2,462.03 3,200.97 4,035.37 2,809.51 3,573.56 4,454.02 6.32 7.91 9.41 1.62 1.87 2.18 12.39 16.11 20.31 14.14 17.98 22.42 401.86 450.10 512.22 2.02 2.27 2.58 80.62 102.69 128.85 0.41 0.52 0.65 Romania - Pseudomonas aeruginosa CRPA OTH - model 55 0.64 0.85 1.12 0.00 0.00 0.00 0.64 0.85 1.12 2.95E-03 3.64E-03 4.38E-03 3.24E-03 4.29E-03 5.66E-03 0.00 0.00 0.00 3.24E-03 4.29E-03 5.66E-03 186.12 234.60 286.13 0.94 1.18 1.44 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Pseudomonas aeruginosa CRPA RESP - model 52 816.10 969.39 1,130.03 2,701.84 3,434.68 4,284.22 3,583.50 4,405.12 5,353.01 2.23 2.62 3.07 4.11 4.88 5.69 13.60 17.29 21.56 18.03 22.17 26.94 1,428.45 1,684.73 1,951.17 7.19 8.48 9.82 87.48 110.13 138.93 0.44 0.55 0.70 Romania - Pseudomonas aeruginosa CRPA SSI - model 54 0.47 0.67 0.94 115.52 148.66 182.74 116.04 149.36 183.68 0.43 0.47 0.50 2.38E-03 3.37E-03 4.71E-03 0.58 0.75 0.92 0.58 0.75 0.92 254.02 318.53 380.40 1.28 1.60 1.91 4.78 6.44 8.18 0.02 0.03 0.04 Romania - Pseudomonas aeruginosa CRPA UTI - model 53 0.89 1.21 1.60 0.00 0.00 0.00 0.89 1.21 1.60 1.67E-03 2.05E-03 2.45E-03 4.50E-03 6.10E-03 8.06E-03 0.00 0.00 0.00 4.50E-03 6.10E-03 8.06E-03 484.10 591.19 707.19 2.44 2.98 3.56 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Pseudomonas aeruginosa ColRPA BSI - model 56 3.72 6.74 11.78 18.34 57.21 123.17 23.38 63.48 130.79 3.72 8.99 14.14 0.02 0.03 0.06 0.09 0.29 0.62 0.12 0.32 0.66 4.59 7.38 11.56 0.02 0.04 0.06 0.53 1.65 3.55 2.66E-03 8.30E-03 0.02 Romania - Pseudomonas aeruginosa ColRPA OTH - model 60 2.76E-03 0.01 0.04 0.00 0.00 0.00 2.76E-03 0.01 0.04 1.55E-03 3.67E-03 6.46E-03 1.39E-05 6.51E-05 1.86E-04 0.00 0.00 0.00 1.39E-05 6.51E-05 1.86E-04 0.94 3.84 7.09 4.72E-03 0.02 0.04 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Pseudomonas aeruginosa ColRPA RESP - model 57 7.66 18.16 30.85 20.25 59.94 138.13 30.81 77.67 163.54 1.63 2.91 4.22 0.04 0.09 0.16 0.10 0.30 0.70 0.16 0.39 0.82 12.49 28.68 46.33 0.06 0.14 0.23 0.58 1.73 3.98 2.94E-03 8.70E-03 0.02 Romania - Pseudomonas aeruginosa ColRPA SSI - model 59 1.25E-03 9.29E-03 0.03 0.37 1.61 2.93 0.38 1.63 2.96 0.31 0.31 0.32 6.28E-06 4.68E-05 1.42E-04 1.87E-03 8.12E-03 0.01 1.89E-03 8.19E-03 0.01 1.19 5.17 9.38 6.00E-03 0.03 0.05 0.01 0.05 0.08 5.40E-05 2.34E-04 4.25E-04 Romania - Pseudomonas aeruginosa ColRPA UTI - model 58 4.84E-03 0.02 0.05 0.00 0.00 0.00 4.84E-03 0.02 0.05 7.68E-04 1.96E-03 3.77E-03 2.44E-05 8.99E-05 2.38E-04 0.00 0.00 0.00 2.44E-05 8.99E-05 2.38E-04 3.44 9.82 17.62 0.02 0.05 0.09 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Pseudomonas aeruginosa MDRPA BSI - model 46 8.00 13.28 21.84 40.23 99.38 205.60 50.24 113.03 222.33 3.87 7.69 13.35 0.04 0.07 0.11 0.20 0.50 1.03 0.25 0.57 1.12 10.23 14.76 20.76 0.05 0.07 0.10 1.43 2.98 5.31 7.21E-03 0.02 0.03 Romania - Pseudomonas aeruginosa MDRPA OTH - model 50 0.01 0.03 0.06 0.00 0.00 0.00 0.01 0.03 0.06 1.95E-03 3.66E-03 5.72E-03 5.43E-05 1.35E-04 2.78E-04 0.00 0.00 0.00 5.43E-05 1.35E-04 2.78E-04 3.35 7.65 12.40 0.02 0.04 0.06 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Pseudomonas aeruginosa MDRPA RESP - model 47 17.64 34.51 58.01 48.91 111.77 230.73 68.62 145.18 280.77 1.58 2.64 4.46 0.09 0.17 0.29 0.25 0.56 1.16 0.35 0.73 1.41 32.67 56.09 81.56 0.16 0.28 0.41 1.64 3.40 6.10 8.24E-03 0.02 0.03 Romania - Pseudomonas aeruginosa MDRPA SSI - model 49 6.76E-03 0.02 0.05 2.03 4.47 7.32 2.04 4.49 7.34 0.38 0.43 0.49 3.40E-05 1.06E-04 2.34E-04 0.01 0.02 0.04 0.01 0.02 0.04 4.59 10.36 16.56 0.02 0.05 0.08 0.09 0.23 0.39 4.47E-04 1.18E-03 1.98E-03 Romania - Pseudomonas aeruginosa MDRPA UTI - model 48 0.01 0.04 0.08 0.00 0.00 0.00 0.01 0.04 0.08 1.00E-03 2.02E-03 3.21E-03 6.93E-05 1.91E-04 3.87E-04 0.00 0.00 0.00 6.93E-05 1.91E-04 3.87E-04 9.64 19.34 30.34 0.05 0.10 0.15 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Staphylococcus aureus MRSA BSI - model 61 763.03 840.97 934.05 5,229.19 5,686.49 6,190.15 6,031.22 6,529.83 7,095.30 5.21 5.47 5.73 3.84 4.23 4.70 26.32 28.62 31.15 30.35 32.86 35.71 1,104.27 1,194.12 1,292.45 5.56 6.01 6.50 196.18 214.22 233.62 0.99 1.08 1.18 Romania - Staphylococcus aureus MRSA OTH - model 65 4.70 5.86 7.24 0.00 0.00 0.00 4.70 5.86 7.24 2.72E-03 3.27E-03 3.89E-03 0.02 0.03 0.04 0.00 0.00 0.00 0.02 0.03 0.04 1,591.83 1,795.71 1,991.49 8.01 9.04 10.02 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Staphylococcus aureus MRSA RESP - model 62 787.56 895.97 997.71 1,543.24 1,750.48 1,945.50 2,343.14 2,645.46 2,933.09 1.36 1.44 1.53 3.96 4.51 5.02 7.77 8.81 9.79 11.79 13.31 14.76 1,624.64 1,827.16 2,029.68 8.18 9.20 10.21 57.58 65.96 73.81 0.29 0.33 0.37 Romania - Staphylococcus aureus MRSA SSI - model 64 3.21 4.21 5.38 737.65 840.03 940.32 744.67 844.61 944.73 0.40 0.43 0.44 0.02 0.02 0.03 3.71 4.23 4.73 3.75 4.25 4.75 1,773.64 1,985.25 2,211.86 8.93 9.99 11.13 37.81 43.79 49.91 0.19 0.22 0.25 Romania - Staphylococcus aureus MRSA UTI - model 63 0.43 0.56 0.73 0.00 0.00 0.00 0.43 0.56 0.73 1.53E-03 1.87E-03 2.24E-03 2.18E-03 2.84E-03 3.66E-03 0.00 0.00 0.00 2.18E-03 2.84E-03 3.66E-03 249.24 304.54 358.94 1.25 1.53 1.81 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Streptococcus pneumoniae PMRSP BSI - model 76 10.29 13.24 17.04 77.42 90.50 105.40 89.97 103.68 119.99 6.98 7.69 8.43 0.05 0.07 0.09 0.39 0.46 0.53 0.45 0.52 0.60 12.08 13.51 15.06 0.06 0.07 0.08 2.09 2.43 2.81 0.01 0.01 0.01 Romania - Streptococcus pneumoniae PMRSP OTH - model 80 4.51E-03 9.17E-03 0.02 0.00 0.00 0.00 4.51E-03 9.17E-03 0.02 1.00E-03 1.91E-03 3.07E-03 2.27E-05 4.61E-05 7.99E-05 0.00 0.00 0.00 2.27E-05 4.61E-05 7.99E-05 3.67 4.88 6.57 0.02 0.02 0.03 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Streptococcus pneumoniae PMRSP RESP - model 77 23.21 35.35 61.15 45.48 69.56 121.92 69.02 105.06 179.70 1.72 2.03 2.38 0.12 0.18 0.31 0.23 0.35 0.61 0.35 0.53 0.90 35.30 52.52 84.00 0.18 0.26 0.42 1.22 1.87 3.15 6.16E-03 9.42E-03 0.02 Romania - Streptococcus pneumoniae PMRSP SSI - model 79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Streptococcus pneumoniae PMRSP UTI - model 78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Streptococcus pneumoniae PRSP BSI - model 71 49.14 55.49 62.68 345.32 377.31 406.56 396.95 432.89 467.15 6.67 7.12 7.54 0.25 0.28 0.32 1.74 1.90 2.05 2.00 2.18 2.35 57.28 60.72 64.28 0.29 0.31 0.32 10.08 10.95 11.79 0.05 0.06 0.06 Romania - Streptococcus pneumoniae PRSP OTH - model 75 0.03 0.04 0.06 0.00 0.00 0.00 0.03 0.04 0.06 1.43E-03 1.94E-03 2.53E-03 1.54E-04 2.17E-04 3.00E-04 0.00 0.00 0.00 1.54E-04 2.17E-04 3.00E-04 19.22 22.31 25.93 0.10 0.11 0.13 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Streptococcus pneumoniae PRSP RESP - model 72 118.26 154.31 198.75 230.60 302.85 392.77 354.93 457.58 592.03 1.64 1.87 2.15 0.60 0.78 1.00 1.16 1.52 1.98 1.79 2.30 2.98 190.72 242.93 306.45 0.96 1.22 1.54 6.85 8.76 11.11 0.03 0.04 0.06 Romania - Streptococcus pneumoniae PRSP SSI - model 74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Romania - Streptococcus pneumoniae PRSP UTI - model 73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total (Median & 95% UIs) 6,594.20 7,696.78 8,946.11 35,881.65 43,098.38 51,418.34 42,769.33 50,796.86 60,074.39 33.19 38.73 45.02 180.58 216.89 258.77 215.24 255.64 302.33 21,567.89 25,077.12 28,822.30 108.54 126.20 145.05 1,232.43 1,469.94 1,744.51 6.20 7.40 8.78 Total (average) - 217.68 256.51 25,118.19 126.41 1,475.82 7.43 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 7,715.68 43,254.56 50,970.24 - 38.83 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 Infection Colistin resistant Acinetobacter spp. 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Acinetobacter spp. (excluding those resistant to colistin) 1.53 2.38 3.54 4.96 12.71 22.73 6.75 15.21 25.72 4.74 8.85 12.98 0.02 0.02 0.04 0.05 0.13 0.23 0.07 0.16 0.26 3.03 5.01 7.10 0.03 0.05 0.07 0.17 0.42 0.76 0.00 0.00 0.01 Aminoglycosides and fluoroquinolones resistant Acinetobacter spp. (excluding those resistant to colistin and/or carbapenem) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Vancomycin resistant Enterococci (E. faecalis and E. faecium ) 0.45 0.93 1.88 4.63 9.63 17.89 5.15 10.56 19.54 5.94 6.15 6.39 0.00 0.01 0.02 0.05 0.10 0.18 0.05 0.11 0.20 2.26 6.62 11.89 0.02 0.07 0.12 0.22 0.46 0.85 0.00 0.00 0.01 Colistin resistant Escherichia coli 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Escherichia coli (excluding those resistant to colistin) 4.20 6.05 8.35 41.92 65.69 95.89 46.76 71.62 103.20 9.90 14.12 18.57 0.04 0.06 0.09 0.43 0.67 0.98 0.48 0.73 1.06 27.41 40.53 55.12 0.28 0.42 0.57 1.34 2.19 3.33 0.01 0.02 0.03 Third-generation cephalosporin resistant Escherichia coli (excluding those resistant to colistin and/or carbapenem) 337.75 373.96 413.70 1,988.39 2,218.23 2,442.21 2,338.10 2,591.23 2,844.66 5.31 5.74 6.21 3.47 3.84 4.24 20.40 22.76 25.06 23.99 26.58 29.18 3,194.27 3,601.38 4,002.14 32.77 36.95 41.06 96.83 110.14 123.19 0.99 1.13 1.26 Colistin resistant Klebsiella pneumoniae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Klebsiella pneumoniae (excluding those resistant to colistin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Third-generation cephalosporin resistant Klebsiella pneumoniae (excluding those resistant to colistin and/or carbapenem) 36.89 41.85 47.03 182.64 200.47 220.27 220.96 242.45 265.91 5.65 5.99 6.37 0.38 0.43 0.48 1.87 2.06 2.26 2.27 2.49 2.73 147.45 167.21 186.99 1.51 1.72 1.92 8.22 9.09 9.95 0.08 0.09 0.10 Colistin resistant Pseudomonas aeruginosa 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Pseudomonas aeruginosa (excluding those resistant to colistin) 83.39 98.23 116.58 378.10 495.50 640.08 469.00 592.88 744.72 8.09 10.17 12.35 0.86 1.01 1.20 3.88 5.08 6.57 4.81 6.08 7.64 221.42 261.51 301.75 2.27 2.68 3.10 13.94 17.73 22.28 0.14 0.18 0.23 Pseudomonas aeruginosa resistant to three or more antimicrobial groups (excluding those resistant to colistin and/or carbapenem) 1.30 2.00 2.91 4.26 9.20 15.63 5.87 11.27 18.37 1.51 2.56 3.63 0.01 0.02 0.03 0.04 0.09 0.16 0.06 0.12 0.19 12.43 20.01 28.01 0.13 0.21 0.29 0.61 1.29 2.16 0.01 0.01 0.02 Methicillin resistant Staphylococcus aureus 51.06 57.55 64.82 246.01 269.14 293.48 299.14 326.63 356.61 8.21 8.71 9.30 0.52 0.59 0.67 2.52 2.76 3.01 3.07 3.35 3.66 175.91 194.27 212.84 1.80 1.99 2.18 8.09 8.88 9.68 0.08 0.09 0.10 Penicillin and macrolides resistant Streptococcus pneumoniae (excluding those only resistant to penicillin) 52.20 60.87 71.32 180.80 198.23 219.28 234.78 259.09 287.58 5.21 5.50 5.81 0.54 0.62 0.73 1.85 2.03 2.25 2.41 2.66 2.95 137.64 153.31 174.06 1.41 1.57 1.79 8.59 9.42 10.45 0.09 0.10 0.11 Penicillin tesistant Streptococcus pneumoniae (excluding those resistant to macrolides) 52.08 61.01 72.93 180.33 199.29 223.88 234.36 260.28 293.17 6.66 7.05 7.44 0.53 0.63 0.75 1.85 2.04 2.30 2.40 2.67 3.01 107.27 120.70 139.88 1.10 1.24 1.44 6.69 7.38 8.30 0.07 0.08 0.09 Total 620.84 704.82 803.06 3,212.05 3,678.09 4,191.35 3,860.87 4,381.22 4,959.49 6.37 7.23 8.24 32.95 37.73 43.00 39.61 44.95 50.88 4,029.07 4,570.54 5,119.78 41.34 46.89 52.52 144.70 166.99 190.94 1.48 1.71 1.96 Model Sweden - Acinetobacter spp. CRACI BSI - model 36 0.94 1.36 1.97 3.75 10.56 19.52 4.90 12.01 21.05 3.06 6.93 10.83 9.61E-03 0.01 0.02 0.04 0.11 0.20 0.05 0.12 0.22 1.36 1.73 2.19 0.01 0.02 0.02 0.12 0.35 0.65 1.28E-03 3.61E-03 6.66E-03 Sweden - Acinetobacter spp. CRACI OTH - model 40 3.19E-05 2.11E-04 6.50E-04 0.00 0.00 0.00 3.19E-05 2.11E-04 6.50E-04 1.49E-03 3.72E-03 6.44E-03 3.28E-07 2.17E-06 6.66E-06 0.00 0.00 0.00 3.28E-07 2.17E-06 6.66E-06 9.83E-03 0.06 0.13 1.01E-04 6.42E-04 1.31E-03 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Acinetobacter spp. CRACI RESP - model 37 0.59 1.01 1.56 1.15 1.98 2.94 1.78 3.03 4.39 1.40 1.64 1.86 6.08E-03 0.01 0.02 0.01 0.02 0.03 0.02 0.03 0.05 1.09 1.88 2.63 0.01 0.02 0.03 0.04 0.07 0.10 3.91E-04 6.78E-04 1.01E-03 Sweden - Acinetobacter spp. CRACI SSI - model 39 2.31E-04 1.19E-03 3.55E-03 0.07 0.17 0.27 0.07 0.17 0.28 0.27 0.27 0.28 2.37E-06 1.22E-05 3.64E-05 7.12E-04 1.75E-03 2.81E-03 7.20E-04 1.76E-03 2.82E-03 0.26 0.63 1.01 2.63E-03 6.46E-03 0.01 2.31E-03 5.67E-03 9.09E-03 2.37E-05 5.82E-05 9.33E-05 Sweden - Acinetobacter spp. CRACI UTI - model 38 4.44E-04 1.30E-03 3.27E-03 0.00 0.00 0.00 4.44E-04 1.30E-03 3.27E-03 8.03E-04 1.97E-03 3.67E-03 4.56E-06 1.33E-05 3.35E-05 0.00 0.00 0.00 4.56E-06 1.33E-05 3.35E-05 0.31 0.71 1.14 3.13E-03 7.26E-03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Acinetobacter spp. ColRACI BSI - model 41 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Acinetobacter spp. ColRACI OTH - model 45 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Acinetobacter spp. ColRACI RESP - model 42 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Acinetobacter spp. ColRACI SSI - model 44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Acinetobacter spp. ColRACI UTI - model 43 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Acinetobacter spp. MDRACI BSI - model 31 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Acinetobacter spp. MDRACI OTH - model 35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Acinetobacter spp. MDRACI RESP - model 32 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Acinetobacter spp. MDRACI SSI - model 34 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Acinetobacter spp. MDRACI UTI - model 33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Enterococcus faecalis and E. faecium VRE BSI - model 66 0.45 0.92 1.86 4.11 7.86 14.79 4.62 8.78 16.42 5.18 5.39 5.62 4.63E-03 9.44E-03 0.02 0.04 0.08 0.15 0.05 0.09 0.17 0.85 1.64 3.04 8.71E-03 0.02 0.03 0.19 0.37 0.70 2.00E-03 3.82E-03 7.18E-03 Sweden - Enterococcus faecalis and E. faecium VRE OTH - model 70 5.94E-04 2.64E-03 7.29E-03 0.00 0.00 0.00 5.94E-04 2.64E-03 7.29E-03 5.68E-04 1.58E-03 3.19E-03 6.09E-06 2.71E-05 7.48E-05 0.00 0.00 0.00 6.09E-06 2.71E-05 7.48E-05 0.51 1.80 3.17 5.24E-03 0.02 0.03 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Enterococcus faecalis and E. faecium VRE RESP - model 67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Enterococcus faecalis and E. faecium VRE SSI - model 69 7.15E-04 4.23E-03 0.01 0.52 1.78 3.10 0.52 1.78 3.11 0.76 0.76 0.76 7.33E-06 4.34E-05 1.33E-04 5.35E-03 0.02 0.03 5.38E-03 0.02 0.03 0.69 2.34 4.09 7.05E-03 0.02 0.04 0.02 0.08 0.15 2.54E-04 8.63E-04 1.51E-03 Sweden - Enterococcus faecalis and E. faecium VRE UTI - model 68 2.70E-04 1.43E-03 3.96E-03 0.00 0.00 0.00 2.70E-04 1.43E-03 3.96E-03 7.40E-04 1.81E-03 3.44E-03 2.77E-06 1.47E-05 4.06E-05 0.00 0.00 0.00 2.77E-06 1.47E-05 4.06E-05 0.21 0.84 1.59 2.14E-03 8.64E-03 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Escherichia coli 3GCREC BSI - model 16 259.25 281.34 306.24 1,653.32 1,824.52 1,991.22 1,922.67 2,104.89 2,287.71 3.87 4.17 4.49 2.66 2.89 3.14 16.96 18.72 20.43 19.73 21.59 23.47 466.67 502.70 541.24 4.79 5.16 5.55 77.83 87.34 96.75 0.80 0.90 0.99 Sweden - Escherichia coli 3GCREC OTH - model 20 0.42 0.55 0.73 0.00 0.00 0.00 0.42 0.55 0.73 2.70E-03 3.32E-03 4.03E-03 4.30E-03 5.65E-03 7.49E-03 0.00 0.00 0.00 4.30E-03 5.65E-03 7.49E-03 137.52 166.34 199.09 1.41 1.71 2.04 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Escherichia coli 3GCREC RESP - model 17 73.86 86.68 99.94 144.93 168.41 193.24 219.77 255.12 291.59 1.03 1.14 1.25 0.76 0.89 1.03 1.49 1.73 1.98 2.25 2.62 2.99 186.64 224.16 259.78 1.91 2.30 2.67 6.71 8.07 9.40 0.07 0.08 0.10 Sweden - Escherichia coli 3GCREC SSI - model 19 0.84 1.14 1.49 190.15 225.29 257.75 191.86 226.42 259.33 0.40 0.42 0.45 8.61E-03 0.01 0.02 1.95 2.31 2.64 1.97 2.32 2.66 459.47 533.23 601.06 4.71 5.47 6.17 12.29 14.72 17.03 0.13 0.15 0.17 Sweden - Escherichia coli 3GCREC UTI - model 18 3.37 4.25 5.30 0.00 0.00 0.00 3.37 4.25 5.30 1.61E-03 1.96E-03 2.34E-03 0.03 0.04 0.05 0.00 0.00 0.00 0.03 0.04 0.05 1,943.97 2,174.94 2,400.97 19.94 22.31 24.63 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Escherichia coli CREC BSI - model 21 3.28 4.44 5.93 37.37 58.18 85.17 41.29 62.51 90.13 7.89 11.74 15.65 0.03 0.05 0.06 0.38 0.60 0.87 0.42 0.64 0.92 4.36 5.42 6.87 0.04 0.06 0.07 1.18 1.91 2.92 0.01 0.02 0.03 Sweden - Escherichia coli CREC OTH - model 25 3.88E-03 0.01 0.02 0.00 0.00 0.00 3.88E-03 0.01 0.02 1.52E-03 3.39E-03 6.55E-03 3.98E-05 1.04E-04 2.44E-04 0.00 0.00 0.00 3.98E-05 1.04E-04 2.44E-04 1.76 3.07 4.59 0.02 0.03 0.05 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Escherichia coli CREC RESP - model 22 0.89 1.54 2.27 1.70 3.00 4.45 2.59 4.54 6.67 1.35 1.67 2.18 9.18E-03 0.02 0.02 0.02 0.03 0.05 0.03 0.05 0.07 1.46 2.71 4.06 0.02 0.03 0.04 0.05 0.10 0.15 5.27E-04 9.88E-04 1.53E-03 Sweden - Escherichia coli CREC SSI - model 24 4.59E-03 0.01 0.03 2.85 4.50 6.27 2.85 4.51 6.28 0.67 0.70 0.73 4.71E-05 1.28E-04 2.95E-04 0.03 0.05 0.06 0.03 0.05 0.06 4.10 6.38 8.88 0.04 0.07 0.09 0.11 0.19 0.27 1.13E-03 1.92E-03 2.75E-03 Sweden - Escherichia coli CREC UTI - model 23 0.02 0.05 0.09 0.00 0.00 0.00 0.02 0.05 0.09 9.42E-04 2.05E-03 3.64E-03 2.01E-04 4.71E-04 9.48E-04 0.00 0.00 0.00 2.01E-04 4.71E-04 9.48E-04 15.72 22.96 30.72 0.16 0.24 0.32 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Escherichia coli ColREC BSI - model 26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Escherichia coli ColREC OTH - model 30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Escherichia coli ColREC RESP - model 27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Escherichia coli ColREC SSI - model 29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Escherichia coli ColREC UTI - model 28 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Klebsiella pneumoniae 3GCRKP BSI - model 1 23.33 26.00 28.81 150.39 162.86 177.19 174.88 188.96 204.89 4.12 4.33 4.57 0.24 0.27 0.30 1.54 1.67 1.82 1.79 1.94 2.10 40.66 43.58 46.66 0.42 0.45 0.48 6.71 7.29 7.89 0.07 0.07 0.08 Sweden - Klebsiella pneumoniae 3GCRKP OTH - model 5 0.04 0.06 0.08 0.00 0.00 0.00 0.04 0.06 0.08 2.59E-03 3.34E-03 4.14E-03 4.42E-04 5.93E-04 7.73E-04 0.00 0.00 0.00 4.42E-04 5.93E-04 7.73E-04 14.70 17.35 19.96 0.15 0.18 0.20 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Klebsiella pneumoniae 3GCRKP RESP - model 2 13.41 15.66 17.97 26.03 30.24 34.48 39.71 45.92 52.17 1.13 1.22 1.32 0.14 0.16 0.18 0.27 0.31 0.35 0.41 0.47 0.54 32.58 37.65 42.39 0.33 0.39 0.43 1.15 1.36 1.55 0.01 0.01 0.02 Sweden - Klebsiella pneumoniae 3GCRKP SSI - model 4 0.03 0.04 0.05 6.21 7.37 8.60 6.26 7.41 8.64 0.40 0.43 0.46 2.67E-04 3.74E-04 5.00E-04 0.06 0.08 0.09 0.06 0.08 0.09 14.71 17.13 19.95 0.15 0.18 0.20 0.36 0.44 0.52 3.70E-03 4.47E-03 5.29E-03 Sweden - Klebsiella pneumoniae 3GCRKP UTI - model 3 0.08 0.10 0.13 0.00 0.00 0.00 0.08 0.10 0.13 1.56E-03 1.98E-03 2.41E-03 7.89E-04 1.03E-03 1.32E-03 0.00 0.00 0.00 7.89E-04 1.03E-03 1.32E-03 44.79 51.50 58.03 0.46 0.53 0.60 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Klebsiella pneumoniae CRKP BSI - model 6 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Klebsiella pneumoniae CRKP OTH - model 10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Klebsiella pneumoniae CRKP RESP - model 7 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Klebsiella pneumoniae CRKP SSI - model 9 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Klebsiella pneumoniae CRKP UTI - model 8 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Klebsiella pneumoniae ColRKP BSI - model 11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Klebsiella pneumoniae ColRKP OTH - model 15 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Klebsiella pneumoniae ColRKP RESP - model 12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Klebsiella pneumoniae ColRKP SSI - model 14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Klebsiella pneumoniae ColRKP UTI - model 13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Pseudomonas aeruginosa CRPA BSI - model 51 24.07 27.53 32.12 180.09 235.51 307.48 207.35 262.48 335.04 5.68 7.30 8.97 0.25 0.28 0.33 1.85 2.42 3.15 2.13 2.69 3.44 32.62 36.28 39.88 0.33 0.37 0.41 6.53 8.31 10.40 0.07 0.09 0.11 Sweden - Pseudomonas aeruginosa CRPA OTH - model 55 0.05 0.07 0.09 0.00 0.00 0.00 0.05 0.07 0.09 2.88E-03 3.66E-03 4.47E-03 5.08E-04 6.94E-04 9.05E-04 0.00 0.00 0.00 5.08E-04 6.94E-04 9.05E-04 14.85 18.48 22.12 0.15 0.19 0.23 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Pseudomonas aeruginosa CRPA RESP - model 52 59.16 70.48 84.18 188.82 248.17 317.90 252.30 318.35 394.69 1.97 2.38 2.86 0.61 0.72 0.86 1.94 2.55 3.26 2.59 3.27 4.05 115.44 134.59 154.66 1.18 1.38 1.59 6.94 8.80 11.11 0.07 0.09 0.11 Sweden - Pseudomonas aeruginosa CRPA SSI - model 54 0.04 0.05 0.07 9.19 11.82 14.69 9.23 11.88 14.77 0.44 0.48 0.52 3.76E-04 5.39E-04 7.58E-04 0.09 0.12 0.15 0.09 0.12 0.15 19.93 25.04 29.97 0.20 0.26 0.31 0.47 0.61 0.76 4.81E-03 6.29E-03 7.82E-03 Sweden - Pseudomonas aeruginosa CRPA UTI - model 53 0.07 0.10 0.12 0.00 0.00 0.00 0.07 0.10 0.12 1.66E-03 2.06E-03 2.50E-03 7.51E-04 9.97E-04 1.27E-03 0.00 0.00 0.00 7.51E-04 9.97E-04 1.27E-03 38.57 47.12 55.11 0.40 0.48 0.57 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Pseudomonas aeruginosa ColRPA BSI - model 56 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Pseudomonas aeruginosa ColRPA OTH - model 60 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Pseudomonas aeruginosa ColRPA RESP - model 57 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Pseudomonas aeruginosa ColRPA SSI - model 59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Pseudomonas aeruginosa ColRPA UTI - model 58 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Pseudomonas aeruginosa MDRPA BSI - model 46 0.40 0.56 0.80 1.86 4.16 6.99 2.38 4.74 7.75 0.91 1.71 2.50 4.06E-03 5.74E-03 8.22E-03 0.02 0.04 0.07 0.02 0.05 0.08 2.14 2.77 3.65 0.02 0.03 0.04 0.27 0.58 0.96 2.75E-03 5.96E-03 9.86E-03 Sweden - Pseudomonas aeruginosa MDRPA OTH - model 50 2.18E-03 5.16E-03 9.54E-03 0.00 0.00 0.00 2.18E-03 5.16E-03 9.54E-03 1.95E-03 3.75E-03 5.74E-03 2.23E-05 5.29E-05 9.79E-05 0.00 0.00 0.00 2.23E-05 5.29E-05 9.79E-05 0.69 1.43 2.11 7.04E-03 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Pseudomonas aeruginosa MDRPA RESP - model 47 0.90 1.42 2.08 2.16 4.55 7.88 3.24 6.02 9.83 0.38 0.59 0.81 9.23E-03 0.01 0.02 0.02 0.05 0.08 0.03 0.06 0.10 6.68 10.27 14.14 0.07 0.11 0.15 0.31 0.64 1.10 3.20E-03 6.56E-03 0.01 Sweden - Pseudomonas aeruginosa MDRPA SSI - model 49 1.28E-03 3.80E-03 8.62E-03 0.24 0.49 0.76 0.25 0.50 0.77 0.21 0.26 0.31 1.31E-05 3.90E-05 8.84E-05 2.46E-03 5.04E-03 7.82E-03 2.55E-03 5.09E-03 7.88E-03 0.94 1.90 2.95 9.65E-03 0.02 0.03 0.03 0.07 0.11 3.47E-04 7.03E-04 1.09E-03 Sweden - Pseudomonas aeruginosa MDRPA UTI - model 48 3.04E-03 7.00E-03 0.01 0.00 0.00 0.00 3.04E-03 7.00E-03 0.01 1.02E-03 2.01E-03 3.19E-03 3.12E-05 7.18E-05 1.36E-04 0.00 0.00 0.00 3.12E-05 7.18E-05 1.36E-04 1.98 3.63 5.16 0.02 0.04 0.05 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Staphylococcus aureus MRSA BSI - model 61 25.25 28.08 31.19 175.67 189.54 204.74 202.14 217.53 235.00 6.22 6.56 6.97 0.26 0.29 0.32 1.80 1.94 2.10 2.07 2.23 2.41 31.26 33.12 35.14 0.32 0.34 0.36 5.50 5.95 6.40 0.06 0.06 0.07 Sweden - Staphylococcus aureus MRSA OTH - model 65 0.12 0.16 0.20 0.00 0.00 0.00 0.12 0.16 0.20 2.62E-03 3.28E-03 3.91E-03 1.27E-03 1.64E-03 2.01E-03 0.00 0.00 0.00 1.27E-03 1.64E-03 2.01E-03 43.93 48.79 53.15 0.45 0.50 0.55 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Staphylococcus aureus MRSA RESP - model 62 25.59 29.19 33.26 50.33 57.27 64.24 76.75 86.49 96.76 1.59 1.73 1.89 0.26 0.30 0.34 0.52 0.59 0.66 0.79 0.89 0.99 44.66 49.81 54.96 0.46 0.51 0.56 1.59 1.79 2.00 0.02 0.02 0.02 Sweden - Staphylococcus aureus MRSA SSI - model 64 0.09 0.12 0.15 20.01 22.33 24.50 20.11 22.43 24.64 0.40 0.41 0.43 9.06E-04 1.19E-03 1.55E-03 0.21 0.23 0.25 0.21 0.23 0.25 49.26 54.39 60.03 0.51 0.56 0.62 1.00 1.13 1.28 0.01 0.01 0.01 Sweden - Staphylococcus aureus MRSA UTI - model 63 0.01 0.02 0.02 0.00 0.00 0.00 0.01 0.02 0.02 1.48E-03 1.87E-03 2.28E-03 1.17E-04 1.56E-04 2.04E-04 0.00 0.00 0.00 1.17E-04 1.56E-04 2.04E-04 6.79 8.16 9.56 0.07 0.08 0.10 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Streptococcus pneumoniae PMRSP BSI - model 76 15.11 16.61 18.36 107.25 112.51 118.21 123.50 129.25 135.00 4.16 4.35 4.55 0.16 0.17 0.19 1.10 1.15 1.21 1.27 1.33 1.38 29.46 29.68 29.93 0.30 0.30 0.31 5.09 5.35 5.61 0.05 0.05 0.06 Sweden - Streptococcus pneumoniae PMRSP OTH - model 80 0.02 0.02 0.03 0.00 0.00 0.00 0.02 0.02 0.03 1.51E-03 1.95E-03 2.50E-03 1.62E-04 2.12E-04 2.75E-04 0.00 0.00 0.00 1.62E-04 2.12E-04 2.75E-04 9.71 10.61 11.67 0.10 0.11 0.12 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Streptococcus pneumoniae PMRSP RESP - model 77 37.07 44.23 52.94 73.55 85.72 101.07 111.27 129.82 152.56 1.04 1.15 1.26 0.38 0.45 0.54 0.75 0.88 1.04 1.14 1.33 1.57 98.47 113.01 132.47 1.01 1.16 1.36 3.50 4.07 4.84 0.04 0.04 0.05 Sweden - Streptococcus pneumoniae PMRSP SSI - model 79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Streptococcus pneumoniae PMRSP UTI - model 78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Streptococcus pneumoniae PRSP BSI - model 71 14.93 16.66 18.50 107.03 113.04 119.34 123.09 129.64 136.00 5.30 5.58 5.85 0.15 0.17 0.19 1.10 1.16 1.22 1.26 1.33 1.40 23.03 23.23 23.42 0.24 0.24 0.24 3.96 4.18 4.40 0.04 0.04 0.05 Sweden - Streptococcus pneumoniae PRSP OTH - model 75 0.01 0.02 0.02 0.00 0.00 0.00 0.01 0.02 0.02 1.47E-03 1.94E-03 2.60E-03 1.21E-04 1.65E-04 2.22E-04 0.00 0.00 0.00 1.21E-04 1.65E-04 2.22E-04 7.58 8.31 9.19 0.08 0.09 0.09 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Streptococcus pneumoniae PRSP RESP - model 72 37.14 44.33 54.40 73.30 86.26 104.54 111.26 130.62 157.15 1.36 1.47 1.59 0.38 0.45 0.56 0.75 0.88 1.07 1.14 1.34 1.61 76.65 89.16 107.27 0.79 0.91 1.10 2.72 3.20 3.90 0.03 0.03 0.04 Sweden - Streptococcus pneumoniae PRSP SSI - model 74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Sweden - Streptococcus pneumoniae PRSP UTI - model 73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total (Median & 95% UIs) 620.84 704.82 803.06 3,212.05 3,678.09 4,191.35 3,860.87 4,381.22 4,959.49 6.37 7.23 8.24 32.95 37.73 43.00 39.61 44.95 50.88 4,029.07 4,570.54 5,119.78 41.34 46.89 52.52 144.70 166.99 190.94 1.48 1.71 1.96 Total (average) - 37.79 45.04 4,572.83 46.91 167.11 1.71 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 706.43 3,683.83 4,390.26 - 7.25 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 Infection Colistin resistant Acinetobacter spp. 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Acinetobacter spp. (excluding those resistant to colistin) 9.67 11.53 13.64 43.42 61.20 79.75 54.13 72.69 92.33 4.63 5.98 7.38 0.47 0.56 0.66 2.10 2.97 3.87 2.62 3.52 4.48 30.91 35.93 41.25 1.50 1.74 2.00 2.38 3.14 3.97 0.12 0.15 0.19 Aminoglycosides and fluoroquinolones resistant Acinetobacter spp. (excluding those resistant to colistin and/or carbapenem) 1.00 1.62 2.37 3.51 8.53 15.00 4.69 10.18 17.15 3.10 5.25 7.50 0.05 0.08 0.12 0.17 0.41 0.73 0.23 0.49 0.83 3.53 5.95 8.51 0.17 0.29 0.41 0.21 0.51 0.90 0.01 0.02 0.04 Vancomycin resistant Enterococci (E. faecalis and E. faecium ) 3.37 4.98 7.39 32.16 45.53 65.61 35.59 50.51 72.72 5.58 6.36 7.04 0.16 0.24 0.36 1.56 2.21 3.18 1.73 2.45 3.53 20.53 31.29 42.92 1.00 1.52 2.08 1.41 1.99 2.73 0.07 0.10 0.13 Colistin resistant Escherichia coli 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Escherichia coli (excluding those resistant to colistin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Third-generation cephalosporin resistant Escherichia coli (excluding those resistant to colistin and/or carbapenem) 108.93 122.75 137.24 646.94 724.41 807.05 761.47 847.79 939.78 4.54 4.95 5.41 5.28 5.95 6.65 31.36 35.12 39.12 36.91 41.10 45.56 1,195.81 1,363.27 1,529.28 57.97 66.09 74.13 36.37 41.97 47.92 1.76 2.03 2.32 Colistin resistant Klebsiella pneumoniae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Klebsiella pneumoniae (excluding those resistant to colistin) 1.22 1.82 2.53 11.81 19.36 28.88 13.36 21.20 31.27 5.00 7.47 10.21 0.06 0.09 0.12 0.57 0.94 1.40 0.65 1.03 1.52 5.33 8.86 12.51 0.26 0.43 0.61 0.71 1.19 1.81 0.03 0.06 0.09 Third-generation cephalosporin resistant Klebsiella pneumoniae (excluding those resistant to colistin and/or carbapenem) 50.32 55.97 62.42 248.23 268.93 289.58 300.40 324.77 349.55 6.34 6.68 7.07 2.44 2.71 3.03 12.03 13.04 14.04 14.56 15.74 16.94 180.10 199.74 219.38 8.73 9.68 10.63 9.97 10.84 11.74 0.48 0.53 0.57 Colistin resistant Pseudomonas aeruginosa 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Carbapenem resistant Pseudomonas aeruginosa (excluding those resistant to colistin) 37.65 44.96 53.03 167.44 225.97 295.16 207.90 271.33 345.37 5.50 6.98 8.56 1.83 2.18 2.57 8.12 10.95 14.31 10.08 13.15 16.74 144.46 172.98 201.83 7.00 8.39 9.78 8.93 11.81 15.16 0.43 0.57 0.73 Pseudomonas aeruginosa resistant to three or more antimicrobial groups (excluding those resistant to colistin and/or carbapenem) 7.35 10.70 14.72 25.14 50.89 81.68 33.94 61.56 94.61 6.63 11.42 16.37 0.36 0.52 0.71 1.22 2.47 3.96 1.65 2.98 4.59 16.85 23.67 30.62 0.82 1.15 1.48 0.83 1.50 2.28 0.04 0.07 0.11 Methicillin resistant Staphylococcus aureus 46.97 53.57 61.64 235.33 260.09 286.23 285.41 314.16 344.31 5.28 5.60 5.92 2.28 2.60 2.99 11.41 12.61 13.88 13.84 15.23 16.69 259.18 287.92 317.52 12.56 13.96 15.39 12.42 13.62 14.92 0.60 0.66 0.72 Penicillin and macrolides resistant Streptococcus pneumoniae (excluding those only resistant to penicillin) 31.32 36.08 42.62 107.43 118.55 132.42 140.46 154.77 173.48 5.65 6.05 6.47 1.52 1.75 2.07 5.21 5.75 6.42 6.81 7.50 8.41 75.48 83.32 94.47 3.66 4.04 4.58 4.69 5.11 5.65 0.23 0.25 0.27 Penicillin tesistant Streptococcus pneumoniae (excluding those resistant to macrolides) 54.24 66.43 86.71 194.55 220.47 259.65 252.54 287.27 340.11 12.86 13.94 14.99 2.63 3.22 4.20 9.43 10.69 12.59 12.24 13.93 16.49 59.68 67.34 78.70 2.89 3.26 3.81 3.73 4.14 4.68 0.18 0.20 0.23 Total 352.04 410.41 484.30 1,715.97 2,003.93 2,341.00 2,089.87 2,416.21 2,800.68 17.07 19.89 23.48 83.18 97.14 113.48 101.31 117.13 135.77 1,991.86 2,280.27 2,576.98 96.56 110.54 124.92 81.64 95.83 111.76 3.96 4.65 5.42 Model Slovenia - Acinetobacter spp. CRACI BSI - model 36 5.65 6.58 7.66 34.45 50.14 66.49 40.92 56.67 73.29 3.33 4.56 5.82 0.27 0.32 0.37 1.67 2.43 3.22 1.98 2.75 3.55 11.50 12.47 13.50 0.56 0.60 0.65 1.89 2.55 3.28 0.09 0.12 0.16 Slovenia - Acinetobacter spp. CRACI OTH - model 40 1.03E-03 1.68E-03 2.49E-03 0.00 0.00 0.00 1.03E-03 1.68E-03 2.49E-03 2.77E-03 3.73E-03 4.84E-03 4.99E-05 8.16E-05 1.21E-04 0.00 0.00 0.00 4.99E-05 8.16E-05 1.21E-04 0.31 0.46 0.61 0.02 0.02 0.03 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Acinetobacter spp. CRACI RESP - model 37 4.01 4.92 5.94 7.78 9.54 11.41 12.00 14.47 17.17 0.99 1.08 1.17 0.19 0.24 0.29 0.38 0.46 0.55 0.58 0.70 0.83 11.46 13.41 15.44 0.56 0.65 0.75 0.41 0.48 0.56 0.02 0.02 0.03 Slovenia - Acinetobacter spp. CRACI SSI - model 39 6.18E-03 9.70E-03 0.01 1.19 1.53 1.85 1.20 1.54 1.86 0.31 0.34 0.38 3.00E-04 4.70E-04 6.79E-04 0.06 0.07 0.09 0.06 0.07 0.09 3.61 4.54 5.49 0.17 0.22 0.27 0.08 0.10 0.12 3.92E-03 4.96E-03 5.99E-03 Slovenia - Acinetobacter spp. CRACI UTI - model 38 7.24E-03 0.01 0.01 0.00 0.00 0.00 7.24E-03 0.01 0.01 1.55E-03 2.02E-03 2.60E-03 3.51E-04 4.96E-04 6.86E-04 0.00 0.00 0.00 3.51E-04 4.96E-04 6.86E-04 4.03 5.05 6.20 0.20 0.24 0.30 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Acinetobacter spp. ColRACI BSI - model 41 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Acinetobacter spp. ColRACI OTH - model 45 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Acinetobacter spp. ColRACI RESP - model 42 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Acinetobacter spp. ColRACI SSI - model 44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Acinetobacter spp. ColRACI UTI - model 43 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Acinetobacter spp. MDRACI BSI - model 31 0.61 0.91 1.32 2.58 6.74 12.28 3.35 7.66 13.42 1.72 3.73 5.84 0.03 0.04 0.06 0.13 0.33 0.60 0.16 0.37 0.65 1.62 2.03 2.57 0.08 0.10 0.12 0.15 0.40 0.73 7.47E-03 0.02 0.04 Slovenia - Acinetobacter spp. MDRACI OTH - model 35 4.22E-05 2.44E-04 7.77E-04 0.00 0.00 0.00 4.22E-05 2.44E-04 7.77E-04 1.59E-03 3.75E-03 6.37E-03 2.05E-06 1.18E-05 3.77E-05 0.00 0.00 0.00 2.05E-06 1.18E-05 3.77E-05 0.01 0.07 0.16 6.72E-04 3.53E-03 7.58E-03 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Acinetobacter spp. MDRACI RESP - model 32 0.39 0.70 1.05 0.75 1.34 2.00 1.16 2.05 2.99 0.78 0.92 1.04 0.02 0.03 0.05 0.04 0.06 0.10 0.06 0.10 0.14 1.26 2.25 3.19 0.06 0.11 0.15 0.04 0.08 0.12 2.17E-03 3.87E-03 5.77E-03 Slovenia - Acinetobacter spp. MDRACI SSI - model 34 3.04E-04 1.37E-03 4.32E-03 0.18 0.46 0.72 0.18 0.46 0.73 0.60 0.61 0.61 1.47E-05 6.64E-05 2.10E-04 8.75E-03 0.02 0.04 8.72E-03 0.02 0.04 0.30 0.76 1.21 0.01 0.04 0.06 0.01 0.03 0.04 5.22E-04 1.32E-03 2.11E-03 Slovenia - Acinetobacter spp. MDRACI UTI - model 33 4.72E-04 1.56E-03 3.73E-03 0.00 0.00 0.00 4.72E-04 1.56E-03 3.73E-03 8.03E-04 2.03E-03 3.55E-03 2.29E-05 7.56E-05 1.81E-04 0.00 0.00 0.00 2.29E-05 7.56E-05 1.81E-04 0.33 0.83 1.39 0.02 0.04 0.07 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Enterococcus faecalis and E. faecium VRE BSI - model 66 3.35 4.94 7.32 29.96 42.09 61.01 33.36 47.02 68.06 5.28 6.04 6.70 0.16 0.24 0.35 1.45 2.04 2.96 1.62 2.28 3.30 5.59 7.83 10.73 0.27 0.38 0.52 1.29 1.79 2.46 0.06 0.09 0.12 Slovenia - Enterococcus faecalis and E. faecium VRE OTH - model 70 7.16E-03 0.01 0.02 0.00 0.00 0.00 7.16E-03 0.01 0.02 1.04E-03 1.62E-03 2.43E-03 3.47E-04 6.62E-04 1.08E-03 0.00 0.00 0.00 3.47E-04 6.62E-04 1.08E-03 5.41 8.45 11.42 0.26 0.41 0.55 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Enterococcus faecalis and E. faecium VRE RESP - model 67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Enterococcus faecalis and E. faecium VRE SSI - model 69 0.01 0.02 0.04 2.20 3.44 4.60 2.22 3.46 4.62 0.29 0.32 0.34 5.58E-04 1.09E-03 1.92E-03 0.11 0.17 0.22 0.11 0.17 0.22 7.03 10.99 15.15 0.34 0.53 0.73 0.12 0.20 0.27 5.71E-03 9.55E-03 0.01 Slovenia - Enterococcus faecalis and E. faecium VRE UTI - model 68 3.93E-03 7.43E-03 0.01 0.00 0.00 0.00 3.93E-03 7.43E-03 0.01 1.22E-03 1.84E-03 2.67E-03 1.91E-04 3.60E-04 6.01E-04 0.00 0.00 0.00 1.91E-04 3.60E-04 6.01E-04 2.50 4.02 5.61 0.12 0.19 0.27 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Escherichia coli 3GCREC BSI - model 16 83.72 92.35 101.46 534.28 593.64 656.89 623.39 686.52 754.10 3.29 3.59 3.90 4.06 4.48 4.92 25.90 28.78 31.84 30.22 33.28 36.56 177.66 191.34 206.63 8.61 9.28 10.02 29.09 33.18 37.67 1.41 1.61 1.83 Slovenia - Escherichia coli 3GCREC OTH - model 20 0.15 0.21 0.28 0.00 0.00 0.00 0.15 0.21 0.28 2.64E-03 3.35E-03 4.13E-03 7.40E-03 0.01 0.01 0.00 0.00 0.00 7.40E-03 0.01 0.01 50.85 63.06 75.83 2.47 3.06 3.68 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Escherichia coli 3GCREC RESP - model 17 23.48 28.14 32.93 46.34 54.14 62.94 69.96 82.40 95.72 0.88 0.98 1.10 1.14 1.36 1.60 2.25 2.62 3.05 3.39 3.99 4.64 69.37 84.27 99.15 3.36 4.09 4.81 2.46 3.04 3.60 0.12 0.15 0.17 Slovenia - Escherichia coli 3GCREC SSI - model 19 0.31 0.43 0.58 66.32 76.63 87.22 66.70 77.04 87.68 0.36 0.38 0.40 0.01 0.02 0.03 3.21 3.71 4.23 3.23 3.73 4.25 175.03 201.96 228.95 8.48 9.79 11.10 4.83 5.76 6.66 0.23 0.28 0.32 Slovenia - Escherichia coli 3GCREC UTI - model 18 1.26 1.62 2.00 0.00 0.00 0.00 1.26 1.62 2.00 1.60E-03 1.96E-03 2.38E-03 0.06 0.08 0.10 0.00 0.00 0.00 0.06 0.08 0.10 722.89 822.64 918.72 35.04 39.88 44.54 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Escherichia coli CREC BSI - model 21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Escherichia coli CREC OTH - model 25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Escherichia coli CREC RESP - model 22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Escherichia coli CREC SSI - model 24 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Escherichia coli CREC UTI - model 23 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Escherichia coli ColREC BSI - model 26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Escherichia coli ColREC OTH - model 30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Escherichia coli ColREC RESP - model 27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Escherichia coli ColREC SSI - model 29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Escherichia coli ColREC UTI - model 28 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Klebsiella pneumoniae 3GCRKP BSI - model 1 31.68 34.75 38.56 204.63 218.98 233.29 237.97 253.67 269.65 4.64 4.86 5.11 1.54 1.68 1.87 9.92 10.62 11.31 11.54 12.30 13.07 49.46 52.11 55.08 2.40 2.53 2.67 8.11 8.70 9.31 0.39 0.42 0.45 Slovenia - Klebsiella pneumoniae 3GCRKP OTH - model 5 0.05 0.07 0.09 0.00 0.00 0.00 0.05 0.07 0.09 2.67E-03 3.34E-03 4.04E-03 2.57E-03 3.35E-03 4.31E-03 0.00 0.00 0.00 2.57E-03 3.35E-03 4.31E-03 18.03 20.77 23.50 0.87 1.01 1.14 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Klebsiella pneumoniae 3GCRKP RESP - model 2 18.46 20.98 23.56 35.82 40.78 45.76 54.51 61.69 69.08 1.27 1.37 1.48 0.89 1.02 1.14 1.74 1.98 2.22 2.64 2.99 3.35 40.11 44.94 49.62 1.94 2.18 2.41 1.43 1.61 1.83 0.07 0.08 0.09 Slovenia - Klebsiella pneumoniae 3GCRKP SSI - model 4 0.03 0.04 0.06 7.78 9.17 10.53 7.77 9.22 10.58 0.43 0.45 0.47 1.52E-03 2.10E-03 2.86E-03 0.38 0.44 0.51 0.38 0.45 0.51 17.79 20.55 23.31 0.86 1.00 1.13 0.43 0.52 0.61 0.02 0.03 0.03 Slovenia - Klebsiella pneumoniae 3GCRKP UTI - model 3 0.10 0.12 0.15 0.00 0.00 0.00 0.10 0.12 0.15 1.58E-03 1.95E-03 2.36E-03 4.62E-03 5.78E-03 7.20E-03 0.00 0.00 0.00 4.62E-03 5.78E-03 7.20E-03 54.71 61.37 67.87 2.65 2.97 3.29 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Klebsiella pneumoniae CRKP BSI - model 6 1.03 1.40 1.88 11.32 18.29 27.23 12.67 19.70 29.00 4.08 6.27 8.63 0.05 0.07 0.09 0.55 0.89 1.32 0.61 0.96 1.41 2.53 3.15 3.95 0.12 0.15 0.19 0.68 1.12 1.69 0.03 0.05 0.08 Slovenia - Klebsiella pneumoniae CRKP OTH - model 10 1.79E-03 4.86E-03 0.01 0.00 0.00 0.00 1.79E-03 4.86E-03 0.01 1.60E-03 3.47E-03 6.57E-03 8.68E-05 2.36E-04 5.64E-04 0.00 0.00 0.00 8.68E-05 2.36E-04 5.64E-04 0.71 1.48 2.27 0.03 0.07 0.11 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Klebsiella pneumoniae CRKP RESP - model 7 0.19 0.41 0.63 0.37 0.78 1.19 0.56 1.19 1.79 0.62 0.88 1.25 9.03E-03 0.02 0.03 0.02 0.04 0.06 0.03 0.06 0.09 0.66 1.36 2.02 0.03 0.07 0.10 0.02 0.05 0.07 1.12E-03 2.34E-03 3.58E-03 Slovenia - Klebsiella pneumoniae CRKP SSI - model 9 6.47E-04 1.83E-03 4.57E-03 0.13 0.30 0.46 0.13 0.30 0.46 0.29 0.32 0.33 3.14E-05 8.85E-05 2.21E-04 6.23E-03 0.01 0.02 6.31E-03 0.01 0.02 0.46 0.94 1.46 0.02 0.05 0.07 9.04E-03 0.03 0.04 4.38E-04 1.23E-03 2.07E-03 Slovenia - Klebsiella pneumoniae CRKP UTI - model 8 1.53E-03 3.81E-03 7.99E-03 0.00 0.00 0.00 1.53E-03 3.81E-03 7.99E-03 9.54E-04 2.09E-03 3.56E-03 7.40E-05 1.84E-04 3.87E-04 0.00 0.00 0.00 7.40E-05 1.84E-04 3.87E-04 0.98 1.92 2.80 0.05 0.09 0.14 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Klebsiella pneumoniae ColRKP BSI - model 11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Klebsiella pneumoniae ColRKP OTH - model 15 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Klebsiella pneumoniae ColRKP RESP - model 12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Klebsiella pneumoniae ColRKP SSI - model 14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Klebsiella pneumoniae ColRKP UTI - model 13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Pseudomonas aeruginosa CRPA BSI - model 51 10.90 12.58 14.72 76.48 106.51 137.25 88.43 119.20 150.95 3.79 4.93 6.14 0.53 0.61 0.71 3.71 5.16 6.65 4.29 5.78 7.32 21.75 24.10 26.66 1.05 1.17 1.29 4.11 5.50 7.02 0.20 0.27 0.34 Slovenia - Pseudomonas aeruginosa CRPA OTH - model 55 0.03 0.04 0.06 0.00 0.00 0.00 0.03 0.04 0.06 2.82E-03 3.67E-03 4.58E-03 1.50E-03 2.17E-03 2.97E-03 0.00 0.00 0.00 1.50E-03 2.17E-03 2.97E-03 9.21 12.27 14.94 0.45 0.60 0.72 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Pseudomonas aeruginosa CRPA RESP - model 52 26.65 32.24 38.10 86.00 112.70 149.55 114.41 145.21 185.86 1.34 1.64 1.97 1.29 1.56 1.85 4.17 5.46 7.25 5.55 7.04 9.01 75.46 88.97 103.26 3.66 4.31 5.01 4.48 5.85 7.58 0.22 0.28 0.37 Slovenia - Pseudomonas aeruginosa CRPA SSI - model 54 0.02 0.04 0.05 4.95 6.77 8.36 4.98 6.80 8.41 0.37 0.41 0.44 1.12E-03 1.71E-03 2.47E-03 0.24 0.33 0.41 0.24 0.33 0.41 12.94 16.60 20.17 0.63 0.80 0.98 0.34 0.46 0.57 0.02 0.02 0.03 Slovenia - Pseudomonas aeruginosa CRPA UTI - model 53 0.05 0.06 0.09 0.00 0.00 0.00 0.05 0.06 0.09 1.52E-03 2.04E-03 2.54E-03 2.21E-03 3.06E-03 4.22E-03 0.00 0.00 0.00 2.21E-03 3.06E-03 4.22E-03 25.11 31.03 36.81 1.22 1.50 1.78 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Pseudomonas aeruginosa ColRPA BSI - model 56 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Pseudomonas aeruginosa ColRPA OTH - model 60 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Pseudomonas aeruginosa ColRPA RESP - model 57 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Pseudomonas aeruginosa ColRPA SSI - model 59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Pseudomonas aeruginosa ColRPA UTI - model 58 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Pseudomonas aeruginosa MDRPA BSI - model 46 2.23 2.99 4.15 11.53 24.36 38.85 14.53 27.34 42.44 4.56 8.28 12.03 0.11 0.14 0.20 0.56 1.18 1.88 0.70 1.33 2.06 2.69 3.29 3.95 0.13 0.16 0.19 0.38 0.70 1.06 0.02 0.03 0.05 Slovenia - Pseudomonas aeruginosa MDRPA OTH - model 50 3.03E-03 6.02E-03 0.01 0.00 0.00 0.00 3.03E-03 6.02E-03 0.01 2.13E-03 3.74E-03 5.39E-03 1.47E-04 2.92E-04 5.32E-04 0.00 0.00 0.00 1.47E-04 2.92E-04 5.32E-04 1.03 1.65 2.40 0.05 0.08 0.12 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Pseudomonas aeruginosa MDRPA RESP - model 47 5.12 7.69 10.54 13.14 25.73 41.70 18.93 33.40 51.00 1.77 2.78 3.91 0.25 0.37 0.51 0.64 1.25 2.02 0.92 1.62 2.47 8.95 12.23 15.44 0.43 0.59 0.75 0.43 0.76 1.15 0.02 0.04 0.06 Slovenia - Pseudomonas aeruginosa MDRPA SSI - model 49 2.02E-03 4.71E-03 8.66E-03 0.47 0.80 1.14 0.48 0.81 1.14 0.30 0.36 0.42 9.81E-05 2.28E-04 4.20E-04 0.02 0.04 0.06 0.02 0.04 0.06 1.40 2.26 3.13 0.07 0.11 0.15 0.02 0.04 0.06 1.06E-03 2.02E-03 2.88E-03 Slovenia - Pseudomonas aeruginosa MDRPA UTI - model 48 4.48E-03 8.45E-03 0.01 0.00 0.00 0.00 4.48E-03 8.45E-03 0.01 1.22E-03 2.02E-03 2.95E-03 2.17E-04 4.09E-04 6.74E-04 0.00 0.00 0.00 2.17E-04 4.09E-04 6.74E-04 2.79 4.24 5.70 0.14 0.21 0.28 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Staphylococcus aureus MRSA BSI - model 61 23.27 25.96 29.29 160.15 174.10 188.36 185.00 200.28 215.48 3.87 4.09 4.31 1.13 1.26 1.42 7.76 8.44 9.13 8.97 9.71 10.45 46.35 49.03 51.95 2.25 2.38 2.52 8.16 8.80 9.50 0.40 0.43 0.46 Slovenia - Staphylococcus aureus MRSA OTH - model 65 0.18 0.24 0.31 0.00 0.00 0.00 0.18 0.24 0.31 2.56E-03 3.27E-03 4.09E-03 8.83E-03 0.01 0.01 0.00 0.00 0.00 8.83E-03 0.01 0.01 65.06 72.24 79.95 3.15 3.50 3.88 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Staphylococcus aureus MRSA RESP - model 62 23.39 27.18 31.79 45.39 52.54 60.70 70.23 80.01 91.16 1.01 1.08 1.16 1.13 1.32 1.54 2.20 2.55 2.94 3.40 3.88 4.42 65.57 73.99 82.37 3.18 3.59 3.99 2.34 2.66 3.02 0.11 0.13 0.15 Slovenia - Staphylococcus aureus MRSA SSI - model 64 0.12 0.17 0.23 29.79 33.44 37.16 29.98 33.61 37.33 0.40 0.42 0.44 5.97E-03 8.29E-03 0.01 1.44 1.62 1.80 1.45 1.63 1.81 72.50 80.70 88.77 3.51 3.91 4.30 1.92 2.16 2.40 0.09 0.10 0.12 Slovenia - Staphylococcus aureus MRSA UTI - model 63 0.02 0.02 0.03 0.00 0.00 0.00 0.02 0.02 0.03 1.44E-03 1.87E-03 2.34E-03 7.77E-04 1.09E-03 1.46E-03 0.00 0.00 0.00 7.77E-04 1.09E-03 1.46E-03 9.70 11.95 14.48 0.47 0.58 0.70 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Streptococcus pneumoniae PMRSP BSI - model 76 8.92 9.90 11.01 63.82 67.43 71.03 73.52 77.36 80.97 4.55 4.79 5.01 0.43 0.48 0.53 3.09 3.27 3.44 3.56 3.75 3.93 16.16 16.16 16.16 0.78 0.78 0.78 2.77 2.91 3.05 0.13 0.14 0.15 Slovenia - Streptococcus pneumoniae PMRSP OTH - model 80 8.40E-03 0.01 0.01 0.00 0.00 0.00 8.40E-03 0.01 0.01 1.48E-03 1.96E-03 2.51E-03 4.07E-04 5.40E-04 7.00E-04 0.00 0.00 0.00 4.07E-04 5.40E-04 7.00E-04 5.32 5.71 6.21 0.26 0.28 0.30 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Streptococcus pneumoniae PMRSP RESP - model 77 22.39 26.17 31.59 43.61 51.12 61.40 66.93 77.40 92.50 1.10 1.26 1.46 1.09 1.27 1.53 2.11 2.48 2.98 3.24 3.75 4.48 54.00 61.45 72.10 2.62 2.98 3.50 1.92 2.20 2.61 0.09 0.11 0.13 Slovenia - Streptococcus pneumoniae PMRSP SSI - model 79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Streptococcus pneumoniae PMRSP UTI - model 78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Streptococcus pneumoniae PRSP BSI - model 71 15.86 18.42 21.66 117.64 126.63 135.12 135.32 145.12 153.94 10.31 11.05 11.72 0.77 0.89 1.05 5.70 6.14 6.55 6.56 7.03 7.46 13.13 13.13 13.13 0.64 0.64 0.64 2.23 2.36 2.50 0.11 0.11 0.12 Slovenia - Streptococcus pneumoniae PRSP OTH - model 75 6.52E-03 9.09E-03 0.01 0.00 0.00 0.00 6.52E-03 9.09E-03 0.01 1.43E-03 1.95E-03 2.63E-03 3.16E-04 4.40E-04 6.13E-04 0.00 0.00 0.00 3.16E-04 4.40E-04 6.13E-04 4.24 4.66 5.20 0.21 0.23 0.25 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Streptococcus pneumoniae PRSP RESP - model 72 38.37 48.00 65.03 76.90 93.83 124.52 117.22 142.14 186.16 2.55 2.89 3.27 1.86 2.33 3.15 3.73 4.55 6.04 5.68 6.89 9.02 42.31 49.55 60.37 2.05 2.40 2.93 1.50 1.78 2.18 0.07 0.09 0.11 Slovenia - Streptococcus pneumoniae PRSP SSI - model 74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovenia - Streptococcus pneumoniae PRSP UTI - model 73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total (Median & 95% UIs) 352.04 410.41 484.30 1,715.97 2,003.93 2,341.00 2,089.87 2,416.21 2,800.68 17.07 19.89 23.48 83.18 97.14 113.48 101.31 117.13 135.77 1,991.86 2,280.27 2,576.98 96.56 110.54 124.92 81.64 95.83 111.76 3.96 4.65 5.42 Total (average) - 97.58 117.58 2,281.21 110.58 96.03 4.66 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 412.61 2,012.87 2,425.48 - 20.00 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 Infection Colistin resistant Acinetobacter spp. 0.85 1.35 1.98 2.90 7.58 13.12 3.90 8.89 14.89 3.89 6.92 9.71 0.02 0.02 0.04 0.05 0.14 0.24 0.07 0.16 0.27 2.40 4.01 5.71 0.04 0.07 0.11 0.14 0.36 0.62 0.00 0.01 0.01 Carbapenem resistant Acinetobacter spp. (excluding those resistant to colistin) 57.83 65.36 73.85 285.30 350.86 426.52 344.43 416.32 493.22 6.51 7.71 8.99 1.07 1.21 1.36 5.26 6.47 7.87 6.35 7.68 9.10 141.74 159.95 177.82 2.61 2.95 3.28 11.21 13.98 16.90 0.21 0.26 0.31 Aminoglycosides and fluoroquinolones resistant Acinetobacter spp. (excluding those resistant to colistin and/or carbapenem) 36.94 42.21 48.16 175.01 222.83 272.77 215.14 265.17 318.45 5.76 6.85 8.01 0.68 0.78 0.89 3.23 4.11 5.03 3.97 4.89 5.87 99.44 115.63 131.77 1.83 2.13 2.43 7.74 9.97 12.37 0.14 0.18 0.23 Vancomycin resistant Enterococci (E. faecalis and E. faecium ) 25.69 31.92 40.44 239.26 298.10 364.97 266.01 329.94 405.28 7.62 8.44 9.32 0.47 0.59 0.75 4.41 5.50 6.73 4.91 6.09 7.48 117.98 150.61 186.83 2.18 2.78 3.45 7.82 9.81 11.95 0.14 0.18 0.22 Colistin resistant Escherichia coli 0.56 0.81 1.15 8.02 13.25 19.02 8.65 14.00 20.11 3.47 5.22 6.92 0.01 0.01 0.02 0.15 0.24 0.35 0.16 0.26 0.37 14.56 20.93 27.36 0.27 0.39 0.50 1.13 1.86 2.65 0.02 0.03 0.05 Carbapenem resistant Escherichia coli (excluding those resistant to colistin) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Third-generation cephalosporin resistant Escherichia coli (excluding those resistant to colistin and/or carbapenem) 240.92 269.18 300.73 1,417.98 1,588.66 1,787.51 1,664.54 1,858.08 2,080.03 5.15 5.58 6.03 4.44 4.97 5.55 26.16 29.30 32.97 30.70 34.27 38.37 2,357.48 2,646.16 2,931.03 43.49 48.81 54.06 70.77 80.68 91.27 1.31 1.49 1.68 Colistin resistant Klebsiella pneumoniae 10.28 13.37 17.11 172.10 237.26 322.49 183.69 250.14 337.71 18.32 23.79 30.12 0.19 0.25 0.32 3.17 4.38 5.95 3.39 4.61 6.23 24.29 31.47 38.82 0.45 0.58 0.72 5.37 6.99 8.97 0.10 0.13 0.17 Carbapenem resistant Klebsiella pneumoniae (excluding those resistant to colistin) 6.15 8.18 10.78 61.41 89.86 121.50 67.99 97.94 131.17 14.19 19.19 24.33 0.11 0.15 0.20 1.13 1.66 2.24 1.25 1.81 2.42 11.37 15.72 20.10 0.21 0.29 0.37 1.53 2.13 2.75 0.03 0.04 0.05 Third-generation cephalosporin resistant Klebsiella pneumoniae (excluding those resistant to colistin and/or carbapenem) 453.56 493.49 537.08 2,219.25 2,365.01 2,516.71 2,687.87 2,861.99 3,042.12 7.04 7.37 7.70 8.37 9.10 9.91 40.94 43.62 46.42 49.58 52.79 56.11 1,459.90 1,590.42 1,721.88 26.93 29.34 31.76 80.69 86.08 91.99 1.49 1.59 1.70 Colistin resistant Pseudomonas aeruginosa 17.76 24.68 32.56 72.72 123.14 186.71 95.64 148.29 216.67 10.36 15.90 21.60 0.33 0.46 0.60 1.34 2.27 3.44 1.76 2.74 4.00 30.33 40.99 52.21 0.56 0.76 0.96 1.68 2.70 3.99 0.03 0.05 0.07 Carbapenem resistant Pseudomonas aeruginosa (excluding those resistant to colistin) 514.13 580.85 653.43 2,410.45 2,937.25 3,509.98 2,955.68 3,519.22 4,128.58 9.47 11.17 12.83 9.48 10.71 12.05 44.46 54.18 64.74 54.52 64.91 76.15 1,228.54 1,389.04 1,547.65 22.66 25.62 28.55 76.77 93.83 112.68 1.42 1.73 2.08 Pseudomonas aeruginosa resistant to three or more antimicrobial groups (excluding those resistant to colistin and/or carbapenem) 23.20 28.43 34.34 92.75 134.14 182.35 119.42 162.69 213.04 4.71 6.35 8.05 0.43 0.52 0.63 1.71 2.47 3.36 2.20 3.00 3.93 89.40 112.79 136.71 1.65 2.08 2.52 4.93 7.20 9.81 0.09 0.13 0.18 Methicillin resistant Staphylococcus aureus 282.69 308.35 338.95 1,381.88 1,476.71 1,580.26 1,668.68 1,786.09 1,910.92 6.75 7.02 7.30 5.21 5.69 6.25 25.49 27.24 29.15 30.78 32.95 35.25 1,208.82 1,310.41 1,417.76 22.30 24.17 26.15 56.47 60.81 65.38 1.04 1.12 1.21 Penicillin and macrolides resistant Streptococcus pneumoniae (excluding those only resistant to penicillin) 9.19 11.11 13.76 31.61 36.10 41.84 41.36 47.24 54.70 4.14 4.48 4.82 0.17 0.20 0.25 0.58 0.67 0.77 0.76 0.87 1.01 29.87 34.34 40.37 0.55 0.63 0.74 1.86 2.11 2.41 0.03 0.04 0.04 Penicillin tesistant Streptococcus pneumoniae (excluding those resistant to macrolides) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total 1,679.75 1,879.28 2,104.32 8,570.64 9,880.76 11,345.76 10,323.01 11,765.99 13,366.90 30.98 34.66 38.82 158.09 182.26 209.28 190.41 217.03 246.56 6,816.10 7,622.46 8,436.00 125.73 140.60 155.61 328.12 378.50 433.74 6.05 6.98 8.00 Model Slovakia - Acinetobacter spp. CRACI BSI - model 36 33.46 37.23 41.72 230.55 287.49 354.31 264.61 324.84 389.13 4.81 5.89 7.04 0.62 0.69 0.77 4.25 5.30 6.54 4.88 5.99 7.18 51.85 55.33 58.80 0.96 1.02 1.08 8.96 11.37 13.93 0.17 0.21 0.26 Slovakia - Acinetobacter spp. CRACI OTH - model 40 4.84E-03 7.25E-03 9.94E-03 0.00 0.00 0.00 4.84E-03 7.25E-03 9.94E-03 2.95E-03 3.74E-03 4.61E-03 8.92E-05 1.34E-04 1.83E-04 0.00 0.00 0.00 8.92E-05 1.34E-04 1.83E-04 1.39 1.94 2.45 0.03 0.04 0.05 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Acinetobacter spp. CRACI RESP - model 37 24.29 28.04 32.00 47.69 54.60 61.80 72.69 82.61 93.55 1.30 1.38 1.48 0.45 0.52 0.59 0.88 1.01 1.14 1.34 1.52 1.73 53.37 59.90 66.65 0.98 1.10 1.23 1.88 2.15 2.43 0.03 0.04 0.04 Slovakia - Acinetobacter spp. CRACI SSI - model 39 0.03 0.04 0.06 7.06 8.78 10.42 7.10 8.82 10.47 0.40 0.44 0.47 5.60E-04 7.90E-04 1.09E-03 0.13 0.16 0.19 0.13 0.16 0.19 16.78 20.26 23.52 0.31 0.37 0.43 0.37 0.46 0.54 6.75E-03 8.43E-03 0.01 Slovakia - Acinetobacter spp. CRACI UTI - model 38 0.03 0.05 0.06 0.00 0.00 0.00 0.03 0.05 0.06 1.61E-03 2.03E-03 2.48E-03 6.30E-04 8.38E-04 1.09E-03 0.00 0.00 0.00 6.30E-04 8.38E-04 1.09E-03 18.35 22.53 26.40 0.34 0.42 0.49 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Acinetobacter spp. ColRACI BSI - model 41 0.53 0.77 1.11 2.12 6.05 10.84 2.80 6.77 11.76 2.16 5.00 7.62 9.72E-03 0.01 0.02 0.04 0.11 0.20 0.05 0.12 0.22 1.09 1.37 1.76 0.02 0.03 0.03 0.10 0.29 0.51 1.86E-03 5.30E-03 9.44E-03 Slovakia - Acinetobacter spp. ColRACI OTH - model 45 2.69E-05 1.66E-04 4.74E-04 0.00 0.00 0.00 2.69E-05 1.66E-04 4.74E-04 1.55E-03 3.78E-03 6.38E-03 4.96E-07 3.07E-06 8.74E-06 0.00 0.00 0.00 4.96E-07 3.07E-06 8.74E-06 9.39E-03 0.05 0.10 1.73E-04 8.91E-04 1.89E-03 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Acinetobacter spp. ColRACI RESP - model 42 0.32 0.58 0.87 0.61 1.14 1.67 0.94 1.73 2.51 0.97 1.15 1.31 5.97E-03 0.01 0.02 0.01 0.02 0.03 0.02 0.03 0.05 0.87 1.52 2.13 0.02 0.03 0.04 0.03 0.05 0.08 5.38E-04 1.00E-03 1.46E-03 Slovakia - Acinetobacter spp. ColRACI SSI - model 44 2.01E-04 9.68E-04 2.73E-03 0.16 0.38 0.61 0.16 0.39 0.61 0.76 0.76 0.76 3.71E-06 1.79E-05 5.03E-05 2.92E-03 7.09E-03 0.01 2.91E-03 7.10E-03 0.01 0.21 0.51 0.80 3.84E-03 9.33E-03 0.01 7.49E-03 0.02 0.03 1.38E-04 3.36E-04 5.33E-04 Slovakia - Acinetobacter spp. ColRACI UTI - model 43 2.98E-04 1.00E-03 2.54E-03 0.00 0.00 0.00 2.98E-04 1.00E-03 2.54E-03 8.36E-04 1.90E-03 3.65E-03 5.50E-06 1.85E-05 4.68E-05 0.00 0.00 0.00 5.50E-06 1.85E-05 4.68E-05 0.22 0.56 0.92 4.00E-03 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Acinetobacter spp. MDRACI BSI - model 31 21.56 24.10 27.17 139.04 180.06 223.41 163.55 204.23 248.60 4.11 5.09 6.13 0.40 0.44 0.50 2.56 3.32 4.12 3.02 3.77 4.59 37.08 40.08 43.06 0.68 0.74 0.79 6.11 8.00 10.06 0.11 0.15 0.19 Slovakia - Acinetobacter spp. MDRACI OTH - model 35 3.34E-03 5.25E-03 7.71E-03 0.00 0.00 0.00 3.34E-03 5.25E-03 7.71E-03 2.87E-03 3.73E-03 4.68E-03 6.16E-05 9.68E-05 1.42E-04 0.00 0.00 0.00 6.16E-05 9.68E-05 1.42E-04 0.97 1.41 1.89 0.02 0.03 0.03 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Acinetobacter spp. MDRACI RESP - model 32 15.34 18.04 20.89 30.01 35.05 39.98 45.58 53.14 60.39 1.15 1.23 1.32 0.28 0.33 0.39 0.55 0.65 0.74 0.84 0.98 1.11 36.93 43.17 49.34 0.68 0.80 0.91 1.31 1.55 1.80 0.02 0.03 0.03 Slovakia - Acinetobacter spp. MDRACI SSI - model 34 0.02 0.03 0.05 5.97 7.72 9.38 5.99 7.76 9.41 0.49 0.53 0.56 3.71E-04 5.68E-04 8.39E-04 0.11 0.14 0.17 0.11 0.14 0.17 11.75 14.64 17.51 0.22 0.27 0.32 0.32 0.42 0.51 5.92E-03 7.71E-03 9.41E-03 Slovakia - Acinetobacter spp. MDRACI UTI - model 33 0.02 0.03 0.05 0.00 0.00 0.00 0.02 0.03 0.05 1.53E-03 2.01E-03 2.57E-03 4.21E-04 6.08E-04 8.34E-04 0.00 0.00 0.00 4.21E-04 6.08E-04 8.34E-04 12.71 16.32 19.96 0.23 0.30 0.37 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Enterococcus faecalis and E. faecium VRE BSI - model 66 25.54 31.70 40.14 220.77 273.43 333.88 247.38 305.04 373.92 7.19 7.96 8.80 0.47 0.58 0.74 4.07 5.04 6.16 4.56 5.63 6.90 31.05 38.21 46.81 0.57 0.70 0.86 7.10 8.76 10.59 0.13 0.16 0.20 Slovakia - Enterococcus faecalis and E. faecium VRE OTH - model 70 0.05 0.07 0.09 0.00 0.00 0.00 0.05 0.07 0.09 1.23E-03 1.65E-03 2.07E-03 8.53E-04 1.24E-03 1.72E-03 0.00 0.00 0.00 8.53E-04 1.24E-03 1.72E-03 32.08 41.05 50.56 0.59 0.76 0.93 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Enterococcus faecalis and E. faecium VRE RESP - model 67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Enterococcus faecalis and E. faecium VRE SSI - model 69 0.07 0.11 0.16 18.49 24.67 31.09 18.56 24.79 31.23 0.43 0.48 0.52 1.37E-03 2.02E-03 2.96E-03 0.34 0.46 0.57 0.34 0.46 0.58 40.18 52.03 65.32 0.74 0.96 1.20 0.73 1.05 1.36 0.01 0.02 0.03 Slovakia - Enterococcus faecalis and E. faecium VRE UTI - model 68 0.02 0.04 0.05 0.00 0.00 0.00 0.02 0.04 0.05 1.43E-03 1.88E-03 2.37E-03 4.47E-04 6.65E-04 9.02E-04 0.00 0.00 0.00 4.47E-04 6.65E-04 9.02E-04 14.67 19.32 24.14 0.27 0.36 0.45 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Escherichia coli 3GCREC BSI - model 16 185.55 203.20 222.34 1,177.24 1,307.68 1,461.78 1,369.57 1,510.44 1,677.25 3.74 4.05 4.38 3.42 3.75 4.10 21.71 24.12 26.96 25.26 27.86 30.94 347.38 372.94 399.63 6.41 6.88 7.37 56.92 64.35 72.37 1.05 1.19 1.33 Slovakia - Escherichia coli 3GCREC OTH - model 20 0.30 0.41 0.52 0.00 0.00 0.00 0.30 0.41 0.52 2.71E-03 3.33E-03 4.07E-03 5.59E-03 7.51E-03 9.61E-03 0.00 0.00 0.00 5.59E-03 7.51E-03 9.61E-03 99.50 122.35 143.82 1.84 2.26 2.65 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Escherichia coli 3GCREC RESP - model 17 52.00 61.63 72.93 100.84 118.85 140.02 152.72 181.09 212.31 1.02 1.11 1.21 0.96 1.14 1.35 1.86 2.19 2.58 2.82 3.34 3.92 135.58 163.31 191.93 2.50 3.01 3.54 4.89 5.87 6.98 0.09 0.11 0.13 Slovakia - Escherichia coli 3GCREC SSI - model 19 0.62 0.83 1.07 139.90 162.13 185.71 139.50 163.02 186.07 0.39 0.42 0.44 0.01 0.02 0.02 2.58 2.99 3.43 2.57 3.01 3.43 334.20 391.49 441.53 6.16 7.22 8.14 8.96 10.46 11.92 0.17 0.19 0.22 Slovakia - Escherichia coli 3GCREC UTI - model 18 2.44 3.12 3.87 0.00 0.00 0.00 2.44 3.12 3.87 1.58E-03 1.96E-03 2.35E-03 0.05 0.06 0.07 0.00 0.00 0.00 0.05 0.06 0.07 1,440.82 1,596.07 1,754.11 26.58 29.44 32.36 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Escherichia coli CREC BSI - model 21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Escherichia coli CREC OTH - model 25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Escherichia coli CREC RESP - model 22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Escherichia coli CREC SSI - model 24 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Escherichia coli CREC UTI - model 23 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Escherichia coli ColREC BSI - model 26 0.44 0.58 0.78 7.30 12.03 17.33 7.80 12.55 18.06 2.90 4.56 6.14 8.11E-03 0.01 0.01 0.13 0.22 0.32 0.14 0.23 0.33 2.30 2.76 3.37 0.04 0.05 0.06 1.02 1.69 2.42 0.02 0.03 0.04 Slovakia - Escherichia coli ColREC OTH - model 30 2.19E-03 5.38E-03 0.01 0.00 0.00 0.00 2.19E-03 5.38E-03 0.01 1.56E-03 3.41E-03 5.94E-03 4.03E-05 9.92E-05 1.90E-04 0.00 0.00 0.00 4.03E-05 9.92E-05 1.90E-04 0.93 1.61 2.27 0.02 0.03 0.04 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Escherichia coli ColREC RESP - model 27 0.11 0.20 0.30 0.19 0.36 0.54 0.30 0.56 0.84 0.33 0.39 0.48 1.98E-03 3.60E-03 5.60E-03 3.58E-03 6.68E-03 9.99E-03 5.59E-03 0.01 0.02 0.82 1.42 2.07 0.02 0.03 0.04 0.03 0.05 0.07 5.32E-04 9.35E-04 1.37E-03 Slovakia - Escherichia coli ColREC SSI - model 29 2.81E-03 6.75E-03 0.01 0.53 0.86 1.15 0.54 0.87 1.16 0.23 0.26 0.29 5.18E-05 1.25E-04 2.44E-04 9.82E-03 0.02 0.02 9.90E-03 0.02 0.02 2.15 3.34 4.44 0.04 0.06 0.08 0.08 0.12 0.16 1.43E-03 2.22E-03 2.95E-03 Slovakia - Escherichia coli ColREC UTI - model 28 0.01 0.02 0.04 0.00 0.00 0.00 0.01 0.02 0.04 1.00E-03 2.02E-03 3.42E-03 2.09E-04 4.37E-04 8.14E-04 0.00 0.00 0.00 2.09E-04 4.37E-04 8.14E-04 8.36 11.79 15.21 0.15 0.22 0.28 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Klebsiella pneumoniae 3GCRKP BSI - model 1 285.97 307.51 331.22 1,831.08 1,932.76 2,045.36 2,128.91 2,243.76 2,366.47 5.19 5.39 5.60 5.27 5.67 6.11 33.78 35.65 37.73 39.27 41.39 43.65 397.96 416.06 434.35 7.34 7.67 8.01 65.86 69.37 73.38 1.21 1.28 1.35 Slovakia - Klebsiella pneumoniae 3GCRKP OTH - model 5 0.45 0.55 0.67 0.00 0.00 0.00 0.45 0.55 0.67 2.79E-03 3.35E-03 3.95E-03 8.30E-03 0.01 0.01 0.00 0.00 0.00 8.30E-03 0.01 0.01 147.22 164.85 182.06 2.72 3.04 3.36 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Klebsiella pneumoniae 3GCRKP RESP - model 2 166.10 184.13 203.60 322.96 357.99 387.87 492.20 542.08 590.01 1.42 1.52 1.61 3.06 3.40 3.76 5.96 6.60 7.15 9.08 10.00 10.88 324.69 357.04 392.59 5.99 6.59 7.24 11.54 12.87 14.24 0.21 0.24 0.26 Slovakia - Klebsiella pneumoniae 3GCRKP SSI - model 4 0.27 0.35 0.44 65.21 74.26 83.47 65.53 74.64 83.81 0.43 0.46 0.48 5.00E-03 6.41E-03 8.07E-03 1.20 1.37 1.54 1.21 1.38 1.55 145.76 163.42 181.73 2.69 3.01 3.35 3.30 3.84 4.37 0.06 0.07 0.08 Slovakia - Klebsiella pneumoniae 3GCRKP UTI - model 3 0.78 0.96 1.16 0.00 0.00 0.00 0.78 0.96 1.16 1.64E-03 1.96E-03 2.30E-03 0.01 0.02 0.02 0.00 0.00 0.00 0.01 0.02 0.02 444.27 489.04 531.15 8.19 9.02 9.80 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Klebsiella pneumoniae CRKP BSI - model 6 5.07 6.31 8.07 58.70 85.39 115.04 64.22 91.59 122.12 11.96 16.37 20.77 0.09 0.12 0.15 1.08 1.58 2.12 1.18 1.69 2.25 4.83 5.62 6.53 0.09 0.10 0.12 1.47 2.02 2.59 0.03 0.04 0.05 Slovakia - Klebsiella pneumoniae CRKP OTH - model 10 4.57E-03 8.88E-03 0.01 0.00 0.00 0.00 4.57E-03 8.88E-03 0.01 2.10E-03 3.47E-03 5.22E-03 8.43E-05 1.64E-04 2.76E-04 0.00 0.00 0.00 8.43E-05 1.64E-04 2.76E-04 1.75 2.63 3.55 0.03 0.05 0.07 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Klebsiella pneumoniae CRKP RESP - model 7 1.07 1.85 2.68 2.19 3.59 5.24 3.25 5.46 7.79 1.80 2.28 2.93 0.02 0.03 0.05 0.04 0.07 0.10 0.06 0.10 0.14 1.52 2.40 3.18 0.03 0.04 0.06 0.05 0.09 0.12 9.91E-04 1.58E-03 2.19E-03 Slovakia - Klebsiella pneumoniae CRKP SSI - model 9 1.69E-03 3.40E-03 6.22E-03 0.51 0.87 1.23 0.51 0.88 1.23 0.43 0.53 0.62 3.12E-05 6.27E-05 1.15E-04 9.48E-03 0.02 0.02 9.48E-03 0.02 0.02 1.03 1.66 2.29 0.02 0.03 0.04 0.01 0.03 0.04 2.66E-04 4.83E-04 7.10E-04 Slovakia - Klebsiella pneumoniae CRKP UTI - model 8 3.66E-03 7.08E-03 0.01 0.00 0.00 0.00 3.66E-03 7.08E-03 0.01 1.28E-03 2.09E-03 3.09E-03 6.74E-05 1.31E-04 2.16E-04 0.00 0.00 0.00 6.74E-05 1.31E-04 2.16E-04 2.23 3.42 4.55 0.04 0.06 0.08 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Klebsiella pneumoniae ColRKP BSI - model 11 8.41 10.31 12.81 167.34 229.76 312.19 177.10 239.59 323.28 16.37 21.44 27.36 0.16 0.19 0.24 3.09 4.24 5.76 3.27 4.42 5.96 9.90 11.22 12.75 0.18 0.21 0.24 5.21 6.75 8.66 0.10 0.12 0.16 Slovakia - Klebsiella pneumoniae ColRKP OTH - model 15 0.01 0.02 0.03 0.00 0.00 0.00 0.01 0.02 0.03 2.36E-03 3.51E-03 4.94E-03 2.06E-04 3.37E-04 5.25E-04 0.00 0.00 0.00 2.06E-04 3.37E-04 5.25E-04 3.84 5.29 6.74 0.07 0.10 0.12 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Klebsiella pneumoniae ColRKP RESP - model 12 1.84 3.02 4.24 3.69 5.89 8.18 5.49 8.90 12.25 1.52 1.86 2.21 0.03 0.06 0.08 0.07 0.11 0.15 0.10 0.16 0.23 3.30 4.80 6.18 0.06 0.09 0.11 0.12 0.17 0.22 2.18E-03 3.18E-03 4.14E-03 Slovakia - Klebsiella pneumoniae ColRKP SSI - model 14 3.83E-03 7.00E-03 0.01 1.08 1.60 2.12 1.08 1.61 2.13 0.43 0.48 0.54 7.06E-05 1.29E-04 2.10E-04 0.02 0.03 0.04 0.02 0.03 0.04 2.30 3.33 4.46 0.04 0.06 0.08 0.04 0.06 0.09 7.25E-04 1.18E-03 1.57E-03 Slovakia - Klebsiella pneumoniae ColRKP UTI - model 13 8.93E-03 0.01 0.02 0.00 0.00 0.00 8.93E-03 0.01 0.02 1.43E-03 2.07E-03 2.87E-03 1.65E-04 2.58E-04 3.96E-04 0.00 0.00 0.00 1.65E-04 2.58E-04 3.96E-04 4.96 6.83 8.69 0.09 0.13 0.16 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Pseudomonas aeruginosa CRPA BSI - model 51 146.40 162.67 179.73 1,132.88 1,400.71 1,675.67 1,290.00 1,561.93 1,842.31 6.74 8.07 9.37 2.70 3.00 3.32 20.90 25.84 30.91 23.79 28.81 33.98 178.36 193.05 208.12 3.29 3.56 3.84 36.19 44.40 53.62 0.67 0.82 0.99 Slovakia - Pseudomonas aeruginosa CRPA OTH - model 55 0.28 0.36 0.46 0.00 0.00 0.00 0.28 0.36 0.46 3.06E-03 3.67E-03 4.29E-03 5.13E-03 6.55E-03 8.41E-03 0.00 0.00 0.00 5.13E-03 6.55E-03 8.41E-03 82.98 97.51 112.77 1.53 1.80 2.08 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Pseudomonas aeruginosa CRPA RESP - model 52 366.84 417.03 472.25 1,229.65 1,479.27 1,767.99 1,616.84 1,898.85 2,218.57 2.32 2.66 2.98 6.77 7.69 8.71 22.68 27.29 32.61 29.82 35.03 40.92 637.03 716.86 791.25 11.75 13.22 14.60 38.55 46.97 56.15 0.71 0.87 1.04 Slovakia - Pseudomonas aeruginosa CRPA SSI - model 54 0.21 0.28 0.36 47.92 57.28 66.32 48.16 57.57 66.62 0.40 0.43 0.47 3.85E-03 5.22E-03 6.68E-03 0.88 1.06 1.22 0.89 1.06 1.23 112.49 132.34 152.79 2.07 2.44 2.82 2.03 2.46 2.90 0.04 0.05 0.05 Slovakia - Pseudomonas aeruginosa CRPA UTI - model 53 0.40 0.51 0.63 0.00 0.00 0.00 0.40 0.51 0.63 1.69E-03 2.05E-03 2.39E-03 7.46E-03 9.38E-03 0.01 0.00 0.00 0.00 7.46E-03 9.38E-03 0.01 217.68 249.28 282.71 4.02 4.60 5.21 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Pseudomonas aeruginosa ColRPA BSI - model 56 5.33 6.86 8.95 32.14 59.52 89.58 40.43 66.64 98.29 7.23 11.67 16.03 0.10 0.13 0.17 0.59 1.10 1.65 0.75 1.23 1.81 4.74 5.65 6.81 0.09 0.10 0.13 0.77 1.30 1.94 0.01 0.02 0.04 Slovakia - Pseudomonas aeruginosa ColRPA OTH - model 60 5.97E-03 0.01 0.02 0.00 0.00 0.00 5.97E-03 0.01 0.02 2.42E-03 3.78E-03 5.21E-03 1.10E-04 1.97E-04 3.09E-04 0.00 0.00 0.00 1.10E-04 1.97E-04 3.09E-04 1.91 2.85 3.91 0.04 0.05 0.07 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Pseudomonas aeruginosa ColRPA RESP - model 57 12.41 17.78 23.56 39.59 62.01 94.93 54.20 80.01 116.13 2.78 3.81 5.08 0.23 0.33 0.43 0.73 1.14 1.75 1.00 1.48 2.14 16.04 21.23 26.51 0.30 0.39 0.49 0.89 1.37 2.00 0.02 0.03 0.04 Slovakia - Pseudomonas aeruginosa ColRPA SSI - model 59 4.10E-03 8.05E-03 0.01 0.99 1.61 2.21 1.00 1.61 2.22 0.35 0.41 0.48 7.56E-05 1.48E-04 2.68E-04 0.02 0.03 0.04 0.02 0.03 0.04 2.54 3.91 5.30 0.05 0.07 0.10 0.02 0.04 0.05 4.21E-04 6.50E-04 8.79E-04 Slovakia - Pseudomonas aeruginosa ColRPA UTI - model 58 8.33E-03 0.01 0.02 0.00 0.00 0.00 8.33E-03 0.01 0.02 1.29E-03 2.01E-03 2.86E-03 1.54E-04 2.70E-04 4.17E-04 0.00 0.00 0.00 1.54E-04 2.70E-04 4.17E-04 5.10 7.34 9.68 0.09 0.14 0.18 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Pseudomonas aeruginosa MDRPA BSI - model 46 6.78 7.98 9.52 42.83 61.82 84.76 51.15 70.00 92.48 3.23 4.47 5.77 0.13 0.15 0.18 0.79 1.14 1.56 0.94 1.29 1.71 13.71 15.60 18.00 0.25 0.29 0.33 2.25 3.29 4.51 0.04 0.06 0.08 Slovakia - Pseudomonas aeruginosa MDRPA OTH - model 50 0.02 0.03 0.04 0.00 0.00 0.00 0.02 0.03 0.04 2.67E-03 3.74E-03 4.92E-03 3.39E-04 5.46E-04 8.06E-04 0.00 0.00 0.00 3.39E-04 5.46E-04 8.06E-04 5.66 7.98 10.14 0.10 0.15 0.19 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Pseudomonas aeruginosa MDRPA RESP - model 47 16.36 20.35 24.69 47.25 68.71 93.06 65.54 88.98 115.88 1.17 1.54 1.89 0.30 0.38 0.46 0.87 1.27 1.72 1.21 1.64 2.14 46.98 58.20 69.78 0.87 1.07 1.29 2.49 3.62 4.92 0.05 0.07 0.09 Slovakia - Pseudomonas aeruginosa MDRPA SSI - model 49 0.01 0.02 0.04 2.66 3.61 4.54 2.69 3.64 4.58 0.30 0.34 0.38 2.47E-04 4.20E-04 6.83E-04 0.05 0.07 0.08 0.05 0.07 0.08 7.76 10.79 13.59 0.14 0.20 0.25 0.19 0.28 0.38 3.51E-03 5.20E-03 6.99E-03 Slovakia - Pseudomonas aeruginosa MDRPA UTI - model 48 0.03 0.04 0.06 0.00 0.00 0.00 0.03 0.04 0.06 1.42E-03 2.03E-03 2.63E-03 5.02E-04 7.53E-04 1.08E-03 0.00 0.00 0.00 5.02E-04 7.53E-04 1.08E-03 15.28 20.22 25.21 0.28 0.37 0.46 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Staphylococcus aureus MRSA BSI - model 61 139.59 150.72 163.40 961.80 1,014.32 1,074.11 1,103.29 1,165.82 1,230.91 5.02 5.21 5.40 2.57 2.78 3.01 17.74 18.71 19.81 20.35 21.50 22.70 213.84 223.76 233.75 3.94 4.13 4.31 37.84 40.26 42.60 0.70 0.74 0.79 Slovakia - Staphylococcus aureus MRSA OTH - model 65 0.87 1.08 1.32 0.00 0.00 0.00 0.87 1.08 1.32 2.71E-03 3.28E-03 3.89E-03 0.02 0.02 0.02 0.00 0.00 0.00 0.02 0.02 0.02 304.25 329.77 356.86 5.61 6.08 6.58 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Staphylococcus aureus MRSA RESP - model 62 141.58 155.66 173.10 276.91 304.42 333.30 420.54 460.39 504.71 1.31 1.37 1.45 2.61 2.87 3.19 5.11 5.62 6.15 7.76 8.49 9.31 305.72 334.70 366.08 5.64 6.17 6.75 10.97 12.05 13.38 0.20 0.22 0.25 Slovakia - Staphylococcus aureus MRSA SSI - model 64 0.58 0.78 0.99 143.17 157.97 172.86 143.90 158.69 173.85 0.41 0.43 0.45 0.01 0.01 0.02 2.64 2.91 3.19 2.65 2.93 3.21 338.63 367.23 397.67 6.25 6.77 7.34 7.66 8.51 9.40 0.14 0.16 0.17 Slovakia - Staphylococcus aureus MRSA UTI - model 63 0.08 0.10 0.13 0.00 0.00 0.00 0.08 0.10 0.13 1.52E-03 1.87E-03 2.23E-03 1.46E-03 1.88E-03 2.40E-03 0.00 0.00 0.00 1.46E-03 1.88E-03 2.40E-03 46.38 54.94 63.39 0.86 1.01 1.17 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Streptococcus pneumoniae PMRSP BSI - model 76 2.63 3.04 3.51 19.00 20.56 21.94 22.01 23.58 25.02 3.31 3.55 3.76 0.05 0.06 0.06 0.35 0.38 0.40 0.41 0.44 0.46 6.65 6.65 6.65 0.12 0.12 0.12 1.12 1.20 1.27 0.02 0.02 0.02 Slovakia - Streptococcus pneumoniae PMRSP OTH - model 80 3.11E-03 4.69E-03 6.44E-03 0.00 0.00 0.00 3.11E-03 4.69E-03 6.44E-03 1.32E-03 1.99E-03 2.65E-03 5.74E-05 8.65E-05 1.19E-04 0.00 0.00 0.00 5.74E-05 8.65E-05 1.19E-04 2.13 2.36 2.66 0.04 0.04 0.05 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Streptococcus pneumoniae PMRSP RESP - model 77 6.55 8.07 10.24 12.61 15.54 19.89 19.34 23.66 29.67 0.83 0.93 1.05 0.12 0.15 0.19 0.23 0.29 0.37 0.36 0.44 0.55 21.10 25.32 31.07 0.39 0.47 0.57 0.74 0.91 1.14 0.01 0.02 0.02 Slovakia - Streptococcus pneumoniae PMRSP SSI - model 79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Streptococcus pneumoniae PMRSP UTI - model 78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Streptococcus pneumoniae PRSP BSI - model 71 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Streptococcus pneumoniae PRSP OTH - model 75 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Streptococcus pneumoniae PRSP RESP - model 72 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Streptococcus pneumoniae PRSP SSI - model 74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Slovakia - Streptococcus pneumoniae PRSP UTI - model 73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total (Median & 95% UIs) 1,679.75 1,879.28 2,104.32 8,570.64 9,880.76 11,345.76 10,323.01 11,765.99 13,366.90 30.98 34.66 38.82 158.09 182.26 209.28 190.41 217.03 246.56 6,816.10 7,622.46 8,436.00 125.73 140.60 155.61 328.12 378.50 433.74 6.05 6.98 8.00 Total (average) - 182.57 217.30 7,626.77 140.68 379.06 6.99 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 1,882.89 9,897.54 11,780.42 - 34.73 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 Infection Colistin resistant Acinetobacter spp. 19.04 28.90 41.82 70.54 156.88 258.77 93.38 186.86 295.61 5.98 10.88 16.32 0.03 0.04 0.06 0.11 0.24 0.40 0.14 0.29 0.46 34.96 49.76 65.70 0.05 0.08 0.10 2.11 4.35 6.59 0.00 0.01 0.01 Carbapenem resistant Acinetobacter spp. (excluding those resistant to colistin) 6.35 10.10 15.13 21.52 54.19 95.48 29.24 64.49 107.55 4.10 7.58 11.01 0.01 0.02 0.02 0.03 0.08 0.15 0.05 0.10 0.17 15.00 24.96 35.52 0.02 0.04 0.05 0.85 2.12 3.74 0.00 0.00 0.01 Aminoglycosides and fluoroquinolones resistant Acinetobacter spp. (excluding those resistant to colistin and/or carbapenem) 18.48 26.39 36.74 69.15 134.44 224.24 90.98 160.92 255.53 5.90 9.62 14.09 0.03 0.04 0.06 0.11 0.21 0.35 0.14 0.25 0.39 34.80 49.97 65.13 0.05 0.08 0.10 2.25 4.17 6.40 0.00 0.01 0.01 Vancomycin resistant Enterococci (E. faecalis and E. faecium ) 223.00 272.88 327.55 2,181.32 2,613.75 3,103.97 2,393.74 2,888.29 3,431.78 5.02 5.60 6.29 0.34 0.42 0.50 3.36 4.03 4.78 3.69 4.45 5.29 1,541.91 1,969.67 2,408.11 2.38 3.04 3.71 107.38 134.13 164.46 0.17 0.21 0.25 Colistin resistant Escherichia coli 278.44 321.33 366.84 4,576.77 5,508.83 6,525.32 4,874.78 5,835.05 6,892.37 13.60 16.07 18.80 0.43 0.50 0.57 7.05 8.49 10.06 7.51 8.99 10.62 2,468.48 2,803.92 3,157.72 3.80 4.32 4.87 207.45 245.43 291.66 0.32 0.38 0.45 Carbapenem resistant Escherichia coli (excluding those resistant to colistin) 77.07 92.63 112.20 768.49 977.48 1,226.39 857.85 1,069.66 1,326.78 7.46 9.24 11.34 0.12 0.14 0.17 1.18 1.51 1.89 1.32 1.65 2.05 761.92 917.10 1,060.09 1.17 1.41 1.63 39.92 50.21 61.69 0.06 0.08 0.10 Third-generation cephalosporin resistant Escherichia coli (excluding those resistant to colistin and/or carbapenem) 3,107.73 3,438.00 3,786.16 18,279.14 20,233.00 22,173.81 21,495.01 23,673.98 25,797.07 4.98 5.38 5.84 4.79 5.30 5.84 28.18 31.19 34.18 33.13 36.49 39.76 31,137.62 35,135.47 39,243.87 48.00 54.16 60.49 936.33 1,075.77 1,222.56 1.44 1.66 1.88 Colistin resistant Klebsiella pneumoniae 20.84 27.32 34.60 335.29 472.32 628.25 361.66 500.37 661.36 9.31 12.19 15.50 0.03 0.04 0.05 0.52 0.73 0.97 0.56 0.77 1.02 91.41 123.03 154.98 0.14 0.19 0.24 20.26 27.31 35.65 0.03 0.04 0.05 Carbapenem resistant Klebsiella pneumoniae (excluding those resistant to colistin) 24.88 33.79 44.16 247.11 363.23 493.63 275.44 397.15 533.81 9.37 12.40 15.93 0.04 0.05 0.07 0.38 0.56 0.76 0.42 0.61 0.82 71.32 97.70 125.44 0.11 0.15 0.19 9.57 13.32 17.61 0.01 0.02 0.03 Third-generation cephalosporin resistant Klebsiella pneumoniae (excluding those resistant to colistin and/or carbapenem) 705.48 787.24 880.97 3,493.17 3,782.09 4,106.88 4,227.18 4,572.67 4,952.15 5.98 6.37 6.80 1.09 1.21 1.36 5.38 5.83 6.33 6.52 7.05 7.63 2,681.67 2,958.82 3,242.30 4.13 4.56 5.00 148.66 160.85 173.49 0.23 0.25 0.27 Colistin resistant Pseudomonas aeruginosa 29.89 47.53 68.68 107.22 237.26 419.45 145.83 284.56 476.33 5.48 9.97 14.99 0.05 0.07 0.11 0.17 0.37 0.65 0.22 0.44 0.73 80.29 128.49 176.56 0.12 0.20 0.27 3.90 8.63 14.33 0.01 0.01 0.02 Carbapenem resistant Pseudomonas aeruginosa (excluding those resistant to colistin) 217.33 262.00 309.32 939.47 1,312.61 1,729.84 1,181.32 1,575.70 2,025.68 6.90 9.02 11.25 0.33 0.40 0.48 1.45 2.02 2.67 1.82 2.43 3.12 645.00 772.36 899.85 0.99 1.19 1.39 39.19 52.49 66.53 0.06 0.08 0.10 Pseudomonas aeruginosa resistant to three or more antimicrobial groups (excluding those resistant to colistin and/or carbapenem) 288.93 351.96 418.08 1,227.69 1,681.62 2,202.87 1,550.46 2,038.81 2,601.35 7.27 9.33 11.65 0.45 0.54 0.64 1.89 2.59 3.40 2.39 3.14 4.01 801.65 960.29 1,133.33 1.24 1.48 1.75 46.65 61.75 79.42 0.07 0.10 0.12 Methicillin resistant Staphylococcus aureus 1,323.95 1,434.76 1,557.09 6,437.59 6,890.04 7,312.38 7,801.14 8,328.94 8,806.84 5.92 6.21 6.50 2.04 2.21 2.40 9.92 10.62 11.27 12.02 12.84 13.58 6,314.63 6,906.89 7,490.37 9.73 10.65 11.55 301.84 326.63 352.69 0.47 0.50 0.54 Penicillin and macrolides resistant Streptococcus pneumoniae (excluding those only resistant to penicillin) 33.26 45.39 68.10 126.75 152.83 197.79 164.84 198.28 260.92 11.74 13.33 15.05 0.05 0.07 0.10 0.20 0.24 0.30 0.25 0.31 0.40 40.03 48.45 62.85 0.06 0.07 0.10 2.51 3.00 3.66 0.00 0.00 0.01 Penicillin tesistant Streptococcus pneumoniae (excluding those resistant to macrolides) 4.03 5.82 9.40 15.35 18.98 25.22 19.95 24.80 34.15 2.96 3.36 3.78 0.01 0.01 0.01 0.02 0.03 0.04 0.03 0.04 0.05 19.30 23.81 35.36 0.03 0.04 0.05 1.20 1.48 1.97 0.00 0.00 0.00 Total 6,378.72 7,186.04 8,076.84 38,896.57 44,589.55 50,724.29 45,562.81 51,800.54 58,459.30 9.83 11.08 12.45 59.96 68.73 78.19 70.23 79.85 90.11 46,740.01 52,970.70 59,357.18 72.05 81.65 91.49 1,870.04 2,171.64 2,502.47 2.88 3.35 3.86 Model United Kingdom - Acinetobacter spp. CRACI BSI - model 36 3.89 5.79 8.40 16.23 44.90 81.75 21.41 50.88 87.78 2.68 5.95 9.18 5.99E-03 8.92E-03 0.01 0.03 0.07 0.13 0.03 0.08 0.14 6.76 8.62 10.94 0.01 0.01 0.02 0.64 1.76 3.20 9.85E-04 2.71E-03 4.94E-03 United Kingdom - Acinetobacter spp. CRACI OTH - model 40 1.53E-04 1.02E-03 3.02E-03 0.00 0.00 0.00 1.53E-04 1.02E-03 3.02E-03 1.56E-03 3.71E-03 6.56E-03 2.36E-07 1.57E-06 4.65E-06 0.00 0.00 0.00 2.36E-07 1.57E-06 4.65E-06 0.06 0.31 0.66 8.67E-05 4.77E-04 1.01E-03 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Acinetobacter spp. CRACI RESP - model 37 2.46 4.30 6.70 5.01 8.57 12.58 7.55 12.87 18.61 1.19 1.39 1.58 3.79E-03 6.63E-03 0.01 7.71E-03 0.01 0.02 0.01 0.02 0.03 5.61 9.30 13.15 8.65E-03 0.01 0.02 0.20 0.34 0.49 3.02E-04 5.18E-04 7.61E-04 United Kingdom - Acinetobacter spp. CRACI SSI - model 39 1.15E-03 5.86E-03 0.02 0.29 0.72 1.14 0.29 0.73 1.15 0.23 0.23 0.23 1.77E-06 9.04E-06 2.63E-05 4.40E-04 1.12E-03 1.76E-03 4.40E-04 1.13E-03 1.77E-03 1.24 3.16 4.98 1.91E-03 4.88E-03 7.67E-03 0.01 0.03 0.04 1.72E-05 4.39E-05 6.91E-05 United Kingdom - Acinetobacter spp. CRACI UTI - model 38 1.87E-03 6.70E-03 0.02 0.00 0.00 0.00 1.87E-03 6.70E-03 0.02 7.92E-04 2.00E-03 3.59E-03 2.88E-06 1.03E-05 2.44E-05 0.00 0.00 0.00 2.88E-06 1.03E-05 2.44E-05 1.33 3.58 5.80 2.05E-03 5.51E-03 8.94E-03 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Acinetobacter spp. ColRACI BSI - model 41 11.54 16.37 23.22 53.64 129.43 218.96 68.72 146.69 238.23 4.10 8.44 13.25 0.02 0.03 0.04 0.08 0.20 0.34 0.11 0.23 0.37 14.33 17.14 20.59 0.02 0.03 0.03 1.58 3.54 5.46 2.44E-03 5.45E-03 8.42E-03 United Kingdom - Acinetobacter spp. ColRACI OTH - model 45 7.97E-04 2.12E-03 4.67E-03 0.00 0.00 0.00 7.97E-04 2.12E-03 4.67E-03 1.89E-03 3.62E-03 5.87E-03 1.23E-06 3.27E-06 7.20E-06 0.00 0.00 0.00 1.23E-06 3.27E-06 7.20E-06 0.24 0.61 1.08 3.64E-04 9.38E-04 1.66E-03 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Acinetobacter spp. ColRACI RESP - model 42 7.49 12.50 18.54 15.32 24.55 35.65 23.07 37.25 53.15 1.47 1.98 2.54 0.01 0.02 0.03 0.02 0.04 0.05 0.04 0.06 0.08 13.06 18.65 24.84 0.02 0.03 0.04 0.46 0.67 0.92 7.07E-04 1.03E-03 1.42E-03 United Kingdom - Acinetobacter spp. ColRACI SSI - model 44 4.55E-03 0.01 0.03 1.57 2.90 4.16 1.59 2.91 4.19 0.40 0.46 0.52 7.02E-06 1.95E-05 4.11E-05 2.43E-03 4.47E-03 6.42E-03 2.44E-03 4.49E-03 6.46E-03 3.50 6.34 9.09 5.39E-03 9.77E-03 0.01 0.07 0.14 0.21 1.12E-04 2.18E-04 3.27E-04 United Kingdom - Acinetobacter spp. ColRACI UTI - model 43 6.21E-03 0.01 0.03 0.00 0.00 0.00 6.21E-03 0.01 0.03 1.08E-03 2.02E-03 3.22E-03 9.57E-06 2.15E-05 3.90E-05 0.00 0.00 0.00 9.57E-06 2.15E-05 3.90E-05 3.83 7.03 10.10 5.91E-03 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Acinetobacter spp. MDRACI BSI - model 31 11.21 15.04 20.56 53.53 109.11 188.65 67.76 124.15 204.94 4.00 7.33 11.39 0.02 0.02 0.03 0.08 0.17 0.29 0.10 0.19 0.32 14.37 17.23 20.44 0.02 0.03 0.03 1.72 3.35 5.28 2.66E-03 5.16E-03 8.14E-03 United Kingdom - Acinetobacter spp. MDRACI OTH - model 35 6.28E-04 2.13E-03 4.87E-03 0.00 0.00 0.00 6.28E-04 2.13E-03 4.87E-03 1.91E-03 3.68E-03 5.81E-03 9.68E-07 3.28E-06 7.51E-06 0.00 0.00 0.00 9.68E-07 3.28E-06 7.51E-06 0.19 0.60 1.11 3.00E-04 9.23E-04 1.70E-03 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Acinetobacter spp. MDRACI RESP - model 32 7.26 11.32 16.13 13.95 22.35 31.31 21.55 33.76 46.27 1.43 1.81 2.21 0.01 0.02 0.02 0.02 0.03 0.05 0.03 0.05 0.07 12.91 18.80 24.60 0.02 0.03 0.04 0.45 0.68 0.91 6.96E-04 1.05E-03 1.41E-03 United Kingdom - Acinetobacter spp. MDRACI SSI - model 34 4.22E-03 0.01 0.03 1.67 2.98 4.28 1.67 2.99 4.29 0.47 0.48 0.48 6.51E-06 1.92E-05 4.22E-05 2.58E-03 4.60E-03 6.59E-03 2.58E-03 4.61E-03 6.61E-03 3.58 6.29 9.03 5.52E-03 9.70E-03 0.01 0.07 0.14 0.21 1.12E-04 2.18E-04 3.23E-04 United Kingdom - Acinetobacter spp. MDRACI UTI - model 33 5.87E-03 0.01 0.03 0.00 0.00 0.00 5.87E-03 0.01 0.03 9.72E-04 2.02E-03 3.31E-03 9.05E-06 2.10E-05 4.14E-05 0.00 0.00 0.00 9.05E-06 2.10E-05 4.14E-05 3.74 7.04 9.96 5.76E-03 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Enterococcus faecalis and E. faecium VRE BSI - model 66 221.07 270.10 323.59 1,947.73 2,307.00 2,720.95 2,158.72 2,578.78 3,045.32 4.61 5.14 5.79 0.34 0.42 0.50 3.00 3.56 4.19 3.33 3.97 4.69 406.32 499.11 607.60 0.63 0.77 0.94 92.52 114.08 138.97 0.14 0.18 0.21 United Kingdom - Enterococcus faecalis and E. faecium VRE OTH - model 70 0.61 0.87 1.19 0.00 0.00 0.00 0.61 0.87 1.19 1.23E-03 1.66E-03 2.09E-03 9.40E-04 1.35E-03 1.84E-03 0.00 0.00 0.00 9.40E-04 1.35E-03 1.84E-03 415.17 535.17 648.50 0.64 0.82 1.00 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Enterococcus faecalis and E. faecium VRE RESP - model 67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Enterococcus faecalis and E. faecium VRE SSI - model 69 1.00 1.44 2.11 233.60 306.75 383.02 234.08 308.17 384.61 0.41 0.45 0.49 1.54E-03 2.22E-03 3.26E-03 0.36 0.47 0.59 0.36 0.48 0.59 527.26 680.78 835.27 0.81 1.05 1.29 14.86 20.05 25.49 0.02 0.03 0.04 United Kingdom - Enterococcus faecalis and E. faecium VRE UTI - model 68 0.32 0.47 0.66 0.00 0.00 0.00 0.32 0.47 0.66 1.43E-03 1.87E-03 2.37E-03 5.00E-04 7.25E-04 1.02E-03 0.00 0.00 0.00 5.00E-04 7.25E-04 1.02E-03 193.16 254.61 316.74 0.30 0.39 0.49 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Escherichia coli 3GCREC BSI - model 16 2,381.04 2,593.66 2,813.95 15,223.00 16,679.91 18,165.74 17,703.96 19,273.28 20,830.59 3.65 3.91 4.22 3.67 4.00 4.34 23.47 25.71 28.00 27.29 29.71 32.11 4,611.23 4,915.53 5,291.89 7.11 7.58 8.16 751.04 850.67 959.88 1.16 1.31 1.48 United Kingdom - Escherichia coli 3GCREC OTH - model 20 4.14 5.43 7.21 0.00 0.00 0.00 4.14 5.43 7.21 2.72E-03 3.35E-03 4.12E-03 6.39E-03 8.37E-03 0.01 0.00 0.00 0.00 6.39E-03 8.37E-03 0.01 1,334.81 1,626.73 1,926.19 2.06 2.51 2.97 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Escherichia coli 3GCREC RESP - model 17 681.75 786.46 898.04 1,304.85 1,527.52 1,744.29 1,995.63 2,316.94 2,632.72 0.96 1.07 1.20 1.05 1.21 1.38 2.01 2.35 2.69 3.08 3.57 4.06 1,797.87 2,167.99 2,557.98 2.77 3.34 3.94 63.64 77.70 92.51 0.10 0.12 0.14 United Kingdom - Escherichia coli 3GCREC SSI - model 19 8.14 11.07 14.97 1,751.29 2,025.56 2,263.78 1,758.63 2,036.95 2,274.56 0.37 0.39 0.42 0.01 0.02 0.02 2.70 3.12 3.49 2.71 3.14 3.51 4,491.76 5,213.80 5,915.71 6.92 8.04 9.12 121.65 147.40 170.17 0.19 0.23 0.26 United Kingdom - Escherichia coli 3GCREC UTI - model 18 32.65 41.38 51.99 0.00 0.00 0.00 32.65 41.38 51.99 1.59E-03 1.96E-03 2.37E-03 0.05 0.06 0.08 0.00 0.00 0.00 0.05 0.06 0.08 18,901.95 21,211.41 23,552.11 29.14 32.70 36.30 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Escherichia coli CREC BSI - model 21 58.47 67.77 80.07 686.38 875.15 1,103.36 756.19 942.48 1,173.48 6.21 7.73 9.52 0.09 0.10 0.12 1.06 1.35 1.70 1.17 1.45 1.81 109.10 122.58 135.89 0.17 0.19 0.21 34.81 43.58 53.69 0.05 0.07 0.08 United Kingdom - Escherichia coli CREC OTH - model 25 0.16 0.24 0.36 0.00 0.00 0.00 0.16 0.24 0.36 2.47E-03 3.46E-03 4.86E-03 2.48E-04 3.74E-04 5.56E-04 0.00 0.00 0.00 2.48E-04 3.74E-04 5.56E-04 54.57 70.86 85.28 0.08 0.11 0.13 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Escherichia coli CREC RESP - model 22 17.51 23.25 29.81 33.86 44.86 56.98 52.04 68.13 84.94 0.88 1.11 1.37 0.03 0.04 0.05 0.05 0.07 0.09 0.08 0.11 0.13 46.93 62.15 76.05 0.07 0.10 0.12 1.67 2.24 2.78 2.57E-03 3.45E-03 4.29E-03 United Kingdom - Escherichia coli CREC SSI - model 24 0.19 0.31 0.45 48.25 57.46 66.05 48.71 57.75 66.50 0.37 0.40 0.44 2.95E-04 4.75E-04 6.93E-04 0.07 0.09 0.10 0.08 0.09 0.10 116.93 145.27 168.54 0.18 0.22 0.26 3.44 4.39 5.22 5.30E-03 6.77E-03 8.05E-03 United Kingdom - Escherichia coli CREC UTI - model 23 0.74 1.06 1.50 0.00 0.00 0.00 0.74 1.06 1.50 1.50E-03 2.06E-03 2.80E-03 1.15E-03 1.64E-03 2.31E-03 0.00 0.00 0.00 1.15E-03 1.64E-03 2.31E-03 434.40 516.25 594.34 0.67 0.80 0.92 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Escherichia coli ColREC BSI - model 26 209.65 235.20 263.21 4,287.44 5,165.38 6,128.03 4,516.46 5,404.93 6,393.85 12.13 14.39 16.87 0.32 0.36 0.41 6.61 7.96 9.45 6.96 8.33 9.86 349.09 375.46 407.69 0.54 0.58 0.63 191.02 225.74 268.68 0.29 0.35 0.41 United Kingdom - Escherichia coli ColREC OTH - model 30 0.55 0.75 1.03 0.00 0.00 0.00 0.55 0.75 1.03 2.69E-03 3.50E-03 4.55E-03 8.45E-04 1.16E-03 1.59E-03 0.00 0.00 0.00 8.45E-04 1.16E-03 1.59E-03 181.37 216.19 249.69 0.28 0.33 0.38 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Escherichia coli ColREC RESP - model 27 65.09 81.14 97.10 126.09 157.18 187.97 191.33 238.79 282.86 1.06 1.25 1.47 0.10 0.13 0.15 0.19 0.24 0.29 0.29 0.37 0.44 154.49 190.07 221.55 0.24 0.29 0.34 5.52 6.81 8.05 8.51E-03 0.01 0.01 United Kingdom - Escherichia coli ColREC SSI - model 29 0.68 0.94 1.27 163.24 186.27 209.32 163.98 187.29 210.39 0.40 0.42 0.45 1.04E-03 1.44E-03 1.95E-03 0.25 0.29 0.32 0.25 0.29 0.32 382.24 442.82 504.72 0.59 0.68 0.78 10.91 12.89 14.93 0.02 0.02 0.02 United Kingdom - Escherichia coli ColREC UTI - model 28 2.47 3.30 4.24 0.00 0.00 0.00 2.47 3.30 4.24 1.62E-03 2.09E-03 2.61E-03 3.81E-03 5.08E-03 6.54E-03 0.00 0.00 0.00 3.81E-03 5.08E-03 6.54E-03 1,401.29 1,579.39 1,774.07 2.16 2.43 2.73 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Klebsiella pneumoniae 3GCRKP BSI - model 1 446.07 488.34 542.26 2,875.21 3,076.91 3,302.18 3,343.90 3,568.97 3,817.01 4.37 4.62 4.91 0.69 0.75 0.84 4.43 4.74 5.09 5.15 5.50 5.88 734.24 772.40 809.50 1.13 1.19 1.25 120.65 128.84 137.32 0.19 0.20 0.21 United Kingdom - Klebsiella pneumoniae 3GCRKP OTH - model 5 0.79 1.02 1.29 0.00 0.00 0.00 0.79 1.02 1.29 2.68E-03 3.37E-03 4.05E-03 1.22E-03 1.57E-03 1.98E-03 0.00 0.00 0.00 1.22E-03 1.57E-03 1.98E-03 270.04 306.57 344.77 0.42 0.47 0.53 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Klebsiella pneumoniae 3GCRKP RESP - model 2 256.73 295.46 334.41 505.17 573.97 653.46 767.78 869.05 979.66 1.20 1.30 1.42 0.40 0.46 0.52 0.78 0.88 1.01 1.18 1.34 1.51 596.96 667.01 739.34 0.92 1.03 1.14 21.22 23.96 26.79 0.03 0.04 0.04 United Kingdom - Klebsiella pneumoniae 3GCRKP SSI - model 4 0.48 0.64 0.85 112.80 131.21 151.25 113.30 131.86 152.02 0.41 0.43 0.46 7.37E-04 9.92E-04 1.32E-03 0.17 0.20 0.23 0.17 0.20 0.23 264.90 302.97 344.10 0.41 0.47 0.53 6.79 8.05 9.38 0.01 0.01 0.01 United Kingdom - Klebsiella pneumoniae 3GCRKP UTI - model 3 1.41 1.77 2.17 0.00 0.00 0.00 1.41 1.77 2.17 1.57E-03 1.96E-03 2.33E-03 2.18E-03 2.73E-03 3.34E-03 0.00 0.00 0.00 2.18E-03 2.73E-03 3.34E-03 815.53 909.88 1,004.59 1.26 1.40 1.55 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Klebsiella pneumoniae CRKP BSI - model 6 20.41 26.07 32.90 235.81 343.78 465.88 259.66 369.89 495.12 7.81 10.45 13.49 0.03 0.04 0.05 0.36 0.53 0.72 0.40 0.57 0.76 30.24 35.18 40.66 0.05 0.05 0.06 9.09 12.55 16.54 0.01 0.02 0.03 United Kingdom - Klebsiella pneumoniae CRKP OTH - model 10 0.03 0.06 0.10 0.00 0.00 0.00 0.03 0.06 0.10 2.00E-03 3.52E-03 5.25E-03 4.46E-05 8.61E-05 1.48E-04 0.00 0.00 0.00 4.46E-05 8.61E-05 1.48E-04 10.34 16.25 22.24 0.02 0.03 0.03 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Klebsiella pneumoniae CRKP RESP - model 7 4.41 7.60 11.06 8.49 14.77 21.09 12.90 22.46 31.84 1.17 1.49 1.90 6.80E-03 0.01 0.02 0.01 0.02 0.03 0.02 0.03 0.05 9.76 14.86 20.03 0.02 0.02 0.03 0.35 0.54 0.74 5.37E-04 8.28E-04 1.13E-03 United Kingdom - Klebsiella pneumoniae CRKP SSI - model 9 9.93E-03 0.02 0.04 2.81 4.67 6.66 2.83 4.70 6.69 0.38 0.45 0.54 1.53E-05 3.27E-05 5.96E-05 4.33E-03 7.20E-03 0.01 4.36E-03 7.25E-03 0.01 6.48 10.33 14.18 9.98E-03 0.02 0.02 0.13 0.23 0.34 2.02E-04 3.58E-04 5.19E-04 United Kingdom - Klebsiella pneumoniae CRKP UTI - model 8 0.02 0.04 0.07 0.00 0.00 0.00 0.02 0.04 0.07 1.25E-03 2.06E-03 3.03E-03 3.51E-05 6.57E-05 1.07E-04 0.00 0.00 0.00 3.51E-05 6.57E-05 1.07E-04 14.50 21.09 28.32 0.02 0.03 0.04 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Klebsiella pneumoniae ColRKP BSI - model 11 16.87 21.06 25.95 325.07 456.45 606.44 347.46 478.24 631.07 8.22 10.90 13.98 0.03 0.03 0.04 0.50 0.70 0.93 0.54 0.74 0.97 38.09 43.99 50.32 0.06 0.07 0.08 19.63 26.32 34.29 0.03 0.04 0.05 United Kingdom - Klebsiella pneumoniae ColRKP OTH - model 15 0.04 0.07 0.11 0.00 0.00 0.00 0.04 0.07 0.11 2.20E-03 3.53E-03 5.10E-03 6.02E-05 1.12E-04 1.77E-04 0.00 0.00 0.00 6.02E-05 1.12E-04 1.77E-04 14.06 20.70 27.22 0.02 0.03 0.04 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Klebsiella pneumoniae ColRKP RESP - model 12 3.88 6.10 8.40 7.46 11.64 16.06 11.36 17.75 24.27 0.78 0.96 1.15 5.98E-03 9.40E-03 0.01 0.01 0.02 0.02 0.02 0.03 0.04 12.01 18.46 25.10 0.02 0.03 0.04 0.43 0.67 0.91 6.68E-04 1.03E-03 1.40E-03 United Kingdom - Klebsiella pneumoniae ColRKP SSI - model 14 0.01 0.03 0.04 2.75 4.23 5.76 2.77 4.26 5.82 0.30 0.33 0.36 2.04E-05 4.13E-05 6.78E-05 4.24E-03 6.53E-03 8.88E-03 4.27E-03 6.56E-03 8.97E-03 8.39 12.95 17.41 0.01 0.02 0.03 0.20 0.32 0.46 3.12E-04 5.00E-04 7.03E-04 United Kingdom - Klebsiella pneumoniae ColRKP UTI - model 13 0.03 0.06 0.09 0.00 0.00 0.00 0.03 0.06 0.09 1.34E-03 2.08E-03 2.95E-03 5.00E-05 8.59E-05 1.33E-04 0.00 0.00 0.00 5.00E-05 8.59E-05 1.33E-04 18.86 26.92 34.93 0.03 0.04 0.05 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Pseudomonas aeruginosa CRPA BSI - model 51 62.77 73.23 84.56 436.44 618.73 808.47 506.06 690.95 887.10 4.82 6.44 8.13 0.10 0.11 0.13 0.67 0.95 1.25 0.78 1.07 1.37 96.45 107.50 118.52 0.15 0.17 0.18 17.89 24.65 31.38 0.03 0.04 0.05 United Kingdom - Pseudomonas aeruginosa CRPA OTH - model 55 0.14 0.20 0.27 0.00 0.00 0.00 0.14 0.20 0.27 2.78E-03 3.66E-03 4.57E-03 2.16E-04 3.10E-04 4.17E-04 0.00 0.00 0.00 2.16E-04 3.10E-04 4.17E-04 42.19 54.63 67.30 0.07 0.08 0.10 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Pseudomonas aeruginosa CRPA RESP - model 52 154.11 188.13 223.90 478.43 662.06 882.33 650.13 852.28 1,098.77 1.69 2.14 2.63 0.24 0.29 0.35 0.74 1.02 1.36 1.00 1.31 1.69 338.59 399.06 458.23 0.52 0.62 0.71 20.03 26.18 33.10 0.03 0.04 0.05 United Kingdom - Pseudomonas aeruginosa CRPA SSI - model 54 0.10 0.16 0.22 24.60 31.82 39.04 24.80 31.99 39.15 0.39 0.43 0.48 1.61E-04 2.43E-04 3.36E-04 0.04 0.05 0.06 0.04 0.05 0.06 57.52 74.17 89.88 0.09 0.11 0.14 1.27 1.66 2.04 1.96E-03 2.56E-03 3.14E-03 United Kingdom - Pseudomonas aeruginosa CRPA UTI - model 53 0.20 0.28 0.38 0.00 0.00 0.00 0.20 0.28 0.38 1.57E-03 2.04E-03 2.61E-03 3.08E-04 4.30E-04 5.88E-04 0.00 0.00 0.00 3.08E-04 4.30E-04 5.88E-04 110.25 136.99 165.92 0.17 0.21 0.26 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Pseudomonas aeruginosa ColRPA BSI - model 56 9.42 13.32 18.18 47.90 112.09 198.61 61.41 125.10 214.39 3.60 7.14 11.04 0.01 0.02 0.03 0.07 0.17 0.31 0.09 0.19 0.33 14.01 17.85 22.38 0.02 0.03 0.03 1.75 4.07 6.75 2.70E-03 6.27E-03 0.01 United Kingdom - Pseudomonas aeruginosa ColRPA OTH - model 60 0.01 0.03 0.06 0.00 0.00 0.00 0.01 0.03 0.06 1.92E-03 3.67E-03 5.63E-03 2.01E-05 4.95E-05 9.85E-05 0.00 0.00 0.00 2.01E-05 4.95E-05 9.85E-05 4.62 9.01 13.41 7.12E-03 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Pseudomonas aeruginosa ColRPA RESP - model 57 20.43 34.11 50.29 56.33 119.29 212.09 81.39 153.48 253.00 1.45 2.34 3.40 0.03 0.05 0.08 0.09 0.18 0.33 0.13 0.24 0.39 42.10 66.68 89.73 0.06 0.10 0.14 2.02 4.28 7.16 3.11E-03 6.60E-03 0.01 United Kingdom - Pseudomonas aeruginosa ColRPA SSI - model 59 8.61E-03 0.02 0.06 2.99 5.88 8.75 3.00 5.91 8.79 0.42 0.48 0.55 1.33E-05 3.71E-05 8.48E-05 4.61E-03 9.06E-03 0.01 4.62E-03 9.11E-03 0.01 6.19 12.33 18.19 9.54E-03 0.02 0.03 0.12 0.27 0.42 1.90E-04 4.23E-04 6.52E-04 United Kingdom - Pseudomonas aeruginosa ColRPA UTI - model 58 0.02 0.05 0.09 0.00 0.00 0.00 0.02 0.05 0.09 1.03E-03 2.05E-03 3.33E-03 3.08E-05 7.10E-05 1.35E-04 0.00 0.00 0.00 3.08E-05 7.10E-05 1.35E-04 13.37 22.62 32.84 0.02 0.03 0.05 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Pseudomonas aeruginosa MDRPA BSI - model 46 85.11 99.75 116.93 567.61 785.59 1,040.09 656.84 885.71 1,150.85 4.98 6.58 8.37 0.13 0.15 0.18 0.87 1.21 1.60 1.01 1.37 1.77 120.70 134.27 151.16 0.19 0.21 0.23 21.29 28.42 36.36 0.03 0.04 0.06 United Kingdom - Pseudomonas aeruginosa MDRPA OTH - model 50 0.18 0.25 0.35 0.00 0.00 0.00 0.18 0.25 0.35 2.86E-03 3.71E-03 4.67E-03 2.70E-04 3.86E-04 5.40E-04 0.00 0.00 0.00 2.70E-04 3.86E-04 5.40E-04 52.21 67.61 84.62 0.08 0.10 0.13 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Pseudomonas aeruginosa MDRPA RESP - model 47 203.26 251.40 300.02 623.48 848.09 1,103.05 856.45 1,104.36 1,389.69 1.81 2.23 2.72 0.31 0.39 0.46 0.96 1.31 1.70 1.32 1.70 2.14 415.39 492.47 571.94 0.64 0.76 0.88 23.50 30.84 39.92 0.04 0.05 0.06 United Kingdom - Pseudomonas aeruginosa MDRPA SSI - model 49 0.13 0.20 0.29 36.59 47.94 59.73 36.75 48.14 59.97 0.48 0.52 0.56 2.02E-04 3.02E-04 4.48E-04 0.06 0.07 0.09 0.06 0.07 0.09 72.15 92.42 113.32 0.11 0.14 0.17 1.85 2.49 3.14 2.86E-03 3.85E-03 4.84E-03 United Kingdom - Pseudomonas aeruginosa MDRPA UTI - model 48 0.25 0.36 0.49 0.00 0.00 0.00 0.25 0.36 0.49 1.56E-03 2.05E-03 2.55E-03 3.86E-04 5.48E-04 7.50E-04 0.00 0.00 0.00 3.86E-04 5.48E-04 7.50E-04 141.19 173.53 212.29 0.22 0.27 0.33 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Staphylococcus aureus MRSA BSI - model 61 653.93 696.60 750.64 4,432.30 4,693.43 4,922.23 5,118.27 5,391.77 5,631.70 4.39 4.59 4.78 1.01 1.07 1.16 6.83 7.23 7.59 7.89 8.31 8.68 1,124.60 1,175.46 1,233.31 1.73 1.81 1.90 198.69 211.27 225.04 0.31 0.33 0.35 United Kingdom - Staphylococcus aureus MRSA OTH - model 65 4.56 5.61 6.97 0.00 0.00 0.00 4.56 5.61 6.97 2.69E-03 3.26E-03 3.92E-03 7.03E-03 8.65E-03 0.01 0.00 0.00 0.00 7.03E-03 8.65E-03 0.01 1,587.30 1,741.44 1,886.68 2.45 2.68 2.91 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Staphylococcus aureus MRSA RESP - model 62 661.93 727.88 793.45 1,291.49 1,414.97 1,542.79 1,960.37 2,145.45 2,316.33 1.13 1.21 1.29 1.02 1.12 1.22 1.99 2.18 2.38 3.02 3.31 3.57 1,597.83 1,771.48 1,933.18 2.46 2.73 2.98 56.68 63.73 70.59 0.09 0.10 0.11 United Kingdom - Staphylococcus aureus MRSA SSI - model 64 3.10 4.13 5.35 713.80 781.63 847.36 717.51 785.57 851.16 0.39 0.41 0.42 4.78E-03 6.37E-03 8.24E-03 1.10 1.20 1.31 1.11 1.21 1.31 1,766.84 1,930.02 2,101.45 2.72 2.97 3.24 46.47 51.62 57.06 0.07 0.08 0.09 United Kingdom - Staphylococcus aureus MRSA UTI - model 63 0.42 0.53 0.68 0.00 0.00 0.00 0.42 0.53 0.68 1.52E-03 1.86E-03 2.27E-03 6.50E-04 8.21E-04 1.05E-03 0.00 0.00 0.00 6.50E-04 8.21E-04 1.05E-03 238.05 288.50 335.75 0.37 0.44 0.52 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Streptococcus pneumoniae PMRSP BSI - model 76 9.82 12.79 16.31 78.91 87.84 97.10 90.96 100.47 110.73 9.55 10.55 11.63 0.02 0.02 0.03 0.12 0.14 0.15 0.14 0.15 0.17 9.52 9.52 9.52 0.01 0.01 0.01 1.55 1.71 1.88 2.39E-03 2.64E-03 2.90E-03 United Kingdom - Streptococcus pneumoniae PMRSP OTH - model 80 3.35E-03 6.61E-03 0.01 0.00 0.00 0.00 3.35E-03 6.61E-03 0.01 1.00E-03 1.95E-03 3.16E-03 5.16E-06 1.02E-05 1.68E-05 0.00 0.00 0.00 5.16E-06 1.02E-05 1.68E-05 2.88 3.36 4.04 4.44E-03 5.18E-03 6.23E-03 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Streptococcus pneumoniae PMRSP RESP - model 77 23.44 32.60 51.78 47.84 65.00 100.69 73.88 97.81 150.18 2.18 2.78 3.41 0.04 0.05 0.08 0.07 0.10 0.16 0.11 0.15 0.23 27.63 35.58 49.29 0.04 0.05 0.08 0.96 1.28 1.77 1.48E-03 1.98E-03 2.73E-03 United Kingdom - Streptococcus pneumoniae PMRSP SSI - model 79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Streptococcus pneumoniae PMRSP UTI - model 78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Streptococcus pneumoniae PRSP BSI - model 71 1.21 1.64 2.17 9.67 10.99 12.33 11.21 12.66 14.17 2.36 2.66 2.98 1.87E-03 2.53E-03 3.35E-03 0.01 0.02 0.02 0.02 0.02 0.02 4.76 4.76 4.76 7.34E-03 7.34E-03 7.34E-03 0.75 0.86 0.96 1.16E-03 1.32E-03 1.48E-03 United Kingdom - Streptococcus pneumoniae PRSP OTH - model 75 1.26E-03 3.10E-03 6.48E-03 0.00 0.00 0.00 1.26E-03 3.10E-03 6.48E-03 7.70E-04 1.87E-03 3.68E-03 1.94E-06 4.78E-06 1.00E-05 0.00 0.00 0.00 1.94E-06 4.78E-06 1.00E-05 1.38 1.66 2.16 2.12E-03 2.56E-03 3.33E-03 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Streptococcus pneumoniae PRSP RESP - model 72 2.81 4.17 7.22 5.68 7.99 12.90 8.74 12.14 19.97 0.60 0.70 0.80 4.34E-03 6.42E-03 0.01 8.76E-03 0.01 0.02 0.01 0.02 0.03 13.16 17.40 28.44 0.02 0.03 0.04 0.44 0.62 1.01 6.83E-04 9.60E-04 1.55E-03 United Kingdom - Streptococcus pneumoniae PRSP SSI - model 74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 United Kingdom - Streptococcus pneumoniae PRSP UTI - model 73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NaN NaN NaN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Total (Median & 95% UIs) 6,378.72 7,186.04 8,076.84 38,896.57 44,589.55 50,724.29 45,562.81 51,800.54 58,459.30 9.83 11.08 12.45 59.96 68.73 78.19 70.23 79.85 90.11 46,740.01 52,970.70 59,357.18 72.05 81.65 91.49 1,870.04 2,171.64 2,502.47 2.88 3.35 3.86 Total (average) - 68.90 80.00 52,992.69 81.68 2,176.86 3.36 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000 7,205.86 44,695.95 51,901.81 - 11.11 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 YLL per 100,000 YLD YLL DALY DALY per Case YLD per 100,000 DALY per 100,000 Cases per year Incidence per 100,000 Deaths per year Mortality per 100,000